<SEC-DOCUMENT>0001564590-17-016988.txt : 20170809
<SEC-HEADER>0001564590-17-016988.hdr.sgml : 20170809
<ACCEPTANCE-DATETIME>20170809162930
ACCESSION NUMBER:		0001564590-17-016988
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20170630
FILED AS OF DATE:		20170809
DATE AS OF CHANGE:		20170809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MERRIMACK PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001274792
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35409
		FILM NUMBER:		171018316

	BUSINESS ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		SUITE B7201
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-441-1000

	MAIL ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		SUITE B7201
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mack-10q_20170630.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mack-10q_20170630.htm
</title>
</head>
<!-- NG Converter v4.0.8.13 -->
<body>

<p style="border-bottom:none 0pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="border-top:Double 2.25pt;padding-top:1pt;border-bottom:none 0pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="margin-bottom:6pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-Q</p>
<p style="margin-bottom:6pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Mark One)</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-weight:bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9746;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the quarterly period ended June&#160;30, 2017</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-weight:bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from <font style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> to <font style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission file number: 001-35409</p>
<p style="margin-bottom:6pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Merrimack Pharmaceuticals, Inc.</p>
<p style="margin-bottom:6pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">04-3210530</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="top"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification Number)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">One Kendall Square, Suite B7201</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cambridge, MA</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">02139</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="top"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(617) 441-1000</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="margin-bottom:6pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9746;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9746;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large accelerated filer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9746;</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated filer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Do not check if a smaller reporting company)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller reporting company</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9746;</font></font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of August 8, 2017, there were 132,793,256 shares of Common Stock, $0.01 par value per share, outstanding.</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FINANCIAL INFORMATION</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.1pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">P<font style="text-transform:none;">age</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1.</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FINANCIAL_STATEMENTS"><font style="text-decoration:underline;">Financial Statements.</font></a></p></td>
<td valign="top"  style="width:4.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#MERRIMACK_PHARMACEUTICALS_INC_CONDENSED"><font style="text-decoration:underline;">Condensed Consolidated Balance Sheets &#8211; June&#160;30, 2017 and December&#160;31, 2016 (unaudited)</font></a></p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17pt;;text-indent:-17pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-24.5pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#MERRIMACK_PHARMACEUTICALS_INC_CONDENSED_"><font style="text-decoration:underline;">Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) &#8211;Three and Six Months Ended June&#160;30, 2017 and 2016 (unaudited)</font></a></p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-24.5pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENTS_CASH_F"><font style="text-decoration:underline;">Condensed Consolidated Statements of Cash Flows &#8211; Six Months Ended June&#160;30, 2017 and 2016 (unaudited)</font></a></p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA"><font style="text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</font></a></p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><font style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</font></a></p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">19</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"><font style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk.</font></a></p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="top"  style="width:47.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_CONTROLS_PROCEDURES"><font style="text-decoration:underline;">Controls and Procedures.</font></a></p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">30</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OTHER INFORMATION</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:8.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1.</p></td>
<td valign="top"  style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_LEGAL_PROCEEDINGS"><font style="text-decoration:underline;">Legal Proceedings.</font></a></p></td>
<td valign="top"  style="width:7.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1A.</p></td>
<td valign="top"  style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><font style="text-decoration:underline;">Risk Factors.</font></a></p></td>
<td valign="top"  style="width:7.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">32</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 6.</p></td>
<td valign="top"  style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_EXHIBITS"><font style="text-decoration:underline;">Exhibits.</font></a></p></td>
<td valign="top"  style="width:7.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">58</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><font style="text-decoration:underline;">Signatures</font></a></p></td>
<td valign="top"  style="width:7.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">59</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:45pt;;text-indent:-45pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#EXHIBIT_INDEX"><font style="text-decoration:underline;">Exhibit Index</font></a></p></td>
<td valign="top"  style="width:7.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">60</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FORWARD-LOOKING STATEMENTS</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our plans to develop and commercialize our clinical stage product candidates and diagnostics;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ongoing and planned discovery programs, preclinical studies and clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing of the completion of our clinical trials and the availability of results from such trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to establish and maintain collaborations for our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our receipt of payments related to the milestone events under the asset purchase and sale agreement with Ipsen S.A or under the license and collaboration agreement between Baxalta Incorporated, Baxalta US Inc., Baxalta GmbH and Ipsen S.A., when expected or at all;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the rate and degree of market acceptance and clinical utility of our products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our intellectual property position;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our commercialization, marketing and manufacturing capabilities and strategy;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the potential advantages of our systems biology approach to drug research and development;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the potential use of our systems biology approach in fields other than oncology; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the outcome of litigation against us; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our estimates regarding expenses, future revenues, capital requirements and needs for additional financing.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q, particularly in Part II, Item 1A. Risk Factors, that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, collaborations or investments that we may make.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE REGARDING TRADEMARKS</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ONIVYDE<sup style="font-size:85%; vertical-align:top">&#174;</sup> is a trademark of Ipsen. Any other trademarks, trade names and service marks referred to in this Quarterly Report on Form&#160;10-Q are the property of their respective owners.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I"></a>PAR</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">T I</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FINANCIAL INFORMATION</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_FINANCIAL_STATEMENTS"></a>Item 1.<font style="margin-left:36pt;"><a name="ITEM_1_FINANCIAL_STATEMENTS"></a>Financi</font>al Statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="MERRIMACK_PHARMACEUTICALS_INC_CONDENSED"></a>Merrimack Pharmaceuticals, Inc.<br /><a name="MERRIMACK_PHARMACEUTICALS_INC_CONDENSED"></a>Condensed Consolidated Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands, except per share amounts)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135,501</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,524</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">275</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,917</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,239</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets held for sale</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,295</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,563</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,435</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,682</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,178</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,212</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets held for sale, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,135</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213,450</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,483</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities, non-controlling interest and stockholders&#8217; equity/(deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable, accrued expenses and other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,989</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,369</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,077</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,014</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued intraperiod tax allocation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,530</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,141</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities held for sale</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,839</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,737</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,222</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,330</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,386</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term debt</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,906</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">216,861</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities held for sale, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,673</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,973</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334,142</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-controlling interest</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,031</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,539</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity/(deficit):</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $0.01 par value: 10,000 shares authorized at June 30, 2017 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2016; no shares issued or outstanding at June 30, 2017 or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2016</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.01 par value: 200,000 shares authorized at June 30, 2017 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2016; 132,741 and 130,197 shares issued and outstanding at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; June 30, 2017 and December 31, 2016, respectively</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,327</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,302</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">578,103</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">702,377</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(472,922</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(954,799</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity/(deficit)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106,508</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(251,120</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities, non-controlling interest and stockholders&#8217; equity/(deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213,450</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,483</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="MERRIMACK_PHARMACEUTICALS_INC_CONDENSED_"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Merrimack Pharmaceuticals, Inc.</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br />Condensed </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="MERRIMACK_PHARMACEUTICALS_INC_CONDENSED_"></a>Consolida</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ted Statements of Operations and Comprehensive Income (Loss)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs and expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,751</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,695</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,356</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,697</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,798</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,138</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,432</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,590</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total costs and expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,549</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,833</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,788</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,287</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from continuing operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,549</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,833</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61,788</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(70,287</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income and expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">382</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">396</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,762</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,858</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,741</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,148</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain on sale of asset</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,703</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,703</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(659</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(661</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(107</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss from continuing operations before income tax benefit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59,885</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,633</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,091</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,348</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,239</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,239</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss from continuing operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,646</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,633</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,852</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,348</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discontinued operations:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income (loss) from discontinued operations, net of tax</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">540,485</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">675</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">539,538</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(268</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">510,839</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,958</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">480,686</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,616</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to non-controlling interest</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(724</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(208</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,191</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(393</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) attributable to Merrimack Pharmaceuticals, Inc.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">511,563</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,750</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">481,877</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,223</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income (loss):</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on available-for-sale securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive income (loss)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">511,563</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,735</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">481,877</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,222</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts attributable to Merrimack Pharmaceuticals, Inc.:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss from continuing operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,922</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,425</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,661</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(88,955</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income (loss) from discontinued operations, net of tax</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">540,485</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">675</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">539,538</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(268</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) attributable to Merrimack Pharmaceuticals, Inc.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">511,563</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,750</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">481,877</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,223</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and dilutive net income (loss) per common share</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss from continuing operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.22</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.41</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.44</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.74</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) from discontinued operations, net of tax</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.08</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.01</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.10</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) per share</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.86</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.40</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.66</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.74</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares used per share calculations&#8212;basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,457</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,161</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,528</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121,112</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash dividend paid per common share</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.055</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.055</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Merrimack Pharmaceuticals, Inc.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONDENSED_CONSOLIDATED_STATEMENTS_CASH_F"></a><a name="CONDENSED_CONSOLIDATED_STATEMENTS_CASH_F"></a>Condensed Consolidated Statements of Cash Flows</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">480,686</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,616</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income (loss) from discontinued operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">539,538</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(268</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from continuing operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,852</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,348</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash interest expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,374</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,505</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on extinguishment of debt</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,887</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,566</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benefit from intraperiod tax allocation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30,239</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,058</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,333</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash activity related to discontinued operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,025</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Gain) loss on sale of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(512</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,529</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,077</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">605</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,141</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable, accrued expenses and other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,494</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,454</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(209</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">579</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in continuing operations for operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,094</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69,898</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in discontinuing operations for operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,416</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,528</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,510</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(104,426</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(287</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,050</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from maturities and sales of available for sale securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds on sale of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,104</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of available for sale securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(84,262</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sale of business</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">575,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60,008</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">515,809</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63,312</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of options to purchase common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,079</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,598</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of Series C preferred stock by Silver Creek Inc., net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,599</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repayment of debt</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(175,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of dividend</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(140,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of Silver Creek convertible promissory notes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,025</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(306,322</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,623</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,977</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(164,115</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents, beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,524</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185,606</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents, end of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135,501</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,491</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Non-cash investing and financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment in accounts payable, accrued expenses and other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">349</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">434</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receivables related to stock option exercises in prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receivables related to property and equipment sale in other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible debt into shares of common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,209</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of cash flows</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for interest</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,872</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Merrimack Pharmaceuticals, Inc.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA"></a><a name="NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA"></a>Notes to Condensed Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of the Business</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Merrimack Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. The Company&#8217;s mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers. All of the Company&#8217;s product candidates, including three in clinical studies and several others in preclinical development, fit into the Company&#8217;s strategy of (1) understanding the biological problems the Company is trying to solve, (2) designing specific solutions and (3) developing those solutions for biomarker-selected patients. This three-pronged strategy seeks to ensure optimal patient outcomes. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 3, 2017,<font style="font-weight:bold;"> </font>the Company completed the previously announced transaction (the &#8220;Asset Sale&#8221;) with Ipsen S.A. (&#8220;Ipsen&#8221;). Pursuant to the Asset Purchase and Sale Agreement, dated as of January&#160;7, 2017 (the &#8220;Asset Sale Agreement&#8221;), between the Company and Ipsen, the Company sold to Ipsen its right, title and interest in the non-cash assets, equipment, inventory, contracts and intellectual property primarily related to or used in the Company&#8217;s business operations and activities involving or relating to developing, manufacturing and commercializing ONIVYDE, the Company&#8217;s first commercial product, and MM-436 (the &#8220;Commercial Business&#8221;). The Company received $575.0 million in cash, subject to a working capital adjustment, and is eligible to receive up to $450.0 million in additional regulatory approval-based milestone payments. The working capital adjustment is currently estimated as a $2.2 million receivable presented in prepaid expenses and other currents assets within the condensed consolidated balance sheets, which is expected to be received in the third quarter of 2017. The Company also retained the right to receive net milestone payments of up to $33.0 million that may become payable pursuant to the license and collaboration agreement with Baxalta Incorporated, Baxalta US Inc. and Baxalta GmbH (collectively, &#8220;Baxalta&#8221;) for the ex-U.S. development and commercialization of ONIVYDE. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s non-commercial assets, including its clinical and preclinical development programs (the &#8220;Pipeline Business&#8221;), were not included in the Asset Sale and remain assets of the Company. As of the closing of the Asset Sale, the Company&#8217;s most advanced programs are as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">MM-121 (seribantumab), a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. The Company is currently conducting the Phase 2 randomized SHERLOC clinical trial evaluating MM-121 in heregulin positive non-small cell lung cancer patients and plans to initiate the Phase 2 randomized SHERBOC clinical trial in 2017 in heregulin positive, hormone receptor positive, ErbB2 (HER2) negative, metastatic breast cancer patients;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">MM-141 (istiratumab), a fully human bispecific tetravalent monoclonal antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1 (&#8220;IGF-1&#8221;) receptor and ErbB3 (HER3) cell surface receptors. The Company is currently conducting the Phase 2 randomized CARRIE clinical trial evaluating MM-141 in previously untreated metastatic pancreatic cancer patients with high levels of free IGF-1 in combination with nab-paclitaxel and gemcitabine; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">MM-310, an antibody-directed nanotherapeutic (&#8220;ADN&#8221;) that contains a novel prodrug of the highly potent chemotherapy docetaxel and targets the ephrin receptor A2 (&#8220;EphA2&#8221;) receptor, which is highly expressed in most solid tumor types. MM-310 was designed to improve the therapeutic window of docetaxel in major oncology indications, such as prostate, ovarian, bladder, gastric, pancreatic and lung cancers. The Company initiated a Phase 1 clinical trial to evaluate safety and preliminary activity of MM-310 in the first quarter of 2017.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to its clinical-stage programs, the Company has several product candidates in preclinical development and a discovery effort advancing additional candidate medicines.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to companies in the biopharmaceutical industry, including, among other things, its ability to secure additional capital to fund operations, success of clinical trials, development by competitors of new technological innovations, dependence on collaborative arrangements, protection of proprietary technology, compliance with government regulations and dependence on key personnel. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of capital, adequate personnel, infrastructure and extensive compliance reporting capabilities.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company w</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ill continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. Until such time, if ever, as the Company can generate sufficient product revenues, the Compan</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y expects to finance its cash needs through a combination of equity offerings, debt financings, collaborations, licensing arrangements and other marketing and distribution arrangements. The Company could also engage in discussions with third parties regard</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ing partnerships, joint ventures, combinations or divestitures of one or more of its businesses as it seeks to further the development of its research programs, improve its cash position and maximize stockholder value.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Basis of Presentation and Consolidation</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements as of June&#160;30, 2017 and December&#160;31, 2016, and for the three and six months ended June&#160;30, 2017 and 2016, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) and generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) for condensed consolidated financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, these condensed consolidated financial statements reflect all adjustments which are necessary for a fair statement of the Company&#8217;s financial position and results of its operations, as of and for the periods presented. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2016 filed with the SEC on March 1, 2017.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information presented in the condensed consolidated financial statements and related notes as of June&#160;30, 2017, and for the three and six months ended June&#160;30, 2017 and 2016, is unaudited. The December&#160;31, 2016 condensed consolidated balance sheets included herein were derived from the audited financial statements as of that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interim results for the three and six months ended June&#160;30, 2017 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2017, or any future period.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2017, the Commercial Business met all the conditions to be classified as a discontinued operation since the disposal of the Commercial Business represented a strategic shift that will have a major effect on the Company&#8217;s operations and financial results. The Company will not have further significant involvement in the operations of the discontinued Commercial Business. The operating results of the Commercial Business are reported as a loss from discontinued operations, net of tax in the condensed consolidated statements of operations and comprehensive income (loss) for all periods presented. The gain recognized on the sale of the Commercial Business is presented in income (loss) from discontinued operations, net of tax in the consolidated statement of operations and comprehensive income (loss). In addition, in the condensed consolidated balance sheets as of December 31, 2016, the assets and liabilities held for sale have been presented separately. For additional information, see Note 3, &#8220;Sale of Commercial Business.&#8221;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These condensed consolidated financial statements include the accounts of the Company and Silver Creek Pharmaceuticals, Inc. (&#8220;Silver Creek&#8221;), representing a variable interest entity that the Company is required to consolidate. All intercompany transactions and balances have been eliminated in consolidation.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2017, the Company&#8217;s unrestricted cash and cash equivalents includes $2.6 million of cash and cash equivalents held by Silver Creek. This $2.6 million held by Silver Creek is designated for the operations of Silver Creek.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the first quarter of 2017, Silver Creek entered into a Series C preferred stock financing, issuing 1.4 million shares of Series C preferred stock at $1.50 per share for proceeds of $2.0 million. In conjunction with this sale in the first quarter of 2017, Silver Creek also issued warrants to purchase 1.8 million shares of Silver Creek Series C preferred stock to investors. In the second quarter of 2017, Silver Creek issued 0.4 million shares of Series C preferred stock at $1.50 per share for proceeds of $0.6 million. In conjunction with this sale in the second quarter of 2017, Silver Creek issued warrants to purchase 0.3 million shares of Silver Creek Series C preferred stock to investors. In June 2017, Silver Creek amended the warrant purchase agreements to increase the number of shares for which each warrant is redeemable. The incremental increase in the number of shares the warrants may be redeemed for as a result of the amendment was 1.3 million shares. As of June 30, 2017, the Company held a 51% ownership interest in Silver Creek and maintained control over the Silver Creek Board of Directors through its voting rights. As such, the Company remains the primary beneficiary of Silver Creek.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The change in the non-controlling interest related to Silver Creek was as follows:</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Controlling</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2016</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,539</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to Silver Creek</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,191</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Silver Creek Series C preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">699</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at June&#160;30, 2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,031</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Controlling</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2015</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">239</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to Silver Creek</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(393</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at June&#160;30, 2016</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(154</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Sale of Commercial Business</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ipsen</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April&#160;3, 2017, the Company completed the sale of the Commercial Business to Ipsen. Pursuant to the Asset Sale Agreement, the Company may be entitled to up to $450.0 million in additional payments based on the achievement by or on behalf of Ipsen of certain milestone events if the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) approves ONIVYDE for certain indications as follows: (i) $225.0 million upon the regulatory approval by the FDA of ONIVYDE for the first-line treatment of metastatic adenocarcinoma of the pancreas (a)&#160;in combination with fluorouracil and leucovorin (with or without oxaliplatin), (b)&#160;in combination with gemcitabine and abraxane or (c)&#160;following submission and filing of regulatory approval by Ipsen for purposes of commercialization by Ipsen; (ii) $150.0 million upon the regulatory approval by the FDA of ONIVYDE for the treatment of small cell lung cancer after failure of first-line chemotherapy; and (iii) $75.0 million upon the regulatory approval by the FDA of ONIVYDE for an additional indication unrelated to those described above.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the sale of the Commercial Business, on April 3, 2017, the Company entered into a transition services agreement<font style="font-weight:bold;"> </font>with Ipsen pursuant to which the Company and Ipsen are providing certain services to each other for a period of 24 months following the closing, including Ipsen&#8217;s agreement to manufacture MM-310 and to perform certain quality related services in accordance with a manufacturing services agreement, the accounting impact of which is immaterial.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the completion of the Asset Sale, on April 3, 2017, the Company irrevocably deposited the redemption price of the 11.50% senior secured notes due 2022 (the &#8220;2022 Notes&#8221;) of $175.0 million outstanding aggregate principal amount, interest of $7.4 million through the redemption date and an additional make-whole premium payment of approximately $20.1 million with U.S. Bank National Association as trustee (the &#8220;Trustee&#8221;) under the Indenture dated as of December 22, 2015 (the &#8220;Indenture&#8221;) and irrevocably instructed the Trustee to apply such amount to the redemption in full of the 2022 Notes on the redemption date of April 27, 2017. The Indenture was satisfied and discharged on April 3, 2017.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the completion of the Asset Sale, on April 3, 2017, the Company entered into a sublease with Ipsen, pursuant to which Ipsen is subleasing from the Company approximately 70,237 square feet of leased space in the Company&#8217;s Cambridge, Massachusetts facility through the end of the term of the lease on June 30, 2019. Payments under the sublease are recorded as an offset to rent expense in the condensed consolidated statement of operations and comprehensive income (loss).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also in connection with the completion of the Asset Sale, on April 3, 2017, the Company entered into an intellectual property license agreement with Ipsen, pursuant to which Ipsen granted to the Company a perpetual, worldwide, non-exclusive, royalty-free, fully paid-up license in and to all patents included in the transferred intellectual property, other than certain patents relating to generic liposomal technology, with respect to which the license will be exclusive, in each case for use outside of the Commercial Business. The Company granted to Ipsen a non-exclusive, royalty-free, fully paid up, perpetual, irrevocable and worldwide license to all patents it owned at the time of the closing of the transaction contemplated by the Asset Sale Agreement for use in connection with the Commercial Business. This transfer of intellectual property did not impact the financial statements as no amounts related to the intellectual property had previously been recorded.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 5, 2017, the Company announced that its Board of Directors authorized and declared a special cash dividend of $140.0 million on the Company's common stock. The special dividend was payable on May 26, 2017 to stockholders of record as of the close of business on May 17, 2017. The special dividend resulted in a decrease to additional paid-in capital.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Discontinued Operations and Assets Held for Sale</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements for the three and six months ended June 30, 2017 and 2016 reflect the operations of the Commercial Business as a discontinued operation. The Company recorded a gain of approximately $598.2 million on the Asset Sale, which is included in gain from discontinued operations on the condensed consolidated statements of operations and comprehensive income (loss).&#160;Discontinued operations for the three and six months ended June 30, 2017 and 2016 includes the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenues, net</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,851</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,135</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,819</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration revenues</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,332</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,797</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,645</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other revenues</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,498</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,973</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,498</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,681</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,905</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,962</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs and expenses:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,872</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,890</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,583</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,302</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,700</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,181</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,542</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,709</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,885</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restructuring expenses</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,216</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,535</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total costs and expenses</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,216</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,716</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,834</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,649</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income and expenses:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,509</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,290</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,743</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,581</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain on sale of commercial business</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">598,120</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">598,120</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income (loss) from discontinued operations</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">592,395</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">675</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">591,448</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(268</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,910</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,910</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total income (loss) from discontinued operations</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">540,485</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">675</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">539,538</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(268</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying value of the assets and liabilities of the Commercial Business classified as &#8220;Discontinued operations&#8221; in the condensed consolidated balance sheets is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,194</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,554</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,547</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets held for sale</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,295</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,553</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,977</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,605</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total long-term assets held for sale</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,135</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable, accrued expenses and other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,613</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenues</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,226</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities held for sale</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,839</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenues, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,673</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities held for sale</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,673</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:8pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory of the Commercial Business as of December 31, 2016 consisted of the following:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,483</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work in process</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,651</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,420</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventory</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,554</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Restructuring Activities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 8, 2017, the Company announced a reduction in headcount by approximately 30% in connection with the Asset Sale and the completion of its strategic pipeline review. Upon the closing of the Asset Sale and the completion of its strategic pipeline review, the Company had approximately 80 employees. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under this corporate restructuring, for the three and six months ended June 30, 2017, the Company recognized total restructuring expenses of $4.2 million and $9.5 million, respectively, which was related to contractual termination benefits for employees with pre-existing severance arrangements. These one-time employee termination benefits are comprised of severance, benefits and related costs, all of which are expected to result in cash expenditures. The majority of these payments were made during the second quarter of 2017. The remaining payments represent severance payments that will be paid over one year. The expense of $9.5 million was included in discontinued operations, as the costs are directly associated with the sale of the Commercial Business.</p>
<p style="margin-bottom:6pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the charges related to the restructuring activities as of June 30, 2017:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accrued Restructuring Expenses at December&#160;31, 2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less: Payments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accrued Restructuring Expenses at June&#160;30, 2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Severance, benefits and related costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,521</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,124</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,397</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,521</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,124</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,397</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These amounts are included in accounts payable, accrued expenses and other in the June 30, 2017 balance sheet.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">License and Collaboration Agreements Related to the Asset Sale</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Baxalta</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 23, 2014, the Company and Baxter International Inc., Baxter Healthcare Corporation and Baxter Healthcare SA entered into a license and collaboration agreement (the &#8220;Baxalta Agreement&#8221;) for the development and commercialization of ONIVYDE outside of the United States and Taiwan (the &#8220;Licensed Territory&#8221;). In connection with Baxter International Inc.&#8217;s separation of the Baxalta business, the Baxalta Agreement was assigned to Baxalta during the second quarter of 2015. As part of the Baxalta Agreement, the Company granted Baxalta an exclusive, royalty-bearing right and license under the Company&#8217;s patent rights and know-how to develop and commercialize ONIVYDE in the Licensed Territory.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 3, 2017, the Baxalta Agreement and all related agreements, including the Company&#8217;s agreement related to the commercial supply of ONIVYDE, were assigned to Ipsen in connection with the Asset Sale. Pursuant to the Asset Sale Agreement, the Company retained the right to receive net milestone payments of up to $33.0 million that may become payable pursuant to the Baxalta Agreement for the ex-U.S. development and commercialization of ONIVYDE, which is comprised of potential payments of $18.0 million from the sale of ONIVYDE in two additional major European countries, $5.0 million related to the sale of ONIVYDE in the first major non-European, non-Asian country and $10.0 million for the first patient dosed in a pivotal clinical trial in an indication other than pancreatic cancer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PharmaEngine, Inc.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 5, 2011, the Company and PharmaEngine, Inc. (&#8220;PharmaEngine&#8221;) entered into an assignment, sublicense and collaboration agreement (the &#8220;PharmaEngine Agreement&#8221;) under which the Company reacquired rights in Europe and certain countries in Asia to ONIVYDE. In exchange, the Company agreed to pay PharmaEngine a nonrefundable, noncreditable upfront </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payment of $10.0 million and up to an additional $80.0 million in aggregate development and regulatory milestones and $130.0 million in aggregate sales milestone</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 3, 2017, the PharmaEngine Agreement and all related agreements, including the Company&#8217;s agreement related to its commercial supply of ONIVYDE, were assigned to Ipsen in connection with the Asset Sale.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Going Concern</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 205-40, <font style="font-style:italic;">Going Concern</font>, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2016, the Company had $21.5 million in unrestricted cash and cash equivalents, had suffered recurring losses from operations and had negative working capital and cash outflows from operating activities. Based on the evaluation completed in connection with the filing of the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2016, including consideration of management&#8217;s plans, the Company previously concluded that there was substantial doubt as to its ability to continue as a going concern within one year after March 1, 2017, the date that the consolidated financial statements were issued.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 3, 2017, the Company closed the Asset Sale with Ipsen and received a $575.0 million upfront cash payment, subject to a working capital adjustment. The working capital adjustment is currently estimated as a $2.2 million receivable expected to be received in the third quarter of 2017. The Company used a portion of the cash payment to redeem the $175.0 million outstanding aggregate principal amount of the 2022 Notes, which also required an additional make-whole premium payment of approximately $20.1 million, and deposited $60.0 million into an escrow account in response to a lawsuit filed by the trustee and certain holders of its 4.50% convertible notes due 2020 (the &#8220;Convertible Notes&#8221;). The Company distributed $140.0 million of the upfront cash payment in the form of a special cash dividend to stockholders, which was payable on May 26, 2017 to stockholders of record as of the close of business on May 17, 2017. After consideration of the Company&#8217;s cash and cash equivalents balance at March 31, 2017 of $17.2 million and the net proceeds from the Asset Sale, the Company has concluded that the previous conditions and events that raised substantial doubt about its ability to continue as a going concern have been alleviated. The Company updated its going concern assessment for the three months ended June 30, 2017 and concluded the Company is able to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Income Taxes</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets and liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using future enacted tax rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company completed the Asset Sale and recorded the income tax implications of the sale in the second quarter of 2017. The Asset Sale generated taxable income for the Company which has resulted in income tax expense.&#160; The Company released a portion of its valuation allowance in the three months ended June 30, 2017 as it is now able to utilize its net operating loss carryforwards to offset the taxable income generated from the Asset Sale. The Company&#8217;s current income tax expense for the six months ended June 30, 2017 is $8.1 million, which is comprised primarily of federal Alternative Minimum Tax and state income tax. </p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intraperiod tax allocation rules require the Company to allocate the provision for income taxes between continuing operations and other categories of earnings, such as discontinued operations. In periods in which there is pre-tax loss from continuing operations and pre-tax income in other categories of earnings, such as discontinued operations, the Company must allocate to continuing operations a tax benefit for the loss in continuing operations with an offsetting tax expense to discontinued operations.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three and six months ended June 30, 2017, the Company recognized an income tax benefit of $30.2 million in continuing operations and income tax expense in discontinued operations of $51.9 million related to the income generated in connection with the Asset Sale. As of June 30, 2017, the Company recorded an accrued income tax provision of $13.5 million. </p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Asset Sale, the Company recorded an income tax provision in discontinued operations of $223.3 million prior to the release of the valuation allowance. The Company released $171.4 million of its valuation allowance in discontinued operations during the three months ended June 30, 2017, resulting in a total income tax expense of $51.9 million in discontinued operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">. Net Income (Loss) Per Common Share</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net income (loss) per share is calculated by dividing the net income (loss) attributable to Merrimack Pharmaceuticals, Inc, by the weighted-average number of common shares outstanding during the period. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to Merrimack Pharmaceuticals, Inc. by the weighted-average number of dilutive common shares outstanding during the period. Dilutive shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options based on the treasury stock method. In a period when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods where a loss is reported, there is no difference in basic and dilutive loss per share. .</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows the two-class method when computing net income (loss) per share, when it has issued shares that meet the definition participating securities. The two&#8211;class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participating rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based on their respective rights to receive dividends, as if all income for the period has been distributed or losses to be allocated if they are contractually required to fund losses. There were no amounts allocated to participating securities for the three and six months ended June 30, 2017 and 2016, as the Company was in a loss position and had no shares that met the definition of participating securities outstanding as of June 30, 2017 and 2016. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as discussed in Note 10, &#8220;Borrowings,&#8221; in July 2013, the Company issued $125.0 million aggregate principal amount of Convertible Notes in an underwritten public offering. Following the repayment and satisfaction in full of the Company&#8217;s obligations to Hercules Technology Growth Capital, Inc. (&#8220;Hercules&#8221;) under its Loan and Security Agreement with Hercules (the &#8220;Loan Agreement&#8221;), which occurred in December 2015, upon any conversion of the Convertible Notes, the Convertible Notes may be settled, at the Company&#8217;s election, in cash, shares of the Company&#8217;s common stock or a combination of cash and shares of the Company&#8217;s common stock. For purposes of calculating the maximum dilutive impact, it is presumed that the conversion premium will be settled in common stock, inclusive of a contractual make-whole provision resulting from a fundamental change, and the resulting potential common shares included in diluted earnings per share if the effect is more dilutive. As of June&#160;30, 2017, $60.8 million aggregate principal amount of the Convertible Notes remained outstanding.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The stock options and conversion premium on the Convertible Notes are excluded from the calculation of diluted loss per share because the net loss for the three and six months ended June&#160;30, 2016 causes such securities to be anti-dilutive. Outstanding securities excluded from the calculation of diluted loss per share for the three and six months ended June&#160;30, 2017 and 2016 are shown in the chart below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding options to purchase common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,915</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,647</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,915</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,647</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of the Convertible Notes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,158</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,158</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,158</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,158</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. Fair Value of Financial Instruments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is determined based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect certain market assumptions. As a basis for considering such assumptions, GAAP establishes a three-tier value hierarchy, which prioritizes the inputs used to develop the assumptions and for measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets for identical assets; (Level 2) inputs other than the quoted prices in active markets that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recurring Fair Value Measurements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of cash, restricted cash, prepaid expenses, accounts receivable, accounts payable and accrued expenses, and other short-term assets and liabilities approximate their respective fair values due to the short-term maturities of these assets and liabilities.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables show assets measured at fair valu</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e on a recurring basis as of June&#160;30, 2017 and December&#160;31, 2016:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,931</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,931</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Silver Creek warrant liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,062</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,062</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,373</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,373</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Silver Creek warrant liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,499</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,499</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, Silver Creek issued warrants to purchase an aggregate of 1.9 million shares of Silver Creek Series C preferred stock (the &#8220;Silver Creek warrants&#8221;). During the first quarter of 2017, Silver Creek issued additional Silver Creek warrants to purchase an aggregate of 1.8 million shares of Silver Creek Series C preferred stock. During the second quarter of 2017, Silver Creek issued additional Silver Creek warrants to purchase an aggregate of 0.3 million shares of Silver Creek Series C preferred stock. <font style="color:#000000;">In June 2017, Silver Creek amended the outstanding warrant purchase agreements to increase the number of shares for which each warrant is redeemable. </font>The Silver Creek warrants were valued at $4.1 million and $1.5 million as of June 30, 2017 and December 31, 2016, respectively, using a Black-Scholes option pricing model, probability-weighted for different exercise scenarios. The key assumptions utilized in the Black-Scholes option pricing model as of June 30, 2017 were a risk-free interest rate of 2.1%, expected dividend yield of 0.0%, expected volatility of 60.4% and expected term of 6.4 years &#8211; 7.0 years. The key assumptions utilized in the Black-Scholes option pricing model as of December 31, 2016 were a risk-free interest rate of 2.3%, expected dividend yield of 0.0%, expected volatility of 61.7% and expected term of 6.9 years. Changes in the fair value of the Silver Creek warrants are recognized as a component of &#8220;other income and expenses&#8221; in the condensed consolidated statements of operations and comprehensive income (loss). The change in fair value for both the three and six months ended June&#160;30, 2017 was $1.0 million, inclusive of $0.8 million incremental change resulting from the amendment to the warrant purchase agreements, and is recorded in other income (expense) on the statement of operations and comprehensive loss.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no changes in valuation techniques or transfers between the fair value measurement levels during the three or six months ended June&#160;30, 2017 or during the year ended December&#160;31, 2016. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Fair Value Measurements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated fair value of the Convertible Notes was $36.7 million as of June&#160;30, 2017. The Company estimated the fair value of the Convertible Notes by using a quoted market rate in an inactive market, which is classified as a Level 2 input. The carrying value of the Convertible Notes was $48.9 million as of June&#160;30, 2017 due to the bifurcation of the conversion feature of the Convertible Notes as described more fully in Note 10, &#8220;Borrowings.&#8221;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed in Note 10, &#8220;Borrowings,&#8221; in December 2015, the Company closed a private placement of $175.0 million aggregate principal amount of 2022 Notes. The Company estimated the fair value of the 2022 Notes by using publicly-available information related to one of the 2022 Notes borrower&#8217;s portfolio of debt investments based on unobservable inputs, which is classified as a Level 3 input. In connection with the completion of the Asset Sale, on April 3, 2017, the liability under the 2022 Notes was satisfied. The Company incurred a loss on extinguishment of $25.0 million as a result of the early repayment of the 2022 Notes, which is included in interest expense on the statement of operations. For additional information, see Note 3, &#8220;Sale of Commercial Business.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8. Marketable Securities</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of both June 30, 2017 and December 31, 2016, the Company maintained only cash equivalents comprised of money market funds. As of June 30, 2017, the Company did not hold any securities that were in an unrealized loss position. There were no realized gains or losses on available-for-sale securities for the three or six months ended June 30, 2017 or 2016.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. Accounts Payable, Accrued Expenses and Other</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable, accrued expenses and other as of June&#160;30, 2017 and December&#160;31, 2016 consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,298</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,692</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued goods and services</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,467</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,233</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,382</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,776</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued drug purchase costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">480</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and related benefits</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,362</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,394</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued severance expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,736</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">774</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,261</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,100</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued dividends payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Silver Creek warrant liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,062</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,499</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax incentives</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,402</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,402</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accounts payable, accrued expenses and other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,989</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,369</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10. Borrowings</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2022 Notes</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 22, 2015, the Company closed a private placement of $175.0 million aggregate principal amount of 2022 Notes. As a result of this placement, the Company received net proceeds of approximately $168.5 million, after deducting private placement and offering expenses payable by the Company. In connection with the completion of the Asset Sale on April 3, 2017, the liability under the 2022 Notes was satisfied. For additional information, see Note 3, &#8220;Sale of Commercial Business.&#8221; The 2022 Notes bore interest at a rate of 11.50% per year, payable semi-annually on June 15 and December 15 of each year, beginning on June 15, 2016.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2022 Notes contained customary covenants, including covenants that limited or restricted the Company&#8217;s ability to incur liens, incur indebtedness and make certain restricted payments, but did not contain covenants related to future financial performance. The 2022 Notes were secured by a first priority lien on substantially all of the Company&#8217;s assets.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assessed the 2022 Notes pursuant to ASC 815, <font style="font-style:italic;">Derivatives and Hedging</font>, to determine if any features necessitated bifurcation from the host instrument. The Company concluded that none of the embedded redemption features within the 2022 Notes required bifurcation, as these features were clearly and closely related to the host instrument.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt issuance costs incurred by the Company are accounted for as a direct deduction to the carrying value of the 2022 Notes and are amortized to interest expense using the effective interest method over the life of the 2022 Notes. In connection with the completion of the Asset Sale, on April 3, 2017, the Company voluntarily settled the principle liability of the 2022 Notes. As a result of the early repayment, for the three and six months ended June 30, 2017 a loss on extinguishment of $25.0 million was incurred As a result of the early repayment, a loss on extinguishment of $25.0 million was recognized in interest expense in the condensed consolidated statement of operations and comprehensive income (loss) for the three and six months ended June 30, 2017. The $25.0 million loss on extinguishment included a $20.1 million prepayment penalty and $4.9 million of amortization expense recognized for the remaining debt discount at settlement as a result of the early repayment, which is included in interest expense on the statement of operations. For the three and six months ended June&#160;30, 2017, interest expense related to the 2022 Notes was $1.5 million and $6.7 million, respectively. For the three and six months ended June&#160;30, 2016, interest expense related to the 2022 Notes was $5.2 million and $10.4 million, respectively. These amounts are included in discontinued operations.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Convertible Notes</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2013, the Company issued $125.0 million aggregate principal amount of Convertible Notes in an underwritten public offering. As a result of the Convertible Notes offering, the Company received net proceeds of approximately $120.6 million, after deducting underwriting discounts and commissions and offering expenses payable by the Company.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Convertible Notes bear interest at a rate of 4.50% per year, payable semiannually in arrears on January 15 and July 15 of each year, beginning on January 15, 2014. The Convertible Notes are general unsecure</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d senior obligations of the Company and rank (i) senior in right of payment to any of the Company&#8217;s indebtedness that is expressly subordinated in right of payment to the Convertible Notes, (ii) equal in right of payment to any of the Company&#8217;s unsecured i</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ndebtedness that is not so subordinated, (iii) effectively junior in right of payment to any of the Company&#8217;s secured indebtedness to the extent of the value of the assets securing such indebtedness and (iv) structurally junior to all indebtedness and othe</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r liabilities (including trade payables) of the Company&#8217;s subsidiaries.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company separately accounted for the liability and equity components of the Convertible Notes by bifurcating gross proceeds between the indebtedness, or liability component, and the embedded conversion option, or equity component. This bifurcation was done by estimating an effective interest rate as of the date of issuance for similar notes which do not contain an embedded conversion option. The gross proceeds received from the issuance of the Convertible Notes less the initial amount allocated to the indebtedness resulted in a $53.8 million allocation to the embedded conversion option. The embedded conversion option was recorded in stockholders&#8217; deficit and as debt discount, to be subsequently amortized as interest expense over the term of the Convertible Notes. Underwriting discounts and commissions and offering expenses totaled $4.4 million and were allocated to the indebtedness and the embedded conversion option based on their relative values.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 13, 2016, the Company entered into separate, privately-negotiated conversion agreements (the &#8220;Conversion Agreements&#8221;) with certain holders of the Convertible Notes. Under the Conversion Agreements, such holders agreed to convert an aggregate principal amount of $64.2 million of Convertible Notes held by them. The Company initially settled each $1,000 principal amount of Convertible Notes surrendered for conversion by delivering 136 shares of the Company&#8217;s common stock on April 18, 2016. In total, the Company issued an aggregate of 8,732,152 shares of its common stock on this initial closing date. In addition, pursuant to the Conversion Agreements, at the additional closings (as defined in the Conversion Agreements), the Company issued an aggregate of 3,635,511 shares of the Company&#8217;s common stock representing an aggregate of $27.7 million as additional payments in respect of the conversion of the Convertible Notes. The number of additional shares was determined based on the daily VWAP (as defined in the Conversion Agreements) of the Company&#8217;s common stock for each of the trading days in the 10-day trading period following the date of the Conversion Agreements. The issuance of 12,367,663 total shares of the Company&#8217;s common stock pursuant to the Conversion Agreements resulted in an increase to common stock and additional paid-in capital of $101.0 million.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the conversion, the Company recognized an overall loss on extinguishment of $14.6 million representing the difference between the total settlement consideration transferred to the holders that was attributed to the liability component of the Convertible Notes, based on the fair value of that component at the time of conversion, and the net carrying value of the liability. The loss on extinguishment was recorded as interest expense during the second quarter of 2016. The remaining settlement consideration transferred was allocated to the reacquisition of the embedded conversion option and recognized as a $39.8 million reduction of additional paid-in capital. Transaction costs incurred with third parties related to the conversion were allocated to the liability and equity components and resulted in an additional $0.2 million of interest expense and a $0.2 million reduction of additional paid-in capital.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The outstanding Convertible Notes will mature on July 15, 2020 (the &#8220;Maturity Date&#8221;), unless earlier repurchased by the Company or converted at the option of holders. Holders may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding April 15, 2020 only under the following circumstances:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">during any calendar quarter commencing after September 30, 2013 (and only during such calendar quarter), if the last reported sale price of the Company&#8217;s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">during the five business day period after any five consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price (as defined in the Convertible Notes) per $1,000 principal amount of Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate on each such trading day; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">upon the occurrence of specified corporate events set forth in the indenture governing the Convertible Notes.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On or after April 15, 2020 until the close of business on the business day immediately preceding the Maturity Date, holders may convert their Convertible Notes at any time, regardless of the foregoing circumstances.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the repayment and satisfaction in full of the Company&#8217;s obligations to Hercules under the Loan Agreement, which occurred in December 2015, upon any conversion of the Convertible Notes, the Convertible Notes may be settled, at the Company&#8217;s election, in cash, shares of the Company&#8217;s common stock or a combination of cash and shares of the Company&#8217;s common stock.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial conversion rate of the Convertible Notes was 160.0000 shares of the Company&#8217;s common stoc</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">k per $1,000 principal amount of Convertible Notes, which is equivalent to an initial conversion price of $6.25 per share of common stock. As a result of the special dividend that was payable </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on May 26, 2017 to stockholders of record as of the close of bus</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iness on May 17, 2017</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the conversion rate of the Convertible Notes was adjusted from 160.0000 shares of the Company&#8217;s common stock per $1,000 principal amount of Convertible Notes to 235.2112 shares of the Company&#8217;s common stock per $1,000 principal amoun</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t of Convertible Notes. The conversion rate will be subject to further adjustment in some events, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the Maturity Date, the Compa</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ny will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with a lawsuit filed by the trustee and certain holders of the Convertible Notes in the Court of Chancery in the State of Delaware, captioned <font style="font-style:italic;">Wells Fargo Bank, National Association, Wolverine Flagship Fund Trading Limited, Highbridge International LLC, and Highbridge Tactical Credit&#160;&amp; Convertibles Master Fund, L.P. v. Merrimack Pharmaceuticals, Inc. </font>(the &#8220;Delaware Action&#8221;), the Company deposited $60.0 million in proceeds from the Asset Sale into an escrow account. The funds will remain in escrow for the duration of the Delaware Action in order to provide security to the plaintiffs for their claims in the Delaware Action. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three and six months ended June&#160;30, 2017, interest expense related to the Convertible Notes was $1.7 million and $3.3 million, respectively. For the three and six months ended June&#160;30, 2016, interest expense related to the Convertible Notes was $1.9 million and $5.3 million, respectively. The year-over-year decrease was primarily attributable to interest expense related to a reduction in the principal based on the conversion of some of the Convertible Notes that occurred in April 2016.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Future Minimum Payments under Outstanding Borrowings</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum payments under outstanding borrowings as of June&#160;30, 2017 are as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remainder of 2017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,368</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,736</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,736</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020 and thereafter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,527</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,367</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,576</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less unamortized discount</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,885</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term debt</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,906</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11. Stock-Based Compensation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2015, there were 2.5 million shares of common stock available to be granted under the Company&#8217;s 2011 Stock Incentive Plan (the &#8220;2011 Plan&#8221;). The 2011 Plan is administered by the Company&#8217;s board of directors and permits the Company to grant incentive and non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, 4.1 million additional shares of common stock became available for grant to employees, officers, directors and consultants under the 2011 Plan. At June&#160;30, 2017, there were 2.3 million shares remaining available for grant under the 2011 Plan. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During both the three and six months ended June&#160;30, 2017, the Company issued options to purchase 19.4 million shares of common stock. During the six months ended June&#160;30, 2016 the Company issued options to purchase 3.8 million shares of common stock. These options generally vest over a three-year period for employees. Options granted to directors vest immediately.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described in Note 3, &#8220;Sale of Commercial Business,&#8221; the Board of Directors authorized and declared a special cash dividend of $140.0 million on the Company's common stock, which was payable on May 26, 2017 to stockholders of record as of the close of business on May 17, 2017. The Board of Directors determined, in accordance with the adjustment provision of each of the Company&#8217;s 1999 Stock Option Plan, as amended, the 2008 Stock Incentive Plan, as amended, and the 2011 Plan (collectively, the &#8220;Equity Plans&#8221;), that the special cash dividend was unusual and non-recurring and that appropriate adjustment to the stock options to purchase shares of the Corporation&#8217;s common stock outstanding under the Equity Plans was required. The Company treated this adjustment as a modification to the original stock option grant because the terms of the agreements were modified in order to preserve the value of the </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">option awards after a large non-recurring cash dividend. The calcu</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lation of the incremental compensation expense is based on the excess of the fair value of the award measured immediately before and after the modification. As a result, the Company recognized an incremental compensation expense of $5.6 million associated </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with the modification in the second quarter of 2017.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of stock options granted to employees during the three and six months ended June&#160;30, 2017 and 2016 was estimated at the date of grant using the following assumptions:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7 &#8211; 2.0%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1 &#8211; 1.5%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7 &#8211; 2.1%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5 &#8211; 1.8%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7 &#8211; 6.1 years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0 &#8211; 5.8 years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7 &#8211; 6.1 years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0 &#8211; 5.9 years</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67 &#8211; 69%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65 &#8211; 68%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66 &#8211; 67%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the simplified method to calculate the expected term, as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. The computation of expected volatility is based on the historical volatility of comparable companies from a representative peer group selected based on industry and market capitalization. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected life of the stock options. Management estimates expected forfeitures based on historical experience and recognizes compensation costs only for those equity awards expected to vest.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-09, &#8220;Compensation &#8211; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,&#8221; which simplifies several areas of accounting for share-based payment transactions, including the income tax consequences, classification of awards as either liabilities or equity and classification of excess tax benefits on the statement of cash flows. This guidance also permits a new entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures when they occur. The Company adopted the guidance, electing to account for forfeitures when they occur, and it did not have an impact on the consolidated financial statements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized stock-based compensation expense during the three and six months ended June&#160;30, 2017 and 2016 as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee awards:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,916</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,465</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,383</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,991</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,818</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,102</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,146</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,086</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,734</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,567</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,529</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,077</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity during the six months ended June&#160;30, 2017:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise&#160;Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December&#160;31, 2016</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,024</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.77</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.97</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,564</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,388</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.46</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,562</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.29</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,935</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.24</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.74%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at June&#160;30, 2017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,915</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.43</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.87</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.74%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at June&#160;30, 2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,870</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.43</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.86</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at June&#160;30, 2017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,560</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.81</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.98</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value per share of stock options granted during the three and six months ended June&#160;30, 2017 was $0.38 and $0.38, respectively. The weighted-average grant date fair value per share of stock options granted during the three and six months ended June&#160;30, 2016 was $3.73 and $3.35, respectively.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value is calculated as the difference between the exercise price of the stock options and the fair value of the underlyi</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ng common stock. The aggregate intrinsic value of stock options exercised during the three and six months ended June&#160;30, 2017 was $0.9 million and $2.3 million, respectively. The aggregate intrinsic value of stock options exercised during the three and six</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> months ended June&#160;30, 2016 was $0.6 million and $2.7 million, respectively.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2017, there was $6.1 million of total unrecognized stock-based compensation expense related to unvested employee stock awards. The Company expects to recognize this expense over a weighted-average period of approximately 2.9 years.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12. Recent Accounting Pronouncements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the FASB issued ASU 2014-09, &#8220;Revenue from Contracts with Customers (Topic 606),&#8221; which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. This guidance was originally effective for interim and annual periods beginning after December 15, 2016 and allows for adoption using a full retrospective method, or a modified retrospective method. Early adoption was originally not permitted. Subsequent to the issuance of ASU 2014-09, the FASB also issued the following updates related to ASC 606, <font style="font-style:italic;">Revenue from Contracts with Customers</font>:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">In August 2015, the FASB issued ASU 2015-14, &#8220;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,&#8221; whereby the effective date for the new revenue standard was deferred by one year. As a result of ASU 2015-14, the new revenue standard is now effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, and early adoption is now permitted for annual periods beginning after December 15, 2016, including interim periods within that annual period.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">In March 2016, the FASB issued ASU 2016-08, &#8220;Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net),&#8221; to clarify the implementation guidance on principal versus agent considerations.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">In April 2016, the FASB issued ASU 2016-10, &#8220;Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,&#8221; to clarify the principle for determining whether a good or service is &#8220;separately identifiable&#8221; from other promises in the contract and to clarify the categorization of licenses of intellectual property.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">In May 2016, the FASB issued ASU 2016-12, &#8220;Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Technical Expedients,&#8221; to clarify guidance on transition, determining collectability, non-cash consideration and the presentation of sales and other similar taxes.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not currently have any revenue generating contracts with customers due to the sale of its commercial business in the second quarter of 2017. The Company expects to adopt the new revenue standard on January 1, 2018 using the modified retrospective approach.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2016, the FASB issued ASU 2016-01, &#8220;Financial Instruments &#8211; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities,&#8221; which contains a number of provisions related to the measurement, presentation and disclosure of financial instruments. This guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within those annual periods. Early adoption of this guidance is not permitted with the exception of certain specific presentation requirements that are not currently applicable to the Company. The Company does not anticipate a material impact to the consolidated financial statements as a result of the adoption of this guidance.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU 2016-02, &#8220;Leases (Topic 842),&#8221; which supersedes all existing lease accounting guidance within ASC 840, <font style="font-style:italic;">Leases</font>. The new standard requires that lease assets and lease liabilities be recognized by lessees for those leases previously classified as operating leases under ASC 840, with limited exceptions. This update also creates a new definition of a lease and provides guidance as to whether a contract is or contains a lease. This guidance will be effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual reporting periods, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the consolidated financial statements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13, &#8220;Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&#8221; which represents a new credit loss standard that will change the impairment model for most financial assets and certain other financial instruments. Specifically, this guidance will require entities to utilize a new &#8220;expected loss&#8221; model as it relates to trade and other receivables. In addition, entities will be required to recognize an allowance for estimated credit losses on available-for-sale debt securities, regardless of the length of time that a security has been in an unrealized loss position. This </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">guidance will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and ea</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rly adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the consolidated financial statements.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2016, the FASB issued ASU 2016-15, &#8220;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,&#8221; which is intended to reduce diversity in practice in how entities present certain types of cash transactions in the statement of cash flows. This guidance also clarifies how the predominance principle should be applied when classifying cash receipts and cash payments that have attributes of more than one class of cash flows. This guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within those annual reporting periods, and early adoption is permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company does not anticipate a material impact to the consolidated financial statements as a result of the adoption of this guidance.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, the FASB issued ASU 2017-09, &#8220;Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting,&#8221; which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard should be applied prospectively to awards modified on or after the adoption date. This guidance will be effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the consolidated financial statements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#8217;s consolidated financial statements upon adoption.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13. Subsequent Events</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2017, Silver Creek issued 1.7 million shares of Series C preferred stock at $1.50 per share for proceeds of $2.6 million. As of June 30, 2017, the Company held a 51% ownership interest in Silver Creek and maintained control over the Silver Creek board of directors through its voting rights. As a result of Silver Creek&#8217;s issuance of additional shares of Series C preferred stock in July 2017, the Company will evaluate whether the Silver Creek financial statements should continue to be consolidated. &#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a>Item 2.<font style="margin-left:36pt;"><a name="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a> Management&#8217;s Discussion and Analysis of </font>Financial Condition and Results of Operations.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and the notes to those financial statements appearing elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto and management&#8217;s discussion and analysis of financial condition and results of operations for the year ended December&#160;31, 2016 included in our Annual Report on Form 10-K. This discussion contains forward-looking statements that involve significant risks and uncertainties. As a result of many factors, such as those set forth in Part II, Item 1A. Risk Factors of this Quarterly Report on Form 10-Q, which are incorporated herein by reference, our actual results may differ materially from those anticipated in these forward-looking statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Our mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers. All our product candidates, including three in clinical studies and several others in preclinical development, fit into our strategy of (1) understanding the biological problems we are trying to solve, (2) designing specific solutions and (3) developing those solutions for biomarker-selected patients. This three-pronged strategy seeks to ensure optimal patient outcomes. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 3, 2017,<font style="font-weight:bold;"> </font>we announced that we commenced operating as a refocused research and clinical development company in connection with the completion of our previously announced transaction, or the asset sale, with Ipsen S.A., or Ipsen. Pursuant to the Asset Purchase and Sale Agreement, dated as of January&#160;7, 2017, or the asset sale agreement, between us and Ipsen, Ipsen acquired our right, title and interest in the non-cash assets, equipment, inventory, contracts and intellectual property primarily related to or used in our business operations and activities involving or relating to developing, manufacturing and commercializing ONIVYDE, our first commercial product, and MM-436, or the commercial business. We received $575.0 million in cash, subject to a working capital adjustment, and are eligible to receive up to $450.0 million in additional regulatory approval-based milestone payments. The working capital adjustment is currently estimated as a $2.2 million receivable expected to be received in the third quarter of 2017. We also retained the right to receive net milestone payments of up to $33.0 million that may become payable pursuant to the license and collaboration agreement with Baxalta Incorporated, Baxalta US Inc. and Baxalta GmbH, collectively Baxalta, which we refer to as the </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Baxalta agreement, for the ex-U.S. development and commercialization of ONIVYDE. As of June 30, 2017, all historical transactions impacting the condensed consolidated statements of operations </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and comprehensive income (loss) related to the asset sale have been reclassified under discontinued operations.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With the completion of the asset sale, we are prioritizing three clinical-stage programs:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">MM-121 (seribantumab), a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. We are currently conducting the Phase 2 randomized SHERLOC clinical trial evaluating MM-121 in heregulin positive non-small cell lung cancer patients in combination with docetaxel or pemetrexed and plans to initiate the Phase 2 randomized SHERBOC clinical trial in 2017 in heregulin positive, hormone receptor positive, ErbB2 (HER2) negative, metastatic breast cancer patients;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">MM-141 (istiratumab), a fully human bispecific tetravalent monoclonal antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1, or IGF-1, receptor and ErbB3 (HER3) cell surface receptors. We are currently conducting the Phase 2 randomized CARRIE clinical trial evaluating MM-141 in previously untreated metastatic pancreatic cancer patients with high levels of free IGF-1 in combination with nab-paclitaxel and gemcitabine; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">MM-310, an antibody-directed nanotherapeutic, or ADN, that contains a novel prodrug of the highly potent chemotherapy docetaxel and targets the ephrin receptor A2, or EphA2, receptor, which is highly expressed in most solid tumor types. MM-310 was designed to improve the therapeutic window of docetaxel in major oncology indications, such as prostate, ovarian, bladder, gastric, pancreatic and lung cancers. We initiated a Phase 1 clinical trial to evaluate safety and preliminary activity of MM-310 in the first quarter of 2017.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our clinical-stage programs, we have several product candidates in preclinical development and a discovery effort advancing additional candidate medicines.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">On January 8, 2017, we announced a planned reduction in our headcount by approximately 30% in connection with the closing of the asset sale and the completion of our strategic pipeline review, and upon the closing of the asset sale we had approximately 80 employees.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have devoted substantially all of our resources to our drug discovery and development efforts, including advancing our systems biology approach, conducting clinical trials for our product candidates, protecting our intellectual property and providing general and administrative support for these operations. <font style="Background-color:#FFFFFF;color:#000000;">We currently have no products approved for sale and all of our revenue to date has been collaboration revenue and through sales of ONIVYDE</font> and, to date, we have financed our operations primarily through private placements of our convertible preferred stock, collaborations, public offerings of our securities, secured debt financings, sales of ONIVYDE and the asset sale of ONIVYDE.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2017, we had unrestricted cash and cash equivalents and marketable securities of $135.5 million. We believe that at our currently forecasted spending rates, our existing financial resources, together with the net milestone payments we expect to receive under the Baxalta agreement, assuming certain milestones under such agreement are met, will be sufficient to fund our planned operations into the second half of 2019.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never been profitable and, as of June&#160;30, 2017, we had an accumulated deficit of $472.9 million. Our loss from continuing operations before income tax expense was $59.9 million and $89.1 million for the three and six months ended June&#160;30, 2017, respectively. Our loss from continuing operations was $51.6 million and $89.3 million for the three and six months ended June&#160;30, 2016, respectively. We expect to continue to incur significant expenses and operating losses for at least the next several years. We expect to continue to incur significant research and development expenses in connection with our ongoing activities, particularly as we continue the research, development and clinical trials of our product candidates, including multiple simultaneous clinical trials for certain product candidates. Until such time, if ever, as we can generate sufficient product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, licensing arrangements and other marketing and distribution arrangements. We also could engage in discussions with third parties regarding partnerships, joint ventures, combinations or divestitures of one or more of our businesses as we seek to further the development of our research programs, improve our cash position and maximize stockholder value. There can be no assurance as to the timing, terms or consummation of any financing, collaboration, licensing arrangement or other marketing and distribution arrangement, partnership, joint venture, combination or divestiture. We may be unable to raise capital when needed or on attractive terms, which would force us to delay, limit, reduce or terminate our research and development programs. We will need to generate significant revenues to achieve profitability, and we may never do so.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Strategic Partnerships, Licenses and Collaborations </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Ipsen</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the asset sale agreement, we are eligible to receive up to $450.0 million in additional regulatory approval-based milestone payments. We also retained the right to receive net milestone payments that may become payable pursuant to the Baxalta agreement for the ex-U.S. development and commercialization of ONIVYDE for up to $33.0 million. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the asset sale, we entered into a transition services agreement with Ipsen, pursuant to which we and Ipsen provide certain services to each other for a period of 24 months, including Ipsen&#8217;s agreement to manufacture MM-310 and to perform certain quality related services in accordance with a manufacturing services agreement. Additionally, we entered into a sublease agreement with Ipsen under which Ipsen is subleasing approximately 70,237 square feet of our leased space in Cambridge, Massachusetts through the end of our lease term on June 30, 2019. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Baxalta</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 23, 2014, we entered into the Baxalta agreement for the development and commercialization of ONIVYDE outside of the United States and Taiwan, or the licensed territory. In connection with Baxter International Inc.&#8217;s separation of the Baxalta business, the Baxalta agreement was assigned to Baxalta during the second quarter of 2015. As part of the Baxalta agreement, we granted Baxalta an exclusive, royalty-bearing right and license under our patent rights and know-how to develop and commercialize ONIVYDE in the licensed territory.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 3, 2017, the Baxalta agreement was assigned to Ipsen in connection with the completion of the sale of the commercial business. We retained the right to receive net milestone payments that may become payable pursuant to the Baxalta agreement for the ex-U.S. development and commercialization of ONIVYDE for up to $33.0 million, which is comprised of potential payments of $18.0 million from the sale of ONIVYDE in two additional major European countries, $5.0 million related to the sale of ONIVYDE in the first major non-European, non-Asian country and $10.0 million for the first patient dosed in a pivotal clinical trial in an indication other than pancreatic cancer.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 3, 2017, in connection with the asset sale, all agreements related to our collaboration with Baxalta and any associated obligations, including our agreement related to commercial supply of ONIVYDE, were assigned to Ipsen. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Actavis</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2013, we entered into a development, license and supply agreement with Watson Laboratories, Inc., or Actavis, which we refer to as the Actavis agreement, pursuant to which we agreed to develop, manufacture and exclusively supply the bulk form of doxorubicin hydrochloride (HCl) liposome injection to Actavis. On April 3, 2017, in connection with the completion of the asset sale, the Actavis agreement was assigned to Ipsen. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Obligations Related to the License and Development of ONIVYDE</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2005, Hermes BioSciences, Inc., or Hermes, which we acquired in October 2009, entered into a license agreement with PharmaEngine, Inc., or PharmaEngine, under which PharmaEngine received an exclusive license to research, develop, manufacture and commercialize ONIVYDE in Europe and certain countries in Asia. In May 2011, we entered into a new agreement with PharmaEngine, which we refer to as the PharmaEngine agreement, under which we reacquired all previously licensed rights for ONIVYDE, other than rights to commercialize ONIVYDE in Taiwan. As a result, we had the exclusive right to commercialize ONIVYDE in all territories in the world, except for Taiwan, where PharmaEngine has an exclusive commercialization right. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 3, 2017, in connection with the asset sale, the PharmaEngine agreement and all related agreements and any associated obligations, including our agreement related to our commercial supply of ONIVYDE to PharmaEngine, were assigned to Ipsen.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Operations Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenues</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the asset sale, all revenue related to the Commercial Business has been reclassified under discontinued operations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, we may generate revenue from a combination of research and development payments, license fees and other upfront payments, milestone payments, product sales and royalties in connection with future collaborations and licenses. We expect that any revenue we generate will fluctuate in future periods as a result of the timing of our or a collaborator&#8217;s achievement of </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">preclinical, clinical, regulatory and commercialization mil</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">estones, if at all, the timing and amount of any payments to us relating to such milestones and the extent to which any of our product candidates are approved and successfully commercialized by us or a</font><font style="Background-color:#FFFFFF;color:#000000;"> collaborator. If we fail, or any future collaborator f</font><font style="Background-color:#FFFFFF;color:#000000;">ails, to develop product candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenue, and our results of operations and financial position, would be materially adversely affected.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and development expenses</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of the costs associated with our research and discovery activities, including investment in our systems biology approach, conduct of preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings. Our research and development expenses consist of:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">employee salaries and related expenses, which include stock-based compensation and benefits for the personnel involved in our drug discovery and development activities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">manufacturing material expense for third-party manufacturing organizations and consultants, including costs associated with manufacturing product prior to product approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">license fees for and milestone payments related to in-licensed products and technologies; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment, and laboratory and other supplies.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense research and development costs as incurred. Conducting a significant amount of research and development is central to our business model. Product candidates in late stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of late stage clinical trials. We expect to maintain or increase our research and development expenses for the foreseeable future as we continue to develop our clinical stage product candidates and further advance our preclinical products and earlier stage research and development projects. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use our employee and infrastructure resources across multiple research and development programs. We track expenses related to our most advanced product candidates on a per project basis. Accordingly, we allocate internal employee-related and infrastructure costs, as well as third-party costs, to each of these programs. We do not allocate to particular development programs either stock-based compensation expense or expenses related to preclinical programs. Costs that are not directly attributable to specific clinical programs, such as wages related to shared laboratory services, travel and employee training and development, are not allocated and are considered general research and discovery expenses.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our principal product development programs, including the research and development expenses allocated to each clinical product candidate, for the three and six months ended June&#160;30, 2017 and 2016:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MM-121</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,312</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,561</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,907</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,039</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MM-141</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,631</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,882</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,418</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,226</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MM-310</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">984</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,794</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,283</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,991</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical, general research and discovery</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,112</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,062</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,100</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,728</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legacy programs (MM-302, MM-151, MM-131)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">797</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,373</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,265</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,165</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,915</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,023</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,383</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,548</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,751</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,695</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,356</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,697</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the asset sale, all expenses related to the Commercial Business have been reclassified under discontinued operations.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The successful developmen</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t of our clinical and preclinical product candidates is highly uncertain. At this time, other than as discussed below, we cannot reasonably estimate the nature, timing or costs of the efforts that will be necessary to complete the remainder of the developm</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ent of any of our preclinical or clinical product candidates or the period, if any, in which material net cash flows from these product candidates may commence. This is due to the numerous risks and uncertainties associated with developing drugs, including</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the uncertainty of:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the scope, rate of progress and expense of our ongoing, as well as any additional, clinical trials and other research and development activities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the potential benefits of our product candidates over other therapies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to market, commercialize and achieve market acceptance for any of our product candidates that we are developing or may develop in the future;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">future clinical trial results;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the terms and timing of regulatory approvals; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the U.S. Food and Drug Administration, or FDA, or another regulatory authority were to require us to conduct clinical trials beyond those which we currently anticipate will be required for the completion of clinical development of a product candidate or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">MM-121 (seribantumab)</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2015, we initiated the Phase 2 randomized SHERLOC clinical trial of MM-121 in patients with heregulin positive non-small cell lung cancer.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, in 2017, we plan to initiate the Phase 2 randomized SHERBOC clinical trial of MM-121 in heregulin positive, hormone receptor positive, ErbB2 (HER2) negative, metastatic breast cancer.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">MM-141 (istiratumab)</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2015, we initiated the Phase 2 randomized CARRIE clinical trial of MM-141 in patients with previously untreated metastatic pancreatic cancer with high levels of free IGF-1 in combination with nab-paclitaxel and gemcitabine.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">MM-310</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2017, we initiated a Phase 1 clinical trial of MM-310 in solid tumors to assess the safety and preliminary activity of MM-310.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General and administrative expenses</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of salaries and other related costs for personnel, including stock-based compensation expenses and benefits, in our commercial, legal, intellectual property, business development, finance, information technology, corporate communications, investor relations and human resources departments. Other general and administrative expenses include costs to support employee training and development, board of directors costs, depreciation, insurance expenses, facility-related costs not otherwise included in research and development expenses, professional fees for legal services, including patent-related expenses, and accounting and information technology services. We expect to maintain general and administrative expenses in future periods as we continue to support the development and commercialization of our clinical products.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restructuring expenses</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the corporate restructuring activities described above, we recognized total restructuring expenses of $4.2 million and $9.6 million during the three and six months ended June 30, 2017, respectively, related to contractual termination benefits for employees with pre-existing severance arrangements and one-time employee termination benefits. These one-time employee termination benefits are comprised of severance, benefits and related costs, all of which are expected to result in cash expenditures. The majority of these payments were made during the second quarter of 2017. The total restructuring expenses for the three and six months ended June 30, 2017 have been recorded within discontinued operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest expense</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense consists primarily of cash and non-cash interest related to our 4.50% convertible notes due 2020, or the convertible notes, for the three months ended June 30, 2017, and our 11.50% senior secured notes due 2022, or the 2022 notes, for all other periods presented.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April&#160;3, 2017, in connection with the completion of the asset sale, we irrevocably deposited the aggregate redemption price of the 2022 notes, plus accrued and unpaid interest of $7.4 million, with U.S. Bank National Association as trustee under the Indenture, dated as of December 22, 2015, or the indenture, and irrevocably instructed the trustee to apply such amount to the redemption in full of the 2022 notes on the redemption date of April 27, 2017. The indenture was satisfied and discharged on April 3, 2017<font style="Background-color:#FFFFFF;color:#000000;">.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Significant Judgments and Estimates</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which we have prepared in accordance with the rules and regulations of the Securities and Exchange Commission, or the SEC, and generally accepted accounting principles in the United States, or GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. Estimates include estimated service periods and services to be completed under a collaboration, useful lives with respect to long-lived assets and intangible assets, accounting for stock-based compensation, contingencies, intangible assets, goodwill, in-process research and development, tax valuation reserves and accrued expenses. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our critical accounting policies and the methodologies and assumptions we apply under them have not materially changed since March 1, 2017, the date we filed our Annual Report on Form 10-K for the year ended December&#160;31, 2016, other than those noted in Note 3,<font style="Background-color:#FFFFFF;color:#000000;"> &#8220;Sale of Commercial Business,&#8221; in the accompanying notes to the condensed consolidated financial statements.</font> For more information on our critical accounting policies, refer to our Annual Report on Form 10-K for the year ended December&#160;31, 2016. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comparison of the three months ended June&#160;30, 2017 and 2016</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,751</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,695</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,798</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,138</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from continuing operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,549</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,833</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">382</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,762</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,858</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain on sale of assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,703</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(659</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss from continuing operations before income tax benefit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59,885</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,633</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and development expenses</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $19.8 million for the three months ended June&#160;30, 2017 compared to $27.7 million for the three months ended June&#160;30, 2016, a decrease of $7.9 million, or 29%. This decrease was primarily attributable to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">$6.6 million of decreased expenses related to our legacy programs </font><font style="color:#000000;font-family:Times New Roman;">as a result of our </font><font style="font-family:Times New Roman;">prioritization of MM-121, MM-141 and MM-310 and close-out activities associated with the legacy programs</font><font style="color:#000000;font-family:Times New Roman;">;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">$4.0 million of decreased expenses related to our preclinical, general research, and discovery efforts related to the refocus of our early stage development spend and lower overhead costs to support general research and development expense related to the reduction in headcount; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">The decreases in expense noted in the bullets above were offset by an increase in stock-based compensation expense of $3.9 million, due to the incremental expense recognized on the modification to the original stock option grants that occurred in the second quarter of 2017. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $14.8 million for the three months ended June&#160;30, 2017 compared to $8.1 million for the three months ended June&#160;30, 2016, an increase of $6.7 million, or 82%. This increase was primarily attributable to costs associated with the transition following the Asset Sale, including legal expenses and stock-based compensation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Interest expense</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense was $26.8 million for the three months ended June&#160;30, 2017 compared to $15.9 million for the three months ended June&#160;30, 2016, an increase of $10.9 million, or 69%. This increase was primarily attributable to interest expense related to the settlement of the 2022 notes and an additional make-whole premium payment of approximately $20.1 million.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Income tax benefit</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended June 30, 2017, the Company recognized an income tax benefit within continuing operations of $30.2 million and tax expense in discontinued operations of $51.9 million related to taxable income generated during the interim period as a result of the Asset Sale. For the three months ended June 30, 2016, the Company did not recognize any tax expense or benefit.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Discontinued operations</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended June 30, 2017 the Company recognized income from discontinued operations, net of tax of $540.5 million as a result of the net gain on the Asset Sale. For the three months ended June 30, 2016, the Company recognized income from discontinued operations, net of tax of approximately $0.7 million.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comparison of the six months ended June&#160;30, 2017 and 2016</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,356</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55,697</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,432</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,590</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from continuing operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61,788</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(70,287</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">396</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,741</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,148</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain on sale of assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,703</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(661</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(107</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss from continuing operations before income tax benefit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,091</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,348</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and development expenses</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $41.4 million for the six months ended June&#160;30, 2017 compared to $55.7 million for the six months ended June&#160;30, 2016, a decrease of $14.3 million, or 26%. This decrease was primarily attributable to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">$9.9 million of decreased expenses related to our legacy programs </font><font style="color:#000000;font-family:Times New Roman;">as a result of our </font><font style="font-family:Times New Roman;">prioritization of MM-121, MM-141 and MM-310 and close-out activities associated with the legacy programs</font><font style="color:#000000;font-family:Times New Roman;">;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">$5.6 million of decreased expenses related to our preclinical, general research and discovery related to the refocus of early stage development spend and lower overhead costs to support general research and development expense related to the reduction in headcount; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">The decreases in expense noted in the bullets above were offset by an increase in stock based compensation expense of $2.5 million, due to the incremental expense recognized on the modification to the original stock option grants that occurred in the second quarter of 2017. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $20.4 million for the six months ended June&#160;30, 2017 compared to $14.6 million for the six months ended June&#160;30, 2016, an increase of $5.8 million, or 40%. This increase was primarily attributable to the costs associated with the transition following the Asset Sale, including legal expenses and stock-based compensation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Interest expense</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense was $28.7 million for the six months ended June&#160;30, 2017 compared to $19.1 million for the six months ended June&#160;30, 2016, an increase of $9.6 million, or 50%. This increase was primarily attributable to interest expense related to the settlement of the 2022 notes and an additional make-whole premium payment of approximately $20.1 million.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Income tax benefit</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the six months ended June 30, 2017, the Company recognized an income tax benefit within continuing operations of $30.2 million and tax expense in discontinued operations of $51.9 million related to taxable income generated during the six months ended June 30, 2017 as a result of the Asset Sale. For the six months ended June 30, 2016, the Company did not recognize any tax expense or benefit.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Discontinued operations</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the six months ended June 30, 2017 the Company recognized income from discontinued operations, net of tax, of $539.6 million, as a result of the net gain on the Asset Sale. For the six months ended June 30, 2016, the Company recognized loss from discontinued operations, net of tax, of approximately $0.3 million.</p>
<p style="margin-bottom:6pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sources of liquidity</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have financed our operations to date primarily through private placements of our convertible preferred stock, collaborations, public offerings of our securities, secured debt financings, sales of ONIVYDE and the asset sale of ONIVYDE. Through June&#160;30, 2017, we have received $575.0 million from the asset sale of ONIVYDE, $268.2 million from the sale of convertible preferred stock and warrants, $126.7 million of net proceeds from the sale of common stock in our initial public offering and July 2013 follow-on underwritten public offering, $38.6 million of net proceeds from our 2015 &#8220;at the market offering&#8221; program, or the ATM offering, $39.6 million of net proceeds from a secured debt financing, $120.6 million of net proceeds from the issuance of the convertible notes in our July 2013 underwritten public offering, $168.5 million of net proceeds from the issuance of the 2022 notes, $487.6 million of upfront license fees, milestone payments, reimbursement of research and development costs and manufacturing services and other payments from our collaborations and $68.9 million of cash receipts related to ONIVYDE sales. We also entered into an arrangement to use our manufacturing capabilities to manufacture drug product on behalf of Actavis, for which we have received $4.9 million in upfront fees and reimbursements as of June&#160;30, 2017. In connection with the asset sale on April 3, 2017, we no longer will receive cash receipts related to ONIVYDE sales or upfront fees and reimbursements related to any manufacturing arrangement, as all rights to receive cash from these activities have been assigned to Ipsen. As of June&#160;30, 2017, we had unrestricted cash and cash equivalents and marketable securities of $135.5 million.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2017, within our unrestricted cash and cash equivalents, $2.6 million was cash and cash equivalents held by our majority owned subsidiary, Silver Creek </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaceuticals, Inc., or Silver Creek, which is consolidated for financial reporting purposes. This $2.6 million held by Silver Creek is designated for the operations of Silver Creek.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash flows</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides information regarding our cash flows for the six months ended June&#160;30, 2017 and 2016:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,510</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(104,426</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">515,809</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63,312</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(306,322</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,623</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,977</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(164,115</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Operating activities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in operating activities of $95.5 million during the six months ended June&#160;30, 2017, of which $49.1 million was used by continuing operations and $46.4 million was used by discontinued operations. The cash used in operating activities was primarily a result of our $58.9 million net loss from continuing operations and a net increase in operating assets and liabilities of $6.6 million. The net increase in operating assets and liabilities during the six months ended June&#160;30, 2017 was primarily driven by the increase in income taxes payable. This increase was offset by non-cash items, including $9.5 million of stock-based compensation expense, $2.4 million in non-cash interest expense, $30.2 million income tax benefit, $15.0 million of non-cash activity related to discontinued operations, and a $4.9 million loss on extinguishment. Cash used in operating activities of $104.4 million during the six months ended June&#160;30, 2016, of which $69.9 million was used by continuing operations and $34.5 million was used by discontinued operations, was primarily a result of our net loss from continuing operations of $89.3 million and a net decrease in operating assets and liabilities of $7.3 million. The net decrease in operating assets and liabilities during the six months ended June&#160;30, 2016 was primarily driven by decreases in accounts payable and accrued expenses. These decreases were offset by $26.7 million of non-cash items, including $6.1 million of stock-based compensation expense and $14.6 million of non-cash loss on extinguishment of convertible notes. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing activities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by investing activities of $515.8 million during the six months ended June&#160;30, 2017 was primarily due to cash received from the sale of the commercial business of $575.0 million, offset by $60.0 million transferred to restricted cash. Cash used in investing activities of $63.3 million during the six months ended June&#160;30, 2016 was primarily due to purchases of marketable securities of $84.3 million in addition to $2.1 million of property and equipment purchases and proceeds from maturities of available for sale securities of $23.0 million.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Financing activities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in financing activities of $306.3 million during the six months ended June&#160;30, 2017 was primarily due to the $175.0 million used to settle the principle balance of the 2022 notes and the $140.0 million dividend paid. Cash provided by financing activities of $3.6 million during the six months ended June&#160;30, 2016 was due to proceeds received from the exercise of stock options.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Borrowings and other liabilities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2015, we closed a private placement of $175.0 million aggregate principal amount of 2022 notes. The 2022 notes bore interest at a rate of 11.50% per year, payable semi-annually on June 15 and December 15 of each year, beginning on June 15, 2016. <font style="Background-color:#FFFFFF;color:#000000;">In connection with the completion of the asset sale, on April 3, 2017, we irrevocably </font>deposited the aggregate redemption price of the 2022 notes<font style="Background-color:#FFFFFF;color:#000000;"> of 111.5% of the principal amount</font>, plus accrued and unpaid interest of $7.4 million, with the trustee and irrevocably instructed the trustee to apply such amount to the redemption in full of the 2022 notes on the redemption date of April 27, 2017. The indenture was satisfied and discharged on April 3, 2017.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2013, we issued convertible notes in the aggregate principal amount of $125.0 million. The convertible notes are convertible into common stock upon satisfaction of certain conditions. The convertible notes bear interest at a fixed rate of 4.50% per year, payable semiannually in arrears on January 15 and July 15 of each year. The convertible notes will mature on July 15, 2020 unless earlier repurchased by us or converted at the option of holders. On April 13, 2016, we entered into conversion agreements with certain holders of our convertible notes. Under the conversion agreements, such holders agreed to convert an aggregate principal amount of $64.2 million of convertible notes held by them. I<font style="Background-color:#FFFFFF;color:#000000;">n connection with a lawsuit filed by the trustee and certain holders of the </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;color:#000000;">Convertible Notes in the Court of Chanc</font><font style="Background-color:#FFFFFF;color:#000000;">ery in the State of Delaware, captioned </font><font style="font-style:italic;Background-color:#FFFFFF;color:#000000;">Wells Fargo Bank, National Association, Wolverine Flagship Fund Trading Limited, Highbridge International LLC, and Highbridge Tactical Credit &amp; Convertibles Master Fund, L.P. v. Merrimack Pharmaceuticals, Inc.</font><font style="Background-color:#FFFFFF;color:#000000;">, or th</font><font style="Background-color:#FFFFFF;color:#000000;">e Delaware Action, we have agreed to deposit, and in April 2017 did deposit, $60.0 million in proceeds from the asset sale into an escrow account. The funds will remain in escrow for the duration of the Delaware Action in order to provide security to the p</font><font style="Background-color:#FFFFFF;color:#000000;">laintiffs for their claims in the Delaware Action. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 10, &#8220;Borrowings,&#8221; in the accompanying notes to the condensed consolidated financial statements for additional information.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Funding requirements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred significant expenses and operating losses to date, and we expect to continue to incur significant expenses and operating losses for at least the next several years. We anticipate that we will continue to incur significant expenses as we:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">initiate or continue clinical trials of our most advanced product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">continue the research and development of our other product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek to discover additional product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek regulatory approvals for our product candidates that successfully complete clinical trials; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">continue to provide the operational, financial and management information systems and personnel to support our product development.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that at our currently forecasted spending rates, our existing financial resources, together with the net milestone payments we expect to receive under the Baxalta agreement, assuming certain milestones under such agreement are met, will be sufficient to fund our planned operations into the second half of 2019. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, and the extent to which we utilize collaborations with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials. Our future capital requirements will depend on many factors, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the progress and results of the clinical trials of our most advanced product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to establish and maintain additional collaborations on favorable terms, and the success of any such future collaborations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing and amount of potential milestone payments related to ONIVYDE that we may receive from Ipsen and Baxalta;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our other product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs, timing and outcome of regulatory review of our current and future product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent to which we acquire or invest in businesses, products and technologies.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate sufficient product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, licensing arrangements and other marketing and distribution arrangements. We also could engage in discussions with third parties regarding partnerships, joint ventures, combinations or divestitures of one or more of our businesses as we seek to further the development of our research programs, improve our cash position and maximize stockholder value. There can be no assurance as to the timing, terms or consummation of any financing, collaboration, licensing arrangement or other marketing and distribution arrangement, partnership, joint venture, combination or divestiture. We do not have any committed external sources of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. For example, if we raise additional funds through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and ma</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rket product candidates that we would otherwise prefer to develop and market ourselves.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations and Commitments</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our contractual obligations and commitments were reported in our Annual Report on Form 10-K for the year ended December&#160;31, 2016, which was filed with the SEC on March 1, 2017. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described more fully in Note 3, &#8220;Sale of Commercial Business,&#8221; in connection with the completion of the asset sale, on April 3, 2017, we assigned to Ipsen all of our contracts relating to the commercial business, including our contracts with Baxalta, Actavis and PharmaEngine. Additionally, in connection with the completion of the asset sale, on April 3, 2017, we entered into a sublease with Ipsen pursuant to which Ipsen subleases from us approximately 70,237 square feet of leased space in our Cambridge, Massachusetts facility through the end of the term of the lease on June 30, 2019. Also, in connection with the completion of the asset sale, on April 3, 2017, we irrevocably deposited the redemption price of the 2022 Notes of <font style="Background-color:#FFFFFF;color:#000000;">$175.0 million outstanding aggregate principal amount, interest through the redemption date and an additional make-whole premium payment of approximately $20.1 million</font> with U.S. Bank National Association as trustee under the indenture and irrevocably instructed the trustee to apply such amount to the redemption in full of the 2022 Notes on the redemption date of April 27, 2017. The indenture was satisfied and discharged on April 3, 2017. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 3, 2017, we entered into an amendment to our facility lease pursuant to which the final date of the term for approximately 29,157 square feet of leased space at our current facility in Cambridge, Massachusetts was reduced from June 30, 2019 to May 15, 2018 or earlier upon the landlord&#8217;s election. As a result of this amendment, our lease payments through 2019 will be reduced by approximately $1.7 million. On June 9, 2017, we entered into a further amendment to our facility lease pursuant to which we terminated the lease on approximately 25,735 square feet of leased space at our current facility in Cambridge, Massachusetts as of June 23, 2017. As a result of this amendment, our lease payments through 2019 will be reduced by approximately $4.4 million in the aggregate.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no other material changes from the contractual obligations and commitments previously disclosed in our Annual Report on Form 10-K.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 12, &#8220;<font style="Background-color:#FFFFFF;color:#000000;">Recent Accounting Pronouncements,</font>&#8221; in the accompanying notes to the condensed consolidated financial statements for a full description of recent accounting pronouncements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"></a>Item 3.<font style="margin-left:36pt;"><a name="ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"></a>Quantitative and Qualitati</font>ve Disclosures About Market Risk.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We invest in a variety of financial instruments, principally cash deposits, money market funds, securities issued by the U.S. government and its agencies and corporate debt securities. The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and investments. We also seek to maximize income from our investments without assuming significant risk.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of interest rates, particularly because our investments are in short-term marketable securities. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our portfolio. We have the ability and intention to hold our investments until maturity, and therefore, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates on our investment portfolio.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have any auction rate or mortgage-backed securities. We do not believe our cash, cash equivalents and marketable securities have significant risk of default or illiquidity, however we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The conver</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tible notes bear interest at a fixed rate of 4.50% per year, payable semi-annually in arrears on January 15 and July 15 of each year, beginning on January 15, 2014. As a result, we are not subject to interest rate risk with respect to the convertible notes</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4_CONTROLS_PROCEDURES"></a>Item 4.<font style="margin-left:36pt;"><a name="ITEM_4_CONTROLS_PROCEDURES"></a>Controls </font>and Procedures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our Chief Executive Officer (our principal executive officer and principal financial officer), evaluated the effectiveness of our disclosure controls and procedures as of June&#160;30, 2017. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June&#160;30, 2017, our Chief Executive Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control Over Financial Reporting</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the three months ended June&#160;30, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a>PART</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> II</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OTHER INFORMATION</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_LEGAL_PROCEEDINGS"></a>Item 1.<font style="margin-left:36pt;"><a name="ITEM_1_LEGAL_PROCEEDINGS"></a>Legal </font>Proceedings.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 15, 2017, the trustee and certain holders of our convertible notes filed the Delaware Action in the Court of Chancery in the State of Delaware. The Delaware Action complaint alleges that the sale of the commercial business to Ipsen was a sale of &#8220;substantially all&#8221; of our assets and therefore constituted a Fundamental Change (as defined in the indenture governing the convertible notes) as of the closing of the asset sale, which would trigger (a) certain obligations under the indenture governing the convertible notes, including an offer to repurchase the convertible notes, and (b) an event of default if Ipsen does not assume the obligations under the indenture and execute a supplemental indenture with respect to the convertible notes. We have decided to proceed directly to trial. In connection with this decision and the plaintiffs&#8217; withdrawal of their motion for a preliminary injunction, we agreed to deposit, and in early April 2017 did deposit, into an escrow account $60.0 million in proceeds from the asset sale. On April 24, 2017, the plaintiffs filed an amended complaint that, among other things, includes additional allegations that an event of default has occurred under the indenture governing the convertible notes. In May 2017, we filed our answer and affirmative defenses to the amended complaint. Fact discovery is ongoing and expert discovery is scheduled to be completed prior to trial. The trial is currently scheduled for November 2017. We believe the Delaware Action is without merit and intend to vigorously defend against all claims asserted. However, if the Delaware Action is successful, we may be required to pay up to $60.8 million to repurchase the convertible notes, as well as additional interest and expenses of the plaintiffs.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 28, 2017, a putative stockholder class action suit was filed by a purported stockholder of ours in the Superior Court of Massachusetts for the County of Middlesex against us and our directors. The case was captioned <font style="font-style:italic;">Robert Garfield v. Merrimack Pharmaceuticals Inc., et al.</font>, or the Garfield Action. The Garfield Action complaint alleged that our directors breached their fiduciary duties by entering into the asset sale agreement with Ipsen and that the definitive proxy statement relating to the asset sale contained inadequate disclosures and omissions. Although we believed that the Garfield Action was without merit, to avoid the risk of the litigation delaying or adversely affecting the asset sale and to minimize the expense of defending the litigation related to the asset sale, we agreed to make supplemental disclosures related to the asset sale and to pay the plaintiff&#8217;s counsel $375,000 in attorney&#8217;s fees in connection with the resolution of the Garfield Action. As a result, the Garfield Action was dismissed with prejudice.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not currently a party to any other material legal proceedings.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_RISK_FACTORS"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 1A.</font><font style="margin-left:36pt;"><a name="ITEM_1A_RISK_FACTORS"></a>Ris</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">k Factors.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following risk factors and other information included in this Quarterly Report on Form 10-Q should be carefully considered. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations. Please see page 1 of this Quarterly Report on Form 10-Q for a discussion of some of the forward-looking statements that are qualified by these risk factors. If any of the following risks occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Sale of our Commercial Business to Ipsen</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because the commercial business represented all of our revenues for fiscal year 2016 and the three months ended March 31, 2017, our business following the sale of the commercial business is substantially different than it was prior to such sale. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the completion of our previously announced asset sale with Ipsen, Ipsen acquired, pursuant to the asset sale agreement, our right, title and interest in the commercial business. The commercial business represented all of our revenues for the fiscal year 2016 and the three months ended March 31, 2017. Following the sale of the commercial business, we retained our non-commercial assets, including our clinical and preclinical development programs, or the pipeline business. Our results of operations and financial condition may be materially affected if we fail to grow our pipeline business, if we are unable to raise additional capital if needed to run the pipeline business, if we must incur significant costs in order to raise additional capital to run the pipeline business or if we are unable to successfully develop and commercialize our remaining product candidates. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The holders of certain of our outstanding convertible securities have asserted that the asset sale constitutes a &#8220;Fundamental Change&#8221; under the indenture that governs those convertible notes. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2013, we issued $125.0 million aggregate principal amount of 4.50% convertible notes due 2020, or convertible notes, of which an aggregate principal amount of $60.8 million remains outstanding as of June 30, 2017. On March 15, 2017, the Delaware Action was filed by the trustee and certain holders of the convertible notes in the Court of Chancery in the State of Delaware, captioned <font style="font-style:italic;">Wells Fargo Bank, National Association, Wolverine Flagship Fund Trading Limited, Highbridge International LLC, and Highbridge Tactical Credit &amp; Convertibles Master Fund, L.P. v. Merrimack Pharmaceuticals, Inc.</font> The Delaware Action complaint alleges that the asset sale is a sale of &#8220;substantially all&#8221; of our assets and therefore constituted a Fundamental Change (as defined in the indenture governing the convertible notes) as of the closing of the asset sale, which would trigger (a) certain obligations under the indenture governing the convertible notes, including an offer to repurchase the convertible notes, and (b) an event of default if Ipsen does not assume the obligations under the indenture and execute a supplemental indenture with respect to the convertible notes. We have decided to proceed directly to trial and requested a schedule for discovery and trial that would result in a trial in fall 2017. In connection with this decision, we agreed to deposit, and in April 2017 did deposit, into an escrow account $60.0 million in proceeds from the asset sale. Although we believe the Delaware Action is without merit and intend to vigorously defend against all claims asserted, if the Delaware Action is successful, we may be required to pay up to $60.8 million to repurchase the convertible notes, plus additional interest. We may also incur significant expenses of litigation and, if the plaintiffs are successful, may be required to reimburse them for their expenses relating to the litigation.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are, and in the future may be, subject to securities litigation, which is expensive and could divert our attention. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed below, we are, and may in the future be, subject to securities class action litigation in connection with the asset sale. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention, which could seriously harm our business. For instance, the Garfield Action was filed by a purported stockholder in the Superior Court of Massachusetts for the County of Middlesex against us and our directors. The case is captioned <font style="font-style:italic;">Robert Garfield v. Merrimack Pharmaceuticals Inc., et al</font>. The Garfield Action complaint alleged that our directors breached their fiduciary duties by entering into the asset sale agreement and that the definitive proxy statement relating to the asset sale contained inadequate disclosures and omissions. Although we believed that the Garfield Action was without merit, to avoid the risk of the litigation delaying or adversely affecting the asset sale and to minimize the expense of defending the litigation related to the asset sale, we agreed to make supplemental disclosures related to the asset sale and to pay the plaintiff&#8217;s counsel $375,000 in attorney&#8217;s fees in connection with the resolution of the Garfield Action. As a result, the plaintiff concluded that the claims in the Garfield Action have been mooted, and the Garfield Action was dismissed with prejudice. Nonetheless, there can be no guarantee that there will not be additional securities class action litigation in connection with the asset sale. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because our business is smaller following the sale of the commercial bus</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">iness, there is a possibility that our common stock may be delisted from the NASDAQ Global Market if we fail to satisfy the continued listing standards. </font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even though we currently satisfy the continued listing standards for the NASDAQ Global Market, following the completion of the sale of the commercial business, our business is smaller and, therefore, we may fail to satisfy the continued listing standards of the NASDAQ Global Market. In the event that we are unable to satisfy the continued listing standards of the NASDAQ Global Market, our common stock may be delisted. Any delisting of our common stock from the NASDAQ Global Market could adversely affect our ability to attract new investors, decrease the liquidity of our outstanding shares of common stock, reduce our flexibility to raise additional capital, reduce the price at which our common stock trades and increase the transaction costs inherent in trading such shares with overall negative effects for our stockholders. In addition, delisting of our common stock could deter broker-dealers from making a market in or otherwise seeking or generating interest in our common stock, and might deter certain institutions and persons from investing in our securities at all. For these reasons and others, delisting could adversely affect the price of our common stock and our business, financial condition and results of operations. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">There can be no guarantee that Ipsen will comply with its obligation to use commercially reasonable efforts in connection with the development of ONIVYDE or that the milestones set forth in the Baxalta agreement will be achieved. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ipsen has agreed to use commercially reasonable efforts to develop ONIVYDE in connection with obtaining the regulatory approval by the FDA of ONIVYDE for certain indications. Although the results of this approval process may enable Ipsen to achieve the milestones necessary for us to receive the contingent payments under the asset sale agreement, there is no guarantee that Ipsen will take the steps set forth in the asset sale agreement and that such development will lead to the successful approval of ONIVYDE for such additional indications. Therefore, there can be no guarantees that any of the milestones set forth in the asset sale agreement will be achieved and that we will receive any future contingent payments. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, although the asset sale agreement entitles us to receive certain net milestone payments of up to $33.0&#160;million that may become payable under the Baxalta agreement, achievement of such milestones and payment of any or all of the $33.0&#160;million is not guaranteed.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Ipsen is not assuming any of the excluded liabilities under the asset sale agreement. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the asset sale agreement, Ipsen assumed only certain specified liabilities set forth in the asset sale agreement and did not assume all of the liabilities associated with the commercial business. Certain liabilities remain with us post-closing. While we believe that we have adequately accrued for these liabilities or are adequately insured against certain of the risks associated with such excluded liabilities, there can be no assurances that additional expenditures will not be incurred in resolving any such liabilities. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The asset sale agreement may expose us to contingent liabilities. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have agreed to indemnify Ipsen for certain breaches of representations, warranties or covenants made by us in the asset sale agreement and for certain specified existing litigation. We have agreed that if we cannot pay our indemnification obligations, Ipsen will have set-off rights against any future contingent payments. Significant indemnification claims by Ipsen could further materially and adversely affect our financial condition and/or significantly reduce any future contingent payments.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Position and Need for Additional Capital</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have incurred significant losses since our inception. We expect to incur operating losses for the foreseeable future and may never achieve or maintain profitability.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, we have incurred significant operating losses. Our net loss from continuing operations before income tax benefit was $89.1 million for the six months ended June&#160;30, 2017. Our net loss was $153.5 million for the year ended December&#160;31, 2016, $147.8 million for the year ended December 31, 2015 and $83.6 million for the year ended December 31, 2014. As of June&#160;30, 2017, we had an accumulated deficit of $472.9 million. To date, we have financed our operations primarily through private placements of our convertible preferred stock, collaborations, public offerings of our securities, secured debt financings, sales of ONIVYDE and the asset sale of ONIVYDE. We have devoted substantially all of our efforts to research and development, including clinical trials and recently to commercialization of our first product, ONIVYDE, which was sold to Ipsen. We have not completed development of or commercialized any other therapeutic product candidates or diagnostics other than ONIVYDE. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We anticipate that our expenses will increase substantially as we:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">initiate or continue clinical trials of our most advanced product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">continue the research and development of our other product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek to discover additional product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek regulatory approvals for our product candidates that successfully complete clinical trials; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">continue to provide the operational, financial and management information systems and personnel to support our product development.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To become and remain profitable, we must succeed in developing and commercializing products with significant market potential. This will require us to be successful in a range of challenging activities, including discovering product candidates, completing preclinical testing and clinical trials of our product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling or partnering those products for which we may seek and receive regulatory approval. We may never succeed in these activities and may never generate revenues that are significant or large enough to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our substantial indebtedness may limit cash flow available to invest in the ongoing needs of our business.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have, and will continue to have, a significant amount of indebtedness. In July 2013, we issued $125.0 million aggregate principal amount of convertible notes, of which an aggregate principal amount of $60.8 million remains outstanding as of June 30, 2017. In December 2015, we issued $175.0 million aggregate principal amount of 11.50% senior secured notes due 2022, or 2022 notes. Although we used a portion of the proceeds from the asset sale to extinguish the 2022 notes, we could in the future incur additional indebtedness beyond such amounts.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our substantial debt combined with our other financial obligations and contractual commitments could have significant adverse consequences, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">requiring us to dedicate a substantial portion of cash flow from operations to the payment of interest on, and principal of, our debt, which will reduce the amounts available to fund working capital, capital expenditures, product development efforts and other general corporate purposes;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">increasing our vulnerability to adverse changes in general economic, industry and market conditions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obligating us to restrictive covenants that may reduce our ability to take certain corporate actions or obtain further debt or equity financing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">placing us at a competitive disadvantage compared to our competitors that have less debt or better debt servicing options.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to satisfy our current and future debt service obligations with our existing cash and cash equivalents and funds from external sources. However, we may not have sufficient funds or may be unable to arrange for additional financing to pay any amounts due under our debt as it exists at any future point in time. Funds from external sources may not be available on acceptable terms, if at </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all. In addition, a failure to comply with the covenants under our existing debt instruments could result in an event of default under those instruments. In the event of an acceleration of amo</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unts due under our debt instruments as a result of an event of default, including upon the occurrence of an event that would reasonably be expected to have a material adverse effect on our business, operations, properties, assets or condition or a failure </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to pay any amount due, we may not have sufficient funds or may be unable to arrange for additional financing to repay our indebtedness or to make any accelerated payments, and the lenders could seek to enforce security interests in the collateral securing </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such indebtedness. In addition, the covenants under our existing debt instruments and the pledge of our assets as collateral limit our ability to obtain additional debt financing.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our obligations.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. We currently do not generate cash flow from operations and, in the future, our business may not generate cash flow from operations sufficient to service our debt and make necessary capital expenditures. If we are unable to generate cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity or debt financing on terms that may be unfavorable to us or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities at all or engage in these activities on desirable terms, which could result in a default on our debt obligations or future indebtedness.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need substantial additional funding in connection with our continuing operations. We expect to continue to incur significant research and development expenses in connection with our ongoing activities, particularly as we continue the research, development and clinical trials of, and seek regulatory approval for, our product candidates. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or commercialization efforts.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of <font style="Background-color:#FFFFFF;color:#000000;">the asset sale with Ipsen, which occurred on April 3, 2017, we received a $575.0 million upfront cash payment from Ipsen,</font> subject to a working capital adjustment<font style="Background-color:#FFFFFF;color:#000000;">. The working capital adjustment is currently estimated as a $2.2 million receivable expected to be received in the third quarter of 2017. We used these proceeds to redeem the 2022 notes, including payment of the $175.0 million outstanding aggregate principal amount, interest through the redemption date and an additional make-whole premium payment of approximately $20.1 million, and our board of directors declared a special cash dividend of $140.0 million, which was payable on May 26, 2017 to stockholders of record as of the close of business on May 17, 2017. Additionally, if certain milestones under the Baxalta agreement are met, we currently expect to receive up to an aggregate of $33.0 million in net mi</font>lestone payments in 2017. We believe that at our currently forecasted spending rates, our existing financial resources, together with the net milestone payments we expect to receive under the Baxalta agreement, assuming certain milestones under such agreement are met, will be sufficient to fund our planned operations into the second half of 2019. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, and the extent to which we utilize collaborations with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials. Our future capital requirements will depend on many factors, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the progress and results of the clinical trials of our most advanced product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to establish and maintain additional collaborations on favorable terms, and the success of any such future collaborations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing and amount of potential milestone payments related to ONIVYDE that we may receive from Ipsen and Baxalta;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs, timing and outcome of regulatory review of our current and future product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent to which we acquire or invest in businesses, products and technologies.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to complete, and we may never generate the necessary data required to obtain regulatory approval and, even if regulatory approval is obtained, achieve product sales of any of our product candidates. In addition, any of our product candidates, even if appro</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ved, may not achieve commercial success. If we fail to generate sufficient revenues from collaborations or the commercialization of any of our product candidates, we will need to continue to rely on additional financing to achieve our business objectives.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our independent registered public accounting firm included an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2016.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The report from our independent registered public accounting firm for the year ended December 31, 2016 includes an explanatory paragraph stating that our losses from operations and required additional funding to finance our operations raise substantial doubt about our ability to continue as a going concern. If we are unable to obtain sufficient funding, our business, prospects, financial condition and results of operations will be materially and adversely affected and we may be unable to continue as a going concern. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our audited financial statements, and it is likely that investors will lose all or a part of their investment. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms or at all.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any committed external source of funds. Sources of funds may not be available or, if available, may not be available on terms satisfactory to us and could result in significant stockholder dilution.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate sufficient product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, licensing arrangements and other marketing and distribution arrangements. We also could engage in discussions with third parties regarding partnerships, joint ventures, combinations or divestitures of one or more of our businesses as we seek to further the development of our research programs, improve our cash position and maximize stockholder value. There can be no assurance as to the timing, terms or consummation of any financing, collaboration, licensing arrangement or other marketing and distribution arrangement, partnership, joint venture, combination or divestiture.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our stockholders. Additional debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, and these covenants may also require us to attain certain levels of financial performance and we may not be able to do so; any such failure may result in the acceleration of such debt and the foreclosure by our creditors on the collateral we used to secure the debt. The debt issued in a debt financing would also be senior to our outstanding shares of capital stock, and may rank equally with or senior to the convertible notes, upon our liquidation. Our existing indebtedness and the pledge of our assets as collateral limit our ability to obtain additional debt financing. If we raise additional funds through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our investments are subject to risks that could result in losses.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have invested and plan to continue to invest our cash in a variety of financial instruments, principally securities issued by the U.S. government and its agencies, investment grade corporate bonds, including commercial paper, and money market instruments. All of these investments are subject to credit, liquidity, market and interest rate risk. Such risks, including the failure or severe financial distress of the financial institutions that hold our cash, cash equivalents and investments, may result in a loss of liquidity, impairment to our investments, realization of substantial future losses, or a complete loss of the investments in the long-term, which may have a material adverse effect on our business, results of operations, liquidity and financial condition. In order to manage the risk to our investments, we maintain an investment policy that, among other things, limits the amount that we may invest in any one issue or any single issuer and requires us to only invest in high credit quality securities.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Development and Commercialization of Our Product Candidates</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We depend heavily on the success of our clinical stage product candidates. All of our product candidates are in preclinical and clinical development. Clinical trials of our product candidates may not be successful. If we are unable to successfully commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We invest a significant portion of our efforts and financial resources in the development of our clinical stage product candidates for the treatment of various types of cancer. All of our product candidates are still in preclinical and clinical development. Our ability to generate meaningful product revenues will depend heavily on the successful development of our product candidates. The success of our product candidates, which include both our therapeutic product candidates and diagnostic candidates, will depend on several factors, including the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">successful enrollment in, and completion of, preclinical studies and clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">receipt of marketing approvals from the FDA and similar regulatory authorities outside the United States for our product candidates, including our diagnostics;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establishing commercial manufacturing capabilities, which we anticipate doing primarily through arrangements with third-party manufacturers;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">launching commercial sales of any approved products, whether alone or in collaboration with others;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">acceptance of any approved products by patients, the medical community and third-party payors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">effectively competing with other therapies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a continued acceptable safety profile of any products following approval; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">qualifying for, maintaining, enforcing and defending intellectual property rights and claims.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop our product candidates, which would materially harm our business.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in connection with our strategic review of our pipeline which was completed in January 2017, we amended several of our clinical trials such as our Phase 2 clinical trial of MM-121 and our Phase 2 clinical trial of MM-141, resulting in changes to their power, design and timing, and also discontinued several trials, including our Phase 2 clinical trial of MM-302. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA or similar regulatory authorities outside the United States or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may never receive approval to commercialize our product candidates in the United States or other jurisdictions. Before obtaining regulatory approval for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more of our clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and successful interim results of a clinical trial do not necessarily predict successful final results.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may experience numerous unexpected events during, or as a result of, clinical trials that could delay or prevent our ability to receive regulatory approval or commercialize our product candidates, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate or patients may drop out of these clinical trials at a higher rate than we anticipate;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">we might have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding of a lack of clinical response or a finding that the patients are being exposed to unacc</font><font style="font-family:Times New Roman;">eptable health risks;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulators or institutional review boards may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of clinical trials of our product candidates may be greater than we anticipate;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the supply or quality of our product candidates, diagnostics or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate or prohibitively expensive; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators to suspend or terminate the trials.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in December 2016, we decided to discontinue our Phase 2 clinical trial of MM-302 in combination with trastuzumab in patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer based on an opinion from the Data Safety Monitoring Board that continuing the clinical trial would be unlikely to demonstrate benefit over the comparator treatments. We do not plan to invest in additional development of MM-302 at this time. Previously, in our Phase 2 clinical trial of MM-121 in patients with non-small cell lung cancer, two of the three cohorts (Groups A and C) failed to meet their primary endpoints, and the third cohort (Group B) did not pass its planned interim analysis and ceased enrolling patients. Additionally, we did not meet the primary endpoints in our previous Phase 2 clinical trials of MM-121 in patients with ovarian cancer or in patients with breast cancer, although our ongoing biomarker analysis in each trial identified a potential subpopulation of patients potentially benefiting from MM-121 in combination with either paclitaxel or exemestane, respectively.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical and clinical data may not be predictive of the success of later clinical trials, and are often susceptible to varying interpretations and analyses. Many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be delayed in obtaining marketing approval for our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">not obtain marketing approval at all;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtain approval for indications that are not as broad as intended;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">have the product removed from the market after obtaining marketing approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be subject to additional post-marketing testing requirements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be subject to restrictions on how the product is distributed or used; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be unable to obtain reimbursement for use of the product.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delays in testing or approvals may result in increases to our product development costs. We do not know whether any clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to commercialize our product candidates and may harm our business and results of operations.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If serious adverse or undesirable side effects are identified during the development of our product candidates or following their approval and commercialization, we may need to modify or abandon our development or marketing of such product or product candidate.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our product candidates are still in preclinical or clinical development and their risk of failure is high. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive regulatory approval, and it is impossible to ensure that safety or efficacy issues will not arise following regulatory approval. Currently marketed therapies for solid tumors are generally limited to some extent by their toxicity. Use of our product candidates as monotherapies in clinical trials also has resulted in adverse events consistent in nature with other marketed therapies. When used in combination with other marketed or investigational therapies, our product candidates may exacerbate adverse events associated with the other therapy. If our products or </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product candidates, either alone or in combination with other therapies, result in undesirable side effects or have characteristics that are unexpected, we may need to modify or abandon their development or marketing. </font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we experience delays in the enrollment of patients in our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to obtain a statistically significant result as required by the FDA or other regulatory authorities. In addition, many of our competitors have ongoing clinical trials for product candidates that could be competitive with our product candidates. Patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates or rely upon treatment with existing therapies that may preclude them from eligibility for our clinical trials.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of the company to decline and limit our ability to obtain additional financing. Our inability to enroll a sufficient number of patients for any of our current or future clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, we forecast enrollment for our clinical trials based on experience from previous clinical trials and monitor enrollment to be able to make adjustments to clinical trials when appropriate, including as a result of slower than expected enrollment that we experience from time to time in our clinical trials. For example, we experienced slower than expected enrollment in our Phase 2 clinical trial of MM-121 in combination with exemestane for hormone receptor positive breast cancer. In response, we revised the entry criteria for the clinical trial to correspond with changes in clinical practice and also expanded the number of sites and countries participating in the clinical trial. It is possible that slow enrollment in other clinical trials in the future could require us to make similar adjustments. If these adjustments do not overcome problems with slow enrollment, we could experience significant delays or abandon the applicable clinical trial altogether.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to successfully develop diagnostics for our therapeutic product candidates, or experience significant delays in doing so, we may not realize the full commercial potential of our therapeutics.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An important component of our business strategy is to develop, either alone or together with third parties, diagnostics for each of our therapeutic product candidates. There has been limited success to date industry-wide in developing diagnostics. To be successful, we will need to address a number of scientific, technical, regulatory and logistical challenges. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our diagnostic candidates are in preclinical or clinical development. We have limited experience in the development of diagnostics and may not be successful in developing appropriate diagnostics to pair with any of our therapeutic product candidates that receive marketing approval. The FDA and similar regulatory authorities outside the United States are generally expected to regulate <font style="font-style:italic;">in vitro</font> companion diagnostics as medical devices and <font style="font-style:italic;">in vivo</font> companion diagnostics as drugs. In each case, companion diagnostics require separate regulatory approval prior to commercialization. Given our limited experience in developing diagnostics, we expect to rely in part on third parties for their design, development and manufacture. If we, or any third parties that we engage to assist us, are unable to successfully develop diagnostics for our therapeutic product candidates, or experience delays in doing so, the development of our therapeutic product candidates may be adversely affected, our therapeutic product candidates may not receive marketing approval and we may not realize the full commercial potential of any therapeutics that receive marketing approval. As a result, our business would be harmed, possibly materially.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any of our product candidates that receive regulatory approval may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if any of our product candidates receive marketing approval, they may nonetheless not gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors that may be uncertain or subjective, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the prevalence and severity of any side effects;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">efficacy and potential advantages or disadvantages compared to alternative treatments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the price we charge for our product candidates;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">convenience and ease of administration compared to alternative treatments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to successfully develop diagnostics that effectively identify patient populations likely to benefit from treatment with our therapeutic products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the strength of marketing and distribution support; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">sufficient third-party coverage or reimbursement.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development and commercialization of new therapeutic and diagnostic products is highly competitive. We face competition with respect to our current product candidates, and will face competition with respect to any products that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Several large pharmaceutical and biotechnology companies currently market and sell products for the treatment of the solid tumor indications for which we are developing our product candidates. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. Many of these competitors are attempting to develop therapeutics for our target indications.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing our product candidates for the treatment of solid tumors. There are a variety of available therapies marketed for solid tumors. In many cases, these drugs are administered in combination to enhance efficacy. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Many of these approved drugs are well established therapies and are widely accepted by physicians, patients and third-party payors. This may make it difficult for us to achieve our business strategy of replacing existing therapies with our product candidates.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are also a number of products in late stage clinical development to treat solid tumors. Our competitors may develop products that are more effective, safer, more convenient or less costly than any that we are developing or that would render our product candidates obsolete or non-competitive. Our competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours. In addition, our ability to compete may be affected because in many cases insurers or other third-party payors seek to encourage the use of generic products. There are many generic products currently on the market for the indications that we are pursuing, and additional products are expected to become available on a generic basis over the coming years.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we are able to commercialize any of our product candidates, those product candidates may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which could harm our business.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulations that govern marketing approvals, pricing and reimbursement for new therapeutic and diagnostic products vary widely from country to country. Some countries require approval of the sale price of a product before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain regulatory approval.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to commercialize any approved products successfully also will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from third-party payors, including government payors such as Medicare and Medicaid, private health insurers and managed care organizations. There have been, and we expect there will </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continue to be, legislative and regulatory proposals to cha</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nge the healthcare system in ways that could impact our ability to sell our products profitably. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. The federal government, state legislatures and foreign governments have show</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> drugs. Adoption of such controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals and the other product candidates that we are developing and could have a m</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">aterial adverse effect our net revenue and results.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party payors decide which drugs they will pay for and establish reimbursement and co-pay levels. The growing emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on drug pricing. Third-party payors are increasingly challenging the prices charged for medical products and services and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. In order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Even with clinical trials, our product candidates may be considered less safe, less effective or less cost-effective than other products, and third-party payors may not provide coverage and reimbursement for our products or any of our product candidates that we commercialize, in whole or in part.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process for determining whether a payor will provide coverage for a drug product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the drug product once coverage is approved. Third-party payors may limit coverage to specific drug products on a formulary, which might not include all of the approved drugs for a particular indication, and a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot be sure that reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Reimbursement may impact the demand for, or the price of, any product for which we obtain marketing approval. Third-party reimbursement may not be sufficient to enable us to maintain price levels high enough to realize an appropriate return on our investment in product development. Obtaining reimbursement for our products may be particularly difficult because of the higher prices often associated with products administered under the supervision of a physician. In addition, coverage policies, third-party reimbursement rates and drug pricing regulation may change at any time. Thus, even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. The marketability of any products for which we receive regulatory approval for commercial sale may also suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate that we successfully develop.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payors also are increasingly considering new metrics as the basis for reimbursement rates, such as average sales price, average manufacturer price and actual acquisition cost. The existing data for reimbursement based on these metrics is relatively limited, although certain states have begun to survey acquisition cost data for the purpose of setting Medicaid reimbursement rates. Centers for Medicare &amp; Medicaid Services, or CMS, surveys and publishes retail community pharmacy acquisition cost information in the National Average Drug Acquisition Cost files to provide state Medicaid agencies with a basis of comparison for their own reimbursement and pricing methodologies and rates. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, there may be significant delays in obtaining reimbursement for any approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or regulatory authorities in other countries. Eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the product and the clinical setting in which it is used, may be based on payments allowed for lower cost products that are already reimbursed, and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future weakening of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and appropriate payment rates from both government-funded and private payors for new products that we develop could therefore have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products, and our overall financial condition.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product liability lawsuits again</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">st us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and an even greater risk related to the commercial sale of any products that we may develop. If we cannot successfully defend ourselves against claims that any of our product candidates caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">decreased demand for the products or product candidates that we may develop;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">injury to our reputation and significant negative media attention;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">withdrawal of patients from clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">significant costs to defend the related litigation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">substantial monetary awards to patients;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">loss of revenue; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the inability to commercialize any products that we may develop.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently hold $10.0 million in product liability insurance coverage, which may not be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any or every liability that may arise.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and managerial resources, we focus on research programs and product candidates for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have based our research and development efforts on our systems biology approach to biomedical research. Notwithstanding our large investment to date and anticipated future expenditures in our proprietary approach to research and development, we may fail to address or develop product candidates or indications based on other scientific approaches that may offer greater commercial potential or for which there is a greater likelihood of success.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also may not be successful in our efforts to identify or discover new or additional product candidates through our systems biology approach. Research programs to identify new product candidates require substantial technical, financial and human resources. These research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have otherwise been more advantageous for us to retain sole development and commercialization rights.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may establish separately funded companies for the development of product candidates using our systems biology approach in some areas outside the oncology field. These companies may not be successful in the development and commercialization of any product candidates.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may apply our systems biology approach to disease areas outside the oncology field, and could do so through the establishment of separately funded companies. For example, we established Silver Creek to research and develop regenerative medicines to repair the heart using our systems biology approach. Silver Creek has received separate funding from investors other than us. To the extent we are not the majority owner of or control Silver Creek or other companies that we establish, Silver Creek or such other companies could take actions that we do not endorse or with which we disagree, such as using our systems biology approach in a way that reflects adversely on us. In addition, these companies may have difficulty raising additional funds and could encounter any of the risks in developing and commercializing product candidates to which we are subject.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incu</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r costs that could have a material adverse effect on the success of our business.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and radioactive and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We also store certain low level radioactive waste at our facilities until the materials can be properly disposed of. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage, use or disposal of biological, hazardous or radioactive materials.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may be required to incur substantial costs to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fluctuations in foreign currency exchange rates could substantially increase the costs of our clinical trial programs.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A significant portion of our clinical trial activities are conducted outside of the United States, and associated costs may be incurred in the local currency of the country in which the trial is being conducted, which costs could be subject to fluctuations in foreign exchange rates. At present, we do not engage in hedging transactions to protect against uncertainty in future exchange rates between particular foreign currencies and the U.S. dollar. A decline in the value of the U.S. dollar against currencies in geographies in which we conduct clinical trials could have a negative impact on our research and development costs. We cannot predict the impact of foreign currency fluctuations, and foreign currency fluctuations in the future may adversely affect our development costs.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Dependence on Third Parties</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may depend on collaborations with third parties for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending on our capital requirements, development and commercialization costs, need for additional therapeutic expertise and other factors, it is possible that we will enter into additional development and commercialization arrangements with respect to either oncology product candidates or product candidates in other therapeutic areas.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our likely collaborators for any distribution, marketing, licensing or broader collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. We will have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaborations involving our product candidates pose the following risks to us:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in their strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing and distribution;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">disputes may arise between us and the collaborators that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborations may be terminated, such as the termination of our license and collaboration agreement with Sanofi effective December 17, 2014, and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For instance, Ipsen has agreed to use commercially reasonable efforts to develop ONIVYDE in connection with obtaining the regulatory approval by the FDA of ONIVYDE for certain indications. Although the results of this approval process may enable Ipsen to achieve the milestones necessary for us to receive the contingent payments under the asset sale agreement, there is no guarantee that Ipsen will take the steps set forth in the asset sale agreement and that such development will lead to the successful approval of ONIVYDE for such additional indications. Therefore, there can be no guarantees that any of the milestones set forth in the asset sale agreement will be achieved and that we will receive any future contingent payments. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, although the asset sale agreement entitles us to receive certain net milestone payments of up to $33.0&#160;million under the Baxalta agreement, achievement of such milestones and payment of any or all of the $33.0&#160;million is not guaranteed.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are not able to establish additional collaborations, we may have to alter our development plans.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product development programs and the potential commercialization of any approved product candidates will require substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face significant competition in seeking appropriate collaborators. Collaborations are complex and time-consuming to negotiate and document. We may also be restricted under existing collaboration agreements from entering into agreements on certain terms with other potential collaborators. We may not be able to negotiate collaborations on acceptable terms, or at all. If that were to occur, we may have to curtail the development of a particular product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of our sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we will not be able to bring our product candidates to market and generate product revenue.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not independently conduct clinical trials of our product candidates. We rely on third parties, such as contract research organizations, clinical data management organizations, medical institutions and clinical investigators, to perform this function. Our reliance on these third parties for clinical development activities reduces our control over these activities but does not relieve us of our responsibilities. We remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA and other international regulatory agencies require us to comply with standards, commonly referred to as good clinical practices, for conducting, recording and reporting the results of clinical trials to assure that adverse event data are reported within required timeframes, that data and reported results are credible and accurate and that the rights, integrity and confidentiality of patients in clinical trials are protected. Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protocols, we will not be able to obtain, or may be delayed in obtaining, regulatory approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our pr</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">oduct candidates.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also rely on other third parties to store and distribute supplies for our clinical trials. Any performance failure on the part of our existing or future distributors could delay clinical development or regulatory approval of our product candidates or commercialization of our products or cause us to incur additional costs, producing additional losses and depriving us of potential product revenue.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also intend to utilize diagnostics in several of our current and planned clinical trials, including current clinical trials of MM-121, MM-141 and MM-310, to preselect patients who will receive specified treatment regimens. We will rely on third-party laboratories to test patient samples in connection with such diagnostics. Any failure on the part of these laboratories to properly perform such testing could jeopardize those clinical trials and delay or prevent the approval of the associated therapeutic candidate.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Manufacturing of Our Product Candidates</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on third parties for the production of our product candidates. This increases the risk that we will not have sufficient quantities of our product candidates at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on third-party manufacturers for most of the aspects of the production of our product candidates, including the production of bulk drug substance and fill-finish and labeling activities. Reliance on third-party manufacturers entails risks, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">reliance on the third party for regulatory compliance and quality assurance;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the possible breach of the manufacturing agreement by the third party; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party manufacturers may not be able to comply with current good manufacturing practices, or cGMP, or Quality System Regulation, or QSR, or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For instance, in 2010, a former fill-finish third-party contractor that we used to fill and package MM-121 experienced FDA inspection issues with its quality control processes that resulted in a formal warning letter from the FDA. As a result, we pulled some MM-121 from clinical trial sites and replaced it with MM-121 that was filled by a different contractor. This restocking resulted in a few patients missing one or two doses of MM-121. It is possible that we could experience similar issues with other contractors.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, our products may compete with the products of other companies for access to manufacturing facilities. Because there are a limited number of manufacturers that operate under cGMP or QSR regulations and that might be capable of manufacturing for us at an appropriate scale, we may not have access to such manufacturers.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the asset sale, we entered into a transition services agreement with Ipsen, pursuant to which we and Ipsen are providing certain services to each other for a period of 24 months, including Ipsen&#8217;s agreement to manufacture MM-310 pursuant to a manufacturing services agreement. Although we are negotiating arrangements with other third parties for our other product candidates, we do not currently have any agreements with third-party manufacturers for the clinical supply to us of any product candidates, and we may be unable to conclude such agreements or to do so on acceptable terms. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently rely on single suppliers for the resins, media and filters that we use for the manufacture of our product candidates. We purchase these materials from our suppliers on a purchase order basis and do not have long-term supply agreements in place. Any performance failure or refusal to supply on the part of our existing or future suppliers could delay clinical development, marketing approval or commercialization of our products. If our current suppliers cannot perform as agreed, we may be required to replace one or more of these suppliers. Although we believe that there may be a number of potential long-term replacements to each supplier, we may incur added costs and delays in identifying and qualifying any such replacements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We likely will rely upon third-party manufacturers to provide us with necessary reagents and instruments to develop, test and manufacture our <font style="font-style:italic;">in vitro</font> diagnostics. Currently, many reagents are marketed as Research Use Only products under FDA regulations.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to commercializ</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e any products that receive regulatory approval on a timely and competitive basis.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to fulfill our obligations under our intellectual property licenses with third parties, we could lose license rights that are important to our business.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a party to a number of intellectual property license agreements with third parties, including with respect to MM-121, MM-141, MM-310, MM-302 and MM-151, and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that our future license agreements will impose, various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, our licensors may have the right to terminate these agreements, in which event we might not be able to develop and market any product that is covered by these agreements. Termination of these licenses or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms. The occurrence of such events could materially harm our business.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to obtain and maintain patent protection for our technology and products, or if our licensors are unable to obtain and maintain patent protection for the technology or products that we license from them, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be adversely affected.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends in large part on our and our licensors&#8217; ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary technology and products. In some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology or products that we license from third parties. Therefore, we cannot be certain that these patents and applications will be prosecuted and enforced in a manner consistent with the best interests of our business. In addition, if third parties who license patents to us fail to maintain such patents, or lose rights to those patents, the rights we have licensed may be reduced or eliminated.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have sought to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and products that are important to our business. This process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our and our licensors&#8217; patent rights are highly uncertain. Our and our licensors&#8217; pending and future patent applications may not result in patents being issued that protect our technology or products or that effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in our owned and licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. Assuming the other requirements for patentability are met, the first to file a patent application is entitled to the patent. Under the America Invents Act enacted in 2011, the United States moved to this first to file system in 2013 from the previous system under which the first to make the claimed invention was entitled to the patent. We may become involved in opposition, interference or derivation proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if our owned and licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. The issuance of a patent is not conclusive as to its scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop or prevent us from stopping others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from comme</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rcializing products similar or identical to ours.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time-consuming and unsuccessful.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe our patents. To counter infringement or unauthorized use, we may be required to initiate infringement lawsuits, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our products and product candidates and use our proprietary technologies without infringing the enforceable proprietary rights of third parties. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference or derivation proceedings before the U.S. Patent and Trademark Office. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. If we are found to infringe a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties can have a similar negative impact on our business.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our patented technology and products, we rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">non-disclosure and confidentiality agreements with parties that have access to them, such as our employees, corporate collaborat</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ors, outside scientific collaborators, sponsored researchers, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. In add</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ition, any of these parties may breach the agreements and disclose our proprietary information, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is di</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or indep</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">endently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive positio</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n would be harmed.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to obtain, maintain or protect proprietary rights necessary for the continued development and commercialization of our products, product candidates and research technologies, including as a result of challenges from companies who seek to sell generic versions of our products after expiration of any orphan drug exclusivity but prior to the applicable patent expiration.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in large part on obtaining and maintaining U.S. and foreign patent protection for our products, our product candidates and our research technologies and successfully enforcing and defending these patents against third-party challenges, including with respect to generic challenges. The validity of our patents in one or more jurisdictions may be challenged by third parties, resulting in our patents being deemed invalid, unenforceable or narrowed in scope, which could compromise the scope or duration of our exclusive rights in the relevant product, product candidate or technology. For example, the validity of a U.S. patent can be challenged in the U.S. Patent and Trademark Office (e.g., through an Inter Partes Review and/or Post Grant Review Proceeding) and/or in U.S. federal district court.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our patents may also be challenged in a federal court in connection with a third party&#8217;s abbreviated new drug application, or ANDA, or a Section 505(b)(2) new drug application, or NDA, seeking FDA approval to market a generic version of our products, resulting in a patent challenge to one or more patents listed in the Orange Book for our product. This patent challenge can result in one or more of those Orange Book patents for our products being deemed uninfringed, invalid, unenforceable and/or narrowed in scope, which could compromise the scope or duration of our exclusive rights in the relevant product. An ANDA or Section 505(b)(2) NDA can be filed at any time after FDA approval of a product. Other challenges to a patent may be mounted without regard to the date of an FDA approval.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patents as issued or as subsequently limited by any litigation might not contain claims that are sufficiently broad to prevent others from circumventing our patent protection and utilizing our technologies. For instance, the issued patents relating to our product candidates may be limited to a particular indication and/or composition and may not cover similar compositions that have similar clinical properties. Consequently, our competitors may independently develop competing products that do not infringe our patents or other intellectual property. Also, our pending patent applications may not issue, and we may not receive any additional patents. We cannot be sure that our patents and patent applications, including our own and those that we have rights to under licenses from third parties, will adequately protect our intellectual property for a number of reasons, including, among other things, the following: (i) the patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions; (ii) the actual protection afforded by a patent can vary from country to country and may depend upon the type of patent, the scope of its coverage and the availability of legal remedies in the country; (iii) the laws of foreign countries in which we market our products may afford little or no effective protection to our intellectual property, thereby easing our competitors' ability to compete with us in such countries; (iv) intellectual property laws and regulations and legal standards relating to the validity, scope and enforcement of patents covering pharmaceutical and biotechnological inventions are continually developing and changing, both in the United States and in other important markets outside the United States; (v) third parties may challenge, infringe, circumvent or seek to invalidate existing or future patents owned by or licensed to us; and (vi) the coverage claimed in a patent application can be significantly reduced before the patent is issued, and, as a consequence, our and our partners' patent applications may result in patents with narrower coverage than we desire or have planned for.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Regulatory Approval of Our Product Candidates</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are not able to obtain required regulatory approvals, we will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates, including our clinical stage product candidates, and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, import, export, sampling and marketing are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in other countries. Failure to obtain regulatory approval for a product candidate will prevent us from commercializing the product candidate. ONIVYDE was our first and only </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product candidate to receive regulatory approval, and so we have only limited experience in filing and supporting the applications necessary to gain regulatory approvals. Securing regulatory approval requires the submission of extensive precli</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nical and clinical data and supporting information to the FDA and other regulatory agencies for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information a</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bout the product manufacturing process to, and inspection of manufacturing facilities by, the FDA or other regulatory agencies. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended sid</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e effects, toxicities or other characteristics that may preclude our obtaining regulatory approval or prevent or limit commercial use.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of obtaining regulatory approvals is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based on a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in regulatory approval policies during the development period, changes in or the enactment of additional statutes or regulations, changes in regulatory review for each submitted product application or approval of other products for the same indication may cause delays in the approval or rejection of an application. Regulatory agencies have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent regulatory approval of a product candidate. Any regulatory approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we pursue development of a diagnostic to identify patients who are likely to benefit from a therapeutic product, failure to obtain approval for the diagnostic may prevent or delay approval of the therapeutic product.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.55%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are attempting to develop diagnostics to identify patients who are likely to benefit from our therapeutic product candidates. We currently rely on and expect to continue to rely on third parties for much of the development, testing and manufacturing of our diagnostics. We will likely rely on such third parties to also obtain any required regulatory approval for and then commercially supply such diagnostics. All of our diagnostic candidates are in preclinical or clinical development. We have very limited experience in the development of diagnostics and, even with the help of third parties with greater experience, may fail to obtain the required diagnostic product marketing approval, which could prevent or delay approval of the therapeutic product.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2014, the FDA issued final guidance that stated that if safe and effective use of a therapeutic depends on an <font style="font-style:italic;">in vitro</font> diagnostic, then the FDA generally will not approve the therapeutic unless the FDA approves or clears this &#8220;<font style="font-style:italic;">in vitro</font> companion diagnostic device&#8221; at the same time that the FDA approves the therapeutic. The approval or clearance of the <font style="font-style:italic;">in vitro</font> diagnostic most likely will occur through the FDA&#8217;s Center for Devices and Radiological Health Office of In Vitro Diagnostics and Radiological Health. Even with the issuance of the final guidance, the FDA&#8217;s expectations for <font style="font-style:italic;">in vitro</font> companion diagnostics remain unclear in some respects. The FDA&#8217;s developing expectations will affect our <font style="font-style:italic;">in vitro</font> diagnostics. In particular, the FDA may limit our ability to use retrospective data, otherwise disagree with our approaches to trial design, biomarker qualification, clinical and analytical validity and clinical utility, or make us repeat aspects of the trial or initiate new trials.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because our diagnostic candidates are at an early stage of development, we cannot yet know what the FDA will require for any of these tests. For several of our clinical stage product candidates, namely MM-121, MM-141 and MM-310, we are attempting to develop an <font style="font-style:italic;">in vitro</font> diagnostic that will help identify patients likely to benefit from the therapy. Whether the FDA will consider these <font style="font-style:italic;">in vitro</font> diagnostics to be &#8220;<font style="font-style:italic;">in vitro</font> companion diagnostic devices&#8221; that require simultaneous approval or clearance with the therapeutics will depend on whether the FDA views the diagnostics to be essential to the safety and efficacy of these therapeutics.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the FDA&#8217;s past practice with companion diagnostics, if we are successful in developing a diagnostic for any of our clinical stage product candidates, we would expect that FDA approval of an <font style="font-style:italic;">in vitro</font> companion diagnostic, or possibly an <font style="font-style:italic;">in vivo</font> companion diagnostic, would be required for approval and subsequent commercialization of each such therapeutic product candidate. We are not aware of any currently available diagnostics that, if necessary, would otherwise allow us to proceed with the approval and subsequent commercialization of our product candidates despite a delay in or failure of our attempts to develop diagnostics.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we expect to rely on third parties for various aspects of the development, testing and manufacture, as well as for regulatory approval for and commercial supply, of our diagnostics, the commercial success of any of our product candidates that require a diagnostic will be tied to and dependent on the continued ability of such third parties to make the diagnostic commercially available on reasonable terms in the relevant geographies.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to maintain orphan drug designation for MM-141, we will have to rely on other rights and protections.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We obtained orphan drug designation in the United States for MM-141 for the treatment of pancreatic cancer. In the United States, under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the company that first obtains FDA approval for a designated orphan drug for the specified rare disease or condition receives orphan drug marketing exclusivity for that drug for that indication </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for a period of seven years. This orphan drug exclusivity prevents the FDA from approving another application, including a full NDA, to market the same drug for the same orphan indication, except in limited circumstances. For purposes of small molecule dru</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gs, the FDA defines the term &#8220;same drug&#8221; to mean a drug that contains the same active molecule and that is intended for the same use as the approved orphan drug. Orphan drug exclusivity may be lost if the FDA determines that the request for designation was</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our therapeutic product candidates for which we intend to seek approval as biological or drug products may face competition sooner than expected.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With the enactment of the Biologics Price Competition and Innovation Act of 2009, or BPCIA, as part of the Health Care and Education Reconciliation Act of 2010, or the Health Care Reform Laws, an abbreviated pathway for the approval of biosimilar and interchangeable biological products was created. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on their similarity to existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until twelve years after the original branded product was approved under a biologics license application, or BLA. The BPCIA is complex and has yet to be fully interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning is subject to uncertainty. While it is uncertain when any such processes may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that any of our products approved as a biological product under a BLA should qualify for the twelve year period of exclusivity. However:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a potential competitor could seek and obtain approval of its own BLA during our exclusivity period instead of seeking approval of a biosimilar version; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA could consider a particular product candidate which contains both drug and biological product components to be a drug subject to review pursuant to an NDA, and therefore eligible for a significantly shorter marketing exclusivity period as provided under the Drug Price Competition and Patent Term Restoration Act of 1984.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear and will depend on a number of marketplace and regulatory factors that are still developing.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, a drug product approved under an NDA could face generic competition earlier than expected. The enactment of the Generic Drug User Fee Amendments of 2012 as part of the Food and Drug Administration Safety and Innovation Act of 2012, or FDASIA, established a user fee program that will generate hundreds of millions of dollars in funding for the FDA&#8217;s generic drug review program. Funding from the user fee program, along with performance goals that the FDA negotiated with the generic drug industry, is significantly decreasing the timeframe for FDA review and approval of generic drug applications.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our products abroad.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to market any product for which we obtain marketing approval, either ourselves or with commercialization partners, both within and outside the United States. This may increase the risks described below with respect to our compliance with foreign regulations.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to market and sell any approved products in the European Union and many other jurisdictions, we or our commercialization partners must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing, including sometimes additional testing in children. The time required to obtain approval in foreign countries may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be sold in that country. We or our future commercialization partners may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">autho</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We or our future commercialization partners</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any market.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any product for which we obtain marketing approval could be subject to restrictions or withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product for which we may obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP or QSR requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if regulatory approval of a product is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. Later discovery of previously unknown problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in actions such as:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">restrictions on such products, manufacturers or manufacturing processes;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">restrictions on the marketing of a product;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">restrictions on product distribution;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">requirements to conduct post-marketing clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">warning or untitled letters;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">withdrawal of the products from the market;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refusal to approve pending applications or supplements to approved applications that we submit;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">recall of products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">fines, restitution or disgorgement of profits or revenue;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">suspension or withdrawal of regulatory approvals;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refusal to permit the import or export of our products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">product seizure; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDASIA provides the FDA with new inspection authorities. A drug or biologic will be considered adulterated, with possible resulting civil and criminal penalties, if the owner or operator of the establishment where it is made, processed, packed or held delays, denies, limits or refuses inspection. The FDASIA also replaces the biennial inspection schedule for drugs and biologics with a risk-based inspection schedule. The law grants the FDA authority to require a drug or biologics manufacturer to provide, in advance or instead of an inspection, and at the manufacturer&#8217;s expense, any records or other information that the agency may otherwise inspect at the facility. The FDASIA also permits the FDA to share inspection information with foreign governments under certain circumstances. The FDASIA is complex and has yet to be fully interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDASIA also provides the FDA with additional authority to exercise against manufacturers of drugs or biologics that are not adhering to pediatric study requirements, which apply even if the manufacturer is not seeking to market the drug or biologic to pediatric patients. As of April 2013, the FDA must issue non-compliance letters to companies who do not meet the pediatric study requirements. Any company receiving a non-compliance letter would have an opportunity to respond, and the non-compliance letter and company response would become publicly available.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Future legislation may increase the difficulty and cost for us to obta</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">in marketing approval of and commercialize our product candidates and affect the prices we may obtain.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any products for which we obtain marketing approval.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in March 2010, then President Obama signed into law the Health Care Reform Laws, which were intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, provide benefits for patients within a coverage gap in the Medicare Part D prescription drug program, implement rules regarding prescription drug benefits under the health insurance exchanges and changes to the Medicare Drug Rebate program, expand the Public Health Service&#8217;s, or PHS&#8217;, 340B drug pricing program, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. These changes impact existing government healthcare programs and are resulting in the development of new programs, including Medicare payment for performance initiatives and improvements to the physician quality reporting system and feedback program. Further, the Health Care Reform Laws impose a significant annual fee on companies that manufacture or import branded prescription drug products. Substantial new provisions affecting compliance have also been enacted, which may affect our business practices with healthcare practitioners.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some states have elected not to expand their Medicaid programs by raising the income limit to 133% of the federal poverty level, as is permitted under the Health Care Reform Laws. For each state that does not choose to expand its Medicaid program, there may be fewer insured patients overall, which could impact our sales of any approved products, business and financial condition. Where Medicaid patients receive insurance coverage under any of the new options made available through the Health Care Reform Laws, the possibility exists that manufacturers may be required to pay Medicaid rebates on drugs used under these circumstances, a decision that could impact manufacturer revenues. In addition, the federal government has also announced delays in the implementation of key provisions of the Health Care Reform Laws, including the employer mandate. The implications of these delays for our sales of any approved products, business and financial condition, if any, are not yet clear.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Health Care Reform Laws appear likely to continue the pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs. Moreover, legislative changes to the Health Care Reform Laws remain possible. We expect that the Health Care Reform Laws, as currently enacted or as it may be amended in the future, and other healthcare reform measures that may be adopted in the future, could have a material adverse effect on our industry generally and on our ability to successfully commercialize our product candidates.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with our reporting and payment obligations under U.S. governmental pricing programs, we could be required to reimburse government programs for underpayments and could pay penalties, sanctions and fines which could have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a condition of reimbursement for any product approved by the FDA, various U.S. federal and state healthcare programs require that certain pricing information be calculated and reported to U.S. federal and state healthcare agencies. For example, average selling price information must be reported to CMS on a quarterly basis in order to compute Medicare Part B payment rates. Price reporting and payment obligations are highly complex and vary among products and programs. The calculation of average selling price includes a number of inputs from contracts with wholesalers, specialty distributors, group purchasing organizations and other customers. Manufacturers are also required to make an assessment of whether these agreements are deemed to be for bona fide services and that the services are deemed to be at fair market value in our industry and for our products. Our processes for estimating amounts due under these governmental pricing programs have involved, and in the future would almost certainly involve, subjective decisions. As a result, our price reporting calculations are subject to the risk of errors and our methodologies for calculating these prices could be challenged under the federal False Claims Act or other laws. In addition, the Health Care Reform Laws modified the rules related to certain price reports and expanded the scope of pharmaceutical product sales to which Medicaid rebates apply, among other things. Uncertainty exists currently, as many of the specific determinations necessary to implement this new legislation have yet to be decided and communicated to industry participants. This uncertainty in the interpretation of the legislation increases the chances of an error in price reporting, which could in turn lead to a legal challenge, restatement or investigation. If we become subject to investigations, restatements or other inquiries concerning our compliance with price reporting laws and regulations, we could be required to pay or be subject to additional reimbursements, penalties, sanctions or fines, which could have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We participate in and have certain price reporting obligations to the Medicaid Drug Rebate program and other governmental pricing programs, and we have obligations to report average sales price under the Medicare program. Pricing and rebate calculations vary among products and programs. The calculations are complex and are often subject to interpretation by governmental or </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory agencies and the courts. For example, the Medicaid rebate amount is computed each quarter based on our submission to the CMS of our average manufacturer price, or AMP, and be</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">st price for the quarter. If we become aware that our reporting for prior quarters was incorrect, or has changed as a result of recalculation of the pricing data, we will be obligated to resubmit the corrected data for a period not to exceed twelve quarter</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s from the quarter in which the data originally were due. Such restatements and recalculations would serve to increase our costs for complying with the laws and regulations governing the Medicaid rebate program. Any corrections to our rebate calculations c</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ould result in an overage or underage in our rebate liability for past quarters, depending on the nature of the correction. Price recalculations also may affect the price that we will be required to charge certain safety net providers under the PHS 340B dr</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ug pricing program.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are liable for errors associated with our submission of pricing data and for overcharging government payers. For example, in addition to retroactive rebates and the potential for 340B program refunds, if we are found to have knowingly submitted false AMP or best price information to the government, we may be liable for civil monetary penalties in the amount of $100,000 per item of false information. Our failure to submit monthly/quarterly AMP and best price data on a timely basis could result in a civil monetary penalty of $10,000 per day for each day the submission is late beyond the due date. In the event that CMS were to terminate our rebate agreement, no federal payments would be available under Medicaid or Medicare Part B for our products. In addition, if we overcharge the government in connection with our Federal Supply Schedule, or FSS, contract or under any other government program, we will be required to refund the difference to the government. Failure to make necessary disclosures and/or to identify contract overcharges could result in allegations against us under the federal civil False Claims Act and other laws and regulations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CMS and the Office of Inspector General of the U.S. Department of Health and Human Services have pursued manufacturers that were alleged to have failed to report these data to the government in a timely manner. Governmental agencies may also make changes in program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. We cannot assure you that our submissions will not be found by CMS to be incomplete or incorrect.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we overcharge the government in connection with our FSS contract or the Tricare retail pharmacy program, whether due to a misstated Federal Ceiling Price or otherwise, we would be required to refund the difference to the government. Failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unexpected refunds to the federal government, and responding to a government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Commercialization of Our Product Candidates</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products. If we are found to have improperly promoted off-label uses while we marketed ONIVYDE, we may become subject to significant fines and other liability.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we are found to have promoted for off-label uses, we may become subject to significant government fines and other related liability. For example, the U.S. government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The government has also required companies to enter into complex multi-year corporate integrity agreements and/or non-prosecution agreements that can impose significant restrictions and other burdens on the affected companies.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, incentives under applicable U.S. laws encourage employees and physicians to report violations of rules governing promotional activities for pharmaceutical products. These incentives could lead to so called whistleblower lawsuits as part of which such persons seek to collect a portion of moneys allegedly overbilled to government agencies due to, for example, promotion of pharmaceutical products beyond labeled claims. Such lawsuits, whether with or without merit, are typically time consuming and costly to defend. Such suits may also result in related stockholder lawsuits, which are also costly to defend.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our relationships with customers and payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers, physicians and others play a primary role in the recommendation and prescription of products for which we obtain marketing approval. Arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing approval. Restrictions under applicable federal, state and foreign healthcare laws and regulations include the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the federal healthcare anti-kickback statute prohibits, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward the purchasing, leasing, ordering or arranging for the purchase, order or recommendation of any item or service reimbursable under Medicare, Medicaid, or other federal healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other, and violations are punishable by imprisonment, criminal fines, civil monetary penalties and exclusion from participation in federal healthcare programs. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the federal False Claims Act prohibits any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. Government enforcement agencies and private whistleblowers have initiated investigations or brought private lawsuits against pharmaceutical companies for a variety of allegedly improper promotional or marketing activities, such as allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates; allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product; or engaging in promotion for &#8220;off-label&#8221; uses. Additionally, the Health Care Reform Laws amended the federal False Claims Act such that a violation of the federal anti-kickback statute can serve as a basis for liability under the False Claims Act;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, or HIPAA, makes it a crime to knowingly and willfully execute or attempt to execute a scheme to defraud any healthcare benefit program and also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the federal false statements statute prohibits, among other things, knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the federal transparency requirements under the Health Care Reform Laws require manufacturers of drugs, devices, biologics and medical supplies reimbursable under Medicare and Medicaid to report to the Department of Health and Human Services information related to payments and other transfers of value to physicians and teaching hospitals, as well as physician ownership and investment interests, and provide for public reporting of the data reported by manufacturers;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the U.S. Foreign Corrupt Practices Act prohibits U.S. companies and their representatives from paying, offering to pay, promising or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity, and encompasses many healthcare professionals in many countries under the definition of a foreign government official;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the Bribery Act, which applies to U.S. companies such as ourselves that conduct business in the United Kingdom, proscribes giving and receiving bribes in the public and private sectors, bribing a foreign public official and failing to have adequate procedures to prevent employees and other agents from giving bribes; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers. In addition, some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government. Other states require pharmaceutical manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures, or prohibit certain marketing-related activities including the provision of gifts, meals or other items to certain healthcare providers.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations involve subs</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded hea</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we do business are found to be not in compliance with applicable laws, they may be su</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of significant resources and generate negative publicity, which could also harm our financial condition. Responding to government investigations or whistleblower lawsuits, defending any claims raised, and any resulting fines, damages, penalties, settlement</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> payments or administrative actions, as well as any related actions brought by stockholders or other third parties, could have a material impact on our reputation, business and financial condition and divert the attention of our management from operating o</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ur business.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our corporate compliance efforts cannot guarantee that we are in compliance with all potentially applicable regulations.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development, manufacturing, pricing, sales, coverage and reimbursement of our products, together with our general operations, are and will be subject to extensive regulation by federal, state and other authorities within the United States and numerous entities outside of the United States. While we have implemented a corporate compliance program based on what we believe are the current best practices, we cannot provide any assurance that governmental authorities will find that our business practices comply with current or future administrative or judicial interpretations of potentially applicable laws and regulations. If we fail to comply with any of these laws and regulations, we could be subject to a range of regulatory actions, including suspension or termination of clinical trials, the failure to approve a product candidate, restrictions on our products or manufacturing processes, withdrawal of products from the market, significant fines, disqualification or debarment from participation in federally-funded healthcare programs or other sanctions or litigation, any of which events may have a significant adverse impact on our business.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Data Protection and Cybersecurity</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our failure to comply with data protection laws and regulations could lead to government enforcement actions, private litigation and/or adverse publicity and could negatively affect our operating results and business.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to data protection laws and regulations that address privacy and data security. The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been an increasing focus on privacy and data security issues. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws and federal and state consumer protection laws govern the collection, use, disclosure and protection of health-related and other personal information. Failure to comply with data protection laws and regulations could result in government enforcement actions, which could include civil or criminal penalties, private litigation and/or adverse publicity and could negatively affect our operating results and business. In addition, we may obtain health information from third parties (e.g., healthcare providers who prescribe our products) that are subject to privacy and security requirements under HIPAA. We could be subject to criminal penalties if we knowingly obtain or disclose individually identifiable health information in a manner that is not authorized or permitted.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Significant disruptions of information technology systems or security breaches could adversely affect our business.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit large amounts of confidential information (including, among other things, trade secrets or other intellectual property, proprietary business information and personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We also have outsourced elements of our operations to third parties, and as a result we manage a number of third-party vendors who may or could have access to our confidential information. The size and complexity of our information technology systems, and those of third-party vendors with whom we contract, and the large amounts of confidential information stored on those systems, make such systems vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees, third-party vendors, and/or business partners, or from cyber-attacks by malicious third parties. Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant disruptions of our information technology systems, or those of our third-party vendors, or security breaches could adversely affect our business operations and/or result in the loss, misappropriation and/or unauthorized access, use or disclosure of, or </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the prevention of access to, confidential information, including, among other things, trade secrets or other intellectual property, proprietary business information and personal information, and could result in financial, legal, business and</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> reputational harm to us. For example, any such event that leads to unauthorized access, use or disclosure of personal information, including personal information regarding our patients or employees, could harm our reputation, require us to comply with fed</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eral and/or state breach notification laws and foreign law equivalents, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information. Security breaches and other inappropriate access can be </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. While we have implemented security measures to protect our information technology systems and infrastructure, there can be no assurance that such</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> measures will prevent service interruptions or security breaches that could adversely affect our business.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Employee Matters and Managing Growth</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain our key executives and to attract, retain and motivate qualified personnel.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent on the principal members of our executive and scientific teams. Although we have formal employment agreements with each of our executive officers, these agreements do not prevent our executives from terminating their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our corporate restructuring and the associated headcount reductions announced in October 2016 and January 2017 may not result in anticipated savings, could result in total costs and expenses and attrition that are greater than expected and could disrupt our business.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 3, 2016, we announced a 22% reduction in headcount as part of a major corporate restructuring with the objective of prioritizing our research and development on a focused set of systems biology-derived oncology products and strengthening our financial runway. Additionally, on January 8, 2017, we announced a further planned reduction in headcount in connection with the closing of the asset sale to Ipsen and the completion of our strategic pipeline review. We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from the restructuring, our operating results and financial condition would be adversely affected. We also cannot guarantee that we will not have to undertake additional headcount reductions or restructuring activities in the future. Furthermore, our restructuring plan may be disruptive to our operations. For example, our headcount reductions could yield unanticipated consequences, such as attrition beyond planned staff reductions, or increase difficulties in our day-to-day operations. Our headcount reductions could also harm our ability to attract and retain qualified management, scientific, clinical, manufacturing and sales and marketing personnel who are critical to our business. Any failure to attract or retain qualified personnel could prevent us from successfully developing and commercializing our product candidates in the future. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have entered into and may continue to enter into or seek to enter into business combinations, acquisitions or divestitures which may be difficult to consummate, disrupt our business, divert management attention or dilute stockholder value.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of our business strategy, we may enter into business combinations, acquisitions or divestitures. Although we acquired Hermes in October 2009 and consummated the asset sale to Ipsen in April 2017, we have limited experience in making acquisitions and divestitures. In addition, acquisitions and divestitures are typically accompanied by a number of risks, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the difficulty of integrating or separating the operations and personnel of the acquired companies or divested product;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the potential disruption of our ongoing business and distraction of management;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">potential unknown liabilities and expenses;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the failure to achieve the expected benefits of the combination, acquisition or divestiture;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">the maintenance of acceptable standards, controls, procedures and policies; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the impairment of relationships with employees as a result of any integration or separation of management and other personnel.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are not successful in completing acquisitions or divestitures that we may pursue in the future, we would be required to reevaluate our business strategy and we may have incurred substantial expenses and devoted significant management time and resources in seeking to complete the acquisitions or divestitures. In addition, with future acquisitions, we could use substantial portions of our available cash as all or a portion of the purchase price. As we did for the acquisition of Hermes, we could also issue additional securities as consideration for these acquisitions, which could cause our stockholders to suffer significant dilution.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Common Stock</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our executive officers, directors and principal stockholders maintain the ability to significantly influence all matters submitted to stockholders for approval.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our executive officers, directors and stockholders who own more than 5% of our outstanding common stock, in the aggregate, beneficially own a large portion of our capital stock. As a result, if these stockholders were to choose to act together, they would be able to significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could allow, delay or prevent an acquisition of our company on terms that other stockholders may desire.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. Among others, these provisions:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">allow the authorized number of our directors to be changed only by resolution of our board of directors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">limit who may call stockholder meetings;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, the repurchase right under the convertible notes in connection with a fundamental change (as defined therein) and any increase in the conversion rate in connection with a make-whole fundamental change could also discourage a potential acquirer.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our stock price has been and may in the future be volatile, which could cause holders of our common stock to incur sub</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">stantial losses.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stock price has been and in the future may be subject to substantial price volatility. The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, our stockholders could incur substantial losses. The market price for our common stock may be influenced by many factors, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the success of competitive products or technologies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">results of clinical trials of our product candidates or those of our competitors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory or legal developments in the United States and other countries;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">developments or disputes concerning patents or other proprietary rights;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the recruitment or departure of key personnel;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">variations in our financial results or those of companies that are perceived to be similar to us;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">changes in the structure of healthcare payment systems;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">market conditions in the pharmaceutical and biotechnology sectors and issuance of new or changed securities analysts&#8217; reports or recommendations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">activism by any single large stockholder or combination of stockholders;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">general economic, industry and market conditions; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the other factors described in this &#8220;Risk Factors&#8221; section.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because we do not anticipate paying regular cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain for holders of our common stock.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not historically declared or paid cash dividends on our common stock. Although <font style="Background-color:#FFFFFF;color:#000000;">our board of directors declared a special cash dividend of $140.0 million, which was payable on May 26, 2017 to stockholders of record as of the close of business on May 17, 2017</font>, we do not currently intend to pay any regular cash dividends in the foreseeable future. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for holders of our common stock for the foreseeable future.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Future sales of shares of our common stock, including by us or our directors and executive officers or shares issued upon the exercise of currently outstanding options, or upon conversion of our outstanding convertible notes, could cause the market price of our common stock to drop significantly, even if our business is doing well.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A substantial portion of our outstanding common stock can be traded without restriction at any time. In addition, a portion of our outstanding common stock is currently restricted as a result of federal securities laws, but can be sold at any time subject to applicable volume limitations. As such, sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, by us or others, could reduce the market price of our common stock. In addition, we have a significant number of shares that are subject to outstanding options, and we may issue shares of our common stock upon conversion of our outstanding convertible notes. The exercise of these options or the issuance of shares of our common stock upon conversion of our outstanding convertible notes and the subsequent sale of the underlying common stock could cause a further decline in our stock price. For instance, in April 2016, we issued an aggregate of 12,367,663 shares of our common stock to certain holders of our convertible notes who had agreed to convert an aggregate of $64.2 million of convertible notes. These sales also might make it difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. We cannot predict the size of future issuances or the effect, if any, that any future issuances may have on the market price for our common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_EXHIBITS"></a>Item 6.<font style="margin-left:36pt;"><a name="ITEM_6_EXHIBITS"></a>E</font>xhibits.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a>SIGNAT</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">URES</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:46.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:53.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">MERRIMACK PHARMACEUTICALS, INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:46.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:53.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:46.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 9, 2017</p></td>
<td valign="top"  style="width:2.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:50.56%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> /s/ Richard Peters, M.D., Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:46.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Peters, M.D., Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:46.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:46.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive and Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:46.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 9, 2017</p></td>
<td valign="top"  style="width:2.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:50.56%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> /s/ John L. Green</p></td>
</tr>
<tr>
<td valign="top"  style="width:46.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John L. Green</p></td>
</tr>
<tr>
<td valign="top"  style="width:46.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate Controller</p></td>
</tr>
<tr>
<td valign="top"  style="width:46.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Chief Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="EXHIBIT_INDEX"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="EXHIBIT_INDEX"></a>EXHIBIT</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> INDEX</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  style="width:91.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Exhibit </p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.9pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1*</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employment Agreement, dated as of May 1, 2017, by and between the Registrant and Daryl C. Drummond</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.9pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2*</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employment Agreement, dated as of February 24, 2015, by and between the Registrant and Jeffrey A. Munsie</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.9pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3*</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employment Agreement, dated as of May 4, 2017, by and between the Registrant and Sergio L. Santillana</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.9pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Retention Bonus Agreement, dated as of April&#160;3, 2017, by and between the Registrant and Yasir B. Al-Wakeel (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2017)</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.9pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Retention Bonus Agreement, dated as of April&#160;3, 2017, by and between the Registrant and Jeffrey A. Munsie (incorporated by reference to Exhibit 10.7 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2017)</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.9pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separation and Release of Claims Agreement, dated as of April 11, 2017, by and between the Registrant and Peter N. Laivins (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2017)</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.9pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separation and Release of Claims Agreement, dated as of April 11, 2017, by and between the Registrant and William M. McClements (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2017)</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.9pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separation and Release of Claims Agreement, dated as of April 11, 2017, by and between the Registrant and Edward J. Stewart (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2017)</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.9pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separation and Release of Claims Agreement, dated as of April 14, 2017, by and between the Registrant and William A. Sullivan (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2017)</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.9pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fifth Amendment of Lease, dated as of April 3, 2017, by and between the Registrant and ARE-MA Region No. 59, LLC (incorporated by reference to Exhibit 10.8 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2017)</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.9pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11*</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sixth Amendment of Lease, dated as of June 9, 2017, by and between the Registrant and ARE-MA Region No. 59, LLC</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.9pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease Agreement, dated as of April 3, 2017, by and between the Registrant and Ipsen Bioscience, Inc. (incorporated by reference to Exhibit 10.9 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2017)</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.9pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1*</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2*</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1+</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.2+</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS*</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH*</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL*</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF*</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB*</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Database</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE*</p></td>
<td valign="top"  style="width:91.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:83.33%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Furnished herewith.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>mack-ex101_188.htm
<DESCRIPTION>EX-10.1 - DRUMMOND EMPLOYMENT AGREEMENT
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mack-ex101_188.htm
</title>
</head>
<!-- NG Converter v4.0.8.13 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.1</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EMPLOYMENT AGREEMENT</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Employment Agreement (this &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;), dated as of May 1, 2017, is entered into by and between Merrimack Pharmaceuticals, Inc., a Delaware corporation with a place of business at One Kendall Square, Suite B7201, Cambridge, Massachusetts 02139 (the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;), and Daryl C. Drummond (the &#8220;<font style="text-decoration:underline;">Employee</font>&#8221;).</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Company desires to continue to employ the Employee on the terms and conditions, and for the consideration, hereinafter set forth, and the Employee desires to continue to be employed by the Company on such terms and conditions and for such consideration.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the foregoing and of the respective covenants and agreements of the parties herein contained, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Term of Employment</font><font style="font-weight:normal;">.&nbsp;&nbsp;Subject to the terms and conditions hereinafter set forth, the Company hereby employs the Employee, and the Employee hereby enters into the employment of the Company, for an employment term commencing on the date set forth above and, unless earlier terminated in accordance with the provisions set forth in Section 7, continuing until December 31, 2017.&nbsp;&nbsp;This Agreement shall renew automatically for successive one (1) year terms, unless either party shall give the other notice of non-renewal in accordance with Section 7.  The initial term of this Agreement, together with any annual renewal terms of this Agreement, shall be referred to as the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Term of Employment</font><font style="font-weight:normal;">.&#8221;&nbsp;&nbsp;The Employee&#8217;s Base Salary (as defined below) for any renewal term shall be as agreed by the parties, provided that (i) the Base Salary shall in no event be less than the Base Salary the Employee received in the immediately preceding term and (ii) in the absence of an agreement otherwise, the Employee&#8217;s Base Salary shall be the same as the Base Salary he received in the immediately preceding term.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Position</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">During the Term of Employment, the Employee shall serve as the Head of Research of the Company and in such additional position(s) as he and the Company shall agree.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Scope of Employment</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">During the Term of Employment, the Employee shall be responsible for the performance of all financial, managerial and administrative duties customarily performed by a Head of Research, together with such other duties as the Chief Executive Officer and the Employee shall agree.&nbsp;&nbsp;The Employee shall be accountable to the Chief Executive Officer and shall perform and discharge, faithfully, diligently and to the best of his ability, his duties and responsibilities hereunder.&nbsp;&nbsp;The Employee shall devote his full working time and efforts to the business and affairs of the Company and its affiliates.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Compensation</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">As full compensation for all services to be rendered by the Employee during the Term of Employment, the Company will provide to the Employee, and the Employee will accept, the following:</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>(a)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Base Salary.&nbsp;&nbsp;</font>During the Term of Employment, the Employee shall receive a base salary of $272,580 per calendar year, less all applicable taxes and withholdings </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(the &#8220;</font><font style="text-decoration:underline;">Base Salary</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), paid in</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> installments in accordance with the Company&#8217;s regularly established payroll procedure.&nbsp;&nbsp;The Employee&#8217;s Base Salary shall be reviewed annually by </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company&#8217;s Board of Directors (the &#8220;</font><font style="text-decoration:underline;">Board</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and may be adjusted from time to time in accordance with normal business practices and taking into account then-current market fact</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ors, but in no event shall the E</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mployee&#8217;s </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base S</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">alary be</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> less than the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ase </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">alary the E</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mployee received from the Company in the immediately preceding year.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Annual Discretionary Bonus.&nbsp;&nbsp;</font>During the Term of Employment, the Employee shall be eligible to receive a discretionary annual performance and retention bonus of up to 35% of his then-current Base Salary, at a time and under circumstances determined by the Board, in its sole discretion.&nbsp;&nbsp;In order to receive this bonus, the Employee must be an active employee of the Company on the date any bonus is determined and no discretionary annual bonus shall be considered earned before such date.&nbsp;&nbsp;Such discretionary bonus, if any, shall be paid no later than sixty (60) days following the date on which the Board approves such bonus.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Stock Options; Equity Grants.&nbsp;&nbsp;</font>The Employee shall be eligible to receive option grants or other equity grants at times and under circumstances determined by the Board, in its sole discretion.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Paid Time Off.&nbsp;&nbsp;</font>The Employee shall be eligible for paid time off in accordance with the Company&#8217;s Paid Time Off Policy contained within the Company&#8217;s Employee Handbook, as amended and/or superseded from time to time.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Insurance.&nbsp;&nbsp;</font>The Employee shall be entitled to participate in, and receive benefits under, all Company sponsored insurance and benefit programs (i.e., health, dental, life, and disability) available to senior management employees of the Company, subject to and on a basis consistent with the eligibility requirements, terms, conditions and overall administration of such programs.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Other Benefits.&nbsp;&nbsp;</font>The Employee shall be entitled to participate in, and receive benefits under, all Company employee benefit plans and arrangements (including but not limited to 401(k) and similar programs), available to senior management employees of the Company, subject to and on a basis consistent with the eligibility requirements, terms, conditions and overall administration of such plans, policies and arrangements.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Expenses</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">The Employee shall be entitled to reimbursement by the Company for all reasonable expenses actually incurred by him on the Company&#8217;s behalf in the performance of his duties during the course of his employment by the Company, upon the prompt presentation by the Employee, from time to time and in accordance with the Company&#8217;s then-current reimbursement policies, of an itemized account of such expenditures together with all supporting vouchers and receipts.&nbsp;&nbsp;All expense reimbursements shall be subject to the terms set forth in Section 5 of </font><font style="text-decoration:underline;font-weight:normal;">Exhibit C</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>6.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Restrictive Covenants</font><font style="font-weight:normal;">.&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, the Employee&#8217;s employment hereunder is subject to and conditioned on the Employee&#8217;s execution and delivery to the Company of the Non-Disclosure, Developments, Non-Competition </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">and Non-Solicitation Agreement </font><font style="font-weight:normal;">(the</font><font style="font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Restrictive Covenants Agreement</font><font style="font-weight:normal;">&#8221;) </font><font style="font-weight:normal;">attached hereto as </font><font style="text-decoration:underline;font-weight:normal;">Exhibit A</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Early Termination.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Death and Disability.&nbsp;&nbsp;</font>In the event of the Employee&#8217;s death during the Term of Employment, this Agreement shall terminate immediately.&nbsp;&nbsp;If, during the Term of Employment, the Employee shall be unable for a period of more than any three (3) consecutive months or for periods aggregating more than twenty-six (26) weeks in a twelve (12) month period to perform the services provided for herein as a result of any illness or disability, the Company may terminate the Employee&#8217;s employment hereunder.&nbsp;&nbsp;The Employee shall be considered unable to perform the services provided for herein if and whenever the Company reasonably determines, based upon the results of a medical examination performed by a mutually agreed-upon professional, that he is mentally or physically incapable of performing his duties hereunder.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Termination for Cause.&nbsp;&nbsp;</font>The Employee may be terminated by the Company without notice for &#8220;Cause.&#8221;&nbsp;&nbsp;The following, as determined by the Board in its reasonable judgment, shall constitute &#8220;<font style="text-decoration:underline;">Cause</font>&#8221; for termination:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Failure to Perform Duties.&nbsp;&nbsp;</font>The Employee&#8217;s material failure to perform (other than by reason of illness or disability) his duties to the Company, or his material negligence in the performance of his duties and/or responsibilities to the Company, provided that the Employee shall have had prior written notice and a reasonable opportunity of not less than thirty (30) days to correct any deficiency in such performance;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Breach of Employment Agreement or Restrictive Covenants Agreement.&nbsp;&nbsp;</font>The Employee&#8217;s material breach of this Agreement or the Restrictive Covenants Agreement;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Misconduct.&nbsp;&nbsp;</font>The Employee&#8217;s conviction for or plea of <font style="font-style:italic;">nolo contendere </font>or guilty to any crime involving fraud, embezzlement or moral turpitude or any felony; or</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Harmful Conduct.&nbsp;&nbsp;</font>Any conduct of the Employee that is materially harmful to the business, interests or reputation of the Company, provided that the Employee shall have had prior written notice and a reasonable opportunity of not less than ten (10) days to correct any such conduct.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Termination By Company Without Cause.&nbsp;&nbsp;</font>The Employee may be terminated by the Company without &#8220;Cause&#8221; upon delivery of written notice to the Employee.&nbsp;&nbsp;In the event the Employee is terminated without &#8220;Cause,&#8221; the Employee shall be entitled to receive the severance benefits set forth in Section 7(f) or 7(g), as applicable.&nbsp;&nbsp;The Company&#8217;s decision not to renew the Term of Employment shall constitute a termination without &#8220;Cause.&#8221;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>(d)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Termination by the Employee for Good Reason.&nbsp;&nbsp;</font>This Agreement may be terminated by the Employee for &#8220;Good Reason&#8221; (as defined below), upon thirty (30) days&#8217; prior written notice to the Company specifying any and all circumstances the Employee believes to </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">constitute the basis for Good Reason, provided that the Company shall have the opportunity to cure the asserted Good Reason within the thirty (30) day period.&nbsp;&nbsp;The Employee shall have &#8220;</font><font style="text-decoration:underline;">Good Reason</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; to terminate this Agreement in the event that the Company, without the express written consent of the Employee: (i) causes a material diminution of the Employee&#8217;s authority, duties or responsibilities; (ii) materially breaches this Agreement, including, without limitation, by materially reducing the Employee&#8217;s Base Salary</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or (iii) relocat</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">es</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the Employee&#8217;s place of business by more than thirty (30) miles from the Company&#8217;s current Cambridge, Massachusetts office.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Notwithstanding the foregoing, the Employee must </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">give notice of his intention to resign within ninety (90) days after the occurrence of the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">grounds for termination for Good Reason</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resign within thirty (30) days </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after the expiration of the Company&#8217;s </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thirty (30) day </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cure period referenced above, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or grounds for termination for Good Reason due to the circumstances specified in the notice are irrevocably waived.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event the Employee terminates his employment for Good Reason, the Employee shall be entitled to the severance benefits set forth in Section </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f) or </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g), as applicable.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Effect of Early Termination.&nbsp;&nbsp;</font>Except for a termination by the Company without &#8220;Cause&#8221; or by the Employee for &#8220;Good Reason,&#8221; in the event of any early termination of the Term of Employment, the Company&#8217;s obligations under this Agreement shall immediately cease and the Employee shall be entitled to only the Employee&#8217;s Base Salary and employment benefits which have accrued and to which the Employee is entitled through the date of such termination, including any bonus that may have been awarded but not yet paid.&nbsp;&nbsp;These accrued salary and benefits shall be paid on or about the date of termination.&nbsp;&nbsp;The Employee shall not be entitled to any other compensation or consideration, including any bonus not yet awarded that the Employee may have been eligible for had his Term of Employment not ceased, except as otherwise set forth in this Section 7(e).&nbsp;&nbsp;In the event of an early termination of the Term of Employment due to the Employee&#8217;s death or disability, as set forth in Section 7(a), the Employee (or his estate, in the event of his death) will be eligible to receive a pro rata bonus determined in the manner set forth in the penultimate sentence of Section 7(f), which bonus shall be paid within thirty (30) days following the date of the Employee&#8217;s termination.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>(f)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Severance Benefits Prior to a Change in Control.&nbsp;&nbsp;</font>If the Term of Employment is terminated by the Company without &#8220;Cause&#8221; (as that term is defined in Section 7(b)) or by the Employee for &#8220;Good Reason&#8221; (as that term is defined in Section 7(d)), in each case prior to a Change in Control (as that term is defined in <font style="text-decoration:underline;">Exhibit B</font>), the Employee shall be entitled to receive his Base Salary and all other employment benefits accrued through the effective date of such termination, which shall be paid on or about the date of termination.&nbsp;&nbsp;In addition, provided the Employee executes and allows to become binding a severance agreement and release of claims drafted by and satisfactory to the Company (the &#8220;<font style="text-decoration:underline;">Release</font>&#8221;) on or before the sixtieth (60<sup style="font-size:85%; vertical-align:top">th</sup>) day after the date of termination, then beginning on the first regularly scheduled payroll date that is sixty (60) days following the date of termination (such date, the &#8220;<font style="text-decoration:underline;">Payment Commencement Date</font>&#8221;), for a period of twelve (12) months (the &#8220;<font style="text-decoration:underline;">Severance Period</font>&#8221;), the Company shall: (i) pay to the Employee as severance pay his Base Salary in accordance with the Company&#8217;s regularly established payroll procedure and (ii) pay for coverage under any medical benefit plans provided pursuant to Section 4(e), provided the Employee is eligible for and elects to continue receiving such benefits pursuant to the federal &#8220;COBRA&#8221; law, 29 U.S.C. &#167; 1161 et. seq., and provided further that the Employee continues to pay the applicable share of the premium for such coverage that is paid by active and similarly situated employees who receive </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the same type of coverage.&nbsp;&nbsp;In addition, the Company shall pay to the Employee, on the Payment Commencement Date, a pro-rata bonus equal to (A) the average of the Employee&#8217;s annual bonus payments over each of the three </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">years prior to the year of termination (or</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, if the Employee is an executive officer,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> such lesser period during which the Employee served as an executive officer of the Company)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or, if such termination occurs prior to the award of the Employee&#8217;s first annual bonus for </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Employee&#8217;s target annual bonus for </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:10pt;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">multiplied by (B) a fraction, the numerator of which is the number of days during the year during which the Employee remained employed by the Company and the denominator of which is 365.&nbsp;&nbsp;The distribution of all severance benefits under this Section </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f) shall be subject to the provisions of </font><font style="text-decoration:underline;">Exhibit</font><font style="text-decoration:underline;"> </font><font style="text-decoration:underline;">C</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Severance Benefits After a Change in Control</font>.&nbsp;&nbsp;If the Term of Employment is terminated by the Company without &#8220;Cause&#8221; (as that term is defined in Section 7(b)) or by the Employee for &#8220;Good Reason&#8221; (as that term is defined in Section 7(d)), in each case within the eighteen (18) month period following a Change in Control (as that term is defined in <font style="text-decoration:underline;">Exhibit B</font>), the Employee shall be entitled to receive his Base Salary and all other employment benefits accrued through the effective date of such termination, which shall be paid on or about the date of termination.&nbsp;&nbsp;In addition, provided the Employee executes and allows to become binding the Release on or before the Payment Commencement Date, the Company shall: (i) pay to the Employee as severance pay on the Payment Commencement Date a lump sum amount equal to thirty-six (36) months of his Base Salary; (ii) pay to the Employee on the Payment Commencement Date a bonus equal to (A) three (3) multiplied by (B) the average of the Employee&#8217;s annual bonus payments over each of the three (3) years prior to the year of termination <font style="font-size:10pt;">(</font>or, if the Employee is an executive officer, such lesser period during which the Employee served as an executive officer of the Company) , or, if such termination occurs prior to the award of the Employee&#8217;s first annual bonus for 2017, the Employee&#8217;s target annual bonus for 2017;<font style="font-size:10pt;"> </font>(iii) accelerate the vesting of all outstanding Company stock options, restricted stock or other equity awards granted to the Employee; and (iv) pay for coverage under any medical benefit plans provided pursuant to Section 4(e) for a period of eighteen (18) months following the Employee&#8217;s date of termination, provided the Employee is eligible for and elects to continue receiving such benefits pursuant to the federal &#8220;COBRA&#8221; law, 29 U.S.C. &#167; 1161 et. seq., and provided further that the Employee continues to pay the applicable share of the premium for such coverage that is paid by active and similarly situated employees who receive the same type of coverage.&nbsp;&nbsp;The distribution of all severance benefits under this Section 7(g) shall be subject to the provisions of <font style="text-decoration:underline;">Exhibit C</font>.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Absence of Restrictions</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">The Employee represents and warrants that he is not a party to any commitment or undertaking by which he is subject to any restriction or limitation upon his entering into this Agreement or performing the services required of him hereunder.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Amendments</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">Any amendment to this Agreement shall be made in writing and signed by the parties hereto.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>10.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Applicable Law/Jury Trial Waiver</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts (without reference to the conflict of laws provisions thereof).&nbsp;&nbsp;Any action, suit or other legal proceeding arising under or relating to any provision of this Agreement shall be commenced only in a court </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">of the Commonwealth of Massachusetts (or, if appropriate, a federal court located within the Commonwealth of Massachusetts), and the Company and the Employee each consents to the jurisdiction of such a court.&nbsp;&nbsp;The Company and the Employee each hereby irrevocably waives any right to a trial by jury in any action, suit or other legal proceeding arising under or relating to any provision of this Agreement.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Entire Agreement</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">This Agreement, together with the Restrictive Covenants Agreement attached hereto as </font><font style="text-decoration:underline;font-weight:normal;">Exhibit A</font><font style="font-weight:normal;"> and executed as a condition of the Employee&#8217;s employment, constitutes the entire agreement between the parties and supersedes all prior agreements and understandings, whether written or oral, relating to the subject matter of these agreements.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Successors and Assigns</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and assigns, including any corporation with which or into which the Company may be merged or which may succeed to its assets or business; provided, however, that the obligations of the Employee are personal and shall not be assigned by him.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Acknowledgment</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">The Employee states and represents that he has had an opportunity to fully discuss and review the terms of this Agreement with an attorney.&nbsp;&nbsp;The Employee further states and represents that he has carefully read this Agreement, understands the contents herein, freely and voluntarily assents to all of the terms and conditions hereof, and signs his name of his own free act.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Miscellaneous</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:0pt;"></font>No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right.&nbsp;&nbsp;A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar to or waiver of any right on any other occasion.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:0pt;"></font>The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:0pt;"></font>In case any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Remainder of Page Intentionally Left Blank]<br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the parties here</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to have executed this Agreement</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as of the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">date</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> first written</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> above</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COMPANY:<font style="font-weight:normal;margin-left:216pt;"></font></p>
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:46.15%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MERRIMACK PHARMACEUTICALS, INC<font style="font-weight:normal;">.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:46.15%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;">/s/ Richard Peters</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:50%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Peters</p>
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:50%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:46.15%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EMPLOYEE:</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:46.15%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Daryl C. Drummond</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Daryl C. Drummond</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:57.69%;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="text-decoration:underline;">Exhibit A</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-Disclosure, Developments, Non-Competition and Non-Solicitation Agreement</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NON-DISCLOSURE, DEVELOPMENTS, NON-COMPETITION</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AND NON-SOLICITATION AGREEMENT</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Non-Disclosure, Developments, Non-Competition and Non-Solicitation Agreement (the &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;), dated as of May 1, 2017, is entered into by and between Merrimack Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;), and Daryl C. Drummond (the &#8220;<font style="text-decoration:underline;">Employee</font>&#8221;).</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration of the Employee&#8217;s employment with the Company and for other valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the Employee, the Employee hereby agrees as follows:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Condition of Employment</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="OLE_LINK1"></a><a name="OLE_LINK2"></a><a name="OLE_LINK1"></a><a name="OLE_LINK2"></a>The Employee acknowledges that his/her<font style="font-weight:bold;"> </font>employment and the continuance of that employment with the Company is contingent upon his/her<font style="font-weight:bold;"> </font>agreement to sign and adhere to the provisions of this Agreement.&nbsp;&nbsp;The Employee further acknowledges that the nature of the Company&#8217;s business is such that protection of its proprietary and confidential information and goodwill with its customers and partners is critical to its survival and success.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Confidential Information</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:0pt;"></font><font style="color:#000000;">The Employee agrees that all information and know-how, whether or not in writing, of a private, secret or confidential nature concerning the Company and its operations and business or financial affairs (collectively, &#8220;</font><font style="text-decoration:underline;color:#000000;">Confidential Information</font><font style="color:#000000;">&#8221;) is and shall be the exclusive property of the Company.&nbsp;&nbsp;By way of illustration, but not limitation, Confidential Information may include</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">models, systems, software and codes, or systems, software and codes in the course of development, or planned or proposed systems, software or codes, customer, prospect and supplier lists, contacts at or knowledge of customers or prospective customers, customer accounts and other customer financial information, strategic partners and/or collaborators, price lists and all other pricing, marketing and sales information, projections, results relating to the Company or any customer or supplier of the Company, databases, modules, products, programs, product improvements, product enhancements and/or developments, designs, specifications, processes, methods, techniques, operations, projects, plans, chemical compounds, chemical or biological materials, engineering data, clinical or technological data, research data, financial data, personnel information, and other confidential agreements or documents (including, without limitation, clinical trial protocols and unpublished patent applications).&nbsp;&nbsp;Except as otherwise permitted by Section 5, the Employee will not disclose any Confidential Information to others outside the Company or use the same for any unauthorized purposes without written approval by an officer of the Company, either during or at any time after his/her employment with the Company, unless and until such Confidential Information has become public knowledge without fault by the Employee.&nbsp;&nbsp;While employed by the Company, the Employee will use the Employee&#8217;s best efforts to prevent publication or disclosure of any Confidential Information.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>(b)<font style="margin-left:0pt;"></font><font style="color:#000000;">The Employee agrees that all Company Property (as defined below), whether created by the Employee or others, that shall come into the Employee&#8217;s custody or possession </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">shall be and is the sole and exclusive property of the Company to be used only in the performance of the Employee&#8217;s duties for the Company.&nbsp;&nbsp;&#8220;</font><font style="text-decoration:underline;color:#000000;">Company Property</font><font style="color:#000000;">&#8221; means any and all written, photographic or any other record containing Confidential Information and shall include, but not be limited to, all agreements, notes, disks, files, letters, memoranda, reports, records, lists, data, drawings, sketches, notebooks, program listings, specifications, software programs, software code, computers and other electronic equipment, documentation, or other equipment or materials of any nature and in any form, containing Confidential Information.&nbsp;&nbsp;Upon the earliest of the Employee&#8217;s termination or a request from the Company, the Employee will return to the Company any and all Company Property in the Employee&#8217;s custody or possession without retaining any copies thereof (including, without limitation, any electronic copy) and without using or allowing others to improperly use such Company Property.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:0pt;"></font><font style="color:#000000;">The Employee acknowledges that the Employee&#8217;s obligations with regard to Confidential Information that are set out in Sections 2(a) and (b) extend to all information, know-how, records and tangible property of customers of the Company or suppliers to the Company or of any third party who may have disclosed or entrusted the same to the Company or to the Employee in the course of the Company&#8217;s business.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Developments</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:0pt;"></font><font style="color:#000000;">The Employee will make full and prompt disclosure to the Company of all inventions, ideas, concepts, improvements, discoveries, methods, techniques, tools, formula, developments, enhancements, modifications, databases,&#160;processes, software and works of authorship, whether patentable or not, that are created, made, conceived or reduced to practice by the Employee or under the Employee&#8217;s direction or jointly with others during the Employee&#8217;s employment with the Company, whether or not during normal working hours or on the premises of the Company (all of which are collectively referred to in this Agreement as &#8220;</font><font style="text-decoration:underline;color:#000000;">Developments</font><font style="color:#000000;">&#8221;).</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>(b)<font style="margin-left:0pt;"></font><font style="color:#000000;">The Employee agrees to assign and does hereby assign to the Company (or any person or entity designated by the Company) all of the Employee&#8217;s right, title and interest in and to all Developments and all related intellectual property rights.&nbsp;&nbsp;Except as, and solely to the extent that, it may be necessary for the Employee to perform&#160;the Employee&#8217;s duties and fulfill&#160;the Employee&#8217;s obligations in the course of the Employee&#8217;s employment with the Company, the Company does not grant the Employee, and the Employee agrees that he/she will not receive, any license or right to use any Development or related intellectual property right.&nbsp;&nbsp;The Employee hereby also waives all claims to moral rights in any Developments.&nbsp;&nbsp;However, this Section 3(b) shall not apply to Developments that do not relate to the present or planned business or research and development of the Company and that are made and conceived by the Employee not during normal working hours, not on the Company&#8217;s premises and not using the Company&#8217;s tools, devices, equipment or Confidential Information.&nbsp;&nbsp;This Section 3(b) also shall not apply to any inventions that the Employee conceived of prior to the Employee&#8217;s employment with the Company, which invention(s) the Employee shall disclose on </font><font style="text-decoration:underline;color:#000000;">Exhibit A</font><font style="color:#000000;"> attached hereto.&nbsp;&nbsp;IF THERE ARE ANY SUCH INVENTIONS TO BE EXCLUDED UNDER THIS AGREEMENT, THE EMPLOYEE SHALL INITIAL HERE; OTHERWISE IT WILL BE DEEMED THAT THERE ARE NO SUCH EXCLUSIONS. ____&nbsp;&nbsp;The Employee understands that, to the extent this Agreement shall be construed in accordance with the laws of any state that precludes the requirement in an employee agreement to assign certain classes of inventions made </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">by an employee, this Section 3(b) shall be interpreted not to apply to any invention that a court rules and/or the Company agrees falls within such classes.&nbsp;&nbsp;To the extent allowed by law, the Employee hereby grants to the Company an exclusive (even unto the Employee), irrevocable, fully paid up, worldwide license to make, use and sell any and all inventions for which assignment cannot be effected.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="OLE_LINK7"></a><a name="OLE_LINK8"></a>(c)<font style="margin-left:0pt;"></font><font style="color:#000000;"><a name="OLE_LINK7"></a><a name="OLE_LINK8"></a>The Employee agrees to cooperate fully with the Company, both during and after the Employee&#8217;s employment with the Company, with respect to the procurement, maintenance and enforcement of all copyrights, trademarks, patents and other intellectual property rights (both in the United States and foreign countries) relating to any Development.&nbsp;&nbsp;The Employee shall sign all papers, including, without limitation, copyright applications, patent applications, declarations, oaths, formal assignments, assignment of priority rights and powers of attorney, that the Company may deem necessary or desirable in order to protect and enforce its rights and interests in any Development.&nbsp;&nbsp;The Employee further agrees that if the Company is unable, after reasonable effort, to secure the signature of the Employee on any such papers, any executive officer of the Company shall be entitled to execute any such papers as the agent and the attorney-in-fact of the Employee, and the Employee hereby irrevocably designates and appoints each executive officer of the Company as the Employee&#8217;s agent and attorney-in-fact for all countries worldwide to execute any such papers on the Employee&#8217;s behalf, and to take any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in any Development, under the conditions described in this sentence.&nbsp;&nbsp;Should the Company engage in litigation to enforce any such intellectual property rights, the Employee agrees to appear and testify at no charge, but at the Company&#8217;s expense.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Non-Competition and Non-Solicitation</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:0pt;"></font>While<font style="color:#000000;"> the Employee is employed by the Company and for a period of twelve (12) months following the Employee&#8217;s termination or cessation of employment for any reason (voluntarily or involuntarily), the Employee will not, directly or indirectly:</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>engage in any business or enterprise (whether as an owner, partner, officer, employee, director, investor, lender, consultant, independent contractor or otherwise, except as the holder of not more than 1% of the combined voting power of the outstanding stock of a publicly held company) that is competitive with the Company&#8217;s business, including, without limitation, any business or enterprise that develops, designs, produces, markets or sells any product or service competitive with any product or service developed, designed, produced, marketed or sold or planned to be developed, designed, produced, marketed or sold by the Company while the Employee was employed by the Company;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>either alone or in association with others, recruit, solicit, hire or engage as an independent contractor, or attempt to recruit, solicit, hire or engage as an independent contractor, any person who was employed by the Company or engaged as an independent contractor for the Company at any time during the period of the Employee&#8217;s employment with the Company, except for an individual whose employment with or service for the Company has been terminated for a period of six (6) months or longer; and/or</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">either alone or in association with others, service, solicit, divert or take away, or attempt to service, solicit, divert or take away, the business or patronage of any of the clients, customers or accounts, or prospective clients, customers or accounts, of the Company that were contacted, solicited or served by the Employee while the Employee was employed by the Company or about which the Employee had access to Confidential Information in the course of his/her employment with the Company.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:0pt;"></font><font style="color:#000000;">The geographic scope of this Section 4 shall extend to anywhere the Company or any of its subsidiaries is doing business, has done business or has plans to do business during the Employee&#8217;s employment with the Company.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:0pt;"></font><font style="color:#000000;">If any restriction set forth in this Section 4 is found by any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:0pt;"></font><font style="color:#000000;">The Employee agrees that during the non-competition and non-solicitation period, the Employee will give notice to the Company of each new job, contract assignment or other work (either as an employee, contractor or otherwise) the Employee plans to undertake at least ten (10) business days prior to beginning any such activity.&nbsp;&nbsp;The notice shall state the name and address of the individual, corporation, association or other entity or organization (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Entity</font><font style="color:#000000;">&#8221;) for whom such activity is undertaken and the Employee&#8217;s proposed business relationship or position with the Entity.&nbsp;&nbsp;The Employee further agrees to provide the Company with other pertinent information concerning such business activity as the Company may reasonably request in order to determine the Employee&#8217;s continued compliance with his/her obligations under this Agreement.&nbsp;&nbsp;During the non-competition and non-solicitation period, the Employee agrees to provide a copy of this Agreement to all person and Entities with whom the Employee seeks to be hired or do business before accepting employment or engagement with any of them.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:0pt;"></font><font style="color:#000000;">If the Employee violates any of the provisions of this Section 4, the Employee shall continue to be held by the restrictions set forth in this Section 4 until a period equal to the period of restriction has expired without any violation.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_4"></a>5.<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Scope of Disclosure Restrictions</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a>Nothing in this Agreement prohibits the Employee from communicating with government agencies about possible violations of federal, state or local laws or otherwise providing information to government agencies or participating in government agency investigations or proceedings.&nbsp;&nbsp;The Employee is not required to notify the Company of any such communications; provided, however, that nothing herein authorizes the disclosure of information the Employee obtained through a communication that was subject to the attorney-client privilege.&nbsp;&nbsp;Further, notwithstanding the Employee&#8217;s confidentiality and nondisclosure obligations, the Employee is hereby advised as follows pursuant to the Defend Trade Secrets Act: &#8220;An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.&nbsp;&nbsp;An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.&#8221;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Other Agreements</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Employee hereby represents that, except as the Employee has disclosed in writing to the Company, the Employee is not bound by the terms of any restrictive covenant agreement with any previous employer or other party relating to the non-disclosure of trade secret or confidential or proprietary information, non-competition and/or non-solicitation of customers, clients, employees or others.&nbsp;&nbsp;The Employee further represents that the Employee&#8217;s performance of all the terms of this Agreement and as an employee of the Company does not and will not breach any such restrictive covenant agreement, and the Employee will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or others.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Employment At Will</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Employee acknowledges that this Agreement does not constitute a contract of employment for any period of time and does not modify the at-will nature of the Employee&#8217;s employment with the Company, pursuant to which both the Company and the Employee may terminate the employment relationship at any time, for any or no reason, with or without notice.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">General Provisions</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Equitable Relief</font><font style="color:#000000;">.&nbsp;&nbsp;The Employee acknowledges that the restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company and are considered by the Employee to be reasonable for such purpose.&nbsp;&nbsp;The Employee agrees that any breach or threatened breach of this Agreement will cause the Company substantial and irrevocable damage that is difficult to measure.&nbsp;&nbsp;Therefore, in the event of any such breach or threatened breach, the Employee agrees that the Company, in addition to such other remedies that may be available, shall have the right to specific performance and injunctive relief without posting a bond, as well as its reasonable attorneys&#8217; fees incurred as a result of any such breach or threatened breach.&nbsp;&nbsp;The Employee hereby waives the adequacy of a remedy at law as a defense to such relief.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Change in Terms/Conditions of Employment</font><font style="color:#000000;">.&nbsp;&nbsp;The Employee agrees that his/her&nbsp;&nbsp;obligations under this Agreement shall continue in full force and effect in the event that the Employee&#8217;s job title, responsibilities, reporting structure, work location, compensation or other conditions of his/her employment with the Company change subsequent to the execution of this Agreement, without the need to execute a new agreement.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">No Conflict</font><font style="color:#000000;">.&nbsp;&nbsp;The Employee represents that the execution and performance by the Employee of this Agreement does not and will not conflict with or breach the terms of any other agreement by which the Employee is bound.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font><font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Severability</font><font style="color:#000000;">.&nbsp;&nbsp;The invalidity or unenforceability of any provision of this Agreement shall not affect or impair the validity or enforceability of any other provision of this Agreement.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Waiver</font><font style="color:#000000;">.&nbsp;&nbsp;No delay or omission by the Company in exercising any right under this Agreement will operate as a waiver of that or any other right.&nbsp;&nbsp;A waiver or consent given by the Company on any one occasion is effective only in that instance and will not be construed as a bar to or waiver of any right on any other occasion.&nbsp;&nbsp;Any waiver of any provision hereof shall be in writing and signed by the Company.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Successors and Assigns</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and assigns, including, without limitation, any corporation or entity with which or into which the Company may be merged or which may succeed to all or substantially all of its assets or business; provided, however, that the obligations of the Employee are personal and shall not be assigned by the Employee.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Governing Law, Forum and Jurisdiction/Jury Trial Waiver</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement shall be governed by and construed as a sealed instrument under and in accordance with the laws of the Commonwealth of Massachusetts without regard to conflict of laws provisions.&nbsp;&nbsp;Any action, suit or other legal proceeding that is commenced to resolve any matter arising under or relating to any provision of this Agreement shall be commenced only in a court of the Commonwealth of Massachusetts (or, if appropriate, a federal court located within Massachusetts), and the Company and the Employee each consents to the jurisdiction of such a court.&nbsp;&nbsp;</font><font style="font-weight:bold;color:#000000;">The Employee and the Company hereby expressly waive the right to a jury trial for any claim relating to his/her/its rights or obligations under this Agreement, or otherwise relating to the Employee&#8217;s employment or separation from employment with the Company.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Captions</font><font style="color:#000000;">.&nbsp;&nbsp;The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Entire Agreement</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement supersedes all prior agreements, written or oral, between the Employee and the Company relating to the subject matter of this Agreement.&nbsp;&nbsp;This Agreement may not be amended, modified, changed or discharged in whole or in part, except by an agreement in writing signed by the Employee and the Company.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THE EMPLOYEE ACKNOWLEDGES THAT HE/SHE HAS CAREFULLY READ THIS AGREEMENT AND UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Remainder of Page Intentionally Left Blank]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.</font></p>
<p style="margin-bottom:24pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COMPANY:<font style="font-weight:normal;margin-left:216pt;"></font></p>
<p style="margin-top:24pt;margin-bottom:0pt;text-indent:46.15%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MERRIMACK PHARMACEUTICALS, INC.</p>
<p style="margin-top:24pt;margin-bottom:0pt;text-indent:46.15%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;">/s/ Richard Peters</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:50%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Peters</p>
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:50%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:50%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:24pt;margin-bottom:0pt;text-indent:46.15%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EMPLOYEE:</p>
<p style="margin-top:24pt;margin-bottom:0pt;text-indent:46.15%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Daryl C. Drummond</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Daryl C. Drummond</p>
<p style="margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><font style="text-decoration:underline;">Exhibit A</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">List of Prior Inventions and Original Works of Authorship</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:478.8pt;;">
<tr>
<td style="width:99.9pt;"></td>
<td style="width:112.5pt;"></td>
<td style="width:266.4pt;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identifying Number or Brief Description</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;margin-left:36pt;"></font> Additional Sheets Attached</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature of Employee:<font style="margin-left:36pt;"></font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Printed Name of Employee:<font style="margin-left:36pt;"></font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:<font style="margin-left:36pt;">________________________</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit B</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Definition of Change in Control </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A &#8220;<font style="text-decoration:underline;">Change in Control</font>&#8221; shall occur upon any of the following events, provided, in each case, that such event constitutes a &#8220;change in control event&#8221; within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(i):</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(A)<font style="margin-left:36pt;">the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="text-decoration:underline;">Exchange Act</font>&#8221;)) (a &#8220;<font style="text-decoration:underline;">Person</font>&#8221;) of beneficial ownership of any capital stock of the Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule 13d-3 under the Exchange Act) 50% or more of either (x) the then-outstanding shares of common stock of the Company (the &#8220;<font style="text-decoration:underline;">Outstanding Company Common Stock</font>&#8221;) or (y) the combined voting power of the then-outstanding securities of the Company entitled to vote generally in the election of directors (the &#8220;<font style="text-decoration:underline;">Outstanding Company Voting Securities</font>&#8221;); provided, however, that for purposes of this subsection (A), the following acquisitions shall not constitute a Change in Control: (1) any acquisition directly from the Company or (2) any acquisition by any corporation pursuant to a Business Combination (as defined below) which complies with clauses (x) and (y) of subsection (C) of this definition;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(B)<font style="margin-left:36pt;">a change in the composition of the Board that results in the Continuing Directors (as defined below) no longer constituting a majority of the Board (or, if applicable, the Board of Directors of a successor corporation to the Company), where the term &#8220;</font><font style="text-decoration:underline;">Continuing Director</font>&#8221; means at any date a member of the Board (x) who was a member of the Board on the date of this Agreement or (y) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided, however, that there shall be excluded from this clause (y) any individual whose initial assumption of office occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board; or</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a>(C)<font style="margin-left:36pt;">the consummation of a merger, consolidation, reorganization, recapitalization or share exchange involving the Company or a sale or other disposition of all or substantially all of the assets of the Company (a &#8220;</font><font style="text-decoration:underline;">Business Combination</font>&#8221;), unless, immediately following such Business Combination, each of the following two conditions is satisfied: (x) all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Company&#8217;s assets either directly or through one or more subsidiaries) (such resulting or acquiring </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">corporation is referred to herein as the &#8220;</font><font style="text-decoration:underline;">Acquiring Corporation</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) in substantially the same proportions as their ownership of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively, immediately prior to such Business Combination and (y) no Person (excluding any employee benefit plan (or related trust) maintained or sponsored by the Company or by the Acquiring Corporation</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) beneficially owns, directly or indirectly, 50%</font><font style="font-weight:bold;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or more of the then-outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such corporation entitled to vote generally in the election of directors (except to the extent that such ownership existed prior to the Business Combination)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit </font><font style="text-decoration:underline;">C</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments Subject to Section 409A</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to this Exhibit C, severance payments or benefits under this Agreement shall begin only on or after the date of the Employee&#8217;s &#8220;separation from service&#8221; (determined as set forth below), which occurs on or after the termination of the Employee&#8217;s employment.&nbsp;&nbsp;The following rules shall apply with respect to distribution of the payments and benefits, if any, to be provided to the Employee under this Agreement:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is intended that each installment of the payments provided under this Agreement shall be treated as a separate &#8220;payment&#8221; for purposes of Section 409A of the Internal Revenue Code and the guidance issued thereunder (&#8220;<font style="text-decoration:underline;">Section 409A</font>&#8221;).&nbsp;&nbsp;Neither the Company nor the Employee shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, as of the date of the Employee&#8217;s &#8220;separation from service&#8221; from the Company, the Employee is not a &#8220;specified employee&#8221; (within the meaning of Section 409A), then each installment of the severance payments and benefits shall be made on the dates and terms set forth in this Agreement.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, as of the date of the Employee&#8217;s &#8220;separation from service&#8221; from the Company, the Employee is a &#8220;specified employee&#8221; (within the meaning of Section 409A), then:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Each installment of the severance payments and benefits due under this Agreement that, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when the Employee&#8217;s separation from service occurs, be paid within the Short-Term Deferral Period (as defined under Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section 1.409A- l(b)(4) to the maximum extent permissible under Section 409A and shall be paid at the time set forth in this Agreement; and</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a>(b)<font style="margin-left:36pt;"></font>Each installment of the severance payments and benefits due under this Agreement that is not described in this Exhibit C, Section 3(a) and that would, absent this subsection, be paid within the six (6) month period following the Employee&#8217;s &#8220;separation from service&#8221; from the Company shall not be paid until the date that is six (6) months and one (1) day after such separation from service (or, if earlier, the Employee&#8217;s death), with any such installments that are required to be delayed being accumulated during the six (6) month period and paid in a lump sum on the date that is six (6) months and one (1) day following the Employee&#8217;s separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth in this Agreement; provided, however, that the preceding provisions of this sentence shall not apply to any installment of severance payments and benefits if and to the maximum extent that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-l(b)(9)(iii) (relating to separation pay upon an involuntary separation from service).&nbsp;&nbsp;Any installments that qualify for the exception under Treasury Regulation Section 1.409A-l(b)(9)(iii) must be paid no later than the last day of the Employee&#8217;s second taxable year following the taxable year in which the separation from service </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">occurs.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The determination of whether and when the Employee&#8217;s separation from service from the Company has occurred shall be made in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-l(h).&nbsp;&nbsp;Solely for purposes of this Exhibit C, Section 4, &#8220;<font style="text-decoration:underline;">Company</font>&#8221; shall include all persons with whom the Company would be considered a single employer under Section 414(b) and 414(c) of the Internal Revenue Code.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during the Employee&#8217;s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company makes no representation or warranty and shall have no liability to the Employee or to any other person if any of the provisions of this Agreement (including this Exhibit C) are determined to constitute deferred compensation subject to Section 409A but that do not satisfy an exemption from, or the conditions of, that section.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:36pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company may withhold (or cause to be withheld) from any payments made under this Agreement, all federal, state, city or other taxes as shall be required to be withheld pursuant to any law or governmental regulation or ruling.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>mack-ex102_187.htm
<DESCRIPTION>EX-10.2 - MUNSIE EMPLOYMENT AGREEMENT
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mack-ex102_187.htm
</title>
</head>
<!-- NG Converter v4.0.8.13 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.2</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EMPLOYMENT AGREEMENT</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Employment Agreement (this &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;), dated as of February 24, 2015, is entered into by and between Merrimack Pharmaceuticals, Inc., a Delaware corporation with a place of business at One Kendall Square, Suite B7201, Cambridge, Massachusetts 02139 (the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;), and Jeffrey A. Munsie, an individual residing at 3 Lexington Circle, Bedford, MA 01730 (the &#8220;<font style="text-decoration:underline;">Employee</font>&#8221;).</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Company desires to continue to employ the Employee as General Counsel; and</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Employee desires to continue such employment upon the terms and conditions set forth in this Agreement.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the foregoing and of the respective covenants and agreements of the parties herein contained, the parties hereto agree as follows:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="font-style:italic;">Term of Employment</font><font style="font-weight:normal;">.&nbsp;&nbsp;Subject to the terms and conditions hereinafter set forth, the Company hereby employs the Employee, and the Employee hereby enters into the employment of the Company, for an employment term commencing on the date set forth above and, unless earlier terminated in accordance with the provisions set forth in Section 10, continuing until December 31, 2015.&nbsp;&nbsp;This Agreement shall renew automatically for successive one (1) year terms, unless either party shall give the other notice of non-renewal in accordance with Section 10.  Both the initial term of this Agreement and any annual renewal term of this Agreement shall be referred to as the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Term of Employment</font><font style="font-weight:normal;">.&#8221;&nbsp;&nbsp;The Employee&#8217;s Base Salary (as defined below) for any renewal term shall be as agreed by the parties, provided that (i) the Base Salary shall in no event be less than the Base Salary the Employee received in the immediately preceding term, and (ii) in the absence of an agreement otherwise, the Employee&#8217;s Base Salary shall be the same as the Base Salary he received in the immediately preceding term.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="font-style:italic;">Position</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">During the Term of Employment, the Employee shall serve as General Counsel of the Company and in such additional position(s) as he and the Company shall agree.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font><font style="font-style:italic;">Scope of Employment</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">During the Term of Employment, the Employee shall be responsible for the performance of all financial, managerial and administrative duties customarily performed by a General Counsel, together with such other duties as the Chief Executive Officer and the Employee shall agree.&nbsp;&nbsp;The Employee shall be accountable to the Chief Executive Officer and shall perform and discharge, faithfully, diligently and to the best of his ability, his duties and responsibilities hereunder.&nbsp;&nbsp;The Employee shall devote substantially all of his working time and efforts to the business and affairs of the Company and its affiliates.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font><font style="font-style:italic;">Compensation</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">As full compensation for all services to be rendered by the Employee during the Term of Employment, the Company will provide to the Employee, and the Employee will accept, the following:</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font><font style="margin-left:36pt;"></font><font style="font-style:italic;">Base Salary.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the Term of Employment, the Employee shall receive a salary </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of $</font><font style="color:#000000;">247,469</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> calendar year, less all applicable taxes and withholdings (the &#8220;</font><font style="text-decoration:underline;">Base Salary</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), paid in</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> installments in accordance with the Company&#8217;s regularly established payroll procedure.&nbsp;&nbsp;The Employee&#8217;s Base Salary shall be reviewed annually by </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company&#8217;s </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Board of Directors</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (the &#8220;</font><font style="text-decoration:underline;">Board</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and may be adjusted from time to time in accordance with normal business practices and taking into account then-current market fact</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ors, but in no event shall the E</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mployee&#8217;s salary be</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> less than the base salary the E</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mployee received from the Company in the immediately preceding year.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Bonus.&nbsp;&nbsp;</font>During the Term of Employment, the Employee shall be eligible to receive a discretionary annual performance and retention bonus of up to 27% of his then current Base Salary, at a time and under circumstances determined by the Board, in its sole discretion.&nbsp;&nbsp;In order to receive the discretionary annual performance bonus, the Employee must be an active employee of the Company on the date any bonus is determined and no discretionary annual bonus shall be considered earned before such date.&nbsp;&nbsp;Such discretionary bonus, if any, shall be paid no later than sixty (60) days following the date on which the Board approves such bonus.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Stock Options; Equity Grants.&nbsp;&nbsp;</font>The Employee shall be eligible to receive option grants or other equity grants at times and under circumstances determined by the Board, in its sole discretion.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Vacation.&nbsp;&nbsp;</font>The Employee shall be eligible for vacation time in accordance with the Company&#8217;s Paid Time Off Policy contained within the Company&#8217;s Employee Handbook, as amended and/or superseded from time to time.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Insurance.&nbsp;&nbsp;</font>The Employee shall be entitled to participate in, and receive benefits under, all Company sponsored insurance and benefit programs (i.e. health, dental, life, and disability) available to senior management employees of the Company, subject to and on a basis consistent with the terms, conditions and overall administration of such programs.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Other Benefits.&nbsp;&nbsp;</font>The Employee shall be entitled to participate in, and receive benefits under, all Company employee benefit plans and arrangements (including but not limited to 401(k) and similar programs), available to senior management employees of the Company, subject to and on a basis consistent with the terms, conditions and overall administration of such plans, policies and arrangements.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font><font style="font-style:italic;">Expenses</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">The Employee shall be entitled to reimbursement by the Company for all reasonable expenses actually incurred by him on the Company&#8217;s behalf in the course of his employment by the Company, upon the prompt presentation by the Employee, from time to time, of an itemized account of such expenditures together with all supporting vouchers and receipts.&nbsp;&nbsp;All expense reimbursements shall be subject to the terms set forth in Section 5 of </font><font style="text-decoration:underline;font-weight:normal;">Exhibit C</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;"></font><font style="font-style:italic;">Restrictive Covenants</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>(a)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Non-Competition.&nbsp;&nbsp;</font>The Employee agrees that, during the Term of Employment and any Severance Period (as defined below), and for a period of one (1) year thereafter, he will not engage, directly or indirectly, in any business that competes with the business of the Company.&nbsp;&nbsp;For purposes of this paragraph, a business competes with the business </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the Company if it is engaged in the research, development, production, sales or marketing of any diagnostic or therapeutics process or product that is directed at any molecular targets or related to any therapeutic candidate compound that the Company developed, produced or sold, or planned to develop, produce or sell, while the Employee was employed with the Company.&nbsp;&nbsp;The Employee will be deemed to be directly or indirectly engaged in a competitive business if he is engaged in such competitive business as proprietor, partner, joint venturer, stockholder (other than the holder of less than two percent (2%) of the outstanding shares of any publicly owned corporation), director, officer, manager, member, employee, consultant, independent contractor, adviser, marketer, or agent or if he otherwise controls such business.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Non-Solicitation.&nbsp;&nbsp;</font>The Employee agrees with the Company that during the Term of Employment and any Severance Period, and for a period of one (1) year thereafter, he will not, directly or indirectly, solicit, entice away, employ, hire or otherwise interfere with the Company&#8217;s relationship with any officer, employee, consultant or agent of the Company.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Waiver.&nbsp;&nbsp;</font>The Company may waive the prohibitions of Sections 6(a) or (b) hereof without waiving any other provisions of this Agreement</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Validity.&nbsp;&nbsp;</font>In the event any provision of Section 6(a) or 6(b) hereof shall to any extent be held to be invalid or unenforceable by reason of geographic or business scope or the duration thereof, such invalidity or enforceability shall attach only to such provision to the extent of such invalidity, and shall not affect or render invalid or unenforceable any other provision of this Agreement and, in such event, such provision shall be deemed to be modified to such extent as may be necessary to cause the geographic or business scope or duration thereof to be valid and enforceable to the maximum extent permitted by law.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Pre-existing Obligations.&nbsp;&nbsp;</font>The Employee agrees that the restrictive covenants contained herein do not cancel or modify the Employee&#8217;s obligations under the Non-Disclosure, Developments, Non-Competition and Non-Solicitation Agreement attached hereto as <font style="text-decoration:underline;">Exhibit A</font> and executed on the date hereof, except to the extent set forth in Section 14.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>7.<font style="margin-left:36pt;"></font><font style="font-style:italic;">Confidential Information</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">While employed by the Company and thereafter, the Employee shall not, directly or indirectly, use any Confidential Information (as hereinafter defined) other than pursuant to his employment by and for the benefit of the Company, or disclose any such Confidential Information to anyone outside of the Company whether by private communication, public address, publication or otherwise or to anyone within the Company who has not been authorized to receive such information, except as directed in writing by the Board. For purposes of this Section 7, &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Confidential Information</font><font style="font-weight:normal;">&#8221; means all trade secrets, proprietary information, and other data and information, in any form, belonging to the Company or any of its clients, customers, consultants, licensees or affiliates, that is held in confidence by the Company.&nbsp;&nbsp;Confidential Information includes but is not limited to computer software, business plans and arrangements, customer lists, marketing materials, financial information, research, and any other information identified or treated as confidential by the Company or any of its clients, customers, consultants, licensees or affiliates.&nbsp;&nbsp;Notwithstanding the foregoing, Confidential Information does not include information which the Company has voluntarily disclosed to the public without restriction, or which is otherwise known to the public at large through no fault of the Employee.&nbsp;&nbsp;The Employee further acknowledges and reaffirms his </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">obligation to keep confidential and not to disclose any and all Confidential Information that he has acquired or will acquire during the course of his employment with the Company, as is stated more fully </font><font style="font-weight:normal;">in</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">the </font><font style="font-weight:normal;">Non-Disclosure, Developments, Non-Competition and Non-Solicitation Agreement</font><font style="font-weight:normal;"> attached hereto as </font><font style="text-decoration:underline;font-weight:normal;">Exhibit A</font><font style="font-weight:normal;"> and executed on the date hereof</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;"></font><font style="font-style:italic;">Developments</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">As a condition of the Employee&#8217;s employment with the Company and the promises contained herein, the Employee acknowledges and reaffirms his obligations, as stated more fully in the Non-Disclosure, Developments, Non-Competition and Non-Solicitation Agreement attached hereto as </font><font style="text-decoration:underline;font-weight:normal;">Exhibit A</font><font style="font-weight:normal;"> and executed on the date hereof, except to the extent set forth in Section 14.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:36pt;"></font><font style="font-style:italic;">Injunctive Relief</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">The parties hereto recognize that irreparable damage will result to the Company and its business and properties if the Employee fails or refuses to perform his obligations under Section 6(a), 6(b), 7 or 8 hereof, and that the remedy at law for any such failure or refusal will be inadequate.&nbsp;&nbsp;Accordingly, in addition to any other remedies and damages available, the Company shall be entitled to injunctive relief, and the Employee may be specifically compelled to perform his obligations thereunder.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.<font style="margin-left:36pt;"></font><font style="font-style:italic;">Early Termination</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Death and Disability.&nbsp;&nbsp;</font>In the event of the Employee&#8217;s death during the Term of Employment, this Agreement shall terminate immediately.&nbsp;&nbsp;If, during the Term of Employment, the Employee shall be unable for a period of more than any three (3) consecutive months or for periods aggregating more than twenty-six (26) weeks in a twelve (12) month period to perform the services provided for herein as a result of any illness or disability, the Company may terminate the Employee&#8217;s employment hereunder.&nbsp;&nbsp;The Employee shall be considered unable to perform the services provided for herein if and whenever the Company reasonably determines, based upon the results of a medical examination performed by a mutually agreed-upon professional, that he is mentally or physically incapable of performing his duties hereunder.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Termination for Cause.&nbsp;&nbsp;</font>The Employee may be terminated by the Company without notice for &#8220;Cause.&#8221;&nbsp;&nbsp;The following, as determined by the Board in its reasonable judgment, shall constitute &#8220;<font style="text-decoration:underline;">Cause</font>&#8221; for termination:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Failure to Perform Duties.&nbsp;&nbsp;</font>The Employee&#8217;s material failure to perform (other than by reason of illness or disability) his duties to the Company, or his material negligence in the performance of his duties and/or responsibilities to the Company, provided that the Employee shall have had prior written notice and a reasonable opportunity of not less than thirty (30) days to correct any deficiency in such performance;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Breach of Employment Agreement.&nbsp;&nbsp;</font>The Employee&#8217;s material breach of this Agreement;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Misconduct.&nbsp;&nbsp;</font>The Employee&#8217;s conviction for or plea of <font style="font-style:italic;">nolo contendere </font>or guilty to any crime involving fraud, embezzlement or moral turpitude; or</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font><font style="margin-left:36pt;"></font><font style="font-style:italic;">Harmful Conduct.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any conduct of the Employee that is materially harmful to the business, interests or reputation of the Company, provided that the Employee shall have had prior written notice and a reasonable opportunity of not less than ten (10) days to correct any such conduct.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Termination By Company Without Cause.&nbsp;&nbsp;</font>The Employee may be terminated by the Company without &#8220;Cause&#8221; upon delivery of written notice to the Employee.&nbsp;&nbsp;In the event the Employee is terminated without &#8220;Cause,&#8221; the Employee shall be entitled to receive the severance benefits set forth in Section 10(f) or 10(g), as applicable.&nbsp;&nbsp;The Company&#8217;s decision not to renew the Term of Employment shall constitute a termination without &#8220;Cause.&#8221;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Termination by the Employee for Good Reason.&nbsp;&nbsp;</font>This Agreement may be terminated by the Employee for &#8220;Good Reason&#8221; (as defined below), upon thirty (30) days&#8217; prior written notice to the Company, provided that the Company shall have the opportunity to cure the asserted Good Reason within the thirty (30) day period.&nbsp;&nbsp;The Employee shall have &#8220;<font style="text-decoration:underline;">Good Reason</font>&#8221; to terminate this Agreement in the event that the Company, without the express written consent of the Employee: (i) causes a material diminution of the Employee&#8217;s authority, duties or responsibilities; (ii) materially breaches this Agreement, including, without limitation, by materially reducing the Employee&#8217;s Base Salary or (iii) relocating the Employee&#8217;s place of business by more than thirty (30) miles from the Company&#8217;s current Cambridge, Massachusetts office.&nbsp;&nbsp;In the event the Employee terminates his employment for Good Reason, the Employee shall be entitled to the severance benefits set forth in Section 10(f) or 10(g), as applicable.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Effect of Early Termination.&nbsp;&nbsp;</font>Except for a termination by the Company without &#8220;Cause&#8221; or by the Employee for &#8220;Good Reason,&#8221; in the event of any early termination of the Term of Employment, the Company&#8217;s obligations under this Agreement shall immediately cease and the Employee shall be entitled to only the Employee&#8217;s Base Salary and employment benefits which have accrued and to which the Employee is entitled to through the date of such termination, including any bonus that may have been awarded but not yet paid.&nbsp;&nbsp;These accrued salary and benefits shall be paid on or about the date of termination.&nbsp;&nbsp;The Employee shall not be entitled to any other compensation or consideration, including any bonus not yet awarded that the Employee may have been eligible for had his Term of Employment not ceased, except as otherwise set forth in this Section 10(e).&nbsp;&nbsp;In the event of an early termination of the Term of Employment due to the Employee&#8217;s disability, as set forth in Section 10(a), the Employee will be eligible to receive a pro rata amount of any bonus he would have received had his Term of Employment not ceased (determined in the manner set forth in the penultimate sentence of Section 10(f)), which bonus shall be paid within thirty (30) days of the date of the Employee&#8217;s termination.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>(f)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Severance Benefits Prior to a Change in Control.&nbsp;&nbsp;</font>If the Term of Employment is terminated by the Company without &#8220;Cause&#8221; (as that term is defined in Section 10(b)) or by the Employee for &#8220;Good Reason&#8221; (as that term is defined in Section 10(d)), in each case prior to a Change in Control (as that term is defined in <font style="text-decoration:underline;">Exhibit B</font>), the Employee shall be entitled to receive his Base Salary and all other employment benefits accrued through the effective date of such termination, which shall be paid on or about the date of termination.&nbsp;&nbsp;In addition, provided the Employee executes and allows to become binding a severance agreement and release of claims drafted by and satisfactory to the Company (the &#8220;<font style="text-decoration:underline;">Release</font>&#8221;) on or before the </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sixtieth (</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">th</sup></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> day after the date of termination, then beginning on the first regularly scheduled payroll that is </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sixty (</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> days following the date of termination (such date, the &#8220;</font><font style="text-decoration:underline;">Payment Commencement Date</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), for a period </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nine (9) months (or </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">twelve (12) months</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> if the Employee was employed by the Company for at least five (5) consecutive years immediately prior to such date of termination)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (the</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;</font><font style="text-decoration:underline;">Severance Period</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), the Company shall:</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (i) pay to the Employee his base salary in accordance with the Company&#8217;s regularly established payroll procedure, (ii) pay for coverage under any benefit plans provided pursuant to Section 4(e), provided the Employee is eligible for and elects to continue receiving such benefits pursuant to the federal &#8220;COBRA&#8221; law, 29 U.S.C. &#167; 1161 </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">et. seq.,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and provided further that the Employee continues to pay the applicable share of the premium for such coverage that is paid for active and similarly situated employees who receive the same type of coverage, and (iii) to the extent allowed by applicable law and the applicable plan documents, continue to provide the Employee with such benefits as described in Section 4(f), subject to and on a basis consistent with the terms, conditions and overall administration of such plans.&nbsp;&nbsp;In addition, the Company shall pay to the Employee, on the Payment Commencement Date, a pro-rata bonus equal to (A) the average of the Employee&#8217;s annual bonus payments over each of the three </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">years prior to the year of termination (or</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, if the Employee is an executive officer,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> such lesser period during which the Employee served as an executive officer of the Company)</font><font style="font-size:10pt;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">multiplied by (B) a fraction, the numerator of which is the number of days during the year during which the Employee remained employed by the Company and the denominator of which is 365.&nbsp;&nbsp;The distribution of all severance benefits under this Section 10(f) shall be subject to the provisions of </font><font style="text-decoration:underline;">Exhibit</font><font style="text-decoration:underline;"> </font><font style="text-decoration:underline;">C</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>(g)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Severance Benefits After a Change in Control</font>.&nbsp;&nbsp;If the Term of Employment is terminated by the Company without &#8220;Cause&#8221; (as that term is defined in Section 10(b)) or by the Employee for &#8220;Good Reason&#8221; (as that term is defined in Section 10(d)), in each case within the eighteen (18) month period following a Change in Control (as that term is defined in <font style="text-decoration:underline;">Exhibit B</font>), the Employee shall be entitled to receive his Base Salary and all other employment benefits accrued through the effective date of such termination, which shall be paid on or about the date of termination.&nbsp;&nbsp;In addition, provided the Employee executes and allows to become binding the Release on or before the Payment Commencement Date, the Company shall: (i) pay to the Employee on the Payment Commencement Date a lump sum amount equal to thirty-six (36) months of his Base Salary; (ii) pay to the Employee on the Payment Commencement Date a bonus equal to (A) three (3) multiplied by (B) the average of the Employee&#8217;s annual bonus payments over each of the three (3) years prior to the year of termination <font style="font-size:10pt;">(</font>or, if the Employee is an executive officer, such lesser period during which the Employee served as an executive officer of the Company);<font style="font-size:10pt;">&nbsp;&nbsp;</font>(iii) accelerate the vesting of all outstanding Company stock options, restricted stock or other equity awards granted to the Employee; (iv) pay for coverage under any benefit plans provided pursuant to Section 4(e) for a period of eighteen (18) months following the Employee&#8217;s date of termination, provided the Employee is eligible for and elects to continue receiving such benefits pursuant to the federal &#8220;COBRA&#8221; law, 29 U.S.C. &#167; 1161 et. seq., and provided further that the Employee continues to pay the applicable share of the premium for such coverage that is paid for active and similarly situated employees who receive the same type of coverage; and (v) to the extent allowed by applicable law and the applicable plan documents, continue for a period of eighteen (18) months following the Employee&#8217;s date of termination to provide the Employee with such benefits as described in Section 4(f), subject to and on a basis consistent with the terms, conditions and </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">overall administration of such plans.&nbsp;&nbsp;The distribution of all severance benefits under this Section 10(g) shall be subject to the provisions of </font><font style="text-decoration:underline;">Exhibit </font><font style="text-decoration:underline;">C</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.<font style="margin-left:36pt;"></font><font style="font-style:italic;">Absence of Restrictions</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">The Employee represents and warrants that he is not a party to any commitment or undertaking by which he is subject to any restriction or limitation upon his entering into this Agreement or performing the services required of him hereunder.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.<font style="margin-left:36pt;"></font><font style="font-style:italic;">Amendments</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">Any amendment to this Agreement, including any extension or renewal of the Term of Employment, shall be made in writing and signed by the parties hereto.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13.<font style="margin-left:36pt;"></font><font style="font-style:italic;">Applicable Law</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts (without reference to the conflict of laws provisions thereof).&nbsp;&nbsp;Any action, suit or other legal proceeding arising under or relating to any provision of this Agreement shall be commenced only in a court of the Commonwealth of Massachusetts (or, if appropriate, a federal court located within the Commonwealth of Massachusetts), and the Company and the Employee each consents to the jurisdiction of such a court.&nbsp;&nbsp;The Company and the Employee each hereby irrevocably waives any right to a trial by jury in any action, suit or other legal proceeding arising under or relating to any provision of this Agreement.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.<font style="margin-left:36pt;"></font><font style="font-style:italic;">Entire Agreement</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">This Agreement, together with the Non-Disclosure, Developments, Non-Competition and Non-Solicitation Agreement attached hereto as </font><font style="text-decoration:underline;font-weight:normal;">Exhibit A</font><font style="font-weight:normal;"> and executed on the date hereof, constitutes the entire agreement between the parties and supersedes all prior agreements and understandings, whether written or oral, relating to the subject matter of these agreements; provided however that the Employee and the Company agree that Section 4(a) of the Non-Disclosure, Developments, Non-Competition and Non-Solicitation Agreement is superseded by this Agreement.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.<font style="margin-left:36pt;"></font><font style="font-style:italic;">Successors and Assigns</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and assigns, including any corporation with which or into which the Company may be merged or which may succeed to its assets or business; provided, however, that the obligations of the Employee are personal and shall not be assigned by him.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16.<font style="margin-left:36pt;"></font><font style="font-style:italic;">Acknowledgment</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">The Employee states and represents that he has had an opportunity to fully discuss and review the terms of this Agreement with an attorney.&nbsp;&nbsp;The Employee further states and represents that he has carefully read this Agreement, understands the contents herein, freely and voluntarily assents to all of the terms and conditions hereof, and signs his name of his own free act.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.<font style="margin-left:36pt;"></font><font style="font-style:italic;">Miscellaneous</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right.&nbsp;&nbsp;A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar to or waiver of any right on any other occasion.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>(b)<font style="margin-left:36pt;"></font>The captions of the sections of this Agreement are for convenience of </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reference only and in no way define, limit or affect the scope or substance of any section of this Agreement.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>In case any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby.</p>
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.</p>
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COMPANY:<font style="font-weight:normal;margin-left:216pt;"></font></p>
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:46.15%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MERRIMACK PHARMACEUTICALS, INC<font style="font-weight:normal;">.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:46.15%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;">/s/ Robert J. Mulroy</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:50%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert J. Mulroy</p>
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:50%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:46.15%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EMPLOYEE:<font style="font-weight:normal;margin-left:216pt;"></font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:46.15%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Jeffrey A. Munsie</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jeffrey A. Munsie</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:57.69%;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="text-decoration:underline;">Exhibit A</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-Disclosure, Developments, Non-Competition and Non-Solicitation Agreement</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NON-DISCLOSURE, DEVELOPMENTS, NON-COMPETITION</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AND NON-SOLICITATION AGREEMENT</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Non-Disclosure, Developments, Non-Competition and Non-Solicitation Agreement (the &#8220;Agreement&#8221;), dated as of February 24, 2015, is entered into by and between Merrimack Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;), and Jeffrey A. Munsie (the &#8220;<font style="text-decoration:underline;">Employee</font>&#8221;).</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration of the Employee&#8217;s employment with the Company and for other valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the Employee, the Employee hereby agrees as follows:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Condition of Employment</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="OLE_LINK1"></a><a name="OLE_LINK2"></a><a name="OLE_LINK1"></a><a name="OLE_LINK2"></a>The Employee acknowledges that his/her<font style="font-weight:bold;"> </font>employment and the continuance of that employment with the Company is contingent upon his/her<font style="font-weight:bold;"> </font>agreement to sign and adhere to the provisions of this Agreement.&nbsp;&nbsp;The Employee further acknowledges that the nature of the Company&#8217;s business is such that protection of its proprietary and confidential information is critical to its survival and success.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Proprietary and Confidential Information</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:0pt;"></font><font style="color:#000000;">The Employee agrees that all information and know-how, whether or not in writing, of a private, secret or confidential nature concerning the Company and its operations and business or financial affairs (collectively, &#8220;</font><font style="text-decoration:underline;color:#000000;">Proprietary Information</font><font style="color:#000000;">&#8221;) is and shall be the exclusive property of the Company.&nbsp;&nbsp;By way of illustration, but not limitation, Proprietary Information may include</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">models, systems, software and codes, or systems, software and codes in the course of development, or planned or proposed systems, software or codes, customer, prospect and supplier lists, contacts at or knowledge of customers or prospective customers, customer accounts and other customer financial information, strategic partners and/or collaborators, price lists and all other pricing, marketing and sales information, projections, results relating to the Company or any customer or supplier of the Company, databases, modules, products, programs, product improvements, product enhancements and/or developments, designs, specifications, processes, methods, techniques, operations, projects, plans, chemical compounds, chemical or biological materials, engineering data, clinical or technological data, research data, financial data, personnel information, and other confidential agreements or documents (including, without limitation, clinical trial protocols and unpublished patent applications).&nbsp;&nbsp;The Employee will not disclose any Proprietary Information to others outside the Company or use the same for any unauthorized purposes without written approval by an officer of the Company, either during or at any time after his/her employment with the Company, unless and until such Proprietary Information has become public knowledge without fault by the Employee.&nbsp;&nbsp;While employed by the Company, the Employee will use the Employee&#8217;s best efforts to prevent publication or disclosure of any confidential or Proprietary Information.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>(b)<font style="margin-left:0pt;"></font><font style="color:#000000;">The Employee agrees that all Company Property (as defined below), whether created by the Employee or others, that shall come into the Employee&#8217;s custody or possession shall be and is the sole and exclusive property of the Company to be used only in the </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">performance of the Employee&#8217;s duties for the Company.&nbsp;&nbsp;&#8220;</font><font style="text-decoration:underline;color:#000000;">Company Property</font><font style="color:#000000;">&#8221; means any and all written, photographic or any other record containing Proprietary Information and shall include, but not be limited to, all agreements, notes, disks, files, letters, memoranda, reports, records, lists, data, drawings, sketches, notebooks, program listings, specifications, software programs, software code, computers and other electronic equipment, documentation, or other equipment or materials of any nature and in any form, containing Proprietary Information.&nbsp;&nbsp;Upon the earliest of the Employee&#8217;s termination or a request from the Company, the Employee will return to the Company any and all Company Property in the Employee&#8217;s custody or possession without retaining any copies thereof (including, without limitation, any electronic copy) and without using or allowing others to improperly use such Company Property.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:0pt;"></font><font style="color:#000000;">The Employee acknowledges that the Employee&#8217;s obligations with regard to Proprietary Information that are set out in Sections 2(a) and (b) extend to all information, know-how, records and tangible property of customers of the Company or suppliers to the Company or of any third party who may have disclosed or entrusted the same to the Company or to the Employee in the course of the Company&#8217;s business.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Developments</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:0pt;"></font><font style="color:#000000;">The Employee will make full and prompt disclosure to the Company of all inventions, ideas, concepts, improvements, discoveries, methods, techniques, tools, formula, developments, enhancements, modifications, databases,&#160;processes, software and works of authorship, whether patentable or not, that are created, made, conceived or reduced to practice by the Employee or under the Employee&#8217;s direction or jointly with others during the Employee&#8217;s employment by the Company, whether or not during normal working hours or on the premises of the Company (all of which are collectively referred to in this Agreement as &#8220;</font><font style="text-decoration:underline;color:#000000;">Developments</font><font style="color:#000000;">&#8221;).</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>(b)<font style="margin-left:0pt;"></font><font style="color:#000000;">The Employee agrees to assign and does hereby assign to the Company (or any person or entity designated by the Company) all of the Employee&#8217;s right, title and interest in and to all Developments and all related intellectual property rights.&nbsp;&nbsp;Except as, and solely to the extent that, it may be necessary for the Employee to perform&#160;the Employee&#8217;s duties and fulfill&#160;the Employee&#8217;s obligations in the course of the Employee&#8217;s employment with the Company, the Company does not grant the Employee, and the Employee agrees that he/she will not receive, any license or right to use any Development or related intellectual property right.&nbsp;&nbsp;The Employee hereby also waives all claims to moral rights in any Developments.&nbsp;&nbsp;However, this Section 3(b) shall not apply to Developments that do not relate to the present or planned business or research and development of the Company and that are made and conceived by the Employee not during normal working hours, not on the Company&#8217;s premises and not using the Company&#8217;s tools, devices, equipment or Proprietary Information.&nbsp;&nbsp;This Section 3(b) also shall not apply to any inventions that the Employee conceived of prior to the Employee&#8217;s employment with the Company, which invention(s) the Employee shall disclose on </font><font style="text-decoration:underline;color:#000000;">Exhibit A</font><font style="color:#000000;"> attached hereto.&nbsp;&nbsp;IF THERE ARE ANY SUCH INVENTIONS TO BE EXCLUDED UNDER THIS AGREEMENT, THE EMPLOYEE SHALL INITIAL HERE; OTHERWISE IT WILL BE DEEMED THAT THERE ARE NO SUCH EXCLUSIONS. ____&nbsp;&nbsp;The Employee understands that, to the extent this Agreement shall be construed in accordance with the laws of any state that precludes the requirement in an employee agreement to assign certain classes of inventions made by an employee, this Section 3(b) shall be interpreted not to apply to any invention that a court </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">rules and/or the Company agrees falls within such classes.&nbsp;&nbsp;To the extent allowed by law, the Employee hereby grants to the Company an exclusive (even unto the Employee), irrevocable, fully paid up, worldwide license to make, use and sell any and all inventions for which assignment cannot be effected.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="OLE_LINK7"></a><a name="OLE_LINK8"></a>(c)<font style="margin-left:0pt;"></font><font style="color:#000000;"><a name="OLE_LINK7"></a><a name="OLE_LINK8"></a>The Employee agrees to cooperate fully with the Company, both during and after the Employee&#8217;s employment with the Company, with respect to the procurement, maintenance and enforcement of all copyrights, trademarks, patents and other intellectual property rights (both in the United States and foreign countries) relating to any Development.&nbsp;&nbsp;The Employee shall sign all papers, including, without limitation, copyright applications, patent applications, declarations, oaths, formal assignments, assignment of priority rights and powers of attorney, that the Company may deem necessary or desirable in order to protect and enforce its rights and interests in any Development.&nbsp;&nbsp;The Employee further agrees that if the Company is unable, after reasonable effort, to secure the signature of the Employee on any such papers, any executive officer of the Company shall be entitled to execute any such papers as the agent and the attorney-in-fact of the Employee, and the Employee hereby irrevocably designates and appoints each executive officer of the Company as the Employee&#8217;s agent and attorney-in-fact for all countries worldwide to execute any such papers on the Employee&#8217;s behalf, and to take any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in any Development, under the conditions described in this sentence.&nbsp;&nbsp;Should the Company engage in litigation to enforce any such intellectual property rights, the Employee agrees to appear and testify at no charge, but at the Company&#8217;s expense.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Non-Competition and Non-Solicitation</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While<font style="color:#000000;"> the Employee is employed by the Company and for a period of twelve (12) months following the Employee&#8217;s termination or cessation of employment for any reason (voluntarily or involuntarily), the Employee will not, directly or indirectly:</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:0pt;"></font><font style="color:#000000;">Engage in any business or enterprise (whether as an owner, partner, officer, employee, director, investor, lender, consultant, independent contractor or otherwise, except as the holder of not more than 1% of the combined voting power of the outstanding stock of a publicly held company) that is competitive with the Company&#8217;s business, including, without limitation, any business or enterprise that develops, designs, produces, markets or sells any pharmaceutical product designed to treat cancer or renders any product or service competitive with any product or service developed, designed, produced, marketed or sold or planned to be developed, designed, produced, marketed or sold by the Company while the Employee was employed by the Company;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:0pt;"></font><font style="color:#000000;">Either alone or in association with others, recruit, solicit, hire or engage as an independent contractor, or attempt to recruit, solicit, hire or engage as an independent contractor, any person who was employed by the Company or engaged as an independent contractor for the Company at any time during the period of the Employee&#8217;s employment with the Company, except for an individual whose employment with or service for the Company has been terminated for a period of six (6) months or longer; and/or</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:0pt;"></font><font style="color:#000000;">Either alone or in association with others, service, solicit, divert or take away, or attempt to service, solicit, divert or take away, the business or patronage of any of the clients, customers or accounts, or prospective clients, customers or accounts, of the Company that were contacted, solicited or served by the Employee while the Employee was employed by the Company or about which the Employee had access to Proprietary Information in the course of his/her employment with the Company.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:0pt;"></font><font style="color:#000000;">The geographic scope of this Section 4 shall extend to anywhere the Company or any of its subsidiaries is doing business, has done business or has plans to do business during the Employee&#8217;s employment.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:0pt;"></font><font style="color:#000000;">If any restriction set forth in this Section 4 is found by any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:0pt;"></font><font style="color:#000000;">The Employee agrees that during the non-competition and non-solicitation period, the Employee will give notice to the Company of each new job, contract assignment or other work (either as an employee, contractor or otherwise) the Employee plans to undertake at least ten (10) business days prior to beginning any such activity.&nbsp;&nbsp;The notice shall state the name and address of the individual, corporation, association or other entity or organization (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Entity</font><font style="color:#000000;">&#8221;) for whom such activity is undertaken and the Employee&#8217;s proposed business relationship or position with the Entity.&nbsp;&nbsp;The Employee further agrees to provide the Company with other pertinent information concerning such business activity as the Company may reasonably request in order to determine the Employee&#8217;s continued compliance with his/her obligations under this Agreement.&nbsp;&nbsp;During the non-competition and non-solicitation period, the Employee agrees to provide a copy of this Agreement to all person and Entities with whom the Employee seeks to be hired or do business before accepting employment or engagement with any of them.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:0pt;"></font><font style="color:#000000;">If the Employee violates any of the provisions of this Section 4, the Employee shall continue to be held by the restrictions set forth in this Section 4 until a period equal to the period of restriction has expired without any violation.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Other Agreements</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Employee hereby represents that, except as the Employee has disclosed in writing to the Company, the Employee is not bound by the terms of any restrictive covenant agreement with any previous employer or other party relating to the non-disclosure of trade secret or confidential or proprietary information, non-competition and/or non-solicitation of customers, clients, employees or others.&nbsp;&nbsp;The Employee further represents that the Employee&#8217;s performance of all the terms of this Agreement and as an employee of the Company does not and will not breach any such restrictive covenant agreement, and the Employee will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or others.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</font><font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Employment At Will</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Employee acknowledges that this Agreement does not constitute a contract of employment for any period of time and does not modify the at-will nature of the Employee&#8217;s employment with the Company, pursuant to which both the Company and the Employee may terminate the employment relationship at any time, for any or no reason, with or without notice.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">General Provisions</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Equitable Relief</font><font style="color:#000000;">.&nbsp;&nbsp;The Employee acknowledges that the restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company and are considered by the Employee to be reasonable for such purpose.&nbsp;&nbsp;The Employee agrees that any breach or threatened breach of this Agreement will cause the Company substantial and irrevocable damage that is difficult to measure.&nbsp;&nbsp;Therefore, in the event of any such breach or threatened breach, the Employee agrees that the Company, in addition to such other remedies that may be available, shall have the right to specific performance and injunctive relief without posting a bond, as well as its reasonable attorneys&#8217; fees incurred as a result of any such breach or threatened breach.&nbsp;&nbsp;The Employee hereby waives the adequacy of a remedy at law as a defense to such relief.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Change in Terms/Conditions of Employment</font><font style="color:#000000;">.&nbsp;&nbsp;The Employee agrees that his/her&nbsp;&nbsp;obligations under this Agreement shall continue in full force and effect in the event that the Employee&#8217;s job title, responsibilities, reporting structure, work location, compensation or other conditions of his/her employment with the Company change subsequent to the execution of this Agreement, without the need to execute a new agreement.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">No Conflict</font><font style="color:#000000;">.&nbsp;&nbsp;The Employee represents that the execution and performance by the Employee of this Agreement does not and will not conflict with or breach the terms of any other agreement by which the Employee is bound.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Severability</font><font style="color:#000000;">.&nbsp;&nbsp;The invalidity or unenforceability of any provision of this Agreement shall not affect or impair the validity or enforceability of any other provision of this Agreement.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Waiver; Amendments</font><font style="color:#000000;">.&nbsp;&nbsp;No delay or omission by the Company in exercising any right under this Agreement will operate as a waiver of that or any other right.&nbsp;&nbsp;A waiver or consent given by the Company on any one occasion is effective only in that instance and will not be construed as a bar to or waiver of any right on any other occasion.&nbsp;&nbsp;Any amendment to or modification of this Agreement, or any waiver of any provision thereof, shall be in writing and signed by the Company.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Successors and Assigns</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and assigns, including, without limitation, any corporation or entity with which or into which the Company may be merged or which may succeed to all or substantially all of its assets or business; provided, however, that the obligations of the Employee are personal and shall not be assigned by the Employee.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)</font><font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Governing Law, Forum and Jurisdiction</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement shall be governed by and construed as a sealed instrument under and in accordance with the laws of the Commonwealth of Massachusetts without regard to conflict of laws provisions.&nbsp;&nbsp;Any action, suit or other legal proceeding that is commenced to resolve any matter arising under or relating to any provision of this Agreement shall be commenced only in a court of the Commonwealth of Massachusetts (or, if appropriate, a federal court located within Massachusetts), and the Company and the Employee each consents to the jurisdiction of such a court.&nbsp;&nbsp;</font><font style="font-weight:bold;color:#000000;">The Employee and the Company </font><font style="font-weight:bold;color:#000000;">hereby expressly waive the right to a jury trial for any claim relating to his/her/its rights or obligations under this Agreement, or otherwise relating to the Employee&#8217;s employment or separation from employment with the Company.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Captions</font><font style="color:#000000;">.&nbsp;&nbsp;The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Entire Agreement</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement supersedes all prior agreements, written or oral, between the Employee and the Company relating to the subject matter of this Agreement.&nbsp;&nbsp;This Agreement may not be modified, changed or discharged in whole or in part, except by an agreement in writing signed by the Employee and the Company.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THE EMPLOYEE ACKNOWLEDGES THAT HE/SHE HAS CAREFULLY READ THIS AGREEMENT AND UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT.</p>
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.</p>
<p style="margin-bottom:24pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COMPANY:<font style="font-weight:normal;margin-left:216pt;"></font></p>
<p style="margin-bottom:24pt;margin-top:24pt;text-indent:46.15%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MERRIMACK PHARMACEUTICALS, INC<font style="font-weight:normal;">.</font></p>
<p style="margin-top:24pt;margin-bottom:0pt;text-indent:46.15%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;">/s/ Robert J. Mulroy</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:50%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert J. Mulroy</p>
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:50%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="margin-top:24pt;margin-bottom:0pt;text-indent:46.15%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EMPLOYEE:<font style="font-weight:normal;margin-left:216pt;"></font></p>
<p style="margin-top:24pt;margin-bottom:0pt;text-indent:46.15%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Jeffrey A. Munsie</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jeffrey A. Munsie</p>
<p style="margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><font style="text-decoration:underline;">Exhibit A</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">List of Prior Inventions and Original Works of Authorship</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:478.8pt;;">
<tr>
<td style="width:99.9pt;"></td>
<td style="width:112.5pt;"></td>
<td style="width:266.4pt;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identifying Number or Brief Description</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;margin-left:36pt;"></font> Additional Sheets Attached</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature of Employee:<font style="margin-left:36pt;"></font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Printed Name of Employee:<font style="margin-left:36pt;"></font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:<font style="margin-left:36pt;">________________________</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit B</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Definition of Change in Control </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A &#8220;<font style="text-decoration:underline;">Change in Control</font>&#8221; shall occur upon the following events, provided, in each case, that such event constitutes a &#8220;change in control event&#8221; within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(i):</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(A)<font style="margin-left:36pt;">the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="text-decoration:underline;">Exchange Act</font>&#8221;) (a &#8220;<font style="text-decoration:underline;">Person</font>&#8221;) of beneficial ownership of any capital stock of the Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule 13d-3 under the Exchange Act) 50% or more of either (x) the then-outstanding shares of common stock of the Company (the &#8220;<font style="text-decoration:underline;">Outstanding Company Common Stock</font>&#8221;) or (y) the combined voting power of the then-outstanding securities of the Company entitled to vote generally in the election of directors (the &#8220;<font style="text-decoration:underline;">Outstanding Company Voting Securities</font>&#8221;); provided, however, that for purposes of this subsection (A), the following acquisitions shall not constitute a Change in Control Event: (1) any acquisition directly from the Company or (2) any acquisition by any corporation pursuant to a Business Combination (as defined below) which complies with clauses (x) and (y) of subsection (C) of this definition;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(B)<font style="margin-left:36pt;">a change in the composition of the Board that results in the Continuing Directors (as defined below) no longer constituting a majority of the Board (or, if applicable, the Board of Directors of a successor corporation to the Company), where the term &#8220;</font><font style="text-decoration:underline;">Continuing Director</font>&#8221; means at any date a member of the Board (x) who was a member of the Board on the date of this Agreement or (y) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided, however, that there shall be excluded from this clause (y) any individual whose initial assumption of office occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board; or</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a>(C)<font style="margin-left:36pt;">the consummation of a merger, consolidation, reorganization, recapitalization or share exchange involving the Company or a sale or other disposition of all or substantially all of the assets of the Company (a &#8220;</font><font style="text-decoration:underline;">Business Combination</font>&#8221;), unless, immediately following such Business Combination, each of the following two conditions is satisfied: (x) all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Company&#8217;s assets either directly or through one or more subsidiaries) (such resulting or acquiring </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">corporation is referred to herein as the &#8220;</font><font style="text-decoration:underline;">Acquiring Corporation</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) in substantially the same proportions as their ownership of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively, immediately prior to such Business Combination and (y) no Person (excluding any employee benefit plan (or related trust) maintained or sponsored by the Company or by the Acquiring Corporation</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) beneficially owns, directly or indirectly, 50%</font><font style="font-weight:bold;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or more of the then-outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such corporation entitled to vote generally in the election of directors (except to the extent that such ownership existed prior to the Business Combination)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit </font><font style="text-decoration:underline;">C</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments Subject to Section 409A</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to this Exhibit C, severance payments or benefits under this Agreement shall begin only on or after the date of the Employee&#8217;s &#8220;separation from service&#8221; (determined as set forth below), which occurs on or after the termination of the Employee&#8217;s employment.&nbsp;&nbsp;The following rules shall apply with respect to distribution of the payments and benefits, if any, to be provided to the Employee under this Agreement:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is intended that each installment of the payments provided under this Agreement shall be treated as a separate &#8220;payment&#8221; for purposes of Section 409A of the Internal Revenue Code and the guidance issued thereunder (&#8220;<font style="text-decoration:underline;">Section 409A</font>&#8221;).&nbsp;&nbsp;Neither the Company nor the Employee shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, as of the date of the Employee&#8217;s &#8220;separation from service&#8221; from the Company, the Employee is not a &#8220;specified employee&#8221; (within the meaning of Section 409A), then each installment of the severance payments and benefits shall be made on the dates and terms set forth in this Agreement.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, as of the date of the Employee&#8217;s &#8220;separation from service&#8221; from the Company, the Employee is a &#8220;specified employee&#8221; (within the meaning of Section 409A), then:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Each installment of the severance payments and benefits due under this Agreement that, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when the Employee&#8217;s separation from service occurs, be paid within the Short-Term Deferral Period (as defined under Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section 1.409A- l(b)(4) to the maximum extent permissible under Section 409A and shall be paid at the time set forth in this Agreement; and</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Each installment of the severance payments and benefits due under this Agreement that is not described in this Exhibit C, Section l(c)(i) and that would, absent this subsection, be paid within the six (6) month period following the Employee&#8217;s &#8220;separation from service&#8221; from the Company shall not be paid until the date that is six (6) months and one (1) day after such separation from service (or, if earlier, the Employee&#8217;s death), with any such installments that are required to be delayed being accumulated during the six (6) month period and paid in a lump sum on the date that is six (6) months and one (1) day following the Employee&#8217;s separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding provisions of this sentence shall not apply to any installment of severance payments and benefits if and to the maximum extent that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-l(b)(9)(iii) (relating to separation pay upon an involuntary separation from service).&nbsp;&nbsp;Any installments that qualify for the exception under Treasury Regulation Section 1.409A-l(b)(9)(iii) must be paid no later than the last day of the Employee&#8217;s second taxable year following the taxable year in which the separation from service occurs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font><font style="margin-left:0pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The determination of whether and when the Employee&#8217;s separation from service from the Company has occurred shall be made and in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-l(h).&nbsp;&nbsp;Solel</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y for purposes of this Exhibit C</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, Section 4, &#8220;</font><font style="text-decoration:underline;">Company</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; shall include all persons with whom the Company would be considered a single employer under Section 414(b) and 414(c) of the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Internal Revenue Code</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during the Employee&#8217;s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company makes no representation or warranty and shall have no liability to you or to any other person if any of the provisions of this Agreement (including this Exhibit C) are determined to constitute deferred compensation subject to Section 409A but that do not satisfy an exemption from, or the conditions of, that section.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:36pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company may withhold (or cause to be withheld) from any payments made under this Agreement, all federal, state, city or other taxes as shall be required to be withheld pursuant to any law or governmental regulation or ruling.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>mack-ex103_186.htm
<DESCRIPTION>EX-10.3 - SANTILLANA EMPLOYMENT AGREEMENT
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mack-ex103_186.htm
</title>
</head>
<!-- NG Converter v4.0.8.13 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.3</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EMPLOYMENT AGREEMENT</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Employment Agreement (this &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;), dated as of May 4, 2017, is entered into by and between Merrimack Pharmaceuticals, Inc., a Delaware corporation with a place of business at One Kendall Square, Suite B7201, Cambridge, Massachusetts 02139 (the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;), and Sergio L. Santillana (the &#8220;<font style="text-decoration:underline;">Employee</font>&#8221;).</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Company desires to employ the Employee on the terms and conditions, and for the consideration, hereinafter set forth, and the Employee desires to be employed by the Company on such terms and conditions and for such consideration.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the foregoing and of the respective covenants and agreements of the parties herein contained, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Term of Employment</font><font style="font-weight:normal;">.&nbsp;&nbsp;Subject to the terms and conditions hereinafter set forth, the Company hereby employs the Employee, and the Employee hereby enters into the employment of the Company, for an employment term commencing on June 12, 2017 (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Effective Date</font><font style="font-weight:normal;">&#8221;) and, unless earlier terminated in accordance with the provisions set forth in Section 7, continuing until December 31, 2017.&nbsp;&nbsp;This Agreement shall renew automatically for successive one (1) year terms, unless either party shall give the other notice of non-renewal in accordance with Section 7.  The initial term of this Agreement, together with any annual renewal terms of this Agreement, shall be referred to as the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Term of Employment</font><font style="font-weight:normal;">.&#8221;&nbsp;&nbsp;The Employee&#8217;s Base Salary (as defined below) for any renewal term shall be as agreed by the parties, provided that (i) the Base Salary shall in no event be less than the Base Salary the Employee received in the immediately preceding term, and (ii) in the absence of an agreement otherwise, the Employee&#8217;s Base Salary shall be the same as the Base Salary he received in the immediately preceding term.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Position</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">During the Term of Employment, the Employee shall serve as the Chief Medical Officer of the Company and in such additional position(s) as he and the Company shall agree.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Scope of Employment</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">During the Term of Employment, the Employee shall be responsible for the performance of all financial, managerial and administrative duties customarily performed by a Chief Medical Officer, together with such other duties as the Chief Executive Officer and the Employee shall agree.&nbsp;&nbsp;The Employee shall be accountable to the Chief Executive Officer and shall perform and discharge, faithfully, diligently and to the best of his ability, his duties and responsibilities hereunder.&nbsp;&nbsp;The Employee shall devote his full working time and efforts to the business and affairs of the Company and its affiliates.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Compensation</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">As full compensation for all services to be rendered by the Employee during the Term of Employment, the Company will provide to the Employee, and the Employee will accept, the following:</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font><font style="margin-left:0pt;"></font><font style="font-style:italic;">Base Salary.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the Term of Employment, the Employee shall receive a </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">base </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">salary of $</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">375,000</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">calendar year</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, less all applicable taxes and withholdings (the &#8220;</font><font style="text-decoration:underline;">Base Salary</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), paid in</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> installments in accordance with the Company&#8217;s </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regularly established payroll procedure.&nbsp;&nbsp;The Employee&#8217;s Base Salary shall be reviewed annually by the</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Company&#8217;s</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Board</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of Directors (the &#8220;</font><font style="text-decoration:underline;">Board</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and may be adjusted from time to time in accordance</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with normal business practices and taking into account then-current market fact</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ors, but in no event shall the E</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mployee&#8217;s </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base S</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">alary be</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> less than the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ase </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">alary the E</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mployee received from the Company in the immediately preceding year.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Annual Discretionary Bonus.&nbsp;&nbsp;</font>During the Term of Employment, the Employee shall be eligible to receive a discretionary annual performance and retention bonus of up to 35% of his then-current Base Salary, at a time and under circumstances determined by the Board, in its sole discretion.&nbsp;&nbsp;In order to receive this bonus, the Employee must be an active employee of the Company on the date any bonus is determined and no discretionary annual bonus shall be considered earned before such date.&nbsp;&nbsp;Such discretionary bonus, if any, shall be paid no later than sixty (60) days following the date on which the Board approves such bonus.  The Employee&#8217;s bonus for 2017 shall be prorated based on the Effective Date.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Stock Options; Equity Grants.&nbsp;&nbsp;</font>Subject to approval by the Board, the Company will grant the Employee an option to purchase 450,000 shares of the Company&#8217;s common stock, with an exercise price equal to the fair market value per share on the date of the grant of the stock option.  The stock option will vest over three years at the rate of 1/6<sup style="font-size:85%; vertical-align:top">th</sup> of the total number of shares granted on the six-month anniversary of the Effective Date and an additional 1/12<sup style="font-size:85%; vertical-align:top">th</sup> of the total number of shares granted at the end of each successive three month period following the six-month anniversary of the Effective Date until fully exercisable, subject to the Employee&#8217;s continued employment with the Company on the applicable vesting date.&nbsp;&nbsp;This stock option shall be subject to the terms and conditions of the Company&#8217;s 2011 Stock Incentive Plan and the applicable Stock Option Agreement.  The Employee shall be eligible to receive additional option grants or other equity grants at times and under circumstances determined by the Board, in its sole discretion.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>(d)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Tuition Reimbursement.</font>&nbsp;&nbsp;The Company shall reimburse the Employee up to $80,000 (the &#8220;<font style="text-decoration:underline;">Tuition Reimbursement</font>&#8221;) for tuition for an executive MBA program (the &#8220;<font style="text-decoration:underline;">Program</font>&#8221;) <font style="color:#000000;">for purposes of helping improve the Employee&#8217;s knowledge and skills required for his role as </font>Chief Medical Officer.&nbsp;&nbsp;The Tuition Reimbursement shall be spread evenly across the number of semesters/tuition payments for the Program (e.g., $16,000 for each of five semesters/tuition payments).&nbsp;&nbsp;The Employee shall submit an invoice from the educational institution along with proof of payment in a form acceptable to the Company.&nbsp;&nbsp;The Employee must continue to demonstrate continued high job performance while participating in the Program, as determined by the Chief Executive Officer.&nbsp;&nbsp;If, prior to the Employee&#8217;s graduation from the Program (the &#8220;<font style="text-decoration:underline;">Graduation</font>&#8221;), the Employee voluntarily terminates his employment with the Company without Good Reason (as defined below) or the Company terminates the Employee&#8217;s employment for Cause (as defined below), the Employee shall repay to the Company within sixty (60) days following his last day of employment with the Company the entire amount of the Tuition Reimbursement received by him.&nbsp;&nbsp;If, after the Graduation but prior to the one-year anniversary of the Graduation, the Employee voluntarily terminates his employment with the Company without Good Reason or the Company terminates the </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee&#8217;s employment for Cause</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Employee</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shall</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> repay </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Company within </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sixty</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0) days following his last day of employment with the Company </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/3</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">rd</sup></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">s</sup></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tuition Reimbursement </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">received by </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">him</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, on or after </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-year anniversary of the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Graduation but</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prior</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">two</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-year anniversary of the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Graduation, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Employee</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> voluntarily terminate</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s his</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> employment with the Company </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">without Good Reason</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terminates the</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Employee&#8217;s employment for Cause</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Employee</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shall</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> repay </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Company within </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sixty</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0) days following his last day of employment with the Company </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/3</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">rd</sup></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tuition Reimbursement</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> received by </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">him</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;The Tuition Reimbursement is considered an advance and is not earned unless the Employee remains employed with the Company in accordance with this </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ection</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 4(d)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, to the maximum extent permitted by applicable law.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Paid Time Off.&nbsp;&nbsp;</font>The Employee shall be eligible for paid time off in accordance with the Company&#8217;s Paid Time Off Policy contained within the Company&#8217;s Employee Handbook, as amended and/or superseded from time to time.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Insurance.&nbsp;&nbsp;</font>The Employee shall be entitled to participate in, and receive benefits under, all Company sponsored insurance and benefit programs (i.e., health, dental, life, and disability) available to senior management employees of the Company, subject to and on a basis consistent with the eligibility requirements, terms, conditions and overall administration of such programs.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Other Benefits.&nbsp;&nbsp;</font>The Employee shall be entitled to participate in, and receive benefits under, all Company employee benefit plans and arrangements (including but not limited to 401(k) and similar programs), available to senior management employees of the Company, subject to and on a basis consistent with the eligibility requirements, terms, conditions and overall administration of such plans, policies and arrangements.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Expenses</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">The Employee shall be entitled to reimbursement by the Company for all reasonable expenses actually incurred by him on the Company&#8217;s behalf in the performance of his duties during the course of his employment by the Company, upon the prompt presentation by the Employee, from time to time and in accordance with the Company&#8217;s then-current reimbursement policies, of an itemized account of such expenditures together with all supporting vouchers and receipts.&nbsp;&nbsp;All expense reimbursements shall be subject to the terms set forth in Section 5 of </font><font style="text-decoration:underline;font-weight:normal;">Exhibit C</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Restrictive Covenants/Other Conditions to Employment</font><font style="font-weight:normal;">.&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, the Employee&#8217;s employment hereunder is subject to and conditioned on the Employee&#8217;s (i) completion of a background check and drug screen analysis satisfactory to the Company, (ii) execution and delivery to the Company of the Non-Disclosure, Developments, Non-Competition and Non-Solicitation Agreement (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Restrictive Covenants Agreement</font><font style="font-weight:normal;">&#8221;) attached hereto as </font><font style="text-decoration:underline;font-weight:normal;">Exhibit A</font><font style="font-weight:normal;">, and (iii) timely providing proof of his right to work in the United States.&nbsp;&nbsp;The Employee further agrees that he shall sign all consents necessary to the accomplishment of any of the foregoing, and that, should he not satisfy the conditions set forth in this Section 6, he shall not commence employment and this Agreement shall be null and void, with no obligations owed to the Employee.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.</font><font style="margin-left:0pt;"></font><font style="font-style:italic;">Early Termination.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Death and Disability.&nbsp;&nbsp;</font>In the event of the Employee&#8217;s death during the Term of Employment, this Agreement shall terminate immediately.&nbsp;&nbsp;If, during the Term of Employment, the Employee shall be unable for a period of more than any three (3) consecutive months or for periods aggregating more than twenty-six (26) weeks in a twelve (12) month period to perform the services provided for herein as a result of any illness or disability, the Company may terminate the Employee&#8217;s employment hereunder.&nbsp;&nbsp;The Employee shall be considered unable to perform the services provided for herein if and whenever the Company reasonably determines, based upon the results of a medical examination performed by a mutually agreed-upon professional, that he is mentally or physically incapable of performing his duties hereunder.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Termination for Cause.&nbsp;&nbsp;</font>The Employee may be terminated by the Company without notice for &#8220;Cause.&#8221;&nbsp;&nbsp;The following, as determined by the Board in its reasonable judgment, shall constitute &#8220;<font style="text-decoration:underline;">Cause</font>&#8221; for termination:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Failure to Perform Duties.&nbsp;&nbsp;</font>The Employee&#8217;s material failure to perform (other than by reason of illness or disability) his duties to the Company, or his material negligence in the performance of his duties and/or responsibilities to the Company, provided that the Employee shall have had prior written notice and a reasonable opportunity of not less than thirty (30) days to correct any deficiency in such performance;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Breach of Employment Agreement or Restrictive Covenants Agreement.&nbsp;&nbsp;</font>The Employee&#8217;s material breach of this Agreement or the Restrictive Covenants Agreement;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Misconduct.&nbsp;&nbsp;</font>The Employee&#8217;s conviction for or plea of <font style="font-style:italic;">nolo contendere </font>or guilty to any crime involving fraud, embezzlement or moral turpitude or any felony; or</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Harmful Conduct.&nbsp;&nbsp;</font>Any conduct of the Employee that is materially harmful to the business, interests or reputation of the Company, provided that the Employee shall have had prior written notice and a reasonable opportunity of not less than ten (10) days to correct any such conduct.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Termination By Company Without Cause.&nbsp;&nbsp;</font>The Employee may be terminated by the Company without &#8220;Cause&#8221; upon delivery of written notice to the Employee.&nbsp;&nbsp;In the event the Employee is terminated without &#8220;Cause,&#8221; the Employee shall be entitled to receive the severance benefits set forth in Section 7(f) or 7(g), as applicable.&nbsp;&nbsp;The Company&#8217;s decision not to renew the Term of Employment shall constitute a termination without &#8220;Cause.&#8221;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>(d)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Termination by the Employee for Good Reason.&nbsp;&nbsp;</font>This Agreement may be terminated by the Employee for &#8220;Good Reason&#8221; (as defined below), upon thirty (30) days&#8217; prior written notice to the Company specifying any and all circumstances the Employee believes to constitute the basis for Good Reason, provided that the Company shall have the opportunity to cure the asserted Good Reason within the thirty (30) day period.&nbsp;&nbsp;The Employee shall have &#8220;<font style="text-decoration:underline;">Good Reason</font>&#8221; to terminate this Agreement in the event that the Company, without the express </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">written consent of the Employee: (i) causes a material diminution of the Employee&#8217;s authority, duties or responsibilities; (ii) materially breaches this Agreement, including, without limitation, by materially reducing the Employee&#8217;s Base Salary</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or (iii) relocat</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">es</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the Employee&#8217;s place of business by more than thirty (30) miles from the Company&#8217;s current Cambridge, Massachusetts office.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Notwithstanding the foregoing, the Employee must </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">give notice of his intention to resign within ninety (90) days after the occurrence of the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">grounds for termination for Good Reason</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resign within thirty (30) days </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after the expiration of the Company&#8217;s </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thirty (30) day </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cure period referenced above, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or grounds for termination for Good Reason due to the circumstances specified in the notice are irrevocably waived.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event the Employee terminates his employment for Good Reason, the Employee shall be entitled to the severance benefits set forth in Section </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f) or </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g), as applicable.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Effect of Early Termination.&nbsp;&nbsp;</font>Except for a termination by the Company without &#8220;Cause&#8221; or by the Employee for &#8220;Good Reason,&#8221; in the event of any early termination of the Term of Employment, the Company&#8217;s obligations under this Agreement shall immediately cease and the Employee shall be entitled to only the Employee&#8217;s Base Salary and employment benefits which have accrued and to which the Employee is entitled through the date of such termination, including any bonus that may have been awarded but not yet paid.&nbsp;&nbsp;These accrued salary and benefits shall be paid on or about the date of termination.&nbsp;&nbsp;The Employee shall not be entitled to any other compensation or consideration, including any bonus not yet awarded that the Employee may have been eligible for had his Term of Employment not ceased, except as otherwise set forth in this Section 7(e).&nbsp;&nbsp;In the event of an early termination of the Term of Employment due to the Employee&#8217;s death or disability, as set forth in Section 7(a), the Employee (or his estate, in the event of his death) will be eligible to receive a pro rata bonus determined in the manner set forth in the penultimate sentence of Section 7(f), which bonus shall be paid within thirty (30) days following the date of the Employee&#8217;s termination.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>(f)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Severance Benefits Prior to a Change in Control.&nbsp;&nbsp;</font>If the Term of Employment is terminated by the Company without &#8220;Cause&#8221; (as that term is defined in Section 7(b)) or by the Employee for &#8220;Good Reason&#8221; (as that term is defined in Section 7(d)), in each case prior to a Change in Control (as that term is defined in <font style="text-decoration:underline;">Exhibit B</font>), the Employee shall be entitled to receive his Base Salary and all other employment benefits accrued through the effective date of such termination, which shall be paid on or about the date of termination.&nbsp;&nbsp;In addition, provided the Employee executes and allows to become binding a severance agreement and release of claims drafted by and satisfactory to the Company (the &#8220;<font style="text-decoration:underline;">Release</font>&#8221;) on or before the sixtieth (60<sup style="font-size:85%; vertical-align:top">th</sup>) day after the date of termination, then beginning on the first regularly scheduled payroll date that is sixty (60) days following the date of termination (such date, the &#8220;<font style="text-decoration:underline;">Payment Commencement Date</font>&#8221;), for a period of twelve (12) months (the &#8220;<font style="text-decoration:underline;">Severance Period</font>&#8221;), the Company shall: (i) pay to the Employee as severance pay his Base Salary in accordance with the Company&#8217;s regularly established payroll procedure and (ii) pay for coverage under any medical benefit plans provided pursuant to Section 4(f), provided the Employee is eligible for and elects to continue receiving such benefits pursuant to the federal &#8220;COBRA&#8221; law, 29 U.S.C. &#167; 1161 et. seq., and provided further that the Employee continues to pay the applicable share of the premium for such coverage that is paid by active and similarly situated employees who receive the same type of coverage.&nbsp;&nbsp;In addition, the Company shall pay to the Employee, on the Payment Commencement Date, a pro-rata bonus equal to (A) the average of the Employee&#8217;s annual bonus payments over each of the three (3) years prior to the year of termination (or, if the Employee is </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an executive officer,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> such lesser period during which the Employee served as an executive officer of the Company)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or, if such termination occurs prior to the award of the Employee&#8217;s first annual bonus for </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Empl</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">oyee&#8217;s target annual bonus for 2017</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:10pt;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">multiplied by (B) a fraction, the numerator of which is the number of days during the year during which the Employee remained employed by the Company and the denominator of which is 365.&nbsp;&nbsp;The distribution of all severance benefits under this Section </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f) shall be subject to the provisions of </font><font style="text-decoration:underline;">Exhibit</font><font style="text-decoration:underline;"> </font><font style="text-decoration:underline;">C</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:0pt;"></font><font style="font-style:italic;">Severance Benefits After a Change in Control</font>.&nbsp;&nbsp;If the Term of Employment is terminated by the Company without &#8220;Cause&#8221; (as that term is defined in Section 7(b)) or by the Employee for &#8220;Good Reason&#8221; (as that term is defined in Section 7(d)), in each case within the eighteen (18) month period following a Change in Control (as that term is defined in <font style="text-decoration:underline;">Exhibit B</font>), the Employee shall be entitled to receive his Base Salary and all other employment benefits accrued through the effective date of such termination, which shall be paid on or about the date of termination.&nbsp;&nbsp;In addition, provided the Employee executes and allows to become binding the Release on or before the Payment Commencement Date, the Company shall: (i) pay to the Employee as severance pay on the Payment Commencement Date a lump sum amount equal to thirty-six (36) months of his Base Salary; (ii) pay to the Employee on the Payment Commencement Date a bonus equal to (A) three (3) multiplied by (B) the average of the Employee&#8217;s annual bonus payments over each of the three (3) years prior to the year of termination <font style="font-size:10pt;">(</font>or, if the Employee is an executive officer, such lesser period during which the Employee served as an executive officer of the Company), or, if such termination occurs prior to the award of the Employee&#8217;s first annual bonus for 2017, the Employee&#8217;s target annual bonus for 2017;<font style="font-size:10pt;"> </font>(iii) accelerate the vesting of all outstanding Company stock options, restricted stock or other equity awards granted to the Employee; and (iv) pay for coverage under any medical benefit plans provided pursuant to Section 4(f) for a period of eighteen (18) months following the Employee&#8217;s date of termination, provided the Employee is eligible for and elects to continue receiving such benefits pursuant to the federal &#8220;COBRA&#8221; law, 29 U.S.C. &#167; 1161 et. seq., and provided further that the Employee continues to pay the applicable share of the premium for such coverage that is paid by active and similarly situated employees who receive the same type of coverage.&nbsp;&nbsp;The distribution of all severance benefits under this Section 7(g) shall be subject to the provisions of <font style="text-decoration:underline;">Exhibit C</font>.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Absence of Restrictions</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">The Employee represents and warrants that he is not a party to any commitment or undertaking by which he is subject to any restriction or limitation upon his entering into this Agreement or performing the services required of him hereunder.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Amendments</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">Any amendment to this Agreement shall be made in writing and signed by the parties hereto.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>10.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Applicable Law/Jury Trial Waiver</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts (without reference to the conflict of laws provisions thereof).&nbsp;&nbsp;Any action, suit or other legal proceeding arising under or relating to any provision of this Agreement shall be commenced only in a court of the Commonwealth of Massachusetts (or, if appropriate, a federal court located within the Commonwealth of Massachusetts), and the Company and the Employee each consents to the jurisdiction of such a court.&nbsp;&nbsp;THE COMPANY AND THE EMPLOYEE EACH HEREBY </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">IRREVOCABLY WAIVES ANY RIGHT TO A TRIAL BY JURY IN ANY ACTION, SUIT OR OTHER LEGAL PROCEEDING ARISING UNDER OR RELATING TO ANY PROVISION OF THIS AGREEMENT.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Entire Agreement</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">This Agreement, together with the Restrictive Covenants Agreement attached hereto as </font><font style="text-decoration:underline;font-weight:normal;">Exhibit A</font><font style="font-weight:normal;"> and executed as a condition of the Employee&#8217;s employment, constitutes the entire agreement between the parties and supersedes all prior agreements and understandings, whether written or oral, relating to the subject matter of these agreements.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Successors and Assigns</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and assigns, including any corporation with which or into which the Company may be merged or which may succeed to its assets or business; provided, however, that the obligations of the Employee are personal and shall not be assigned by him.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Acknowledgment</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">The Employee states and represents that he has had an opportunity to fully discuss and review the terms of this Agreement with an attorney.&nbsp;&nbsp;The Employee further states and represents that he has carefully read this Agreement, understands the contents herein, freely and voluntarily assents to all of the terms and conditions hereof, and signs his name of his own free act.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.<font style="margin-left:0pt;"></font><font style="font-style:italic;">Miscellaneous</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:0pt;"></font>No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right.&nbsp;&nbsp;A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar to or waiver of any right on any other occasion.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:0pt;"></font>The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:14.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:0pt;"></font>In case any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Remainder of Page Intentionally Left Blank]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the parties here</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to have executed this Agreement</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as of the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">date</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> first written</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> above</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COMPANY:<font style="font-weight:normal;margin-left:216pt;"></font></p>
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:46.15%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MERRIMACK PHARMACEUTICALS, INC<font style="font-weight:normal;">.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:46.15%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;">/s/ Richard Peters</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:50%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Peters</p>
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:50%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:46.15%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EMPLOYEE:<font style="font-weight:normal;margin-left:216pt;"></font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:46.15%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Sergio L. Santillana</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sergio L. Santillana</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:57.69%;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="text-decoration:underline;">Exhibit A</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-Disclosure, Developments, Non-Competition and Non-Solicitation Agreement</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NON-DISCLOSURE, DEVELOPMENTS, NON-COMPETITION</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AND NON-SOLICITATION AGREEMENT</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Non-Disclosure, Developments, Non-Competition and Non-Solicitation Agreement (the &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;), dated as of June 12, 2017, is entered into by and between Merrimack Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;), and Sergio L. Santillana (the &#8220;<font style="text-decoration:underline;">Employee</font>&#8221;).</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration of the Employee&#8217;s employment with the Company and for other valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the Employee, the Employee hereby agrees as follows:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Condition of Employment</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="OLE_LINK1"></a><a name="OLE_LINK2"></a><a name="OLE_LINK1"></a><a name="OLE_LINK2"></a>The Employee acknowledges that his/her<font style="font-weight:bold;"> </font>employment and the continuance of that employment with the Company is contingent upon his/her<font style="font-weight:bold;"> </font>agreement to sign and adhere to the provisions of this Agreement.&nbsp;&nbsp;The Employee further acknowledges that the nature of the Company&#8217;s business is such that protection of its proprietary and confidential information and goodwill with its customers and partners is critical to its survival and success.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Confidential Information</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:0pt;"></font><font style="color:#000000;">The Employee agrees that all information and know-how, whether or not in writing, of a private, secret or confidential nature concerning the Company and its operations and business or financial affairs (collectively, &#8220;</font><font style="text-decoration:underline;color:#000000;">Confidential Information</font><font style="color:#000000;">&#8221;) is and shall be the exclusive property of the Company.&nbsp;&nbsp;By way of illustration, but not limitation, Confidential Information may include</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">models, systems, software and codes, or systems, software and codes in the course of development, or planned or proposed systems, software or codes, customer, prospect and supplier lists, contacts at or knowledge of customers or prospective customers, customer accounts and other customer financial information, strategic partners and/or collaborators, price lists and all other pricing, marketing and sales information, projections, results relating to the Company or any customer or supplier of the Company, databases, modules, products, programs, product improvements, product enhancements and/or developments, designs, specifications, processes, methods, techniques, operations, projects, plans, chemical compounds, chemical or biological materials, engineering data, clinical or technological data, research data, financial data, personnel information, and other confidential agreements or documents (including, without limitation, clinical trial protocols and unpublished patent applications).&nbsp;&nbsp;Except as otherwise permitted by Section 5, the Employee will not disclose any Confidential Information to others outside the Company or use the same for any unauthorized purposes without written approval by an officer of the Company, either during or at any time after his/her employment with the Company, unless and until such Confidential Information has become public knowledge without fault by the Employee.&nbsp;&nbsp;While employed by the Company, the Employee will use the Employee&#8217;s best efforts to prevent publication or disclosure of any Confidential Information.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>(b)<font style="margin-left:0pt;"></font><font style="color:#000000;">The Employee agrees that all Company Property (as defined below), whether created by the Employee or others, that shall come into the Employee&#8217;s custody or possession </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">shall be and is the sole and exclusive property of the Company to be used only in the performance of the Employee&#8217;s duties for the Company.&nbsp;&nbsp;&#8220;</font><font style="text-decoration:underline;color:#000000;">Company Property</font><font style="color:#000000;">&#8221; means any and all written, photographic or any other record containing Confidential Information and shall include, but not be limited to, all agreements, notes, disks, files, letters, memoranda, reports, records, lists, data, drawings, sketches, notebooks, program listings, specifications, software programs, software code, computers and other electronic equipment, documentation, or other equipment or materials of any nature and in any form, containing Confidential Information.&nbsp;&nbsp;Upon the earliest of the Employee&#8217;s termination or a request from the Company, the Employee will return to the Company any and all Company Property in the Employee&#8217;s custody or possession without retaining any copies thereof (including, without limitation, any electronic copy) and without using or allowing others to improperly use such Company Property.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:0pt;"></font><font style="color:#000000;">The Employee acknowledges that the Employee&#8217;s obligations with regard to Confidential Information that are set out in Sections 2(a) and (b) extend to all information, know-how, records and tangible property of customers of the Company or suppliers to the Company or of any third party who may have disclosed or entrusted the same to the Company or to the Employee in the course of the Company&#8217;s business.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Developments</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:0pt;"></font><font style="color:#000000;">The Employee will make full and prompt disclosure to the Company of all inventions, ideas, concepts, improvements, discoveries, methods, techniques, tools, formula, developments, enhancements, modifications, databases,&#160;processes, software and works of authorship, whether patentable or not, that are created, made, conceived or reduced to practice by the Employee or under the Employee&#8217;s direction or jointly with others during the Employee&#8217;s employment with the Company, whether or not during normal working hours or on the premises of the Company (all of which are collectively referred to in this Agreement as &#8220;</font><font style="text-decoration:underline;color:#000000;">Developments</font><font style="color:#000000;">&#8221;).</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>(b)<font style="margin-left:0pt;"></font><font style="color:#000000;">The Employee agrees to assign and does hereby assign to the Company (or any person or entity designated by the Company) all of the Employee&#8217;s right, title and interest in and to all Developments and all related intellectual property rights.&nbsp;&nbsp;Except as, and solely to the extent that, it may be necessary for the Employee to perform&#160;the Employee&#8217;s duties and fulfill&#160;the Employee&#8217;s obligations in the course of the Employee&#8217;s employment with the Company, the Company does not grant the Employee, and the Employee agrees that he/she will not receive, any license or right to use any Development or related intellectual property right.&nbsp;&nbsp;The Employee hereby also waives all claims to moral rights in any Developments.&nbsp;&nbsp;However, this Section 3(b) shall not apply to Developments that do not relate to the present or planned business or research and development of the Company and that are made and conceived by the Employee not during normal working hours, not on the Company&#8217;s premises and not using the Company&#8217;s tools, devices, equipment or Confidential Information.&nbsp;&nbsp;This Section 3(b) also shall not apply to any inventions that the Employee conceived of prior to the Employee&#8217;s employment with the Company, which invention(s) the Employee shall disclose on </font><font style="text-decoration:underline;color:#000000;">Exhibit A</font><font style="color:#000000;"> attached hereto.&nbsp;&nbsp;IF THERE ARE ANY SUCH INVENTIONS TO BE EXCLUDED UNDER THIS AGREEMENT, THE EMPLOYEE SHALL INITIAL HERE; OTHERWISE IT WILL BE DEEMED THAT THERE ARE NO SUCH EXCLUSIONS. ____&nbsp;&nbsp;The Employee understands that, to the extent this Agreement shall be construed in accordance with the laws of any state that precludes the requirement in an employee agreement to assign certain classes of inventions made </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">by an employee, this Section 3(b) shall be interpreted not to apply to any invention that a court rules and/or the Company agrees falls within such classes.&nbsp;&nbsp;To the extent allowed by law, the Employee hereby grants to the Company an exclusive (even unto the Employee), irrevocable, fully paid up, worldwide license to make, use and sell any and all inventions for which assignment cannot be effected.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="OLE_LINK7"></a><a name="OLE_LINK8"></a>(c)<font style="margin-left:0pt;"></font><font style="color:#000000;"><a name="OLE_LINK7"></a><a name="OLE_LINK8"></a>The Employee agrees to cooperate fully with the Company, both during and after the Employee&#8217;s employment with the Company, with respect to the procurement, maintenance and enforcement of all copyrights, trademarks, patents and other intellectual property rights (both in the United States and foreign countries) relating to any Development.&nbsp;&nbsp;The Employee shall sign all papers, including, without limitation, copyright applications, patent applications, declarations, oaths, formal assignments, assignment of priority rights and powers of attorney, that the Company may deem necessary or desirable in order to protect and enforce its rights and interests in any Development.&nbsp;&nbsp;The Employee further agrees that if the Company is unable, after reasonable effort, to secure the signature of the Employee on any such papers, any executive officer of the Company shall be entitled to execute any such papers as the agent and the attorney-in-fact of the Employee, and the Employee hereby irrevocably designates and appoints each executive officer of the Company as the Employee&#8217;s agent and attorney-in-fact for all countries worldwide to execute any such papers on the Employee&#8217;s behalf, and to take any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in any Development, under the conditions described in this sentence.&nbsp;&nbsp;Should the Company engage in litigation to enforce any such intellectual property rights, the Employee agrees to appear and testify at no charge, but at the Company&#8217;s expense.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Non-Competition and Non-Solicitation</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:0pt;"></font>While<font style="color:#000000;"> the Employee is employed by the Company and for a period of twelve (12) months following the Employee&#8217;s termination or cessation of employment for any reason (voluntarily or involuntarily), the Employee will not, directly or indirectly:</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>engage in any business or enterprise (whether as an owner, partner, officer, employee, director, investor, lender, consultant, independent contractor or otherwise, except as the holder of not more than 1% of the combined voting power of the outstanding stock of a publicly held company) that is competitive with the Company&#8217;s business, including, without limitation, any business or enterprise that develops, designs, produces, markets or sells any product or service competitive with any product or service developed, designed, produced, marketed or sold or planned to be developed, designed, produced, marketed or sold by the Company while the Employee was employed by the Company;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>either alone or in association with others, recruit, solicit, hire or engage as an independent contractor, or attempt to recruit, solicit, hire or engage as an independent contractor, any person who was employed by the Company or engaged as an independent contractor for the Company at any time during the period of the Employee&#8217;s employment with the Company, except for an individual whose employment with or service for the Company has been terminated for a period of six (6) months or longer; and/or</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">either alone or in association with others, service, solicit, divert or take away, or attempt to service, solicit, divert or take away, the business or patronage of any of the clients, customers or accounts, or prospective clients, customers or accounts, of the Company that were contacted, solicited or served by the Employee while the Employee was employed by the Company or about which the Employee had access to Confidential Information in the course of his/her employment with the Company.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:0pt;"></font><font style="color:#000000;">The geographic scope of this Section 4 shall extend to anywhere the Company or any of its subsidiaries is doing business, has done business or has plans to do business during the Employee&#8217;s employment with the Company.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:0pt;"></font><font style="color:#000000;">If any restriction set forth in this Section 4 is found by any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:0pt;"></font><font style="color:#000000;">The Employee agrees that during the non-competition and non-solicitation period, the Employee will give notice to the Company of each new job, contract assignment or other work (either as an employee, contractor or otherwise) the Employee plans to undertake at least ten (10) business days prior to beginning any such activity.&nbsp;&nbsp;The notice shall state the name and address of the individual, corporation, association or other entity or organization (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Entity</font><font style="color:#000000;">&#8221;) for whom such activity is undertaken and the Employee&#8217;s proposed business relationship or position with the Entity.&nbsp;&nbsp;The Employee further agrees to provide the Company with other pertinent information concerning such business activity as the Company may reasonably request in order to determine the Employee&#8217;s continued compliance with his/her obligations under this Agreement.&nbsp;&nbsp;During the non-competition and non-solicitation period, the Employee agrees to provide a copy of this Agreement to all person and Entities with whom the Employee seeks to be hired or do business before accepting employment or engagement with any of them.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:0pt;"></font><font style="color:#000000;">If the Employee violates any of the provisions of this Section 4, the Employee shall continue to be held by the restrictions set forth in this Section 4 until a period equal to the period of restriction has expired without any violation.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_4"></a>5.<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Scope of Disclosure Restrictions</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a>Nothing in this Agreement prohibits the Employee from communicating with government agencies about possible violations of federal, state or local laws or otherwise providing information to government agencies or participating in government agency investigations or proceedings.&nbsp;&nbsp;The Employee is not required to notify the Company of any such communications; provided, however, that nothing herein authorizes the disclosure of information the Employee obtained through a communication that was subject to the attorney-client privilege.&nbsp;&nbsp;Further, notwithstanding the Employee&#8217;s confidentiality and nondisclosure obligations, the Employee is hereby advised as follows pursuant to the Defend Trade Secrets Act: &#8220;An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.&nbsp;&nbsp;An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.&#8221;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Other Agreements</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Employee hereby represents that, except as the Employee has disclosed in writing to the Company, the Employee is not bound by the terms of any restrictive covenant agreement with any previous employer or other party relating to the non-disclosure of trade secret or confidential or proprietary information, non-competition and/or non-solicitation of customers, clients, employees or others.&nbsp;&nbsp;The Employee further represents that the Employee&#8217;s performance of all the terms of this Agreement and as an employee of the Company does not and will not breach any such restrictive covenant agreement, and the Employee will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or others.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Employment At Will</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Employee acknowledges that this Agreement does not constitute a contract of employment for any period of time and does not modify the at-will nature of the Employee&#8217;s employment with the Company, pursuant to which both the Company and the Employee may terminate the employment relationship at any time, for any or no reason, with or without notice.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">General Provisions</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Equitable Relief</font><font style="color:#000000;">.&nbsp;&nbsp;The Employee acknowledges that the restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company and are considered by the Employee to be reasonable for such purpose.&nbsp;&nbsp;The Employee agrees that any breach or threatened breach of this Agreement will cause the Company substantial and irrevocable damage that is difficult to measure.&nbsp;&nbsp;Therefore, in the event of any such breach or threatened breach, the Employee agrees that the Company, in addition to such other remedies that may be available, shall have the right to specific performance and injunctive relief without posting a bond, as well as its reasonable attorneys&#8217; fees incurred as a result of any such breach or threatened breach.&nbsp;&nbsp;The Employee hereby waives the adequacy of a remedy at law as a defense to such relief.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Change in Terms/Conditions of Employment</font><font style="color:#000000;">.&nbsp;&nbsp;The Employee agrees that his/her&nbsp;&nbsp;obligations under this Agreement shall continue in full force and effect in the event that the Employee&#8217;s job title, responsibilities, reporting structure, work location, compensation or other conditions of his/her employment with the Company change subsequent to the execution of this Agreement, without the need to execute a new agreement.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">No Conflict</font><font style="color:#000000;">.&nbsp;&nbsp;The Employee represents that the execution and performance by the Employee of this Agreement does not and will not conflict with or breach the terms of any other agreement by which the Employee is bound.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font><font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Severability</font><font style="color:#000000;">.&nbsp;&nbsp;The invalidity or unenforceability of any provision of this Agreement shall not affect or impair the validity or enforceability of any other provision of this Agreement.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Waiver</font><font style="color:#000000;">.&nbsp;&nbsp;No delay or omission by the Company in exercising any right under this Agreement will operate as a waiver of that or any other right.&nbsp;&nbsp;A waiver or consent given by the Company on any one occasion is effective only in that instance and will not be construed as a bar to or waiver of any right on any other occasion.&nbsp;&nbsp;Any waiver of any provision hereof shall be in writing and signed by the Company.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Successors and Assigns</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and assigns, including, without limitation, any corporation or entity with which or into which the Company may be merged or which may succeed to all or substantially all of its assets or business; provided, however, that the obligations of the Employee are personal and shall not be assigned by the Employee.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Governing Law, Forum and Jurisdiction/Jury Trial Waiver</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement shall be governed by and construed as a sealed instrument under and in accordance with the laws of the Commonwealth of Massachusetts without regard to conflict of laws provisions.&nbsp;&nbsp;Any action, suit or other legal proceeding that is commenced to resolve any matter arising under or relating to any provision of this Agreement shall be commenced only in a court of the Commonwealth of Massachusetts (or, if appropriate, a federal court located within Massachusetts), and the Company and the Employee each consents to the jurisdiction of such a court.&nbsp;&nbsp;</font><font style="font-weight:bold;color:#000000;">The Employee and the Company hereby expressly waive the right to a jury trial for any claim relating to his/her/its rights or obligations under this Agreement, or otherwise relating to the Employee&#8217;s employment or separation from employment with the Company.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Captions</font><font style="color:#000000;">.&nbsp;&nbsp;The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:0pt;"></font><font style="text-decoration:underline;color:#000000;">Entire Agreement</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement supersedes all prior agreements, written or oral, between the Employee and the Company relating to the subject matter of this Agreement.&nbsp;&nbsp;This Agreement may not be amended, modified, changed or discharged in whole or in part, except by an agreement in writing signed by the Employee and the Company.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THE EMPLOYEE ACKNOWLEDGES THAT HE/SHE HAS CAREFULLY READ THIS AGREEMENT AND UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Remainder of Page Intentionally Left Blank]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.</font></p>
<p style="margin-bottom:24pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COMPANY:<font style="font-weight:normal;margin-left:216pt;"></font></p>
<p style="margin-bottom:24pt;margin-top:24pt;text-indent:46.15%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MERRIMACK PHARMACEUTICALS, INC<font style="font-weight:normal;">.</font></p>
<p style="margin-top:24pt;margin-bottom:0pt;text-indent:46.15%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;">/s/ Richard Peters</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:50%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Peters</p>
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:50%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="margin-top:24pt;margin-bottom:0pt;text-indent:46.15%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EMPLOYEE:<font style="font-weight:normal;margin-left:216pt;"></font></p>
<p style="margin-top:24pt;margin-bottom:0pt;text-indent:46.15%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Sergio L. Santillana</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sergio L. Santillana</p>
<p style="margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a><font style="text-decoration:underline;">Exhibit A</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">List of Prior Inventions and Original Works of Authorship</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:478.8pt;;">
<tr>
<td style="width:99.9pt;"></td>
<td style="width:112.5pt;"></td>
<td style="width:266.4pt;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identifying Number or Brief Description</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;margin-left:36pt;"></font> Additional Sheets Attached</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature of Employee:<font style="margin-left:36pt;"></font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Printed Name of Employee:<font style="margin-left:36pt;"></font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:<font style="margin-left:36pt;">________________________</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit B</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Definition of Change in Control </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A &#8220;<font style="text-decoration:underline;">Change in Control</font>&#8221; shall occur upon any of the following events, provided, in each case, that such event constitutes a &#8220;change in control event&#8221; within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(i):</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(A)<font style="margin-left:36pt;">the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="text-decoration:underline;">Exchange Act</font>&#8221;)) (a &#8220;<font style="text-decoration:underline;">Person</font>&#8221;) of beneficial ownership of any capital stock of the Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule 13d-3 under the Exchange Act) 50% or more of either (x) the then-outstanding shares of common stock of the Company (the &#8220;<font style="text-decoration:underline;">Outstanding Company Common Stock</font>&#8221;) or (y) the combined voting power of the then-outstanding securities of the Company entitled to vote generally in the election of directors (the &#8220;<font style="text-decoration:underline;">Outstanding Company Voting Securities</font>&#8221;); provided, however, that for purposes of this subsection (A), the following acquisitions shall not constitute a Change in Control: (1) any acquisition directly from the Company or (2) any acquisition by any corporation pursuant to a Business Combination (as defined below) which complies with clauses (x) and (y) of subsection (C) of this definition;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(B)<font style="margin-left:36pt;">a change in the composition of the Board that results in the Continuing Directors (as defined below) no longer constituting a majority of the Board (or, if applicable, the Board of Directors of a successor corporation to the Company), where the term &#8220;</font><font style="text-decoration:underline;">Continuing Director</font>&#8221; means at any date a member of the Board (x) who was a member of the Board on the date of this Agreement or (y) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided, however, that there shall be excluded from this clause (y) any individual whose initial assumption of office occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board; or</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a>(C)<font style="margin-left:36pt;">the consummation of a merger, consolidation, reorganization, recapitalization or share exchange involving the Company or a sale or other disposition of all or substantially all of the assets of the Company (a &#8220;</font><font style="text-decoration:underline;">Business Combination</font>&#8221;), unless, immediately following such Business Combination, each of the following two conditions is satisfied: (x) all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Company&#8217;s assets either directly or through one or more subsidiaries) (such resulting or acquiring </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">corporation is referred to herein as the &#8220;</font><font style="text-decoration:underline;">Acquiring Corporation</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) in substantially the same proportions as their ownership of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively, immediately prior to such Business Combination and (y) no Person (excluding any employee benefit plan (or related trust) maintained or sponsored by the Company or by the Acquiring Corporation</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) beneficially owns, directly or indirectly, 50%</font><font style="font-weight:bold;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or more of the then-outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such corporation entitled to vote generally in the election of directors (except to the extent that such ownership existed prior to the Business Combination)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit </font><font style="text-decoration:underline;">C</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments Subject to Section 409A</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to this Exhibit C, severance payments or benefits under this Agreement shall begin only on or after the date of the Employee&#8217;s &#8220;separation from service&#8221; (determined as set forth below), which occurs on or after the termination of the Employee&#8217;s employment.&nbsp;&nbsp;The following rules shall apply with respect to distribution of the payments and benefits, if any, to be provided to the Employee under this Agreement:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is intended that each installment of the payments provided under this Agreement shall be treated as a separate &#8220;payment&#8221; for purposes of Section 409A of the Internal Revenue Code and the guidance issued thereunder (&#8220;<font style="text-decoration:underline;">Section 409A</font>&#8221;).&nbsp;&nbsp;Neither the Company nor the Employee shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, as of the date of the Employee&#8217;s &#8220;separation from service&#8221; from the Company, the Employee is not a &#8220;specified employee&#8221; (within the meaning of Section 409A), then each installment of the severance payments and benefits shall be made on the dates and terms set forth in this Agreement.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, as of the date of the Employee&#8217;s &#8220;separation from service&#8221; from the Company, the Employee is a &#8220;specified employee&#8221; (within the meaning of Section 409A), then:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Each installment of the severance payments and benefits due under this Agreement that, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when the Employee&#8217;s separation from service occurs, be paid within the Short-Term Deferral Period (as defined under Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section 1.409A- l(b)(4) to the maximum extent permissible under Section 409A and shall be paid at the time set forth in this Agreement; and</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a>(b)<font style="margin-left:36pt;"></font>Each installment of the severance payments and benefits due under this Agreement that is not described in this Exhibit C, Section 3(a) and that would, absent this subsection, be paid within the six (6) month period following the Employee&#8217;s &#8220;separation from service&#8221; from the Company shall not be paid until the date that is six (6) months and one (1) day after such separation from service (or, if earlier, the Employee&#8217;s death), with any such installments that are required to be delayed being accumulated during the six (6) month period and paid in a lump sum on the date that is six (6) months and one (1) day following the Employee&#8217;s separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth in this Agreement; provided, however, that the preceding provisions of this sentence shall not apply to any installment of severance payments and benefits if and to the maximum extent that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-l(b)(9)(iii) (relating to separation pay upon an involuntary separation from service).&nbsp;&nbsp;Any installments that qualify for the exception under Treasury Regulation Section 1.409A-l(b)(9)(iii) must be paid no later than the last day of the Employee&#8217;s second taxable year following the taxable year in which the separation from service </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">occurs.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The determination of whether and when the Employee&#8217;s separation from service from the Company has occurred shall be made in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-l(h).&nbsp;&nbsp;Solely for purposes of this Exhibit C, Section 4, &#8220;<font style="text-decoration:underline;">Company</font>&#8221; shall include all persons with whom the Company would be considered a single employer under Section 414(b) and 414(c) of the Internal Revenue Code.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during the Employee&#8217;s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company makes no representation or warranty and shall have no liability to the Employee or to any other person if any of the provisions of this Agreement (including this Exhibit C) are determined to constitute deferred compensation subject to Section 409A but that do not satisfy an exemption from, or the conditions of, that section.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:36pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company may withhold (or cause to be withheld) from any payments made under this Agreement, all federal, state, city or other taxes as shall be required to be withheld pursuant to any law or governmental regulation or ruling.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>5
<FILENAME>mack-ex1011_189.htm
<DESCRIPTION>EX-10.11 - SIXTH AMENDMENT OF LEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mack-ex1011_189.htm
</title>
</head>
<!-- NG Converter v4.0.8.13 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.11</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">SIXTH AMENDMENT OF LEASE</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Sixth Amendment of Lease (this &#8220;<font style="font-weight:bold;">Sixth Amendment</font>&#8221;) is made and entered into as of June&#160;9, 2017 (the &#8220;<font style="font-weight:bold;">Effective Date</font>&#8221;), by and between <font style="font-weight:bold;">ARE-MA REGION NO. 59, LLC</font>, a Delaware limited liability company (&#8220;<font style="font-weight:bold;">Landlord</font>&#8221;), as successor-in-interest to DWF IV One Kendall, LLC, as successor-in-interest to RB Kendall Fee, LLC (&#8220;<font style="font-weight:bold;">Original Landlord</font>&#8221;), and <font style="font-weight:bold;">MERRIMACK PHARMACEUTICALS, INC.</font>, a Delaware corporation (&#8220;Tenant&#8221;), with reference to the following:</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">RECITALS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.<font style="margin-left:36pt;">Pursuant to that certain Indenture of Lease dated as of August 24, 2012, as amended by (i) that certain First Amendment of Lease dated March 18, 2013, (ii) that certain Second Amendment of Lease dated September 12, 2013, (iii) that certain Third Amendment of Lease dated February 23, 2015, (iv) that certain Fourth Amendment of Lease dated July 22, 2015, and (v) that certain Fifth Amendment of Lease dated as of April 3, 2017 (the &#8220;</font><font style="font-weight:bold;">Fifth Amendment</font>&#8221;) (as amended, the &#8220;<font style="font-weight:bold;">Lease</font>&#8221;), Tenant leases certain premises (the &#8220;<font style="font-weight:bold;">Existing Premises</font>&#8221;) as more particularly described in the Lease, at the improved real property being Building 600/650/700 located at One Kendall Square, Cambridge, Massachusetts.&nbsp;&nbsp;The Existing Premises consists of approximately (a) 31,747 rentable square feet of space on a portion of the second (2nd) floor of Building 600/650/700 (the &#8220;<font style="font-weight:bold;">2nd Floor Space</font>&#8221;), (b) 4,773 rentable square feet of space on the fourth (4th) floor of Building 650/700 (the &#8220;<font style="font-weight:bold;">Additional Space</font>&#8221;), (c) 30,626 rentable square feet of space on the fourth (4th) floor of Building 600/700 (the &#8220;<font style="font-weight:bold;">4th Floor Space</font>&#8221;), (d) 7,245 rentable square feet of space on the mezzanine level of Building 700 (the &#8220;<font style="font-weight:bold;">Mezzanine Space</font>&#8221;), (e) 8,686 rentable square feet of space on the first (1st) floor of Building 600 (the &#8220;<font style="font-weight:bold;">1<sup style="font-size:85%; vertical-align:top">st</sup> Floor Space</font>&#8221;), (f) 132 rentable square feet in the basement of Building 700 (the &#8220;<font style="font-weight:bold;">Basement Premises</font>&#8221;), (g) 2,922 rentable square feet of space in the basement of Building 700 (the &#8220;<font style="font-weight:bold;">Storage Space</font>&#8221;), (h) 8,763 rentable square feet of space located on the fourth (4th) floor of Building 700 (the &#8220;<font style="font-weight:bold;">Expansion Space I</font>&#8221;), (i) 3,388 rentable square feet of space located on the fourth (4th) floor and the fourth (4th) floor mezzanine of Building 650 (the &#8220;<font style="font-weight:bold;">Expansion Space II</font>&#8221;), (j) 10,375 rentable square feet of space located on the fifth (5th) floor of Building 600 (the &#8220;<font style="font-weight:bold;">Expansion Space III</font>&#8221;),<font style="font-weight:bold;"> </font>(k) 491 rentable square feet of space on the first (1st) floor of Building 700 (the &#8220;<font style="font-weight:bold;">Chemical Storage Space</font>&#8221;), (l) 8,155 rentable square feet of space located on the second (2nd) floor of Building 600 (the &#8220;<font style="font-weight:bold;">600 Expansion Space</font>&#8221;), (m) 784 rentable square feet of space located on the second floor (2nd) of Building 600 (the &#8220;<font style="font-weight:bold;">Hallway Space</font>&#8221;), (n) 3,617 rentable square feet of space located on the fifth (5th) floor of Building 600 (the &#8220;<font style="font-weight:bold;">Expansion Space IV</font>&#8221;), (o) 31,620 rentable square feet of space on the fifth (5th) floor of Building 600/650/700 (the &#8220;<font style="font-weight:bold;">Third Amendment Premises</font>&#8221;), (p) 7,145 rentable square feet of space on the first (1st) floor of Building 700 (the &#8220;<font style="font-weight:bold;">Former Addgene Space</font>&#8221;), (q) 5,687 rentable square feet of space on the first (1st) floor of Building 700 (the &#8220;<font style="font-weight:bold;">Former OmniGuide Space</font>&#8221;), (r)&#160;311 rentable square feet of space on the basement level of Building 700 (the &#8220;<font style="font-weight:bold;">Equipment Room</font>&#8221;), and (s) 700 rentable square feet of storage space in the basement of Building 700 (the &#8220;<font style="font-weight:bold;">Fourth Amendment Storage Space</font>&#8221;).&nbsp;&nbsp;Capitalized terms used herein without definition shall have the meanings defined for such terms in the Lease.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B. <font style="margin-left:36pt;">Tenant desires to reduce the term of the Lease for a portion of the Existing Premises and surrender such portion of the Existing Premises to Landlord on the Sixth Amendment Reduction Date (as defined below), and Landlord is willing to shorten such term and accept such surrender of such portion of the Existing Premises on the Sixth Amendment Reduction Date subject to the terms of this Sixth Amendment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the foregoing and of the mutual promises made herein, and for other good and valuable consideration the receipt of which is hereby acknowledged, Landlord and Tenant agree as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;">Sixth Amendment Reduction Space/Sixth Amendment Reduction Date</font>.&nbsp;&nbsp;Effective as of the date that is the later of (a) Tenant&#8217;s completion of the Demising Work (as defined in <font style="text-decoration:underline;">Section 4</font> below), and (b) May 15, 2017 (the &#8220;<font style="font-weight:bold;">Sixth Amendment Reduction Date</font>&#8221;), Landlord and Tenant hereby terminate the term of the Lease with respect to that certain portion of the Existing Premises containing approximately 25,735 rentable square feet of space on the fifth (5<sup style="font-size:85%; vertical-align:top">th</sup>) floor of </p></td></tr></table></div>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building 600/700, as more particularly described in </font><font style="text-decoration:underline;">Exhibit A</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> attached hereto (the &#8220;</font><font style="font-weight:bold;">Sixth Amendment Reduction Space</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; and the remainder of the Existing Premises is the &#8220;</font><font style="font-weight:bold;">Sixth Amendment Remaining Premises</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;, as more particularly described in </font><font style="text-decoration:underline;">Exhibit B</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">).&nbsp;&nbsp;The Sixth Amendment Reduction Space consists collectively of (a) a portion of Expansion Space II, containing approximately 2,035 rentable square feet, (b) all of Expansion Space III, containing approximately 10,375 rentable square feet,&nbsp;&nbsp;(c) all of Expansion Space IV, containing approximately 3,617 rentable square feet, and (d) a portion of the Third Amendment Premises containing approximately 9,708 rentable square feet.&nbsp;&nbsp;Accordingly, from and after the Sixth Amendment Reduction Date, (i) the rentable square footage of the Expansion Space II shall be reduced to approximately 1,353 rentable square feet, and (ii) the rentable square footage of the Third Amendment Premises shall be reduced to approximately 21,912 rentable square feet.&nbsp;&nbsp;Nothing herein shall affect or diminish Tenant&#8217;s rights or obligations under the Lease with respect to the Sixth Amendment Remaining Premises remaining following the Sixth Amendment Reduction Date.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-weight:bold;">Definition of Premises</font>.&nbsp;&nbsp;As of the Sixth Amendment Reduction Date, the defined term &#8220;Premises&#8221; in Article 2 of Exhibit 1, Sheet 1 of the Lease shall be amended to remove the Sixth Amendment Reduction Space, and the rentable square footage of the Premises shall be accordingly reduced by approximately 25,735 rentable square feet and shall thereafter, through the Reduction Date (as defined in the Fifth Amendment), consist of approximately 141,432 rentable square feet.&nbsp;&nbsp;Notwithstanding anything to the contrary contained in the Fifth Amendment, Landlord and Tenant hereby agree that on the Reduction Date (as defined in the Fifth Amendment), the square footage of the Premises shall be reduced by an additional approximately 29,157 rentable square feet (as identified in the Fifth Amendment) and shall thereafter consist of approximately 112,275 rentable square feet.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-weight:bold;">Yearly Rent</font>.&nbsp;&nbsp;Commencing on the Sixth Amendment Reduction Date, Tenant shall have no further obligation to pay Yearly Rent, Operating Costs (including Building Operating Costs and Common Area Operating Costs), Taxes (including Building Taxes and Common Area Taxes) or other costs with respect to the Sixth Amendment Reduction Space and Article 9 of Exhibit 1, Sheet 1 of the Lease shall be amended to reflect the removal of the Sixth Amendment Reduction Space from the Existing Premises.&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-weight:bold;">Reduction and Surrender/Demising Work</font>.&nbsp;&nbsp;Tenant shall voluntarily surrender the Sixth Amendment Reduction Space on or before the Sixth Amendment Reduction Date in accordance with all surrender requirements contained in the Lease and in the condition required under the Lease (as amended by this Sixth Amendment).&nbsp;&nbsp;Prior to the Sixth Amendment Reduction Date, Tenant, at its sole cost and expense, shall complete and perform all of the work described in <font style="text-decoration:underline;">Exhibit C</font> attached hereto (the &#8220;<font style="font-weight:bold;">Demising Work</font>&#8221;).&nbsp;&nbsp;Tenant shall complete the Demising Work in a good and workmanlike manner using contractors approved by Landlord.&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-weight:bold;">Electrical Closet</font>.&nbsp;&nbsp;Tenant hereby acknowledges that the Sixth Amendment Reduction Space contains an electrical closet that will continue to serve the remaining Premises following the Sixth Amendment Reduction Date and that Landlord will be leasing out the Sixth Amendment Reduction Space to a third party tenant and that Tenant&#8217;s access to and use of the electrical closet following the Sixth Amendment Reduction Date shall be subject to the terms of the following provision, which is contained in the third party tenant&#8217;s lease (in which references to &#8220;Tenant&#8221; mean the third party tenant and &#8220;Premises&#8221; means the Sixth Amendment Reduction Space:</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>&#8220;Tenant acknowledges that there is an electrical closet, as shown on <font style="font-weight:bold;">Exhibit I</font> hereto (the &#8220;<font style="font-weight:bold;">Electrical Closet</font>&#8221;), that is located within the confines of the Premises, but is not part of the Premises and is instead part of the premises currently leased to Merrimack Pharmaceuticals (the &#8220;<font style="font-weight:bold;">Existing Tenant</font>&#8221;) pursuant to a lease between Landlord and Existing Tenant (as such lease has been or may in the future be amended, the &#8220;<font style="font-weight:bold;">Existing Lease Agreement</font>&#8221;).&nbsp;&nbsp;During the Term, subject to the terms and conditions of this <font style="text-decoration:underline;">Section 40(o)</font>, Tenant agrees to permit designated </p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">employees of the Existing Tenant, the designated employees of any assignee of or subtenant under the Existing Lease Agreement whose premises is being served by the Electrical Closet, and designated contractors of Existing Tenant or any assignee of or subtenant under the Existing Lease Agreement whose premises is being served by the Electrical Closet (as reasonably approved by Tenant to the extent required below, the &#8220;</font><font style="font-weight:bold;">Approved Invitees</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) and Landlord, to access the Premises solely to make any necessary repairs, maintenance, alterations or improvements to the Electrical Closet (including any conduits, cabling or wiring extending from such electrical closet to the Existing Tenant&#8217;s premises).&nbsp;&nbsp;Notwithstanding anything to the contrary in this Lease, any access by the Approved Invitees to the Premises for purposes of accessing the Electrical Closet contemplated under this Section shall be subject to the following conditions (the &#8220;</font><font style="font-weight:bold;">Electrical Closet Access Conditions</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;):&nbsp;&nbsp;(i) prior to access, all contractors and individuals that seek to be Approved Invitees must be identified in writing to Tenant and subject to Tenant&#8217;s approval, which approval shall not be unreasonably withheld, conditioned or delayed, but may be withheld in Tenant&#8217;s sole and absolute discretion if Tenant reasonably and in good faith determines that such individual or contractor is directly or indirectly employed by a competitor of Tenant or otherwise poses a risk to the security of the Premises or Tenant&#8217;s confidential information, (ii) except as provided below, such access shall be limited to regular business hours and only after not less than one (1) business day&#8217;s prior written notice to Tenant, (iii) except as provided below, at all times during access to the Premises or the Electrical Closet, an Approved Invitee must be accompanied by a designated employee of Tenant, and (iv) all such access shall be subject to Tenant&#8217;s reasonable security and confidentiality requirements, which may include, without limitation, the execution of reasonable non-disclosure agreement by Existing Tenant and any Approved Invitee.&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, in the event of an emergency, an Approved Invitee shall be permitted to access the Electrical Closet outside of normal business hours and without being accompanied by a designated employee of Tenant (but otherwise subject to the requirements of this </font><font style="text-decoration:underline;">Section 40(o)</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">), provided, that (i) to the extent possible, Tenant shall be given prior notice of such access, and, in all events Tenant shall be informed of such access on the next business day following such access and (ii) Landlord shall be required to provide a security escort for such Approved Invitee during such access.&#8221;</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Tenant shall have no obligation to modify and/or restore the electrical closet. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-weight:bold;">No Further Obligations</font>.&nbsp;&nbsp;Landlord and Tenant each agree that the other is excused as of the Sixth Amendment Reduction Date from any further obligations with respect to the Sixth Amendment Reduction Space, excepting only such obligations under the Lease which expressly survive the termination of the Lease. In addition, nothing herein shall be deemed to limit or terminate any common law or statutory rights Landlord may have with respect to Tenant in connection with any Hazardous Materials or for violations of any governmental requirements or requirements of applicable law. Nothing herein shall excuse Tenant from its obligations under the Lease with respect to the Sixth Amendment Reduction Space prior to the Sixth Amendment Reduction Date.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-weight:bold;">Removal of Personal Property</font>.&nbsp;&nbsp;Tenant agrees that the Sixth Amendment Reduction Space shall be surrendered free of all personal property of Tenant.&nbsp;&nbsp;Any personal property of Tenant remaining in the Sixth Amendment Reduction Space after the Sixth Amendment Reduction Date is hereby agreed to be abandoned by Tenant and may be disposed of by Landlord, in Landlord&#8217;s sole discretion, without obligation or liability of any kind to Tenant.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-weight:bold;">Parking Spaces</font>.&nbsp;&nbsp;As of the Sixth Amendment Reduction Date, Tenant shall forfeit its rights to twenty-six (26) of the parking passes in the OKS Garage that were allocated to Tenant under the Lease.&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9. </font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;">OFAC</font>.&nbsp;&nbsp;Tenant and all beneficial owners of Tenant are currently (a) in compliance with and shall at all times during the Term of the Lease remain in compliance with the regulations of the Office of Foreign Assets Control (&#8220;<font style="font-weight:bold;">OFAC</font>&#8221;) of the U.S. Department of Treasury and any statute, executive order, or regulation relating thereto (collectively, the &#8220;OFAC Rules&#8221;), (b) not listed on, </p></td></tr></table></div>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and shall not during the term of the Lease be listed on, the Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders List or the Sectoral Sanctions Identifications List, which are all maintained by OFAC and/or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c) not a person or entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-weight:bold;">Miscellaneous</font>.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.<font style="margin-left:36pt;">This Sixth Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions.&nbsp;&nbsp;This Sixth Amendment may be amended only by an agreement in writing, signed by the parties hereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.<font style="margin-left:36pt;">This Sixth Amendment is binding upon and shall inure to the benefit of the parties hereto, and their respective successors and assigns.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.<font style="margin-left:36pt;">This Sixth Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which when taken together shall constitute one and the same instrument.&nbsp;&nbsp;The signature page of any counterpart may be detached therefrom without impairing the legal effect of the signature(s) thereon provided such signature page is attached to any other counterpart identical thereto except having additional signature pages executed by other parties to this Sixth Amendment attached thereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d.<font style="margin-left:36pt;">Except as amended and/or modified by this Sixth Amendment, the Lease shall remain in full force and effect.&nbsp;&nbsp;In the event of any conflict between the provisions of this Sixth Amendment and the provisions of the Lease, the provisions of this Sixth Amendment shall prevail.&nbsp;&nbsp;Whether or not specifically amended by this Sixth Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this Sixth Amendment.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES ON FOLLOWING PAGE</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">IN WITNESS WHEREOF, the parties have executed this Sixth Amendment as of the date first written above.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">TENANT:</p>
<p style="margin-bottom:24pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">MERRIMACK PHARMACEUTICALS, INC.<font style="font-weight:normal;">,<br />a Delaware corporation</font></p>
<p style="margin-bottom:24pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;">/s/ Jeffrey A. Munsie<br /></font>Its:<font style="text-decoration:underline;">General Counsel</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD:</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">ARE-MA REGION NO. 59, LLC<font style="font-weight:normal;">,<br />a Delaware limited liability company.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:38.46%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">By:&nbsp;&nbsp;Alexandria Real Estate Equities, L.P.,<br />a Delaware limited partnership,<br />managing member</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:46.15%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">By:ARE-QRS CORP.,<br />a Maryland Corporation,<br />general partner</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:46.15%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">By:<font style="text-decoration:underline;">/s/ Eric Johnson</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:46.15%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Its:<font style="text-decoration:underline;">Senior Vice President, Legal Affairs</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><img src="g201708092014007253357.jpg" title="" alt="" style="width:623px;height:806px;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><img src="g201708092014007363358.jpg" title="" alt="" style="width:623px;height:806px;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><img src="g201708092014007613359.jpg" title="" alt="" style="width:623px;height:806px;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><img src="g201708092014007773360.jpg" title="" alt="" style="width:623px;height:806px;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><img src="g201708092014007953361.jpg" title="" alt="" style="width:623px;height:806px;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><img src="g201708092014008133362.jpg" title="" alt="" style="width:623px;height:806px;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><img src="g201708092014008303363.jpg" title="" alt="" style="width:623px;height:806px;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><img src="g201708092014008463364.jpg" title="" alt="" style="width:623px;height:806px;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>mack-ex311_9.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mack-ex311_9.htm
</title>
</head>
<!-- NG Converter v4.0.8.13 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATIONS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Richard Peters, M.D., Ph.D., certify that:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this Quarterly Report on Form 10-Q of Merrimack Pharmaceuticals, Inc.;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:2.27%;text-indent:2.27%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:20%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 9, 2017</p></td>
<td valign="top"  style="width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard Peters, M.D., Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Peters, M.D., Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>mack-ex312_6.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mack-ex312_6.htm
</title>
</head>
<!-- NG Converter v4.0.8.13 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATIONS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Richard Peters, M.D., Ph.D., certify that:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this Quarterly Report on Form 10-Q of Merrimack Pharmaceuticals, Inc.;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:2.27%;text-indent:2.27%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:20%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 9, 2017</p></td>
<td valign="top"  style="width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard Peters, M.D., Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Peters, M.D., Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>mack-ex321_8.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mack-ex321_8.htm
</title>
</head>
<!-- NG Converter v4.0.8.13 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Quarterly Report on Form 10-Q of Merrimack Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the period ended June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Richard Peters, M.D., Ph.D., President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his knowledge:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 9, 2017</p></td>
<td valign="top"  style="width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard Peters, M.D., Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Peters, M.D., Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>mack-ex322_17.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mack-ex322_17.htm
</title>
</head>
<!-- NG Converter v4.0.8.13 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Quarterly Report on Form 10-Q of Merrimack Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the period ended June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Richard Peters, M.D., Ph.D., President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his knowledge:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 9, 2017</p></td>
<td valign="top"  style="width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard Peters, M.D., Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Peters, M.D., Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g201708092014007253357.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201708092014007253357.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,G G # 2(  A$! Q$!_\0
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M&>PXH[^G/I1T]NE'X>O&,?Y_^M0 ?TYQCIUH/'X9[#BEY_\ KX[TGZ=.W2@
M[^G/I1_3G&.G6C\/7C&/\_\ UJ7G_P"OCO0 AX_#/8<4=_3GTH_3IVZ4?AZ\
M8Q_G_P"M0 ?TYQCIUH/'X9[#BEY_^OCO2?IT[=* #OZ<^E'].<8Z=:/P]>,8
M_P __6I>?_KX[T (>/PSV'%'?TY]*/TZ=NE'X>O&,?Y_^M0 ?TYQCIUH/'X9
M[#BEY_\ KX[TGZ=.W2@ [^G/I1_3G&.G6C\/7C&/\_\ UJ7G_P"OCO0 AX_#
M/8<4=_3GTH_3IVZ4?AZ\8Q_G_P"M0 ?TYQCIUH/'X9[#BEY_^OCO2?IT[=*
M#OZ<^E'].<8Z=:/P]>,8_P __6I>?_KX[T (>/PSV'%'?TY]*/TZ=NE'X>O&
M,?Y_^M0 ?TYQCIUH/'X9[#BEY_\ KX[TGZ=.W2@ [^G/I1_3G&.G6C\/7C&/
M\_\ UJ7G_P"OCO0 AX_#/8<4=_3GTH_3IVZ4?AZ\8Q_G_P"M0 ?TYQCIUH/'
MX9[#BEY_^OCO2?IT[=* #OZ<^E'].<8Z=:/P]>,8_P __6I>?_KX[T (>/PS
MV'%'?TY]*/TZ=NE'X>O&,?Y_^M0 ?TYQCIUH/'X9[#BEY_\ KX[TGZ=.W2@
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M_OKZ?Y__ %T   XX'_?/T_S_ /JH^O\ +WH!''(_[Z^G^?\ ]= XX_KCO0
M#C@?]\_3_/\ ^J@ <<#_ +Y^G^?_ -5 (XY'_?7T_P __KH!''(_[Z^G^?\
M]= !]?Y>]  XX'_?/T_S_P#JH''']<=Z 1QR/^^OI_G_ /70  #C@?\ ?/T_
MS_\ JH^O\O>@$<<C_OKZ?Y__ %T#CC^N.]   ..!_P!\_3_/_P"J@ <<#_OG
MZ?Y__50"..1_WU]/\_\ ZZ 1QR/^^OI_G_\ 70 ?7^7O0 ..!_WS]/\ /_ZJ
M!QQ_7'>@$<<C_OKZ?Y__ %T   XX'_?/T_S_ /JH^O\ +WH!''(_[Z^G^?\
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MGTI!V_3C_/O0,<<_C_GO0.W;VSTXZ4 !.#1TZ?S_  I3G/4T=_?W/O0 GKW
M[9S1SZ_Y_P _SH]CG/O1SU_F:  ]3V-'T.<].:,=N:7GWH 0GOGMD?\ UN*7
M//'/7O1W],FD[<CVY- !GW)_*C/^U^HI>>^?6DY[GN,\T &?]KVZ_A1G_:_(
MCO2\Y _#K2?7MR<T &?]K&?<49[YQ_3ZT#/3..W7_/-+SD=>O>@!,GU.?3BE
MS_M'GH?\_6DYP>OTH/7_ #Z\4 &>^<?T^M&3ZG/IQ2\Y[]>])S@]?I0 N?\
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M?^?\YHSCH>/;TH'M^5'/3GW&>: %SSC)/Y<TF3Z_G_G_ #FEYXYS[BD'M^5
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MGP7K7T$%U+%'"L[,S[BP4%N6) S7+:CI_BJ[6^56UR6*]75X6MY2?+5%'[C
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M''KQ[=OI0 O/?/7OBDY(QSTP>:!\OMCK@?3O1C!&0.,#I_GO0 ?KW&,?Y_\
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M3\J #_/3O_\ KI><GZ^E'? [>Y_SZTG';_/_ .N@ [=#^7T_,T=CP.,]LT'
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M:NG'//K_ /KH .HXY';FCZ>N>G^>]'?./PZ^E&.W^?Y4 +T(ZC/_ .ND';W
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MJ_E[8MFQ ,*0P;D=SDBD^UZ_INDB2TUC5;NXO/#(OV,[>:4FW1@L@Q\N%=N
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M'/ _[Y^O^?\ ]=![Y[Y[?YS0 IS@]<?6D/<\]^_:CC<.!U]/K1]>/?\ SWH
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M "89"L4BJQD#@'"MDC[PR>G->S9.>O\ XZ:8\BQ0O+(X2-%W,S$  #KD]NE
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MHEAX<TZ.U8 Y N95!<9_V$"K_P "->AY/O\ E445O!;M(884C,CF1RB@%F.
M6/J< <T >?:SI>J:]HOBC519SBXFVVMA;.GS_9XG!; />1@Q^@6F7S7&HZ_-
MXB@TC4)+"&:P!62U997\MI2[+&1N8+YB]!V..E>D]3[Y_P _TI!]?2@#G/"<
M<QDUO4)+>XMHK_4&EACGCV/L$:)NVGD9*DX(!Q72<Y'U]:.?\>*0=NW3MB@
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M#CR%.T;P-N_ Z<#Z4 >H7^J6&GVEQ<WUU%%;P$"9W(Q&20%SZ9R/S%6P,C(
MPWZ_YXKR'4I8;*\\626EUJ,>H7"64UOODEWR1'R0S;2,9!R/4988XJS?ZE='
MQ#<H+_5?^$A36DCMK&-I/(:SWKR4QLV>7N);KGOVH ]6[\]"<<UEW_B#1](N
MX+74-2MK6YG \J.60*S9( Q^/'UKB]#%Z=>L-1DU35)6N-8O[1X9)V,/D+YN
MP!.@P47!Z^]+XRU"/2_$_P!NTJZD_MTQ0P/ILUFTD=]'OR C8X8;FY4_4=Z
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MJVWQ%BC"D&YM&)8#(R/7OG"\#ZUT^2>1G';'>N6\2*(/$.A794[1*4=^< 9
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MRZ!/JT_B26^749#%8Q)9Q>?*L1<V_P VU00&.[@UZ+GV('7I0,YZ]?0_Y^E
M'F']FVFIP6!L_P"U4BM-#N73YYXW$P=,*6.&X93A>G'3&*V-92_OO 7A\[I_
MMTEQI[RR"+<Z-N0LQ7V/)R*[;/ .?3O2\@C)_#_/^>* . \0V.NP:E;FWN9[
M[4$TC41!<I"$(D/E;%X^4'T]<5C?Z6UI?/X<?7A8G3XOM)D6;S/.,J[VB,G.
M_P O?G:,<#'->KCA>O'K_GVI<G\?Z_G0!Y8ZW%TMQ!HUQK8T274+&)99'F64
M,7(FV%_G";=F2>ASBO3+2TBL+.*TA:0QQ+M4RRLS'ZL<D]N2:GSG\NH'Y4F3
M]/;_ #_GF@ [_P#U_>C.!U'].G7Z4 @=#Q_2CGU(^O\ GVZ4 '&>G3L.HZ4#
MJ/\ &COP?UI?S_\ K4 )GCJ/^^L^E'?\?RYH!XZYZ=Z/Q[]_RH .H]>,XS_G
M-+W_ !-)[9X]_P!*4<^O^'^?ZT (>I]NI_SVH/\ GG_Z]*>#[ YZ4G0X[]<"
M@!><<'GO]:3J#^.*.W;&,9 XQ1U!^GIVH /_ *XZTO?O2=_?IT_SBC\N?]F@
M!><CK^-)S[_Y_2CMTP,>G]*/8CCZ4 +SG/OU_&DZ=> ?\_X4=^?3GCG_ #TH
MP<\CG_/?\ORH 7G.<=1C(_S]:"3],4GOC_QW_/>C@>@P1T&/:@!2>?IVKEO'
MNJG2-"ANOM4EO&+E1,\4OEDKM8X!YQD@#I74<XZ'\/UK@OB^P'@9SO _TE><
M_P"RU #K>P\?("]AJ-BMI(%>..]D>>1<@9RY0?ECO7+^*KWQ3I5Q;VE_K,\6
MHW+>>)-/F9D$8(78(<+CC+%BW9O2N<U%-1G74I-42_@:VT>XO;,R7<H.\20A
M9 I;(P"1SZ]#BK5GK#0?$'2KW59FCMX03ODF>0;<N!C<3R3QQU- %[4U\<6&
MFF[GUC6$0CY"JI\YQG Q,<]#V/ S6SI6A>,/$=C'K%EXLEL;2Y^:*U=Y)S&
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MDYZY[XH/K_7WI><?Q?IZ4=\\T )P".G7%'&.V",=<]J49]Z.>.M "=^>N?\
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M^%6]-U:WU,SB*.XB> J'2Y@:-AD9'WNV*T,_YQ618?\ (R:R>!\L'/\ P%J
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MXZCD^] '$KX_NVLY)#X.\0+,I"K"8!E^F2#G QSW[>]1#XBWY5C_ ,(+XD#
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MC1VX'TPOM1Q[=?7KTH!''(_[Z^E "]#W]O>DZ#O@?AQ0../ZX[T>AX_/Z=Z
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M Y]*JZ7I<.E6\D,,LTRO.\Q,S!B&=MQYQTR<U:CEBGB$L4B21G.'5@01[$4
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MOZ>]''MCKG_/UZT=<_RR3^GXT '/?/O1VZ=NP_SR*._KS_6C^$'VZY_SCZT
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M =+=YY#:K(I#+$6)4$'G\^V*OZEQI5X1G(@?_P!!- %/PLJIX1T54"JOV"$
M ?\ 3,5K=?0C-<GX:\3^'X?"FD1OK>F12+90AE-W&"IV#(//6M9/$^@2RK'%
MKFEO([!45;N,L23T S0!K#WZURWP\_Y$/33R!B3IQ_RT;FNANKVTT^#S[RY@
MM8!@%YI%103T&3Q7/?#LY\!:8V<_+(0<>LC<B@#J.AI/QX/0YH]>/RH[^I^F
M/U_"@!><CZ^M)SCO^.*/7_#G_/6C QC _P"^: %[_CQFDYQD9Z=L4'OGOGM_
MG-'?_$>] !Z\=Z/QSS^='X<=,;>W%![Y].X_SQ0 O('.<#W_ ,_Y%)]?QY_S
M_D4'@]A[X_SZ_P Z7_'TH .<\]1[_P"?>D[>F!^7I1]?Y>]'IV_"@!3[Y_+M
M2<G.>?;/^?6CIS@ ]?N_6CVQ[8Q^E !G'<_YQ1Z@G]?\]J.?Q^G>CV_+(S0
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MGW* -P.N.&&!V!'%)O3NR\CG)%8@\%^&>/\ B3VO&,?*:5O!OAML?\2:UXZ
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M+FUNC<I)YH'G.6RQVYQGG ]!Q5OP]H4.ARW+QW,,@F51\B[<X+'<QR<L=W;
MXZ53;X9>#6(+:'"Q'0M(YQ]/FXI7^&G@^0 /HR$#I^^D_P#BJ &RZ)I<U[/=
MC4;5II3,2DS>9'\X 'R[L C'48)!([U/I&FVFFWOVR?6_M,WE>4 ;DA N]V
MVECN W8&[)'KS59/A=X)C*%/#]LI3."&<'\3GG\:>_PS\&NFU]#@*YR09'QQ
M_P "H Z'^TK$C/VRWZ<CSE_QH;4+ @AKNV*D8.95P17-/\*_!$C%F\/6W/96
M<#\@<4#X6>"!G_BGK;D8Y=^/I\W% &I_9OA7_GRT;_OU%_A7->.+#P['X89[
M&UTI+@7EIL>&.,,/](CS@CGIGI6E_P *N\%?] "W_P"^W_\ BJ0?"WP0-N-
MMP5)P0[@GZG=S0 GC[R)T\/VLPCD\S6[7=#( =ZY.?E/44O@"YM8/ VF1RW-
MO&0KG:9%& 78CCZ5/>?#GPIJ$HEO=+-S(%VAYKF9V Y. 2_ R34'_"J_!.TK
M_8$&#_TTD_\ BJ .E_M"Q/2\M\XX_>C(_6C[?9?PW<'X2CC]:YH?"SP2IR-
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MZ4'O_A2\Y/U]* $QR<C)[CC_ #_^JCZ^^3FCVP>G2CWZ^X% !CU')X[?Y_\
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MCH?J#[>M ST';T_S_G% !WZ_D<^O^?\ ]5'&.P'L>!Q0?4YXYYQ0??.>WO0
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MV1XMW9_X2ZWQC_H$+GV_Y:4?V/XM_P"AMML_]@E>?_(E=-GK[\=?ZT=/I^5
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MJ-%:4P[&8@DEF.3N)+<FNI[\XR?\_P!*7OW% "$=>,]>U!QU."/4CM_DT <
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M N0/PZT=2>O^31W_ !]?>D].?QH 7/U..??\J.AQ^ R:3/'8?CC'%'?KU]Z
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M=./3KB@<X[T +WZ'/TH^@Z=./\^U(/\ /%'3_/O_ %H 7/'&>.GMQZ4N>?\
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MQJS;Z]J]V+>RM[>U75"\HG%RDD21A IZ9))/F)R"1U^E '6\]LXS2#T'I_\
MJJCHVHC5]%L]0\ORC/$'*%@=OKSW^M4?$]_JNEZ>;S35L&2,$RQW1?<S'&Q4
MV_Q$G'/J* -WJ>O7D<TGZ9%<RNO:H+HB2VM!;P74-E<E'??YKJN63C!4%U'/
M/6I=$UZ\U":P-S;VT,-_;/<VQBD8L I7Y6R,?=<'CC.?:@#HOS%(.WY=:IWV
MJZ=IBQM?WUO:K(<*T\JIN.,D GOWJ2SO[/4H#<65U!=0YVF2%U92?3(^OZT
M6!V_+K1W]ZP=<\2)I>HV-A"B33SS1K.&D"^3$[B,.1W)8\ =<$]JHOX@UC3Y
M[C^U+;3UM;>6*.5[:21W_>$ $*5YP#R.: .M&>.M)W'X=:Q]&UZ+6[S45MU_
M<6LB(CL&4ON0,<JP!&#Q536->O;/Q%::1906K/<0F0-<-(O.[ 'R*V/J<"@#
MI.>.N?>DZX[_ %QS6,-7N&T*"]CAC^U7#B*.,MA Y?;R>N.I_.JYUK4?MO\
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MSV]:=_%SZ^M(?O'V_P#K4 )GGKW]?\^_^12CM[&D[XZ]N3[TO4=>OK_GZ<4
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M,(G4?:(RS,5?Y?5G^[@_,:MR^'(IM02>6_O)+>.=;B.S9E,:2+]TK\NX <<
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M'";R -V1QGDC'%9;>/;2ZTZ>6WM;VU+V$UY:7%S;@I,(QEB%#9.,@X)&>QH
MCC\)ZO$LJH-.59%95 N+D>2&8,PC^;Y,D9X]!VXI&\):R8@H>Q$HD:3[0+NZ
M$Q+  Y?=G& !CIP*N3^-[*PE^SSVM]+Y*P?:;J* >5%YJC:S?-D#)Z<XS5H>
M,+ :\FEO#.F^X-JER0OEM,!DH.=WMG&,C% $%IIGB>Q?_1Y-(2%84B2 &;RT
M"YQA<\$YY/? J2ZL/$MYY/G_ -BR>3*LT8(F #KG!(SS@GH>^#V%=)^OXY_S
MTHXQV/X_YZT <[9^')9-4;4=5$7G"995CLYI1$S@8#NA."P 7GV]JO:7X>T_
M292]F+@80QQI).[K"AYPBD_*,@=/05J'^?M_GFC@G'R\^_U[4 (RJ_+(&^JT
M!54$*JKG/08I??\ 'I1T[_YYH J7NEV6H;#=6ZR-'(DBL1\RE&#+SZ9'2D;3
M+1YY9V5C)++'*Q\P_>3&W'H..G?FKAY]/SS1GF@""*SMX+NYN8TQ+<LIF).=
MVT;1[#C%'V* :C]O*$W/E>1NR?N;L].G6I^.G'IUQ1_G_/UH Q4\+6"++&9;
M]HI,XA:[<HAW;@5&?E((!!'2IO[ L?LZQEKGS%D\T7!N'\[=C&=V<_=XQZ=J
MU/7'UXS1VP/7UP* ,U- TV.TEMA;L4EB$,A9V+,H+$'/][<Q.>N3FM%0-JC.
M<8')R:7CKD>N?ZT=<#_Z^/\ .* ,_73_ ,4YJG/_ "YR_P#H!S5JUQ]B@'_3
M)<\>PJ'5H9+G1+^WA7=++;21HN>K%#@<U1@UJ6.WBC;1-5W(@!Q$F.,?[= &
MUU_/_/Z4 YYS[UD?V[)_T!=6/_;%?_BZ#KLG_0%U;_ORA]?]J@#8'7)_'C_/
M^12>W?Z?Y[UD?VX__0#U;Z>2G;_@5']NR#.-%U;I_P \4_\ BJ -?'<C\US_
M )[UE6V?^$KU+U%G;]!_M2TW^W''_,$U7C_IBO\ \5[4W2VFN=;O[U[*YMH7
M@AB3SU 9BID)Q@GCYAS[T ;/T[=,#ZT?0?D/K1Q_L\C_ #]11Q^= "^AZ^GI
M28'H/Q7G_/6CZ\?A[?SHXQCCIT!_3]#0 ?4?I1CL0.PZ<4=_SHX]A^./\]Z
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M^?4?E3CU[_7%-S\W7]?>@!,>F>O7'3_/-.P.HIO7WXY[_P">IIQ_7_>/^>]
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M+^W<_F6-6K/P9::>%>T\*ZM#=+*)5NX[ZW$JG:5P&W\+@G([UZ3G'4XZ=_\
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M+WZ<TG'MCZ].QHX]NOKC_/6@ _EWY/\ D=J.H_\ KYHSQDGJ.N<4>_7IGB@
M[_7ID?Y]*/P/3\:.W;IW[_\ ZZ./\\?Y-  >I_\ KT?49]?_ -5'&.W^/X=Z
M#_GGK0 =:,Y[X_X%TH_7']*.G7L/6@ [8Z>V<>U!Y]._?-'3VQZYH[8]1T-
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M2%A*[K*L05$ ^8DGL<C:01G-:.G^,=%U34(+&TNI)+B:,2(/)<+]W=@MC ;
M/!.>#23>#=!GFEFEM)#+)(7+"YDRC%A(2GS?*2P!^7%3V7A?1=.DADM+/RGA
M8.K"5CRJ&,$Y//RL>O\ .@#'G^(&G27-K;:7'-=W%Q>);C=%)&FQF(\P-M.Y
M058<=2/2M*3QCHT4]Q%)<2J8)9878Q-MW1HSO@@<X53^5/L_".AV%REQ;6;K
M)'('C)F=A'C=A5!)POSL<#CGZ5!=^!O#M_/<SW-C(\US)YDLGGR!B=I7&0W
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M\JTD7SK06;DSR$B$#A02>/P-1)X(\/QBU5;24BTPL -U+\H!W ?>Z \CT[4
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MQ;#&WRY,9_Y^)/7ZU/:V%M:L6@1AN&,M(S\#GN>/_P!561G/?_)I/PY]_6@
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M@9Z?G_7\*.^!CCMG_..E  >N/7CD?6COT_(8]?\ /_ZZ/Z_K1QCL!['@<4
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MOZCMW_7O1GOZ=SCBE[XY_/\ SZ4 )W/K^(_STZT=_K^%'!'// ZFC_/7_/-
M!U''ICALT9R>OY&E[^^:.<#.1]30 @[<]: <#TQ^0XI><<@X[_E2<]SW&>:
M YZ'WX]?THR/4<'\:.1T%+UZ9Q['_/\ D4 )TXX&/\/Y49Q^G?\ SS1]._3!
MX]:/;GOWH /UQTYHSQU_S_D=*.OOWX_S_G%&?3_]5 !TX'Y9^E'KCW/!//\
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MT[?Y-!]QV[KGUH'48QVZ4<8[=.QQZT ![C'K_#1GW[_A[4'./S]>*,^_\_\
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M =1CK^'UI>I]><]*3V/\S_D]:.H['C-  !TX_2CM[<=J./;C]:.^._\ ]>@
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M !SSC-)^/X_6EP/0=>.*/\.1W&: #G'!)Y/]:3Z?48-*<<DC\3VH/T_ ]S0
M9Y'.>>*3D_4CU_SQ2\#^IZ4<=\'UQ0 <\\']*.?]K]*,+W"]<'_/X_K1@'^%
M>O- !WX!I.GKZ>_K2X'' YZ9%''&,<],>E !S_M?I_G_ /72'WS^G-+M_P!E
M:,#TZ^W6@!,^I_'/ZT8]1]>/SI>?\\\T8'H.OI0 G(Z_SZG_ #[4O/\ M?I_
MG_\ 71Q[=>H^M&!GH,]\]?\ /% "8['./P_S_P#KHS_CUI0.. /3CM1D=00!
MC/7\Z  9Z#MZ4F3CJ<^A(I<#I@<=O:C'L._>@ .<YP>/I_G_ /72=O7CC_&E
MX)S\ISS1CCD?7WH /KG'X4G.#D].O/M2XY^Z,CGI1@9X XZ#- !WP..M)S[\
M]L]>M+CVSZ^]+CGH.O:@!.1U)_3VI.W7IU.:4 =E _2C''0]/RH .<_0^M)U
M[9XZ'TIWUSUI. .1TZ^GUH .1SDX]:!GI[#O1CCH.!QB@X]A]?6@!.<=3^/Z
M4O/3_P#71QVQ^'ZT8!XP/8$4 ')Z9_PI.<9Y'XTIQU/UY'2C&#T&>^!_GWH
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M'ITQV_I0.W'IV/\ G\*,C;VZ?WL4 *<G\\\BCJ/KV_H:0]3T_'^='M]."?\
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M'_?/^?3^5 "]<'D]Q2=/7Z_I01ZC/U7-+^'?J!0 <Y_'_P#70,\=<4@Z=/R
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M?PS0 O?'OZTG4=CQ]?2C(Z@_K1P3C=GMDG_/M0 'IU[GF@]<X'T_+]:,^O\
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MD#G/X_Y_I0 <^_?O2YY]NO6D_P 1U%'^3D?2@!?F /7I_G_.*3O@<>G/^?\
M(HXP#^.<?U_.C'&  >,8[=^* #Z=\]Z#W)]_RH[_ )<T=N!],+[4 +WY/?GG
MZ4G^>3T_^O1Z<\=C^7>CMQV'8>E !SGWH/7_ #Z\4'OGOGM_G-&.>GY#WYH
M4^N#]2<4G.>.M'&?UZ<_YYH[?GQM/^?\^]  >/H/Z4#@X_# -'_Z^E'^<9_^
MO0 9Z$GWSG]:!^O^>O\ GO1_GI_G-'&?IZC..E  >F3GWYI>3P>>QQ2=N!],
M+[4<>O'8\?A0 9Z$GWSG]:.>W\_TH]3T[]*..GX<C/I0 >PS^'I2\],?48X-
M)CU'UR*./ZGY<4 'O]#G(HYQCGITH_G_ %]J#W_'C::  ]">WU^M*>O.>O?Z
MTAZY[^ZY]:7OWXXZ4 '/J<T ]/<>M)VZ=NPQ2_Q?C0 '[W3GZTG ]/Q./\]*
M7^+\:09P ,@4 ' ]\4<>OMUQ_GK1^?/O2\GO^6/\_P#ZJ $R,'IS^M''L>?S
M_P YHYQ]?0T$]>?7O0 9XZCU^]1Q@CCWY_G^M+S_ +7Z4'/J>OY4 (<<\^O_
M .NCOV'U[?YS1]/J,&C_ #P>O6@ ]CCKTS]*.G'?ZX_SUH[<'MVI>A_,T )D
M=<^_7&:/;(/X\T9/KS]:7G(!)_$_Y]* $R#GH<YZ<T<9[=?7/K1DXSSZXI><
MXS]* $]..N/\^_2CC'8\?GZ=Z/?D9[_Y[TO.1]?6@!#C/!_\>(_SUHR,]>O>
MEYQWX]*3)]>?K0 #''3VY^G2CH.H_/'K2\]B??I29Q[=^<4 &.WX>OTS1W]/
MI2\^^>@-(.@QQD<4 '0>GM^F*.,XXZ_G_G%&.P&,BER>W<\4 )VZCZYSCBCK
MGCZCTHZC/)XX/_ZJ7OWSV!H 3(/0]?\ :_SZT<<\C!SU_G2Y]SUQGC_/_P"N
MDYQU/X_I0 >O'ZT=3]>G/UZ4'_//_P!>C^?MW/\ G^5  ,'G@_YZT?Y_S]:/
MKSV[<T9Z$GWSG]: #M[?4_Y%'?MG/Y_YQ1@^AZ4O/3G/?% "=.1V^M'MGO\
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MGX=AT':CK]>.WY<4#MC^7/YT '\QTX.*.@[X'X<48XZ=N./;^5'&>".N0>*
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MCC/T]1G'2@9'0?I]>/I1TQC/'3B@ ';MT[8H'3&/3HN/2CV_I^='_P"OU[T
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M/Z]*,X.>._>CIZ'_ /7_ #H /RX''']*.,]!U],^E''3CKZ]>U&>G(_/'I0
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M>^>W^<TO?UP12<#\.O/^?:@ [_CZ>]&..@Z?W<>E'O\ KD^]'8CVZ9SZ4 !
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MZT )GW^M';W XI>??\Z3J![CB@!?;)QTX_S_ )Q29]3]>?K1G_'K1[#Z#F@
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M[\'Z4 'X_4Y_/_/M1W[9'OC_ #V_.EP>G-)U[''<4 &>O.1Z?THSZ'/X]?\
M.*#G!Z^^:#W_ ,?K0  GGG/0_6@<]^O?-+SGOUXS2=0/0C\Q0 ?IGM]:,^_/
M^>W]*/?/'4\T<]#_ /JH "?<<<]>E''3/'IW_*EY]QGIDC_/_P"JDYQ_]?\
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M?/('T,CZ'>R0W"/K%PIEN_M*.GRF+ML'/W>AP<@\^M;F<]^O?- QZ>W';VH
MPDT&Y_M*QNI-2=Q;0Q(P^8%V7>&;&['S;N>#TI++P_=6L4<3ZK(ZI>BZ[DD;
M3F,DG[N<'VK>S[CZT=LC ';T'% &;I>G7E@\YGU$W2S2-,0R8*EL<*<GY1S@
M5@>(+W1H-7N$U#1[F=FA"RW$<@5&4 OS\PY4#(/49X-=C_GDYILB)+$T<B!X
MV4AD89##T((]/YT >=V6J:-;W-M=PZ7=8+_:8MLBN "J]>OW1*VT#CKWJ6/6
M?#L0N7;0;NV6]B\N5]X(D0@''RN2 /,'3H">P-=_%''!$L4*1QQ(-JJB@*H'
MH!V%/W'_ #_*@#S:[N?#UM:V\]YX:FE?[''<_NY"Q&Y<GJ02P+8SU_*FC4_"
MLK20#0KB:((@A3><E3M'(9Q@@GC&2,9XXKTO)]>#T.* 2?\ ]5 'F\.NZ#8R
MROIWAZ]CNXE&%,A4' +C.&(/"@]^N/6M*74?#>H"XO[O2YG=)8Q(Q)^;S(U;
MGYL;<(%*GC*XQSSVV[Z?G1N..WX<]J /.A!H%TFE&YT,,+G*Y$\I$"*66'?[
MEAC!Z9//',,.I>$8H([MM%N(YF1E81RM@OY6XC[_ '!V@L!GZ8KTK(!SQ^?^
M?2E'#8_R?>@#S&34O"JZ='&GA^X,$-R9T!G())&UG#!CSQC:3V["K45]H+1:
ML%T&43K TLR^:Q5PLV-N03AP0A./;!.*]#S\I&!SVI<Y],=OTH \VMM7\)VU
MM=-'HLZSS!(+A$+.&)Y ;G=@;!D[?;G!%23ZAX=M;L/>:5'&R+$X\N9B[&89
MPBY'R@NV>V,<< 5Z)N[\=/7_ #Q1A=W1?3./T_"@#S&*^\&H^X:#<Y 6%\3,
M1D*I"#+@$#..WW2*MWO_  C-K=7%A=Z0&A28?(MP[2R,R(^\@D=,<Y/4+C)-
M>B;L_P!W\_I44\$-U \-Q$DL4BX96&01W'TH X&[UOP[<7+W TV>03R#S&DE
M=<O]QAL#'YBH*\#L0>*F\,0^%V62WM8;MYE@+(UY*,LL@D^52IQD!7Z#(%=Y
MC'&!GTSUIK1HS(QC4E#E,J/E..WOU_.@#SW0]7\(V]S8+#I<MG=9$BLTOR1E
MT7<=S/R ,=1SC@<&O0U8.H((*D9SV.?\:7@'H!Z9'^?\FCIT'3MZ4 *.WZ\4
MF#Q_AW[T<8['C\_THZG''.: #./;C/3%&,<8'I]WZ4OY]O6DSQU'3^]CUH .
MW3KU^6@]\]\]O\YH)'/(_P"^L>M'?KU]Z  _A_WS1T&,#'IC HR#W'/^U_GU
M_E0.<?TH #UZY^JT#V'0^G^>U _7ZTHZCV_^O_G-  <YZD#IVHYR/KZT$?-T
MY^G]?PI/Z]\4 '/3GV!/TI<<]#U_S^E)QTP,'VQ_GBCC^I^7% !SCC/3MBEY
M_P!K]*0C\?JI/K00.>!_WS]?\_\ ZZ #OQ[TISUYXYR<<4A[Y[Y[?YS1WX'/
M/;ZT 'KUXXZ]*S)_#VDW+PO/9(Q@D>6/#$;&8[F/![GFM/\ /VXI?3T!XXZ4
M 4+;1K"TCBCAM@!%+YJ%V+G?M*[LDDYV\<GIBJD7A30HHECCTZ,()/. 9BWS
M>O)Z>HZ'O6SQQGT&<^U'U]>XH R8?"^C0;?*L=H$WG%3(^"_J><'J>#QFIK'
M0],TYG:TMA'YK;WS(S;B<\G)]3^=:'X?08_*C\?QSZ_C0!#:6D%C:1VMK$L4
M$8PB(.%_R<U-GH3GU'2EY[^H/3I2#/4=>_ZT 'U/3MFCD?IGZT#MU[=NU'OC
M\A0 ?GZ=:/U/:CL?7&#Q2\]/7MCK0 G? _PH[>F!^7I1V[_E]/UHY[#N<<4
M+@Y[]:0?E@4<9XP??&?3O1]?Y>] !V^G'7.#Q2_F#VI/3_#I0.,<8]L?Y_R*
M #IS@Y/T_P __JHQ@'K^./S_ ,^M 'X?A_G_ ":/<#G_ ': %Y]^M)R1W/Y4
M8'U'N,T=1SSGU&?:@!><XYI.X_#K1]?Y>] [=NG;% "\_P"U^E)SVSG';%
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M3H.^!^'%+WYZ_3_/O^=  1S[\]N])@>G!Z9'^?RI3][GO^M)GOQ]<]?_ *U
M!UYP?P_E1Q[=O_UT'OS^)X[49]_7_/6@ Z\_R_\ K4=P,D&C_P#5UY_GUHSW
M]1V[_KWH .,<8&1Z_E1_^OG)I<\]>](,?ESC_P"M0 G&/P__ %TI R<CK^M'
MZXP.]'4>HQSSG]* #OU_GZT>^/R%'^>IHZ@]#QG@]>E !Z^O3CU_R:#QS_/-
M!Y[]SS1QU_S_ )- !@=,<4=2.,_A_GVH[^O/KGO0,<<Y_'/I0 8XQCMCI^='
M?/X]*!CV/?KGTH'Z@CH: #MQVZ<>WZ4$=L>P']*!T &/\^U P>XP>O/^?6@
M/?C\<=/\\T8&>G'^<4>F:!U'3\/Y4 &..<\_6@=OS/!HXQGC\\_K1P/08]\?
MI^%  /3O1QGIQGT_SWHZ?Y]_ZT<=,@=A0  <C(Y_S_6CWQGTX/X4<>W)Z'_/
M7- QQSZ=Z #'.,>W/>COSTXZ]Z!CTZ\$49[Y'U/XT 'Y\]3C% ZC^GUH^N.,
M=?ZT>F?UH .G7H/6C'MQ]/S[4?Y_S]:.N>A_'/K^5 !CCD>YXH[\^O<4<9X(
M]L#_ #Z]:.GH,?\ U_TH /R'?I1C\.?\\_YZT \]?U_"@=1^'>@ [^_TY[T>
MXZ#GCTHXQVX_^MVH/7!_G]: #'/(S_GBCH/7Z^OXT=?3D<\49[_R.?\ /6@
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M>O&?\^E%% !R,=L\#FD'(XZ8X_I110 O.>_X8_S_ /KHP<T44 )SP.<XZ4'
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(MDC-%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g201708092014007363358.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201708092014007363358.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,G G # 2(  A$! Q$!_\0
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MC</6FGO^76@]_P NM #MP]:-P]::>_Y=:#W_ "ZT .W#UHW#UII[_EUH/?\
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M.!TZ4#M_@/RH_#/7MUI>?KWH 3ICVXZ?RH';VXX'3I1]!]./\_Y-'X9Z]NM
M .W^ _*CICVXZ?RI>?KWI/H/IQ_G_)H !V]N.!TZ4#M_@/RH_#/7MUI>?KWH
M 3ICVXZ?RH';VXX'3I1]!]./\_Y-'X9Z]NM  .W^ _*CICVXZ?RI>?KWI/H/
MIQ_G_)H !V]N.!TZ4#M_@/RH_#/7MUI>?KWH 3ICVXZ?RH';VXX'3I1]!]./
M\_Y-'X9Z]NM  .W^ _*CICVXZ?RI>?KWI/H/IQ_G_)H !V]N.!TZ4#M_@/RH
M_#/7MUI>?KWH 3ICVXZ?RH';VXX'3I1]!]./\_Y-'X9Z]NM  .W^ _*CICVX
MZ?RI>?KWI/H/IQ_G_)H !V]N.!TZ4#M_@/RH_#/7MUI>?KWH 3ICVXZ?RH';
MVXX'3I1]!]./\_Y-'X9Z]NM  .W^ _*CICVXZ?RI>?KWI/H/IQ_G_)H !V]N
M.!TZ4#M_@/RH_#/7MUI>?KWH 3ICVXZ?RH';VXX'3I1]!]./\_Y-'X9Z]NM
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M]?RHX]L'(XI3G.?F_2D/7_/KQ0 9XSQ^>.U!Z9X[]_K^5+SSP?TH.<Y^;]*
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M?GCM0>F>._?Z_E2\\\']*#G.?F_2@!./;!R.*,\9X_/':@]?\^O%+SSP?TH
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MGZ_Y_P#UT'\NO;'?F@D<\C_OKZ_Y_P#U4'U_K[T ! YX'_?/U_S_ /KH('/
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MU]?\_P#ZJ  @<\#_ +Y^O^?_ -=!_+KVQWYH)'/(_P"^OK_G_P#50?7^OO0
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M@D<\C_OKZ_Y__50?7^OO0 $#G@?]\_7_ #_^N@@<\#_OGZ_Y_P#UT$CGD?\
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M?K29[YQ_3ZT'K_GUXI><]^O>@!,GU.?3BES_ +1YZ'_/UI.<'K]*#U_SZ\4
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M4'KT_-<_YZ"@' ],?D.*!UX[?YZ?G0 <9]/H/2@#';\0,4#T_I[T#''0].]
M .@X].@HQTX[8HZCUXQ1Q]>_3]: #MP.OMUH]Q]10<?[/_?7^?2@^O\ 7WH
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M*&FC]W+HVM). &:$6NYD!Z;@#QT]*C?XMZ$L+2BPU@JH^\;;"Y[9.[ H [W
M[#MU H_#]*X0_%72([G[-)8:@TN 5%NJ3YX_V6/..?I0?BQH2J6;3M9"J<$F
MTP <X_O>M '=CH..?848'8=NH%<.OQ3T<^41I^JOYH+1"*$.Q4'&2H;(YR.?
M2FCXKZ&4D<:=K&V$XE8VG$9_VCNX_&@#NOP_2@=!QS["N)_X6AHY8B/3-8E
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M<4 '3N,#W]Z,^YXZ^W2E!/YTG.!@=.G'M0 N#QP>/I2#MST[48YX&?\ @/\
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M,1C5?+4W1(;CYN1S\W2@#)MO#NF:9I%MK&IV:WEG>,0UJUTR7$# D!(0&Q*
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MM1SV_G^E Z\=?R[=Z/3K@=..E "\Y _K2#H.W3'M0!VP.G3&,T#KQU_+MWH
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MM SM/3&:O^ C!-K6H37T^MOXB$$:S)JT21LD!8E?+5/EV%L]\YJ#6)VT^_\
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M<*6V<D#MDYXKNNO7VSQ0 #. 1D^E*<^Y[TG4=CQS\N?6@@<\#_OGZ_Y__70
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M9:JJ;O+$D2QAH]C!-GR@@=\8Y/->B9![@\^N?\]:X/X9P?9XM3B*)&^8/,"
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M=<8_S_\ KI03Z?CTI ,\>WITH .W/*_AC'^?Y4O/O_C2=\X^G%'7/?/H.O\
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M==2*-18I$YP=2G/0$_WZK:7XIT;2)-4L[^Z,5PNHW+%#!(W!<D<A<=#5B_\
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MM?L31VQ:6=6DF%P%VOGYFY!!W<<5EF33?^$6\4(+J7[;]JF-Q&))-J)]I.&
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M!]3],C_/^<4'@?3C_/I0>I]?ISWH 7ZC/K_G^E SD9_SQ2<=>,=<X]Z,8_\
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MD59=6N6574JPRW<'D'V-=07"#+L .Y/&*YGP0[2VFL2%2I.L71VD]/G_ %H
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MX[&7S%)!VDACCCCO7#S:1H:_#'3]1T_[3]LEM[<(RWDP)8D!_EW8 X8=,>E
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M^>QN)$:'[!!&$P!UZCUH ]!QST'6DQ_LCM7-?\)7<=?^$5U\GW@B_P#BZ/\
MA*IQT\*:]Q_TPB_^+H Z7OQMSR,4CRI$ADDD5(U!+,Q  ^IKF_\ A*[C&/\
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M .*I?^%<^'RS,1J.XGEO[0FY_P#'OK^= #OB(0O@NZ+8 \R+DG'_ "T'6G>
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M#Y@=O%Z^2 >>$YKI?$FG3:GHS16R(UU$ZRP&2:2$!QWW)\PXSS^=<S\(\?\
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M Z=./:C ]..F<4'&,\8^G'K1QGKCGKZ>]  .P/'X4#/T_P \T8[8'T_*CO\
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M .@Z].O-'\77G.*.GX4<="1COD]N: #GW''N?\]*.GM^G^>M'Z'^7Z4=#Z4
M'..GZFCN:./;\#_6C\/T/^1WH /\\\_YYH_^MV[>] /3ISZ'K1V'H?<_SH .
MM Z].>]'ISU[T#&/3OP.G% !VQW_ !':@]/\?THZ<<#\>E QVZ8[$_Y]* #'
M/3CZ'_/K1R?KP:.OI^!S_GO1UQ_3GK0 9Y^F._X5SWBN#3O[/>[N(#)=QHL4
M+1RA)%+2IC:3D+\X0EB.,<UT([8Q^'X5S'B"VN)=9MYK;21J 2PN5D1BH24-
MY>(BYSUP3C&* *6D6,4>KV>CZMIZ%XM.DCMU^U"YC,>]-^\%5(<G;SC!QQ77
M?9+<W2W7DI]H6,Q++M^8(2#MSZ<"N*O-(NK#2;B&TT/3M,$\D08VM]B2X'F#
M,(8HNW<,@<]\<9K:T^>YN_%+W$EG=V$36>TPW,RDRL'!#+&K, !N(+<9W#TX
M +GB<9\*ZN#U-E+_ .@FN&^'7A?0]5\.37&H:9#>3I>S1":<;G*KC&3WKN?$
MIQX4U<^EE*>O7Y37._"P,OA:Y#J\;?VC.2KKM89P>0?_ *] &K_P@?A,#_D
M66,'^ =*4> O"><_\(_8Y'_3(5T/?Z_A6?J&LP:=<06YBGN+J?/EV]O'N<@8
MRQS@*HR.2: / H=UKK,92/-I'%DQLI:,MM[C.!QC&?3WKU'P?X1\/:EX1TV]
MO=%LYKJ:+?*[QY+-D]:YKPSX4U+7HTU"'48H+.1Y(9D$>YHR@ 0CU.<@\@<=
M*]/\/:6=#\/V6EM.)C;1[?- V[NO.* *'_"!^%!_S +(?2.@> _"G;0;/O\
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M%5K==.7[4 H4^8'$">^-N/QZ58O%UH2^&0#IXOQ++L.U_*"^0V,C[V: ,O\
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MD#NQDC #%1D@]\\5<GFOO^$/\48@@6V6ZNC#+YAW,_GMD,N.!GODTW3IK_\
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M_B:X7Q+HMUH^E+=6WB376D-U!%A[H$;7E5#_  ^A/XUK_P#"(L/^9G\0=O\
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MI8MK6PN8(II9;:)C SJ@ 5C('PV1T4@'/7FNYW \YX^M<!J0TK4=?EBU/PC
MU[)<I!'/=/"#*GR@M][<< G 4'H/?'=P0Q6T,<$"+'#& B(HP !@ "@"3/J/
M?O1GL><'FDXX[YQ^- (]1_WU0 OX'/U]: 1T'X#/2D&/\_YZT=L$]L'/^?K0
M OX8SZ>O2C//3_Z_%(>"?\<49QW'YYQ0 N?<XSUH& 0/PZ8_STI/ID<?6CC&
M.@Z8'/\ GI0 9&/7CGC-+]1^.*3//)'_ 'U_GT-'?K@_7_.: %R>?\* >0,^
MW:DXQVZ?E_\ 6XI1UZ_SH .<].F<9IG\1YY/_P!?_/XT_ W'(IO0GN1Z?Y]Z
M  $Y[TN2!G\<FD&![X]OKZ4N,$< 8XH 7';''3%(.Q^ASD48]N3ZXZ]:7O\
MCZT  ZC.12=N_0?A1^';GCZ_K1^ ^E !S[]^]'KC^='!^AQ^-!]\<#G/^>E
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MRH]N_P!3G_Z_6@ [=<Y'YT?H/IT_^O1VSZCKG_.*,_-U'7L?K0 <^F.<]/\
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M\&>,)-QMX0;K-GY.S_EC'AAN 8#@X!]>:ZVWTW7I+6!TUZV"[ 4_XEHX&/\
M?]*Y2X\C^S_'I^PR&Y/VS_3S&-H7RD_=[\Y]\=*]#T__ )!MK@#B%/Y#% &7
M_9>O[B?[=M#N/S9TT<_^/_A7GEI%Y]CH9MO#Z6U\)X/,OX[) A992' 8\#Y1
MG([@BO7QC(_3FO&K/35:?2[^7PS/)"]U)YC?N[C[60920(F;"X&?F]C[4 ;=
MKX@NH_$]U]G:%99VMHIM,,161LA@[*V1C;]X\8P#Z@U+ +G_ (0SPV@U5)))
M+NT,;K$F+8;#@$ _-R#R?6JUE8ZLGB21F-Y=:K&UJ9+IB%A@B*9D1P" QP6
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MCW_$<?TH 7UZ\>AHYR/KZTG].G%' ]L=<=@* #Z@^^?\_P J.>Y[C/-&,>G
M[+1CMCV&!0!B^+467PQ=*V=K-$#S_P!-%K/^&[&3P!IKM@[C*3M'!_>/_GO5
MWQD9O^$5O/L_E^>3$(_,.U<^8N,D]!R.<U4^'4;P^!M.BE96D1I59@0V2)6!
M((X(]Q0!U'/KSTZ_C2\XYW8[]/\ /_ZJ0=,>V,<4<9_7IS_GF@!><T<_[7Z4
MGU_E[T #C@?]\_3_ #_^J@ P??/X49Z'KW'2@ <<?^.X]/\ /_ZJR/$>N?\
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M(1^-:O@\8\&:*"/F%G$"0/\ 9% &WW[Y'7_(H&1USQU[]J3\/T[T>P[=./\
MZU %:?3;&ZD\RYT^VF<=&DB5C^9%1#1-('']DV0&?^?=/\/\YJ]C'8#_ (#_
M )]!1@#MCZ#%  JJB*B*(U PJ@  ?E1CI@8Z8X_SVH[\ ?\ ?/UHX_#K]W%
M ,XR/3UKSSQM=V]EXZT">[N?)@CB+,-FXOB:,]!SQC=P.U>A_3D_[OUKA_$\
MI3XA^'HUDV*Z8*8'SXE3C^9X]* .3'B?3I/">HZ>=6 DN;DO!;?8&!CS=%MY
M;D/D$'!QTQUK4/C/3'\2Z?>IKJD6]D\5W>#3I")AYJ$(%_AS@\\XS[T]4T]/
M!&MNNF3+*UYFZF,) NE^UGA6_BP,C';.*TC#ID?BK05&CW"VBV3FTMOLC9MY
M#,GS,!RH'')X'XT <]-XLTQM!\2PG64*7KW+6EK]D<-\S'#;\<@^A Q5R]\9
MV$VJZ*T?B)?.MEG-S=G3),!6VX79V) QG)Z>]6'6T31/&4BV4HO\W8EO%A94
M==YP@?/) QQ6AJ<UBNK^'6_LV_:U;[4PM1 _F!]R?.R9SMR2>1CF@#F9/%.F
M#3/%J)K*M%J#W#6MK]C?<[,B@-OZ8X/&!ZFNTL_'_AQK:*,ZA(TZ1 NJV<V0
M0.>-G'>L6>[+Z-XZ@=+LS W;).T;>4J^6H"ASQGO@5)JDT*P^'88HM6MXB]P
MK+#;L;AF\HJ6"L"<'<>2._:@#8_X6-X4# ?VMSD#FWE'';JOO7%+XHTQM'T&
MV@U:*"ZMK^2=GDM))!"I67!(&-V=PZ'C/M72V\RVM]XFMDBN2\*D03B-MD:I
M:QX!?[H;OBLR6WT5O"WAJ+^QIS8R7@,]JUHQ:=C;.2P3JV3CGIQWH 2R\:Z+
M#XHU6]&L1I8W*Q;E^QRYG<1X)5OX<<<$?XUEKXGLO^$7\.6+:S";^TN8),BP
MD(MD6,]1GYR,@9!YST[UU.G1V#_$+6Y);&5[N)8H[:?R6*P1_9P2I;HN<G@\
MG-8T*:;)X$\/XTVY$$EY;F[C-K(S7!$1R5'5@<#D<4 3V_C?23XI:]&N1BS%
ME!'<2?89#YS R9VG^#!93T.<^U8EQJD:_"U;(ZQ9^>BJT,7E%"%&[<,D_.3Z
MCUZ5J>)8[)=9E86#!K:#2Q:$PD"V4W!!4_W21Q^&*Q+J)9?!$^H3QA81,B1(
M8Y56261R/-)) 88. %X )SDXP >B_#Q'C\!Z3&ZLDD<11E9<%2&8'K[_ ,JZ
M;]/KVKG/ >T^"=-*QQH"KG;&/D'SMP ><>E='Z=L^V* #\^?I2\_[7Z?Y_\
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M ^6^1NS@[V[]^_-=(>.?Z8[T &.V,?THZC(!Z9ZGWHXSVZ]OQHZC.!R/KF@
MXSSVS]:.GL?KC_\ 71^.<^AZYHZC(_1O\^M &%KGB";2;F.W@L89F>,N)9[Z
M.!!@XQ\QW$\#H,>]2Z/J]SJL$QFL_LKIPDR3I/$Y_P!EE/.#U! Z5G^*M'N-
M3N[62*RENE1&!*-;@+D_]-8V/Y$=*T_#]G-8:(L#0>1,"Q$3^7QDG&?*55_(
M4 <S;:MXFBUU;.>_^V+'>1PNL&D.J.A"EF\W<53&[D'GCWKN_7Z_Y_2N 0WB
M>,]H2X$CW$371M5N_(\S8F[)'[O&,=?;-=_D=L>PH .W;H?I[T=^G?T]Z.G?
MIZD^_P#G-'?K^1SZ_P"?_P!5 !VQUXQSFCKT_F:.,=@/8\#B@GGM]"?I0 =?
M_P!>3_GK1[X]^E!(]1Q_M?6CO^??- !C';I_^O\ 6@]>G^>M'X?ACT_"C@>G
M'?- "\YZ=_?^=)VZ'\<_Y[T8^G&.U Z?E^/O0 9SC'?D9- ZCC]* >G/7WZT
M C/4<^_^<]J %[G@'\>AIG<\^PY^O^?UI_5OY9H/)/UZ>] #>N.<G-* ??TI
M.O YXQS^E+WZ=_3WH !SVX/./8T>F<_CC_/K1U'.3QS_ %H_('KTZT &.V.N
M:,]_7T[T8QVZ>WUI>>>O2@!.A_S_ )Z4O/')_P ]:3CD=O3%'IT)]_7_ #_*
M@ [ ^HZ_R_S[TO<=:3WQ^..:,<'CCO@4 ';]/\_2CJ/Y<_YYHYYS].G^?6CK
M^/J/\^M  >1Q_CSFE[_CZTF?\^GI0.@ XST]/\\4 '/OG\,TO0]QS_6DXZ8&
M#[8_SQ1_G@8]* #GWS^&:7OZ8YY/3K2>OOGM1^G/''UH YKQX[Q>$9WC9D99
MH6#+C<,2*>,YY&!ZT?#Z22;P'I,TO,LL;.YQC<Q<DL>.IZ_C3?B"0O@ZZSP/
M-A[?]-%'XTOP\&/A]H@*X/V<9&"?XC0!TW<?AUI>2.=WZ4@[=NG;%  XX'_?
M/T_S_P#JH ,_7\_K1U]3],&CG'0_A^M''?D'GIF@!><X_3-<WXP)V:%_V&;;
M^9KH_8_E^/-<KX[NX+#3M)O+J01V\&K6\DKE3\J@G)]: .K)P3_C2?B>.IXX
MKE_^%C^%,*PU,A6^Z?LLN&Y[?+S6WI6JV6LV0N]/F,L.XH&,;+@KP1@@=#0!
M@Z-_R4CQ3_UQLNO^Z]=7CCD'I7-:-&/^$[\42Y.0+1<=L>6372]^@SUR!_G_
M ": &3W$5M$9+B98DZ;G8*,^F3_GBN9U2[MKKQMX7%O<13%6NB=CAL?NO:M7
MQ#8Z7>Z+,FL6)O+.,B0Q+$SDD<#"KR37%^'-*TN'Q?IFJ:3H\>G65Q%<1P*1
M\\J@(3(1R4YRH'7&<XX% &S\2)[C3?##:S93O!?6#@PN IX<A&!R.F#^@K;\
M-1K%X5TB-<E19Q<GOE17-?%J\@@\"W%O+)MFNI$6%=I^9@P8C(Z< _E6_H&H
MV2^&]*5KRV5A91 @RJ"/D''7B@#;Y//OZ_Y_R*.<CK_A7G7B"3P_>>/D.KM'
M<67V"-%VNS!7+R= AZ\?K51]'\.I+XHM'TZW%[IZR2VB R'$8A5@6.[!^8GK
MZT >H8/N,_3_ #_^J@9ZCCO7E]QIW@SR=!O5M46RN9G2XD5IADB)FQUSC=_*
MGV^@^%V\2ZW8/9*S)'&UG&7E/'D[V)YP.O<^U 'IF#CH>E+@G/XXKR./3_"O
M_".>'-2^SJ8I9HXK^4O-G/DLQ&,Y^]@\"M.PT#PG)XQOM-ELAL,,#6<6^;YL
MHSLQYZ\#KZ>M 'I/?OUKSWQ>RK\2O":LS G(5<_>.Y>OX9/X5S6C-J>C>'HK
MG3/&,4%C+=JLD9T\R>2[]B6Y.-N./ZU9D_M;_A8_A5-1U1=6$R&:*2&W\G;&
M<G)'U4'Z<4 :I^V'X?W'F&W6W_M(?8BK/N)^V_\ +3CIGT[5K[M6_P"%AZ?N
M6R^T'2F^U ,^P)YPSLXSGIU]ZYH-8GP%J*F\D^TM>QI?)YTFR$&[/*#^'C/W
M>N.]:X?1W\;:*!?W)MVT[%JS3R[YG$X(#'JPX.=W% %2X^V#P!XEW_9_L1N[
MDQD%Q)O^TG.[MM^AK8OVUG_A+/#VY+#^TOL]UYBAW\GR]T>2#C.[&.HQUYKG
MI&L_^$0\5[;J9KO[7.98C-)LC3[2<$#[JD^JUIWYT:;7/#>-2NQ8>3="*0SS
M>9(_F1?*6^\1G(^;C'X4 +-]L'AWQKN2V^P%[LJVYO,,F!G(Z;<>]7;Y]<_M
M#PR5CTXZ@?/R/-D\G9L'.<;B<8ZCK62QL18>.0+B0ZA_I9D@\Q]HCP,,%/R@
M].1S4?B*[LK?3-!N=,N[BY@0W+1R2W$^]V"YV[E!?J, =.U &WNOOM'C !8/
M[/S(68EO-W_9X\ #&-N/?-9%OJ6K71\-Q;-'_<%1"8M2+%B;=ARFSK@\>^!W
MYM6]S92:CXH>:ZFCU*2!G-H)7"*GV:(D[?N[@>,]:Y;3([%+G39;N_M'\J4%
M98H[J(Q*8R/D(0;CWR3U]!Q0!T&BWNJ076H1W>G7BF[MXDNKB8 LLZP!6)PV
M . ?7!J>(ZLWA7PAY45D;I;F'[,&E?8R"W?!<X# XR2 #VKG--MM,N-226:\
M@.K6@MQ9[1+F:".#)8 [>'P<LPP,GD\5JQ/HX\#>&S+J-RMJ+Q/M,RW$H:)_
ML[9"M]Y0., < 4 .\2-?C5]6+K $/]D_:0&;*OY_\'&",\<XXJ"^DN5^%5D+
MQK>WMA<6_D212N7"!\DG(X<8) &1P*=X@DTX:[=E[F9\_P!E>0HG8><OFGEA
MT8XYR>:IS26(^&-M]DOI))DOK=K@22/*L4H;<J!?[N0/E7UXSW .Z\ D'P/I
M1#$@QM\Q/7YS^IKHQ_+K7.^ _P#D2=,YSE7^8*1GYV['IGT-=$.@X''MTH .
M<'KGOC'I2^_7G_/\J3MVZ?W?;TH[_P"(]Z #N/PZTO/&=WZ4G;@=L?=]J"![
M'/\ LY]?\_\ ZZ .;\;V]W>:"+.QNFM[JXF6-/WS1&0E3\N] 2.F?0[<=ZET
M&5CH%V^J2_,DLPN?G9A$%R"H8@'  ZCWQ4'CJ)KCP^8 +,*\HR]V$V1D!B#\
MS+@E@JY[9S2>#OM'_"$Q_9XH(Y\2^0H153.XXW;"PY/4@DGGO0!QNGG3[/4(
M[V-M#M;=+L3"?^W9I6\H8_Y99^9RO'/MQQ7J\4JSQI*A)C<!E/3((R#7&6&I
MW"ZK;KJNB:)!=SW9A2:.[0R;E4;B!MRQ!]P>17:\?GZ_Y[T  SQP<49XR?K1
M^'/T_P ^E'IS[@XH #[YSV]Z">,Y..<T=CC.,>G^<T<_B": %YSW_#%)S[_B
M>_\ GTHXSQ@^^,^G>C\.PZ#M0 <8XQC'M^%+W[_G29]>W\Z/J/TH .N/PQ0.
M<?ACFCZ_CQ2^@///I0 F>.IY''-*,YZ&D[?4#/'_ -:@#GMG_=_S[_G0 O?^
M@/\ GVI._/X\4O.>_7O35.?Q/0'_ #]: $_SG_/XT[IVX[?I1SGDX/O1WS^=
M !V['L.?\\T<>W]/8T<^O/U[XH_R,'ZT '?I^?X?G]:!VZ?S]/S^M'?CH?0]
MC1UY(_R: #MV'X^U![^OUQ_GK1STYS[8I3^(_&@!.,YX(/Z]*.._MG-'?C\<
M4>P^@YH /\_Y^M!QST_SG\OK2^A[9X.>*.<@?AUH 3C/48Z<&C([G'XX]:.>
M^?Q-+D^O)XZ\9H 3..O\Z#Q_GWH[\>]'?TYQ[_Y[T ';CH1P<]>E'?CU]?\
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MP2H7P7I02,1@0?<3C:<G(_/-;_TY^GO6)X.R?!VC[EVG[,N0W4>WKG_"MO\
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M2&+9B)W8QN^8\^U '1<8[?X].U'L.<CKG&>M*,X'7'L0?2D[C\.M  ,'\_\
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M/3]/\_C1CT&.* #VS_X]^% Y([^X_#]*7G/?KWHY]S0 =\?_ %J9U+?Y]?\
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MHZ<#CZ4<8[<^_6CCGOG/;K0 #@\#'T'^?:@=1TSCT_S_ )-'OVSZTHZX/\Z
M#^+\::<9.._?K_G_ .L*=_%3,8!'U_K_ )[T +DY_IG_ #_DTO&.QX_/].])
MW/UZ?C2CMSUQSZT +^HSCUI ??WX_P \T=A_G_)H.0.<\"@ ]OIZ_P"?QHR1
MS1Z_7UX_S_C1TZ<=OUXH #CN?S_G[49]>ON?\^U+SGC/!Z9HZ'\S0 F1R<]<
M]\49YSD?GTZT<X/7/?&/2ESR.<\\4 )^A]SS_P#7ZT9YZ_K[T#../Y_I1[#/
MM@B@ 'MSC]11GCKV]>M9EYX@TRPU6UTZXNHX[BY5WC#.,+M )W'MD'CUI;+7
M;#4=4N].M)O-FM8XY)2ARF'W;?F!//RG]* -+Z\C/X4?ASUZ_P"?:CK^/O1]
M>!GV_P __KH ..G'7KGKVH/OC\>G^?:CL>O3.,_7\:/7'KZB@#C_ (EEO^$2
MPHRQN4 &['4'J:O^!5">"-*5%"!8B-JG(4[CP,=0#^E4/B7SX2P&8$7*8*'!
MXST.?PK3\& #P;I?!4>42 >HY/7W]?>@#=W<'![''/\ GWH[]>OO2\]\CZD?
MY_\ U4F>??VQSC_/ZT '?Z^AI>>#ZTG3/)XZT=_?MG% !VSQ]?PZYJCJ^J6^
MC:=+?7*N8HRH*H!NRS!1C) ZM^M7OI[@<TV6*.>-HIHQ)&W#(ZY!'T[T 5],
MU&#5M-MM0M]PAN$#H'7# 9]/_KXJT#_M#GWS_GK38T2&-8XT6.-!A44;0 /2
MG\@9.[\<4 (#T[<]/PZ4<]/;ID_Y[=:.G7MUYHQQ@C\.WT_SZ4 &?YY_S^E9
M]EKVE:C>RV5EJ-M<74(/F11R;F7!P<C/8UHCKZ_RKA/"?AW5].\3275[91PV
MZ07$22+,&,A>Y:4' Z?*V.?2@#H?$NOZ=X>L8KK4HYI(GE 00Q&0[AR#[=.M
M<1;W6F:CX-\4ZA:V%PLET;B1[B2V9/-0R'";CU('&!7IYW?*%8#D?>]/\>*X
M"Y2__P"$0\6,TL!M3<W?D*$;>K>:<[CG!&?04 2W\>BM?^&U.CW'V)4NO*M?
MLKAXWW1_,4ZK@Y.3TSFN0\0"SEUCQ-Y\6E%HYI2%9S%*S;5VDN$.X C(56'.
M=W%>@:@FK_\ "1^'QY]G]N6&Z,C^2WE,N8L@#=D'&.<FN0UEKF)/%#/_ &J[
M">X\AK5Y/+B.%*EB'VA,=05SUYXH N7VF:-%+HI6UUI+6X>Y8P1/.'B.,MLC
M&"%))YQC'UJOJ+W!U#Q7<$7\.JAI888X=/\ -B>+RU"[G"\%E ).X8S[59U+
M4/$HURQ9-CZC:_:]MJ+!A&451MV-GYMX Y!XSTXIEWH^N%/%]U:ZE$L:R7*3
M0NSL)T:)6 .3A&0, "!SC!XH GFMM&30_#<2Z/<'33=,9K7[(Y>5OL[?.$ZD
M=\@>]:%DELWC;Q&39NUZNQ;:Z$)*Q*+=?E+ 8'4\'K2W']IE?"21R6?VUI7:
MWD,3^4(Q;-PR[L[N?6GV?VP>)/%\BO"+-2GG#8WF;OLRX*D'&/;K]* .?2/2
MV\'^%HDTR80/?P"ZC-NX-PQMV)91U<'U&1P:T;*\TJZ^(BRZ=8KJ">3#$MW&
MQ9;+:LN02 0.P.2/O=Z;LU-?"_@H-+:?:#=6_P!F/DN%53;OC>-V2?H15_P_
MIC:5XTU>TTV.VBLEAMWND(D9W9EDY0EB%YQQZ4 8MBE@WP^@9+%@9+ZU-_N@
M<BY'GC.S/W_3C-:\4>EGQ_8YT^<HFEV_V-?L[DV_SR8+?W../FK,M!?K\/-#
M EM]CW]H+$F)\H/.X\T;OF[=/_KUT,*Z@?B$<R6WF+I4'VK$;D-^\D^X=WR\
M^N>* .4MHK+_ (5_J0ATZ7[3)>(+F1K9\3J;S@*>CX&1Q^7-;!CTE?%^A*FF
M3BR2P;[-$;9]T#F=,,5ZJ,]SQ5:.'47^';J[VGDR7T?V4!')4F\R=_/S#..F
M.];+C5?^$\TQ6>S^TC3)/M+B-RFWS4SL&>">,9ST[T 8,\6G+X9\5E;&87<D
MUP+B?RFVRH+A@ &Z,<'H.:A\7R6=E/X2FTW36%O;&ZD@LYH)5.Y0"!M'S [A
MP<8Y!/%7[M;P>"/$9E>W-FU[/]G C;>'^TG[QS@C=CI5[65U(>,O!HDDM6O0
M;LR,J,(RNP9P,Y!Q[]: ,R[%DNG^-YOLDXORER&N!"VWR]B?+N^[G)''7BG:
MDFBD^&8SI=RVF![DFU^RR&0R!!@A<;L9R<].AJ34/M0\-^.FD,#6&^YVH%;S
M ^Q<Y.<;:N:DFLC7O"JF6P_M "Z(;RW\K9L7C&[.<=\]?RH ILEF+OQQ*;=S
M?A)PEQY3; GV>/(W_=SGMG-0S6^B#1/#$3Z9<_8&FD,MNMO*&D;[.V2%^\1G
M\*T"+S[+XW^>#["&N,J4;S!)]G3G=TQC\:DF76Q%X57S; :B99-K;',6W[.^
M,C=G.,=#0!S_ (B6P'B6^=K>?SQ?6'ENL3?(OEC@L?E!]CS_ $AU*:SM?A[H
M4EC;>01>VS2FYCD13*(QE^>=G')&1Z9K0\3"X&IZD2T0M!JMAY@VL7+;$QCG
M&,[??K5?61JD?@CPJ9EM9)%NK?R%C9T4Q^6-H<G/S9Z]O:@#M/!0V^!]$!((
M%G']",>_:M[Z\XZC%8/@C_D1=$P2?]#CY'KBM[KQ[T '/3O]:._J1TSGW_SF
MCGG''T[?_7HXZ=AV-  .V.G'K1GCKV]?UH]^_7I_]:CGH,]\4 <;XBN)X->G
M2U\/C4FEM88YO/E/EE6E94PFU@=K$ECQ@<UM^&5C30((X[:.U$;2)Y4#LZ*1
M(X.TG!VD@D<=Q65XEUW4=.UF"UAN8+"U:'S!<3V4EP)'W'*#81MP #SUSQTJ
M_P"$UE_L,74QNA+=2-*T=P\AV'.!M$GS*&P&VD\;J ,."+2_^$N$$6LS3*E_
M)<+9I8DA;CYM^9]N, LW!/7C/:NZY[_I7G-A>);^.)+:)VC6749$DL5OY2X)
M#$S-&1MV-@''3YASFO1?UY]N?_KT &><G'7)H''X?_JH'L,CV-+^9 Z\T )T
MX! YXHS[]/7M[THS[TG;C/0T '3V/OU_^OUH/ (_#FEYR<9_S_G]*3TQW],4
M !SS^/K1GGKW_P ]Z#W/Y_SI>>1S^!H 0GW[=,\G_/-&??OZXH[>W?& /?\
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M&."/P/%''3C&<>WI1U'KQZ_TH /KS@\C%'8^WM_GZT9YZ]_7WHZ@#VQ_G\J
M&R1K(H# [58.,''(.?YUQMUX8E@\->(2MOYVHZC).Q6*1B'1I"5 !( .WKC]
M:[3J>/\ ]7^'6N0D\4ZFGA_5]9%I9F"VFDAMD\Y]SLLIC^?C &?3- $6M:;I
MEIJ/A^*2TOCI\/VA5,0G<I(Q0KN*Y;'WOO'''M7+WEN4O_%%W +%&4WGVEI1
M,'F@RN[E5P=IP  >,GUKNKK5]:@U+3=+CMM/:^NH99YB97\M0C(/E.,DD-W
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M>WTB6WT[1;#Q9HH=X$TR[D>W?Y]DQ9'C?IYF21DGDG.: /<3G=QVI/7^6?\
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MV^T&;+J_E*"A3'0<X.?PJ2YNM4%SX3;['"+W,P6V^V?(Z^3][=LZ@>W?'?-
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MQ2DG\O>CJ.._0CM1C/;W!QTH 3GW_/\ SZ4'N3[_ )4IQWP..A_6CWX./04
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MCN(O^$ATW5;>/;Y:6$$<*PCG.0C$<GGMT- &_<SV\486ZGCB29A$OF,%W%N
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MB[P H Y/WOK7I)[YSC\/\_\ ZZYK2?!UOH6IQW.G7<T=J(/):SD56&WD@*V
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M8?:E60%B<+AN.?FK2;6] A\36E[)I,_V=;2"VM!]@8>1-YC849 "GYE (]*
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M_P (1X6S_P @"Q)'/^J%;V1_48'^?6CZ_P O>@#!_P"$'\*C_F7[ #_KB/\
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M$_6@^G?MS2\_[7Z4?R'I0 G&>",'WQ_GK1D'N.?]K_/K_*CG!ZY[XQZ4O/\
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M#Z?Y]_SH #@-SQ[_ .?I2=B/7C]:4Y&[''O^%!R >M "=\''O_GOUHZ<]_\
M/%'3/M[\?Y_QHZ?3IZ4 &<>GUSZ4>N/YDT<XZG\?TI><]^O&: $X[8]O\_CU
MHX([=_I2\^_:D/3)ST[^F* #/X?4_P"?:CZ'/IR>?\\<TO.<9_*DY[9]J #C
M/7KT/]?UHXQV ]CP.*7GMG&:3GWS^&>E !D9SQZGV^OY4=!Z?3/^32G/O2'O
MG\S0 #KCCZ YQ_G%&>.3Z=Z7KU!Y[$_Y_P B@9]_?D>U "=\#'_?7^?3^=&<
M?A[_ (4O/?/XD>U(/;\J #M^G6CC';G\O\\T?B1V_P YHYZ@'IV_^O\ YYH
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M<9P/J!Q02<9(Z<T 'KSS]?PHSWS_ /JI>0<?R^M)S[Y_#- !_L@C\_\ /O\
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M;:<R!0&SQW.X_E4$<?CDR7+L;6-I I0!PZ!OE! SRJX!(Z\DYKL>W\LGI_\
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M[XSZ=Z  YQSGIWQ1Z_7L:.W ^F%]J.^/P'^>M "\]^?3/3-(/0$\<<8_S_\
MJH]P/R'UHQQ@C@>V?\\4 +SU'?\ /Z4<@\GIUR:3'J/TZT<XZ>XX[XH 7)(_
M#MZT'/?BCOWX/ITI .., X[?E0 O7IW-)D^N/K0>2?;VI>GK^5 "<\XX^G;_
M .O1]/Y^]&!C'IQR,T=?\_G0 O?J>3V/UH&2._/<4GN?Y8XH[\\_\!/M_G_]
M5 !GZ_G]:7H>XY[_ .?\\4GMT_\ U\T>^/\ ]= !V^GO_6E[\GOSS]*3]?J/
M\^]!_D,9]J #G&<GIGFE[XSW]:0^_P">/\]J7O\ CZ>] "=<CU%!S@G\>>@H
M^O\ +WH]P.?]V@ [\^N,49Z$GWSG]:7\Z3Z<]\C_ #S0 O/';&!UI.N!U[=<
MT=_Q/ HZ]\]/_P!=  "<?7O1T[<?3M1UQQGCGO\ 6C_.<?YYH .V"?8_E2\G
MUI.W'I@8'2COV]N/?_\ 50 N3C/]?\\4<GU./IQ2<$_C^5 Z#Z="* #MC'';
MVH]QQGIBCC\.OW<4=#_/C_/K0 I]\^_-)R?K]?\ /2C'^&<4>_\ 3/\ GI0
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M8[=.O^<=J.,9X_/_ #B@ X/H<_RHXQS]3QUHR.>?R/3M1[<#VSB@ Z]?H?\
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MV?:C''(Z]>*.^<>]'0=N.G^?PZ4 '..AHQZ 'TP./:CZ8_#M_GTH[_CW_"@
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/HHH #G!R31SGO110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g201708092014008463364.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201708092014008463364.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,G G # 2(  A$! Q$!_\0
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M>O4\#VHQ_,#@4 '![?@1^%'09(]^GXT<8'3H/3O1T.3UZG@>U !CG@<^N/\
M/K1P>WX$?A1C^8' HXP.G0>G>@ Z#)'OT_&C'/ Y]<?Y]:.AR>O4\#VHQ_,#
M@4 '![?@1^%'/I[]/QH[8_3'>CU(_E^- !@=P/Q'7_/-&/F!P<#J .#0?R[4
M'K^/7% !TSQ^GUHQSP.1[?Y]<T>^/<\4=OZ8- !P>WX$?A1T&2/?I^-''?@?
MTHZ')Z]3P/:@ QSP.?7'^?6C@]OP(_"C'\P.!1Q@=.@].] !T&2/?I^-&.>!
MSZX_SZT=#D]>IX'M1C^8' H .#V_ C\*.@R1[]/QHXP.G0>G>CH<GKU/ ]J
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M@=1QVS1Z<CT!HYQQGD9ZT'UY'O\ G0  ],$?G0.!U'';-'MU]11SCC/(SUH
M/3D>@- /3!'YT'UY'O\ G1[=?44  X'4<=LT>G(] :.<<9Y&>M!]>1[_ )T
M /3!'YT#@=1QVS1[=?44<XXSR,]: #TY'H#0#TP1^=!]>1[_ )T>W7U%  .!
MU'';-'IR/0&CG'&>1GK0?7D>_P"=  #TP1^= X'4<=LT>W7U%'..,\C/6@ ]
M.1Z T ],$?G0?7D>_P"='MU]10 #@=1QVS1Z<CT!HYQQGD9ZT'UY'O\ G0
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M/7\*.O;/?D?Y^E'\_P"M';C!_'/^>U !T.<#Z[?\^_YT<X]?PHXSVQFC^?\
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M]^O:@ _$\4=/\FCMZX'/X48]L]NG6@ SCO\ F>*/Q/%&>^<]^O:CMZX'/X4
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M (31;K[-&;;[-Y?G>4-P.3QNZ_A[T 0:/H6C76G"9M+MB6FE W1@D 2, /P
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MF_W[G_P#F_\ B*/^$CTWD;[GZ?8YO7_=H U>WZ<4>X[^W6LK_A(],_YZ7/\
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M\^U !Z=C1D=<^_WOQH_3.:,Y[^V,]* #V'7D?YYH)ZG/N#FCOC/X_I1UY[T
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M=4GL;JV?2I/WDJF/#1JH0,.#\YR>#V[CI5]-0N80(DT&^"KP-KPX'_C] #-
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MG\?7_/I2'K^G(H/J0?R[4 './;'TI><]_K2=^GY=Z/\ .<<?YS0 #V_3_/\
MG-9>AY-K=Y)_X_K@?^1&K5[CC\,=*RM!!%K=$C'^G7!!QV\UJ -3/.?ZT=!Z
M8]:.?\BCI_\ JH /P/%!'U/_ .JC^8]O\_Y-''IQ["@ [YS^-+S[_I2?Y^M'
M?ID_2@!3GG[WZ>]!SS][]/>DQCMTZ<?Y]*,8[=.G'^?2@!3GG[WZ>]!SS][]
M/>DQCMTZ<?Y]*,8[=.G'^?2@!3GG[WZ>]!SS][]/>DQCMTZ<?Y]*,8[=.G'^
M?2@!3GG[WZ>]!S_M?I28QVZ>W^?2C&.W3V_SZ4 +S[_I1GUS^=)C';I[?Y]*
M../3UQ[4 '('>EY'<TGX<_2COTH 7D=S1R.YI/\ /2C\/TH 7D=S1R.YI._K
MZ?Y_&C'_ .O% "\CN:.1W-)Q_G_/O1WZ4 +R.YHY'<TG].^*._3]* %Y'<T<
M^])Q_D?Y]Z/Y_2@ R?4THS[_ .<4GT_E1Q[>G2@!1GW_ ,XI!GU/2CK]?I6?
MIVL0:I//'!#,!"64NZ@*Q#$''/J.O_UZ -#MWQ]:/\\'ZT?YY7_/M1_+_/6@
M!?H3^=)S[_Y__71^'7UH[Y ^G'TH /\ &@^Y-'IV^HH_E0 9Y_'UH_$T?YZ4
M4 ';O[\TO/3Z4G?W^E&,=OTH /Q_6E_/\Z/\:3ICC]* #]?QI<GU-)_3VHZ8
M_P * #GW_2J-O_R&[[_KE#_[/5[C'08^E48/^0W?]/\ 50_^ST 7O;U[<4?3
M^='^>E'7M^%  ,]N_I1T'<#''-'?U^H^E'..X)]O\^M  <\]>O:COQWY_P _
MY[T8]!W]/\]Z/<<YYZ4 ';/XY_K1CKQG_/\ ^J@]"3^>*#WSS_P$F@ []3QU
M_P#K_P">U'7@_3G^5'MVSZ8_S_\ 7HS_ #_#K0 >Y^IZ?Y__ %4<C )]._\
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MGOUZ\TIZXR?S_P _Y%)S[@GW_P _Y% !SWZ^GO1],=,@D_UH'MWYX-'/O^=
M!CCIP/2C\LT=>>3^7/\ G^M'/KG(XYZT '']/?\ SS1^6>YHR<]>GK0!]<<C
M_/\ GO0 <4=!_P#KHSZGTH[]3DCMC_/>@ ]N!Z#/^?\ )HX]@/K1^8S1GU..
MYH ,^I^O/YT?7'YT9/\ DT?G^=  .N..M9?A\EM(#,V2;B<Y)_Z;-6J.2._^
M>M97AS/]C+U_U\_3'_/9Z -,G:N?09KF+SQYI5C*L4]OJ(=\[5%HS'@<]/3-
M=)/_ ,>\I_V">O/3_P#77DN@1K%HK3(@$TLDJO)M&]OJV <=* .AN/B)X6U,
M0P3+J*F1@8'%LZ$,> RL.1UZ^]0#XK:'I40BOIKRX"N8VNH[0X!'0/VW=>G7
M';.*QVF<Q&/R8S&0  V"#CVQQS_*HUG=8)H/(01E=I5%!4 CTQ0!V,'Q(\/W
M-LUPC7@C618SNMF!RW3CK4C_ !$\/11-(\MV%1<D_9)./?I7&71MH/LD[Q1)
MM90S^6%.-N<$GICBGW6HVKV<VZ[MVB=-N#(#PW'/^>U ';/XWTM7*I#?R8)&
MZ.U8C/.1D?2G#QMIC1[O)OQAL;3:MGV-<)I$<*Z9$L,%N/O991][YSWZU>")
M@XBBSW;8/UH ZQ/&VF,RC[/?C<<9:U8#Z_SIY\9Z5N4;+TY[K:OC/>N1\J+;
M@V\17KR@IVQ%7 BBVCL%H ZL^-M*2)Y)4OD2/)9GMF XK:LKM+ZU2XCCD2.0
M?*LB;6 ]P:\TFBA>W=6M87&UN"@[@\UUOP^);P58,79R3)EF))/[P]Z .F_P
M]>]8/BQL:9$NZ1=\N!LF$62%8@;B,8.,=*WN??/M6-XF<)IF"E\VYL9L21*O
M!.1@'(_"@#,>2*WUK38X$;]U;P1[A.1E2<#(4[3C([<Y]JK:#=MHMIJ,][%,
MPC>*(L4*D=<@!L'8N>">O/-69VM9/%-K.)4.^%)$4D;QA21D%"<=R=PQCI5%
M)9I/#]P3//\ :3+;NOFRJSQDMPL8+$8X.W=UYSTH [.SN1>64-R$V"5=P4L&
MP/J,CI65J/B:WTZX^S/;S2SM(%CB1EW29.,@9X [FK/AW \/V861'PIRZDX)
MR<GGWZCUZ<5RUF-GB#Q-,BKN;451FQ\V!!&0,^G7\Z -B;Q;]FB,T^E7"1XR
M2)8C[_WN?PS1'XOAN$\RVTV\GBYV2*8P'PV"1\V<=\U3!Y5NN.AHW,5SG!(X
MP,8% $\7CJSFNY+2*QO&N8B=Z?)@# ).[.WN!UI;GQK;V4'FW6FW4*;MO+1_
MA_%4'S9^\V/0M]/\*QO$-ULAM?,$(C^TQF3S#@9R0!GT_K0!T$7C>VFB62/3
M+THRY!S'R/\ ONH[?Q[8W<DBV^GWTOEX\S 3Y"<X!^;KP:YE;VW9BYPFWJI(
M/]:L03[X0PV[&.X$'C_Z] &KJ7BO37832V]_8W<41>"8A,MR!LQN^89.=OM^
M-+9_$ -=RV%YHE]!?0IYC1JR$.G]Y22,CU Z5FJ3@<#:#^5/$C!0IY(Z$]1Z
MXXX!]* .MTCQ!::P<6ZNJ^7Y@+$$$<9Y!/(SCZ@UK=ZX+P2H3Q3JAV*KM;1L
MVU0-QWMS^7>N]]L_3F@ [=NN:. .W HSWYJGJ[B/1KYF4,JV[EE)'3:<]>/S
M% %M75F8*0Q4X;'8^_X&N6\(DO<7<HCC02(I?:Y)E;<W[PKM&TD=N>@YJYX0
MDMY-*D-L%\H7,H5M@0MSQE>Q XQZ+57PI;S07-V'1HU*H1%),KL@Y"]!QP#W
MZ^^: );=[D^+I+?^T)GC#-,UME=JH5P.0<_>.<'!Z'ZSZFMP=9MREY-$A,8$
M2./WARV1MZCCJ?PJ&SBOU\5W+M$&M&W#S'C!8#C #@\C)QM(R,>U.U)=1;Q'
M;&"(36H\LN&"D+RP/.=PX(/3&5^M !XN3S+&W5$BEF:4B*.90ZN2A[$C)]/Y
M59U>-;;PK-#R46!8L!.3G"\#'7TXZFJ7C*"&?3X/.GCC4RE<,%RV5(^4EEP?
MQ_EQ<U*/_BF?+$A4[(E#$').5Y^7O]": $\+QM'H2!H&B^=R%>$1-C)Y91P#
M^G2MGOVK/T5S)I%O*2QWKO4MG.">,YY''K6AW_\ KT '&.P_S_\ KHH[<GMG
MK1SWH /RHX(P0#]1WHY]_P Z* $8!EP<$ Y'X=/Z4HPO   '0"LGQ%J-QI>G
M+<6_E%C*JD2D@$'MGH">.3Q5ZRN3=V$%RT?E^;&KE"V<9'3/?ZT 6,_0T?YZ
MT9_SFB@ [9XJA:?\A;4_]Z+G_@ J_P#YZU0M/^0KJ?\ O1_^@4 7^V.*.OIS
M[TOY_G2?C]>?\^E !QC/I_G^M'KR/S]Z/_U]J.>^:  \9Z?C1WX]?7^GYT<_
M_7S^M&??OZ^] !D8YZ>Y[?\ ZJ#UYQU]<4#_ #^=&<#Z=<'^?Y4 '7@]>E''
M4]^>3C_/%'08!([=J. ?\CO0 9'<C_OK_/O^5'X?KC_/:C..YXZ\T?7MQP:
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MN6)VICKR2,XH^8*2&)X.!M_^O0 \$#@YZXI0O/&.E,CWD?O#L;T S^M+\P?
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MP(WGT^*>>2&)Y'#%9C'_ ,LVQR#ZUJ_B?SJ*>UM[N,1W5O'.@.=LJ!@#ZX-
M'':Z\6GVTBV>I3"-UB\Q_MKOM!GC!(8D[?E)YJA;SFWUB!8]3N99&,Q -WO&
M C'IGZ<UW2Z7IL<;QQZ?:HD@Q(HA0!P.Q&.:6+3-.@??%I]K&XXW)$H(SQZ>
ME '&021K86LRW]R\Q6!@?M[DEB4SE=V#U/%4[J662^U-Y-7NE*W<ZJB7C($
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MP?H ,8H [G^U=.Z'4;7/<>>O^-*-6TW_ *"-I_W_ %_QK-M/"6B6@91IEFZ
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M ]/\:/:CM^'<4OKUZ^E "<^OZT<^_N:![?E1_GI0 ?Y-'2CZ?AQ1[]!]/QH
M/SZXZT?UH_G]*/?^E !S[\T>G)H_#]*/\]* #_/6J&L1Q3:;(DQC"DJ1YC[5
M)# C)P>#CT/XU?\ \]*R?$A(T&YQ%!)PH*3J"IY'8D G\: (_#"M'I]PK.'8
M7#*Q5]RY 4'![\@_4UM=JP?".[^QI&<IEKF1_D4!>3D8 Z YSCWK>_STH /I
M^AHS[_K1_GI2_P">E "?T'KVH^O]*.>/\*7OQ0 G/^/-9>D9^UZQQ_R_=_\
MKE'6IZ<'VXJAIOW]0Z?\?;=L_P *T 7\^F?P-'Z_CUH^OX\4<_Y% !R"?3T-
M'?UQ[T?3C\*/P_2@ Z=#^M'/8YX&*/PH]C[=J #\?UHR??/UHYZ4=NG'TH ,
M]_QZT8Q1SD9_E1Q@<?I0 BL&&5)(SC\O_P!5+U'KQ2\].>:3K_/% !U!QR#^
MO%*,YXZ?6D_^MR1_GO0.3T]^G-  <9QD?G]*.GL?7_/\J7^+K2=3G_ZW^?\
MZU  #[]QC_/TH'7'_LQ_SVI>>O/>D[;1].HH /R^E''0%?SS_GM2\]1G';&/
M\_\ ZZ3G.,F@ XZ]N*.V#^M'O0/0$T ''?'^<T=#VHS[X_&CV_K0 G&.U+[\
M=Z,\9R?KFCO_ #H /7I1_GK1^/-';VH #P#GCBLSPY_R+6F?]>R8_(5IG(5N
MH.*S/#G_ "+&F]?^/9/_ $&@!OB?/_"):SM!)^PS8P.OR'M7G]G*EQI]K-$X
M>-H$PRG(/R@5Z)XAFE@\-:K-;R,DR6DK1NIP5;:<$?I7G%K90V]E;1"(?)$O
M+-ELD9.3ZY)_.@"QR.>/SJ)&,@=SSN(P-OW<#'YT-&N3\BYQT%$6 K@'/9CU
M'3/Y<T .#C<2GS>O HY7DQ@CO\W(_'\JCA4QJ"TF]RHY(]NG'M4A^>/!.<CG
M/'-  "Y0$J"#U&>H_E3@Q$89E/3/(I JJH"X..AS0Z-(J[7:-D)((/7C'_UZ
M 'D^M)G'7ZCBFA6:,*#QLX_3_P#73CNYRV>>,T -,L(M997=1$J$LV[&!CU_
M&NN\(0I<>!M/B<,4EA)/K@DGCTZUQLMI;W,4@:-0X!D1U RK9R&'OD5W7@Z9
M[KP;I%Q,VZ:6V61B>,D\D_G0!I6,SNCPS?ZZ!]C?[7HWX@YJT/;^9JG=[+28
M7Y&%"^7,1DY3/!_ _H35P'.#UY_SB@ ]AQZ530&XU!Y2 T4 V(,?QG[W]!^=
M37<WV:TDD.<A?E&.IZ ?G26<#6UK&DA#2XW2$="QY)_G0!..O]:\[T5(PFJ.
ML:B275;O>P'+;92!D^V:]%[UY]IJP_;-8>UAECMS?/GS'W!IP[B4H,G ^[]:
M +W. ,]?4T D'*G!]C2$GH>?QH&3T!H 7<S#YF9L=,T-GISC\/\ /K1@J<$$
M?ATI&'//;T_S]: $R?Q[T#.<>U&1D<&AN/3\Z ' _7KWI .>O^>:0=.>>>X_
MSZT'=MX(!XP3_G_.* )O!FW^T]=V_=,D';K\E==VSQZUQG@(G[3K7F>9]H$L
M?FA@N!P=H7';;CWKL_\ /6@ XSCBCBC/OUYZT=N_TH ._7]:.V./Q/\ GUH_
MK1D^I_,4 'Y?C1],9H_/\Z.0._YT ''M11T[_K10 =J./:CZ?SH[?_7H /RK
M,U]6;1YPEP;=AM*RK_"0P/=E]/4?TK4_/\ZQO$[;-"EP'8[T"B-PI)W 8#'A
M?J>* (O"2>7H\B J0MS(%(?<" >"#_3/'3M6[_2L7PN3_9DPVE-MU(FTC!7!
M"[3ZD8QGOC(ZUM=NN/QH ,8'_P"NCOGCK63KE[]E6!%OOL;2,22+4SE@!R,#
MIU'-7KJ1H]-FE,A4K"S>9MSC"]=O]* +'3T'Z4<=#C_.:R]$N+BYBFEDNQ<P
M[@(G-LT+8QDY!'/)ZCBM2@ [Y.,_6J&F\2:CV_TML<_["UH<CK^IJAIG^LU#
M'_/VW_H*T 7N*.]'YTO/?- "=OP]>*#P?\:/\FCMCUH /IC\#_GM1G ["C\Z
M.<XSCMUH ..F/PS1Q[4<].1WZT?YZT 'Y?7G_/XT>_\ G_/^-!I>_P#7- "<
M#TH]C_/_ #ZT9/X_6CD=,_A0 =??Z?2E')'U^M)[]>I%+CD#TXH #U_ETI!V
MQGIQT_S_ /JH[\<?A0<=SVSR.M !CV/Z48XQSCZ4?AW["CMQ[<XXH ,9SD#^
M='TXH]..GMTH_#]* #\*.O\ ^NC_ #TH_G0 >_-'^>U'^>G2C_/2@ _I1C]*
M._\ ]:CU_P * #_'F@>M'U_E1C_.*  C"G_=/:LSPX/^*9TSC_EV3_T&M(_=
M8X['M5#0HS%X?T^,D$BV3H..@H 3Q H;PWJ@:18U-I+EWZ+\IY->:V-P]S8V
MTS0&%GB!(!XP. 0",CIT->C^)L?\(KK&>ALIO;^ UP9.0@!&Q455/8@  8/<
M4 1Y)ZKSC=RW2F1\RS[EZLN1G/.!4H'/KQTQ_G%1E-PD7)Q)R,=OEYQ0 1D,
M6.YBV0?;';%2<@X^;K4<9#-Y@:(E@ 3&@ )]\5)TX'K_ (4 *#TR:;*Q&T M
MN)XQWX[TX YZ 4CG Y8(PSM.>AH 4;%&,8 4XSVZ4[_&D3:J'/ VXS[\=Z<.
MQ'6@"KJ$[VMA--&H+*.K9PO."3CT'->@^%(HX?"6DQ0R>9&MJ@60+@,,#G%<
M4I 20E@BA#DDX&,5V_AHAO"VDGULXS@^FT4 :C*LB,KJ"K @@^G>J=A(R,]E
M(I$D&-K?WD_A(_#@^_UJ[_GD52O\P[+U21]G!9QC[T?\7Y=?PH )BT^HQ0+D
M10 32>YY"C^OX"KO<],Y]?\ /:JFG[F@:X?A[AO,&3T4_='Y?UJW^?Y4  QZ
MUYSH\H>?5X=YW0ZC<,\1'W0TK%3SZA3^5>CCM7G.DEQ<:JTTC3237LHW,V2J
M1R.JKGV'Y?C0!IGOR.]5=0=TTJ;R96B<R0KN1]AP9 #R.G'%6,\>H/>D9-R-
M&P1D?AE=0P/<9!^@H J6OF">ZB:>>51'$P$TYE*DNXZ]N *N^G(X.*CABBBC
MVQ10Q(<%O+B5>G3.!V_K4F>2,+P<@&@!,8_ TT?B?<_2G<EOQH'J/7@T '"C
M'?VHVY; !))X HQ@\C [T$@D%N@YZ]<4 .\#;/[2U_RW21%EA3='C!*I@@?0
MY'US79<=#T[UR'@B-H;K6HO,=XTDB,8<[BFY Y'3IEC77^OT/ H .>?7V-'X
M=Z#CTX]*/Y]^* #WY]_RH[?IVP/\_P!*.HY_E1W_ /K4 'OBC\*./0=NHH]C
M_*@ ]J/?^M'^>E'^>E !_G'%'T^M'^>E'X<T ''3\.U9VMR^5I<DI.$0AGP-
MV5[\#D__ %JT>W3]*S]:L)=0L1%$JLZRI( TA0<'U /^?2@"OX;VFRNBBD*;
MN9AG.>6SGGGO6QW]_P *R]!LKFPL98KM8A*UQ+)B,DK@MD?TK4 XQ_3Z4 <]
MXN>..RMB\"SGS@%B8CYL\<*?O'!.!ZXS6U(%:P<$94PG(90,C'.:S-?T>YU8
MVWD2QQB,.'#CJ& '&0?3TK1GMF.DR6D6-WD&)-QXSMP,F@#,\+>7_9TA2".+
M]Y_RS_C48VL3@;CCJ1QZ5N5DZ!I$FD6K),XDD.T9#;OE48 ^Z/>M;MZT  Z^
MG/\ G_/O5#31^\U X_Y>VZ?[JU?_ ,]*SM)?S'U'Y<8O7'/L%YH T>_2C'M^
M>*/H/T_*CCMCIV% !_\ K[?Y[T?RZ=J/\]*/8^W6@ _R:.A]/6CT_P /\_Y%
M'^<8H ,=L?E_G_.*/\_A1[4?YX'>@ ^HH^O7W- Z_ITH_3CTH ,=J/IWY[4?
MYY%';H<4 &#Z']*7'/3O28]0/^^?\^_YT <]O^^?\^_YT !/)YQ^/^?:D/\
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M:.WK2\^_O0 GU_&C/KC_ #S1S^1HSQU/YT ''M1]<4?YZTO.>_% "<>H_/\
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M %JR2*'['%:R+/;K!<^6ZMNRIE3C/Z5>.??GCFH])9=1O-'-RH/VJTG)VX7
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M_2@#1!]OUH_#]*3C';';_/XT<>WY_6@!<]\?E1[4G^>M% "Y^M)^';THZ4<
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MT/@V*ZGUC4+Z41K#$BV:X/S,X)<G'IAQCFN;LPZZ19DS'8+?_5;<Y.3Z=?\
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MZ4 '2CIWZ>]%'OS^G^>] !V[CZFC_)'%']** #G_ "?I0<X[_C1W[T#CM^5
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M1LI\;2SQSQ%'A,<D6[YP4&<XZCKUSC!]: %\..DFJZJXDB:1I.1&ZMQN?G@
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MX^ K;%;T/&?QJF]KJ=G86,4_V$Q+=6D,C),S,Q\U0"!M'7%>B,Q!8*QQDXH
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ME89!'<4OU^M16YW6L+%0I,:G&>G'^>:E[GCI[F@ _#\J.G4?S-''2CMV]^:
M#'M1[4>M'^/K0 >^/YT8HH[9ZT 'X4?A_P#7H/X4=^WI0 O?_P"L:S]'8/I^
MX#@SS8X/_/5JO\9'OS65X<Q_8D>!C]]-P3G_ ):O0!JCZ?I1]!T[?Y_"CCV_
M$T>GM0 8[8_G1_\ KHXZ<?Y_R** #'M^E';./?O1QC_/\Z/0_G0 44?E[T4
M'TX^E&.G&!_G\J..O'6C^?\ ^N@ _K1^%''M1VYH /\ ]76E'4?X4GY4HZB@
M ZD_E3.['_/>G_Q?_6II&">: #Z_YYI?\]:3^?T_S_G%+0 >_P#GO1[9]NM'
M^1Q1^GIQ0 9X^G7F@Y'<_P!*.3[?AG%']?;_ #[T +WZ]#W-)U]2/J/>CU^A
MZB@]>?7CCZ4 '/3G-&.3R>>E';C^7'%'3_\ 5TH #GDTO.>_Z4GX?ITH_P ]
M/\^E %35?^0+??\ 7M)_Z":LQ?ZJ/J/E%5M5_P"0-??]>\G_ *":LQ?ZF,$8
M^4<8H YGX@N5\&705V3,D2G:V#@N!CCU%<ML2/\ =0QB-%&%4< #L*ZKX@^7
M_P (7>^:9@-R;3"!NW;AMQG ^]C/XUR8$@1!,,2[%:3..6P-W3WH DC&;E!C
MC<"<]^17G=C=V<WBW4X)+:-YWNIP9[:7RU4JSD950-VX #G/()]J]!1<NHW?
MQ 9_'FN2TO7(I-3N]/GT^R6]$EUOF2TD695RV"2$V@XVC.<'USU -&?2;6?Q
M/]LDNU+%X]N(C\K+MS\W0GH,?[7-;'RE79A&4+OD<G'SL*H7#D^(]RA6N R#
MR6<@2$ 8;., < [3Z>]7;8?ZPLQR9')_[[:@"P".A(Z]JA3(N"%^XR[_ 'SW
M_"INGS<#OT]JA(,EP%#D8C//'J!0!-GC<<BHI<C Q\O0 #G-.,;G:8Y"#GD;
M1T]^E,*/\TF]@0.%SD"@"MK**VD73%F5HUWHRM@J>QKUFU_X]( ,?ZM?Y"O)
M->9DT:;_ %BQ,0)FB4,X3V!_"O6H"J6,3,VU1$"2> !CU]* )RP"DDD #G)Z
M53):_P @$I:\@G'^M^GM_.F1O_:P9GCD6T5ODR<><!_%CJ%]/7KTZW\8&!Q@
M< "@"O);;95FA(C9< C/RLOT]AWK(T6&ZBUB^\U(]F=I?S][[MVX C' PV1S
MQ6__ )X%4;ZQ:61;JU=8;V,85V!(<9SL8=P<=>HZCW +K'"'(R,9(XY%>5:9
M)>P6VAVT^RTDAOI+>>VF0!W*VTA 7 (SA@<Y''?M7I:W#2VDOFQF*9(RSINR
M <9X/&1[^U>::0Y_L[PW_HR74MQ<-+)<S.6>-S:R$N.>I  YSQV[T =!&0(D
MSQA0?Y?X4[<<8 Z?Y_S]*;'S%'C/"C^G^%.QW_6@  -+_P#JY_&COU--)YZ_
M3_/^>U "YY&1DU'<_P#'K.6D,86-OFQU&.AS3R,'C/'3BEY ;G/'<"@#(U35
M;D:K86.F76GJLMO+),]Q'YA!5D4#AAC.\GWQ5JTNFU+1X97>W,TL3;MCA59@
M67C)XSCU[U.]A8O@RZ=8R.N</);*S#\<4DJ0002-';6R*B':B0JH! /:@#2\
M#W4-[I&HRP?,AOY\,!][D<@]ZJ2)?ZAX9N+;5HYLQ31M&R0$/@$$ +M.6&,<
M#!]:M>"(1#H5_'!O(6]G2-9"?E"G '/(''Y5E[+?3- -S<2+&JWD33/Y9(W;
M2?NE5(!W >V>Q% '7:%"EOH-C'')))&(5VL^-V,9P<=Q6)X=D8^(-162S2.3
M#[I1#LR!*PX(..>I^Z2<'!ZUK^',?V!9D?,"I8$Y^8;B0?FYYZC-0Z4]D=4O
M?)^PF64EA]G)WLH.&WYXSDC\Z -H]ST_S_G\Z4CGO2?U]L4=^1^E !_7WHH[
M?AU H/>@#AW#_P!OZLZ/,,K.BJB*SYVKRN&W=3QP.O6DBL);G0K=8+B6WGM[
ML[BLPB*C:-ZAG4EN.YYS]*M3.8-8UJ6:V9;<6Y^1[8^7(>I8N#R#GH?7CI6=
MJ,<C>&X[-+6*U N9@T<<@98 !GDNP5@<^P^;':@#NK01BRMQ 2T0B782>HQQ
M7.>* XU&TG6>1%B5255_E?\ >+PW]U3W;ITS6BFK$:M;:<L \MXE)D ( ^4D
M*,#'8\$Y],U3\0Q32:E9*@@"2?NR[*A?[P. &<$C@< 'Z4 =*>I^O/-)]:7O
MR*3MS_*@ HZ\X]Z,>WZ4>W]* #_]77WH[9_/FCW_ *4?R^E "\^_6D';K1C_
M #BCK_,\4 *.WO63X<_Y B_]=I__ $:]:O<9K+\/J1HT>0N3+*1@=C*V#^/%
M &KWX_G2<^]!_E[4=\9[T 'Y]?;_ #_^NB@?3]*/\]* #\_<YI>>IS^7^?2D
M]Q]>E'T_]!Y_SS0 9]?Y_C1^?YT?YX'2CK_^J@ ]_P"M+S_DTG7^72CK_GI0
M ?T]Z/SH_P ?2CZ_RH ,]_Y&E'7']:2E'7\?2@ _B[4C?>-+SGO_ (TPG)/O
M0 O\J4^G]:3OR#2_Y- !Z_XT9&<C'YT9_P Y_P _Y-'?J?SH ,8X]L4=^<>_
M-'YY]O\ /^<T?C^OK0 ?YZD4>A'_ .NE[]Q_^JD_G_+/^?TH .#W![9_S^%
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MP=ZEYX^O% &;K<[1VMN1<W-L#.^\PR["X$1(&?3(%4@\L8&=4U#GNUWC^?\
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MVKF61@$1Y"TBH Y]3CDT -RP!/ ],_2@GKQCGKWHP<9/7/\ 2C&0P'!/&<4
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MZ4<4 +Z_Y[TGO^?%'X#/;BCWX]N?QH .@_\ K4'O_A_]:C@>E&* #_/2CO\
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M&?\ 7Z41WQ;R'!R/]JL)!XEEUMK^^U3376.1G2-+ H),H4^9@03A6(&3VZT
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M )78-RYR<@D<B@#8T2Z636[HM9R+<S)^^EV;0-C$*&&."0?4YQ73<9YQC/\
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M,=0!^&*/?KSZ4 +SZ_K2#M1_^K.*/P_2@ _SUH[_ /UZ7'^<4G:@ Y_R:/\
M/6C_ /7TH_STH /Q_7_/O2CKT/O2?G^72COV'.?Z4 !ZD<?3/^?;\Z.O3G^5
M*<YQD_I_G_\ 52?TYX[4 (.I)_#_ #^5+TZGI[T#\?3C''^?Z4?3]#0 >W'I
M1Q1S[\^]'4?6@ /X'ZT?Q?YS1G/?]>E'Y_3- !QCMT]:,YZFCO\ _7HZ^N*
M#_/7_/O1[<#\?\^U'./_ *]'0T 'MGKQ1^7.*!VY_,_Y_P FCG'?- &7KW_'
ME:_]?UM_Z-6M0]>U9>O?\>5J>WVZV_\ 1JUJGKW]* $H[<8I?S_.DZ__ *Z
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MX_\ KD4 'X?I1W''Z48YZ?I1VX _*@ ';O\ A1_GI1P??OTH_#]* #FCH/\
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MA^E'?_ZU'T'Z4 '^>E'?I^GM1_GI1QTZ#/I^5  /;C\*/\]*.WI^%'?&/TH
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M?^0%J7YQ?_%T?VM=?] +4<?6+_XNM7)XZTG.>I_$T 9?]K76/^0%J//O%_\
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M<=>*._XT?G^='7UH .,=J._XT<THZT !ZXQQ]*3C\_:@X!YHZ?\ ZZ #N/\
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M_GUH_']:.W<<>O\ ]>E_QH 3O1^/ZTOY_G2=N] !VZT4=L_UI>_>@! >G/\
M6C/'![< 4<^I_.CTY/YT '0]>E'/K^M'3UHZ=_UH /;BBCV/X\T<_P"30 ?C
M^M&?>C\>/K1R.Y_.@ ^IZ=?\_G1S^5+^=)VS0 =\49SWZ_Y]*/:C/'?\_:@
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M\G/>E&<CK^- "=3C''IC_/\ DT<TIZ_CZTF1U./Q- !UY'?VH_STH_+\Z.*
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M1[UTI_\ U9HXZ\$?Y- '/WV@ZG//-)::Y/:[W#( I8+PN1C."./UJM#X;UM
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MU_G1^?'%+WX_"D_STH ,>U&?\YHQST_2CM_];O0 >G^-'?OFCO\ _6H_STH
M*/Z^M']?:CG_ "* #\3^='^>M'3KV]J/;G\J #GWH_G^%![_ *\4?A^E !1^
M?YTO4_4^E)V_^M0 =^OZT=?7\Z,]Z.W3..V* #\_SHYZ]?ZT'_/%'?\ 'N/\
M^U !T[G\Q]**.@';\.E'Z^Q% !^='Y\>]'\OI1_GI0 ?G^='-':C_'TH 7GI
MR:3OWZ48]!^E''3''TH /PI?\:3^?TH_STH .<=311^'OTH_STH .??\Z/\
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M.W4<?I1QGMUH ,8_^O1C_.*!^M'Y&@ H_"@44 'X4=:.** #KV_2CK^/^?\
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$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g201708092014007613359.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201708092014007613359.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,G G # 2(  A$! Q$!_\0
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MC</6FGO^76@]_P NM #MP]:-P]::>_Y=:#W_ "ZT .W#UHW#UII[_EUH/?\
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M.!TZ4#M_@/RH_#/7MUI>?KWH 3ICVXZ?RH';VXX'3I1]!]./\_Y-'X9Z]NM
M .W^ _*CICVXZ?RI>?KWI/H/IQ_G_)H !V]N.!TZ4#M_@/RH_#/7MUI>?KWH
M 3ICVXZ?RH';VXX'3I1]!]./\_Y-'X9Z]NM  .W^ _*CICVXZ?RI>?KWI/H/
MIQ_G_)H !V]N.!TZ4#M_@/RH_#/7MUI>?KWH 3ICVXZ?RH';VXX'3I1]!]./
M\_Y-'X9Z]NM  .W^ _*CICVXZ?RI>?KWI/H/IQ_G_)H !V]N.!TZ4#M_@/RH
M_#/7MUI>?KWH 3ICVXZ?RH';VXX'3I1]!]./\_Y-'X9Z]NM  .W^ _*CICVX
MZ?RI>?KWI/H/IQ_G_)H !V]N.!TZ4#M_@/RH_#/7MUI>?KWH 3ICVXZ?RH';
MVXX'3I1]!]./\_Y-'X9Z]NM  .W^ _*CICVXZ?RI>?KWI/H/IQ_G_)H !V]N
M.!TZ4#M_@/RH_#/7MUI>?KWH 3ICVXZ?RH';VXX'3I1]!]./\_Y-'X9Z]NM
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M]?RHX]L'(XI3G.?F_2D/7_/KQ0 9XSQ^>.U!Z9X[]_K^5+SSP?TH.<Y^;]*
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M?GCM0>F>._?Z_E2\\\']*#G.?F_2@!./;!R.*,\9X_/':@]?\^O%+SSP?TH
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MGZ_Y_P#UT'\NO;'?F@D<\C_OKZ_Y_P#U4'U_K[T ! YX'_?/U_S_ /KH('/
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MU]?\_P#ZJ  @<\#_ +Y^O^?_ -=!_+KVQWYH)'/(_P"^OK_G_P#50?7^OO0
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M@D<\C_OKZ_Y__50?7^OO0 $#G@?]\_7_ #_^N@@<\#_OGZ_Y_P#UT$CGD?\
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M?K29[YQ_3ZT'K_GUXI><]^O>@!,GU.?3BES_ +1YZ'_/UI.<'K]*#U_SZ\4
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M%' X&#CW_I^%+WP.WN?\^M "<8XQC'4"COZ<^E&>,^GJ?:C.._\ X]D_YXH
M/T_"CW_/^M _#CL#F@'IR/S_ ,YZT 'X?I0.@XY]A1V'^.?2E[\=O<_Y]: $
MP.P[=0*#W&/7^&C/0\>W/^?7K1@8QVZ4 +W_ !]/>D ]N,8X7'I1GO\ CU_'
M\J#Q^'3_ #^% ![D<GH<?Y]:!D=!CVQBCHW7&:.HXQCT!R.U  .P[<=5_P _
MY^E ZCI^7^?>C(/<'GUS_GK0#TY_7ZT +_%^-)SCG(&.>?\ /^12]#GM]*3'
M;'..PY_SS0 '.#DXXYY_S_D4O//U]>E)]/J.,T<<?3C/- "]_P ?6D[?3_/Y
MT#L/IZC_ /50.GX>G^<4 '3N,#W]Z,^YXZ^W2E!/YTG.!@=.G'M0 N#QP>/I
M2#MST[48YX&?^ _Y]/Y4?H./\_TH  3@8YP.QZTO.>_XTG/?]11@>G'^[0 <
MXXST[?\ UZ7OT-(?<?7(_.C'.,?DM "C)QR<'_/:D'0=NF/:JFJ37%OH][/:
M)YES';N\2XSN<+E1CZ]J\RM-:T^31TN[KXJW$=\\8D9 (5"-CE?**;B,YXX-
M 'K'/;^?Z4O.0/ZUF>';RYU'PUIE[>ILN9[9))%"%<$KDX!Y&?2M(#M@=.F,
M9H !T';ICVHY[?S_ $H'7CK^7;O1Z=<#IQTH 7G(']:0=!VZ8]J,<8XZ>G7\
M*.,G]?7\_P J %&<#\NM<#X@\1ZY:>)Y[*UDN%LH@@(@T>2[9<H6)+*V,YP-
MO7G-=Z?<>N>,_P"17G103?&V1)-QCC@655#'&\1D!L#J<''- &$WC3QM;VGV
MG4+FSL(@FYY+G1;I4B/HS8(SSCCWYJ.U^)>H_;X8KWQ5I"VK!M\MKID[%" -
MHVL!G/3CTKMO'-YXDM+.Z:PM],;23:LMQ+<R,)%9OER!TV@'/^<5YA90/::E
M;SOKOAPP6Y!$*:MC><=#E3QWP!U H TU^)VLNNY?%.@1 Y^233[C</KM!'Z_
MC5ZW\=^(!<1/?ZY8)8,K,]U;Z-<MY8P""=P P?7Z5B#RE2Z U?PX[36Q@!;6
M VWY"N?N>_Z 5Z)?W*7'P9N)HW5E.C'E6!'^KQC.>V"* .)_X6=JKX8>*-#1
M?F!633Y]_4[>BD D!3U-31?$C6Y7=(M>TZ\D6*24K9:;,Y4*I.6#!?ES@$YX
MYK+\-ZG;1>&],MXKD:5?01OYFI*R2,5:5F$?E;L-U',@XSQS5VVU6QFN([9$
MC$D.GWYN+LSA_M+M$H#DL=X/!^4\#C'% %JS\9^.[FW>;RU5"/W)31;AA(",
MA_E!^7'XU:D\5^-HH9&:1%\N,L"=$NE0D9ZDKP",8_'.*[KP^TB^%M'P<NNG
MP''ML7'ZYJSJF[^RM3 Y06\V[=[J?\* /.[;Q;XSNA')%+&8)8%DCF71[AE9
MF[9"G( .<CKVJ4^)_&P5_P!\K,(\KC1;D M[$ITX/IU!]:[/PNSIX-\/LF<_
MV=;Y]"-B_P#UZI>+'N98M%MK;4+VUCO-3CA>6WEV2&,QR$@'GT% '*#Q=XO:
M\CM/M=OYS0>9,G]CW):+. ,KLS@G=SS]WK4@\1^/20#<6R]FSHMW^!'R<^XK
ML])\-V^CZG<WXO\ 4+NXGB6*22\N1*50$L ...I/XUJ/(X0%F;DC9QR3CG]*
M /,=/\;^,'\0:7I][);K]IDB\Z+^S9HV0,V""6QCOSR.@ZUZX>OZ\G\Z\?\
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M'^?6CM]?;_/-'4\]#[?Y_P F@ _']>]+T.>1SG)I.>O<#T_I1CGCKZ[?\^]
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M4>_],_YZ4  / Y./SHY[\XZCWHZ?EUQ1[8^G'\J #/&<YQWS1QGGW-'?/XY
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M ,E%0#J-H9F'K[=Z[\]?I[4 )@^AXZ<_3\:7G/X\9I,>O/J=M'4?7KQQGI0
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M3KEU-+9WMSHVF>-;2^ED\X(%D2(MD%N,G&1GM78>'8TM_#&D10E(%%E$5VC
MY0$C [YY_&I=:U0Z/H>H:D87F6VC:;R$8*3@CN>..M $E]JEGHVEK>:C.88D
M,:OA&8EF( ^502<M63_PF_AT.6\^].3\V[3[@Y&<X^Y2^,B3H=FVTC.I6!SW
M_P!>O'U%=)O<,Y\S(+>I 4;CU_E0!S?_  G'A[Y<3WHVXQ_H%Q[\_<YH_P"$
MX\/#(6YO@#U_XE]QSQC^YTKHPYS&0Y.%^[O.6ZCI3?-/E@+*6W<[LGY>#^-
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M\#.MU=/=7;/=6_GRX!?;(Z*3CCH*SO$7C;11J=KIJ^*;2PM'B::>[MY4=VY
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M/(SZBD[8[XZ8HQV&?ICZ_A0 9Z$GWSG]:.A';I_GWI><D_CTI,=L>V,?7]*
M#M^G7_Z]';V[8H[_ )<T>_?'I_G_ ": #K^/I^M'7/T__5_G%!SSQS]/RHXZ
M=0?3WH 7D9/(Q[TGYX^O:CT/'X#_ #[T=_4CID'W[T +ST]Z3/J??DT=N!G\
M*,CDY]^,4 '.#P?Q]:4=<]LFD([>WI2_Q4 !QGVS_6D!Z<C\_P#/K2D'/]:.
M>GKVSS0 G;_ZY'^>:._U_"EYSGG/?%&,=NGO0 F>.#CZ=^O:CO@?3@_Y]*.<
M8)Y],]:7GWH 3/>C//7OZ_6EYSWZ^M)SCOGT.* #MU'USG'%&>?3VW?3_/\
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M=2UBST]6G6^FL[.42*P&$ )C/&=W*^W- '9Z/I^I62S?VGK)U-W;*,;=8O+
M&, +U_SZUI]1V_SV_.N9\'/9O:W9L]7U?4D$@+-J:LICXZ+N13COWKI^?<\T
M )D>H/?USWHX'7^?YT<XY)]O?^M+S[_I0 A]Q_\ KKRV?4[2Q^,UVU]=?8K=
M("#/,P2(EHDP-Q.-_H#VW>M>IX.>X]Z\T$5O<_&.\67S)U\DGR6&^ $1*,X.
M0'_7!- '2?\ "4^']C ^(-&)XQ_ID8W=CGG\>?>@>*/#^X9\0Z/@@?,+V,%>
M.WS5=^PZ<W"V-F2" 6:W1<9[=/7C\*4Z=8!E_P! M#N VJ;9/WGR_3O_ $%
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M:_#9SJI4/# Y.UL97YG.<X'/7\A5[_A$?%V?^1SEZ_\ /(_XT 0:U\WQFT/
MR/LBG('_ %WKT$]?I[FO)H[#5--^+.AVNIZN=0<P[PY^4@;9\#;SNP=WS<8S
M[UZS@\\=?I0 AQZ_^/'_ #ZT'IR!^-+SG_Z])@^ASC_&@ X)ZCGWZ_YYHZ]<
M>_\ G^E+]>G/'M1R.H/ ]>] "9[Y'(.<&COC/_CWU_S_ /JI>??\:/KG'X4
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ME/=3*0+88BA"J%PHW'!(Y-=#_/&1ZUS?@_1+K1;6Z2[TS1K!I90P72@X5_E
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M%#%;*BL7E8D#[S#WYK(T7PCIRF[O;[P_IMHD\B+#9-&DIA09&6/(WLQ.<<
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M_"7W&<_\(AXA_P# >+_XY[4 =1]>>QXZTON?3J*Y;_A+KC_H4?$7'_3O%_\
M'/K1_P )=<?]"CXB_"WB_P#CGU_R: .H/OR.^:9Y\7_/9/?##BN9?Q;<E& \
M)>(AE2!_H\7'_D2LOPIX T$^%-,.K^';8:CY"FX\Z+YP_?/O0!H?$._L;?PF
MS7=L+R,W,'[KY3G]X&/7CH"/QK+\)Q:+<>)Q>VUK8:=-';LD%E#*&E;)&]WQ
M\N0 % !.,G/7 S/B5X4T/1?"?VS2=&M;6\%S$JRPQ , 20>_I6_#X;O$\&+'
M]HLO[5@N&O[6X16,<3EMX SS@KE3Z@T 6?%=O;QZWX8GC@C6:76%$DBH SXA
MEQD]376]Z\WM/^$O\8V&DZNCZ%!':W37$*%)LEEWQX;DC')/%;S?\)VD;,3X
M:PHSC9/V_&@!W@W_ %WB;U_MN?\ ] CIWCJUOIM BGTZU^U3V-Y!>>27VF18
MF#$ \\X%<-::SXYTBRN-0T[1-/U"WU&_:4^6)&?S& S\H/RJ-F,DU(_Q"\96
M1LAJ6E:38->P/+ LRR*V$(!5@S#:3NXR: .I\1>,Y=-L=#O+*".6UOV26>3S
M =D)VYV\C+'=@<]JHCXQ^&BX00:GN.,?Z,!UYZ[L?X=ZY^/2?$E^FFZQ86L"
MQ.QN((+,L8DE\Q3B1)'PB$@DF+)//KFNYQX\_O\ AO\ [XG_ ,: ,[_A:F@M
M'N$-\%)V;ML?!Q_OU3M+.YU+X%)962?:;J73BB(A!WMGMSBK2Z%XS7Q&^N>=
MX?\ M3P"WV[)MH4'.?7.?>J^CP>/5BU.TBU+17FBNF5II8IB$8HC81> % 8<
M<\Y/>@#L-+UFRU-I8;<R)/;MMFAFC:*1>P.T\D''!Z''6M'\#V[UYS+8>/-*
MU"+6KO4="NY@BV0 MI$R))4 R1R<'G\3ZUO;/'F,;O#7_?N?T^M &=K&/^%K
M:1QSY46#C_9N_P#ZWY>U=S],&O-HTUUOBWI@UF.P<"S+;[16VJ1YVS[QSGE^
MG'%>D=NGTX_S_D4 +VXZ'IBC@^AS^HI..W/^?_U4=SGO^O\ D4 *.?QZX]:/
M?N.W]*3T.<]^A/K1C ^@QTS_ )[4 ._/ZTG3I^7K28'3 QT^[0/7^GYT +QZ
M]!U/:E[^ASQFF]![#_/X4>OOUXH 7';"CL/Z4IY['H>]-XZGTYQQ01[ _P#
M?\^] #CGUQV&*/<*.E-QS]/;WHXQT''^SCTH 7V(R??TH_'Z>])C  QW].*.
M_'7% #NI]>_(Z4G&WVQV/ I,=OYBCOGI^= #CR2#S[4F??VSVI,<=,_A_GWH
M^AY['/K0 O'<''/O2]_Y\4W&.@_3\J48R,=,]?PH #R<<=?6DS[_ ,_\_A2G
MDX.<'Z4<^_'/- "=NH]>N:.AQQU[TO)ZY//MC_/^%)SC'/\ GU_.@ Z=>@/>
MCCZ]O_K4=_?_ #S1GKG/OS0 #IGK^?K1D =NG]['^>E+SGGU'/:CG'\73VH
M3H<<?X_YXYH';!^G/^>U'?CWI?S]<CTH 0$#G@8_E1[9 _'^GY?G1R!W&!^7
M^?>EYSC)_.@!...!],Y].U'ITY'K_7OWI1G/?_)I/PZ^W6@#-\0:3_;OA^^T
MHS>0;J(Q^9MW;2>^W//;O7+S>"?$+R7DX\88N+V!;>Y9M,CVLBAL  'C&]OS
MKNATX)Z9XQ_G_P#51^&.P'3MTH JZ99C3-)LK!7WBU@CA#G +;5 Z>^!^=<?
M>>!-9GGOEM/%"6UE=W_V[[.;!9"LFY6^\6R<%1^72NZ)XSDXZ_A2\^^?48H
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MTF)2/)?3F9P,9)'F[??H3[<UW?Y]?7_/I0 AYSQ^&?I1D<G/7/?%'\^.M Z
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ML8 .YL@#CJ>IK7DW N3"3PV)!V&!Q['MQ0 DH;;M,X&<G?D^HXS]>?\ ZU/
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MMD<C_&I;2'Q5<V<%Q_;6F+YL:OM_LU^,@''^M[4 4;7PCKMA:6]K9>);98(
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M]>.F/\]Z."><')Z9^M'Z_GS0 9S^?>CL1ZCGCD_Y]Z/J>@Q_G\J,^O\ ,\4
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MU:DR.Y'O\W^??\J!C/)'O@T .YSW_3_/_P"JF_CTZ4I'S<_R_K32?4_KCUH
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M9^;)-E-C)[;#0!PWACQ4UK86ID\'>(+B>8^9<ZB+82^9(?O.#G)7/  Z# '
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M$7V>[FF$Y$+6RHVR0H0N\,",$_Q<;>N>*V_"R%/#-BK0R0OY9WQRX)#%CG.
M!@DDC '% &Q[<]^]+D]<]??K2=?SR>*.H^HYXS0 =L=NG7C_ #_A2\\9[4G7
MZ_3G_P"M2_3'U H 3D#G( '2EYSW_#%)VX'TPOM1QGC!]\9].] !VQT[=>GM
M^M&>O/;- [8'TX_^M1Z?AV_^M0 O.3C(SUI/7M^- _#\J.W'8>G\J %(.>C?
MI1R>_7H128YX _[Y_P ^@HX/]>.<4 !SC_/X4HZY[9-)]>_'3UI0><]Z  ?>
MQ_6D)^;N/QIW.[OBFGA_3_(H .OH?Q_K0<?7(X[YH&< \]*.<CUX_.@ X]CS
M^?\ G-&>.H]?O4=N_IU^O'UI><]_PQ0 G?J.OKG_ #_^NC( X/';)Q2\X_B_
M'_ZU)GT)/XCG_/\ 6@ ]>?\ QX_Y'2EYZ_CWI.?4]Z#CGM[F@ ZC'7MUS1P?
M3G\?_P!8YI>XSG\:/SH 3O\ X_6@8QS^(]>/YT8[?AQ1GU/OR: #\N>#_G]*
M/?CZTO/N<=:3Z^^3F@ ]OY]1_G/6CC'\/Y\=/UHY_'N,_P"?2EYSW[XH 3OC
M_'UHXQVY]/Z?GUH/^>?_ *]+SC^>#UH 0^O&/7Z4>HZCO]/I1U(Z\]#Q1]>W
M)_\ U4 *.O7\CG_/>O*O!9+_ !%\1J)#_JY\#8" /M!R0??I[8KU3''/0>IX
M[5XUH+ZP?'WB'^Q);"6=6G,D-Z'547[1V*<Y/OGI0!ZGO18P=K;%R"H;DX48
M_(<?6GNZAF'\6&R0>P ZCZ''UKF&E\>!C(T/AC.W#,9;CCD9 X[4OF^/M[X@
M\+\$E@)ISCOD\?3\Z #Q?>B[TC5/#ME'/=:I<V#A;:W7=Y>_A6D;HH/N>QX-
M="%40B,AMRQA9'S\KXV@X[?_ *C7%G2_'\5S>W5M>Z/;37<GFMB4L@;:J<AH
MLD#8._&:[G!0#<8PHQ\H)&QL]?PR?SH XK4XUO/BK86,DURL+Z0\K?9KEXBY
M61L;BI!ZDD=JZ_3X+>QLTLK8;((%2-1YA(QGU.22>M<K-@?%VU"+C&DMWSNY
M;'Y=/QKKD9 -H*H$VD*& V<\?SQWH JWVGV>JQ0Q7D<W#J\?E2-&\;#(!#*0
M<\GTX)I=/L[/2K26*W63RVF$LC-.\C.QP,[F))^Z./0#Z5>4L-H,H+'!?_;Z
MC(_E^51IYC*%(^[A@S9P@P<Y_#B@!5*B2+!92?N]/D7:>OZ_F*C4A(V 5\*<
M$;O]GC'T_G61#XC.ISQ0Z#$EU)Y0FNI[C?%'"A VG:5RQ<#( P"!G/K@^$[>
M_P#$OA>SUF\\3:U;R32S%HX)D"!1(P"CY">,#UZ&@#=U&6^OO$PT6.\:QM6T
MUKAY8%'G$[PFT,V=O&.<9ST-:UK!;V-C:VEM 8;6!!''&N,@ #GW_P 36#_P
MB$;W8NF\2:\;H1>49A<QAPA(;'$?3//Y=J@\%75](VOVEUJ=U>+8ZB;>*:Z8
M%MH7U '?F@#.T69G^*5R&.29Y0"H.TA?/'YC@'WS7I?M[],Y_P ]J\GT#RO^
M%LSL+R-IC>W:M:JN&10),,3GGDG\Z]9YP,YXH 08X[]/>CMGMC/7/I69XAU?
M^P=!NM2: S^2%Q&'V[F9@HY[#+>G:N;M[?Q]KL:7$^I:=H5K(-XBM(?M$VTK
MW=OES] : .XY[ ^W)I...AZ8/K7%)X&U802B3QUKIF(&QE9 %]R"#GUZBF?V
M)X^TF/.G>)[350B@"'4K783SR=Z'.>.__P!>@#N/\_Y^M''0>O8GVKG?!WB2
M?Q)IL\MU9K:W-K,89424R*6 !)!P#CD_E71<X[\>_ Z4 >??%8;K3P[GF,ZJ
MGF=#\FUMWX8S^%=UJ'D_V;=?:H_-M_)?S8SC#K@Y'..HKBOB> R>'E,FS.J+
MSP?X&XY]>G3O73>*IHX/"FK2."5%M(IQUY&,?2@#SS0M&^'^JFQN;ZZT-;]V
M\X65I)&D:94_NR.K8!R23]Y<\=*[&7PYX*FAMQ<V>G3JBE86N)!(<%B2 S$D
M\D]ZK>$?"WA^Z\(Z7-<Z'ITTKP*SO);(Q8^I)'-3>+= T0>%[ZZ;1M.DEM;1
MQ 3;J?+ZGY>..3GCN: -73=,T&'2)[+2[:R_LZ4L)8K?:T;D@!L@<<CBLB/P
MGX!D=8X])T9F;A54(2?H :E\!6%I;^"[(P6L,7VE"\Y2,+YK$D9;'4XQ^0K,
M\4^&M!TN#1KC3]&L+2=-8M LD%NB,/W@'4#TH W;;P3X7L[J&[M=!LH;B!P\
M<B1 %&'0\5OCK@8X]#0>I_E2=0#DGTZ?Y_\ UT >7>!M0'VZ**]G,=HL$N8K
MA(EA7#1^5L.,Y(,A/)]Z[[[9H1Y-QIA'<AX_\:<?#^B,Y+:-IY).<FV3)_2C
M_A'=#_Z FG_^ L?^% '$^*[^+^U)H[:\*VK69!2%(C;MF.;?O?&0V0F.1V]:
M[S2@XT:Q$H(D^SQA@>,':/ZU#_PCVAC!_L33Q_VZQ_X5H_3CMQ^5 ' 6 )^.
M.K,X'EKIR%">S?+G],_E7?CKC.#]>?\ Z]<'IZ(_QKU@ELLFGQE5P/ER%&1_
M*N]^O3T/O0 F>.P_'&.*._7K[T<].<^V*#U_SZ\4 &<]UY]\T'ISQCU[<4I]
MR1]3VI.?3GZ4 </\0K*"=]-B%I$\U[/Y4CBVAEE*(CN,&4A!@D]3T)Q72^'H
M5M_#]C JLJQP*H!5%.![1Y7I_=)%<]\1(I+BVTJVCCM9M]T6,-P8@9-JDX4R
M J.,YZ'%=!X<@FMO#EA!.L"RK",K;A?+7N NWC ! R!B@#4]^M'?Z<=:7WYQ
MS[TAR/;OUH ,C;VZ?WL4'IGCOW^OY4N3D]>/3'^?_P!=)]<^@)Q_G_\ 70 '
MK@_S^M&<GJ!^/]/RHZ<X.3]/\_\ ZJ7MC)ZXH 3CVZ_Y_G1_G_/UI1G/?_)I
M![?E0 'D_3\_\]:.N.G\_3_.:7GCK[4F> <\8SU_^O0  _C]&)]/\_\ ZZ,@
M=QQ[X_STI>>^?TH&>.#^E "=.>/SI1UQG]:3\\]^>>E+SGO[T &/FSC/O2'A
M_3_(I<?-_P#6^M(3RV#C\10 @QC.!TSZ_P"?_K4N.WT'3_ZU'ICZCBC\,^G'
M6@ ]_P#/7BC [ ?ETHQ]?R_.CK[Y]O\ /% !@>G'/;M1R!\WXY_6C_.<?YYH
M QT&#]* #L<C/!_&CO\ CS1^'IVH[>F!^7K0 ?08/?IFCMP/T]^E&,\8_2CK
MUYS[?2@ ..?QZ_K1ZG\^?\\T>_X]*7\_3_)H 3KU&?Y4?X]>/\YH[YXSCTHQ
M^G% !VSCC]*/7/XY_K1WR?;G%';_  'U_6@ [].O4 ]*.N,\_E^E&1[$=OYT
M?X^G\Z #J,]<]>1S_GI1[<9S^'^<T?G]/Z4'I_\ 6H  !G@8_P __6KS'P@
MGQ#\1#S2O[J1RI'0-<-SD9X.. >>O7->G]QQT)XKS#P8US/X]\4-)<6[Q0*T
M210DED!F8C?C^(8/YT =[D8VM"3DL#&2<GW_ )K3VSO88. #ND .,9'&.F2.
M*81E')DW$$EGP1C@<?UISG$C9<*,,2N22.0=WX9SQZT +SA1]X=T (S\V,\#
MO_2FOC,@*9/\3C^+GH/KQ^5#;<!S*5.3N?![,/Y<]?Y4YLJ"2ZXR2$_N_-G/
MX?UH XZ1A_PN"V&[<PTO<"<G(^;UKL48;6S\V-N9,DA^3Z?G_G-</KD^IZ3X
MY35H-%N;^V;3_*5XRX56!<D956.>,8(_BK6C\3:BD(D;P7KXSA@@:$[3VP-^
M>^.GUH Z&($>26CX!7]V1R@.>?SYYKA/#V@VVN6^KWFH3ZH\HU>ZAC5-1GC7
M8KX&T*V..>@_E6I=^*=2MHDV^#=;+!@,S&/9WP6,9=NG'"GMTJ3P5AO#]S)C
M#2:I=ODD_(3*WR_GP1ZYH V;'3;*P*_9+98RT<<+,"Q94C0A QSV&1^-1Z5I
MEGHNDQ:=I]NT=K%O*0%V8Y.6)R>3R?UJ^N1*I\T<#..<M\O7_/I22*75AYV6
M4_?.0%X''X\&@!, /\B[<<,P7A< ?+Z9P<?Y-<AX*&W4/%C$%P^LL?3<,8_H
M1QQQ78Y#2##@*V> 3DY (;T]^*XO0M=TRPNO$"2W,L,KZM-N(@E?D8[A2!]*
M ,3P_P#\EFNN/^7BX[]/];7KN.. /3\J\=\*%[KXNW=WP;9[JZ6(-&RN<!CG
MYAC'SD8ZY["O8OU^H- '->/UW^"=04$*6,6">/\ EJI_QK<T[G2[,^L"<<?W
M?YUA^/\ CP-J;;0V$7AAP?F7K6WI@_XE-F.O[B,'C_9H M?XGH?K2CD]0>])
MR3GOBC\^V,T >>?#[4]-L+35TO-0M;>;^TI 8YIU1P1@=&Y'ZUV/_"0Z%T_M
MG3L?]?2<?K3I]!T6ZG>>XT>PFF<_-));(6;CN2,U'_PC7A__ * 6F=,_\>D?
M^% '&_$'4['43H$=C?6]U+'J D=+=UE(4*020#P.>O05V7B2VN+GPWJ5O9Q[
MKB2!Q&B@98D=,$XY]37,>-=#TZQ@TR>Q?2]& O-LLS6J!2&1AS@KZ#_(KIO#
MU[>7VB17FI*B22%F!6,Q QY.QBI)*Y7!P3QD4 <IIWB>_P##'AS3K/4?"VII
MY2+ )/-@VN^"0!\^<G!QQ5K6]8UO5=#OM/B\(:LDMS"T2N\EO@$C'.).E98M
M]%@6*U\7:AJ;S0W2^3++>S207+;OD<;20"1U4XQSVYKTOG@G/TH \^\)^(-3
MM?"VGPP^%-6GC6'"RQO %89/(!?/YT[Q!J6N:O;V,4/@_54^SW\%TVZ2#[L;
MAB!B3J<5OCP1X:4G;IBJ">0)' Y)[;O6LOQ+X3T*R\+:M=V]AY<\%G+)&PED
M^5@A(/WO84 5+CQOKQULVMMX7O L7E>;;.FZ5PY;)#HQC0 +GYB,\UK_ /"3
MZMU/@O63_P!M+?\ ^.5/H^?^$NUSU^S6?7Z25T.3_D4 <?!XWO;B[NK:'PCK
M#SVK*LZ!X 4++N&?WF#E2#4__"3ZL/\ F2]9]/\ 66_'_D2G:!_R.GB\_P#3
M>USQ_P!,%KI^?4]/2@#D(?&E]/=W-M%X/U=IK8HLRB2 ;"R[A_RT[C'2I_\
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MCTYK&\6@MX,UM4&6-A, %.?X#T%:,NH65M:+=S7MO%:L 5G>51&0>F&/'-6
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MG^?>CC'8?CTXHP<8ZXXX_P#KTN>1SGGB@!._3TX-'&.O;K0.W^-+S[^V3WH
MXSQ])>J=*^P3RFX$Y=;2-9F$^W#9/EC/RXZ'@[NAKH]$22+0K%9VD:40H7:5
M65LXR<AN1CWKC/B&9+_4=+L8["XN9(C)*L3V[O#."F"<HZMN7_V:NP\/R13>
M&],D@55B:UC*!0RC!7H WS#\3GWH TN._P#G_P#701[>U&??\J.,\@=<$<4
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M.0_3Z=!TI J^:Q4XEQAU_A4;N<>_^- "H3^[(521MR-OW1D\CT/?\*$W;/\
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M6;KQ5J6C:S'IJK91;FEM!(.<(3][MB3\Q573=-U7Q'XIL?$]Z-/&FQB9+>)
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MD9YZ9Z48]R.PS0 G^?\ /UHS[^O^>M+CL/P&:#WY/Y4 )Q^6/_U4=/\ /O\
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M<_Y^E(?&?A$LS#Q'I@4C+ W*],\XZ8- &K>V5MJ"QPWMG:W4288QS1*ZKUY
M.1G;GI5D!C_#'M(79P!Z^_H16"OC+PF6C3_A)=,W1D'_ (^$R.?7Z^E21^*_
M"\BX77]+;S/F8&[C'3.2,GCDX^E &K+:07T8MKR"WN(CM,D,D:L@(';/IQ^M
M>?>&/'6G^'K&\TVZLKM[B._NG(MEC* -,^!C>/RKKH/%OAEC R^)-**\;?\
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M32>_\AT_^O0.N./H&_SZ&@!?48X],49_ ]OY4@P>/_U__6ZT=>_7T)]O\YH
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M1RS>9^OZ5J'5OB*"0=&TA@.XD'7OUE[4 =R9HE;!D4$'D%A_C7)?#XC[/KI
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M)Y_$X--&-Q&PA@07<Y ?D]#CU&: )69_,C_TA" %WC/7K_,4@R%4DA6R",,
M%R"/UZ5$R_/#\H(!7 !Y4\G)!Z\\\U(!B%AMZ8W<_>/7(./J?QH JW^D6FMP
M1VM^#)&KK(?+F:-M^TC(*X/()!]0361X'0?\(;9I'A&%S= '. H\Z3_ZU=%
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M--;UE+Z\M)_$=])*DEU%;QQ6\/F3R1.BJJKY9)SOY],9Z4 7/"A_XNSXL^\
M!U+\'_5]!VQW_#\/1L=L#'T_#^5>:^ K:>'QWXF-]=)<WT85)Y$)&23GI@ ?
M*%Z>G.*]*[G\?>@ ]SGGOC'^?QHY[#N<<4=._MQ_GD\4<=,#TQ_2@!?SQ^-)
M]?Y>]&1CDCIUSBCO^/K[T <+XGU_5O#^MEI++2KJSDC9K8RM()D ";LA$<[0
MW).,<CTY[2UF%Q9P3YC/F1J^8\LO(S\I[BN5\4R:=>7R126/B"6>V1HVGTR*
M10$;!9"_ 8$!3@9.1ZUT.BSVLVCV_P!BBGAMXE\F..XC>-T"?+A@W/;K0!?Y
M&<9'X4<]AW..*#@9_'V_SUH(YZ#GU/7K0 '\?0<?Y]*.OOGV[4''//K_ /KH
M)Y]/7GZ4 'O^/2@]QCV]<T=^V?3\:..<8/?C_/O0 >X^O2E[]^#Q[4G7C/7/
M>C@\?I_];\: #''3MZ?_ %NW:@]\]\]O\YH[]NO?]*/_ -77\* #O_B/>@=O
MP_A/^?\ /M1GN3P??\:,@=Q_WU_GT- !^'8=!VI1G/O]*3MU'YYQQ2C&0>F3
M_G]: #^*FG /7OCKVQ3N-_Z]*9WX_G0 9_#/O^?^?\*><^_7\Z;_ !#KD_Y_
MS]:49SG'/T_K0 >OKG']:/\ (P?K0.F.W _#Z4=>O<<]* #_ ",'ZT?C^1^M
M'7KWZ\4HSG///M0 <^A_.COW]_6D !'0>GW:/3/3Z8H .0.3]>:7GL#U[8_S
M_P#KI!USQ_WS_GU-'4=NG]W/K0 >P_GCBC/J??DT'OGOGM_G-'<X.#]* #D\
M?3KV]Z/7^6?\\T=OUZ?THZ'Z=/\ "@!><G]:3!Z<^M'8'@CMQ_*C Z8X'7Y:
M %_/KTI!G QQGBC'J/KQ1^6>O(_S[4 +SD=>O>CG_:_2DXSZ?A0 ..!_WS]/
M\_\ ZJ %7T]O_P!5>3_"0".3Q#F16!:!N%VE,^9QQUQUS[UZN"..G8_G7E/P
MI<,==*R*V/("@#/.9!M/U.?\B@#T9L _+)@*3\^?]KD8/I_6D'$AR=NT#Y!G
MY 6/.3Z=./Y4+N;!\D>8O('9!NX..G/]*4!D8 HJ@G )SE^>!U],_P Z $3!
ME3#XVA3YG/S<G..WMSZ^]*F1@EL]/D/_ "S'(]>O5:0?ZU&V_-QP5X0<D?CC
MFG;?EW"%0I((X/S\]^_3GZT *2/W0\XL!@8*GY^O'ISTK'UOPU;^(["WM[B6
M2+R7+9C19.6C*G(=2.C$9QD$#FMCE6C/EIE0 ?E.8Q@YY_*N9\4VT=Y=^&[%
MI+B*WN=19)1!.\+.!!(P!*D'J!^5 '3K&X*$+)B+  /5P%Z]._X=*XRUTBRN
M_%X%CH(TZ/2K@W%U<,N)+ECNV>6JD@HQW,2?[N,5HKX,T)P2'U3Y?O?\3:XX
M(Z@_/VJ*U^'7ANUXM;6]MS(1YABU"=,^YPW.#QSZT =.H"DY)0@, -IY_P!K
M\^>/6D196Y5GXS^\VGN0,?S->=^%/^$CL-%6^C=[W3$O[H20;Y)[@Q[S&#@G
MY@FS.T$D@G'/!V-/T33?$;W^J3MJ;"6[D$6R[N;=?+7 &$R,?E0!UZ1N&4E#
MPV-F#@#=U^OT]:Y#X3Y_X1:^.#_R%KKM_MU>'@?1?,*N=50;L*W]JW.#SC^_
MUK/^$T?E^$;I #M&IW04GDD!\9SW/'OTH SO"$<ME\5M<TAYA-%9P2S1.(%5
MB9Y$D8,PZX. ,^]>G<Y[_P"37F?AJ6&X^.7B::&=9$-E&H,;!E; C!Y![$8_
M.O2P!QP/^^?I_G_]5  /;\J7GC)(^N*3MV_$<4#KD#]/\^M "\X[T<]3G@^E
M(/\ ) Y'^>:.AZ=/:@ ^IZ=LT=N>>QR>^*!P.#VP.*.G3\./I0!P'CO'_":^
M# 23FXD 7&<_/#UX/'?IU Z5W_7/\JX3QOL'CCP8K, &GD4(5)W'=$>W3IG)
MXX]Z[SOTZ'/ H 3J.YXXY'^?_P!='7C/7CJ#1ZCU_7_/]*/?GIZ4 +WZ4@_(
M&@CKQZ]J.^1W[X_S[?E0 =OP]._;M1WZ],D=Z,9[=?;M_G^5+R?7F@ YR!^'
M6D]^GKF@>P_3'%'N!]./\_Y- %=M1LHI"CWD"N#\RM*H(^HKG_!2J?[?? +?
MVW= -C/&5KSWQ=\//$6KZQJSVFD6ACN;PS+<DQ%Y5(4!2S'*@%3P!_$>M>B>
M"L>5KHV@8UFX!Y)R?EH R?"+@_$7QBH?)$T9*]=ORC^>/TKO.<=^?U_^O7 ^
M$6S\2O&2E0=LD9#8/=>G_CHZ>M=]W/'TXQWH #WYR,=<_6@]SSW[]J!U_P 1
M^M'TY_#OB@!><]_PI.?J>M!P.<=/4?U_#^5'3Z#V_P _Y% 'D_C/2VO_ !+J
M<MM;7%ZMK&CW(>)&AB!B/RD-*I9,?.% X< Y/2O2]($7]B6'V>5YHOLL?ERR
M#YG&T88^Y')KC?$'A.[U+6]5U>[32Y(+=4%K#J%LLD;QK&"VYEPZ_,&Y.[I]
MVNUTRZ@O],M;FW>WDADB4JUNX>,CC(4]U'3I0!:/?MU[XH[G'?- ^O4_3G%'
MK[Y[4 +TXY':D_I^E'?I^0QZ_P"?_P!= ZCV]J %YQWX["D/IR3[XH].,^F1
MG_/2C'48X^G% "]>.<'\?6CDC^+'M_G_ #FDZ_CZJ?\ /^31WR /^^?\^O\
M.@ [^G/8T=!W&!SSVHZ# /;'3%'0],?A0 O//7/M1S_M?I2?7^7O0 ..!_WS
M]/\ /_ZJ %SR.<\\4#L1DY%)Z'Z"EQS[Y]* #^+GUIG<\\Y_S_G-/_B_^O\
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M<<<_2C\\?7M1T)[=>W^<T8YZ8QZ#I0 O).<'@^W^?_UT<]LGUI/3OCV^E&.
M,<>F* %[]3_C2=,=L?3 H'U]SQ1QCICCKC% "\X&21^5 SGO_DTG0Y[^_P#G
MZ48XQ_-: #)QU/X^M+SGO^E(?7V_+UI1][H.O]WZ_P"?_P!= !_%^/KFF''5
M<<=.?\_Y^M/[\D\\=:9R2?\ /K0 [H.N.O)/_P!>CCI@>F/Z4T'IS^OT]Z><
M^_Y]>M "9[Y'U/XT?YZ\_P">:,^_OUXHYZ9]NM !U_'OG'^>]!]2?QZ49'U'
MIFCOC)Y^E !W_P#K^] QQ_3\/\XH['/X@G^='/3G_.* #/?^N:.^!C_OK_/I
M_.EZ\\\]_6DR<9Y/I_D4 &/3M[?Y[T=__K^]'09].<TO(./Y?6@!.W4?7.<<
M4=^G7_/]*.?0YHY_'\LT &1Z\>['_/:CT_+KFEY_VOTI#UY^G./6@ ZC_P#7
MQFC/OU]/Y_RI><C/7\*/SH 08XZ>W/TZ4=B/;I_GU^E&2!UYX[]Z. /8'\J
M#@'.?7FO'?A]HRZBNM317^JZ9Y=RHD2RN457)!^;[I]O?K[5Z_-_Q[R?[A[]
M./\ Z]>7_",%+#6&\K86N(=CD]_+QD]>_% '2?\ ",N6 'B?Q*5)ZB[0GK@G
MA*3_ (1I\,#XG\2 K_T^I@G..NSUK>"[77+YSC+9R'YX''7 ./J:D#.A'[Q0
MN0$!8'!R>O\ GK0!SP\-.67/B?Q*-P&/],0GG/&-G^>O:@^&7Z?\)/XDR"!_
MQ^)WS_L>H_+FNB7)E4-(&/ 8@_>Z]/P_E4<;2+\LCIP%"X;@'!Z^^,#ZB@#
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MYSCW)X[5V_0]!]/Y5E>']#M= TZ2UM'F9))FF9II0[$GCD@>P_QK5^G?..U
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M][Z_Y_\ U4<GIGK0,DYYQ^% !CYO3/''^?K28Y]2"*7^+_ZU(<Y/&>?_ *]
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M38 \;,&8Y7=ST_ECC_\ 72NS99BX(7<=O.<XZ_3OQ37=\*!)M8E@'.<=A_\
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M)_PI<X;J/^^OI2'KG^E "<X&?KS_ )_SBG<YX'?H*0\#CZ9S_GTHR-W7\<T
M+]..W I,^I_SWH YQ@?GTZ4=NO\ ];OS0 O/ZY/%)S@C/(%''Y^_^?6CO_\
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MFDW3B5+:YMDGCA48^558X!Z_-C/-=QGG)Q[T +D^_P#GKVHYSWI.._\ G_\
M71WZ=^GK0  ]/08'I1SZGF@=..P]?Z4?KS]: #MW]>AI>>WZ#'>D'('?\<T<
M8YP/Q]OYT +DYY[<^O:DYQCG_/%'3KQZ\_G_ /KH/K_GK0 O^3P:3)QGV[T<
M8[=^_P#G%'&>W4XH 7GU/Y49/;-)P#UZ>K'_ #VHQ[>G<_SH 7GH"?3H: 2<
M'L>12#IQV'8_T_"E'WNW7U^O^<4 '\7)/Z?Y_P#U4TG&<=N,@4[^+CC)]/\
M/O28)P>3CU_SUH 3O^/7\?\ Z].YQ_%_G_/Z4@[#N..E&.. .G]WVH 7'/3C
M-)S[Y_#-'?.,YYSC_/M^5&..@Z>E  >O^?7BE[_CZT=_Q]/>D';Z=L4 'IQC
MTSCBEYQ_%TI.,=,<=<8HQSTY]Q_7\!0 N<D<TG7'?/OG_(H[_ES1VY^IX^E
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M<G_]5&>.&/3(Z>]''<^O_P"N@ [_ (_X=J!Z?T]Z.?\ ZV?\]Z.F0.W3^E
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M_#TH_'(!Y]*,_CB@ X/H<^^:,\9_D<_Y_P#U49/3=^O^?\FC//7KZGWH /\
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M>_OUHZCKGTS_ )ZT=_I[T '<=/Q/X4#L0><>O7_/-&?]K\B/\]Z,^_O@'\Z
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M//?OVH !TSU_/UHR-O;I_>Q2\YYZ_P">E S@=<>Q!]* $)'/(_[Z^O\ G_\
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M]: #MGI[YZ?YQ1QGGCZG'^>U!]3[Y(/^<4HSG^=  >#T'_?/^??\Z3V_S_\
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M]?>C(Y&1^=!Z_P"?7BE.>>3[=* $R >W7N<?YZ?I1]WT_/'K2\]LXS2#MB@
M/'^?>CZ<],'F@=B/3MUH^G7^O2@ '8Y'UHX]O;G'^?\ Z]'X]CU/:E).3UP/
M_K4 )QUR/7/]:4=<?3KS2'([_K^5'K^(Y- !Z9'7'7^5';MSS_7_ !I1G/'K
MS2=Q^'6@ [8Z]J./\\?Y-'! )Y&.^.] SQSS]?SH ._^)]Z,],]O7M2C/^U^
ME)T]AC/7'% !V^GOG%&<GK[<'_/I_.CG'.<XXS^%+SSP?TH 3O\ _7]Z.H['
MC^]GTI>G'([4<D<[OTH 3/T/7OUH/?..G<T?GZX!^M'?&3S]* #COCK_ (T>
MG/ZY]J49R#SC/K_G_(I/?_/7B@ [8X^GX=,4'J><=>?ZTIZXYYXZXI._'O0
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M:4]>O?\ *D[=A_3C]* #T[9]L4<$]!_WS_GU_G0>I_'M1G!ZC_OKZ_Y__50
M=1DC\US2_P"//K2< _\ U^?\]:.!VZ?_ %J #J.>?J,^M![_ (]031W^G&?6
MCH.?QY([4 +SD_7TI,>WMTZ=J#CGI_/U_/Z4''/3\_KWH !USW[\4#M].V*.
M_KSZY[T9X['CUZT 'IQ]/E^E'X=AT':CCVZ^O7I1U ]^G.>U  ??TZ_SH/.?
M?VHXZ_Y_R:.^,_\ CWU_S_\ JH "!SP/^^?K_G_]=+[^YSBD[=A^/3B@X_\
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M_/M1T'I[XQ1G)SQSBCMU XZ_U]^E !TZ=O8_Y-'K[>O-''?_ .O]*/KZ^N:
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MR;:)XK9FE76(%E9..255MN,@;<=?4<>AZ58.F^(9]/O+*YOH6>21)(+E&(9
M&4[" !V4\]\UTAXY_ICO1Q@C@X[4 <]I5AXFMK\OJ.HV]W; 811\K=<Y.% )
M].F/?K70X&>F">^/K_\ 7H)YZ]*,XZ$>W.!0 ?IW'%'!_(8SVHXQV/T/^>:7
M/.<]_P #0 G/)Q^E+^?_ -:D[=O\_P J.^./\Y_+ZT +S@Y_'BD[\@<]>/\
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M]Z7GUYSBDZ=!T]%I?;GJ* $YQQGIVQ2\_P"U^E)U'8\<_+GUH('/ _[Y^O\
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MM^GY4#'K_C_GF@8XZ>W/TZ4 '3U]N3_D_P#ZZ, =N_?CUH''']<=Z!U'X=Z
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M** $SSC/?']?Y4#VSQQQVHHH 7!Z4G7.!^5%% "G@$G.!SS2'C(Z'Z_@***
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5]J** %Y]_P * ".V/I_GI110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g201708092014008133362.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201708092014008133362.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,G G # 2(  A$! Q$!_\0
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M;A33G&3GISS2\Y/7'>@!=PHW"F\]_P"=!SC)STYYH =N%&X4G.3UQWI.>_\
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MT'UY'O\ G0  ],$?G0.!U'';-'MU]11SCC/(SUH /3D>@- /3!'YT'UY'O\
MG1[=?44  X'4<=LT>G(] :.<<9Y&>M!]>1[_ )T  /3!'YT#@=1QVS1[=?44
M<XXSR,]: #TY'H#0#TP1^=!]>1[_ )T>W7U%  .!U'';-'IR/0&CG'&>1GK0
M?7D>_P"=  #TP1^= X'4<=LT>W7U%'..,\C/6@ ].1Z T ],$?G0?7D>_P"=
M'MU]10 #@=1QVS1Z<CT!HYQQGD9ZT'UY'O\ G0  ],$?G0.!U'';-'MU]11S
MCC/(SUH /3D>@- /3!'YT'UY'O\ G1[=?44  X'4<=LT>G(] :.<<9Y&>M!]
M>1[_ )T  /3!'YT#@=1QVS1[=?44<XXSR,]: #TY'H#0#TP1^=!]>1[_ )T>
MW7U%  .!U'';-'IR/0&CG'&>1GK0?7D>_P"=  #TP1^= X'4<=LT>W7U%'..
M,\C/6@ ].1Z T ],$?G0?7D>_P"='MU]10 #@=1QVS1Z<CT!HYQQGD9ZT'UY
M'O\ G0 9XZCZYH..G'X_Y^E*.HZ@YI.WIW//^?\ (H ,^AZ@XY_^O1P>>,?7
M_..*.>A..?6@Y/L30 =3@]^Q/^?>CC/8?C_GVI>3R,\],8H'!X!XH #R3QU/
M7%)VR1^8S2D<]._]*3O_ $SS_GI0 8_V?T_S_DT?J?I1].>!_P#6H[]/\_YS
M0 =Q]:.WH??C_//\Z!TX^G!_SCM1GCCC_P#5Z4 '?/ZX_P ^E&#CI]..E'';
M''O1Z=.<=Z #OG\?>CICU'M1Q_\ 6SS1QC/&,=NE !CMC/X4>_'_ 'S_ )]Z
M._8\_P"?Z4?YZD9_SS0 <X]?PHZ]L]^1_GZ4?E_D_P"?I1VXP?QS_GM0 =#G
M ^NW_/O^='./7\*.,]L9H_G_ %H .O;/?D?Y^E'0YP/KM_S[_G1VXP?QS_GM
M1QGMC- !SCU_"CKVSWY'^?I1_/\ K1VXP?QS_GM0 =#G ^NW_/O^='./7\*.
M,]L9H_G_ %H .O;/?D?Y^E'0YP/KM_S[_G1VXP?QS_GM1QGMC- !SCU_"CKV
MSWY'^?I1_/\ K1VXP?QS_GM0 =#G ^NW_/O^='./7\*.,]L9H_G_ %H .O;/
M?D?Y^E'0YP/KM_S[_G1VXP?QS_GM1QGMC- !SCU_"CKVSWY'^?I1_/\ K1VX
MP?QS_GM0 =#G ^NW_/O^='./7\*.,]L9H_G_ %H .O;/?D?Y^E'0YP/KM_S[
M_G1VXP?QS_GM1QGMC- !SCU_"CKVSWY'^?I1_/\ K1VXP?QS_GM0 =#G ^NW
M_/O^='./7\*.,]L9H_G_ %H .O;/?D?Y^E'0YP/KM_S[_G1VXP?QS_GM1QGM
MC- !SCU_"CKVSWY'^?I1_/\ K1VXP?QS_GM0 =#G ^NW_/O^='./7\*.,]L9
MH_G_ %H .O;/?D?Y^E'0YP/KM_S[_G1VXP?QS_GM1QGMC- !SCU_"CKVSWY'
M^?I1_/\ K1VXP?QS_GM0 =#G ^NW_/O^='./7\*.,]L9H_G_ %H .O;/?D?Y
M^E'0YP/KM_S[_G1VXP?QS_GM1QGMC- !SCU_"CKVSWY'^?I1_/\ K1VXP?QS
M_GM0 =#G ^NW_/O^='./7\*.,]L9H_G_ %H .O;/?D?Y^E'0YP/KM_S[_G1V
MXP?QS_GM1QGMC- !SCU_"CKVSWY'^?I1_/\ K1VXP?QS_GM0 =#G ^NW_/O^
M='./7\*.,]L9H_G_ %H .O;/?D?Y^E'0YP/KM_S[_G1VXP?QS_GM1QGMC- !
MSCU_"CKVSWY'^?I1_/\ K1VXP?QS_GM0 =#G ^NW_/O^='./7\*.,]L9H_G_
M %H .O;/?D?Y^E'<=.OIC_/?\Z.,=>/K_GM1G\_K_GTH .W3Z<4=_;/I1T_#
MO_GVH'7@ ?0_Y]Z  9]?RH^GL.E'![^P/^3Z4<'^E !UQQ^8Z4#&1TZ\<>U'
M'?'OG_/UH!]_\YH #U_'UH'L>/:EYSWI/3.<>M !UZ8SU_SQ0.O'\\4<]>?P
M]:.@X/&.H]* #MSSQW'_ -:C/&<Y'KFC'MZ4?4\^I_S_ )S0 <\9-'4'GMS[
M_I]*/SY]31GWR.WO_G^E "\Y[]?6DXQUZ<?A1CVSVZ4>^>W!./\ /_ZZ  GW
MQZ\].M&><GC\:7GMG\^E)GC//YT  SQSD_6CMR<<>I'^>]+SV/<BDZ=B,>U
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M'=%C-OJL;3W,EZ_G[4<'=Y>SY=Z@8&<&O08=--MJ]S>Q7<BQW"CS+8@%/,
M#CN"0 ".AP.]<-XKU^QBN6OYK&6V:SO%C-[')^\DCCF02)A""1AN <YYKIO#
M_C?1O$][+::9)<M+''YK>;;O&-N<<$CGDB@#HLFCZ4?2B@ HH_&B@ HHH_"@
M HHHH *._P!:/PHH XBPT;3]:\4>+H=2M4N(TOK=U#9!!^S1C.1[<5VO(ZYS
M7GR:_P#V#XK\6/\ 8Y+K=<QRN(W52D:6T6YOFZ_>' KT'&./PZ?Y]J #&/6C
MG/K^-'X#TZ4?GS[&@ 'U/4=31^?'^?\ /UH_+IC&/\^U''7CUZ?Y]J #V_#
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M.P8@$@9QP0?2J-OXB7[)JNFZ)IUS<V'V9I CW4/^C+@J0H\PL4Z$+CCD=P*
M/2%V[%VGY=HQSVK/\0/Y?AW4GSC%M)SNQCY3WK1&  !Q61XJ;;X2U9@V"+23
MGT^4T :HSL4<CY0*=D]L]J0#Y0,'ICI1_/Z4 '('?@=":.G'.!Z>E&/08].*
M._3]/\_Y% "\Y&?6D'3\N^,4?AT'I1CM^7'ZT ';G..]'?GZ\4'IGZ_Y_*E[
M_CZ4 )T&.?I1C_(X^M X'3&?;_/M^5'X>_3WH .2,\\C/%'X_KZ_C1CGIWZX
M_P ^WY4?CUH ,Y/I^-'7Z'WH[9]1Z9_6CZ_CQ0 <GKW]?\_YQ1R1QW'7ZT?S
M_P!W-!ZY([]Q[T !]<'\J.<<\?CQ1@8Z<=.GX4>^,>^/\^M ![8Z=N.*4=L=
M,=J3\/TH'8_S&?\ />@!3U/'\Q2>WOSQ0<9QD?G]*,\=?QS0 ?AR/;_/I1@9
MP1^G/^>OYT<=.,>QZ=J.OISUXH .<9YSC_/\Z,#I@8^E'7I@Y/K^-'TY].3_
M )]* #M[X]O\]:._3]/\_P"11QTSUZ<T<8R?K]: #'3_  [T8]L=.U'W>?2C
M Z9'H/Y4 ';//3CO1]![=*/?CUXH[]J #';^E9GB+<?#6J)$VV:2TE2+Y@N7
M*$ 9)ZY('XUI]NU4]5M].NM+N(]6AMYK (7F2= R;5YR0?3&?P% '(:;X:\2
MZ)HMA+H>M/YBVT?G:9JQ,T1?:,A9!\Z<Y[D>U=M;M.]K"]S&L<[(#)&IW!&Q
MR >_.1FO*&O[#38OM/AQ/%^C6"KY@F_LYY['9_>\I\L%QS\NVO2- EU&?2(I
MM3EL9I9/FCFL@PCDC(RK8;D$CG&2!0!J'Z?I]:.?U]*.GI10 >V#^(S1R><<
MGU'^?;\J /\ (S1WYY[GC^GY4 &/0#V^7_/M^5'X<8].U'0=N._;_/%'?I_G
M_.: #Z\^O%'US0 ,8QD=J4=>OOTQ_GM0!R?BJPTVPMX=12RB6XFU*T\R5(\N
M^9D_P'Y5UOTKSW7O%.Z6ZAN$MQ;6%]&Y$4FZ8".:,$LAP!G=D<\XKH?#_C/2
MO$MY+;:>;CS(D\QO-A*<9QP3]10!T-%'X4E "T?C110 4444 'X44?A10 4=
MZR]=U^P\.V27FHO*L+RB)3%"TC%B"0,*">@-9-M\0O#UU!+-')?;8N6SITX[
M9_N>E %/3='T[5O%GBM=0LH;H17T#()%SM)MXZ[3J?PKRFP\<0PZSXBU+38H
MYK>ZN5D'VMFMV/EP1 J 1G<2> <=*]6([<4 '^>E&/;]/SH_*C_/^% !VYSZ
M]*.??\J./;\ZIZO(\.E7,D3%75<J1U'(H N$=_Z4?A^E+P/SI/RH XSQWH6G
MIX<UC4+>V1;^Y,*R3$DD_O8_7IT'0=J[0]<?EQ7&>--;L7TJZTZ"Y'VQ)X 8
MVC< XEC) ;&"1N' SC-=F>IZ4 )^'Z4>_P#2CM1Q[4 'X=..E8OC!%?P;K(;
M)!LY#U_V?\_E6U6)XPE6/P=K!+8S:NJ^[$8 'J23Q0!!X!C$/@G3HP-JKY@4
M#L/,;'Z5!I,,;>/M>D*JSB.#!*CY2 >_K65X'\8>&K/P;IMO<Z_803(C;H9[
MA%DCRQ(5AG@@4W2O%OAR/QGKEW)KVF)!*D*QR&Z0!R <XYYQ0!T^M:9J-UJF
MFWVFRVL<MJLT;&X5B '"C( ZD;>F16'JVE1Z?JGA*U65Y?)NI&:23EI')#%C
MVR6)-:__  G'A3K_ ,))I7_@6G^-86L^)-%U/Q)X9&GZI9WC"[9#Y$ZN5)VX
MR ?8_E0!W!MK=F+&"$L3R2HR:YG6[>W76Y<%;=#HET&D2+=M&Z/G ^]CT[UU
M=<?K]O=:KJVI06L)9K?27B^\ 7DD9610,^D9&3CK0!N:#JBZGI%M*\\$MUY2
M?:%@8?(Y R" 3M/L>E9/C34[?^P;VQCO(1,P5;F-<2210$@2/L!SPISFH'T>
M>Z\+Z5?Z,@MM7%O"BS+M4^6^T.&Z!L*21Z$ C/>IXJT@65O:6.DZ;),\]K=V
MX$97<SNB_,[,03T))R30!W0 V@#IC'(H_P ]*!PH'' QU]J.!GI0 8Z\?7BC
M'/0=>N/\^WY4=,]NOX5GZEKFDZ. -1U"UM<KN"RR ,5]EZXXH T....,_P"?
MUHZ#M[G'^?K56QU.QU2!IK"\@N8U.&:&4. ?0XZ?C[5:/X9'I0 <9^GMTH'Z
M],X_SZ4>HHX(['/Z_K0 ?IVQMHZ_CUH[X]Z,9'3J/3U_"@ Z]1]>/\]J/K[4
M>A]??WHX&,_KQ0 ?AV]/SHQST'Y?Y_R*/RX]\^U' ].!Q^'X4 &!Z#\!1VZ<
MGK\O^?6CCZXHZ>GX=/>@ /OG\LT?YZ48X(QQSVI>_3O0 F!Z=_3- Y(]?<?Y
M_P FC@#';'<T \\G]: %/7&3^?\ G_(HYSWHYSQQ]!28R,=OITH .?4]J.>G
M(]LT9YS^-'0@?0>GK0 =LYX/?-'/U/<9[\49ZGIP3TY_STH]@.G^10 9XX).
M?\*/<?H<_P"?_KTOYXR*0?CQR>* #\._]*.<<9/N*,=L?I_];M1P??/JO^?6
M@ [G_&C_ /71]?Y4?YZ4 'YU3U=;5]%OEOF9;,V\@N&!.1'M.X\>V:N=_P#Z
MU9OB&2VA\-ZI+>([VJV<S3)'PS($.X#W(H \J;4]?;1VAEOO%)\.-;'-TVBP
MF7R,=2V[.-G.=N?:O7-*CMHM(LH[)]]HENBP/G[T84;3GZ5Y=J4>JVUG)IUM
MJGB6_P!+CT]+NZ6*2U#16[[L()&7<[;4;D'.!UY%>H:0;4Z+8&Q#"S^S1_9]
MPY\O:-OZ8H N?B?SHY]_SKF=<\8V7AWQ!9V.J-Y-G=6SRK<!&?#JRC:0JG (
M).3W%;&DZQ8:Y9?;--N!/;[RGF!"OS#J,$ T 7L?7_/^<T?G^!_S_DT?0?3C
M\NU'Z>G% !R?<^M&>^??K_\ 7H(R>1^G^??\Z/J?8T %'8^E'?TH[@?S_P _
MYQ0!A^(8HHK>WE6W'F-?6P9D3+-^\7TY-;NT \*!^%>=ZOXT>WN[U;F6Q6UL
M+Y&8AF#0HLJ(3)P< ABPQZ=*Z[2?%&BZ[</#IFH1W,B)YC*@/"YQGD4 :]%%
M% !^-%%'XT %'X444 %'^>E'X44 ']*7-)10!R>A6\<_BWQ:9H%D47L!4N@(
MR+>/IGTKJOKZ<UYS)X@FT?Q/KK6[VI6YU *3=.R@>7!"&1 .KL6X^AKT.=O*
M@DDR!M4G)Z<"@!S.J+EV"CU8X%9S^(=&0E?[3M2XZHD@9OR&37'3QWBR"XOX
M[&[N+^S>\C+0O((&#1*%"LY!7$A[#)K<&HWVFW*:-_9UH;Z49LWMQY<+H/OL
MPY*;>,@$YW+CKP 69/&N@13B"2^=)FQMC:WE#-DX&!MR>>.*@UCQ)I$NC72_
M;4C9E 59E:(L<]@P!-9EUIVH70\07,VJ?/ Z!D%MA&,2"5,9)(&Y^<') [&G
M^)M6OM+TN:PU989Y+E0EG<01E5E?<H*NOS;2 <YR00#W&* .S2>*<9BE1\'^
M!P?Y4X'OS7G=_;7$NOMHOD:7'>7&#'=0V[1F',<C\%6!8_)U..O2NO\ #]]=
M7MI<"\6+SK:ZDMBT0(5@I !P?\: ,+QEI-A9:9-J,-M_I=Q=0*[F1F W2IN*
MJ3@'Y1T':NS.<]ZXGQKK6GW6F/I]O<B2[AO+?S$VGC$J9YQ@D9&<'O7;$?X]
M* $]Z7GW_.D[_P#UJ/\ /2@ _P ]:AO+."_M)+6Y3?#(,.N2,C/J,$'/.1TJ
M;_/2J][>VVFV<EW=R"*WCP6<C/L.!R3GT]: *]EH6E6%I':V^GVZPQC"@H&/
MKR3DGZFK']G:?_SY6W_?E?\ "J$'BG0+B(2)J]ECGAY0C @X(*M@@]N14O\
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M[]?\_P"?:D/?T//2@=>V?]W_ #[T !QGG'\N]'?G'7O]:4GGKW]:3H.O'UH
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MG)K0T1-(BLI(-%@MX+6&>2)H[>((BR!L/P.,Y[T :7^>M*,\=>O_ ->D[?\
MUJ,?YQ0 =N_ Z>G^?Z4O?_/K2=^GX4>YY_"@ ZC\/6C\?UH_STH]N<]NWI0!
MSWBFYN+>*TBCCL!:3RF.>6^A+Q(<93< 1P6XR> <5G^$/!EAI=A?"].FZI)=
MWLESYB6Z[4# ?(,YX&/6I="UJ\U7Q-J%C/*D]G%YZR1?9MHA990J*7Z,60[L
M52^%R+'I.M)'&J1KK-SM95V@\C^1ROX4 =5_8&BYS_9%AG_KV3_"E_L'1O\
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MJY_GI0 >V !^E9'B@ ^';C(&"T7'_;1:U_\ /2L?Q6VSPW<MSD-%[?\ +1:
M$\4:+-KFF1QVMPMM>VUQ'=6TCIO3S$.5WKW7G^M97A[P[X@\-:4NF6>HZ9-;
M)([H\UJX?YV+-G:X'4G'MBNP/?G'%8(UG5)Y[E;/11/##,T/F-=HFXJ>?EP<
M?C0!F#P#9:A'?-KN)IKJX,Q%K/-%&H^3("[SU*9/KFKMYX)TV[N%F%WJMO($
MV9@OY%RN<X//;G\S5G1/$46JW-Y92I';ZA:2%);83"0X 'S9&,CG!]#D5MT
M<K_P@5G@?\3G7^/^HE)_G_/UH7P%9*NT:QKV.W_$RD-=5T__ %UC^(/$^C^%
M[2.YU>[6W21MD8P69SWPHY.._P#]>@#-_P"$"LLY_MC7_P#P92?XTC_#^PD
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M]?QI1UZ4GZ?\!H&,CIUXX]J  GKR,_[W^?:CL0.GMZ4ISR.?\_Y_2CU]CTH
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M< LJ%7 '&9LC@$5R%YK,LQN+Q[**6^CN$>"QE@B>T@M_-C5Y69?[SQA,Y.%
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MJ1I.KY5G&1V)&=IQ7IE<KXO\4:7I4)TF:?.I7<>Z"V5&8MEL#) ^49[GW]*
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MAXI8G*20L/XD8<@]:I^$;2WT_17L[.$0V\%U-'&@)("AR.],_P"$/TGUOO\
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MB,5I")C$2B/&QD<;O9'4\>M 'L1/^<TF?_KTV.1)HDEC8-&X#*P/!!Y!%.H
M/;^M&?\ .:!1Z?XT '^/K7)^.?*%KIYEMXW\R9XO.EE=%A#1L"?D!)) P.,
MX-=9_GK7.:YHTNHZO#')JBP6-TBQS6@++)-Y99\(P88!S\V!G"]: )/!=[;W
MGA>T%NCQM$NV:-BY9'/+ E@"3DYS6_VX[_UK-LHYM$\.PQW+37DMK#AS"&=W
MQV4$DD_4FJ4/B6XDG42^'-8@A=E592D;X)Q]Y5<LN.^1]: -_//&>??_ #Z4
M#MSZ4<X[C/'/_P"NEY/3/6@!!CTZ>G^?PHSSU/'O1[#CL!1GT_#F@ Z#J<#Z
M8_SQ1D=S]>>?\_X4<XR,].",49/8^_!'^?2@ ZGU]11DYZ_G1U]\^E'?V_Q_
MS^M !SC/)_'_  H[]<\^O6CKS@],T<D=R".V.: #)]303[\'W^M&>O/3/&:7
MG..1SQDT )GGK^M*#_C^=)[?-^=+SD<=* $/Y=_3_/\ ]>E[C^HI"<$\]_7_
M #VH_P#U<9H /3.>O<4=L$?I_G_)H^F!QQS1QZ\?7M_G% !]>>:.W3MTQ1UZ
M_7_&COR?\_Y- !1V_P#K4<>WTS1Q['- !^'Z4#_/%'Y44 'M_2C_ #TH_P \
M44 '^>E'^<8HX]J/RH /P_2C_/2C\J/RH /\]*/\]*/RH^O<T 'X'GVH_P ]
M*/KC_/\ DT?E0 ?YZ4?YZ4?UH_*@ [US/BC=/>Z?;V,RVVJ*&DBO6<!;>/@-
MN!^_NX 7N1G(QFNF'7-9NI^']&UJ2.35-,M;QH@51IXPVT'&>M 'G^L65O=>
M*@UV+?4+P20Q12/"AA9BBG+#DXWJI(4YVJ>VZL,:5I3VD\WV.%H!("\HAA#%
M]CLHC.-H&?,+9Y^X?NUFQ:1<:+XSU'3(=-BVK;REK-;O9%<QLPS&HP0K/'\H
MSM/'7C%3KK]ZNM#2A<V$5TEG]ICN#?'RX82AWJ"(^I41/TX\L^I% &G+H^D!
MYG.CVJNEN[L@MT 2 1QYX(W"3RRN-W'F%L_PT+I.FR7%@9M*M68W+K !;1MO
MD$ZAMVT<QA_+V[>=@<=:S[O6+ZRD\N[@T^P5[QH(X9K\_-<90B=<1GY%D8RY
M)^[)CI@!3JVIVVG-J=V+&U$>]KDS7QW31I*R+#@1\L )(L]2)5)YQ0!I:5I,
M/B"QU;3-/M_#\,[RR6LDTT4<LBO\WF-&L8RJ[MVTL3P%KH;&ZO+/4=/TZWU>
M86D=X+5U:R86[*A($4<F.&XP<YR1P17/^&R=;U_PU";:Q58B=166VF$DL=ND
M8$2,2@(7]Z@/)R4)X.:V[J"VM?%HO9+[13.+L7)A@M7DF,.,$Y4D!^1SC/7!
MH M_$#R7EL5NXYY+?RY,I;JI=OF3=WSTZ8_BQCG%8 V_VAJ+S19O=P^V,I_<
MG_2>?+[_ .LV$;OX0^/FS6OXLU6YN=0LSIT-S82"-MMU>_N(V.]-IY!. W4%
M1][\1Q\\?B.36M),%W;V.C6THDEM!+N>T&778^5!)P6B!'&YAGGF@#6M?*WZ
M5]DM#',(T;3O-QM3*3;3* >F?.SM^7:8\?+FH572SH,XBBO?[/)S(K8\QG%M
MA,=5'[L/NSSNV9^4BIQ-%OB2XN?M)EB#7$,8RVI Q')3CG<!& 01S"YQG@RM
M+=?96E;6;>6Y3?MOUP8X08U+!CCC+[91\I^5"?:@":X\F.]O#)!(9A;2!R>
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M4=_Q]*/T_"@ H_/\Z/P_2C^GM0 ?C^M'Y_G1_GI1_GI0 ?C^M%'\Z/\ /2@
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M44 %%'Y4=_Y<T '?FBBCB@ H_*C\J/\ /6@ H[44>_% !]***/RZ4 'X49/
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M+R(;=9 OF-RY!FYSRFXC=SYF,?-D5SNB>(8]9O9]-.C[EM;>.6>.&=&1Y79
M_..ZJBA3@Y4@G)W#I=S22SRR&W:1F5)KM77;.?-8X0=OW@$O?Y 1QC) .?\
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MZ=8M?+<MYEQ;JCDJSX9<&4E5Q\Q< '( QS0!ZS0.W_UZ.!QGI1[_ )T '/\
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MWBRHMJCO=,QPXV@ER6P<=^>:X_P/=-)K4EI!>+<VT1GDQ;W\;1!7D)4B':&
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M-,U>SU.V@>"[MI)7B5VCBE5RN1ST/OB@!;G6=-L]1AL+F\ACO)\>5"Q^9LG
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M_P#]>CGW_.@ X]O\_P"11[\4?B:/S_.@ ]J*/\]:.<^] !WH_*C]/QH_/\Z
M#\J.>V*/\]:7G/6@#PFQO;>Z^(OB"Y299;41S-++& '6'=)N\LGD/R ,=<MG
MBM]C(B@;[#[43(D*[HO*;B-6#=MWF[%'?86'3%<I;:#9-\0-3T^ZBAODMHY(
M;62^162VPTIWN,#*#N2>,KUP!5Z?PYX;6Q1_[ @\L2',(_UK_(C<,5YPNZ/&
M/OL#GG@ WF*O)<"/9);"4"!Y=ID,IG^02Y.2F\29W=0L?\5(C#= SNI_=JT^
M%7=Y6'*^1M_C\K)_=\>9G'5JY?6/!NDOJ</D:+YD44KI=?V=-Y(F4R *$7&,
MC(4+DG]VWH6K:\/M:?V7HBZ=$88%A1K-9I 6MCODR\F,;U,@,G!4;0> !R 5
M+$^7J>N*[Q>>9(5*-L\C M5SPWR;L;,?5_X<UM3;UGF.U6?YMV[;O\W>@ _O
M>49< @_+Y8&?X:Y&]UAM*NM8,NCZA<6$HAF#6Z@",+;!<F0@C*[F)X_C!.,;
M3KOK<CSRJOAW62\2-&K#RAB ^6A4C<2'\HJF<GYL\9X !G7_ -G@M=/O=0TR
M2]ACDERD,C+@$R[6R 2#ECV[C-;6JP_8?#.D2WF@:C+93!5M+1=?D9ES$Q V
M[<<(&'7BI] U&R@TF.34=+N9+/=.UU 8 P4%V!;&<;01C@_P]ZWO''V_6-0T
MC3=$L[AY]/U.)[BX$"O!"C1LK9W'!(60';CH: /-?MOAI_M0'P\NY5%P89HU
MU!R)) 3U^7C!4\<=.AIHN_"T,IAD\"7<4EJ5"32W\CB'<Y .,8 W-T.,UVES
MHGB9+/5#:Z+8QR_VG%#;""U166(&+=.A)QL;8<QGUZGN:CX?\1*_B 1Z-9R1
M(+6*!(;91YR@D.\/S?NR%VY4]P<4 <OX7\:+X T:]M-8TJ1M2>SA6.W_ '48
M95C.S>#(6);=SA>F.*]=T#1]CKJMU!9PW,T 6*&U@"+"AY(R1DL>,DXZ=*IW
M^F7&B:6VL:<EN;F&P19K6Z3*S>6OR_,.5;DC/(Z<<5H^&O$UMXEBNFMU0?97
M6.1HIEE0L5#'#*2#C./6@#0FU?3K;48=/EO(4O)AF* MAG'/0?@?RIFN_P#(
MN:I_UZ2_^@&JUWH1NM=AU-+Z2-4$8E@$:D2;"Q7D\C[YZ>U6M<Y\/:H,?\ND
MO_H!H \UU+0([W7OMUIK%W:W4/&^UL+AGC+I'N4N@P>%4\>M0:39CP'+/J=G
M</<^:(XITGTRY5I?WG_/1N WS8&>. *]#\,8$>I <#[4/_14=)XT_P"17F/_
M $\6W_H^.@#=XQ_GBO(]?L;?QU);7VK>(-%TX6YF2WM6<B2,>8 &9O,'S?N^
MP'WB*]>[_6O$(?$%I;Z);P.4MULY)[J6Z%F99%;[4ZG P59=C,3G/IG(H V]
M#\,V\?B./4&\86.J7>4+#S?,F<1ABJJ=Y[D]CP*]&T=%BT:Q0<*L" =>FT5Y
MO8ZS8W=_I]M'<1W,G]HV\L$HT_[.3&T+-S@8[_E7I.E'.CV1];=/_010!YU-
MH4^@^)C)/<K<;[8;6"$D,9&^9G=FV,V=H/W&^ZPYKG_%U@^I:IX?2",/MN9$
M=8Y'A881L+DD80,<$'YDR5S@K7;^+%+^*;90&#-9%8R(@Q)+'('9L@<QMPXR
M =V*YG4[R&VO;>UEG1$E64F+S@S3)Y9&Q<\N2/E1Q\PQL;D T 00:#IWFVY+
MSJ8BKLHOIBH3>SAH\/DL4W$[<_O%&.K"JG_",Z08'4Q>>)"LD)GN&D.T1DEG
M#/M#;60K_M%QRN36[""OV#=98?[1F*-R"8F,Q)E8#&X&0+*,;<HI'&#FE#<0
MR6D[[!("8_,82I_I#[9&&UMN%"MO8C!R)5/3Y2 03Z+9S7R742&&6S\Q87CF
M;]W,VU=JJ3\T7F_+\PV^61T&"8;KPW<23%;*XLWF=@[+*O[I5+%5;,;K\QPS
M-MR243^+ .K+- +IT:(%HX'#@8_<1B) 8\=G,3"+))^?MR-JL(RUN?[,>2-K
MAS'#$0S,_G*'DZ<JQ$> ,?ZMQG/S4 8EEX?@2VC::UNRDHB6.:WU1SOP'?+*
MS@C*DR <$29QU(JQ;II%H_E;+BRD^R_9[CS5D,D7[L$I"[Y. VS S@J[Y.T
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M)+73IM;CM DB"VO1NB$J, ZJS$N&7.",[>>,XH [;CMBCCVH_P ]:/S_ #H
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M*T =E>?%)+%]06?0+L'3F1;K;=0'RR_"_P ?_P!>G/\ $\1I>LWA^[/V(@7
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M8#IUR)Y[:-4:*4>2KPJ /F"ML0=#B5AG()(!3UAX[;5AJ,&IW[WS/B.6*[V
MNORA0AC.W"R&3<V%VR<'&:R]2T31I[]GN-5N[:^M4AMX])AQ-+9@;AM8L,,,
M=QQF0<[<5MZQ8&1R[6D+WZK(8[*/31,)$S\F[()^:16BY.,*. ,@IH]Q<'Q"
MUK*8EB>SMI;=2FUKSYV8EN<X^=V(Z#RD.,<4 .AT65;>.$ZWK;BX@C6=8KG:
MMXQCV;$&W"YV"$;R.5((SC,_P[8K\2KB(3FZCV3M%=3>8995&T$$L I"M\O
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MECC- !]?QH_*E _"C''>@!/R_$T?E_G_ "*7'O1@^IH 3\N:._\ ]>EQ]:*
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M^D\/6,D=O$TKHEK'N( R<9&.E $K^+M(.K6^GP7#7,MPP026R^9'&2"5#N.
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M/Y4=^G^?\YI0.G)]* ..O!';M0 G0<>G'/\ GVI1C/'KCBC'?')I>,@YSWH
M,_-WIC<DC^?Y4_\ BJ/)]^G6@!^:/PI!P/Z"CVXH 7-&?:D_$44 +^%&:3CU
MXHH 7\*/PI/K1WH 7-'?O2>U';M0 N?8T?Y%)W[49^E "_A1GCI2?Y_S^5%
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M_6@!<T9^M)U].>E&><_E_G\: %X_N_IUHSR._I2#!Z8^F?I1QZ\=^?\ /M0
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MWI/S_.H+2]M+]6DLKN"YC4X+0R*X!^HK*?QCX=CDDB?5K8/&Q5@"3@C@C@4
M;G]:.??\ZPO^$T\-X/\ Q-[?]?\ "I(?%F@7%W';0ZK;M/*P1$R<LQZ#ZT 0
M>.F*> ?$#!BI&GS8(.#]P]ZV;/\ Y!]M@?,(DZ_05SWQ!O[2V\"Z[!-=013R
M:?,(XY)%5G^0] 3S70V/_'A:_P#7)/Y4 >+6L/B"TUG6(XX['496OBA6]N2$
MWJ8@SA67&6)3//W<C' J^+C73*SQZ=ICPF4"-WOR9&/G,=KDQYQPV=P'W4/W
MABK4K(MYX@CFC,T#ZM<%H(F E<^7$"02#P5)08Q\S#G."+,QD:XO!+=127(R
M+B2,_(ZET!5%QD,<1@9).8W'7+4 <[>)XCN]+N+1=+TF+?:;)W%V6$:F"0 Q
MJ$R2 0V(\C=N]6PM[J.N:3X?9[K1M(4QQ^6H2\5DP(HE)9=NT\[< D'!8#*\
MUO02,\]HD<F""K6S%LB,DN=\F -P\P&3@J-F.@!!XGQ=.)OM%N+^5H'2W7[
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M2)(KUHC]I5(+9460MD[&C8MC/8C'KSQ76&ZM-'\/0O?2&TMXH8XF,KY9#@
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MH_3_ #_]>@ ]R/T_S[4=O_K4?E0>A''XT 'Y]>F*.W'MSCBCOQ@_C1_];J:
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M(<"ZC<*J;95951@!EDEW-@@'$B D\&@#EK"X>YDUG4=0TZXMKZ_U!3);;Q"
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MQVEGL"32F)9':1E=EPI[8C.?K4/BO2QI?PJU+3A-YNR$C?L"#YI <!1P ,X
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MM_H_R] H/<4 9=O;^)(YK!CK>GP".*+=,; [;(B*3*'+8RA;!W<YESUXKG_
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MY5S&$1>H#JW&3FL_5B\T-L0WRNTH2V@E42R.9E+NHV-O!=8V7:%(\MADDDT
M9\NMVFH>%IKG$CVXNEM8$)VL\H=AF5QV5"LFY@/GR<'D5:T+[,T,DTC-&T,3
M6MPR31RRIM)\PP[3D(9"H QM*,W08-8]I++<0$&65]4>Z62]CF8BUN)?-D)!
M 38 K@RX.1COU!ZJT%D)H1IZZ>ET+4- ?W>;=/);;YH SNVF12>FYT)!!  !
M%\/M9OHM=32;J#387CU"Y22.VDP<R>8^Y4 QM!5EW9S@*/<]DUV4\77366L6
M=E!&Z+?QW,@;SW"@_(NX>6P3:"QSGC@XS7*_"N.Q,-F;6PD@3[9?",W2?O0
M1@$]\*RJ?=6]:[;Q9I=A-IPGDL;5YGN[8-(\"EC^^0<DCGCB@#H8[B&:/S(I
MDD3&=R,",>N:59$<X1U8CG (-<;H?@[PWJ>@V=S>:+9R2R*6=A'M#?,W! QD
M<G@\5J2>!O"TB;#H=J .FQ"I_,4 ;IFB#8\Q,CC&X9I6D1#AG53[G%81\#^%
MO+*?V!9;?3RAS34\"^%HDVC0K0@C!+IN)^I)R>M &Y<SQ6T+233Q0#[JO(P
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M _SUH_/\Z,?_ %^*/Y_2@ [?_7KSSQREJ-=CMY+G2]/CN;)Y&GN;)'9I%88
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MH /;\.OI^-*.O'3/K29Y/MS2]_Q]/\]J #^+_P"O_GVIG<_U_P _2G_Q=?\
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M'3M9M$M[J]EOVFNS-$L012TC.D8$A+;@3U4@D&NF\)-(-7<2@V6]&,<&.;D
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M8?9M0O+>WBU(?9XY8Y)(((V1&15=I<LP)V*XRI'.>,T =7=*D6ES*T;-&D#
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M=Q?/RE]A0*3_ !;L<9H >\BM>6ZVT1GDEMMEG'.<I.A@RIE)_B:,.Q! ^:-
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MV;-XDDD%N-C1B/"K\Q7$J;L_\M=V,C%=';>"M9LO'^HZIIC66G6#IY<#E-Y
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M<8G5Y7**JW2L58H@"\/E0WRD@B,C X-6-7\0::EAIG]GWUN98KVW9?*E\QH
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M$R5Z=?F]J .I\1V]U-I$DUGJ$]E/:YG5X8Q(6VJV5*'[P(/3UQZ5A^#-:O\
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M!9QW&HJYM9[/4I)EC98,;WC8 $E!M\P>P/;/IG'M_G_]5 !_GI1_GI1_G%%
M!_G-86M:9<>=/K%EJ4MI<1VA0A8T<,%RP^\#CD]JW>/:J&N,5T#4F7[PM9<'
M_@)H \J3QS&VH7$D]E<ZAJ26[16MX]E*LR12(A8-'''P _0G!(Z=:Q]!\20>
M#]7O=8_L>:"!X/("&SN85)^3!W,A ^Z>#ZUW5E#:&^\17$EV+)K<6\J78&3"
M1$N"?4=05SR#CO4=_.VO^&O$USK"-%J-IILL?]G2*=MN#&2) #]XMC(;MC'4
M&@"_IWC37]5L(K[3_"37%I*,Q3)>J%D4'&0& ./J!4%Q8:OXDL-:O]6T#R;N
M*#RM-LY)5E .,EQSC<3@9X( %:/PNP/AAX>YR/LHY''<UU_- 'B-UX1UZ\NU
MN9- N598EC"Q71C#XV<OM8;N$P/3(]*M:+X<UC1]32\/A&YNMJ1JL9ORBJZ-
MN#G+$-R!@$<8%>R9HS0!X7<:OJX\5:Q)<:%#"DAFO+S$@^TVR1VT2$QMW<!P
M1@<[VYP<C;\-W#W?BOPI=>1#%%.MX\7D* KCR8@V<9'RM\@Y' QBN[E\%^&Y
M]6N=4N-(MYKVY(,LLH+DX&. 3A>..,9K.7X7>#(VS%H_E8)*^5=3(%)ZX <8
MS[4 :OB:^O=/TH/I]K<S7$TR0EK:'S'B4_>DV]\#..V<9XKSZ%K:ZUZ066DZ
MFMPIA_M"755/VE,*Y1U;<>B>8P"CAD7 R>-VS\+> K[5'TZTM[F2XC5F.V[N
M@A"D*V'W[3@E0<&M ?##P?YWF_V4YEX_>&\F+<# YWYXH \HL8+71=0U&9=,
M@)>[%K;2QE@61X%?#H3C+!D;KG>6' .1T%I?7EQJ&LVE]:V\;V  G> -F!Y%
M7;$&."R;@(^FW83S@9/0^%O!_A[^U/%%B^DVTUK!?QK%',OF!1Y$9Q\Q/=C^
M=;=Y\./"%[<_:I]%B$OE^66BD>/*8Q@A6 (QQS0!RG@QKB/QQ=6Z03V^VYF-
MS;I;CRA&\2%9'<9^9F3^]SM' Z5UWBG2+"6WLW%E;B1]1MM\BQ@,1YJYY'-7
MM!\+Z)X:6X_L:Q6U^TL'F(=F+D9 )W$^IH\0D"WL23C.H6PY_P"N@H J^#+-
M+;PQ9;&EP\8.UY&?;C(XST%=![X_2L[0HQ#H-E&#TB],5HG'M0 ?YZ4?YZ4?
M3'YT?E0!R/Q _P"05:_]=)<=O^6,E=3)YOV,^05\[R_DSTW8XS^-<QX^!.EV
MI!'WY/\ T2]=4F?*CQ_=% 'C&G^%_'VESS21:797*S3&0?:C&SI\V_\ A8#.
MYF/_  %.@'%M='^("PK$=)M&V8S(Q0O/@$9E/F?,<DOQ_$<UZ_CTQ[<T 'CG
M]: /('TKXA.)572K:))00'A9$D@&  L9\SY5 7;CT9O6I#I7CM95<:%8-Q\T
M/R"$G.=VWS/O=%_W5 KUOZG]:.0,D].M 'C_ /8'C^>WCM_L%M&P(+W$DH#R
M'!!9R'.3D[^GWE4]JI^(/AKXFE1K73;6R%K-#&TOV:8(1/'O","XS@[]S9R3
MD\UZF_B*WBU2>SFAGCC@E2%[G@QAV4, <'('(&2,9.*V!^.>] 'ELOPZU@0M
M% NFA6LOLQ#R.$+^6J"0J!]_ 9<C'#52BT?X@>5$9=-A:9&RTF8]T@SDH3OY
M0_+Q@<*OI7KYX!^GO06QU..: /&-1\+^-]3MI+673$2W8QE$1H\1E&W97]YP
M2WS$G))_2S)HGCJ9ANT>S51DNB[0LA("Y;][DD#=CGC>QZ\UZ\#GH2:7IWH
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M,FC6:W$1AE\H;XR>5/H<>E7>W7]34<%Q!=6ZSVT\<\+\K)&X96^A'!J7G/\
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M'/XUZ[Q0 GY^G6C^M+1CVH 3\Z.:6C ]* $_.CM2X%&!Z4 )ST_K12_SHXH
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M>E !^='XFCM_]:C_ #TH /\ /6C_ #UH_P ]*.__ -:@ [4<^]'^>E'X?I0
M>_X]:/7O@9P:.^?Z4=1[?YYH ,>V>W2CH?\ /-'X>_3\:/7]/SH !U S[=:!
MV_E_G_/%'8\<?2E'4>N?3_/^30 'J?\ 'Z4G'M_G_P#72GKW_2D_SUH /R_S
M_DT<8[44<T %''M1T]:.W_UZ #CVHH_/\Z* #ZT?E1^/ZT>N<^] !^5%'/\
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M'U_E1WY]?2C_ #TH /\ /2C_ ">*/P_2CI_^J@ Z?_JH_P ]*/\ #THH /\
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MH>/\_P#UZ #Z9_ 4G^>E!QD\_K1Q[4 '^>E'^>E'Y44 '^3Q1^'Z4?E1]<4
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M@-<UY;EID\(.TKQ1^<3\NXKN)0$\'J<'W-,;7/%$2O,F@R2[&?$?DX9RVXJ
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MQH_*@#C?[ \82LT<_B.)[9TV,$38Q!ZX(7CN,BKEII?BB'3[B.;5+9Y_)A2
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MS$\,5)[]\],<=:ZV+S?)3SE02X&\(25![XSU%.X]A^-% !_3VH_E]**._:@
M_P ]*.W_ -:BB@ _STH_STH_+FC\J #_  STI?\ /3\Z3MC_ /71QW"_0'_/
MO^5  /;K[ #WI1P?TX%)G S_ )_SFE P?IQ0 AZ_KUH_SUH[\<?A1U_&@ _/
M\Z/\]:/\]*/Z>U !_GK1[<T?YZ4?YZ4 '^>M%'^>E'^>E !^='Y^]&.WX=*.
MV?Z4 'UH]/\ &C_/2C^G3B@ ']/6C_/6CM_]:C_/2@ YY[9ZT?G^=';@?I_G
M_(H_STH .?\ )H_&C_/2C^GM0 ?G^=+W[TGX?I1_GI0 =J.?\FCZ4?YZ4 %'
MO1[?TH_STH **/\ /2CM_P#6H /SHYZ_UH[_ /UJ/K_*@ Z>N*/\]:/Y_2B@
M _']:.?_ *U'^>E'\_I0 ?YZT<T4?YZ4 '^>M'Z4=L?TH/?W]J #_/6CO^-'
MO_2C_/2@ Y]\_6C\Z/\ /2C_ ">* #ZY]Z/\]:/K_*C_ #TH /;^M';O^='^
M>E'^>E !_GK1V_#UH]?\*/\ /2@ YH_SUH_R>*.W_P!:@ _']:/\]:/\]*/\
M]* #\Z/SHQV_I1_GI0 ?YZT?YZT>G^%'3U'X4 'X_K2_G2<_Y%'^>E !_GK1
MS[_G1_GI1T__ %4 'XG\Z.__ ->C_/2CM_\ 6H *7O\ _7I/P_2C_/2@ ^E'
MT_G1_GI1_GI0 <X_E1_G^=';_P"M1_GI0 OYTG^>31_GI1_GI0 ?G^='^>M'
M^>E'^>E !VH_/WYH^G\J/\CB@ Y_R:/S_.C_ #TH_P ]* #M_P#7H)///OUH
M[_\ UO>CT_/I0 O?O_6D ]N_K^%'L!^E+U.?YB@!#SGCK[=:._\ ]:AN_3D4
M<>HZ^OO0 ?YZ48]!^E'MQ1Q[?Y__ %T &/0?I1^'Z4?E1Q[4 '^>E'%'^>M'
MY4 'X?I1BC\J/RH />C';'Z=:/?BCI^% !11W[44 'X?I1C_ #BCVX_.C\J
M#_/2C\/PQ1^5'Y4 %'^>E'\_K1Q[4 'X4?YZ444 &..GZ4?AQ]*/RH_*@ Q_
MG%&/;]*.*/RH /?%'?\ ^M1Q_DT?E0 8XZ?I1^'Z4?Y_S_GUHH ,4?AQ]*/R
MHH ,?YQ1Q_D44=__ *] !^%&/\XH_$4?E0 ?YZ4?A1[?UHH ,<?_ %J.]%%
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MU/XT<_G110 8/O2?3/J*** %Y]Z.3TSUHHH 3MGFEY]^:** #D4<]!G\Z**
M$_I1@X[XHHH #WZ_G2\^_P"=%% !S[T?3-%% "<_I1SUHHH ,<>PI>>O-%%
E!S^?O1S[T44 )^)_.C/!)SP.>:** #DDXSQ2_P 7?WHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g201708092014007773360.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201708092014007773360.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,G G # 2(  A$! Q$!_\0
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MSS1WZ<9]*,'\>/S_ "HQQP.WI^7:@ [<CMZ?GVHY].>:./3CGMVHP?QX_/\
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M';D=O3\^U'09QP/;\:".WX=* #ZCK[4?Q>_N*#WSZ'L*4=?H?2@!#U_'^E'
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M.Q[?GVI>_3O28[?ATH]_QZ>OX4 &/;T[?_6HQQT['M^?:C\/T]/PHQV_#I0
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M_P!?RH_#]/R[4>_X]/7\*/P_3T_"@ Q_G'Y]J,'\?Z_E1CM^'2CW_'IZ_A0
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M/R[4<>G'T["C!_'^OY4?A^GY=J #';'M_CVH]_QZ?EVHQ_G'Y]J,'\?Z_E0
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M>OX4?A^GI^%'O^/3\NU''IQ].PH ,=OPZ4>_X]/7\*,=L>W^/:CW_'I^7:@
M_#]/3\*,=OPZ4<>G'T["C';'M_CVH /?\>GK^%'X?IZ?A1[_ (]/R[4<>G'T
M["@ QV_#I1[_ (]/7\*,=L>W^/:CW_'I^7:@ _#]/3\*,=OPZ4<>G'T["C';
M'M_CVH /?\>GK^%'X?IZ?A1[_CT_+M1QZ<?3L* #';\.E'O^/3U_"C';'M_C
MVH/3)'KG(_SVH .,\\?EV_S^M><W_B'QBWB*^M]'@M+FWBN'MX;<P'=E5B)+
ML6 "YE R,GVKT?D'W^G6O.4U*#P]\3]2CN99S:RP27>$@:4AF$(;[H)"@(*
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MDU2XOIG2V:(A]JB-F()R8\;5&,=:],OM0L]+M&N[^[AM;9,!IIG"*,].3[T
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MS*$8?Q>8I)V\XV9^;;52*QM);F4K]M^SRS6QM]]Y(KKEY7(E)8;28PXYY$A
M&"30 FEV.K6"&+1O$6HQ27H1K-/L\0$XVL5W$D[3E)5Q[ YP<TQ=.,$5[?W&
MHS74$T966[$&)48KYI;9N  ,;&08Y#1CI@9J&".308+J&:[00VZ/<;[M][H$
MVN(QNY!C* $?+D2?P@UI&TFMIA#;O:,TB3']Y<":!2&A Y<E<"7#?WO+//44
M 7)H&>]U)9HX8)G#_:XH5XLX]T9,T39^9E!BD P/FF<]1MK,TJQU:TL].B-Q
M8Q2>;Y5IYMJS[G\_!61@R\"4E,X(VR'!(SBW<QM-)'#;9AL9+T(BW$ACG+>8
M^T2,"'V^:LA.[G!C'WJBM[2W:XLP'O=]O#%)+MNY<2Q[I,",AOGD\K<I6/\
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MPQ+$#KDG- %QO&_A<2"-=>L)6*D@13"0XXR?ESQS3E\:^%G02+XBTO!Y&;I
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M2&:V=1Y,*LS;9E(/#,V_)YR(U.!C!J0:IID<LD@U))4C>W$4DN[-RH:8,TO
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M &!K-M;I=6=Y/;M=2S3VRW8M9V#719#N,:J0K*R;%R ,F-NF,'H&>8)YDM[
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M]QBE&<]Z3';% [?X?Y]Z  G!//?U_P ]J/UQQ3OXNOZTW\R,=OQH /Q'/?\
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M*VTT33Z8EUY,KO/IK.5AA52P)!S@E"=BXQP<X(P!U#+.+N,I/;+,)!N#B,Q
M&8["O8-D2Y*_-_J\_-BN.\?"-O")BW3M$SXMD49F+$,8_- ^8@IG<&_BSWW8
M /;/#:LGA31T<;76QA!!['8M:G]*SO#VW_A&=)$;;T%E#M8#&X;!SBM'GWH
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M8YI8TD +QM&JF1B@!_O_ .LW%.=WE_Q4TO;K;J);HBW#QF$LT894*O\ ZX]
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M<;CDOGT- '(F>\U*228W5Y>W$9:,FXA\Q4148GYBQP0H?\NM=5-X6\4ZFPU
M:?<+;3R13*;,QEF&%)PS29P<!P>1O)..]6+YC"MQ##8VTEQ-9R+=FWMTR&,(
M+NI&"(=YC(/((\SJO3V"&]%CH"WNI/ @@MA+/) "8QA<DIWV^E 'EVD^'M6T
M^2ZVZ#J4,+78-NBI&S1PAU96+>8<R*%V#L S'G.*J:3:SVLMO;W4;Q7T5RB_
M96P4>3RAMB=\\+N98^APKXYSE?5]*\2:=K5[<6MF;GS8(UD<36\D7RL6 QO
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MJG'0#VC1.= TWC ^R1<?\ %>#VUJ]AX@TC33HFG01R*DBSVTTS"?;'+AOF4
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MV5G4E1B2W$2_,Q/)D\G<Q!XWA0> N0"P1(UTOD6,;DM\ULR$+&#+D2#)^4L
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M)$,C#8HVC!F+*0>J-A>M &Q<Z1'=2S7MU-)#''#]GG*A&2R;RP#$F5/"L8U
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M\9I1U_GC_/UI/_U=L^M*.W4@=* #^+_ZU)Z^Q[?Y_P YH/WCCK]:#C/;Z>M
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M9PTV(SB0'&["$DD =90>6&*E+JH?"D*B%5;!Q$/+0>1C&,[28,Y+;B2!G=@
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M22<-G'M^ H"@  # % !_GI1T_P#U4?E10 =__K4?ACTX]J.W_P!>CWSQGU-
M!WX'TX_S[T<=>#^'^?:@\<G_ /7_ )XH/'&>>W-  >_^'6CUXZ^WUHZ?A]1_
MGI1T]>OO_GTH ,XYS[_7_/O2X.?I29QW[^M'^>?:@ ^GIZ<_K^%'0>P]J._'
MK_GC\Z ./Y<'_/IQ0 >V?;_/- Y(/KSTS^OYT9'7/O\ >_&@8SU'7U_SZ4 !
M/7]>:/4?Y]J4]>OYTG/O^= !D>O'J#1W]#WHY]31_7W_ ,^U !FC/;/ZT4<^
M_P"= !1_GK1^='- !^/ZT?G^='I10 ?G^=%'^>M'^>: #/\ G-%'^>M'^>M
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MC5^-$GE?#2\;C_70C!&1RX'Y_P!:R;;YK.$RE(&(4Q>4D8#CRV)+A3MR(RK
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M'%QJ$/AV^-O:P2[F5;K"@M ^8M_E?Q% P0+QC:Q[!<^U67_(.M3_ -,E_D*
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M7;Q$;K<^3B06^,D*$,6W:",M)SMR0 9,NJZ/+:A1K;.AWJ]Z;>7S(SY:KM
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M[\#D ],C.*\1U=#/K,4<T=O/";X!S(2S[_M%N)0<\[0V57/_ "SQVQ7M_0X
MH 3M_/FC_/-%'XT 'X_K1[_UHH]^: #\?;_.:,^GXCC_ #[4?Y'-'/N/3F@
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M-"E]$KA J@!(^A.%&7YXQ)@';DT 7K>UM(KAYH+>S$Q8)<20!5CF!F_Y98'
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MN61U\_?"RR?<E-P=SOC&Y&=4<8V_(C>^8$:-K6ZD5WBWF+[06<8<['*M'Q@
M,7<C!RKJ>G!M+M:YMBSLI. RMG_2AO9?)YQDJ"8/GQR_L,Q*&^RLOVK?Y>T(
M=K[K3*$%.F[Y\"/CC]T?XN* ,?Q'!9_V-(HAG:2*"%+8 _ZE-L>Q9!_>520W
M/5EXY 'M-I_QY0 =HU_E7B/CN^>S\.W!CNG*7,T22+&/^/D,JL9LXVC>RAAW
MX/<D#VVRR=/MMPY,29'O@4 3?YZ4?YZ4?E10 #K_ /6KR./3->U'Q=K*P69>
MTNS<"43J8=H,B(RB3802T<:8QG@D]:]<_I1GCF@#S&[\(>)+[3&@2TLX7!5X
MC+=@D.9A+(S;8^=S*N,8V@>YJPWAOQ&"^W3XB?-61RUZA,A4EEVGRL !Y)#@
MCN!]T8KT;ODXHH \QL?!6NV4"1?8K5GC\U87%Z-J1N2,$>5]X([C/(RV2.
MZ/P3JK77GRZ9;F/R%A$?]H8(PY8\B+O\HXP< \Y((],[8XH_SU- 'EE]X/\
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MM<KXOS%I^G7;VZ2HEWY#V5TKE(/.A>)<;ASM(*\9YA'K76ABETH!AW0LK3G
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M<*U_S%>9^(;*7^V]2U%M'4PB8VZQQ7\D,EP3&A,A0,%D4G:I4?-A>_2O3/\
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M&1XF"!%#8^<^8&Y!RB@@9S0!NR6<+^:TFG1G]TT37+C=Y!"HOV<8^7 <>3P
M?G)'(8E?[,@+6X&AV\[K(Q%EY1 YFR'S_M8*<\8BX^7-9KO?2:W<+')$J-;A
MK198"XNK<PY+,VX$2F,&0J0.47D=UOUN[?1Y9UU:(V]N9I8YX[/#LZD,RD[^
M%SL<$<_.>X(H U4L;,3.S:=;26\C1L+PPC_3,.YQZ#()EPH_@Y^4BH-)M)++
M2;.&X\R"6WMDCN)Y1\U@1&QS\ORC;E9,'D>9US@UG6&KL;C6I;H;KRW:%[FT
M@C&(H#\X>-=Q#,)&"8R,*QXYP+=CJ]E=:C8VMD9YKQ85%DEQ 8UN0(VQO+=
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MJF26V,""9_L:FR$JC9-&8"%,OS?>*^;D=/W: D#!(!EM+K^Q$_X1RV\PL_\
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M)Z]J /3*/\]:/\]*/P_2@#DM=UJ[AFU(6=GK9-K%Y9:WBB\K<</O4MEB<''
M(Y/&:ZWH*\G\0W"GQCJ%E&\TUX;B+9=)'<F6S#*,!57Y6'&1T')R#S7K'X8Y
M],T ! [^O]:X#PFZ3>+[J6>0O=B.:-9%9/*,8ESA (P>,\_,<'.<YKNYRX@=
MHR%<+P6!(_3DUPOA":TNO$C7%K+<2Q-%,\<<EI<1K;[I 2 9'*98]E';MTH
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M"TN]3AU!8A)']HV.6/FH H53U!(]_6MBY9OMEVTA29V&)I0<),ID0&-1T#,
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M_DT ''<CW!/UHSQU'XFEY]Z3/OQUZ_Y]* #'\\4?ET_'_/-']/THQQ@C\.U
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M^CV#7:00QO*^[SE4IO!&00..,@D]N0#JOAW=VUW/KP@MO*V3P!AEF!Q @X+
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M#:G&6/E@PY^4EAS@CEIE=HTD&HDRK&WEW,<IVPKY8+(6"\%B%<?*>(F.?X:
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M5+-$3<7AGM3%/_RWBC&5AQ*"2AS@E3L[#_6L>>5H :GV@.K/(L:18\Y@6/\
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M+(=/*3'<PLD#D2XC"E\ Y^5B(!@X.\X&<FF6,S"33S!;R2R82.S1]G^D+^]
M+G/RJ3OX&1L0#)!S3&>,:=*<3_8H\%YV*;LF#[H4MCF,;B<Y+;>!B@#)\7@M
M>:0\</G+_:BA;B3.P=05'.W(*E%PO2$$8YS[F3SWKPGQF[C4='EEC$5P=1C
MBD"M@;!CG.XG;L)POWR2<<"O=#C)H 7-'X&D_*B@!<^U&?K2?6C\J %S1GZT
MGY4=NU "YHS]:3\J/RH P/%5CXBU"WM8M!OX;1=Y-UO8H[KC@*X5MO?G%9_A
MSP]J6E:F)I],T9$=6$MS'<S3W+'_ 'Y!G&>HSC^5=?\ E1^7YT +FC\Z3_&C
MVXH XGQ7IM]?:T?LNG7DT<D,0FFBNVBC9%=B4*J<EQNR.,<G\>RMX?LUO' )
M)91&H7?*VYF]R>YKA?%SO'XLMIBZR6L<4!F#_:-MOF5@')C8*-QP.0?N\C%=
M^>O:@"&[BDN+.>&&X:WEDC94F4 F,D<, >#CBN;\/Z'J\&H7%SK]TM^\01;1
MV*N 0"&=1L!C)X! )[Y)KH;Z[AL+"XO+@L(((VDD95+$*!D\=3P*Q-&UDWNI
MPV_F:DX^RO+NN;+R$?YUPP) )(#8XXQUYH H^+-4UZSU95TF:(6\5F\TX9XU
M$?W@)'WC.P8!^7T.:[",DQ(6(9L#) X)Q7G7Q&94U2T+QZ<^80D:7# /,26R
MI'F)E 57.<CD_2O11PH'' QQTH =[8HS]:2C\J %[T9]J3CVH_*@!?SHS['\
MJ3_/^?RH_*@!>.P]N!03SW'O2=OY<T=.F/;V_P \4 +NY_F#1]1G\/UI.,]>
M^.O^>]&,]1_GO0 OU'.1DFE'7IBF_0\G_/\ A0,9'3V_I_*@!?XN.U,Q@XI_
M.?QXS]*;G)S^5 "XYZBCGWI,TO>@ HY]?I110 4O?O248[4 'I11_C1Z4 'Y
M_G1_6BCM0 <^_P"=%'^>M'>@ _$_G1]<T44 '^>M%%&/:@#RCXF>8GC+07A@
MM?/>Y@6*>Y*X5@)CM(/&#QD^V!S@U(QB&##(Z1_:5^RB94#!][[3+W*X\P'=
M_$4Q\U1?%*2"3Q5X>MYH)IQ]KB=X80=S+ME'7!'7MWJU/*WVBX\R>.=MW[Z5
M1\LP,G(C&."6"'J>(F''WB 0;8)'/F-DB-?M!CV!V3RVX@(Y_P!6%_U?&_=C
M^*HG9HAF9[<S&-Q$<Q")5V)NW?P;M_ED9YV!OX<5)$3YMKY4ZQ-L1K8R-N%N
MV';?(-HW8?,IR5^5E],&-I8H[0[XS'!R7AW_ #L1#@,#MX"KN0X4_-*IST4
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M8PXD(C;;YBR[A@ONYV"3>3OXVF//.*IW3NOAX"&:U^T&T7<[F,1LN7\L1G&
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MM1REONC$*R;#)'\[A?-_X!O7Y\_O"N/FR:<RJPC!MWFBWM^X4C>6WHI8\=&
M50,#'EL,D'<''S7EE+L))"RB296&VYS,Q.SC"Y8"7C/RI@X !( U1*4*SE)$
M%NINDM]F^3,+9\C';;Y8&W R),#&021[AK4GS;+[6%D*3,4\E1M4MN.-F[S
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M\YEW?NP@DD\@EOW'*'[3\ORDC/G87G]X0/XJ>K2+-%A=JYP9<L//Q+M\K_@
M/E9?C$N?NBLNXUW31]K5;L2^4[XE$;N\TFY,09P,HS9CQ@91%].98=4@DN(?
M)2:1W.&3[-)B)!(2LJ*!P[)OD)&[+1*?]F@!=.L$TZ$V]NTK&,H?*D9B;(Y9
M-@.,_-M%O\O]W)Y(JX)-RB14^T)+%O\ L_/^G_NC^]/8%\%\'YLP?WC7-:+X
MNL]6U6XTNV\Z4Q,&M[A4.;M5W*SR=\JO[U<D?/O]1CI'.V*Z,TAAB2,I/+$A
M_P!"?RP&CBP?NJQC48'25QGJU $4LR;1)_:LUOD/C4U5]QR%.S;U^4$SC/'S
M''&:F8;)I_W9M?+8XMSG;9_O>9 >AVA@/E'2?GY<5%)'<^:D,>GV\MYABEBZ
MXB"ETPYP<9+@Q'GE5!P!P9=P)9XYO.MGFQ'.RDO<-YA(5^>A'F$\+S"A]%H
MCAES-;(TTDBLH'E_,/MYPZ[&R, ,1Y/S\_N@>I6L;Q---'X<M[RVU2:1[>Y
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M;YAJZ WDB(';DAL\YYD#C[N,1J/2O?#UH 3\/TH[_P#UJ.*./:@ _P ]*/\
M/2CZ]Z* #\/TH[?_ %J/RH_I0 '_ #Q1_GI1^5'^>M !_3VH_P ]*./:CO0
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MHH_*@ [<_P J,?YQ1W[4=NW/K_GWH /4X_2C&??GT_"@^V.>G_UJ.IZYYXH
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M/+V 9R/,![XIR#,]H9,21><1;[<;S)]I&\D@<J92A7;_  [_ .+-,9F\R:$
MQVT;LT-O]TPRAT(F(_N*Y,O!/RRKP1T?&TCS0JC)'(S(LLDA^29?,*B,?+@L
MJ%H2"%^:1?0-0!9\-Z9::GJ5PGEQ.SLLFH.-H1F5Y#MC*]_-W_>ZH5 XKJXO
M"&CPO;.(Y&^SPB%-TF05",G([_*Y'/H/05Q_@&YFO;Z(WUB8WB<K;11J5-H
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MD=,*?G/I7H)^Z>P-<#X1\,16FK_VC)/HMVZQLG^@Q(/+E5@NX8&03EMW/4X
MXH OZQXHUBRN[J"+1]/;RWV0//J**\W3E8\9/4C&0<C%=@>M>8:YI>_Q=)/;
M>'?L>Z=3-?,D-P;OOQ$[ +G^]PW'2O3CU_QH .V<?A1WH[_RHH **/ZT?YZT
M %'T%'Y4<>U !G'..U&!C''3']*/RZ>O]/PH[X/\_>@ Y]^?<T<]OZT<>QX]
M?;_/YT<9SQD'UH /H..GI0.HR/YT=./2@8SCCKZ_YSTH 7^+']:9T-/[^G--
MSR<T )3N?Q^M)QZTN/\ ./\ /^10 ?G1_GK1^'Z4?YZ4 'X_K1S1^'Z4?YZ4
M '^>M'KG/O1_GI1]/Y4 '/\ DT?Y'-'^>E'^>E !_6C_ #UH_P GBC_/2@ Y
MSWHH_P ]*/\ /2@ Y_R:*/?^E'K^O% 'C/Q!-RWQ?T%+%;9KK,)5+H QGB7.
M[/MTQSGIS5[?PKQ_Z@RK]G#!?-',AQ-GMY8?A_\ EIC^+-9WQ,DA_P"%DZ7!
M>6\UU9NT#O! ?G9E$N,>N-V<?7D5?\U//NW(+7!E3[5-E=EP?.<CR^/E_> 2
M<[OD4CC&2  PD),\.Z)8?]-\H#>/W)WBVQSMVE-NWY?OX^7=2W#R^5^\BLA=
M$.%P(_LW(3=G/R;O-V]>?+SGC;1;,J+IIA'D3^1&+224@BT'ER%?-]=I+,3\
MO#J< ?*:]R+)='F86\Z6C,?,M3)^\=A J@AMO01YBQC[[#DD\ %QQ^\F$*E8
M=[>0'QYQE\Y=OF X;RQ+OSNR-K)GG%$ /FVX@V;R(PVW804\QRHBQU;R_,!,
M?/F;.^:>Q5K^_&]I)BKI+(C?)(A,8,:CLQC"1@Y^_&P[Y"1-'OL$F$DHD<",
M*P)$C3DL[<#<K.$D7&WY8W]#D 98W[6OV>XM)4 B\M[?:T8)3RF)$^" "8MI
M&XYWAL<9-:P\4ZG'Y8FO8V6W@(NBD2YED$?S,@[IN>-L]-H8YVUS?A_2+'0+
M":&U+IYDL;3-).I\YAN*E&*\*KCS3D-\C YQQ6DWF"55618F@ML6[2, +5/)
M^5'!'WE4NI)/62,D=  "U=ZQJUY;BSNKRR:X$QE#8C,'#JJ EC@XD#9 YP5Z
M-MJF@B"Q&UFQ&)4^SK)CS,^8VWSN_3S@=_\ %L(^?-*YL_LR 6;FW<R[;42
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M5(6E@>ZN8[8_N2C,&8-QD%S'G (SM->@GKT_2@ YSW_.D_SUH_G]*/\ /2@
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M,.I )Y/ !0\6RSW/BR,7%M:B,A([<S6,3S1 .065FE&0Q&1D$8[=<^I'&?\
MZ]>:>*+VZU34;I%L[T6]@^R]@\I%#Q*XVLDAC)+OG*J".%/(->EGJ>: $[4?
ME1_GK10 ?U]Z/RH_SUHY_P F@ _*C\J.??\ .C\_2@ H[_7WH_SUH[=\'MZT
M '7_ ">*.G_ZS[4?CFC'/3UZ4 '].,T#'!XQV_S^5'N:4=>O?!SB@ _B/UII
MZT[O]/:F=S[4 +_$!ZTM)WI>G_ZJ "C^M'M_2C_/2@ HH_I[4?YZ4 'T_"CZ
M4>WK[4?A^E !11_GI1_7VH /\]**/P_2C_/2@ KS?QC?6]GXRCM9]3TG0X[B
MQ$WVRXLDF>9PY!3+<  8/J?PKTC_ #TKS;XA>(-3TC6[4+>3V5BJ02(T=J)$
MN&,X657?#;0L?.!C.3S0!UOA*Z6\T7S5UVWUH"5E^UV\*1KVPN%.,C^M,\6Z
MU=:+IUJ]DUG'/<W*VZS7K8ABRK'<V"#VQUZFF>#[ZZU/3KZ\G\TV\E_-]B,L
M'EEK?(V'& <=<$\D8--\:RW,6F6;Q637ME]L3[?;I:B=V@P=V$/'7;GOC- '
MCNN^($\1>,?"=SJ;%$D@M;J5;(;BEP=X*_>R,83@9.#]*ZG,:S7PEA83*Z&]
MZ"-3Y[X$?/3S>.<?NR<?Q5S6KSP#XEZ ^@6T>CZ49E"?:K46X,Q5@WRD9.Y,
M 9QD]"*Z-)55#&GRQQ2+]FB9P&M5.X8D]&,8\H9S\X['D@$\)0OI(ACD,WV=
M/[.61<JR>5)L\[G@_P"L#;>,!/X<FJ+)ITFCS#%RUCYSB9GV&;/DQGY<G'^I
M^;)Y\S'^S5O?YD<:3R&:.:(O=QH<-?-Y67:''4/B,@C _=N<=5IS2W/E&634
MK87BEECNMRB!!E#M^Z1GS,2]/]6>O/ !+=*CWNJ"8LEX5?SM@!14WQ;]N?FW
M[-A&1]\O_%@4R/[,S::95<?O +8(%#&3SVW!L'[@EVA0N?D+8/WJL A3-"CB
M&%6)CMI&!E@83*4D<<G"N9'.21M=![A+9Q]KM=MT@+K&LDA<$W*;G5$C.!EA
M&6B)7!+L.F,D Q= U2#5--NYA8SVD@DA%W#<QJHW;7,9CYP5)+ Y/W !]T$U
ML;5,JL@#RFU)MA($PT7D#!D).=QCWD@\;A'G@*3"CYLOGF1Q"5$6'7,.8CN#
M?+U9 JC@_,C'U4RO+N>Y)E5T96>:-&&9I-J$RKQG87"R YQL4\$'  (7^QI'
M 7%PEJKRD,0OF!MZ>8.3V7801SO+?Q8%5O$,D,&D:P]X1%>(86F6+:(1B\CW
MG@YP#C&>V[J=V-)IIC/;XO;99MS 3LXVD";Y5'R]58N2  <.@R<A@U'@DMT6
M.U988W!BAE(WV_S. ) 1Q\FZ/G/S,HX(W$ ZP_$;P9G_ )&?3/\ O^M<'\3O
M%>A:]IME9:5=VVIL//=C!*2;<B)@LF%R>&(Y(QFM#SIH9]Y'F1R)YMTL)!:[
M_=<^6 /F)'EXQM&8I#CJ#5DN;\Z[83'5[5IUM;]8;C>-L#>7!RQ*X"ELL 1C
M:10!PMOX@\1W=_K"R7^FVL]LKK<M=%(&D&5W;59-V[Y5;D Y!(Y8T)K_ (@&
ML:?8QZEHR2DNT4IEB6*-Q*QRQV\#>"R@?POCH:[MH;7SY8Q%"88IB\4,I5I(
M9O-*K*X()VAC+G);B5![AT/D21+A(9/M 072+M/VR/# (G W-Y0\H@;27 Z8
MY /.S?W5M?/>W,N@W4J1-:LAF0_-EF!&U?FP05^A49 Q6K?W5Q=6\CSZ5H=Y
M!:VBRI%%?LSQ((HP&!5,[PH/)Q\WT4'J97M4MT<O;ADC,<4\;*JVZE,L"=O#
M/M3'!YB<@]5-#7HTA:-(#"'#RR1NBA52?$1-RX'_ "Q+L9!R1M;.,'  +&EZ
M>=.TW3;&[24".1E_=,7=I?M*F3YC@[!)Y>TKS@OQNJTV<WOFQ[;@O&;QHD7;
MGSWVB/GIYW'S=8^G>IWF;[3&8)XHI68 SLXV2*)MJQCCDJI="/EYD3GHU0^9
M$%:-&VHA401.,-: [TQ)QP3&/)'WOW@/(/4 QO$BA=*L7B\Q=IMO).P9\DQ.
M4W#D;^&W \$!.U:4EUI1TB20)>_V:)I-Q2(>:7V1KQVQY9W'/.\9]*I:_P"9
M)96IR;A6O;=I#$W^MD,9WRH?[K_+MX(^1CM[5L/=L [Q:M!'>J7VWA!,6TX?
M;]W&3(&DZ9"C&?0 CNXI?^$C9RD0N0LHOV4*<#S4_P!5_$3G9U]7_BR*KV.E
M[;C1IK"2:4I+YT,4Y78&,D@;/EC./-Y&"1L)YZXO"&T>\BNDD>-+8'[/:S/\
MUMOEX:12,@ ;AR3S(H_VJH3[[_4-*M&N'4M:O/)<0G/VC"LL:0G WR!&V$?*
M"<]Z +3_ &4Z3(44F%MIEX3!80DKMYV]/,W;CT"9^4U1\0)>-<LUB(W,2O-,
MDK!1) JQ;0203N*;2<@8<Y["K/EW4EA'<C7U!BW*CB-/+0E$8ASM_B8+C@Y5
M&^E%_97$-KJD$FI75U"%FG:/RD4Y#@LS%<84F0N!W4I^  V_NYK-].DN4$UL
MUW*'6SCWR+)YJD*A)P5\P(JD<G>W0USUIX3O[NYO]0U*ZM(;NYNHI;B""%9#
M"HE;")EBNTR*-P/!49!(R*Z^UW0FQ\J18F\L)O=^L0D8)'G RZ*61@ .9%&<
M\T\*K6JQA<0)L6*,OS!\KC#''_//]SWRX/0CD ;%Y0:U:W:,S?9D%H)]H5X_
M)?;YOOM\W/\ #Q'_  XJ.5[9K'=-N^PEY&.W89=^Q<XSQ_J\>_F]>=M3R?O#
M,LX^TQ/&7N(UDR;L^6"7C('*L51@>.(6..<4^269G^TK=)'<_,!?%_W00,"%
M^[P1(?-Z?<(Y(Y !SWBUW.N^'Q=;#<CQ!&"8&79YFX9('+!<8'/?=WS7MQZU
MX;XE2)-2\*0P0&WACUZ,);.?GB&XX5ACJ.O4\,/3)]R[_P#UJ $[4=Z/\]*/
M\]* "BC_ #TH_P ]* #_ #THH^@_2C_/2@ HH_STH_STH .E&.U'^>E'^>E
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M<4 +2T8&/_KT<T %'IBC^7UHY_R: #CV-'>C_/6CGW_.@ HX]J/\]:.GKB@
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M7EQYTJ_,>K;F_+/%9/C6V%O&KI+K<]UJ=Y%#!;6=\(0&5'. 3PJD;BW7) H
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M^>E)S_.E_+\Z #_/2C_/2C\N:* #V_I1_G&**./PH /\]*/_ -?2CZ_C1]:
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M(JW*[;AC+;#/R[#C;R/D"_=QSD]R" %H?^)-_IH"P_-Y[0JN4?[/E=@S@@Q
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M)SZGCWI:.* $Y]Z,\_\ ZJ7BB@!.WT%'(^OX4M'04 )ZB@YY_6EP!V_2CB@
M[_\ UZ3_ /72\4<9H 2C]:7_ #FB@!/\]:/\]:7 ]*7% #?Q/YT?U'K2XH_"
M@!,^_6CGW_.EQQTHQ[4 &3ZFC)]3^.*,#\J/6@!/QHYQU(I>,T?SH .?>DR?
M4TN/04<8H ,GUI/\]:=CGI2>] "<XZ_K2]^]&/;I1CVH 3_/6C_/6EXS1VH
M3\?UHI<>U&!CH* $HY_I3N,TF!Z?I0 GY_G1VZ_K2X]NM&/\_P"?\\4 )S12
MX]J,>HH 3M_]>J%QJB6\\D3Q2$KC:1_&,$DCV'&?<BM&N;U:)_M,CY^5V.7V
M\H?+X4#.3NZ\8Y4#WH O?VVN6'V>3<H!8;A\IQG:??)"_4^W%JQO5OHW<1M'
MM8J58C)]_I_AWKGG \V?!#95@/21"J'>??&7Z9R.OKK:",0W W;]LK#=GO\
MW<>@^O?MTH U?\]:/SI?R]J7'M0 W_/6C_/6EHXH 3WYH[TN*..] ">W]:/S
MI?PHQ0 G/X_6C\3^=.[CBDH ._?\Z3\?UI>/2C% "?XYHZ#/I[TO^11@>G H
M 0CM2CKT/YT8'/0^O%+CGMQSTH 3O_\ 6I""3TH/6B@ ';_"C)HX]J/Q% "\
M^]'^>E)]?YT?E^- !_GI1V_^M11^5 !S_D4O/O2?_KZT4 &:7G_(I/RH_+F@
M#"\9WM]IO@_4KW32XO8(M\12,.1R,_+@YXSVK@M4\;PS:3XJM+&SE6&3;_9J
M-HTFV1V0&0N&0@DN3]X=QUKUK/?BESQU_*@"*$9MXP5_A&1MQV'L*\IL9YO$
MD>EZ)86.G6NL0F9M1O&TI&%A&KMMC56&-Y+#VQN/>O6L\YXS]?\ /I2Y/KTH
M Y?X?SM/X2B#16Z>3<3VX>VMQ#',$D91($& -V,G'%<?XXUW4[+Q+J@@U35(
M9K6& V%G!9-+;3;A^\,N%(;KT)&,"O5P !@ !0,8I<F@#C/ 5U:74=^\.JZS
MJ%P&43MJ%LT"(?FP(HRJA1G.0/09[5V?.:,YZXI* #/'M2\^_P"5)^5&1STH
M 7GW_*CFD_*C\O6@ SQ2\Y_^M2?THXH /K_*C)]:/;BC_/6@ YI:2C\: #-+
MSZTE'T_G0 >_3\*/\]*..V/\_P"110 9_P XI>?Z=*2C\J #G^O2EY_R*3C/
M7OFC\LT '-+S_D4G&1T_.CC% !S1SV_E11^5 "_YZ49-)1_GO0 ?G^5'X_I1
M]:.] !GC)_E2\_Y%)V[4>] !S[_E2\_Y%)Q[4?E0 ?Y'%&?K1Q[4=* %Y_R*
M3G_(HHX]L4 '^>E'^>E%'\J #I_^JC_/2C_.:/RH ,_6L2_L;FYGE=(OXR$&
M%PP,>"2#P2#@#/J1TYK;H_*@#GWTRY,EQ^[+!U+[L@9?"MM'?&X8P>W'85IZ
M9;26T$@D7:Q=L =,9.#QQGU]>]7>W:CVH 7GL:3/^<4=11[\4 'M2Y]Z3Z4<
M4 '/^12\^])1^5 !VI>??\J2CZ]Z #/O1[>OM1_#2+N(&\ ,>H!H =D^])S[
M_E1Q1^5 !GGKUZ&CO_\ 6H_+\Z/Y?6@ SQUZCBE'7VS2=^H_.E')S_G_ #Q0
M ?Q?_7I/I0>O\\?Y]*.?\B@!><TG^>M';_ZU'X?I0 O.>])_GK1_GI1_GI0
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M]*/\]* #\_SH_P ]:/\ /2CV_I0 ?C^M'^>O^?\ (H_#]*/\]* "C^E'^>E
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M'ZT4?YZT %'%&>>M'XT %'Y<T?YZT?C^M !Q[4?6BCOU_6@ ]N**/Q_6C\:
M"BBC\: #CVHX[XHH_&@ HHSSUH_']: #\J.**,^_ZT 'Y44?C^M'XT &>_\
M6CUHS_G-'MF@ HHSWS^M% !1Q1^-&>>M !1^5'T_G1^/3WH /RH_3\>E'X_K
M1_GK0 <>U'Y4?Y%&??\ 6@ HHS[T>W]: "CCVH_'-&??]: "C\J/QH_']: #
M_/6CTH_&C_/6@ H_*CUYS1^/ZT %'ZT9]Z/Z4 '&.V,4#K_]?I1^/XYH[]:
M%.<]_P Z3Z4IZGCW_E2?YZ4 '\OK1_GK1_GI1_3VH /S_.CW_K1^'Z4?YZ4
M'^>M']:/\/2C_/2@ _SUH^F:/\]*/\]* #^7UHY]_P Z/?\ I1_GI0 ?G^='
M^>M']/:CT_PH /\ /-'Y^M'X?I1W^O3B@ _SUHY_2C_/2CZ?RZT '^>M'Y\4
M?YZ4?X^E !SZT4?YZ4#^7M0 ?YZT?GT]:/\ /2CMT_2@ H_SUH]OZ4?YZ4 '
MMS^=%'>CT_PH /Y?6CGWH_STH_R>* #^M%'^>E'^>E !_GK1_A1_GI1_GI0
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MJ,>WZ4 'X?I1_GI11V^GM0 ?YZ48]?Y4?YZ4?YZ4 'X?I1_GI1_GI1^''TH
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MI1^5'Y?Y_P#U4 '^>E'^>E%'&.U !_GI1T_#VH_*CB@ _P ]*/\ /2BC'X4
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MJ>#[@T 3]/\ ]5'^>E'%'Y9H /\ /2CZ_P J./;\Z.,4 '^>E'^>E'Y"C^M
M!_GIUHH_SUHX]OSH ,?YQ2@<YQ^E)[T#&1TX- "GKW_S_P#KI,_YS2GJ>/KT
MI.?\F@ H_']:*/S_ #H /\]:/\]:/S]J* "C\?UHH_/\Z #\?UH_3\:/S_.B
M@ S[T?C^M%'Y_G0 >G^-'T/ZT?UH_P ]: "C_/6BCZ4 'X_K1^-'\J/?G\Z
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M"(D:KQN^\21R.#G% '5?YZ4?A^E<%:+>RR:?#)<:S,B:?(MZZB>*3<,,N P
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MT44 )_6EY]\T44 )T]>!ZTO.>_YT44 )@X[_ )TO3KQ_]>BB@ YS2=N^***
M%YS^M'/'6BB@!.>G.:/SZ\444 +R>F>M)^=%% "\^])_3FBB@!><]Z3G'>BB
M@!>>O-'/O110 #.!UQ]:.<9Y_.BB@!.V><4O/O\ G110 <T<@XYHHH !G ZX
MI.V><?6BB@!<'WHY]_SHHH .?>D_.BB@!>1ZXHY]\_6BB@!/SX%+S[_G110
MG.>]+S[_ )T44 &#[TGT].*** %YSWS1@^]%% "<^_YT?GZ=:** #K1[\BBB
M@!><]Z.??CWHHH 3\^M+R.>:** $Y]\T>_-%% "\\GG\Z.<]Z** $H]>N![T
M44 +SUYH]N:** $]<TO/4YHHH .??-'OSBBB@ Y'K^='/OQ[T44 &/2DY([T
I44 +S[\4G^'6BB@ ]>OKUI<'W_.BB@ Y(XS^= SGH?\ /^?UHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g201708092014007953361.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201708092014007953361.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,G G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W[(]>E&X>
MM(<\]?:D_P#KCK0 [</6C</6FGO^76@]_P NM #MP]:-P]::>_Y=:#W_ "ZT
M .W#UHW#UII[_EUH/?\ +K0 [</6C</6FGO^76@]_P NM #MP]:-P]::>_Y=
M:#W_ "ZT .W#UHW#UII[_EUH/?\ +K0 [</6C</6FGO^76@]_P NM #MP]:-
MP]::>_Y=:#W_ "ZT .W#UHW#UII[_EUH/?\ +K0 [</6C</6FGO^76@]_P N
MM #MP]:-P]::>_Y=:#W_ "ZT .W#UHW#UII[_EUH/?\ +K0 [</6C</6FGO^
M76@]_P NM #MP]:-P]::>_Y=:#W_ "ZT .W#UHW#UII[_EUH/?\ +K0 [</6
MC</6FGO^76@]_P NM #MP]:-P]::>_Y=:#W_ "ZT .W#UHW#UII[_EUH/?\
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M.!TZ4#M_@/RH_#/7MUI>?KWH 3ICVXZ?RH';VXX'3I1]!]./\_Y-'X9Z]NM
M .W^ _*CICVXZ?RI>?KWI/H/IQ_G_)H !V]N.!TZ4#M_@/RH_#/7MUI>?KWH
M 3ICVXZ?RH';VXX'3I1]!]./\_Y-'X9Z]NM  .W^ _*CICVXZ?RI>?KWI/H/
MIQ_G_)H !V]N.!TZ4#M_@/RH_#/7MUI>?KWH 3ICVXZ?RH';VXX'3I1]!]./
M\_Y-'X9Z]NM  .W^ _*CICVXZ?RI>?KWI/H/IQ_G_)H !V]N.!TZ4#M_@/RH
M_#/7MUI>?KWH 3ICVXZ?RH';VXX'3I1]!]./\_Y-'X9Z]NM  .W^ _*CICVX
MZ?RI>?KWI/H/IQ_G_)H !V]N.!TZ4#M_@/RH_#/7MUI>?KWH 3ICVXZ?RH';
MVXX'3I1]!]./\_Y-'X9Z]NM  .W^ _*CICVXZ?RI>?KWI/H/IQ_G_)H !V]N
M.!TZ4#M_@/RH_#/7MUI>?KWH 3ICVXZ?RH';VXX'3I1]!]./\_Y-'X9Z]NM
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M]?RHX]L'(XI3G.?F_2D/7_/KQ0 9XSQ^>.U!Z9X[]_K^5+SSP?TH.<Y^;]*
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M?GCM0>F>._?Z_E2\\\']*#G.?F_2@!./;!R.*,\9X_/':@]?\^O%+SSP?TH
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MGZ_Y_P#UT'\NO;'?F@D<\C_OKZ_Y_P#U4'U_K[T ! YX'_?/U_S_ /KH('/
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MU]?\_P#ZJ  @<\#_ +Y^O^?_ -=!_+KVQWYH)'/(_P"^OK_G_P#50?7^OO0
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M@D<\C_OKZ_Y__50?7^OO0 $#G@?]\_7_ #_^N@@<\#_OGZ_Y_P#UT$CGD?\
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M?K29[YQ_3ZT'K_GUXI><]^O>@!,GU.?3BES_ +1YZ'_/UI.<'K]*#U_SZ\4
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M4'KT_-<_YZ"@' ],?D.*!UX[?YZ?G0 <9]/H/2@#';\0,4#T_I[T#''0].]
M .@X].@HQTX[8HZCUXQ1Q]>_3]: #MP.OMUH]Q]10<?[/_?7^?2@^O\ 7WH
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M&>: %[_CZTG;Z?Y_.@=A]/4?_JH'3\/3_.* #IW&![^]&?<\=?;I2@G\Z3G
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M^E+SD#^M)Z=<#IQTH [8'3IC&:  =!VZ8]J.>W\_TH'7CK^7;O1Z=<#IQTH
M7G(']:0=!VZ8]J .V!TZ8QF@=>.OY=N] !SV_G^E+SD#^M)Z=<#IQTH [8'3
MIC&:  =!VZ8]J.>W\_TH'7CK^7;O1Z=<#IQTH 7G(']:0=!VZ8]J .V!TZ8Q
MF@=>.OY=N] !SV_G^E+SD#^M)Z=<#IQTH [8'3IC&:  =!VZ8]J.>W\_TH'7
MCK^7;O1Z=<#IQTH 7G(']:0=!VZ8]J,<8XZ>G7\*._\ /CG\_P J %'3OQU^
ME)Z=>.G(_P ^M'4$ <X^GXT=3ST/M_G_ ": #\?U[TO0YY'.<FDYZ]P/3^E&
M.>.OKM_S[T  STY'TQ_G_P#52]^^<]Z3\./I1^'T&/RH ,\#GM_^K_.:7G/?
M]*0^_IU_G2C[W0=?[OU_S_\ KH #U/';N,T?X\^O^>E!ZG&/_KXI..PX]/RH
M /\ /3O_ /KI><GZ^E'? [>Y_P ^M)QV_P __KH .W0_E]/S-'8\#C/;-!P!
MCY?QX_STH/0]^O;K0 OM[]*3C^7449'J.#^-'3C@8_P_E0 8X[_E1[C]*/P_
M ]:.,=?U[?6@ QQQCIV'^?3^5'!]#^'^?I1W[9_K2_\ UST/K0 GY_E[?SJ*
MZE:"TFE52S(C,%7JQ )QBI<=O\_RJO?V5KJ=A/97B"2VF0K(OF$9'U'([4 <
M#H]CXQM="TW5$>TUUIK5)9++4H5AN49@"524#!QG^,9XZ^G?V4\US90SSVTE
MM,Z!G@=@S1MU*DJ<<>M>72>(-,TB:1O#_C]FMT;:;75(9;NV!]!.!N4>^XUZ
M'X?OM3U"P,NJ6%O;2!AY<EK<B>*=2,AT( (!SW% &K]/P],=J,9XZ_4?Y]ZY
MWQ%JNJZ1J>ES6>G76H6$@E6ZBM45F1OEV/EB./O#&><^U7]$U6?5K1[B?2KO
M3-DA58KL*&8 ?>&"1CG]* -/K]?=3_GTH]??KQFC@<>G0'_#\*7O@=O<_P"?
M6@ [_CGI534;^#2]-N+ZYW>3;H9'"IEB/8>IJT,>N/Q_I^-8GB]E3P;JS-PJ
MVY)P,X&/3^G% &==?$'3+& 3W=AJ44+-LWO$F"W0C(;'M[5"OQ-\.E YDDY[
M%H@?Q&_K63X&T'1/$.C7]UJ%@EWC49DC^TC)51C"XZ#!)_.M/7_!WA73M(:Z
MCT&U4I-$"(H=S$&500%'7()&* '#XF:(;'[:;74#9B3R_.\E=F[IC.[U.,].
M::WQ2\.*Y0O.3MSE3'@_COQFO-8/#M^D%O')X>OSMDS(%L)=C#Y,%EZ-_%P:
M]'\+^$/#&I^&[&]N-$LI)958EC#@GYCU'Z4 3?\ "R]&-J+D6NHM 9?*$@@!
M5G&.!\WN*:_Q.T- -]KJ(YP=UNN.?7YN.]8[>&M'@O\ QBMMI<.VPM(I;..,
M$"-S"YRN#P20.E9TEC8LWDQ W&D\"35/M$TDD QA@%\S][C_ )Z 849R&P:
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ME:$9+B*VQA6<;PN[''3MTKT7PO':0^%M*BL)VGLUM(Q!*R[6D3:,$CC':@#
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M9,."%R"I!'"COSBM;Q!X)TFTT::XTVQG,\;(6_TB>0B/<-Y5?,&XA<D#/.*
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MG96MK?&%+F2/,4>X[1T&23G [^]>C+;W/C/2M-L4O;ZVBM(4DO;S8\;27 0
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MT'WSGM[TO.3]?2D['@].>/\ .:  GC.3CG-+SGO^&*3_ #T_S_GZT'&#P/\
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ML:?#%&TB0@+'(6:=4W98'(V!3C@#RSSWJ1K"*?<9[^^N095,KB^94NRSLNY
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M:OK_ (:U/4K.\MO&UG8W%JKJ#&T3[@Q7/WP0#A<9'K79_9[?'$$.,<?(/?\
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MV/9[(;:!1 F(K9@T2#:,!"  5'8UY/>2?9K[6[74=<\)6UUINV.*.[T>-7G
MB5@0"_W>=HQGI7J?AV?[3X:TN<Q+$9+.*0QK'L"$H,@+_".V,4 <YXU;RM9T
MN>PFU1-:6*81#3K:.X;R"4\S>LA"@;MF#G/:M#P3;"VT>X9XM4CGFNI)KAM3
MC2.621L;F 3@(>,8_I69XVA>YU[2(["#6)=62*=XSIUS' $BR@?>T@((SMP/
M\*U/!-W]KT64-/J<EQ#=207"ZE(CRQ2KC<@90%91U!&>M '2\XYS2=.G';]>
M*.#Z8/\ *C_/3'_UZ  ]?\^O%8?C-RO@_4PJEV>,1HB]2S,%4=?4C\ZW._\
M];'>N<\>Y'@;4MI(.U,8X(.]>E 'E.EVMX;>:X9ML<E_>R+9M$")6"E&+G?M
M(4L@"GD[FQQS6Y<0OONI1%A&:1'D.-WG9C41<G<8_-_=X( ,7!. "W*V&C6=
MQ!>7EU&LD<>I74,J2+\SCRF92KGC*E3DG."5)]]B;0-)1IXAIEK]H1))"26"
MB(*C%2N=PDV';DD@2$Y^\, $L:3W6L6C0QP1PZ;.Q" 8RNYU9P,_*Y'FG*[F
M)B0X!(%%Q=6NG6,5Y,&%LSQ+!)Y.\W );F4#.2(F60;L$2$XR2<4+O2--L[1
MK^QM;2.>"Y5[=WSG<EPH<GGD'*A,8.%<'GFM&[DMX[/49)[EHDW1B^GCF5=[
M^>Y7R3M( \[+X(),9&,<Y (EU.U69!-'>VXEA4SO%8RJUJ?*(983MRJ+A, 9
M $CC.#FHCJT<MO&_V-S,'8&W&G2F <(<[<?>\S]WG^X%'89LV)O%U)&BNKZ.
M58U.GKJ<B$6R"%R&D"C("@R#'^U&Q!!Q1(T$6G0B073:<96*Q!QYS-Y:#GL5
M\K;'C@B0'))(P 06OEC4;Z;RYVM=0:*:SEN"/-N?F5-LQ!)VGYB0^/F53U&*
MMV 6UB@@WR&V@MT%U<L<R6R"-L&%AR&\LJWR;AO9NO)%:QLTMKK7(GCM%F%V
MT=RUJ@$30^8G[M%YVMOVD9SP'Q@\U=MBOVC3O)XNBB-8/* 4B.96+28^\-X=
M\KM&PK@8!! (WBN3'%$]C:+=#<8[547RG3RT!9AD+N\S8@);.QF_AYJ1RK&=
MHU,L;MMBD?F2:8RJ%C<G!:-I!(K;@/ECC)YP#5E:Q313MAG^Q,V)(2ZB5W%L
M,%3C&!'YBGC[[*>A %NZ+?;=3\^1)9D64W,D(!5HMT0=8_XE=E$0&XGYTD'W
MN0 49/M"SZK((+&-%LX&9F(4QCRY?F7!X.P[N,_.1QR<7!YABA@FAA667+)$
MBJL<P\GYF<;B,J/*QD@_.X'&6K,GO-$M==E?4[6-W:.%H9)[43(N!*6+;1RA
MDPQ"[25QCO3K":VE\-0R1$&U 2.X^[S*L+;=NX8"J"X8$$\ISM&* +$);_A-
M]&PC-&VHPAI>PD"R"2/GG:K95./NKZ8)]L[],<UXJB*?'&CR2!_M"7UH@P2%
M6+RI/+4@_P 84*&SSD>AKVKJWX^E "<XXST[8I>A],=J3&?3\14<US!;)OGF
MBB3^\[!?U)^E $@]/PQF@9QGG\,>E51J5BVTB\MSN 88E4Y_6I(KJWG+"*>*
M0K][:X;'Z\=J )C[_D:#D=2?Q[_YQ2]#P._84G;O_G_]5 'G<UU;K\=06GC7
MR](*.68#:=V<?7!!KNGO=.DB>*2YM6C<;61I%(((P01FO/[S2K34?C4]M?00
MWMI_9IN##<1JZ(Y*KT(_V >>GXUULGA#PK%&TC^']*5$&69K9  !R23CI@4
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M(;J(+')N#'=P6(X/&#U'84 =F=!U'Q!=)XDF5;#4H!G3+::+<(TSG]^.[-Z
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ML* #M^G6EYYQG\"*3H?IT_PH[ \$=N/Y4 '?U.:49XQR/K2?YX&*7'/X]<4
M(>O';W_&C( ZCVYP,?Y%+SGN:.?>@!.AQ^63_GVH]OZ?K2\].>F#S2'./>@
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MGS32,655/WV4<* !PHZ=Z@U[4_$3^*ET;0KBQB=K83C[9&2O!P>1SW&/H?P
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M?Y].]+]1QS[TG/X_6@ R!W'_ 'U_GT-'3_/O_6EY[D@>O%'/TQUYZ4 )^/\
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M-_X5[X/#;O\ A&].W<C_ %(H AG\2W[7D5S:QVJZ+]M6T::8G?.<[6=""%5
M1C)SN(/3C,7@6]LX-!N!+>VZ,^H73A3,N0#,V.Y_F>M:&K>%K*^\/6^B6T%K
M%902QLMO+$7B**?NE<@_3GKBN M/AUK-C:/:?\(UX5OA&[!;BZ,GF3*6X)P.
M.#T]N] %N759H/C;>-IEM%J$MQI@C5!<! <#<<-@\_+[=>M>DZ9?IJEBEPBO
M&V2DD<@&Z*13AE/N"#_^JO/M ^&CC5[BZUJSL+2%,BVCTF66(Y;&26!!  &
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M"Q^T2PO)]C+JX<LV1@$9F^;D&10?X159M-UY[2&"2[MP/,$R6/V.4.ZK%@D
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MR*Q%\$6&U?\ B9:Z.!Q_:DW'3_:]JBF\*:/:*C7&MZO"&^ZTFKRJ#^;?3\J
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M^G?WZ^E<[X/:S^P75O:6EU:BVN3'+#<7/GD-M4C#;F^7!& #Q71<\]<_U]Z
M#(ZYXZ]:.<]\TO?\?6DZCU&,<=_SH /89]L$49'KGJ1S_GWI3[Y]@:.?4_Y_
MS^M !SGOP?\ /2DXQP<_E_G_ /71SC.#ZCV_.EYS_A]: #O@YQG!SBDSQUY^
MOM1R!QD8'Y4OYX_&@! 1VX'48_"C/')^O/YTN#T/?K[TG..I_']* #H?<>G^
M>]*.O!SZ],T'/O[<_6CG/?@^U !_%^/I32/FQV[_ *4[^+C^=(1EB>N/_K4
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ML:2V>YD87_)_=KG&2!&(<MCY@>GRYFCF=A;S-?2,ZG:+H/(OE QC*9V[OWC
M$8&/W)/WLB@##T:QMUL[6>W-TDAM;F1R9SL$8*Y0@84-Y>4(((WLN>,5J3A&
M6RC@LVE:2Z<P1R2A"C^?'O8G'*L5C4$8QL?.2":SM-O3)8V\%Q;7,VR"<I.#
MF,L7203YSE55OWIP./0Y-:LK7*)%*E]<QW6X1&2VEPUPIE$8B#%<,8PS<M@
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MC;PYX@:5B?&MZ 3D*MG ,#GC[O\ G'Y(OA[Q(DNY?&MR0< +)80GC'/8<^]
M&GX<N=/NM"@FTVV^RVF^15BV!=K*[!NAQU#<]ZQ?%OBBQ@LM2T>*"ZN[B33I
M'=[2-72%"&7+G/ R#4_@/Y/!<._=(1/=!N.7Q/)G@<9.*YW17MK#P=K6GS0_
M9;U=.EE6VELO(>*)@P5-Y'[S!&-WK0!LP:U$_P +KBZ*7%LUMIY@(E7:X<1
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M 0!Z#T_"CVX/X_7M0 <@_P"3V_7O1CV_SV_E0,'IWZ\\_P">E''MU_S_ #H
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M'J1U-)R/K]?I1VXZ>H_SSQ1CMC\,=: #GH,]\4O?N2#^5)_^OIU_SBC'&,#
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M-RHR_P"__>1GJ517$2#K\LC'U R])NKI[2RMTT]C#]FVK,)(RBOYJLCN ?\
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M$91YCGRFVE6V\!0TF1M/,J'_ &:AU60C2UG(-Z"]J6W)+B\Q*02^!GY<"'#
MM\G.25JI_;&IW$4IM+F+SHDW_:EEG#PJ20X4R*.6"A@"V"8L_>SD V9]ANKI
M?^6RQ2 R(VW]T%C5H@N#MD,9$(.6^=6X)/"@1DV2M;RO&]PQBB&&*.9P&=AC
MYD9A&0!M^6*09ZDQMYZ0RI.ZI,$9GMX2=L9W*XN!M^0,F[S\(3GS..-U9.N_
M:5N=.5'M[C=O6::XE1//42\0G<03L^YEN,/_ '30!J%V:*9F4L?,C^TL<8N#
M^\99$.SA5<-*PP?E9.PP9/F0IB!X7CM,V\C* MM&(-PCD7;GS%1G4MD_/*IP
M<@# ::SC,LD>I7)E1@OF[ IBPK?NP=^XJ6X^7C" G)P*5GL55HOMMT5V,1#Y
M<960[!B9OGVY)W.?XN%'WLT ;DJPB-0-/G>U>1LVL1!DWAD5B#MY4H5C XPR
MN,DG<)+!I(O&%I-((WF6Y+2/$N$ED6*[RZX_A.!CT ZG&3@Q/:S7%I$FK2Q"
M2<B6[N  9(]_W&8/NP!@9/RYD.. 34JSS6NMV,VEP1-'/=1Q"W699!#(XF00
M9)S\J$@$87//3% 'M'AYM_AG26QC=90G&>GR#M^5:7<\_7M5'1K:6RT'3K29
M=DL%K%&ZJV=K!0#]>15[OZ<]C0 'OG'H?\]NE!XY_ICO0.W^/THY]\X[GF@
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M '/OGUHZ\=,]J!VZ=!T&:.W_ -;- !QUQ_G-  ]!P.<"CH?SHZ#/! Z<?RH
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M3,"K@9X+-OR>3B)#M!^4\TEM<F]E?^P<_:+?=%#/>ADBC\K+.X8_,_EA/O8
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MXS.K7AF_TW:1Y3#[3TC'4'S-F-W.T28^;)H H176I6C2)<Z8[3I!;\6=L_\
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M7M]3\+:5?W6JZX;BYM(Y9"NI3 ;BH)(&>!FM7_A"+# _XFVO8[?\32;_ !H
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MMILD;1,/*9QAEV3;T8[?17.,XX09Q@UMRBV;27:2&;[&OGYD\M&D63R5/1F
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M\IL",$@8*B1FYSE$! 7FM6/9)JNNB]U+2K26:2* +<3[&>!XH\R$M@LZHJL
M<8<L>PJCI F@T"!H)XHW26ZCMY7=3'%&#EHY6(VEMPC8$@G8K'..!HZ3H_\
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M)]: /?OPX]A1W]3[@^]9OAZ_EU?PYI]_/Y9FN+=)'* A<D=AZ=:TCW_^*^M
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M]?\ /M^=.YSG--PV<^_K]*  '/)/7WH''&?\YI0#@=>E&.W(_']* $]. .E
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M6I7NFZE)!@V=H!<RW";N"%D#8Y[\#UZ5VFC1W\6C6B:E*TM\(QY[G;RYY(X
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MN_FCRL84DN556(.. !S@A+YY8Y;-K2S:[<3LZH&V?: ;5RMP3NP'<9D/ .5
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M$?GQLS&8C@ [43GJ#8$MW'*J-H.HJ+51)(-L?[L_,X=,R$!F7=(<[OG1>HX
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M3[?Y/:@ ^OMU7K1QM]@/\BCCKGWS_6C^+J,_6@ _BQG/;W_S_A1CU''?C^E
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MNNC@@C.Z."-6QR50"I<Y[DCVH \V\9^#H++1+W5VU34KNXAB6-/M<JO@%P,
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MUS7PV9VN_$;M^\<W?+ 8#'S)>1V]ZU?%^KPZ/J7AN:6"ZG)O'"Q6Z;W<F%U
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M#2 R ;FWVTA1U 'W1*[D<=)5H VYGN5-R\S.(U23[05=5<2[4WB/^+RO-\L
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M7\LNY*@_/L/4D#'U WD>CWR6DED4AA?RRZ9:7_1\L&VG;O6(JV3D[W< $9-
M&E!'OGBMUM7F66S0I9$GRKT^0I!/8%L&3(&<P@##9)9J6Z30KIOM,MSOM)U2
MY*MODQ&I6,X(.,9F],D@#A@:%K>,T$<UY+"=/N ]O]HB %Q$QVHBKR<J2J+G
MCY68' P:O:RJOI%\LAM_M!LI3+%&Z&(*=O*\XWEU9>,G8HXX&0"&+3K>-+JV
M_LV")G"":U2(CR,/M9MW&XJ2$X[39.5P*?9P6MMJ&E2Q6\>9BT31Y5!?!DEW
M(P?CEP(<-S\@)ZKBQLCC;$,T)A.Q;61Y8]\Y5F8"7!Y!3S'.[&&"'ECBL>_O
MI8=,N&>&T6VMIK>TN241RC8VMY&&Q&%0@\9^=GQQDT .T96M_#$GD,]J$OKQ
M3<0[@]L=H_=@+\_"J9>O_+$#K5K5?M4.HP_9K62-TDO-MNDFU;<^6K;U/W>5
M/G8']\CIFL^#4K.&QFAN3%!<1WMTZ6MU$3&R2;9$+C&W<3M7.?\ 5EO2I;_5
M="EU9 +Z.>*-;HQ/,K%79MH E; )4L7'/\"K[ @&K97=WJ$5A,\,J+.[(%,G
MF"Z7SF!C8_=QDK!ENTN3QC$1>X6V?'GAT90K 29M_D8"-2#N(<@IP>/(_O$5
M6M]9T5&M(_MUO&J[4.V/8($#.BM'@?NW\LF0XSB3;W)Q#_:VC_979KZU) "!
M#$<2+Y1!+KT)7"!<GJ\@Z?, #8E:XB=_+:23="Y\I,A;@M&K>>". 6P9R!\W
MR8'.[,,P^TP0)<3F2#S^;BXC+KD2*0K*?[H^;+<8N./E4U3EU?1S+< ZE;NH
M5R[!#N!*HVR,XR8R^(\$ &/(X !)+K^DI+%.U[:2,9B3 D1=!B4$.% X=LNQ
M(S_JXS@$;: -!6N#OC:&:W$;H8[<%L61WN,*W\1/_'M\O'0GC;3U\^40HD#W
M@DMPS)RHU',1PQ_NLQSU^;-O_>:LV#5=)C^8ZK#)$AC"22HPDN.6!,O]["$2
MY.,2GN<X3^U](EV1MJ,*AH07D@5LVQ\H@K#CD*-J*%&?]9*,]Z )-225]"NI
MC+)*=K+]LDSN8;XF$9#<XZW [?/A>,U=N_.6YO0()HC#(Q%N68BT82']ZIZ?
M*#CY>OVGGY!61<ZUHQL9"]S:RS$.ILXPZHPS&01M.0Q8%,CK&H.!@ N.LZ:;
M[4(O[562V#I);W<T#+-+^]RR2MCYEZOG /R)GIMH U8_/9XXY$:7SU598V+#
M^T3AQL;=ZX%OE^Z@G^&G>%0'\>Z9*<7+$S[KK R<01@>_J,'D8/0DUGQZQI!
MEMU&I6R1N )6AW9M/ED7="0#M(!#X&</(1DYRLWA"[COOB#I;VY4[#<&00JW
MEQ[H$"@'& /E; YQC\P#VCG_ &O\_P"?UI.H[D>O%!'M^E'Y'N#MS0 ?Y].M
M'UY_KZT>W2CKQZ]10 =N>1W[T<],\_6C/?TYY%&,#']/2@ !ST)YYX(_S_\
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MX,F8,PJ=F/O8<@S<<#RB/O9H Y^'3)TU^ZN8+V6ZM DHG62&2,R1$*K1#>"
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MCZ"@]STZ\TO.3]?2D_/\O;^=  0.<X_+ZT8'<#WX_P ^M'/8=SCBC@'Z>M
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M(.X[@,YS\M*QNH;NPCM8#;&Z5(U6VA<MYH$!W94/_  I7! S(XZ_-5G6]/\
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M(B//W7VLIP!\L*GI\M8VEIN\)K'=QE;-9YO-V1JLR':G0-@;?).X8_Y:;?\
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MDED6:;[7'-;JUQ I.=1_T<DF/@?>"H ?EYMV.,_*:[RW+6:R-J40D7S%CO\
M.(T&U"4)VYY?$_3A1P><"S);R_:LK:O:B. !YD+,=,(A;*@]"5)4\@MFX/\
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M6PQ\]3C<%%/\%K;Q_$-(H8VMY(XYEDMF!S'D JK'U5<#\^] 'KO'J",^N?\
M/:C_ #_GZTO?'/Y_6@9SW_R: $^G;T/]/PHZ>G'X=OY4=>.?TXHZ]![\>AH
M/H>>WS?Y]/YT=_\ /K2\^I/TQBD'0?ACIC\* #T/K[FCMC_$?_J^E&/7/3_/
MO1SZ\].O^?\ (H ,@]Q^?K_G^5<9\09$BBTIIK6YG@>?9.(W<(T1VAE<*I)R
M/IT(SSSVG.,G</RX_P _TKBO&ECJ<MY;WEHERPB#1K]DFF#*K#+%EC=><@8Q
MGKS0!T/AR/R?#6F1^7)%LMD&R;[ZC X;@<\>E:?3CO\ YYK-\.R02>&],>U
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MY)5?E(8Y&Z1SC@K3;B^ N;P7&MQ.GVF4 1P1+)(PD&V,L^3M\W[V\[=BJ#U
MIMJ9CJFF2Q26AE\P)Y9:W\MH1D@C;]Z3?O.8_F^YT)% &O;Q$7,H,/[Q9(S/
M J<6I#R#;'SR/,)@R,83GD$884=M2L-D4=P\ENX@B?A;Y?((!?/=L/D$Y'D*
M,G(-,MQ ($"J&MU:-K4.T9;:(Y"3,.F[R1QNY\S.,?-3I?LT=WON/,$*)+]L
M"C)WB",/Y6T?<YBV_P .#+CY: .>\/17,JW4CZA]EC21-TTEMY[JRH#@'>#A
M4"R=2 5X^[SLM9ZG&LR2WUK!,DF;N(:< MN PRRXDP2KLA&,<2GMD5B^"U)N
M+DVZQ_:O-1<7*H(P,H5ZXYWGG&3MQ_LUT2R1^1%Y+L8C.OV1Y0IE+;VV^?WQ
M@2D[_P"()_'Q0!3$>H)<VX@N(BTJ!+5O[,&R0[O+,<G[S@Y+QX;(PHY[BO:V
M45C:HEKK%W)"NY-_]EDF,!78#/F@J&!9L#',8.!@9OQM (XY)Q&L2P8NW@V;
MU3R6)\G;T/EE#^[R-Y?'&ZH+EQ%ITKN+-)R)C'A8C P"H""OW2_F[% Y8QDC
M&W% #K7[4USJ\D_EDAR[7"0")74)$6G #8W1J1(!C<2Q.1R*GU*QGNKC3EAB
M9Q]I *F1H1=IO9'B<\E51G2,9SD2D\#@5K)%6.ZO91>/->RK(3=!%E$^]%1'
M4'(B+JX8-@;0O? J&_N[58K9;I+62.<@3_:&VI%&!(\1C:/)5BN<E<_/C^(F
M@"Y9W-U+#,[V8@,5RL;-%(\@C;#*H3HQ$C9A)'&(QU.&JPZ/]ID41QNTD)9(
MV4D7*^6#YS8;&YES-C[Q:(#.<DU8 MKI]O'<+!',(AM6'RS&^(1YF_\ A)5-
MA3=@[F?'RY-3&/)N6>.$!@RS,%7<)CY:LJ'KY7F[$Z;?+)R0N,@#<*4A=YY(
MUB=C]JBC.[B0$IC.=J95@3D'SR0-H*TZ,2>9,K0;71E+6H!VV?SNNU,'GYL0
M?)CY6R<C #E\U9H!Y5N]P) 3"PC,6#,Q4YSPYQ(6*DG*1Y&_ J-8X?(B$;LM
MN^W[-(57S)4VN<S>I\K<XW8_>].<X )%224P!4%XSPIY4/.W4 87 =^3M+X8
M8;+9@49R0P?X-EW?$2'R[J:YBF2YD:1I,AF&U0Q7IN9<'UZ^]5G:',IF*0HD
M1%Z80OF0,(1O$&#]S_5 ;?EP\@SMR:M^$97;XD1Q2/;B6,78>&$@A"2">W"@
MY"C/((H ]:]OZ>]'U'Z4 <X_EQ1UY/X\]/\ /- !CC'' ]/Z4?AT]J/<\>O:
M@\#G]3[>M !_,>HSBCZY'^?\]*.N>A_'/KVH[G_'% !WX S_ +OUH'ISVXHR
M,]1_WU_GU%'L./QZ4 '3\/\ 9_S[_G7)^*-"U'7M12T>.V;2=BN)V"F:%UW[
M@@8$$O\ (-QX !XKK.W''X]/\.U9>NR:A%%8G3EDR;Z%)O+0,1"6P_!Z#'?\
M: +&D17$&C6,5VL:W,<"K*L0&T, ,@8 &,^@%7!Q@?R%+W]L]_K2=!S^/)':
M@ [#CI[=/\XHQCMCCM0>O^!_S[T?S'^?UH /7WZ\4=<9_(BCOC/_ (]]?\__
M *J,X'8?CC'% !VZ?^.T$=>.OM1W]AZ<_P">U*!G'Y=<T )QSGI@GIC^=&.<
M8_):!V(Z=NIH_P \GT__ %4 '.._3T_6CH?SHZ=NGL>?\\48_+H>^: # Z8X
M'7Y:7OS_ "I.HSG\?3CUI1C(/3)_S^M !WZ_E3.I/?V_S^5//7'7V]:9W([Y
M)_SQ]* #ZYQ]/\^M.[^_X_Y/6D YXX]/I_G^E+G@GMUZX'^?\: #G'X>_%!/
M7D8[\T'CM[=/RI>>>3_@: #OC/?UI,\<GT[TO7CJ"3Q2#.,\_ACTH ,^I_'-
M'IT_/Z=Z7GGK]:3OZ'IP10 9XSD?GD#BCM_B?\]Z7W.?T_S_ /JI.>O7W'^?
M:@ X'L/RHZ>P_2CV'?N.]'ICOZ8H #G]/>N5\<_9X+2POY-0L+*6UO!+&;U"
MT<S;67:0IW$X)(QT(KJNOX^_^?>N3\>RQ6MGIMZVHK8W%K=^; S6K7!D.Q@5
M"*>?E+9/;&>.M $'@BX74M2U;4SJ-C<7%PL*/!81ND484-M)+@%F.3R.P%7_
M !(^M6FJ:=J.F64]_!"DR36D$ZQEG8*$9@Q *C!^F<T_PSJEW?R7,5WJMK>R
M+%#,@@M'@VI("RD[F.<@=NF#5OQ1J5SH_AF_U&T$?G6\>Y!,#L'(Y..P&: .
M=T?1-;TO7]&N+BZO[F:[CFDU9FN"]NC8!154G"X8X&!T!KN,Y!P<]^#UKS.]
M^(>H*);>WNM#6ZM5EFF9+@S13QHB,JQG*G<V_'?E37I2,9(E?:PW -@CD<>]
M #OQ[^M>8_&.1TL+)!+&OGQR+\X.3B2$X4==Q/?T!KT__'UKRSXRRJ(=+@,:
M2.Z2C#,-R#=%\P'4G@CCU- &+)::HE_"YO[>W,$&W>;(A;'$3X4_/D,"W\63
MF<'[QP(UL[](H([J*.>$3R-)IL5L\4DHV(@(.6/3$(XQG(!/+#2N%9[U\ SN
MT'[N)E.V_'DY#OSPQ"LQ'WLVZC.[YC \D?V>-FU:Y\M9),ZB8V9D)V-MP#G
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M&94,##;E7"[0!EOFC;J<XTK2U\C48YKF[2Z:XN2LB) $?*R(H<,#]P^6K8P
M?+<9Q\U7+J79]OD5XRS122BPSE$.]2LX8?*S XF 3DF;CC-,@EOQ+8>>-AF;
MFZ0.%)$BYMW5CE=I=HP6)3$W9>* )+9OGF>6X$Q>:-II$? N#O=]T?RX"B3,
MYX/R$>F"KA_M%NBW,:%+>187E;(M(Q;@!)?=0SJ3SS,AQ_#1&C_>,+Q!&10G
M[S-E]X;5[G<?]&RO'[L9Y*TDBL=8M@R)<K)!-((/N_;/W4>9R3R"^"_'S#R?
M[V: ,7PK))/8NEQ<27T0EPENDI,@^2-=V<9(*[8P..4(XSE=]II'2X:6X2:3
M?BXFC8;+H&3YO+&.-S*KCD_+&PXY8\YX0<QZ?)<!A:*9!F[5W)?"QDIQ_=R7
M.>/WASP&K;N/,@T>Z9(VM5@1BD88YTS!?!&>#L_U7R_WQGY<4 2P1R+)9>3F
M*940V\TAW+:_+(0TF5^8!M\A/RC;(AP ,%)[-)=-C1%N[>W>3S4@#*9F=80
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M)_P_SUZ4<X'7...?I2C[V/YT  ^]_GFF9&2<_P NN/RS3Q][']:9W_\ K_\
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M$JH!Y3K=-&0'CD$2;DB!.=F[RAC[NUI.=N"6LMX)X8UBLI;YW;Y9%3[.5,J
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MY[D],<UYWX8T46?C9FMIK=[*(7!CD&H^<9DD*%4\LDD;,$9/8CK7HOTXSTH
M._<9KSCXDVYO;^VMVE,<0T^>X=0@;<8WCP.>@^8^]>CX'!QBO.OB),MOK%GN
M('FZ9=0+P<%F>( < X)QQG ]Z ,'3O"^BR6K2ZQ):Z>_V5;[<;*(1R0L =R$
MC)VY"D')!P><BL:7P[9)K02]:.PM# EQ$'MU5PC2C#2!1P<#=M[ \G :NJLI
MM/\ $6C:<E_K%II\&FV\26222)YAN551YKJ?X5.5"'[W)/:J4VHSZ]XK;RK:
MTO=0BM(EDB4B6%V64?,I!QL.0>N1W!Q@@&:VA::9;M_[/M(G:8*ULT;%;/\
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MPN+)6OI<SEN+D?:F^4 9' 8KR0/WX[9Q!J-@%M[HZ?HMI<%Y_+:8VR[HW,J
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M-K%&JYD."%.X8'(XV#KTKM4B<S9*LZ2/&4N'CD4WG+MSDY^[_I)QCD8.1M
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MTQ (CBQ,=[$( RC)5 \;=#N91V!*6UA96\+2"VMEW.C)'&JDVN4;=&Q\O(+
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MY[]^U*0.<X],D?Y]:.,YXZYZ4 '/<^QP:,9QD'_(H/ /L.OM]:,#/(')P>*
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M8ETW_6\XZ?*,KZG/I77_ )^_%><>#WTN/7;&&UT[11?,EZEQ/8)M95CD548
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M'' )Z]._>@#SKX?W5E>:@MS#JFE0W$UN9'TC2[18E3[OWVQN9EZ<X&37HO\
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M>H_LKQ /^9EC&.?^0>G'_CW^<5N]L]._3I[_ *TO^/I0!@_V5XAY \3)GO\
M\2]/_BJCN="UZ[M);:;Q*#%,C1N!8("5(P>]=#]?Y>]  XX'_?/T_P __JH
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MEE(!-A:'&>_^JJUX5\&2>'+OSGU%;I8[86T,:P;/*7.>#N/^2>M=7_D9!/\
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M*7G.,G_.*3 QC _[YH/?/?/;_.: #\3[GB@\#ICN>GUH/O\ G0<YZ<Y]/:@
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M_P"JC/.<Y'7K2_-[_AC_ #_^J@!._KSZY[T CCG_ ,>^E+W&<_C1SC^+\<4
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M'X]_7B@!,9^AZ8_SZ49[T>F?QS1ST.?< T '8^P/3O1Q^&>O;UHZ^_?C_/\
MG%';/ZYZ?C0 #KC.#]?K1G [#\<8XI>>X)'IQ1R.<G'K0 AX]/;)H. #QP.F
M/\\4<CZ]/K2]^^?YT )W/.?7!HSWR/KTS2\\=<]LXI.^>?T^M  /\\'_ #ZT
M#''(_.CC'T/7^M*,Y&<CZX_S_P#JH #UX'?T[XH_.C^+\?2DQ[>G:@!1V.>/
M;G-)CL0/?Y?\^IH'8]^_% Z=.V. /RH .V1QQU"T8'( ]N%H_P ]/K1QR??T
MS0 'GT.>?NY_S_GUH[\ 9_W?K1TY[]^/K1CL!G\*  =,?3\OI1U'8\<_+GUH
M[?A_=HZY_'\* #OP!G_=^M';'X<_X4=^GX?Y[T=/7\NM !UZ#'X=*.G88^E'
M^?NGWHZ=,#GCC\* #MC';&,<4'KG^8]Z.OTZ>OX4=_0]>G?I0 8[>_I^M'7\
M?:C@\>O'O1^'7/&* #Z<9_"E[_4^F/\ /%)V^HZXSG_.:#WX]>W_ -:@ QGM
MU]OI1UZ]^O%+CG\>N/:DQQT[#M_];M0 HSG///M28X''T^7_ #BC\/7C'_UJ
M,<\C_P =^E "CKQFD[#Z8'&*.OZ=OQH_#L.@[4 'J1@_US]/\\4'@9],]OK1
MVYQZ'C-'?TY[B@ QCH.G/"TO?OP:3'MG_@/7_.*#TZ\=<T  SQ@?3C'^11VP
M#TZ<4?0#.?3\J/IT]10 =^ ,_P"[]:.,8]!QD=L>E&>/UY^OU[4>W;W% "GK
MSG_)I/K_ .@T>N<=.X_S[4>O^% !@#L./]G_ #Z?RHXQ_/ ]*.,_CZ?Y]J/K
MZ>G_ -:@ YQ^/I_GO0.GM_\ 7H(Z\>O:C@YZ'ZC- !SCH?P_6EYS[TG!!X]1
MT]>:.<GUY_.@ _\ K=11QUZ_\!S_ )Z48'3''3IVHY(SWQZ=_P#(H .<<=O;
MIQ1QGVXY_P#KT<=L8[8'Y48YZ?D/?F@  '' _P"^?I_G_P#50.W;IVQ1_+WH
M_GCL* #T_J/\^M'?TZ4'IGC!R?;_ #WH[YQT]J # QT!_P" _P"?>@^_3W%'
ML?H<T8]<_E0 =#SCCN!C_/>CH1ZCOM-&>_'K1QT('Y=>U !@8'Y<C/M1QW Y
M_P!G_/K_ #H]S^/'O1R.!UZ T ';GIWS1VZ?7CO]*.G0=/1:._Z=,T '&?3\
M*.W3&.O% _SQ1CV_,?Y[T &/;Z<<4=_RYHQST'MD?Y]J/\].: #^?TYH_P >
MPZ?YS1Z'C'7.*.!QV']* #KGCK[4>_\ 0T=N>>,=.U'^/- !CGI^0]^:/P^@
MQCWHQQTZ^U'KC^1H .#[CM[T>O/3G)_*@]3V_"CGL.G3B@ XST_\=/\ GM_*
MCN.GY8_SWH_EWX_S_DT?Y- !TZYH'8=/H,4#J.WX8_"CM^'7!% !CV _X#_G
MV_*CMP.V.G6C&,\8]MO^?2C'7ZX/'/\ GI0 '_Z_3^5+WZ=3V&/6D&?Q//X]
M*4=>_P#GO0 AZGG]?:CC/;KT!]Z4\G&:3.<'\B<4  Z#OT[]:/X>QX_.EYXZ
M^U(.Q]L_A_G^=  <<].O<_Y[T>GZ'_Z]'.#USWQCTH[^G./?_/>@ XSBCK_+
M\Z,\>P&<9P!_G%'0$=@.A/;G]* #K^/N3^GXT=1QT/OG_/6@Y]3^-*>_?'K0
M AQSDCG/7_/M0>^<?C^-'/09HZGZ^A[4 'X?^/'_ #WH_P!H<\9SCK1R3[T'
MGZGU]>M !QQTZ]SUH''']<=Z7G/?K2>W3MC/Z?Y]* #M@XZ=":/7_P"O1R,G
MI_+_ #_C2XZ#!Z\4 )Q]>_3]:/;(]N?PH'\//O1SCOCZ_2@ _#\,>GX48[8]
MO\\=Z..?K_\ 7H_ ?2@ _P#U].?Y=:./]D?1O\^]'OGWSG]:7G@<T )W]3QV
MH&,?AS[_ .<4#H#SCJ.]';Z<=<X/%  .O'Z-G_/>@$#G@8_E1[>^,9HY[9]J
M #VXX[?_ %OPHX!^GJ3_ )[4O\L^OO2#T'I_^J@ /3D]/T]Z."><#V)^E+Z'
MMG@YXHY]3GWQ0 @/3\.]&>XQ^!Z_YS1^/8]3VI<\Y^O4T )[9^GS4<'C]/\
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M'7_Z]&.Q&?8\BE'7\?7WI.WI_P#J_6@ _P \KUZ4?AV'0=J#P3_CBCM[?6@
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M/PQ1SMSSTX.>E  1QV]#_G'>CO@GCT/^?\XI>^.?_K4<Y'7^7IVH 3/?_/\
M^NC@G&[/;)/^?:EY]_SHYX'(/I0 F>.<>^31T')^M )P,>G8T?\ ZL^A_P F
M@ [\''THZ\Y[>W>EYSWI.<9'X<T !_(T$X)YH^F11W].>QH /QSZ'(^E&3D\
M_G^E+S_M?I2#V_*@ SSP<_3O1GT/;KQ^?\J.QS^.>M+S_DT )WZ\=>M&<#@C
M\_K1_DY/TI>0,G=^.* $[>H_G1G'<?B:"#T_S[=J7\P>U "'CZ]?K^E'MG(Z
M<]#1TYP<GZ?Y_P#U4O.>#GGK0 G/3)_SQ1SZX_S_ (T>W(_'IZ4?IGCC_/\
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M[4);QVAV6LC7+-$Q==W##CYOG.<>HJ$ZSHFG)=Z'>_;(;-7>-&><N6\L*64
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M^HQS[5TW;)Z@^F?>CW&#WH[8ZX![]: #O_D]Z/J/3/%&>>O?U]Z!CV/X]?\
M.<T '4=CQS\N?6@_EU[8[\T9XZCI_>QZT=^OZYQS0 >Q''TH^O?V^E'7DXY]
M#_6CO[_C_D]: #MCKGK1[_CQ^5';\.Q/^31G!Y/^<=?I0 O.3]?2@=1QWZ$?
MC2<=,?A^5*.H/'/O]: !N^<XI.F<<8]QC_/^-*>OZ]/PI.W?CIQ_GF@!<8/
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M8Y(P?UZT 'X?IWHXQG]?RYHX[_C1[GCU[4 'K[<\_P"?QHP.F..G2C/KV/\
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MP?>BB@ &<_0\\]* #_DT44  R>1G!I,\$G/'4]QQ110 N#Z<T=>F<9['_/\
MD444 &#Z8^F*3(!.>PR<&BB@!0#[TG49 X//'I110 N"<C]?\FC)89&<$=C1
K10 8;O\ I1\V1110 <Y )/XT@(VAOX<?_7HHH 7YL=_P^E'/X9HHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g201708092014008303363.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201708092014008303363.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,G G # 2(  A$! Q$!_\0
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M#&>U #MPHW#\_:F]>3Z?B*.>_&??_/O0 [</\BC<*;UXQ]1_G\:/?]?3_/-
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M4>_X]/7\* #WQ[]/_K48_P X]/PH_#]/3\*,=OPZ4 &.V/;\_P */?'OT_\
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MT_+M1C(Z=1Z>OX4>^/4]/_K4 ''IQ].PHQVQ[?X]J,=OH.GI1C(Z=1Z>OX4
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M.E'O^/3U_"C';'M_CVH]_P >GY=J #\/T]/PHQV_#I1QZ<?3L*,=L>W^/:@
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M>W^/:CW_ !Z?EVH ,<=.Q[?_ %N]+CG\>N*3CTX^G848[8]O\>U !^'IV_\
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MUU!>VT5U:SQS02J'CDC;<KJ>A!'45QGQ:+'P!<#,84W, D#]QY@X'OG'X9H
M?X:U.>ZTQ-8^SQ0W.JA+F= Y90#\J[0>3\J'CU(K8;6Y1$9"$&_F,'MU8AO0
MX('/<&N;\(C'A'P^H(*_94;'(V98DD^HR W..(S6LQ80R'<6R07Y/[S@G(..
M,$[N!_&.^!0!A^+_ !WK>CZIINGZ5:VL]Q<H5=9E()DW!1MYZ'.1GM59?$OQ
M2'7PI:XSM&&';_@?2LOQJ"?'WA,%U9 4"*.J+YZ80^XZ?A797PL'UJ]%_JFI
M3%[@1I:VC3;2 @/E848R,EOE.>>?2@# O/&'Q$TG3[B_U'PQ8K;0C+N9L;1Z
MX#$FK5MXH^)-U;17$7@VQ,<JAT)O0/E(R.,_2GZZPC^#^N!KS[2JI*@+EP8O
MGP(R6^8E>G-=GX?R/#>ECN+.$?\ C@H \_3QM\0CYQ;P=91K"P61Y+L!03TY
M)P?P]:LVWBKXB7D1D@\'6156*'=>!2".Q!-:\D+7FG7Z65O+),JHI9XE$<I\
MP%@JDJ6''4FMOPX\S:)")SF9"R2,<;B0Q'S;21NP!GD\T <9<^*?B5:6TUS-
MX,L%AAC:1V^VKPH&3_%]:WO /BZ;QAH+ZA=VL-K(DYBVQR;@WR@YYY[BMCQ+
MSX4UG)X^PS_^@-7B_P -;F7_ (0+R9K6*WL9[IDFU9X_-$(V(-NT<J<<!C\H
MH ][_K1WJ&TMXK6S@MX"3%'&J)N;)*@<<UYOKOCWQ+%XZN/#>A:39W;Q*,"1
MCN;Y-Q).0 .: ,_Q.,_'O03CG$73Z25M:EH^KQ>-=?OH_#KZGI^IVT4&4NTA
M.%49ZG/4>W2L6ST3QMK'Q(TO7M:T.&SB@*B5XYT90JJW(&2<DM7KV?PH X>Y
MN=?O8$MYO!5P(UD65]NJ1 RLN,;R/O<@'\*:+?Q!K'CS0]6O=!?3[6PCG1V:
MZCESO7 .!]/3O7=<^OZ_Y]Z,Y/\ ]>@"EK) T+4>@_T67G/^R:\I^!X5K9F4
MYQYH_P#'(*]-\4.4\'ZTX;#+83L#GIB,UYU\%50Z5 Z!1O:ZWX'4C[.* /6^
M]'Y8H]Z/QH /RSQ_G\Z.,<=,]>WK1]#1QGK[T 'M^F>:..G;MS1GCKT[YHY(
MZ_ES0 =LD^^1T_.CIU/UY/\ GUHR#S_7M1TZG'N30 ?D>W7_ #[T9],'Z'_/
MM1GWQU[T9]3CZG% !]/PY)_SVHR.N??[WXT=\9'_ 'U_GW_*CGUZ]* #@?AV
M]?PHQVQ[=*.H]N]'.>V?\^U !^F>>_\ GM1QST[]Z/I_GVHS_M?K0 <9Y(Z_
MUH].GL:.?_U'\Z!U'(R..M !Q[#C\J,<]/R_S]:![>V/\_2CV_GU_P B@ Z^
M^1_.CWQ[]/\ ZU'/KZ]Z/H![?TH ,?YQZ?A1CMCV_/\ "C'^<?GVHP?Q_K^5
M ![X]^G_ -:C'^<>GX4?A^GY=J,?YQ^?:@ (XY_'^O:COR/<_P"?RHZ')Z]:
M/U _SZ4 ';K^-'X?0<T?K1_7\,T 'U[>M'0>GXFC..<@#KUXH_+\_P"OZ4 '
ML<#_ .O1D=\>O)_S[T?CC)HSWS^5 !T')'OSC_/>C'8^AS_G%'?K^M'ITP3G
MVH ,]?\ 'O1P!D=/:CG'&>E'?^6: #CVZ^M QD=/P/2C/J>W?BE[\GJ?7WH
M#UQD_G_G_(I#TY],D'I2]^/6D''Y>G6@!>1W/U-)SCOF@9';GZ?Y]_SHX[8/
MOMS_ )[4 +C)P?UQTI/?!]>E&.V#CTQ1^'N?EH  .@Q_]:CTX[<=J,>H[<\?
MGVHP<_UQ0 =?7Z\4#V].Q[4=>??Z_P">:7V^G6@!.V?7I@TO?O2?_KZ?Y]J/
M\]* #_/6CVYH_#]*/Z>U &-XFM)[[2!!!I4.IMYT<A@FNC;K\IW!MP!Z$#CO
M7F#BW?2V\22^!;8V)NB)+A=<E)!\W8T@7;RN[TY([5ZEXAO;VPTY9K*YTRWE
M:5(]^I.R1'<<  CG<3@ 5Y:]CI[ZJ3-J'@AI&NO,EM/[7N!$TN_D^5NV;MW^
MSU[4 >T\YKRSQ9XAM[#Q_#;ZI<:9;V(FACEBNK-&::$Q.S2F1@>%<*H Z$\]
M:]2_SS7E_CW5+JQ\2"*PNM4M[IXU(>]CB.ECCNT@)4^NTB@#M?!\US<>#=)F
MNXQ'.]LK.JP^4 2/[F!MSUQ67\2+/^TO#=MIP98S>:C;6XDV[O+S(/FQWQZ5
MT&BSW%WHEE/=2VDUQ)"K2269W0LQ'5">J_XUD^-B?L6D%6V$ZO:X8C./G]*
M/+O#'C/58M(_LRS\*7FJG3&-J]Q;,<2!7.W>H'ID8YX)K:;Q9XB((_X5UJP
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M^GI^%&/;/;I1QGIQGTHZ#M[G'^?K0 #/;F@].?3G.*#WX]>H'-'7_/K_ )-
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MXYZ]/\_Y% #N>A_,4>^,=^33<>@[^E&../SQ_GUH =_7CZT9&<],_K3?P/\
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M\Z $[_7WHSWXHH_.@ Z4?3'M12]^] "<>V/\_P"%'3TX_P _X4?G^='/O^=
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M\T 'T]>.<"@8R.?U_P ^E'([X]Z49H 0CGI^G^??\Z/<=^^/\/PI>,\X_/\
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MP?B3Q!J&O_">>>VTF"'2B(HS*UYND&R5!]T+SR!WKI?ABH_L:.3^+^S[-?\
MR&:XZ-MO[.=PYXQ,"3_V\+76?"N29](8/$(U6SLPA#YW#R^&Z<9]* .__P \
M&BCOQ^AHH /Q_6C\?UH_SUH_.@ SWS^M&?<_G1WH[=_SH ,^_P"M&?7MSUH[
MT#VS0 9QW_7KC\:,\C'3/'/^?\BCGW_3-'7W!]\T '^>OZ>M''T_&CG![\=#
MWHY(R,GC@\?Y[4 '7KS[9HXXSSG]:7W&>M)GT/7W%  #G'/7WHY]S^/>@]\]
M.^31_GZ<4 &>^?U'^?\ ]=&>>3Q@\Y_S_DT#)_S_ )_R*/Q(]<F@ R?4C\O\
M_P#ZJ,]^^*.3Q_G^=!]3WYYZ4 ''K]>?PH_$Y^O-'Z?4_EWI?SYH 3/&1QQQ
MC].U'.<9QSZT#/\ ]>CG'/''<T &0>_Z^M&>_/3U&:4YSZ9Z<TG./\^M !GW
M[>O6CCIG\\?YZ_SH]^<?6@=OY4 &?4^G>CK_ /KS^5'..IQCJ*,^I_6@ R,=
M?7'-'.<<YHY[^H'6CIUZ=Z #/?)]:!Z \^Q'^?7\J/KZ^O>CGU[X_P _Y[T
M';C/3ID49 /;\Z/T_'U_&EY_VOT_S_\ JH 0]<$_G^%&?KW[T?F,T<]^"?PH
M ,C.<^_44H)SU_4?Y_\ U4F3C.>V3T_S_P#KI><]SCKS0 AZ'T'M_G_)I3G_
M "*0XSDX_/I1_GGVH ._X],4#CGIWHXW8_KC_/>C\/\ )H /PZ#THZ?G1U'X
M'MFC/7_'O0 ?U[XZT>AQQQC@?Y]*#CG].>M']/\ &@ H_P ]*/\ /6C\J #Z
M?AQ1_GI1^5% !_GI1]?Y4?YZT<>U !_GI1_GI1W_ /KT4 'U_E1_GI11_DT
M'OU_"N"^*#I'90L[JJBQU#YB<#_CW(_K^M=[Q[5YW\6T#Z$Y;.4T^]88;'.Q
M1_6@!?@L/^*!QC_E]FSQ]*]#[=/T_P _Y%>=_#.*ZT7P-I\.(9WOLW:$$H%\
MP;E4@CK\K#\ >G3K%UJ0Q^:;9-FX@X?G&-V0,<\?RQZ4 8_Q2_Y)SJF#_%"/
M3_ELE=@>.37'^+X+GQ)X;U#0XC#;SR%#YCLS* DBLW09SC'&.N1VKH3JB^:B
M)&2'8JI!]]O3Z_IS0!@Z9X>_M*YOI_$WAC0UF:3,4D2"5I!SRVX=>GZUI?\
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M_I[4 'Y_G1^/ZT?YZ4=LT '_ .NCG_)HZ?A[48[?TH /8?SHH]_Z4=!_]:@
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M_P!?2E&>O-(>??V(H[]<^^/I0 <],G/O_G_.:7GGJ:3M@#_QW%'!XXZ\<>U
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M)/O@ ;@>4O[Q\#.)"K97C&",YP<9^JXZ\TKL5$X\PHY+?(%S@<?O.#C/_+3
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MIZ<?Y].E'/\ AQ1QG'X=?\^U' ] />@ X]./8=J.??-'&,'GC!%''?UZ]?\
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MYT?A1_GI1_GI0 ?G1ZT?3\.*/?\ I0 <_P"31W[T?R^E'X=O2@ H_P ]:/\
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M,D0#9N 5[9Z\ #GGY/6@",M#';!AO$.?FY&X';QSC'3=GW(]JDEV>;.[L?,
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M;]V<6_!.>>,D?.<YZ#VJ,8^S0+AL8R(QO'F_+DL>_&0?J_K4RQR>;%A(R/\
MEBNT@MUX?L!N.T8SQGKFH!%_HZJ)$(4CS6V'.[;A549Z$[L\CA0/>@"*_,?]
MG:H9))%4Q2*\B$Y0[0/+&.#@_)P,]?>K7@.9Y_#KR21^6WVAALP!C 4=O\:@
MN_,-M?;=A=[=_+&"0$VCECW;;\W;D_G+X!;=X>F8(R_Z4_#=>@% '4Y[\?G1
M11Z]: #CVH_+I1_GK10 4?E1_GK1_GK0 <4=/3\Z*7\_SH 3U'L<T=_U./\
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MNC?,H\Q\C;<'>V2OISAQC/0CIU>LDAE"JT<3B!2DI&?L_P"[)VMGK@Y/./\
M6"@!AD):/=.GV@@D2XQ&_P!W=U&,[P&]=N?:D'R_:5C^6)9#M27[RGS,*6]1
MNW9R>A7OBAI2;>$"!?+<L1 >2#M7&#UQ@F/ '7%/E9O,O"ZK+M9@\@Z.-RAE
M [;AA?JA% #E)-Q!AP047<.#N7+8 /=MNX<?Q >]0HY%FH$T?!!5N, >7SGL
M/EVD?1NU2(Y2YMD,*Y8 AP3\A+L2_N-P5^>,"HED86CLT!#%E4_-PQV,>#CC
M!)/_  ,&@#+\;$GP=XA^<*QM9=ZY&=V4R1WQGI[8]J[^U7R[2! ,!8U '3'
M[5Y_XU(7PAKT80_\>3*&R?D V84C'4 A>O7ZG'HH^ZI[$"@"KJDJP:1?3-]V
M.WD8_0*37BOPMT?7]9\,S2Z7XGDTZVCF\L0O:K,/N!C@MT'S?='OZU[)KO\
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MT=^G ]O\^_YT?7G_ ("?\^M !P.PX^G^?2CI[]^>]&>>3W_^M0/IWYX_SWH
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M>SU/0=/!.0+^[#NP]2J'Y?Q.>*9_PFTV?^1K\'X_[:?_ !==[]G@'_+&(?\
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M(9EFB26-PT<BAD8'A@0#F@!_0^G?_P"M[]Z.W&,CT/\ GO1^?]?6@\^_;M0
M=_\ ZWO1Q[>_.?\ />CMGG'<Y%*<YY/I_G_/K0 A]\?C1C^>#1[]B>N>M'].
M>.<4 'O_ )_STH)ZGTZ48/3&.W6C/KG/UH /UQ[DT=_\\T'/N>?SH_/\Z "C
M\OSH.?S]3VI?\XH 3@^F:.O/'//6BB@ X]JXOX@122G2S:WEU#?(TK0):VKS
MNYP,G:K+TX^]D<XKM/S_ #KSCX@1RW%TD5[:3M9QRK);S-+:(F=OS(ID=6YY
MS_A0!TG@O1IM%T,Q3/DSR>>L>QD,8*J""&)(8D%FYZL:Z.L_046/P]IJ1D%5
MMD"X93Q@?W25/X'%:'T_#F@ _P ]:/RH_/\ .CWYH *./;'UQ1T&/2CG/>@
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M (B.GWAVJWX?GBGT&Q,$JNL4*QL4!QN50#]:R/&C3B&S^QSRPW3R,B21S"/
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M'Y4OXT=^M "?UH_*EQ1CZ\4 )WHI?QYHQSUZT )1Q[4O;O1^)H 3M1W[4O\
MGK1^)H 3C_/^?I7!^-? VJ^+Q>VXO;*WL[@V^W*,SJ(BYY[')<_D*[W'N:K2
M7]G#)Y<MW!'(,?*\@!YZ9'O0!Q-O\-[RU@C@B\=>)(XHU"HBSJ%4 < #' %/
M_P"%?:EM(3Q]XDW=MTX/Y\5W@S[BC!_R: ."/P\U0D'_ (3[Q+UY G7GKC%,
M'P\UGC_BX'B#)S_RT_*O0,']:.??F@#S[_A7>N=_B#K^<<_-Q_.E'P\UP'_D
MH.N'ZO\ _95Z!@\CF@YSWH X#_A7NM_]#_K?_?9_^*J.7X<ZW+$Z-\0-:964
M@JS$@@CH?FZ5Z$6 ."P'U-)N7^^/SH \BT?X,SZ<($GGTN=8YXY/.,+^8H61
M'P.<=%V].C'K7=>+FU6VMXM5T_4+>SALHY7N!/O*,"F%)"@[MIYQ71@@GAL\
M>M!4.I5AE3P0>0?;% '$6BQ+X8UN'4+W2'6\@>2.UM"%C5?*P>#@Y)!8Y]:\
MS\,>%=/UJ:"-8$DW:2URL<5UY >;SV1 S?-@[0>@["O<M1T#2]0M)XI[&TR\
M;+YAA4E21UZ?C7CATK2/#'BDZ==Q6FH:?;6$7F72LD4T1:4XE4Y)9ESSC'&/
M2@#?TGX665[Y;7^DW-C"P+$KJ[2.ISP"OE@?K7,Z-H>FO>^&;>6U@GA?6]3A
MD^T(&W1QJP4,?XL;<X.>?2O4-)O[*T,#-JS79 \MIY=41D?L7V[L>_2O-]!G
MDEUKPEMMV,+ZWJ[#)!#DJ2O/IR>_8GI0!W0\+>'U(_XD&F1J/XVM1B#Y3][L
M<<'GGYL'G%(WA;0=FW_A&]/ZDF'[/AC\N,CG/!^7ZG/6M1"0P"1"1P@\M2!B
MX&"!GGC/S+@YX4<\TQGC%JK;I/).2)2N67Y<@8SW7+=>JCZT >5?%/1-)TJY
MT"6PTVVM_M5[*CO;)L$B@)C(!_AR1QW!/%=]X,36-+\.QS6$2WFG"\NE:R(V
MRPJ)G \IS]_IG#G)SUKCOC Q4>'SM,4BW\VY'/R[ML>#GW&&S[FO3?  ?_A"
M[-Y"/,DDFD?!) +2N2 3U SQ0!K:1K-EK-MYUG(<J=LD3J5DB8=0RGD&O-?#
M/A*V\4Q:Y-=W"/%'K=T%CDMED!;H9,G)W$''!P !QFO1]3T*WU&9;I7>TOXP
M1'>0?+(H]#V9?8Y%<)I%WX@\#17=M>Z$ER+_ %2:=+O[7'##\_3=P=A.._'.
M,T 1^)? =AX<\)ZIJEFT*S6ML\A*VB(TJ '=&7'S*&&0=I'7BNC\-^';:Y^%
MUAHDY#P7%B"N4_U>_P"9< G^$D8)YX!S5+Q#)XM\0^&M0TJ+PO;PB^MFA$_]
MJ(P4,",X"\C\:N:1=^*M,TFPT]O"L;K:VT<)==2C!.U0"0-OMZT 9W@;Q5=2
M6<1\1Z@C"\4/97#1"-#M+(\98<;@5SR>=W'>J?PPO+O4O$OBG4KZ4337(MF9
M@H55 \P*H [!0O7DYSWK$\*^+X='TO2)KN^G:R:'[)/I?V4D)(9G/G!\?-@<
M$+G./:NN\#WEOJ/BWQ?>V$_FV3S6J1G;M VPC( QT&<?A0!W)P/\_P"?>C\L
MTH!]Q2?G0!R/CN\BM[>UBEDO(U<2RLUM>^0=B!2W!XD//"\9YYK7\,6]I:Z!
M;PV5Q#<P 966.,(6R!RV#][IDGGVJ+Q!XBM=#*"XLY+EO)>X(0H-B(5R?F(S
MRPX&35K0M5M]8LI)[:!H!',T+QG:<,,9Y4D'J.030!I?EVZ4?S ]?\^]+CW-
M&/?M0 G&"./2@]?0_7_/K2GZG\J,<\$]: $XXZ8[?Y_*CG'KP/6EQGH3R.^:
M#SWX/- "<>Q].?\ /M^='&>W7O\ YZTO8\_ES1QSS^5 "<#\OI1^5+^)HQ_*
M@!/Z]Z*7'UHQSUZT )12X]Z,?6@!/>N.US5M3T[7+N1=;TJWMH(HY(;"[D1/
MM .0V7SN0YP >1[=:[+\?RK@?$(C'B>X6WTE+G4\QSQ2W0;R8T6)PSE@AX .
MW;DY8@X% '8:.UP^B6+WCK)<M;HTK@@AF*\G*\'D]N*N^_O5'0PG_"/Z;LC>
M)/LD6V-S\RC8.#P.1]!]*OX^M "?EZT4O3G)HQQUH 3Z44N/>CISDT )1^5+
MCWHQSWH 3KTY_&C\1^)_S[4I&1Z\''2CH>N,<\F@!,CUX]S_ )]Z/PY]?0TH
MX[],#BC!]_\ "@!/P_3\NU QD<C\_P#/M2X]CT]J7OU/TH ,\]_\:9SDC'/T
MZ]:=_%3/7C\,4 .W9].32YY[_2FY]_Q_R:7D=L8[4 +GKZT$GW[XQ28P,>GK
MVH_3^E "Y[\X-&?QI,CKD?G^/6CVZ^E "YHS]:3M_P#KHH 7-'&.G%)^/^?\
MYH_2@!<T9I/P_P#K44 +^%&:2CB@!<T9I/RH^M "UY!\4(\IJBQD(]Q?V$+N
M!SM*/P3UQD _A7KWM7D?Q,8&>[0YR=4T_'/7Y'H 6?X90VTS0S^/YHG4 F.2
M0AAGID&6J>J_#1[/0;W6(/&M]<QVL+2;8F;:Q49QD2'TKO[B#4+KQ3>W46C6
M8-G"L<,UP&S=*PW$!A\HP5QR"?H#5/4[N\U'P'XI\W3VTY8XIEACEC,9*B,$
ML>Q^;=R.#B@#Q'48KJWTNROH-4UHK<-"A::21$+NC%PI)^8 @8(X.:VX?"^I
M7WB2VT73]=U$W302R2?:YY8PA20KQCKP%.0",FE^(;.?AIX$9>/]#DR/^V:5
MZ)=_+\5=)64.$'AZ4.!G</F[=\]: .77X;>)KA9#%XDMW\LD.4U*8[2>N>.*
MHZSX9\4>&XM,^U>))C;W]U':@VUY*S M_$-V.P/?TK>2.Q@\'174ULVE@6;B
MSU: H1.A# 13@#&XC&=W&[)!!JWXZC4>%/!,:@@+J%GA3@8PG3'_ .N@#"\)
MZ'I^H^(M8M];GU"_CM+)9V^T2R1R(VYMPP&'8#VK=?1O#4,*W8\,:DMB%1Y)
MVOV VO\ =* 2'?[@']:L-J=IIWQ6\3?:=0MK)Y-,@6&2X<!=W..O7DCBGSZN
MD>BJEGXMTIKAX=DL5S?1L(Y.!OCD X(/;&/I0!SGQ$TJT\(W^@SZ";BSEEGW
M.ZW$C%@'C&,,QXPQ[5[1W_&O%_BOK&FZK=>'SIVH6UV(YCO\B4/C+Q8S@]^:
M]H;K0!SGCZXEM?A_K\T#M%*EC(58'!!Q7EW@CX?Z=KO@[3[VYE=))"\8"QYP
M%8CKD=?S]Z],^(SA/ASX@R2/]!D QZX_G61\-(9(/A[IR2P88-)O4-G'SDT
M8_\ PIK0&QF79CG/E=?UJUI_PPCTR_L[VSU^[!LW=X(60&%"Z[20IX!()^O%
M=N%82$A7#8ZYW4@#>7@1L<=!@T 8-S#=VUY<P3:V(XI(1(A%F"03\I5 #D8
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M;0!G!QTK0_7\: #W_I1_GI11^5 !W_\ K4?YZ4?E1V[4 'X?I1_GI1Q[>M%
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MTGEX&"1M'7N<4 7[?0#=:QJD":C<6T%HRE3)/(<>N3D5*?#,1;;_ ,))\SL
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MYHZ\<]:*/Z^U !_GFE]N?Q-)[<?E1^'Z?Y]: #TZ_G1_DT?YZ4?YZ4 '/O\
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M ']:*/Q'YT<>W^?\F@ HH_*C_/6@ YH_7TZT=^,4?YYH */PH[?A10 4444
M%%'Y4?E0 ?A_.O-_$DDT-[XBFB34HM)(VZ@]MY+EG\D?PLA=5*%5W G&2<
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M_.C</[P_.@#B==\,^*_$6CSZ9>ZQHXMYL;S'8.&X(;C,A[CTKM(EV1HIQE5
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MOPJCK_Q4>G*.-PW$9&?I3V\=^$!"?*U^U8GE50Y/)P!B@#8^S6Q3/V2W#?\
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M<@Y.>H4=:Z'X=W'VGPR[ V\D:W<Z1W%O;I!%<(&^6154 8(QS['K0!UPZ_\
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M\XH]OZF@ ^O\J/\ /2BCCV_.@ _STH_#]*/;BC\N?>@ _P ]*/\ ]?2BC_\
M70 =/_U5E>);^XTGPOJFH6BJUS:VLDT09<@LJDC(ZGFM6D9U1&=F5549+$\
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M>71TJX9DECU%U/V8!20RN6)P< ;3GVP>#S^HZG;76LRRVFHV3QSRW#M+-=S
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M #TH_P ]**#CVQ_2@ 'XX_E0,\9Z_2C\?Q% QGH!^/3_ #B@!?XN_P"G^?\
M]5-;G(_3/6G\;OYTWKWXS_A0 G?\12\@<?YYHP,<].X/8?Y%+CGH">_% ">X
M]/;WI?Q/YT?6B@!*.?6EQ1CVH 3_ #UH_P ]:7%&!Z4 )_GK1_GK2\48YZ4
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M=BLZDJ.W&* .QH[4N..E&!UZT )_GK_GTH]>M+QWHQ0 G/X_6BEQ010 G/\
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M3GQ?JK -_P (/KX8G. 5 %=)_P )+:Y(\FX'U"?_ !51S>*[*#R]\5R#*X1
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MBD/?_"LO3KJ:>\E61B%"D[&'(.0<9 QE22IY[?6M3\J %[TF3ZFBB@!><_\
MUJ3G_(HXHX]J #)H_P ]**/RH .>G]*/U_"C\J/RH 7FC)]32?2CW&,=J #G
M'&>/3Z4O?^7%)UZ'/X_E0,9Q_4B@!W\5-X)/&0:._'7MQ1U/O]/>@!,G'J!Z
M_2EZ'KTXR,4#MV]/:CTQZ?Y% "\Y/^/UI,G&<D?C1_GI1C]?:@!>_>D_SUH_
MQ]*,?YQ0 ?G1_GK1_GI1_GI0 ?G^=']*/\]*/;^E !V_^O63XHT=_$/AC4-)
MBF6%KN+8LCJ6"G(.<#'I6M_GI1UZ]_:@#SVY\%^*KI]:=]9T96UB%(+EET^3
M(15*@+^\X.&/)SUKT%1@*#R0 ,TOX?ABC_/2@#A-/\"WHU*"'5[FRO-$L[JX
MNX+<1$O/+*S$--GY6VAFQCO@]JW_  ?HLWA[PQ;:9/Y.^-Y7VP?<0/(SJHR!
MP P'X5N4?YZ4 -DBCE7;+$DBYSAP#5=],T^1B7T^U9CW,2D\=.U6O\]*/\]*
M *;:3IKL6;3K-F/4F!?\*3^Q]*'_ ##+,?\ ;!?\*N_YZ4>_]* *1T;2L?\
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M)_[YH[YQWST]OI1QQQQ]!^5';/'3J!_GWH !Q^'M1['O[4=^GZ4?YZ4 'O\
MTH_#]**/\]* #_/2C_/2C\/TH_STH /\]*/\GBC\/THQV_#I0 ?YZ4?YZ4?A
MS]*/\CB@ _STH_STH_STH]\?I0 =/_U48_SBC\/THQ_G% !_GI1V_P#K4?YZ
M4?UH /\ /2C\/TH_STH]>/TH /\ /3_/^31[?TH[]/TH_P ]* #_  ]*._\
M]:C_ #TH_P ]* "CM_\ 6H^O\J._/KZ4 '?_ .M1_GI1_7VH_P ]* #Z?AQ1
M_GI1W_\ K4?A0 ?A^E']/:C'^<4?U]J #_/2BC_/2C^GM0 ?U]J/Y_2C_/2C
M_/2@ _STH_STH_STH^G\J #O_P#6H[?_ %O\_P"11]/PXH_#]* #_/2COT_2
MC_/(H_STH /\]*.G;I[4=_\ ZU&/;]* #M[?2C\.OM1_/Z4?YZ4 '^>E'M_2
MC\/TH^E !^'Z4?YZ4<?Y%'X?I0 ?AU]J.O\ ^JC_ #TH_#]* #_/2CO_ /6H
M_P ]*/\ /2@ ^G\J/I_*C_\ 7TH_STH /\]*/K_*CI_^JC\/TH ._P#]:CT_
MPH_STH_STH /\]*/\]*/\]*/\]* #Z_R^E'^>E'^>E _SQ0 ?YZ4?3^5'^>E
M'?\ ^M0 ?A^E'^>E'X?I1^H^E !_GIUH_P ]*/\ /2CMTH /7_"CO]/:CV_#
MI1^'Z4  [#^E'IP:/\]*/Z>U !CH!V'I0.HX^G%&/7GZC_/K2]_?Z4 (3@GG
MOZ_Y[4'N/YGKTI>_7OC^M)T_#MF@ S[]?ZT=<=/;^='/3U]^IQ1WS_\ 6^E
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M3CYL?A67I>N:GJ=[;0W7AA[:UN=XEDF#90JHZC9T). 21P#]*ZE41!\B!?\
M= % "_C^M']:/\]:/\F@ _']:*.??\Z* #\:/\]:/\]:/\]: #_/6CG\Z/SH
MH .G3C]*7O2?C^M*/O?CZT '.3C^5)]/IP.G^>*#R2.#[49]QWP1^= !QQ^%
M'O\ R'^%&><9_(T?Y_&@ ^F,^PH^G\J/U']*/KB@ _I[4?YZ44?YS0 ?YZ4?
ME37571D/"L,'GVKSY?#BV#:>MOX=N$/]HO=>9;E2;9%8!5^9QRZJI)YX+>U
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M.^:./:@#D!H_C 6OV<ZM:F,$+U)+)L(/)7<&+$'.3@<#WDO=(\2F]EEL;V%
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M_GI0 44=_P#ZU'7_ /50 <T?B?SH_P ]*._3]* "C_)H_P ]*!_+VH **/\
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M2C^OO10 ?XT8XZ=O2BB@ HP*/RH_(4 '\^U&!CVH]:/RH /P_2C\/THHX]J
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M110 <^_/O2\GIGK110 <GUQ1R<'G%%% "<\'GVI?;FBB@ P?>CG/_P!>BB@
MP?>C!]_SHHH .<]Z3_\ 4:** #G^E+R>F>M%% "?GS[TO/O^=%% !SGZT@SZ
M&BB@!>??-)V]A110 N#Z'\Z/SHHH 3GIS1R?7WHHH 7DCCO1^?%%% "?GS1_
M^JBB@!>?\:3G //YT44 !!QWQ2\]:** #VYH&>O-%% ">GO[TO.1G-%% "#.
M._YTN#TYHHH .3Z_G1@^_P"=%% "?UHY]Z** %Y/3/6D_.BB@ _.EY]^?>BB
?@ Y/K2>_//2BB@ YHYQQFBB@!><'KWHP<]Z** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>18
<FILENAME>mack-20170630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFS ActiveDisclosure(SM) XBRL Instance Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2017-08-09T19:46:29.6525140+00:00 -->
<!-- Version            : 2.4.9.2 -->
<!-- Package ID         : A96D3A1EC002FD8DA16B9E2A7F952981-0001274792-001706 -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<xbrl xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.xbrl.org/2003/instance" xmlns:mack="http://www.merrimackpharma.com/20170630" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="mack-20170630.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <unit id="U_shares">
    <measure>shares</measure>
  </unit>
  <unit id="U_iso4217USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="U_iso4217USD_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="U_pure">
    <measure>pure</measure>
  </unit>
  <unit id="U_utrsqft">
    <measure>utr:sqft</measure>
  </unit>
  <unit id="U_mackEmployee">
    <measure>mack:Employee</measure>
  </unit>
  <unit id="U_mackSecurity">
    <measure>mack:Security</measure>
  </unit>
  <context id="C_0001274792_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_20170808">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
    </entity>
    <period>
      <instant>2017-08-08</instant>
    </period>
  </context>
  <context id="C_0001274792_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="C_0001274792_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001274792_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_20160401_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_20160101_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mack:SilverCreekPharmaceuticalsIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="C_0001274792_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170403">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mack:AssetPurchaseAndSaleAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mack:IpsenSAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-04-03</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170403">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mack:AssetPurchaseAndSaleAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mack:IpsenSAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-04-03</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapCounterpartyNameAxis_mackBaxaltaMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20170403">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mack:BaxaltaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-04-03</instant>
    </period>
  </context>
  <context id="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mack:SilverCreekPharmaceuticalsIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20170331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mack:SilverCreekPharmaceuticalsIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20170101_20170331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mack:SilverCreekPharmaceuticalsIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mack:SilverCreekPharmaceuticalsIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mack:SilverCreekPharmaceuticalsIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_mackWarrantPurchaseAgreementsMember_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mack:WarrantPurchaseAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mack:SilverCreekPharmaceuticalsIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapDeferredRevenueArrangementTypeAxis_mackClinicalTrialsInPancreasAsFirstLineTreatmentMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170403">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mack:IpsenSAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mack:AssetPurchaseAndSaleAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">mack:ClinicalTrialsInPancreasAsFirstLineTreatmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-04-03</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapDeferredRevenueArrangementTypeAxis_mackClinicalTrialsInSmallCellLungCancerMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170403">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mack:IpsenSAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mack:AssetPurchaseAndSaleAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">mack:ClinicalTrialsInSmallCellLungCancerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-04-03</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapDeferredRevenueArrangementTypeAxis_mackOtherUnrelatedClinicalTrialsMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170403">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mack:IpsenSAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mack:AssetPurchaseAndSaleAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">mack:OtherUnrelatedClinicalTrialsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-04-03</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170402_20170403">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mack:AssetPurchaseAndSaleAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-02</startDate>
      <endDate>2017-04-03</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170402_20170403">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mack:AssetPurchaseAndSaleAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mack:SeniorNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-02</startDate>
      <endDate>2017-04-03</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170403">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mack:AssetPurchaseAndSaleAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mack:SeniorNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-04-03</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170403">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mack:AssetPurchaseAndSaleAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mack:IpsenSAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-04-03</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170402_20170403">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mack:AssetPurchaseAndSaleAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mack:IpsenSAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-02</startDate>
      <endDate>2017-04-03</endDate>
    </period>
  </context>
  <context id="C_0001274792_20170404_20170405">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
    </entity>
    <period>
      <startDate>2017-04-04</startDate>
      <endDate>2017-04-05</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mack:AssetPurchaseAndSaleAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160401_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mack:CommercialBusinessMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mack:CommercialBusinessMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160101_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mack:CommercialBusinessMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mack:CommercialBusinessMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mack:CommercialBusinessMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mack:JanuaryTwoThousandSeventeenCorporateRestructuringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20170107_20170108">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mack:JanuaryTwoThousandSeventeenCorporateRestructuringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-07</startDate>
      <endDate>2017-01-08</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapRestructuringCostAndReserveAxis_us-gaapContractTerminationMember_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mack:JanuaryTwoThousandSeventeenCorporateRestructuringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapRestructuringCostAndReserveAxis_us-gaapContractTerminationMember_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mack:JanuaryTwoThousandSeventeenCorporateRestructuringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapRestructuringCostAndReserveAxis_us-gaapOneTimeTerminationBenefitsMember_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mack:JanuaryTwoThousandSeventeenCorporateRestructuringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapDisposalGroupClassificationAxis_us-gaapDiscontinuedOperationsDisposedOfBySaleMember_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mack:JanuaryTwoThousandSeventeenCorporateRestructuringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_us-gaapRestructuringCostAndReserveAxis_us-gaapEmployeeSeveranceMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mack:CommercialBusinessMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_us-gaapRestructuringCostAndReserveAxis_us-gaapEmployeeSeveranceMember_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mack:CommercialBusinessMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mack:CommercialBusinessMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapDeferredRevenueArrangementTypeAxis_mackDevelopmentAndCommercializationMilestonesMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170402_20170403">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mack:IpsenSAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mack:AssetPurchaseAndSaleAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">mack:DevelopmentAndCommercializationMilestonesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-02</startDate>
      <endDate>2017-04-03</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapDeferredRevenueArrangementTypeAxis_mackSaleMilestoneInMajorEuropeanCountriesMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170402_20170403">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mack:IpsenSAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mack:AssetPurchaseAndSaleAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">mack:SaleMilestoneInMajorEuropeanCountriesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-02</startDate>
      <endDate>2017-04-03</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapDeferredRevenueArrangementTypeAxis_mackSaleMilestoneInMajorNonEuropeanAndNonAsianCountryMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170402_20170403">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mack:IpsenSAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mack:AssetPurchaseAndSaleAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">mack:SaleMilestoneInMajorNonEuropeanAndNonAsianCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-02</startDate>
      <endDate>2017-04-03</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapDeferredRevenueArrangementTypeAxis_mackClinicalTrialsInLungCancerMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170402_20170403">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mack:IpsenSAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mack:AssetPurchaseAndSaleAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">mack:ClinicalTrialsInLungCancerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-02</startDate>
      <endDate>2017-04-03</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapCounterpartyNameAxis_mackPharmaEngineIncMember_20110505_20110505">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mack:PharmaEngineIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-05-05</startDate>
      <endDate>2011-05-05</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapCounterpartyNameAxis_mackPharmaEngineIncMember_us-gaapDeferredRevenueArrangementTypeAxis_mackDevelopmentAndRegulatoryMilestonesMember_20110505_20110505">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">mack:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mack:PharmaEngineIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-05-05</startDate>
      <endDate>2011-05-05</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapCounterpartyNameAxis_mackPharmaEngineIncMember_us-gaapDeferredRevenueArrangementTypeAxis_mackSalesMilestonesMember_20110505_20110505">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">mack:SalesMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mack:PharmaEngineIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-05-05</startDate>
      <endDate>2011-05-05</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170402_20170403">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mack:AssetPurchaseAndSaleAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mack:IpsenSAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-02</startDate>
      <endDate>2017-04-03</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20170403">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-04-03</instant>
    </period>
  </context>
  <context id="C_0001274792_20170331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20130731">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-07-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockCompensationPlanMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockCompensationPlanMember_20160401_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockCompensationPlanMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockCompensationPlanMember_20160101_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapConvertibleDebtSecuritiesMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapConvertibleDebtSecuritiesMember_20160401_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapConvertibleDebtSecuritiesMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapConvertibleDebtSecuritiesMember_20160101_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_mackWarrantLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mack:SilverCreekPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mack:WarrantLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_mackWarrantLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mack:SilverCreekPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mack:WarrantLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mack:SilverCreekPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mack:SilverCreekPharmaceuticalsIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mack:SilverCreekPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mack:SilverCreekPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mack:SilverCreekPharmaceuticalsIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapLongtermDebtTypeAxis_us-gaapSeniorNotesMember_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapSeniorNotesMember_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_20151222">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mack:SeniorNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-22</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mack:SeniorNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mack:SilverCreekPharmaceuticalsIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_20151221_20151222">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mack:SeniorNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-12-21</startDate>
      <endDate>2015-12-22</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mack:SeniorNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapInterestExpenseMember_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mack:SeniorNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_20160401_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mack:SeniorNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_20160101_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mack:SeniorNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20130701_20130731">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-07-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20130730_20130731">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-07-30</startDate>
      <endDate>2013-07-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20160412_20160413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-12</startDate>
      <endDate>2016-04-13</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20160413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-04-13</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20160417_20160418">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-17</startDate>
      <endDate>2016-04-18</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20160418">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-04-18</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20160401_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapInterestExpenseMember_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_us-gaapRelatedPartyTransactionAxis_mackTransactionCostsIncurredWithThirdPartiesMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mack:TransactionCostsIncurredWithThirdPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_us-gaapRelatedPartyTransactionAxis_mackTransactionCostsIncurredWithThirdPartiesMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mack:TransactionCostsIncurredWithThirdPartiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_us-gaapRangeAxis_us-gaapMinimumMember_20130730_20130731">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-07-30</startDate>
      <endDate>2013-07-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_us-gaapRangeAxis_us-gaapMaximumMember_20130730_20130731">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-07-30</startDate>
      <endDate>2013-07-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20170525_20170526">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-05-25</startDate>
      <endDate>2017-05-26</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20160101_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapPlanNameAxis_mackStockIncentivePlan2011Member_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mack:StockIncentivePlan2011Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapPlanNameAxis_mackStockIncentivePlan2011Member_20160201_20160229">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mack:StockIncentivePlan2011Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-29</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapPlanNameAxis_mackStockIncentivePlan2011Member_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mack:StockIncentivePlan2011Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="C_0001274792_us-gaapPlanNameAxis_mackStockIncentivePlan2011Member_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mack:StockIncentivePlan2011Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapPlanNameAxis_mackStockIncentivePlan2011Member_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mack:StockIncentivePlan2011Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapPlanNameAxis_mackStockIncentivePlan2011Member_20160101_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mack:StockIncentivePlan2011Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapPlanNameAxis_mackStockIncentivePlan2011Member_us-gaapTitleOfIndividualAxis_mackEmployeeMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mack:EmployeeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mack:StockIncentivePlan2011Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20160401_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20160401_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20160101_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20160101_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20160401_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20160101_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20160401_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20160101_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20160401_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20160101_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001274792_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20170731">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mack:SilverCreekPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-07-31</instant>
    </period>
  </context>
  <context id="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20170730_20170731">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001274792</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mack:SilverCreekPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-07-30</startDate>
      <endDate>2017-07-31</endDate>
    </period>
  </context>
  <dei:DocumentType id="F_000000" contextRef="C_0001274792_20170101_20170630">10-Q</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001274792_20170101_20170630">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000002" contextRef="C_0001274792_20170101_20170630">2017-06-30</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus id="F_000003" contextRef="C_0001274792_20170101_20170630">2017</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="F_000004" contextRef="C_0001274792_20170101_20170630">Q2</dei:DocumentFiscalPeriodFocus>
  <dei:TradingSymbol id="F_000005" contextRef="C_0001274792_20170101_20170630">MACK</dei:TradingSymbol>
  <dei:EntityRegistrantName id="F_000006" contextRef="C_0001274792_20170101_20170630">MERRIMACK PHARMACEUTICALS INC</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000007" contextRef="C_0001274792_20170101_20170630">0001274792</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate id="F_000008" contextRef="C_0001274792_20170101_20170630">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityFilerCategory id="F_000009" contextRef="C_0001274792_20170101_20170630">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityCommonStockSharesOutstanding id="F_000010" contextRef="C_0001274792_20170808" decimals="INF" unitRef="U_shares">132793256</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000011" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">135501000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000012" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">21524000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashCurrent id="F_000013" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">102000</us-gaap:RestrictedCashCurrent>
  <us-gaap:RestrictedCashCurrent id="F_000014" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">102000</us-gaap:RestrictedCashCurrent>
  <us-gaap:ReceivablesNetCurrent id="F_000015" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">43000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent id="F_000016" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">275000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000017" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">5917000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000018" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">2239000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent id="F_000019" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">33295000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
  <us-gaap:AssetsCurrent id="F_000020" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">141563000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000021" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">57435000</us-gaap:AssetsCurrent>
  <us-gaap:RestrictedCashNoncurrent id="F_000022" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">60682000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:RestrictedCashNoncurrent id="F_000023" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">674000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000024" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">11178000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000025" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">14212000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OtherAssetsNoncurrent id="F_000026" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">27000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000027" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">27000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent id="F_000028" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">9135000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
  <us-gaap:Assets id="F_000029" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">213450000</us-gaap:Assets>
  <us-gaap:Assets id="F_000030" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">81483000</us-gaap:Assets>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="F_000031" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">33989000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="F_000032" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">29369000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:DeferredRentCreditCurrent id="F_000033" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">2077000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:DeferredRentCreditCurrent id="F_000034" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">2014000</us-gaap:DeferredRentCreditCurrent>
  <mack:AccruedIntraperiodTaxAllocation id="F_000035" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">13530000</mack:AccruedIntraperiodTaxAllocation>
  <us-gaap:TaxesPayableCurrent id="F_000036" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">8141000</us-gaap:TaxesPayableCurrent>
  <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent id="F_000037" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">56839000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000038" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">57737000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000039" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">88222000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRentCreditNoncurrent id="F_000040" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">2330000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent id="F_000041" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">3386000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="F_000042" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">48906000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="F_000043" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">216861000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent id="F_000044" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">25673000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
  <us-gaap:Liabilities id="F_000045" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">108973000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000046" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">334142000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies id="F_000047" xsi:nil="true" contextRef="C_0001274792_20170630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000048" xsi:nil="true" contextRef="C_0001274792_20161231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:MinorityInterest id="F_000049" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">-2031000</us-gaap:MinorityInterest>
  <us-gaap:MinorityInterest id="F_000050" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">-1539000</us-gaap:MinorityInterest>
  <us-gaap:PreferredStockValue id="F_000051" xsi:nil="true" contextRef="C_0001274792_20170630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000052" xsi:nil="true" contextRef="C_0001274792_20161231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockValue id="F_000053" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">1327000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="F_000054" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">1302000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000055" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">578103000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000056" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">702377000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000057" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">-472922000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000058" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">-954799000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="F_000059" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">106508000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000060" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">-251120000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000061" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">213450000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000062" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">81483000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000063" contextRef="C_0001274792_20170630" decimals="INF" unitRef="U_iso4217USD_shares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000064" contextRef="C_0001274792_20161231" decimals="INF" unitRef="U_iso4217USD_shares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000065" contextRef="C_0001274792_20170630" decimals="INF" unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000066" contextRef="C_0001274792_20161231" decimals="INF" unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="F_000067" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="F_000068" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="F_000069" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000070" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000071" contextRef="C_0001274792_20170630" decimals="INF" unitRef="U_iso4217USD_shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000072" contextRef="C_0001274792_20161231" decimals="INF" unitRef="U_iso4217USD_shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000073" contextRef="C_0001274792_20170630" decimals="INF" unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000074" contextRef="C_0001274792_20161231" decimals="INF" unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000075" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_shares">132741000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000076" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_shares">130197000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000077" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_shares">132741000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000078" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_shares">130197000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000079" contextRef="C_0001274792_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">19751000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000080" contextRef="C_0001274792_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">27695000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000081" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">41356000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000082" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">55697000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000083" contextRef="C_0001274792_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">14798000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000084" contextRef="C_0001274792_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">8138000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000085" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">20432000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000086" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">14590000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:CostsAndExpenses id="F_000087" contextRef="C_0001274792_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">34549000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses id="F_000088" contextRef="C_0001274792_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">35833000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses id="F_000089" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">61788000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses id="F_000090" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">70287000</us-gaap:CostsAndExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000091" contextRef="C_0001274792_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">-34549000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000092" contextRef="C_0001274792_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">-35833000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000093" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-61788000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000094" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-70287000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InvestmentIncomeInterest id="F_000095" contextRef="C_0001274792_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">382000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest id="F_000096" contextRef="C_0001274792_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">122000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest id="F_000097" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">396000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest id="F_000098" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">194000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InterestExpense id="F_000099" contextRef="C_0001274792_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">26762000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="F_000100" contextRef="C_0001274792_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">15858000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="F_000101" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">28741000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="F_000102" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">19148000</us-gaap:InterestExpense>
  <us-gaap:GainsLossesOnSalesOfAssets id="F_000103" contextRef="C_0001274792_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">1703000</us-gaap:GainsLossesOnSalesOfAssets>
  <us-gaap:GainsLossesOnSalesOfAssets id="F_000104" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">1703000</us-gaap:GainsLossesOnSalesOfAssets>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000105" contextRef="C_0001274792_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">-659000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000106" contextRef="C_0001274792_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">-64000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000107" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-661000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000108" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-107000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000109" contextRef="C_0001274792_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">-59885000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000110" contextRef="C_0001274792_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">-51633000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000111" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-89091000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000112" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-89348000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000113" contextRef="C_0001274792_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">-30239000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000114" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-30239000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest id="F_000115" contextRef="C_0001274792_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">-29646000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest id="F_000116" contextRef="C_0001274792_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">-51633000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest id="F_000117" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-58852000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest id="F_000118" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-89348000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="F_000119" contextRef="C_0001274792_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">540485000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="F_000120" contextRef="C_0001274792_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">675000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="F_000121" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">539538000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="F_000122" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-268000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
  <us-gaap:ProfitLoss id="F_000123" contextRef="C_0001274792_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">510839000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000124" contextRef="C_0001274792_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">-50958000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000125" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">480686000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000126" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-89616000</us-gaap:ProfitLoss>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest id="F_000127" contextRef="C_0001274792_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">-724000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest id="F_000128" contextRef="C_0001274792_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">-208000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest id="F_000129" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-1191000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest id="F_000130" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-393000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetIncomeLoss id="F_000131" contextRef="C_0001274792_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">511563000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000132" contextRef="C_0001274792_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">-50750000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000133" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">481877000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000134" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-89223000</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent id="F_000135" contextRef="C_0001274792_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">15000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent id="F_000136" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="F_000137" contextRef="C_0001274792_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">15000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="F_000138" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000139" contextRef="C_0001274792_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">511563000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000140" contextRef="C_0001274792_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">-50735000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000141" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">481877000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000142" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-89222000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:IncomeLossFromContinuingOperations id="F_000143" contextRef="C_0001274792_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">-28922000</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:IncomeLossFromContinuingOperations id="F_000144" contextRef="C_0001274792_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">-51425000</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:IncomeLossFromContinuingOperations id="F_000145" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-57661000</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:IncomeLossFromContinuingOperations id="F_000146" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-88955000</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity id="F_000147" contextRef="C_0001274792_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">540485000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity id="F_000148" contextRef="C_0001274792_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">675000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity id="F_000149" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">539538000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity id="F_000150" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-268000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="F_000151" contextRef="C_0001274792_20170401_20170630" decimals="2" unitRef="U_iso4217USD_shares">-0.22</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="F_000152" contextRef="C_0001274792_20160401_20160630" decimals="2" unitRef="U_iso4217USD_shares">-0.41</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="F_000153" contextRef="C_0001274792_20170101_20170630" decimals="2" unitRef="U_iso4217USD_shares">-0.44</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="F_000154" contextRef="C_0001274792_20160101_20160630" decimals="2" unitRef="U_iso4217USD_shares">-0.74</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare id="F_000155" contextRef="C_0001274792_20170401_20170630" decimals="2" unitRef="U_iso4217USD_shares">4.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare id="F_000156" contextRef="C_0001274792_20160401_20160630" decimals="2" unitRef="U_iso4217USD_shares">0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare id="F_000157" contextRef="C_0001274792_20170101_20170630" decimals="2" unitRef="U_iso4217USD_shares">4.10</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare id="F_000158" contextRef="C_0001274792_20160101_20160630" decimals="2" unitRef="U_iso4217USD_shares">0.00</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000159" contextRef="C_0001274792_20170401_20170630" decimals="2" unitRef="U_iso4217USD_shares">3.86</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000160" contextRef="C_0001274792_20160401_20160630" decimals="2" unitRef="U_iso4217USD_shares">-0.40</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000161" contextRef="C_0001274792_20170101_20170630" decimals="2" unitRef="U_iso4217USD_shares">3.66</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000162" contextRef="C_0001274792_20160101_20160630" decimals="2" unitRef="U_iso4217USD_shares">-0.74</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000163" contextRef="C_0001274792_20170401_20170630" decimals="-3" unitRef="U_shares">132457000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000164" contextRef="C_0001274792_20160401_20160630" decimals="-3" unitRef="U_shares">126161000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000165" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_shares">131528000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000166" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_shares">121112000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:CommonStockDividendsPerShareCashPaid id="F_000167" contextRef="C_0001274792_20170401_20170630" decimals="INF" unitRef="U_iso4217USD_shares">1.055</us-gaap:CommonStockDividendsPerShareCashPaid>
  <us-gaap:CommonStockDividendsPerShareCashPaid id="F_000168" contextRef="C_0001274792_20170101_20170630" decimals="INF" unitRef="U_iso4217USD_shares">1.055</us-gaap:CommonStockDividendsPerShareCashPaid>
  <us-gaap:PaidInKindInterest id="F_000169" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">2374000</us-gaap:PaidInKindInterest>
  <us-gaap:PaidInKindInterest id="F_000170" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">3505000</us-gaap:PaidInKindInterest>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="F_000171" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-4887000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="F_000172" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-14566000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation id="F_000173" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-30239000</us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000174" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">2058000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000175" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">2333000</us-gaap:DepreciationDepletionAndAmortization>
  <mack:NonCashActivityRelatedToDiscontinuedOperations id="F_000176" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">15025000</mack:NonCashActivityRelatedToDiscontinuedOperations>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="F_000177" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">512000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="F_000178" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-228000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <mack:AllocatedShareBasedCompensationExpenseIncludingNonEmployees id="F_000179" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">9529000</mack:AllocatedShareBasedCompensationExpenseIncludingNonEmployees>
  <mack:AllocatedShareBasedCompensationExpenseIncludingNonEmployees id="F_000180" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">6077000</mack:AllocatedShareBasedCompensationExpenseIncludingNonEmployees>
  <us-gaap:IncreaseDecreaseInReceivables id="F_000181" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-232000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInReceivables id="F_000182" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-11000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000183" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">4022000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000184" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-605000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable id="F_000185" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">8141000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="F_000186" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">2494000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="F_000187" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-8454000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <mack:IncreaseDecreaseInDeferredRent id="F_000188" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-209000</mack:IncreaseDecreaseInDeferredRent>
  <mack:IncreaseDecreaseInDeferredRent id="F_000189" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">579000</mack:IncreaseDecreaseInDeferredRent>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="F_000190" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-49094000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="F_000191" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-69898000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations id="F_000192" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-46416000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
  <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations id="F_000193" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-34528000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000194" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-95510000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000195" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-104426000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000196" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">287000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000197" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">2050000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities id="F_000198" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">23000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="F_000199" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">1104000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities id="F_000200" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">84262000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets id="F_000201" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">575000000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
  <us-gaap:IncreaseDecreaseInRestrictedCash id="F_000202" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">60008000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000203" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">515809000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000204" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-63312000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000205" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">6079000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000206" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">2598000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="F_000207" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">2599000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:RepaymentsOfLongTermDebt id="F_000208" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">175000000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:PaymentsOfDividends id="F_000209" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">140000000</us-gaap:PaymentsOfDividends>
  <us-gaap:ProceedsFromConvertibleDebt id="F_000210" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">1025000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000211" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-306322000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000212" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">3623000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="F_000213" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">113977000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="F_000214" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-164115000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000215" contextRef="C_0001274792_20151231" decimals="-3" unitRef="U_iso4217USD">185606000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000216" contextRef="C_0001274792_20160630" decimals="-3" unitRef="U_iso4217USD">21491000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000217" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">349000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000218" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">434000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <mack:ReceivablesFromStockOptionExercises id="F_000219" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">13000</mack:ReceivablesFromStockOptionExercises>
  <us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1 id="F_000220" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">155000</us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 id="F_000221" contextRef="C_0001274792_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">64209000</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:InterestPaid id="F_000222" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">28872000</us-gaap:InterestPaid>
  <us-gaap:NatureOfOperations id="F_000223" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1. Nature of the Business&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Merrimack Pharmaceuticals, Inc. (the &amp;#8220;Company&amp;#8221;) is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. The Company&amp;#8217;s mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers. All of the Company&amp;#8217;s product candidates, including three in clinical studies and several others in preclinical development, fit into the Company&amp;#8217;s strategy of (1) understanding the biological problems the Company is trying to solve, (2) designing specific solutions and (3) developing those solutions for biomarker-selected patients. This three-pronged strategy seeks to ensure optimal patient outcomes. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 3, 2017,&lt;font style="font-weight:bold;"&gt; &lt;/font&gt;the Company completed the previously announced transaction (the &amp;#8220;Asset Sale&amp;#8221;) with Ipsen S.A. (&amp;#8220;Ipsen&amp;#8221;). Pursuant to the Asset Purchase and Sale Agreement, dated as of January&amp;#160;7, 2017 (the &amp;#8220;Asset Sale Agreement&amp;#8221;), between the Company and Ipsen, the Company sold to Ipsen its right, title and interest in the non-cash assets, equipment, inventory, contracts and intellectual property primarily related to or used in the Company&amp;#8217;s business operations and activities involving or relating to developing, manufacturing and commercializing ONIVYDE, the Company&amp;#8217;s first commercial product, and MM-436 (the &amp;#8220;Commercial Business&amp;#8221;). The Company received $575.0 million in cash, subject to a working capital adjustment, and is eligible to receive up to $450.0 million in additional regulatory approval-based milestone payments. The working capital adjustment is currently estimated as a $2.2 million receivable presented in prepaid expenses and other currents assets within the condensed consolidated balance sheets, which is expected to be received in the third quarter of 2017. The Company also retained the right to receive net milestone payments of up to $33.0 million that may become payable pursuant to the license and collaboration agreement with Baxalta Incorporated, Baxalta US Inc. and Baxalta GmbH (collectively, &amp;#8220;Baxalta&amp;#8221;) for the ex-U.S. development and commercialization of ONIVYDE. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s non-commercial assets, including its clinical and preclinical development programs (the &amp;#8220;Pipeline Business&amp;#8221;), were not included in the Asset Sale and remain assets of the Company. As of the closing of the Asset Sale, the Company&amp;#8217;s most advanced programs are as follows:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:7.87%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;MM-121 (seribantumab), a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. The Company is currently conducting the Phase 2 randomized SHERLOC clinical trial evaluating MM-121 in heregulin positive non-small cell lung cancer patients and plans to initiate the Phase 2 randomized SHERBOC clinical trial in 2017 in heregulin positive, hormone receptor positive, ErbB2 (HER2) negative, metastatic breast cancer patients;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:7.87%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;MM-141 (istiratumab), a fully human bispecific tetravalent monoclonal antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1 (&amp;#8220;IGF-1&amp;#8221;) receptor and ErbB3 (HER3) cell surface receptors. The Company is currently conducting the Phase 2 randomized CARRIE clinical trial evaluating MM-141 in previously untreated metastatic pancreatic cancer patients with high levels of free IGF-1 in combination with nab-paclitaxel and gemcitabine; and&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:7.87%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;MM-310, an antibody-directed nanotherapeutic (&amp;#8220;ADN&amp;#8221;) that contains a novel prodrug of the highly potent chemotherapy docetaxel and targets the ephrin receptor A2 (&amp;#8220;EphA2&amp;#8221;) receptor, which is highly expressed in most solid tumor types. MM-310 was designed to improve the therapeutic window of docetaxel in major oncology indications, such as prostate, ovarian, bladder, gastric, pancreatic and lung cancers. The Company initiated a Phase 1 clinical trial to evaluate safety and preliminary activity of MM-310 in the first quarter of 2017.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition to its clinical-stage programs, the Company has several product candidates in preclinical development and a discovery effort advancing additional candidate medicines.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to risks and uncertainties common to companies in the biopharmaceutical industry, including, among other things, its ability to secure additional capital to fund operations, success of clinical trials, development by competitors of new technological innovations, dependence on collaborative arrangements, protection of proprietary technology, compliance with government regulations and dependence on key personnel. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of capital, adequate personnel, infrastructure and extensive compliance reporting capabilities.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. Until such time, if ever, as the Company can generate sufficient product revenues, the Company expects to finance its cash needs through a combination of equity offerings, debt financings, collaborations, licensing arrangements and other marketing and distribution arrangements. The Company could also engage in discussions with third parties regarding partnerships, joint ventures, combinations or divestitures of one or more of its businesses as it seeks to further the development of its research programs, improve its cash position and maximize stockholder value.&lt;/p&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock id="F_000224" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2. Basis of Presentation and Consolidation&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The accompanying condensed consolidated financial statements as of June&amp;#160;30, 2017 and December&amp;#160;31, 2016, and for the three and six months ended June&amp;#160;30, 2017 and 2016, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) and generally accepted accounting principles in the United States of America (&amp;#8220;GAAP&amp;#8221;) for condensed consolidated financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, these condensed consolidated financial statements reflect all adjustments which are necessary for a fair statement of the Company&amp;#8217;s financial position and results of its operations, as of and for the periods presented. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended December&amp;#160;31, 2016 filed with the SEC on March 1, 2017.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The information presented in the condensed consolidated financial statements and related notes as of June&amp;#160;30, 2017, and for the three and six months ended June&amp;#160;30, 2017 and 2016, is unaudited. The December&amp;#160;31, 2016 condensed consolidated balance sheets included herein were derived from the audited financial statements as of that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interim results for the three and six months ended June&amp;#160;30, 2017 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2017, or any future period.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March 31, 2017, the Commercial Business met all the conditions to be classified as a discontinued operation since the disposal of the Commercial Business represented a strategic shift that will have a major effect on the Company&amp;#8217;s operations and financial results. The Company will not have further significant involvement in the operations of the discontinued Commercial Business. The operating results of the Commercial Business are reported as a loss from discontinued operations, net of tax in the condensed consolidated statements of operations and comprehensive income (loss) for all periods presented. The gain recognized on the sale of the Commercial Business is presented in income (loss) from discontinued operations, net of tax in the consolidated statement of operations and comprehensive income (loss). In addition, in the condensed consolidated balance sheets as of December 31, 2016, the assets and liabilities held for sale have been presented separately. For additional information, see Note 3, &amp;#8220;Sale of Commercial Business.&amp;#8221;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;These condensed consolidated financial statements include the accounts of the Company and Silver Creek Pharmaceuticals, Inc. (&amp;#8220;Silver Creek&amp;#8221;), representing a variable interest entity that the Company is required to consolidate. All intercompany transactions and balances have been eliminated in consolidation.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June&amp;#160;30, 2017, the Company&amp;#8217;s unrestricted cash and cash equivalents includes $2.6 million of cash and cash equivalents held by Silver Creek. This $2.6 million held by Silver Creek is designated for the operations of Silver Creek.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the first quarter of 2017, Silver Creek entered into a Series C preferred stock financing, issuing 1.4 million shares of Series C preferred stock at $1.50 per share for proceeds of $2.0 million. In conjunction with this sale in the first quarter of 2017, Silver Creek also issued warrants to purchase 1.8 million shares of Silver Creek Series C preferred stock to investors. In the second quarter of 2017, Silver Creek issued 0.4 million shares of Series C preferred stock at $1.50 per share for proceeds of $0.6 million. In conjunction with this sale in the second quarter of 2017, Silver Creek issued warrants to purchase 0.3 million shares of Silver Creek Series C preferred stock to investors. In June 2017, Silver Creek amended the warrant purchase agreements to increase the number of shares for which each warrant is redeemable. The incremental increase in the number of shares the warrants may be redeemed for as a result of the amendment was 1.3 million shares. As of June 30, 2017, the Company held a 51% ownership interest in Silver Creek and maintained control over the Silver Creek Board of Directors through its voting rights. As such, the Company remains the primary beneficiary of Silver Creek.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The change in the non-controlling interest related to Silver Creek was as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Controlling&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December&amp;#160;31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,539&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to Silver Creek&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,191&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance of Silver Creek Series C preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;699&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at June&amp;#160;30, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,031&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Controlling&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December&amp;#160;31, 2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;239&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to Silver Creek&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(393&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at June&amp;#160;30, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(154&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock id="F_000225" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3. Sale of Commercial Business&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Ipsen&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April&amp;#160;3, 2017, the Company completed the sale of the Commercial Business to Ipsen. Pursuant to the Asset Sale Agreement, the Company may be entitled to up to $450.0 million in additional payments based on the achievement by or on behalf of Ipsen of certain milestone events if the U.S. Food and Drug Administration (the &amp;#8220;FDA&amp;#8221;) approves ONIVYDE for certain indications as follows: (i) $225.0 million upon the regulatory approval by the FDA of ONIVYDE for the first-line treatment of metastatic adenocarcinoma of the pancreas (a)&amp;#160;in combination with fluorouracil and leucovorin (with or without oxaliplatin), (b)&amp;#160;in combination with gemcitabine and abraxane or (c)&amp;#160;following submission and filing of regulatory approval by Ipsen for purposes of commercialization by Ipsen; (ii) $150.0 million upon the regulatory approval by the FDA of ONIVYDE for the treatment of small cell lung cancer after failure of first-line chemotherapy; and (iii) $75.0 million upon the regulatory approval by the FDA of ONIVYDE for an additional indication unrelated to those described above.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the sale of the Commercial Business, on April 3, 2017, the Company entered into a transition services agreement&lt;font style="font-weight:bold;"&gt; &lt;/font&gt;with Ipsen pursuant to which the Company and Ipsen are providing certain services to each other for a period of 24 months following the closing, including Ipsen&amp;#8217;s agreement to manufacture MM-310 and to perform certain quality related services in accordance with a manufacturing services agreement, the accounting impact of which is immaterial.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the completion of the Asset Sale, on April 3, 2017, the Company irrevocably deposited the redemption price of the 11.50% senior secured notes due 2022 (the &amp;#8220;2022 Notes&amp;#8221;) of $175.0 million outstanding aggregate principal amount, interest of $7.4 million through the redemption date and an additional make-whole premium payment of approximately $20.1 million with U.S. Bank National Association as trustee (the &amp;#8220;Trustee&amp;#8221;) under the Indenture dated as of December 22, 2015 (the &amp;#8220;Indenture&amp;#8221;) and irrevocably instructed the Trustee to apply such amount to the redemption in full of the 2022 Notes on the redemption date of April 27, 2017. The Indenture was satisfied and discharged on April 3, 2017.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the completion of the Asset Sale, on April 3, 2017, the Company entered into a sublease with Ipsen, pursuant to which Ipsen is subleasing from the Company approximately 70,237 square feet of leased space in the Company&amp;#8217;s Cambridge, Massachusetts facility through the end of the term of the lease on June 30, 2019. Payments under the sublease are recorded as an offset to rent expense in the condensed consolidated statement of operations and comprehensive income (loss).&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Also in connection with the completion of the Asset Sale, on April 3, 2017, the Company entered into an intellectual property license agreement with Ipsen, pursuant to which Ipsen granted to the Company a perpetual, worldwide, non-exclusive, royalty-free, fully paid-up license in and to all patents included in the transferred intellectual property, other than certain patents relating to generic liposomal technology, with respect to which the license will be exclusive, in each case for use outside of the Commercial Business. The Company granted to Ipsen a non-exclusive, royalty-free, fully paid up, perpetual, irrevocable and worldwide license to all patents it owned at the time of the closing of the transaction contemplated by the Asset Sale Agreement for use in connection with the Commercial Business. This transfer of intellectual property did not impact the financial statements as no amounts related to the intellectual property had previously been recorded.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 5, 2017, the Company announced that its Board of Directors authorized and declared a special cash dividend of $140.0 million on the Company&apos;s common stock. The special dividend was payable on May 26, 2017 to stockholders of record as of the close of business on May 17, 2017. The special dividend resulted in a decrease to additional paid-in capital.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Discontinued Operations and Assets Held for Sale&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The condensed consolidated financial statements for the three and six months ended June 30, 2017 and 2016 reflect the operations of the Commercial Business as a discontinued operation. The Company recorded a gain of approximately $598.2 million on the Asset Sale, which is included in gain from discontinued operations on the condensed consolidated statements of operations and comprehensive income (loss).&amp;#160;Discontinued operations for the three and six months ended June 30, 2017 and 2016 includes the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenues, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,851&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,135&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,819&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License and collaboration revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,332&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,797&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,645&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,498&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,973&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,498&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,681&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,905&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,962&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs and expenses:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,872&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,890&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,583&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,302&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,700&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,181&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,542&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,709&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restructuring expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,216&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,535&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total costs and expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,216&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,716&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,834&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,649&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other income and expenses:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,509&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,743&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,581&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gain on sale of commercial business&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;598,120&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;598,120&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income (loss) from discontinued operations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;592,395&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;675&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;591,448&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(268&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(51,910&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(51,910&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total income (loss) from discontinued operations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;540,485&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;675&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;539,538&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(268&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying value of the assets and liabilities of the Commercial Business classified as &amp;#8220;Discontinued operations&amp;#8221; in the condensed consolidated balance sheets is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.58%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts receivable, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,194&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,554&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,547&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current assets held for sale&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,295&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,553&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,977&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,605&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total long-term assets held for sale&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,135&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts payable, accrued expenses and other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,613&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,226&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current liabilities held for sale&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,839&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenues, net of current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,673&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total liabilities held for sale&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,673&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:8pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory of the Commercial Business as of December 31, 2016 consisted of the following:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,483&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,651&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,554&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restructuring Activities&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 8, 2017, the Company announced a reduction in headcount by approximately 30% in connection with the Asset Sale and the completion of its strategic pipeline review. Upon the closing of the Asset Sale and the completion of its strategic pipeline review, the Company had approximately 80 employees. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under this corporate restructuring, for the three and six months ended June 30, 2017, the Company recognized total restructuring expenses of $4.2 million and $9.5 million, respectively, which was related to contractual termination benefits for employees with pre-existing severance arrangements. These one-time employee termination benefits are comprised of severance, benefits and related costs, all of which are expected to result in cash expenditures. The majority of these payments were made during the second quarter of 2017. The remaining payments represent severance payments that will be paid over one year. The expense of $9.5 million was included in discontinued operations, as the costs are directly associated with the sale of the Commercial Business.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the charges related to the restructuring activities as of June 30, 2017:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued Restructuring Expenses at December&amp;#160;31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;"&gt;
&lt;p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;"&gt;
&lt;p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued Restructuring Expenses at June&amp;#160;30, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Severance, benefits and related costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,521&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,124&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,397&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Totals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,521&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,124&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,397&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;These amounts are included in accounts payable, accrued expenses and other in the June 30, 2017 balance sheet.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;License and Collaboration Agreements Related to the Asset Sale&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Baxalta&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 23, 2014, the Company and Baxter International Inc., Baxter Healthcare Corporation and Baxter Healthcare SA entered into a license and collaboration agreement (the &amp;#8220;Baxalta Agreement&amp;#8221;) for the development and commercialization of ONIVYDE outside of the United States and Taiwan (the &amp;#8220;Licensed Territory&amp;#8221;). In connection with Baxter International Inc.&amp;#8217;s separation of the Baxalta business, the Baxalta Agreement was assigned to Baxalta during the second quarter of 2015. As part of the Baxalta Agreement, the Company granted Baxalta an exclusive, royalty-bearing right and license under the Company&amp;#8217;s patent rights and know-how to develop and commercialize ONIVYDE in the Licensed Territory.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 3, 2017, the Baxalta Agreement and all related agreements, including the Company&amp;#8217;s agreement related to the commercial supply of ONIVYDE, were assigned to Ipsen in connection with the Asset Sale. Pursuant to the Asset Sale Agreement, the Company retained the right to receive net milestone payments of up to $33.0 million that may become payable pursuant to the Baxalta Agreement for the ex-U.S. development and commercialization of ONIVYDE, which is comprised of potential payments of $18.0 million from the sale of ONIVYDE in two additional major European countries, $5.0 million related to the sale of ONIVYDE in the first major non-European, non-Asian country and $10.0 million for the first patient dosed in a pivotal clinical trial in an indication other than pancreatic cancer.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;PharmaEngine, Inc.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May 5, 2011, the Company and PharmaEngine, Inc. (&amp;#8220;PharmaEngine&amp;#8221;) entered into an assignment, sublicense and collaboration agreement (the &amp;#8220;PharmaEngine Agreement&amp;#8221;) under which the Company reacquired rights in Europe and certain countries in Asia to ONIVYDE. In exchange, the Company agreed to pay PharmaEngine a nonrefundable, noncreditable upfront payment of $10.0 million and up to an additional $80.0 million in aggregate development and regulatory milestones and $130.0 million in aggregate sales milestones. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 3, 2017, the PharmaEngine Agreement and all related agreements, including the Company&amp;#8217;s agreement related to its commercial supply of ONIVYDE, were assigned to Ipsen in connection with the Asset Sale.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
  <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock id="F_000226" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. Going Concern&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;In accordance with Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 205-40, &lt;font style="font-style:italic;"&gt;Going Concern&lt;/font&gt;, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&amp;#8217;s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2016, the Company had $21.5 million in unrestricted cash and cash equivalents, had suffered recurring losses from operations and had negative working capital and cash outflows from operating activities. Based on the evaluation completed in connection with the filing of the Company&amp;#8217;s Annual Report on Form 10-K for the year ended December&amp;#160;31, 2016, including consideration of management&amp;#8217;s plans, the Company previously concluded that there was substantial doubt as to its ability to continue as a going concern within one year after March 1, 2017, the date that the consolidated financial statements were issued.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 3, 2017, the Company closed the Asset Sale with Ipsen and received a $575.0 million upfront cash payment, subject to a working capital adjustment. The working capital adjustment is currently estimated as a $2.2 million receivable expected to be received in the third quarter of 2017. The Company used a portion of the cash payment to redeem the $175.0 million outstanding aggregate principal amount of the 2022 Notes, which also required an additional make-whole premium payment of approximately $20.1 million, and deposited $60.0 million into an escrow account in response to a lawsuit filed by the trustee and certain holders of its 4.50% convertible notes due 2020 (the &amp;#8220;Convertible Notes&amp;#8221;). The Company distributed $140.0 million of the upfront cash payment in the form of a special cash dividend to stockholders, which was payable on May 26, 2017 to stockholders of record as of the close of business on May 17, 2017. After consideration of the Company&amp;#8217;s cash and cash equivalents balance at March 31, 2017 of $17.2 million and the net proceeds from the Asset Sale, the Company has concluded that the previous conditions and events that raised substantial doubt about its ability to continue as a going concern have been alleviated. The Company updated its going concern assessment for the three months ended June 30, 2017 and concluded the Company is able to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000227" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. Income Taxes&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Deferred tax assets and liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using future enacted tax rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company completed the Asset Sale and recorded the income tax implications of the sale in the second quarter of 2017. The Asset Sale generated taxable income for the Company which has resulted in income tax expense.&amp;#160; The Company released a portion of its valuation allowance in the three months ended June 30, 2017 as it is now able to utilize its net operating loss carryforwards to offset the taxable income generated from the Asset Sale. The Company&amp;#8217;s current income tax expense for the six months ended June 30, 2017 is $8.1 million, which is comprised primarily of federal Alternative Minimum Tax and state income tax. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intraperiod tax allocation rules require the Company to allocate the provision for income taxes between continuing operations and other categories of earnings, such as discontinued operations. In periods in which there is pre-tax loss from continuing operations and pre-tax income in other categories of earnings, such as discontinued operations, the Company must allocate to continuing operations a tax benefit for the loss in continuing operations with an offsetting tax expense to discontinued operations.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the three and six months ended June 30, 2017, the Company recognized an income tax benefit of $30.2 million in continuing operations and income tax expense in discontinued operations of $51.9 million related to the income generated in connection with the Asset Sale. As of June 30, 2017, the Company recorded an accrued income tax provision of $13.5 million. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the Asset Sale, the Company recorded an income tax provision in discontinued operations of $223.3 million prior to the release of the valuation allowance. The Company released $171.4 million of its valuation allowance in discontinued operations during the three months ended June 30, 2017, resulting in a total income tax expense of $51.9 million in discontinued operations.&lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="F_000228" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6. Net Income (Loss) Per Common Share&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net income (loss) per share is calculated by dividing the net income (loss) attributable to Merrimack Pharmaceuticals, Inc, by the weighted-average number of common shares outstanding during the period. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to Merrimack Pharmaceuticals, Inc. by the weighted-average number of dilutive common shares outstanding during the period. Dilutive shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options based on the treasury stock method. In a period when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods where a loss is reported, there is no difference in basic and dilutive loss per share. .&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company follows the two-class method when computing net income (loss) per share, when it has issued shares that meet the definition participating securities. The two&amp;#8211;class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participating rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based on their respective rights to receive dividends, as if all income for the period has been distributed or losses to be allocated if they are contractually required to fund losses. There were no amounts allocated to participating securities for the three and six months ended June 30, 2017 and 2016, as the Company was in a loss position and had no shares that met the definition of participating securities outstanding as of June 30, 2017 and 2016. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition, as discussed in Note 10, &amp;#8220;Borrowings,&amp;#8221; in July 2013, the Company issued $125.0 million aggregate principal amount of Convertible Notes in an underwritten public offering. Following the repayment and satisfaction in full of the Company&amp;#8217;s obligations to Hercules Technology Growth Capital, Inc. (&amp;#8220;Hercules&amp;#8221;) under its Loan and Security Agreement with Hercules (the &amp;#8220;Loan Agreement&amp;#8221;), which occurred in December 2015, upon any conversion of the Convertible Notes, the Convertible Notes may be settled, at the Company&amp;#8217;s election, in cash, shares of the Company&amp;#8217;s common stock or a combination of cash and shares of the Company&amp;#8217;s common stock. For purposes of calculating the maximum dilutive impact, it is presumed that the conversion premium will be settled in common stock, inclusive of a contractual make-whole provision resulting from a fundamental change, and the resulting potential common shares included in diluted earnings per share if the effect is more dilutive. As of June&amp;#160;30, 2017, $60.8 million aggregate principal amount of the Convertible Notes remained outstanding.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The stock options and conversion premium on the Convertible Notes are excluded from the calculation of diluted loss per share because the net loss for the three and six months ended June&amp;#160;30, 2016 causes such securities to be anti-dilutive. Outstanding securities excluded from the calculation of diluted loss per share for the three and six months ended June&amp;#160;30, 2017 and 2016 are shown in the chart below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.56%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.56%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,915&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,647&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,915&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,647&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion of the Convertible Notes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="F_000229" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7. Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is determined based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect certain market assumptions. As a basis for considering such assumptions, GAAP establishes a three-tier value hierarchy, which prioritizes the inputs used to develop the assumptions and for measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets for identical assets; (Level 2) inputs other than the quoted prices in active markets that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recurring Fair Value Measurements&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying values of cash, restricted cash, prepaid expenses, accounts receivable, accounts payable and accrued expenses, and other short-term assets and liabilities approximate their respective fair values due to the short-term maturities of these assets and liabilities.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables show assets measured at fair value on a recurring basis as of June&amp;#160;30, 2017 and December&amp;#160;31, 2016:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;128,931&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Totals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;128,931&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Silver Creek warrant liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,062&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Totals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,062&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,373&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Totals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,373&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Silver Creek warrant liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Totals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2016, Silver Creek issued warrants to purchase an aggregate of 1.9 million shares of Silver Creek Series C preferred stock (the &amp;#8220;Silver Creek warrants&amp;#8221;). During the first quarter of 2017, Silver Creek issued additional Silver Creek warrants to purchase an aggregate of 1.8 million shares of Silver Creek Series C preferred stock. During the second quarter of 2017, Silver Creek issued additional Silver Creek warrants to purchase an aggregate of 0.3 million shares of Silver Creek Series C preferred stock. &lt;font style="color:#000000;"&gt;In June 2017, Silver Creek amended the outstanding warrant purchase agreements to increase the number of shares for which each warrant is redeemable. &lt;/font&gt;The Silver Creek warrants were valued at $4.1 million and $1.5 million as of June 30, 2017 and December 31, 2016, respectively, using a Black-Scholes option pricing model, probability-weighted for different exercise scenarios. The key assumptions utilized in the Black-Scholes option pricing model as of June 30, 2017 were a risk-free interest rate of 2.1%, expected dividend yield of 0.0%, expected volatility of 60.4% and expected term of 6.4 years &amp;#8211; 7.0 years. The key assumptions utilized in the Black-Scholes option pricing model as of December 31, 2016 were a risk-free interest rate of 2.3%, expected dividend yield of 0.0%, expected volatility of 61.7% and expected term of 6.9 years. Changes in the fair value of the Silver Creek warrants are recognized as a component of &amp;#8220;other income and expenses&amp;#8221; in the condensed consolidated statements of operations and comprehensive income (loss). The change in fair value for both the three and six months ended June&amp;#160;30, 2017 was $1.0 million, inclusive of $0.8 million incremental change resulting from the amendment to the warrant purchase agreements, and is recorded in other income (expense) on the statement of operations and comprehensive loss.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were no changes in valuation techniques or transfers between the fair value measurement levels during the three or six months ended June&amp;#160;30, 2017 or during the year ended December&amp;#160;31, 2016. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other Fair Value Measurements&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The estimated fair value of the Convertible Notes was $36.7 million as of June&amp;#160;30, 2017. The Company estimated the fair value of the Convertible Notes by using a quoted market rate in an inactive market, which is classified as a Level 2 input. The carrying value of the Convertible Notes was $48.9 million as of June&amp;#160;30, 2017 due to the bifurcation of the conversion feature of the Convertible Notes as described more fully in Note 10, &amp;#8220;Borrowings.&amp;#8221;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As discussed in Note 10, &amp;#8220;Borrowings,&amp;#8221; in December 2015, the Company closed a private placement of $175.0 million aggregate principal amount of 2022 Notes. The Company estimated the fair value of the 2022 Notes by using publicly-available information related to one of the 2022 Notes borrower&amp;#8217;s portfolio of debt investments based on unobservable inputs, which is classified as a Level 3 input. In connection with the completion of the Asset Sale, on April 3, 2017, the liability under the 2022 Notes was satisfied. The Company incurred a loss on extinguishment of $25.0 million as a result of the early repayment of the 2022 Notes, which is included in interest expense on the statement of operations. For additional information, see Note 3, &amp;#8220;Sale of Commercial Business.&amp;#8221;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock id="F_000230" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8. Marketable Securities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;As of both June 30, 2017 and December 31, 2016, the Company maintained only cash equivalents comprised of money market funds. As of June 30, 2017, the Company did not hold any securities that were in an unrealized loss position. There were no realized gains or losses on available-for-sale securities for the three or six months ended June 30, 2017 or 2016.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock id="F_000231" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9. Accounts Payable, Accrued Expenses and Other&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts payable, accrued expenses and other as of June&amp;#160;30, 2017 and December&amp;#160;31, 2016 consisted of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,298&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,692&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued goods and services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,467&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,233&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued clinical trial costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,382&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,776&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued drug purchase costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;480&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued payroll and related benefits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,362&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,394&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued severance expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,736&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;774&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,261&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,100&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued dividends payable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Silver Creek warrant liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,062&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax incentives&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,402&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,402&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accounts payable, accrued expenses and other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,989&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,369&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:DebtDisclosureTextBlock id="F_000232" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;10. Borrowings&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;2022 Notes&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 22, 2015, the Company closed a private placement of $175.0 million aggregate principal amount of 2022 Notes. As a result of this placement, the Company received net proceeds of approximately $168.5 million, after deducting private placement and offering expenses payable by the Company. In connection with the completion of the Asset Sale on April 3, 2017, the liability under the 2022 Notes was satisfied. For additional information, see Note 3, &amp;#8220;Sale of Commercial Business.&amp;#8221; The 2022 Notes bore interest at a rate of 11.50% per year, payable semi-annually on June 15 and December 15 of each year, beginning on June 15, 2016.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2022 Notes contained customary covenants, including covenants that limited or restricted the Company&amp;#8217;s ability to incur liens, incur indebtedness and make certain restricted payments, but did not contain covenants related to future financial performance. The 2022 Notes were secured by a first priority lien on substantially all of the Company&amp;#8217;s assets.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company assessed the 2022 Notes pursuant to ASC 815, &lt;font style="font-style:italic;"&gt;Derivatives and Hedging&lt;/font&gt;, to determine if any features necessitated bifurcation from the host instrument. The Company concluded that none of the embedded redemption features within the 2022 Notes required bifurcation, as these features were clearly and closely related to the host instrument.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Debt issuance costs incurred by the Company are accounted for as a direct deduction to the carrying value of the 2022 Notes and are amortized to interest expense using the effective interest method over the life of the 2022 Notes. In connection with the completion of the Asset Sale, on April 3, 2017, the Company voluntarily settled the principle liability of the 2022 Notes. As a result of the early repayment, for the three and six months ended June 30, 2017 a loss on extinguishment of $25.0 million was incurred As a result of the early repayment, a loss on extinguishment of $25.0 million was recognized in interest expense in the condensed consolidated statement of operations and comprehensive income (loss) for the three and six months ended June 30, 2017. The $25.0 million loss on extinguishment included a $20.1 million prepayment penalty and $4.9 million of amortization expense recognized for the remaining debt discount at settlement as a result of the early repayment, which is included in interest expense on the statement of operations. For the three and six months ended June&amp;#160;30, 2017, interest expense related to the 2022 Notes was $1.5 million and $6.7 million, respectively. For the three and six months ended June&amp;#160;30, 2016, interest expense related to the 2022 Notes was $5.2 million and $10.4 million, respectively. These amounts are included in discontinued operations.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;text-indent:4%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible Notes&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2013, the Company issued $125.0 million aggregate principal amount of Convertible Notes in an underwritten public offering. As a result of the Convertible Notes offering, the Company received net proceeds of approximately $120.6 million, after deducting underwriting discounts and commissions and offering expenses payable by the Company.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Convertible Notes bear interest at a rate of 4.50% per year, payable semiannually in arrears on January 15 and July 15 of each year, beginning on January 15, 2014. The Convertible Notes are general unsecured senior obligations of the Company and rank (i) senior in right of payment to any of the Company&amp;#8217;s indebtedness that is expressly subordinated in right of payment to the Convertible Notes, (ii) equal in right of payment to any of the Company&amp;#8217;s unsecured indebtedness that is not so subordinated, (iii) effectively junior in right of payment to any of the Company&amp;#8217;s secured indebtedness to the extent of the value of the assets securing such indebtedness and (iv) structurally junior to all indebtedness and other liabilities (including trade payables) of the Company&amp;#8217;s subsidiaries.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company separately accounted for the liability and equity components of the Convertible Notes by bifurcating gross proceeds between the indebtedness, or liability component, and the embedded conversion option, or equity component. This bifurcation was done by estimating an effective interest rate as of the date of issuance for similar notes which do not contain an embedded conversion option. The gross proceeds received from the issuance of the Convertible Notes less the initial amount allocated to the indebtedness resulted in a $53.8 million allocation to the embedded conversion option. The embedded conversion option was recorded in stockholders&amp;#8217; deficit and as debt discount, to be subsequently amortized as interest expense over the term of the Convertible Notes. Underwriting discounts and commissions and offering expenses totaled $4.4 million and were allocated to the indebtedness and the embedded conversion option based on their relative values.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 13, 2016, the Company entered into separate, privately-negotiated conversion agreements (the &amp;#8220;Conversion Agreements&amp;#8221;) with certain holders of the Convertible Notes. Under the Conversion Agreements, such holders agreed to convert an aggregate principal amount of $64.2 million of Convertible Notes held by them. The Company initially settled each $1,000 principal amount of Convertible Notes surrendered for conversion by delivering 136 shares of the Company&amp;#8217;s common stock on April 18, 2016. In total, the Company issued an aggregate of 8,732,152 shares of its common stock on this initial closing date. In addition, pursuant to the Conversion Agreements, at the additional closings (as defined in the Conversion Agreements), the Company issued an aggregate of 3,635,511 shares of the Company&amp;#8217;s common stock representing an aggregate of $27.7 million as additional payments in respect of the conversion of the Convertible Notes. The number of additional shares was determined based on the daily VWAP (as defined in the Conversion Agreements) of the Company&amp;#8217;s common stock for each of the trading days in the 10-day trading period following the date of the Conversion Agreements. The issuance of 12,367,663 total shares of the Company&amp;#8217;s common stock pursuant to the Conversion Agreements resulted in an increase to common stock and additional paid-in capital of $101.0 million.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As a result of the conversion, the Company recognized an overall loss on extinguishment of $14.6 million representing the difference between the total settlement consideration transferred to the holders that was attributed to the liability component of the Convertible Notes, based on the fair value of that component at the time of conversion, and the net carrying value of the liability. The loss on extinguishment was recorded as interest expense during the second quarter of 2016. The remaining settlement consideration transferred was allocated to the reacquisition of the embedded conversion option and recognized as a $39.8 million reduction of additional paid-in capital. Transaction costs incurred with third parties related to the conversion were allocated to the liability and equity components and resulted in an additional $0.2 million of interest expense and a $0.2 million reduction of additional paid-in capital.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The outstanding Convertible Notes will mature on July 15, 2020 (the &amp;#8220;Maturity Date&amp;#8221;), unless earlier repurchased by the Company or converted at the option of holders. Holders may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding April 15, 2020 only under the following circumstances:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;during any calendar quarter commencing after September 30, 2013 (and only during such calendar quarter), if the last reported sale price of the Company&amp;#8217;s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;during the five business day period after any five consecutive trading day period (the &amp;#8220;measurement period&amp;#8221;) in which the trading price (as defined in the Convertible Notes) per $1,000 principal amount of Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company&amp;#8217;s common stock and the conversion rate on each such trading day; or&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;upon the occurrence of specified corporate events set forth in the indenture governing the Convertible Notes.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On or after April 15, 2020 until the close of business on the business day immediately preceding the Maturity Date, holders may convert their Convertible Notes at any time, regardless of the foregoing circumstances.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Following the repayment and satisfaction in full of the Company&amp;#8217;s obligations to Hercules under the Loan Agreement, which occurred in December 2015, upon any conversion of the Convertible Notes, the Convertible Notes may be settled, at the Company&amp;#8217;s election, in cash, shares of the Company&amp;#8217;s common stock or a combination of cash and shares of the Company&amp;#8217;s common stock.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The initial conversion rate of the Convertible Notes was 160.0000 shares of the Company&amp;#8217;s common stock per $1,000 principal amount of Convertible Notes, which is equivalent to an initial conversion price of $6.25 per share of common stock. As a result of the special dividend that was payable on May 26, 2017 to stockholders of record as of the close of business on May 17, 2017, the conversion rate of the Convertible Notes was adjusted from 160.0000 shares of the Company&amp;#8217;s common stock per $1,000 principal amount of Convertible Notes to 235.2112 shares of the Company&amp;#8217;s common stock per $1,000 principal amount of Convertible Notes. The conversion rate will be subject to further adjustment in some events, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the Maturity Date, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with a lawsuit filed by the trustee and certain holders of the Convertible Notes in the Court of Chancery in the State of Delaware, captioned &lt;font style="font-style:italic;"&gt;Wells Fargo Bank, National Association, Wolverine Flagship Fund Trading Limited, Highbridge International LLC, and Highbridge Tactical Credit&amp;#160;&amp;amp; Convertibles Master Fund, L.P. v. Merrimack Pharmaceuticals, Inc. &lt;/font&gt;(the &amp;#8220;Delaware Action&amp;#8221;), the Company deposited $60.0 million in proceeds from the Asset Sale into an escrow account. The funds will remain in escrow for the duration of the Delaware Action in order to provide security to the plaintiffs for their claims in the Delaware Action. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the three and six months ended June&amp;#160;30, 2017, interest expense related to the Convertible Notes was $1.7 million and $3.3 million, respectively. For the three and six months ended June&amp;#160;30, 2016, interest expense related to the Convertible Notes was $1.9 million and $5.3 million, respectively. The year-over-year decrease was primarily attributable to interest expense related to a reduction in the principal based on the conversion of some of the Convertible Notes that occurred in April 2016.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future Minimum Payments under Outstanding Borrowings&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum payments under outstanding borrowings as of June&amp;#160;30, 2017 are as follows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Notes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remainder of 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,368&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,736&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,736&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020 and thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63,527&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,367&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,576&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less unamortized discount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term debt&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,906&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000233" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;11. Stock-Based Compensation&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;As of December 31, 2015, there were 2.5 million shares of common stock available to be granted under the Company&amp;#8217;s 2011 Stock Incentive Plan (the &amp;#8220;2011 Plan&amp;#8221;). The 2011 Plan is administered by the Company&amp;#8217;s board of directors and permits the Company to grant incentive and non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, 4.1 million additional shares of common stock became available for grant to employees, officers, directors and consultants under the 2011 Plan. At June&amp;#160;30, 2017, there were 2.3 million shares remaining available for grant under the 2011 Plan. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During both the three and six months ended June&amp;#160;30, 2017, the Company issued options to purchase 19.4 million shares of common stock. During the six months ended June&amp;#160;30, 2016 the Company issued options to purchase 3.8 million shares of common stock. These options generally vest over a three-year period for employees. Options granted to directors vest immediately.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As described in Note 3, &amp;#8220;Sale of Commercial Business,&amp;#8221; the Board of Directors authorized and declared a special cash dividend of $140.0 million on the Company&apos;s common stock, which was payable on May 26, 2017 to stockholders of record as of the close of business on May 17, 2017. The Board of Directors determined, in accordance with the adjustment provision of each of the Company&amp;#8217;s 1999 Stock Option Plan, as amended, the 2008 Stock Incentive Plan, as amended, and the 2011 Plan (collectively, the &amp;#8220;Equity Plans&amp;#8221;), that the special cash dividend was unusual and non-recurring and that appropriate adjustment to the stock options to purchase shares of the Corporation&amp;#8217;s common stock outstanding under the Equity Plans was required. The Company treated this adjustment as a modification to the original stock option grant because the terms of the agreements were modified in order to preserve the value of the option awards after a large non-recurring cash dividend. The calculation of the incremental compensation expense is based on the excess of the fair value of the award measured immediately before and after the modification. As a result, the Company recognized an incremental compensation expense of $5.6 million associated with the modification in the second quarter of 2017.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of stock options granted to employees during the three and six months ended June&amp;#160;30, 2017 and 2016 was estimated at the date of grant using the following assumptions:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.58%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.58%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.7 &amp;#8211; 2.0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.1 &amp;#8211; 1.5%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.7 &amp;#8211; 2.1%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.5 &amp;#8211; 1.8%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.7 &amp;#8211; 6.1 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.0 &amp;#8211; 5.8 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.7 &amp;#8211; 6.1 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.0 &amp;#8211; 5.9 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67 &amp;#8211; 69%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65 &amp;#8211; 68%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66 &amp;#8211; 67%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company uses the simplified method to calculate the expected term, as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. The computation of expected volatility is based on the historical volatility of comparable companies from a representative peer group selected based on industry and market capitalization. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected life of the stock options. Management estimates expected forfeitures based on historical experience and recognizes compensation costs only for those equity awards expected to vest.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2016, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2016-09, &amp;#8220;Compensation &amp;#8211; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,&amp;#8221; which simplifies several areas of accounting for share-based payment transactions, including the income tax consequences, classification of awards as either liabilities or equity and classification of excess tax benefits on the statement of cash flows. This guidance also permits a new entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures when they occur. The Company adopted the guidance, electing to account for forfeitures when they occur, and it did not have an impact on the consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognized stock-based compensation expense during the three and six months ended June&amp;#160;30, 2017 and 2016 as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee awards:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,916&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,465&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,383&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,991&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,818&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,102&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,146&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,086&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,734&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,567&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,529&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,077&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes stock option activity during the six months ended June&amp;#160;30, 2017:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands, except per share amounts)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&amp;#160;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&amp;#160;Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December&amp;#160;31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.77&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.97&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,564&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,388&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.46&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,562&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,935&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.24&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.74%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at June&amp;#160;30, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,915&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.43&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.87&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.74%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;440&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest at June&amp;#160;30, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,870&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.43&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.86&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;440&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at June&amp;#160;30, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,560&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.81&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.98&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;440&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average grant date fair value per share of stock options granted during the three and six months ended June&amp;#160;30, 2017 was $0.38 and $0.38, respectively. The weighted-average grant date fair value per share of stock options granted during the three and six months ended June&amp;#160;30, 2016 was $3.73 and $3.35, respectively.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the stock options and the fair value of the underlying common stock. The aggregate intrinsic value of stock options exercised during the three and six months ended June&amp;#160;30, 2017 was $0.9 million and $2.3 million, respectively. The aggregate intrinsic value of stock options exercised during the three and six months ended June&amp;#160;30, 2016 was $0.6 million and $2.7 million, respectively.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June&amp;#160;30, 2017, there was $6.1 million of total unrecognized stock-based compensation expense related to unvested employee stock awards. The Company expects to recognize this expense over a weighted-average period of approximately 2.9 years.&lt;/p&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock id="F_000234" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;12. Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;In May 2014, the FASB issued ASU 2014-09, &amp;#8220;Revenue from Contracts with Customers (Topic 606),&amp;#8221; which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. This guidance was originally effective for interim and annual periods beginning after December 15, 2016 and allows for adoption using a full retrospective method, or a modified retrospective method. Early adoption was originally not permitted. Subsequent to the issuance of ASU 2014-09, the FASB also issued the following updates related to ASC 606, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2015, the FASB issued ASU 2015-14, &amp;#8220;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,&amp;#8221; whereby the effective date for the new revenue standard was deferred by one year. As a result of ASU 2015-14, the new revenue standard is now effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, and early adoption is now permitted for annual periods beginning after December 15, 2016, including interim periods within that annual period.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2016, the FASB issued ASU 2016-08, &amp;#8220;Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net),&amp;#8221; to clarify the implementation guidance on principal versus agent considerations.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2016, the FASB issued ASU 2016-10, &amp;#8220;Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,&amp;#8221; to clarify the principle for determining whether a good or service is &amp;#8220;separately identifiable&amp;#8221; from other promises in the contract and to clarify the categorization of licenses of intellectual property.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2016, the FASB issued ASU 2016-12, &amp;#8220;Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Technical Expedients,&amp;#8221; to clarify guidance on transition, determining collectability, non-cash consideration and the presentation of sales and other similar taxes.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company does not currently have any revenue generating contracts with customers due to the sale of its commercial business in the second quarter of 2017. The Company expects to adopt the new revenue standard on January 1, 2018 using the modified retrospective approach.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2016, the FASB issued ASU 2016-01, &amp;#8220;Financial Instruments &amp;#8211; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities,&amp;#8221; which contains a number of provisions related to the measurement, presentation and disclosure of financial instruments. This guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within those annual periods. Early adoption of this guidance is not permitted with the exception of certain specific presentation requirements that are not currently applicable to the Company. The Company does not anticipate a material impact to the consolidated financial statements as a result of the adoption of this guidance.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU 2016-02, &amp;#8220;Leases (Topic 842),&amp;#8221; which supersedes all existing lease accounting guidance within ASC 840, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt;. The new standard requires that lease assets and lease liabilities be recognized by lessees for those leases previously classified as operating leases under ASC 840, with limited exceptions. This update also creates a new definition of a lease and provides guidance as to whether a contract is or contains a lease. This guidance will be effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual reporting periods, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU 2016-13, &amp;#8220;Financial Instruments &amp;#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&amp;#8221; which represents a new credit loss standard that will change the impairment model for most financial assets and certain other financial instruments. Specifically, this guidance will require entities to utilize a new &amp;#8220;expected loss&amp;#8221; model as it relates to trade and other receivables. In addition, entities will be required to recognize an allowance for estimated credit losses on available-for-sale debt securities, regardless of the length of time that a security has been in an unrealized loss position. This guidance will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2016, the FASB issued ASU 2016-15, &amp;#8220;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,&amp;#8221; which is intended to reduce diversity in practice in how entities present certain types of cash transactions in the statement of cash flows. This guidance also clarifies how the predominance principle should be applied when classifying cash receipts and cash payments that have attributes of more than one class of cash flows. This guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within those annual reporting periods, and early adoption is permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company does not anticipate a material impact to the consolidated financial statements as a result of the adoption of this guidance.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2017, the FASB issued ASU 2017-09, &amp;#8220;Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting,&amp;#8221; which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard should be applied prospectively to awards modified on or after the adoption date. This guidance will be effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&amp;#8217;s consolidated financial statements upon adoption.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
  <us-gaap:SubsequentEventsTextBlock id="F_000235" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;13. Subsequent Events&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;In July 2017, Silver Creek issued 1.7 million shares of Series C preferred stock at $1.50 per share for proceeds of $2.6 million. As of June 30, 2017, the Company held a 51% ownership interest in Silver Creek and maintained control over the Silver Creek board of directors through its voting rights. As a result of Silver Creek&amp;#8217;s issuance of additional shares of Series C preferred stock in July 2017, the Company will evaluate whether the Silver Creek financial statements should continue to be consolidated. &amp;#160;&lt;/p&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000236" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;In May 2014, the FASB issued ASU 2014-09, &amp;#8220;Revenue from Contracts with Customers (Topic 606),&amp;#8221; which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. This guidance was originally effective for interim and annual periods beginning after December 15, 2016 and allows for adoption using a full retrospective method, or a modified retrospective method. Early adoption was originally not permitted. Subsequent to the issuance of ASU 2014-09, the FASB also issued the following updates related to ASC 606, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2015, the FASB issued ASU 2015-14, &amp;#8220;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,&amp;#8221; whereby the effective date for the new revenue standard was deferred by one year. As a result of ASU 2015-14, the new revenue standard is now effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, and early adoption is now permitted for annual periods beginning after December 15, 2016, including interim periods within that annual period.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2016, the FASB issued ASU 2016-08, &amp;#8220;Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net),&amp;#8221; to clarify the implementation guidance on principal versus agent considerations.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2016, the FASB issued ASU 2016-10, &amp;#8220;Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,&amp;#8221; to clarify the principle for determining whether a good or service is &amp;#8220;separately identifiable&amp;#8221; from other promises in the contract and to clarify the categorization of licenses of intellectual property.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2016, the FASB issued ASU 2016-12, &amp;#8220;Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Technical Expedients,&amp;#8221; to clarify guidance on transition, determining collectability, non-cash consideration and the presentation of sales and other similar taxes.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company does not currently have any revenue generating contracts with customers due to the sale of its commercial business in the second quarter of 2017. The Company expects to adopt the new revenue standard on January 1, 2018 using the modified retrospective approach.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2016, the FASB issued ASU 2016-01, &amp;#8220;Financial Instruments &amp;#8211; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities,&amp;#8221; which contains a number of provisions related to the measurement, presentation and disclosure of financial instruments. This guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within those annual periods. Early adoption of this guidance is not permitted with the exception of certain specific presentation requirements that are not currently applicable to the Company. The Company does not anticipate a material impact to the consolidated financial statements as a result of the adoption of this guidance.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU 2016-02, &amp;#8220;Leases (Topic 842),&amp;#8221; which supersedes all existing lease accounting guidance within ASC 840, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt;. The new standard requires that lease assets and lease liabilities be recognized by lessees for those leases previously classified as operating leases under ASC 840, with limited exceptions. This update also creates a new definition of a lease and provides guidance as to whether a contract is or contains a lease. This guidance will be effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual reporting periods, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU 2016-13, &amp;#8220;Financial Instruments &amp;#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&amp;#8221; which represents a new credit loss standard that will change the impairment model for most financial assets and certain other financial instruments. Specifically, this guidance will require entities to utilize a new &amp;#8220;expected loss&amp;#8221; model as it relates to trade and other receivables. In addition, entities will be required to recognize an allowance for estimated credit losses on available-for-sale debt securities, regardless of the length of time that a security has been in an unrealized loss position. This guidance will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2016, the FASB issued ASU 2016-15, &amp;#8220;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,&amp;#8221; which is intended to reduce diversity in practice in how entities present certain types of cash transactions in the statement of cash flows. This guidance also clarifies how the predominance principle should be applied when classifying cash receipts and cash payments that have attributes of more than one class of cash flows. This guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within those annual reporting periods, and early adoption is permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company does not anticipate a material impact to the consolidated financial statements as a result of the adoption of this guidance.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2017, the FASB issued ASU 2017-09, &amp;#8220;Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting,&amp;#8221; which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard should be applied prospectively to awards modified on or after the adoption date. This guidance will be effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&amp;#8217;s consolidated financial statements upon adoption.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock id="F_000237" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The change in the non-controlling interest related to Silver Creek was as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Controlling&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December&amp;#160;31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,539&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to Silver Creek&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,191&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance of Silver Creek Series C preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;699&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at June&amp;#160;30, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,031&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Controlling&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December&amp;#160;31, 2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;239&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to Silver Creek&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(393&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at June&amp;#160;30, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(154&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock>
  <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock id="F_000238" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Discontinued operations for the three and six months ended June 30, 2017 and 2016 includes the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenues, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,851&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,135&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,819&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License and collaboration revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,332&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,797&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,645&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,498&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,973&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,498&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,681&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,905&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,962&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs and expenses:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,872&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,890&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,583&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,302&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,700&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,181&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,542&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,709&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restructuring expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,216&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,535&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total costs and expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,216&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,716&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,834&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,649&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other income and expenses:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,509&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,743&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,581&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gain on sale of commercial business&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;598,120&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;598,120&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income (loss) from discontinued operations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;592,395&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;675&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;591,448&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(268&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(51,910&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(51,910&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total income (loss) from discontinued operations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;540,485&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;675&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;539,538&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(268&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
  <us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock id="F_000239" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The carrying value of the assets and liabilities of the Commercial Business classified as &amp;#8220;Discontinued operations&amp;#8221; in the condensed consolidated balance sheets is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.58%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts receivable, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,194&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,554&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,547&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current assets held for sale&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,295&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,553&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,977&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,605&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total long-term assets held for sale&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,135&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts payable, accrued expenses and other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,613&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,226&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current liabilities held for sale&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,839&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenues, net of current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,673&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total liabilities held for sale&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,673&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock id="F_000240" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Inventory of the Commercial Business as of December 31, 2016 consisted of the following:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,483&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,651&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,554&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock id="F_000241" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="margin-bottom:6pt;margin-top:12pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table summarizes the charges related to the restructuring activities as of June 30, 2017:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued Restructuring Expenses at December&amp;#160;31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;"&gt;
&lt;p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;"&gt;
&lt;p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued Restructuring Expenses at June&amp;#160;30, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Severance, benefits and related costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,521&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,124&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,397&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Totals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,521&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,124&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,397&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000242" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Outstanding securities excluded from the calculation of diluted loss per share for the three and six months ended June&amp;#160;30, 2017 and 2016 are shown in the chart below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.56%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.56%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,915&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,647&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,915&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,647&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion of the Convertible Notes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock id="F_000243" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following tables show assets measured at fair value on a recurring basis as of June&amp;#160;30, 2017 and December&amp;#160;31, 2016:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;128,931&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Totals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;128,931&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Silver Creek warrant liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,062&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Totals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,062&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,373&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Totals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,373&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Silver Creek warrant liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Totals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock id="F_000244" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Accounts payable, accrued expenses and other as of June&amp;#160;30, 2017 and December&amp;#160;31, 2016 consisted of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,298&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,692&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued goods and services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,467&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,233&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued clinical trial costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,382&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,776&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued drug purchase costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;480&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued payroll and related benefits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,362&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,394&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued severance expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,736&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;774&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,261&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,100&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued dividends payable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Silver Creek warrant liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,062&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax incentives&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,402&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,402&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accounts payable, accrued expenses and other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,989&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,369&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
  <us-gaap:ContractualObligationFiscalYearMaturityScheduleTableTextBlock id="F_000245" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Future minimum payments under outstanding borrowings as of June&amp;#160;30, 2017 are as follows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Notes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remainder of 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,368&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,736&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,736&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020 and thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63,527&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,367&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,576&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less unamortized discount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term debt&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,906&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000246" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The fair value of stock options granted to employees during the three and six months ended June&amp;#160;30, 2017 and 2016 was estimated at the date of grant using the following assumptions:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.58%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.58%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.7 &amp;#8211; 2.0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.1 &amp;#8211; 1.5%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.7 &amp;#8211; 2.1%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.5 &amp;#8211; 1.8%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.7 &amp;#8211; 6.1 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.0 &amp;#8211; 5.8 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.7 &amp;#8211; 6.1 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.0 &amp;#8211; 5.9 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67 &amp;#8211; 69%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65 &amp;#8211; 68%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66 &amp;#8211; 67%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <mack:ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock id="F_000247" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The Company recognized stock-based compensation expense during the three and six months ended June&amp;#160;30, 2017 and 2016 as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee awards:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,916&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,465&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,383&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,991&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,818&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,102&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,146&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,086&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,734&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,567&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,529&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,077&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</mack:ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="F_000248" contextRef="C_0001274792_20170101_20170630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table summarizes stock option activity during the six months ended June&amp;#160;30, 2017:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands, except per share amounts)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&amp;#160;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&amp;#160;Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December&amp;#160;31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.77&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.97&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,564&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,388&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.46&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,562&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,935&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.24&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.74%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at June&amp;#160;30, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,915&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.43&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.87&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.74%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;440&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest at June&amp;#160;30, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,870&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.43&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.86&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;440&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at June&amp;#160;30, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,560&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.81&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.98&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;440&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <mack:AssetSaleUpfrontCashPayment id="F_000249" contextRef="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170403" decimals="-5" unitRef="U_iso4217USD">575000000</mack:AssetSaleUpfrontCashPayment>
  <mack:AssetSaleFutureMilestonePayments id="F_000250" contextRef="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170403" decimals="INF" unitRef="U_iso4217USD">450000000</mack:AssetSaleFutureMilestonePayments>
  <mack:WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset id="F_000251" contextRef="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170403" decimals="-5" unitRef="U_iso4217USD">2200000</mack:WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset>
  <mack:NetMilestonePaymentsEntitledToReceiveAfterAssetSale id="F_000252" contextRef="C_0001274792_us-gaapCounterpartyNameAxis_mackBaxaltaMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20170403" decimals="-5" unitRef="U_iso4217USD">33000000</mack:NetMilestonePaymentsEntitledToReceiveAfterAssetSale>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000253" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20170630" decimals="-5" unitRef="U_iso4217USD">2600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PreferredStockSharesIssued id="F_000254" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20170331" decimals="-5" unitRef="U_shares">1400000</us-gaap:PreferredStockSharesIssued>
  <us-gaap:SharesIssuedPricePerShare id="F_000255" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20170331" decimals="INF" unitRef="U_iso4217USD_shares">1.50</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="F_000256" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20170101_20170331" decimals="-5" unitRef="U_iso4217USD">2000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000257" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20170331" decimals="-5" unitRef="U_shares">1800000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:PreferredStockSharesIssued id="F_000258" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20170630" decimals="-5" unitRef="U_shares">400000</us-gaap:PreferredStockSharesIssued>
  <us-gaap:SharesIssuedPricePerShare id="F_000259" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20170630" decimals="INF" unitRef="U_iso4217USD_shares">1.50</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="F_000260" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20170401_20170630" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000261" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20170630" decimals="-5" unitRef="U_shares">300000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000262" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_mackWarrantPurchaseAgreementsMember_20170630" decimals="-5" unitRef="U_shares">1300000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <mack:OwnershipPercentageHeldByParentAndItsDeFactoAgents id="F_000263" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20170630" decimals="2" unitRef="U_pure">0.51</mack:OwnershipPercentageHeldByParentAndItsDeFactoAgents>
  <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance id="F_000264" contextRef="C_0001274792_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">699000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
  <us-gaap:MinorityInterest id="F_000265" contextRef="C_0001274792_20151231" decimals="-3" unitRef="U_iso4217USD">239000</us-gaap:MinorityInterest>
  <us-gaap:MinorityInterest id="F_000266" contextRef="C_0001274792_20160630" decimals="-3" unitRef="U_iso4217USD">-154000</us-gaap:MinorityInterest>
  <mack:AssetSaleFutureMilestonePayments id="F_000267" contextRef="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapDeferredRevenueArrangementTypeAxis_mackClinicalTrialsInPancreasAsFirstLineTreatmentMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170403" decimals="-5" unitRef="U_iso4217USD">225000000</mack:AssetSaleFutureMilestonePayments>
  <mack:AssetSaleFutureMilestonePayments id="F_000268" contextRef="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapDeferredRevenueArrangementTypeAxis_mackClinicalTrialsInSmallCellLungCancerMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170403" decimals="-5" unitRef="U_iso4217USD">150000000</mack:AssetSaleFutureMilestonePayments>
  <mack:AssetSaleFutureMilestonePayments id="F_000269" contextRef="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapDeferredRevenueArrangementTypeAxis_mackOtherUnrelatedClinicalTrialsMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170403" decimals="-5" unitRef="U_iso4217USD">75000000</mack:AssetSaleFutureMilestonePayments>
  <mack:TransitionServicesAgreementPeriod id="F_000270" contextRef="C_0001274792_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170402_20170403">P24M</mack:TransitionServicesAgreementPeriod>
  <us-gaap:RepaymentsOfLongTermDebt id="F_000271" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170402_20170403" decimals="-5" unitRef="U_iso4217USD">175000000</us-gaap:RepaymentsOfLongTermDebt>
  <mack:PaymentOfMakeWholePremiumOfLongTermDebt id="F_000272" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170402_20170403" decimals="-5" unitRef="U_iso4217USD">20100000</mack:PaymentOfMakeWholePremiumOfLongTermDebt>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="F_000273" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170403" decimals="INF" unitRef="U_pure">0.1150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentPeriodicPaymentInterest id="F_000274" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170402_20170403" decimals="-5" unitRef="U_iso4217USD">7400000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
  <mack:AssetSaleSubleaseArea id="F_000275" contextRef="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170403" decimals="0" unitRef="U_utrsqft">70237</mack:AssetSaleSubleaseArea>
  <us-gaap:LeaseExpirationDate1 id="F_000276" contextRef="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170402_20170403">2019-06-30</us-gaap:LeaseExpirationDate1>
  <us-gaap:DividendsPayableDateDeclaredDayMonthAndYear id="F_000277" contextRef="C_0001274792_20170101_20170630">2017-04-05</us-gaap:DividendsPayableDateDeclaredDayMonthAndYear>
  <us-gaap:DividendsCommonStockCash id="F_000278" contextRef="C_0001274792_20170404_20170405" decimals="-5" unitRef="U_iso4217USD">140000000</us-gaap:DividendsCommonStockCash>
  <us-gaap:DividendPayableDateToBePaidDayMonthAndYear id="F_000279" contextRef="C_0001274792_20170101_20170630">2017-05-26</us-gaap:DividendPayableDateToBePaidDayMonthAndYear>
  <us-gaap:DividendsPayableDateOfRecordDayMonthAndYear id="F_000280" contextRef="C_0001274792_20170101_20170630">2017-05-17</us-gaap:DividendsPayableDateOfRecordDayMonthAndYear>
  <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax id="F_000281" contextRef="C_0001274792_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">598200000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
  <mack:DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet id="F_000282" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">12851000</mack:DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet>
  <mack:DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet id="F_000283" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">16135000</mack:DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet>
  <mack:DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet id="F_000284" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">22819000</mack:DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet>
  <mack:DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues id="F_000285" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">19332000</mack:DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues>
  <mack:DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues id="F_000286" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">7797000</mack:DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues>
  <mack:DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues id="F_000287" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">30645000</mack:DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues>
  <mack:DisposalGroupIncludingDiscontinuedOperationOtherRevenue id="F_000288" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">1498000</mack:DisposalGroupIncludingDiscontinuedOperationOtherRevenue>
  <mack:DisposalGroupIncludingDiscontinuedOperationOtherRevenue id="F_000289" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">1973000</mack:DisposalGroupIncludingDiscontinuedOperationOtherRevenue>
  <mack:DisposalGroupIncludingDiscontinuedOperationOtherRevenue id="F_000290" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">1498000</mack:DisposalGroupIncludingDiscontinuedOperationOtherRevenue>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue id="F_000291" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">33681000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue id="F_000292" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">25905000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue id="F_000293" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">54962000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold id="F_000294" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">1872000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold id="F_000295" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">3890000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold id="F_000296" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">2583000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
  <mack:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses id="F_000297" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">13302000</mack:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses>
  <mack:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses id="F_000298" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">3700000</mack:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses>
  <mack:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses id="F_000299" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">18181000</mack:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense id="F_000300" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">12542000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense id="F_000301" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">8709000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense id="F_000302" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">23885000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
  <mack:DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses id="F_000303" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">4216000</mack:DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses>
  <mack:DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses id="F_000304" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">9535000</mack:DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense id="F_000305" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">4216000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense id="F_000306" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">27716000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense id="F_000307" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">25834000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense id="F_000308" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">44649000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense id="F_000309" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">1509000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense id="F_000310" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">5290000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense id="F_000311" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">6743000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense id="F_000312" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">10581000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
  <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax id="F_000313" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">598120000</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
  <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax id="F_000314" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">598120000</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
  <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax id="F_000315" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">592395000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
  <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax id="F_000316" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">675000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
  <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax id="F_000317" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">591448000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
  <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax id="F_000318" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-268000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
  <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation id="F_000319" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">51910000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
  <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation id="F_000320" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">51910000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="F_000321" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">540485000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="F_000322" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">675000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="F_000323" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">539538000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="F_000324" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">-268000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet id="F_000325" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20161231" decimals="-3" unitRef="U_iso4217USD">17194000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent id="F_000326" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20161231" decimals="-3" unitRef="U_iso4217USD">14554000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent id="F_000327" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20161231" decimals="-3" unitRef="U_iso4217USD">1547000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
  <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent id="F_000328" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20161231" decimals="-3" unitRef="U_iso4217USD">33295000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent id="F_000329" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20161231" decimals="-3" unitRef="U_iso4217USD">1553000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent id="F_000330" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20161231" decimals="-3" unitRef="U_iso4217USD">3977000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent id="F_000331" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20161231" decimals="-3" unitRef="U_iso4217USD">3605000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent id="F_000332" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20161231" decimals="-3" unitRef="U_iso4217USD">9135000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
  <mack:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent id="F_000333" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20161231" decimals="-3" unitRef="U_iso4217USD">20613000</mack:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent id="F_000334" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20161231" decimals="-3" unitRef="U_iso4217USD">36226000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent>
  <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent id="F_000335" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20161231" decimals="-3" unitRef="U_iso4217USD">56839000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent id="F_000336" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20161231" decimals="-3" unitRef="U_iso4217USD">25673000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent>
  <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent id="F_000337" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20161231" decimals="-3" unitRef="U_iso4217USD">25673000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
  <us-gaap:InventoryRawMaterials id="F_000338" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20161231" decimals="-3" unitRef="U_iso4217USD">4483000</us-gaap:InventoryRawMaterials>
  <us-gaap:InventoryWorkInProcess id="F_000339" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20161231" decimals="-3" unitRef="U_iso4217USD">8651000</us-gaap:InventoryWorkInProcess>
  <us-gaap:InventoryFinishedGoods id="F_000340" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20161231" decimals="-3" unitRef="U_iso4217USD">1420000</us-gaap:InventoryFinishedGoods>
  <us-gaap:InventoryNet id="F_000341" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20161231" decimals="-3" unitRef="U_iso4217USD">14554000</us-gaap:InventoryNet>
  <us-gaap:RestructuringAndRelatedActivitiesInitiationDate id="F_000342" contextRef="C_0001274792_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20170101_20170630">2017-01-08</us-gaap:RestructuringAndRelatedActivitiesInitiationDate>
  <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent id="F_000343" contextRef="C_0001274792_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20170107_20170108" decimals="2" unitRef="U_pure">0.30</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
  <mack:RestructuringAndRelatedCostNumberOfPositionsAfterHeadcountReduction id="F_000344" contextRef="C_0001274792_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20170107_20170108" decimals="INF" unitRef="U_mackEmployee">80</mack:RestructuringAndRelatedCostNumberOfPositionsAfterHeadcountReduction>
  <us-gaap:RestructuringCharges id="F_000345" contextRef="C_0001274792_us-gaapRestructuringCostAndReserveAxis_us-gaapContractTerminationMember_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20170401_20170630" decimals="-5" unitRef="U_iso4217USD">4200000</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringCharges id="F_000346" contextRef="C_0001274792_us-gaapRestructuringCostAndReserveAxis_us-gaapContractTerminationMember_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">9500000</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringAndRelatedActivitiesDescription id="F_000347" contextRef="C_0001274792_us-gaapRestructuringCostAndReserveAxis_us-gaapOneTimeTerminationBenefitsMember_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20170101_20170630">One-time employee termination benefits are comprised of severance, benefits and related costs, all of which are expected to result in cash expenditures. The majority of these payments were made during the second quarter of 2017. The remaining payments represent severance payments that will be paid over one year.</us-gaap:RestructuringAndRelatedActivitiesDescription>
  <mack:SeverancePaymentsPaymentPeriod id="F_000348" contextRef="C_0001274792_us-gaapRestructuringCostAndReserveAxis_us-gaapOneTimeTerminationBenefitsMember_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20170101_20170630">P1Y</mack:SeverancePaymentsPaymentPeriod>
  <us-gaap:RestructuringCharges id="F_000349" contextRef="C_0001274792_us-gaapDisposalGroupClassificationAxis_us-gaapDiscontinuedOperationsDisposedOfBySaleMember_us-gaapRestructuringPlanAxis_mackJanuaryTwoThousandSeventeenCorporateRestructuringMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">9500000</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringCharges id="F_000350" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_us-gaapRestructuringCostAndReserveAxis_us-gaapEmployeeSeveranceMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">9521000</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringCharges id="F_000351" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">9521000</us-gaap:RestructuringCharges>
  <us-gaap:PaymentsForRestructuring id="F_000352" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_us-gaapRestructuringCostAndReserveAxis_us-gaapEmployeeSeveranceMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">8124000</us-gaap:PaymentsForRestructuring>
  <us-gaap:PaymentsForRestructuring id="F_000353" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">8124000</us-gaap:PaymentsForRestructuring>
  <us-gaap:RestructuringReserveCurrent id="F_000354" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_us-gaapRestructuringCostAndReserveAxis_us-gaapEmployeeSeveranceMember_20170630" decimals="-3" unitRef="U_iso4217USD">1397000</us-gaap:RestructuringReserveCurrent>
  <us-gaap:RestructuringReserveCurrent id="F_000355" contextRef="C_0001274792_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mackCommercialBusinessMember_20170630" decimals="-3" unitRef="U_iso4217USD">1397000</us-gaap:RestructuringReserveCurrent>
  <mack:MaximumCollaborativeArrangementMilestonePayments id="F_000356" contextRef="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapDeferredRevenueArrangementTypeAxis_mackDevelopmentAndCommercializationMilestonesMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170402_20170403" decimals="INF" unitRef="U_iso4217USD">33000000</mack:MaximumCollaborativeArrangementMilestonePayments>
  <mack:PotentialMilestonePaymentsReceivable id="F_000357" contextRef="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapDeferredRevenueArrangementTypeAxis_mackSaleMilestoneInMajorEuropeanCountriesMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170402_20170403" decimals="INF" unitRef="U_iso4217USD">18000000</mack:PotentialMilestonePaymentsReceivable>
  <mack:PotentialMilestonePaymentsReceivable id="F_000358" contextRef="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapDeferredRevenueArrangementTypeAxis_mackSaleMilestoneInMajorNonEuropeanAndNonAsianCountryMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170402_20170403" decimals="INF" unitRef="U_iso4217USD">5000000</mack:PotentialMilestonePaymentsReceivable>
  <mack:PotentialMilestonePaymentsReceivable id="F_000359" contextRef="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapDeferredRevenueArrangementTypeAxis_mackClinicalTrialsInLungCancerMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170402_20170403" decimals="INF" unitRef="U_iso4217USD">10000000</mack:PotentialMilestonePaymentsReceivable>
  <mack:CollaborativeArrangementUpfrontPaymentObligation id="F_000360" contextRef="C_0001274792_us-gaapCounterpartyNameAxis_mackPharmaEngineIncMember_20110505_20110505" decimals="-5" unitRef="U_iso4217USD">10000000</mack:CollaborativeArrangementUpfrontPaymentObligation>
  <mack:CollaborativeArrangementMaximumMilestonePaymentObligation id="F_000361" contextRef="C_0001274792_us-gaapCounterpartyNameAxis_mackPharmaEngineIncMember_us-gaapDeferredRevenueArrangementTypeAxis_mackDevelopmentAndRegulatoryMilestonesMember_20110505_20110505" decimals="INF" unitRef="U_iso4217USD">80000000</mack:CollaborativeArrangementMaximumMilestonePaymentObligation>
  <mack:CollaborativeArrangementMaximumMilestonePaymentObligation id="F_000362" contextRef="C_0001274792_us-gaapCounterpartyNameAxis_mackPharmaEngineIncMember_us-gaapDeferredRevenueArrangementTypeAxis_mackSalesMilestonesMember_20110505_20110505" decimals="INF" unitRef="U_iso4217USD">130000000</mack:CollaborativeArrangementMaximumMilestonePaymentObligation>
  <mack:AssetSaleUpfrontCashPaymentReceived id="F_000363" contextRef="C_0001274792_us-gaapCounterpartyNameAxis_mackIpsenSAMember_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170402_20170403" decimals="-5" unitRef="U_iso4217USD">575000000</mack:AssetSaleUpfrontCashPaymentReceived>
  <us-gaap:DividendsCommonStockCash id="F_000364" contextRef="C_0001274792_us-gaapTypeOfArrangementAxis_mackAssetPurchaseAndSaleAgreementMember_20170402_20170403" decimals="-5" unitRef="U_iso4217USD">140000000</us-gaap:DividendsCommonStockCash>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="F_000365" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20170403" decimals="INF" unitRef="U_pure">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:EscrowDeposit id="F_000366" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20170403" decimals="-5" unitRef="U_iso4217USD">60000000</us-gaap:EscrowDeposit>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000367" contextRef="C_0001274792_20170331" decimals="-5" unitRef="U_iso4217USD">17200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CurrentIncomeTaxExpenseBenefit id="F_000368" contextRef="C_0001274792_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">8100000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation id="F_000369" contextRef="C_0001274792_20170401_20170630" decimals="-5" unitRef="U_iso4217USD">51900000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
  <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation id="F_000370" contextRef="C_0001274792_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">51900000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
  <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation id="F_000371" contextRef="C_0001274792_20170401_20170630" decimals="-5" unitRef="U_iso4217USD">223300000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
  <mack:DiscontinuedOperationValuationAllowanceFromDisposalOfDiscontinuedOperation id="F_000372" contextRef="C_0001274792_20170401_20170630" decimals="-5" unitRef="U_iso4217USD">171400000</mack:DiscontinuedOperationValuationAllowanceFromDisposalOfDiscontinuedOperation>
  <mack:UndistributedEarningsLossAllocatedToParticipatingSecurities id="F_000373" contextRef="C_0001274792_20170401_20170630" decimals="INF" unitRef="U_iso4217USD">0</mack:UndistributedEarningsLossAllocatedToParticipatingSecurities>
  <mack:UndistributedEarningsLossAllocatedToParticipatingSecurities id="F_000374" contextRef="C_0001274792_20160401_20160630" decimals="INF" unitRef="U_iso4217USD">0</mack:UndistributedEarningsLossAllocatedToParticipatingSecurities>
  <mack:UndistributedEarningsLossAllocatedToParticipatingSecurities id="F_000375" contextRef="C_0001274792_20170101_20170630" decimals="INF" unitRef="U_iso4217USD">0</mack:UndistributedEarningsLossAllocatedToParticipatingSecurities>
  <mack:UndistributedEarningsLossAllocatedToParticipatingSecurities id="F_000376" contextRef="C_0001274792_20160101_20160630" decimals="INF" unitRef="U_iso4217USD">0</mack:UndistributedEarningsLossAllocatedToParticipatingSecurities>
  <mack:ParticipatingSecuritiesOutstandingShares id="F_000377" contextRef="C_0001274792_20170630" decimals="INF" unitRef="U_shares">0</mack:ParticipatingSecuritiesOutstandingShares>
  <mack:ParticipatingSecuritiesOutstandingShares id="F_000378" contextRef="C_0001274792_20160630" decimals="INF" unitRef="U_shares">0</mack:ParticipatingSecuritiesOutstandingShares>
  <us-gaap:DebtInstrumentFaceAmount id="F_000379" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20130731" decimals="-5" unitRef="U_iso4217USD">125000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:LongTermDebt id="F_000380" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20170630" decimals="-5" unitRef="U_iso4217USD">60800000</us-gaap:LongTermDebt>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000381" contextRef="C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockCompensationPlanMember_20170401_20170630" decimals="-3" unitRef="U_shares">18915000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000382" contextRef="C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockCompensationPlanMember_20160401_20160630" decimals="-3" unitRef="U_shares">21647000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000383" contextRef="C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockCompensationPlanMember_20170101_20170630" decimals="-3" unitRef="U_shares">18915000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000384" contextRef="C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockCompensationPlanMember_20160101_20160630" decimals="-3" unitRef="U_shares">21647000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000385" contextRef="C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapConvertibleDebtSecuritiesMember_20170401_20170630" decimals="-3" unitRef="U_shares">12158000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000386" contextRef="C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapConvertibleDebtSecuritiesMember_20160401_20160630" decimals="-3" unitRef="U_shares">12158000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000387" contextRef="C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapConvertibleDebtSecuritiesMember_20170101_20170630" decimals="-3" unitRef="U_shares">12158000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000388" contextRef="C_0001274792_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapConvertibleDebtSecuritiesMember_20160101_20160630" decimals="-3" unitRef="U_shares">12158000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AssetsFairValueDisclosure id="F_000389" contextRef="C_0001274792_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170630" decimals="-3" unitRef="U_iso4217USD">128931000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000390" contextRef="C_0001274792_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170630" decimals="-3" unitRef="U_iso4217USD">128931000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure id="F_000391" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_mackWarrantLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170630" decimals="-3" unitRef="U_iso4217USD">4062000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure id="F_000392" contextRef="C_0001274792_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20170630" decimals="-3" unitRef="U_iso4217USD">4062000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000393" contextRef="C_0001274792_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">12373000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000394" contextRef="C_0001274792_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">12373000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure id="F_000395" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_mackWarrantLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">1499000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure id="F_000396" contextRef="C_0001274792_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">1499000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000397" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20161231" decimals="-5" unitRef="U_shares">1900000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:WarrantsAndRightsOutstanding id="F_000398" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20170630" decimals="-5" unitRef="U_iso4217USD">4100000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WarrantsAndRightsOutstanding id="F_000399" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20161231" decimals="-5" unitRef="U_iso4217USD">1500000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate id="F_000400" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20170101_20170630" decimals="3" unitRef="U_pure">0.021</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate id="F_000401" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20160101_20161231" decimals="3" unitRef="U_pure">0.023</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedDividendRate id="F_000402" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20170101_20170630" decimals="3" unitRef="U_pure">0.000</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedDividendRate id="F_000403" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20160101_20161231" decimals="3" unitRef="U_pure">0.000</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="F_000404" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20170101_20170630" decimals="3" unitRef="U_pure">0.604</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="F_000405" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20160101_20161231" decimals="3" unitRef="U_pure">0.617</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedTerm id="F_000406" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20160101_20161231">P6Y10M24D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedTerm id="F_000407" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20170630">P6Y4M24D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedTerm id="F_000408" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20170630">P7Y</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAdjustmentOfWarrants id="F_000409" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">1000000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants id="F_000410" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20170401_20170630" decimals="-5" unitRef="U_iso4217USD">1000000</us-gaap:FairValueAdjustmentOfWarrants>
  <mack:FairValueAdjustmentOfWarrantsIncrementalChangeResultingFromAmendment id="F_000411" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">800000</mack:FairValueAdjustmentOfWarrantsIncrementalChangeResultingFromAmendment>
  <mack:FairValueAdjustmentOfWarrantsIncrementalChangeResultingFromAmendment id="F_000412" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20170401_20170630" decimals="-5" unitRef="U_iso4217USD">800000</mack:FairValueAdjustmentOfWarrantsIncrementalChangeResultingFromAmendment>
  <mack:FairValueInstrumentsTransfersBetweenLevels id="F_000413" contextRef="C_0001274792_20170630" decimals="INF" unitRef="U_iso4217USD">0</mack:FairValueInstrumentsTransfersBetweenLevels>
  <mack:FairValueInstrumentsTransfersBetweenLevels id="F_000414" contextRef="C_0001274792_20161231" decimals="INF" unitRef="U_iso4217USD">0</mack:FairValueInstrumentsTransfersBetweenLevels>
  <us-gaap:LongTermDebtFairValue id="F_000415" contextRef="C_0001274792_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapLongtermDebtTypeAxis_us-gaapSeniorNotesMember_20170630" decimals="-5" unitRef="U_iso4217USD">36700000</us-gaap:LongTermDebtFairValue>
  <us-gaap:LongTermDebt id="F_000416" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapSeniorNotesMember_20170630" decimals="-5" unitRef="U_iso4217USD">48900000</us-gaap:LongTermDebt>
  <us-gaap:DebtInstrumentFaceAmount id="F_000417" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_20151222" decimals="-5" unitRef="U_iso4217USD">175000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="F_000418" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">-25000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1 id="F_000419" contextRef="C_0001274792_20170630" decimals="INF" unitRef="U_mackSecurity">0</us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGains id="F_000420" contextRef="C_0001274792_20170101_20170630" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGains id="F_000421" contextRef="C_0001274792_20160101_20160630" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGains id="F_000422" contextRef="C_0001274792_20170401_20170630" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGains id="F_000423" contextRef="C_0001274792_20160401_20160630" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
  <us-gaap:AccountsPayableCurrent id="F_000424" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">8298000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000425" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">2692000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000426" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">5467000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000427" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">8233000</us-gaap:AccruedLiabilitiesCurrent>
  <mack:AccruedClinicalTrialCosts id="F_000428" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">10382000</mack:AccruedClinicalTrialCosts>
  <mack:AccruedClinicalTrialCosts id="F_000429" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">8776000</mack:AccruedClinicalTrialCosts>
  <mack:AccruedDrugPurchaseCostsCurrent id="F_000430" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">480000</mack:AccruedDrugPurchaseCostsCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000431" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">1362000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000432" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">3394000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:RestructuringReserveCurrent id="F_000433" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">1736000</us-gaap:RestructuringReserveCurrent>
  <us-gaap:RestructuringReserveCurrent id="F_000434" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">774000</us-gaap:RestructuringReserveCurrent>
  <us-gaap:InterestPayableCurrent id="F_000435" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">1261000</us-gaap:InterestPayableCurrent>
  <us-gaap:InterestPayableCurrent id="F_000436" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">2100000</us-gaap:InterestPayableCurrent>
  <us-gaap:DividendsPayableCurrent id="F_000437" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">19000</us-gaap:DividendsPayableCurrent>
  <us-gaap:DividendsPayableCurrent id="F_000438" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">19000</us-gaap:DividendsPayableCurrent>
  <mack:WarrantLiabilityCurrent id="F_000439" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20170630" decimals="-3" unitRef="U_iso4217USD">4062000</mack:WarrantLiabilityCurrent>
  <mack:WarrantLiabilityCurrent id="F_000440" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_20161231" decimals="-3" unitRef="U_iso4217USD">1499000</mack:WarrantLiabilityCurrent>
  <us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent id="F_000441" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">1402000</us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent>
  <us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent id="F_000442" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">1402000</us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent>
  <us-gaap:ProceedsFromDebtNetOfIssuanceCosts id="F_000443" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_20151221_20151222" decimals="-5" unitRef="U_iso4217USD">168500000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="F_000444" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_20151222" decimals="INF" unitRef="U_pure">0.1150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="F_000445" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_20170401_20170630" decimals="-5" unitRef="U_iso4217USD">-25000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="F_000446" contextRef="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapInterestExpenseMember_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">-25000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:PaymentsOfDebtExtinguishmentCosts id="F_000447" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">20100000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
  <us-gaap:AmortizationOfDebtDiscountPremium id="F_000448" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">4900000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:InterestExpense id="F_000449" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_20170401_20170630" decimals="-5" unitRef="U_iso4217USD">1500000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="F_000450" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">6700000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="F_000451" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_20160401_20160630" decimals="-5" unitRef="U_iso4217USD">5200000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="F_000452" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_mackSeniorNotesDueTwoThousandTwentyTwoMember_20160101_20160630" decimals="-5" unitRef="U_iso4217USD">10400000</us-gaap:InterestExpense>
  <us-gaap:ProceedsFromDebtNetOfIssuanceCosts id="F_000453" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20130701_20130731" decimals="-5" unitRef="U_iso4217USD">120600000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="F_000454" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20130731" decimals="INF" unitRef="U_pure">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent id="F_000455" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20130731" decimals="-5" unitRef="U_iso4217USD">53800000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
  <mack:DebtIssuanceCostsUnderwritingDiscountsCommissionsAndOfferingExpenses id="F_000456" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20130730_20130731" decimals="-5" unitRef="U_iso4217USD">4400000</mack:DebtIssuanceCostsUnderwritingDiscountsCommissionsAndOfferingExpenses>
  <us-gaap:DebtConversionOriginalDebtAmount1 id="F_000457" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20160412_20160413" decimals="-5" unitRef="U_iso4217USD">64200000</us-gaap:DebtConversionOriginalDebtAmount1>
  <mack:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock id="F_000458" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20160413" decimals="INF" unitRef="U_iso4217USD">1000</mack:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 id="F_000459" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20160417_20160418" decimals="INF" unitRef="U_pure">136</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <us-gaap:CommonStockSharesIssued id="F_000460" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20160413" decimals="INF" unitRef="U_shares">3635511</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000461" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20160418" decimals="INF" unitRef="U_shares">8732152</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000462" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20160630" decimals="INF" unitRef="U_shares">12367663</us-gaap:CommonStockSharesIssued>
  <mack:ValueOfAdditionalSharesIssuedForConversion id="F_000463" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20160412_20160413" decimals="-5" unitRef="U_iso4217USD">27700000</mack:ValueOfAdditionalSharesIssuedForConversion>
  <mack:TradingPeriodOfCommonStock id="F_000464" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20160412_20160413">P10D</mack:TradingPeriodOfCommonStock>
  <mack:IncreaseToAdditionalPaidInCapitalDueToConversion id="F_000465" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20160401_20160630" decimals="-5" unitRef="U_iso4217USD">101000000</mack:IncreaseToAdditionalPaidInCapitalDueToConversion>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="F_000466" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20160401_20160630" decimals="-5" unitRef="U_iso4217USD">-14600000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <mack:ReductionInAdditionalPaidInCapitalAttributableToEmbeddedConversionOption id="F_000467" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20160630" decimals="-5" unitRef="U_iso4217USD">39800000</mack:ReductionInAdditionalPaidInCapitalAttributableToEmbeddedConversionOption>
  <mack:DebtConversionCostsIncurredAndPaid id="F_000468" contextRef="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapInterestExpenseMember_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_us-gaapRelatedPartyTransactionAxis_mackTransactionCostsIncurredWithThirdPartiesMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">200000</mack:DebtConversionCostsIncurredAndPaid>
  <mack:DecreaseToAdditionalPaidInCapitalDueToConversionTransactionCost id="F_000469" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_us-gaapRelatedPartyTransactionAxis_mackTransactionCostsIncurredWithThirdPartiesMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">200000</mack:DecreaseToAdditionalPaidInCapitalDueToConversionTransactionCost>
  <us-gaap:DebtInstrumentMaturityDate id="F_000470" contextRef="C_0001274792_20170101_20170630">2020-07-15</us-gaap:DebtInstrumentMaturityDate>
  <mack:DebtInstrumentConversionObligationCommonStockClosingSalesPriceTradingPeriod id="F_000471" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_us-gaapRangeAxis_us-gaapMinimumMember_20130730_20130731">P20D</mack:DebtInstrumentConversionObligationCommonStockClosingSalesPriceTradingPeriod>
  <mack:DebtInstrumentConversionObligationNumberOfConsecutiveTradingTerm id="F_000472" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20130730_20130731">P30D</mack:DebtInstrumentConversionObligationNumberOfConsecutiveTradingTerm>
  <mack:ConvertibilityOfDebtStockPriceTestTargetPercentageOfClosingStockPriceToConversionPriceThatMustBeExceeded id="F_000473" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20130730_20130731" decimals="2" unitRef="U_pure">1.30</mack:ConvertibilityOfDebtStockPriceTestTargetPercentageOfClosingStockPriceToConversionPriceThatMustBeExceeded>
  <mack:DebtInstrumentConversionObligationNumberOfConsecutiveBusinessPeriodAfterConsecutiveTradingTerm id="F_000474" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20130730_20130731">P5D</mack:DebtInstrumentConversionObligationNumberOfConsecutiveBusinessPeriodAfterConsecutiveTradingTerm>
  <mack:DebtInstrumentConversionObligationPeriodOfConsecutiveTrading id="F_000475" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20130730_20130731">P5D</mack:DebtInstrumentConversionObligationPeriodOfConsecutiveTrading>
  <mack:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock id="F_000476" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20130731" decimals="INF" unitRef="U_iso4217USD">1000</mack:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock>
  <mack:ConvertibilityOfDebtDebtPriceTestPercentageOfClosingStockPriceUsedInCalculation id="F_000477" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_us-gaapRangeAxis_us-gaapMaximumMember_20130730_20130731" decimals="INF" unitRef="U_pure">0.98</mack:ConvertibilityOfDebtDebtPriceTestPercentageOfClosingStockPriceUsedInCalculation>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 id="F_000478" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20130730_20130731" decimals="INF" unitRef="U_pure">160.0000</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 id="F_000479" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20170525_20170526" decimals="INF" unitRef="U_pure">235.2112</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 id="F_000480" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20130731" decimals="INF" unitRef="U_iso4217USD_shares">6.25</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:EscrowDeposit id="F_000481" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20170630" decimals="-5" unitRef="U_iso4217USD">60000000</us-gaap:EscrowDeposit>
  <us-gaap:InterestExpense id="F_000482" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20170401_20170630" decimals="-5" unitRef="U_iso4217USD">1700000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="F_000483" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">3300000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="F_000484" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20160401_20160630" decimals="-5" unitRef="U_iso4217USD">1900000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="F_000485" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20160101_20160630" decimals="-5" unitRef="U_iso4217USD">5300000</us-gaap:InterestExpense>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear id="F_000486" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20170630" decimals="-3" unitRef="U_iso4217USD">1368000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo id="F_000487" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20170630" decimals="-3" unitRef="U_iso4217USD">2736000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree id="F_000488" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20170630" decimals="-3" unitRef="U_iso4217USD">2736000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
  <mack:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter id="F_000489" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20170630" decimals="-3" unitRef="U_iso4217USD">63527000</mack:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter>
  <mack:DebtInstrumentCarryingAmountIncludingContractualInterest id="F_000490" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20170630" decimals="-3" unitRef="U_iso4217USD">70367000</mack:DebtInstrumentCarryingAmountIncludingContractualInterest>
  <mack:ContractualInterestIncludedInPayments id="F_000491" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20170630" decimals="-3" unitRef="U_iso4217USD">9576000</mack:ContractualInterestIncludedInPayments>
  <us-gaap:DebtInstrumentUnamortizedDiscount id="F_000492" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20170630" decimals="-3" unitRef="U_iso4217USD">11885000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:LongTermDebtNoncurrent id="F_000493" contextRef="C_0001274792_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleDebtMember_20170630" decimals="-3" unitRef="U_iso4217USD">48906000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000494" contextRef="C_0001274792_us-gaapPlanNameAxis_mackStockIncentivePlan2011Member_20151231" decimals="-5" unitRef="U_shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized id="F_000495" contextRef="C_0001274792_us-gaapPlanNameAxis_mackStockIncentivePlan2011Member_20160201_20160229" decimals="INF" unitRef="U_shares">4100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000496" contextRef="C_0001274792_us-gaapPlanNameAxis_mackStockIncentivePlan2011Member_20170630" decimals="-5" unitRef="U_shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000497" contextRef="C_0001274792_us-gaapPlanNameAxis_mackStockIncentivePlan2011Member_20170401_20170630" decimals="-5" unitRef="U_shares">19400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000498" contextRef="C_0001274792_us-gaapPlanNameAxis_mackStockIncentivePlan2011Member_20170101_20170630" decimals="-5" unitRef="U_shares">19400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000499" contextRef="C_0001274792_us-gaapPlanNameAxis_mackStockIncentivePlan2011Member_20160101_20160630" decimals="-5" unitRef="U_shares">3800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000500" contextRef="C_0001274792_us-gaapPlanNameAxis_mackStockIncentivePlan2011Member_us-gaapTitleOfIndividualAxis_mackEmployeeMember_20170101_20170630">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost id="F_000501" contextRef="C_0001274792_20170401_20170630" decimals="-5" unitRef="U_iso4217USD">5600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000502" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20170401_20170630" decimals="3" unitRef="U_pure">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000503" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20170401_20170630" decimals="3" unitRef="U_pure">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000504" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20160401_20160630" decimals="3" unitRef="U_pure">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000505" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20160401_20160630" decimals="3" unitRef="U_pure">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000506" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20170630" decimals="3" unitRef="U_pure">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000507" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20170630" decimals="3" unitRef="U_pure">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000508" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20160101_20160630" decimals="3" unitRef="U_pure">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000509" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20160101_20160630" decimals="3" unitRef="U_pure">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000510" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170401_20170630" decimals="2" unitRef="U_pure">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000511" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20160401_20160630" decimals="2" unitRef="U_pure">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000512" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20160401_20160630" decimals="2" unitRef="U_pure">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000513" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20170630" decimals="2" unitRef="U_pure">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000514" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20170630" decimals="2" unitRef="U_pure">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000515" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20160101_20160630" decimals="2" unitRef="U_pure">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000516" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20160101_20160630" decimals="2" unitRef="U_pure">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000517" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170401_20170630" decimals="2" unitRef="U_pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000518" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20160401_20160630" decimals="2" unitRef="U_pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000519" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170101_20170630" decimals="2" unitRef="U_pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000520" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20160101_20160630" decimals="2" unitRef="U_pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000521" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20170401_20170630">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000522" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20170401_20170630">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000523" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20160401_20160630">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000524" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20160401_20160630">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000525" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20170630">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000526" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20170630">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000527" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20160101_20160630">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000528" contextRef="C_0001274792_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20160101_20160630">P5Y10M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000529" contextRef="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">4916000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000530" contextRef="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">1465000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000531" contextRef="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">5383000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000532" contextRef="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">2991000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000533" contextRef="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">3818000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000534" contextRef="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">2102000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000535" contextRef="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">4146000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000536" contextRef="C_0001274792_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20160101_20160630" decimals="-3" unitRef="U_iso4217USD">3086000</us-gaap:AllocatedShareBasedCompensationExpense>
  <mack:AllocatedShareBasedCompensationExpenseIncludingNonEmployees id="F_000537" contextRef="C_0001274792_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">8734000</mack:AllocatedShareBasedCompensationExpenseIncludingNonEmployees>
  <mack:AllocatedShareBasedCompensationExpenseIncludingNonEmployees id="F_000538" contextRef="C_0001274792_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">3567000</mack:AllocatedShareBasedCompensationExpenseIncludingNonEmployees>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000539" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_shares">19024000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000540" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_shares">19388000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000541" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_shares">2562000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000542" contextRef="C_0001274792_20170101_20170630" decimals="-3" unitRef="U_shares">16935000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000543" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_shares">18915000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_000544" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_shares">18870000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000545" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_shares">12560000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000546" contextRef="C_0001274792_20161231" decimals="2" unitRef="U_iso4217USD_shares">5.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000547" contextRef="C_0001274792_20170101_20170630" decimals="2" unitRef="U_iso4217USD_shares">2.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000548" contextRef="C_0001274792_20170101_20170630" decimals="2" unitRef="U_iso4217USD_shares">2.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000549" contextRef="C_0001274792_20170101_20170630" decimals="2" unitRef="U_iso4217USD_shares">6.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000550" contextRef="C_0001274792_20170630" decimals="2" unitRef="U_iso4217USD_shares">2.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice id="F_000551" contextRef="C_0001274792_20170630" decimals="2" unitRef="U_iso4217USD_shares">2.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000552" contextRef="C_0001274792_20170630" decimals="2" unitRef="U_iso4217USD_shares">2.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000553" contextRef="C_0001274792_20160101_20161231">P5Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000554" contextRef="C_0001274792_20170101_20170630">P5Y10M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 id="F_000555" contextRef="C_0001274792_20170101_20170630">P5Y10M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000556" contextRef="C_0001274792_20170101_20170630">P3Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000557" contextRef="C_0001274792_20161231" decimals="-3" unitRef="U_iso4217USD">7564000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000558" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">440000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue id="F_000559" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">440000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="F_000560" contextRef="C_0001274792_20170630" decimals="-3" unitRef="U_iso4217USD">440000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000561" contextRef="C_0001274792_20170401_20170630" decimals="2" unitRef="U_iso4217USD_shares">0.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000562" contextRef="C_0001274792_20170101_20170630" decimals="2" unitRef="U_iso4217USD_shares">0.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000563" contextRef="C_0001274792_20160401_20160630" decimals="2" unitRef="U_iso4217USD_shares">3.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000564" contextRef="C_0001274792_20160101_20160630" decimals="2" unitRef="U_iso4217USD_shares">3.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000565" contextRef="C_0001274792_20170401_20170630" decimals="-5" unitRef="U_iso4217USD">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000566" contextRef="C_0001274792_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000567" contextRef="C_0001274792_20160401_20160630" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000568" contextRef="C_0001274792_20160101_20160630" decimals="-5" unitRef="U_iso4217USD">2700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="F_000569" contextRef="C_0001274792_20170630" decimals="-5" unitRef="U_iso4217USD">6100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000570" contextRef="C_0001274792_20170101_20170630">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:PreferredStockSharesIssued id="F_000571" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20170731" decimals="-5" unitRef="U_shares">1700000</us-gaap:PreferredStockSharesIssued>
  <us-gaap:SharesIssuedPricePerShare id="F_000572" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20170731" decimals="INF" unitRef="U_iso4217USD_shares">1.50</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="F_000573" contextRef="C_0001274792_deiLegalEntityAxis_mackSilverCreekPharmaceuticalsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20170730_20170731" decimals="-5" unitRef="U_iso4217USD">2600000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>19
<FILENAME>mack-20170630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFS ActiveDisclosure(SM) XBRL Schema Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2017-08-09T19:46:29.6525140+00:00 -->
<!-- Version            : 2.4.9.2 -->
<!-- Package ID         : A96D3A1EC002FD8DA16B9E2A7F952981-0001274792-001706 -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:mack="http://www.merrimackpharma.com/20170630" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.merrimackpharma.com/20170630" xmlns="http://www.w3.org/2001/XMLSchema">
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <import schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" namespace="http://fasb.org/us-gaap/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2014-01-31" />
  <import schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" namespace="http://fasb.org/us-types/2017-01-31" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <import schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" namespace="http://xbrl.sec.gov/country/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" namespace="http://xbrl.sec.gov/invest/2013-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2011-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2011-01-31" />
  <annotation>
    <appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.merrimackpharma.com/20170630/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mack-20170630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mack-20170630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mack-20170630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mack-20170630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" id="Role_StatementCondensedConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="Role_StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" id="Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss">
        <link:definition>100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2" id="Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2">
        <link:definition>100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="Role_StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>100050 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNatureOfBusiness" id="Role_DisclosureNatureOfBusiness">
        <link:definition>100060 - Disclosure - Nature of the Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBasisOfPresentationAndConsolidation" id="Role_DisclosureBasisOfPresentationAndConsolidation">
        <link:definition>100070 - Disclosure - Basis of Presentation and Consolidation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusiness" id="Role_DisclosureSaleOfCommercialBusiness">
        <link:definition>100080 - Disclosure - Sale of Commercial Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureGoingConcern" id="Role_DisclosureGoingConcern">
        <link:definition>100090 - Disclosure - Going Concern</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShare" id="Role_DisclosureNetIncomeLossPerCommonShare">
        <link:definition>100110 - Disclosure - Net Income (Loss) Per Common Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureFairValueOfFinancialInstruments" id="Role_DisclosureFairValueOfFinancialInstruments">
        <link:definition>100120 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureMarketableSecurities" id="Role_DisclosureMarketableSecurities">
        <link:definition>100130 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOther" id="Role_DisclosureAccountsPayableAccruedExpensesAndOther">
        <link:definition>100140 - Disclosure - Accounts Payable, Accrued Expenses and Other</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowings" id="Role_DisclosureBorrowings">
        <link:definition>100150 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100160 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureRecentAccountingPronouncements" id="Role_DisclosureRecentAccountingPronouncements">
        <link:definition>100170 - Disclosure - Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100180 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureRecentAccountingPronouncementsPolicies" id="Role_DisclosureRecentAccountingPronouncementsPolicies">
        <link:definition>100190 - Disclosure - Recent Accounting Pronouncements (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBasisOfPresentationAndConsolidationTables" id="Role_DisclosureBasisOfPresentationAndConsolidationTables">
        <link:definition>100200 - Disclosure - Basis of Presentation and Consolidation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessTables" id="Role_DisclosureSaleOfCommercialBusinessTables">
        <link:definition>100210 - Disclosure - Sale of Commercial Business (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShareTables" id="Role_DisclosureNetIncomeLossPerCommonShareTables">
        <link:definition>100220 - Disclosure - Net Income (Loss) Per Common Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables" id="Role_DisclosureFairValueOfFinancialInstrumentsTables">
        <link:definition>100230 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherTables" id="Role_DisclosureAccountsPayableAccruedExpensesAndOtherTables">
        <link:definition>100240 - Disclosure - Accounts Payable, Accrued Expenses and Other (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowingsTables" id="Role_DisclosureBorrowingsTables">
        <link:definition>100250 - Disclosure - Borrowings (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100260 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail" id="Role_DisclosureNatureOfBusinessAdditionalInformationDetail">
        <link:definition>100270 - Disclosure - Nature of the Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBasisOfPresentationAndConsolidationAdditionalInformationDetail" id="Role_DisclosureBasisOfPresentationAndConsolidationAdditionalInformationDetail">
        <link:definition>100280 - Disclosure - Basis of Presentation and Consolidation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBasisOfPresentationAndConsolidationScheduleOfNonControllingInterestInSubsidiaryDetail" id="Role_DisclosureBasisOfPresentationAndConsolidationScheduleOfNonControllingInterestInSubsidiaryDetail">
        <link:definition>100290 - Disclosure - Basis of Presentation and Consolidation - Schedule of Non-Controlling Interest in Subsidiary (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessAdditionalInformationDetail" id="Role_DisclosureSaleOfCommercialBusinessAdditionalInformationDetail">
        <link:definition>100300 - Disclosure - Sale of Commercial Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfDiscontinuedOperationsAndAssetsHeldForSaleDetail" id="Role_DisclosureSaleOfCommercialBusinessScheduleOfDiscontinuedOperationsAndAssetsHeldForSaleDetail">
        <link:definition>100310 - Disclosure - Sale of Commercial Business - Schedule of Discontinued Operations and Assets Held for Sale (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfCarryingValueOfAssetsAndLiabilitiesClassifiedAsAssetsHeldForSaleRelatesToCommercialBusinessDetail" id="Role_DisclosureSaleOfCommercialBusinessScheduleOfCarryingValueOfAssetsAndLiabilitiesClassifiedAsAssetsHeldForSaleRelatesToCommercialBusinessDetail">
        <link:definition>100320 - Disclosure - Sale of Commercial Business - Schedule of Carrying Value of Assets and Liabilities Classified as Assets Held for Sale Relates to Commercial Business (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfInventoryOfCommercialBusinessDetail" id="Role_DisclosureSaleOfCommercialBusinessScheduleOfInventoryOfCommercialBusinessDetail">
        <link:definition>100330 - Disclosure - Sale of Commercial Business - Schedule of Inventory of Commercial Business (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessSummaryOfChargesRelatedToRestructuringActivitiesDetail" id="Role_DisclosureSaleOfCommercialBusinessSummaryOfChargesRelatedToRestructuringActivitiesDetail">
        <link:definition>100340 - Disclosure - Sale of Commercial Business - Summary of Charges Related to Restructuring Activities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureGoingConcernAdditionalInformationDetail" id="Role_DisclosureGoingConcernAdditionalInformationDetail">
        <link:definition>100350 - Disclosure - Going Concern - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100360 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShareAdditionalInformationDetail" id="Role_DisclosureNetIncomeLossPerCommonShareAdditionalInformationDetail">
        <link:definition>100370 - Disclosure - Net Income (Loss) Per Common Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedLossPerShareDetail" id="Role_DisclosureNetIncomeLossPerCommonShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedLossPerShareDetail">
        <link:definition>100380 - Disclosure - Net Income (Loss) Per Common Share - Schedule of Outstanding Securities Excluded from Computation of Diluted Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" id="Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>100390 - Disclosure - Fair Value of Financial Instruments - Schedule of Assets Measured at Fair Value on a Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail" id="Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail">
        <link:definition>100400 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail" id="Role_DisclosureMarketableSecuritiesAdditionalInformationDetail">
        <link:definition>100410 - Disclosure - Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail" id="Role_DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail">
        <link:definition>100420 - Disclosure - Accounts Payable, Accrued Expenses and Other - Schedule of Accounts Payable, Accrued Expenses and Other (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowings2022NotesAdditionalInformationDetail" id="Role_DisclosureBorrowings2022NotesAdditionalInformationDetail">
        <link:definition>100430 - Disclosure - Borrowings - 2022 Notes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowingsConvertibleNotesAdditionalInformationDetail" id="Role_DisclosureBorrowingsConvertibleNotesAdditionalInformationDetail">
        <link:definition>100440 - Disclosure - Borrowings - Convertible Notes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowingsScheduleOfFutureMinimumPaymentsUnderLoansPayableDetail" id="Role_DisclosureBorrowingsScheduleOfFutureMinimumPaymentsUnderLoansPayableDetail">
        <link:definition>100450 - Disclosure - Borrowings - Schedule of Future Minimum Payments under the Loans Payable (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>100460 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail" id="Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail">
        <link:definition>100470 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Calculate Fair Value of Options Granted to Employees (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail" id="Role_DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail">
        <link:definition>100480 - Disclosure - Stock-Based Compensation - Schedule of Recognized Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail">
        <link:definition>100490 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" id="Role_DisclosureSubsequentEventsAdditionalInformationDetail">
        <link:definition>100500 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </appinfo>
  </annotation>
  <element id="mack_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_AccruedIntraperiodTaxAllocation" name="AccruedIntraperiodTaxAllocation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_NonCashActivityRelatedToDiscontinuedOperations" name="NonCashActivityRelatedToDiscontinuedOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" name="AllocatedShareBasedCompensationExpenseIncludingNonEmployees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_IncreaseDecreaseInDeferredRent" name="IncreaseDecreaseInDeferredRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_ReceivablesFromStockOptionExercises" name="ReceivablesFromStockOptionExercises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_SilverCreekPharmaceuticalsIncMember" name="SilverCreekPharmaceuticalsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" name="ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="mack_AssetSaleUpfrontCashPayment" name="AssetSaleUpfrontCashPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_AssetSaleFutureMilestonePayments" name="AssetSaleFutureMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset" name="WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_NetMilestonePaymentsEntitledToReceiveAfterAssetSale" name="NetMilestonePaymentsEntitledToReceiveAfterAssetSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_IpsenSAMember" name="IpsenSAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_BaxaltaMember" name="BaxaltaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_AssetPurchaseAndSaleAgreementMember" name="AssetPurchaseAndSaleAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_RegulatoryAssetsAbstract" name="RegulatoryAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_WarrantPurchaseAgreementsMember" name="WarrantPurchaseAgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents" name="OwnershipPercentageHeldByParentAndItsDeFactoAgents" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="mack_ClinicalTrialsInPancreasAsFirstLineTreatmentMember" name="ClinicalTrialsInPancreasAsFirstLineTreatmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_ClinicalTrialsInSmallCellLungCancerMember" name="ClinicalTrialsInSmallCellLungCancerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_OtherUnrelatedClinicalTrialsMember" name="OtherUnrelatedClinicalTrialsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_SeniorNotesDueTwoThousandTwentyTwoMember" name="SeniorNotesDueTwoThousandTwentyTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember" name="JanuaryTwoThousandSeventeenCorporateRestructuringMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_DevelopmentAndCommercializationMilestonesMember" name="DevelopmentAndCommercializationMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_SaleMilestoneInMajorEuropeanCountriesMember" name="SaleMilestoneInMajorEuropeanCountriesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_SaleMilestoneInMajorNonEuropeanAndNonAsianCountryMember" name="SaleMilestoneInMajorNonEuropeanAndNonAsianCountryMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_ClinicalTrialsInLungCancerMember" name="ClinicalTrialsInLungCancerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_DevelopmentAndRegulatoryMilestonesMember" name="DevelopmentAndRegulatoryMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_SalesMilestonesMember" name="SalesMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_PharmaEngineIncMember" name="PharmaEngineIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_TransitionServicesAgreementPeriod" name="TransitionServicesAgreementPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="mack_PaymentOfMakeWholePremiumOfLongTermDebt" name="PaymentOfMakeWholePremiumOfLongTermDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_AssetSaleSubleaseArea" name="AssetSaleSubleaseArea" type="num:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" name="DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" name="DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" name="DisposalGroupIncludingDiscontinuedOperationOtherRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" name="DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" name="DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" name="DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" name="DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" name="DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_CommercialBusinessMember" name="CommercialBusinessMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent" name="DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_RestructuringAndRelatedCostNumberOfPositionsAfterHeadcountReduction" name="RestructuringAndRelatedCostNumberOfPositionsAfterHeadcountReduction" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="mack_SeverancePaymentsPaymentPeriod" name="SeverancePaymentsPaymentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="mack_MaximumCollaborativeArrangementMilestonePayments" name="MaximumCollaborativeArrangementMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_PotentialMilestonePaymentsReceivable" name="PotentialMilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_CollaborativeArrangementUpfrontPaymentObligation" name="CollaborativeArrangementUpfrontPaymentObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_CollaborativeArrangementMaximumMilestonePaymentObligation" name="CollaborativeArrangementMaximumMilestonePaymentObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_AssetSaleUpfrontCashPaymentReceived" name="AssetSaleUpfrontCashPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_DiscontinuedOperationValuationAllowanceFromDisposalOfDiscontinuedOperation" name="DiscontinuedOperationValuationAllowanceFromDisposalOfDiscontinuedOperation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_UndistributedEarningsLossAllocatedToParticipatingSecurities" name="UndistributedEarningsLossAllocatedToParticipatingSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_ParticipatingSecuritiesOutstandingShares" name="ParticipatingSecuritiesOutstandingShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="mack_WarrantLiabilityMember" name="WarrantLiabilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_FairValueAdjustmentOfWarrantsIncrementalChangeResultingFromAmendment" name="FairValueAdjustmentOfWarrantsIncrementalChangeResultingFromAmendment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_FairValueInstrumentsTransfersBetweenLevels" name="FairValueInstrumentsTransfersBetweenLevels" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_AmortizedCostAndFairValueDebtSecuritiesAbstract" name="AmortizedCostAndFairValueDebtSecuritiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_AccruedClinicalTrialCosts" name="AccruedClinicalTrialCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_AccruedDrugPurchaseCostsCurrent" name="AccruedDrugPurchaseCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_WarrantLiabilityCurrent" name="WarrantLiabilityCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_AccountsPayableAndAccruedLiabilitiesLineItems" name="AccountsPayableAndAccruedLiabilitiesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_AccountsPayableAndAccruedLiabilitiesTable" name="AccountsPayableAndAccruedLiabilitiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_ScheduleOfDebtInstrumentsLineItems" name="ScheduleOfDebtInstrumentsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_ScheduleOfDebtInstrumentsTable" name="ScheduleOfDebtInstrumentsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_TransactionCostsIncurredWithThirdPartiesMember" name="TransactionCostsIncurredWithThirdPartiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_DebtIssuanceCostsUnderwritingDiscountsCommissionsAndOfferingExpenses" name="DebtIssuanceCostsUnderwritingDiscountsCommissionsAndOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_ValueOfAdditionalSharesIssuedForConversion" name="ValueOfAdditionalSharesIssuedForConversion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_TradingPeriodOfCommonStock" name="TradingPeriodOfCommonStock" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="mack_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" name="DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_IncreaseToAdditionalPaidInCapitalDueToConversion" name="IncreaseToAdditionalPaidInCapitalDueToConversion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_ReductionInAdditionalPaidInCapitalAttributableToEmbeddedConversionOption" name="ReductionInAdditionalPaidInCapitalAttributableToEmbeddedConversionOption" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_DebtConversionCostsIncurredAndPaid" name="DebtConversionCostsIncurredAndPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_DecreaseToAdditionalPaidInCapitalDueToConversionTransactionCost" name="DecreaseToAdditionalPaidInCapitalDueToConversionTransactionCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_DebtInstrumentConversionObligationCommonStockClosingSalesPriceTradingPeriod" name="DebtInstrumentConversionObligationCommonStockClosingSalesPriceTradingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="mack_DebtInstrumentConversionObligationNumberOfConsecutiveTradingTerm" name="DebtInstrumentConversionObligationNumberOfConsecutiveTradingTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="mack_ConvertibilityOfDebtStockPriceTestTargetPercentageOfClosingStockPriceToConversionPriceThatMustBeExceeded" name="ConvertibilityOfDebtStockPriceTestTargetPercentageOfClosingStockPriceToConversionPriceThatMustBeExceeded" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="mack_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessPeriodAfterConsecutiveTradingTerm" name="DebtInstrumentConversionObligationNumberOfConsecutiveBusinessPeriodAfterConsecutiveTradingTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="mack_DebtInstrumentConversionObligationPeriodOfConsecutiveTrading" name="DebtInstrumentConversionObligationPeriodOfConsecutiveTrading" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="mack_ConvertibilityOfDebtDebtPriceTestPercentageOfClosingStockPriceUsedInCalculation" name="ConvertibilityOfDebtDebtPriceTestPercentageOfClosingStockPriceUsedInCalculation" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="mack_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" name="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_DebtInstrumentCarryingAmountIncludingContractualInterest" name="DebtInstrumentCarryingAmountIncludingContractualInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="mack_ContractualInterestIncludedInPayments" name="ContractualInterestIncludedInPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="mack_StockIncentivePlan2011Member" name="StockIncentivePlan2011Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="mack_EmployeeMember" name="EmployeeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>20
<FILENAME>mack-20170630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2017-08-09T19:46:29.6525140+00:00 -->
<!-- Version            : 2.4.9.2 -->
<!-- Package ID         : A96D3A1EC002FD8DA16B9E2A7F952981-0001274792-001706 -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mack-20170630.xsd#TemplateLink" roleURI="http://www.merrimackpharma.com/20170630/role/TemplateLink" />
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:href="mack-20170630.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" />
    <loc xlink:href="mack-20170630.xsd#mack_AccruedIntraperiodTaxAllocation" xlink:type="locator" xlink:label="mack_AccruedIntraperiodTaxAllocation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:type="locator" xlink:label="us-gaap_MinorityInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_MinorityInterest" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="mack_AccruedIntraperiodTaxAllocation" order="10150.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10200.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" order="10220.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10230.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ReceivablesNetCurrent" order="10250.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10260.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="10270.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="mack-20170630.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnSalesOfAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ProfitLoss" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InvestmentIncomeInterest" order="10130.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestExpense" order="10140.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_GainsLossesOnSalesOfAssets" order="10150.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10160.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10170.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10180.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2" xlink:href="mack-20170630.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="10020.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:href="mack-20170630.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows">
    <loc xlink:href="mack-20170630.xsd#mack_IncreaseDecreaseInDeferredRent" xlink:type="locator" xlink:label="mack_IncreaseDecreaseInDeferredRent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" />
    <loc xlink:href="mack-20170630.xsd#mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" xlink:type="locator" xlink:label="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <loc xlink:href="mack-20170630.xsd#mack_NonCashActivityRelatedToDiscontinuedOperations" xlink:type="locator" xlink:label="mack_NonCashActivityRelatedToDiscontinuedOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDividends" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDividends" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="10110.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" order="10130.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="10140.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="10150.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" order="10160.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="10170.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_PaidInKindInterest" order="10180.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10190.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" order="10200.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10210.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="mack_NonCashActivityRelatedToDiscontinuedOperations" order="10220.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10230.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" order="10240.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="10250.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10260.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="10270.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10280.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="mack_IncreaseDecreaseInDeferredRent" order="10290.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfDiscontinuedOperationsAndAssetsHeldForSaleDetail" xlink:href="mack-20170630.xsd#Role_DisclosureSaleOfCommercialBusinessScheduleOfDiscontinuedOperationsAndAssetsHeldForSaleDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfDiscontinuedOperationsAndAssetsHeldForSaleDetail">
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" order="10110.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" order="10130.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfCarryingValueOfAssetsAndLiabilitiesClassifiedAsAssetsHeldForSaleRelatesToCommercialBusinessDetail" xlink:href="mack-20170630.xsd#Role_DisclosureSaleOfCommercialBusinessScheduleOfCarryingValueOfAssetsAndLiabilitiesClassifiedAsAssetsHeldForSaleRelatesToCommercialBusinessDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfCarryingValueOfAssetsAndLiabilitiesClassifiedAsAssetsHeldForSaleRelatesToCommercialBusinessDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfInventoryOfCommercialBusinessDetail" xlink:href="mack-20170630.xsd#Role_DisclosureSaleOfCommercialBusinessScheduleOfInventoryOfCommercialBusinessDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfInventoryOfCommercialBusinessDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterials" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcess" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods" order="10030.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail" xlink:href="mack-20170630.xsd#Role_DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" />
    <loc xlink:href="mack-20170630.xsd#mack_WarrantLiabilityCurrent" xlink:type="locator" xlink:label="mack_WarrantLiabilityCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_DividendsPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:type="locator" xlink:label="us-gaap_RestructuringReserveCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:href="mack-20170630.xsd#mack_AccruedDrugPurchaseCostsCurrent" xlink:type="locator" xlink:label="mack_AccruedDrugPurchaseCostsCurrent" />
    <loc xlink:href="mack-20170630.xsd#mack_AccruedClinicalTrialCosts" xlink:type="locator" xlink:label="mack_AccruedClinicalTrialCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="mack_AccruedClinicalTrialCosts" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="mack_AccruedDrugPurchaseCostsCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_RestructuringReserveCurrent" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_DividendsPayableCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="mack_WarrantLiabilityCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowingsScheduleOfFutureMinimumPaymentsUnderLoansPayableDetail" xlink:href="mack-20170630.xsd#Role_DisclosureBorrowingsScheduleOfFutureMinimumPaymentsUnderLoansPayableDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowingsScheduleOfFutureMinimumPaymentsUnderLoansPayableDetail">
    <loc xlink:href="mack-20170630.xsd#mack_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" xlink:type="locator" xlink:label="mack_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <loc xlink:href="mack-20170630.xsd#mack_ContractualInterestIncludedInPayments" xlink:type="locator" xlink:label="mack_ContractualInterestIncludedInPayments" />
    <loc xlink:href="mack-20170630.xsd#mack_DebtInstrumentCarryingAmountIncludingContractualInterest" xlink:type="locator" xlink:label="mack_DebtInstrumentCarryingAmountIncludingContractualInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="mack_DebtInstrumentCarryingAmountIncludingContractualInterest" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="mack_ContractualInterestIncludedInPayments" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mack_DebtInstrumentCarryingAmountIncludingContractualInterest" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mack_DebtInstrumentCarryingAmountIncludingContractualInterest" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mack_DebtInstrumentCarryingAmountIncludingContractualInterest" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mack_DebtInstrumentCarryingAmountIncludingContractualInterest" xlink:to="mack_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" order="10080.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail" xlink:href="mack-20170630.xsd#Role_DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="mack-20170630.xsd#mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" xlink:type="locator" xlink:label="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10010.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>21
<FILENAME>mack-20170630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2017-08-09T19:46:29.6525140+00:00 -->
<!-- Version            : 2.4.9.2 -->
<!-- Package ID         : A96D3A1EC002FD8DA16B9E2A7F952981-0001274792-001706 -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <roleRef xlink:type="simple" xlink:href="mack-20170630.xsd#TemplateLink" roleURI="http://www.merrimackpharma.com/20170630/role/TemplateLink" />
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:href="mack-20170630.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:type="locator" xlink:label="us-gaap_InterestPaid" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" />
    <loc xlink:href="mack-20170630.xsd#mack_ReceivablesFromStockOptionExercises" xlink:type="locator" xlink:label="mack_ReceivablesFromStockOptionExercises" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDividends" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="mack-20170630.xsd#mack_IncreaseDecreaseInDeferredRent" xlink:type="locator" xlink:label="mack_IncreaseDecreaseInDeferredRent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <loc xlink:href="mack-20170630.xsd#mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" xlink:type="locator" xlink:label="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <loc xlink:href="mack-20170630.xsd#mack_NonCashActivityRelatedToDiscontinuedOperations" xlink:type="locator" xlink:label="mack_NonCashActivityRelatedToDiscontinuedOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="mack-20170630.xsd#mack_SilverCreekPharmaceuticalsIncMember" xlink:type="locator" xlink:label="mack_SilverCreekPharmaceuticalsIncMember" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain_2" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10300.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mack_SilverCreekPharmaceuticalsIncMember" order="10380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="10530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="10570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="10730.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10770.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" order="10810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mack_NonCashActivityRelatedToDiscontinuedOperations" order="10890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10930.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" order="10970.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11010.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="11090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="11170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="11210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="mack_IncreaseDecreaseInDeferredRent" order="11250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="11290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" order="11330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="11530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="11570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" order="11610.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" order="11650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="11690.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11730.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11770.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="11890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="11930.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDividends" order="11970.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="12010.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="12090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="12210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="12290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="mack_ReceivablesFromStockOptionExercises" order="12330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" order="12370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="12410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="12530.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:href="mack-20170630.xsd#Role_DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail">
    <loc xlink:href="mack-20170630.xsd#mack_NetMilestonePaymentsEntitledToReceiveAfterAssetSale" xlink:type="locator" xlink:label="mack_NetMilestonePaymentsEntitledToReceiveAfterAssetSale" />
    <loc xlink:href="mack-20170630.xsd#mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset" xlink:type="locator" xlink:label="mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset" />
    <loc xlink:href="mack-20170630.xsd#mack_AssetSaleFutureMilestonePayments" xlink:type="locator" xlink:label="mack_AssetSaleFutureMilestonePayments" />
    <loc xlink:href="mack-20170630.xsd#mack_AssetSaleUpfrontCashPayment" xlink:type="locator" xlink:label="mack_AssetSaleUpfrontCashPayment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <loc xlink:href="mack-20170630.xsd#mack_AssetPurchaseAndSaleAgreementMember" xlink:type="locator" xlink:label="mack_AssetPurchaseAndSaleAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_BaxaltaMember" xlink:type="locator" xlink:label="mack_BaxaltaMember" />
    <loc xlink:href="mack-20170630.xsd#mack_IpsenSAMember" xlink:type="locator" xlink:label="mack_IpsenSAMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mack_IpsenSAMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mack_BaxaltaMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mack_AssetPurchaseAndSaleAgreementMember" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RangeAxis" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mack_AssetSaleUpfrontCashPayment" order="10380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mack_AssetSaleFutureMilestonePayments" order="10400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mack_NetMilestonePaymentsEntitledToReceiveAfterAssetSale" order="10440.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBasisOfPresentationAndConsolidationAdditionalInformationDetail" xlink:href="mack-20170630.xsd#Role_DisclosureBasisOfPresentationAndConsolidationAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBasisOfPresentationAndConsolidationAdditionalInformationDetail">
    <loc xlink:href="mack-20170630.xsd#mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents" xlink:type="locator" xlink:label="mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="mack-20170630.xsd#mack_WarrantPurchaseAgreementsMember" xlink:type="locator" xlink:label="mack_WarrantPurchaseAgreementsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_SilverCreekPharmaceuticalsIncMember" xlink:type="locator" xlink:label="mack_SilverCreekPharmaceuticalsIncMember" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="mack_SummaryOfSignificantAccountingPoliciesTable" />
    <loc xlink:href="mack-20170630.xsd#mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="mack_SummaryOfSignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mack_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mack_SummaryOfSignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mack_SilverCreekPharmaceuticalsIncMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mack_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mack_WarrantPurchaseAgreementsMember" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10580.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="10670.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10690.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents" order="10810.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBasisOfPresentationAndConsolidationScheduleOfNonControllingInterestInSubsidiaryDetail" xlink:href="mack-20170630.xsd#Role_DisclosureBasisOfPresentationAndConsolidationScheduleOfNonControllingInterestInSubsidiaryDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBasisOfPresentationAndConsolidationScheduleOfNonControllingInterestInSubsidiaryDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:type="locator" xlink:label="us-gaap_MinorityInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestTable" xlink:type="locator" xlink:label="us-gaap_MinorityInterestTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:type="locator" xlink:label="us-gaap_MinorityInterestLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_MinorityInterestTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MinorityInterestTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_MinorityInterest" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" order="10200.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessAdditionalInformationDetail" xlink:href="mack-20170630.xsd#Role_DisclosureSaleOfCommercialBusinessAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessAdditionalInformationDetail">
    <loc xlink:href="mack-20170630.xsd#mack_CollaborativeArrangementMaximumMilestonePaymentObligation" xlink:type="locator" xlink:label="mack_CollaborativeArrangementMaximumMilestonePaymentObligation" />
    <loc xlink:href="mack-20170630.xsd#mack_CollaborativeArrangementUpfrontPaymentObligation" xlink:type="locator" xlink:label="mack_CollaborativeArrangementUpfrontPaymentObligation" />
    <loc xlink:href="mack-20170630.xsd#mack_PotentialMilestonePaymentsReceivable" xlink:type="locator" xlink:label="mack_PotentialMilestonePaymentsReceivable" />
    <loc xlink:href="mack-20170630.xsd#mack_MaximumCollaborativeArrangementMilestonePayments" xlink:type="locator" xlink:label="mack_MaximumCollaborativeArrangementMilestonePayments" />
    <loc xlink:href="mack-20170630.xsd#mack_SeverancePaymentsPaymentPeriod" xlink:type="locator" xlink:label="mack_SeverancePaymentsPaymentPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDescription" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDescription" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <loc xlink:href="mack-20170630.xsd#mack_RestructuringAndRelatedCostNumberOfPositionsAfterHeadcountReduction" xlink:type="locator" xlink:label="mack_RestructuringAndRelatedCostNumberOfPositionsAfterHeadcountReduction" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesInitiationDate" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesInitiationDate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:type="locator" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:type="locator" xlink:label="us-gaap_DividendPayableDateToBePaidDayMonthAndYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsCommonStockCash" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStockCash" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xlink:type="locator" xlink:label="us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <loc xlink:href="mack-20170630.xsd#mack_AssetSaleSubleaseArea" xlink:type="locator" xlink:label="mack_AssetSaleSubleaseArea" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <loc xlink:href="mack-20170630.xsd#mack_PaymentOfMakeWholePremiumOfLongTermDebt" xlink:type="locator" xlink:label="mack_PaymentOfMakeWholePremiumOfLongTermDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <loc xlink:href="mack-20170630.xsd#mack_TransitionServicesAgreementPeriod" xlink:type="locator" xlink:label="mack_TransitionServicesAgreementPeriod" />
    <loc xlink:href="mack-20170630.xsd#mack_AssetSaleFutureMilestonePayments" xlink:type="locator" xlink:label="mack_AssetSaleFutureMilestonePayments" />
    <loc xlink:href="mack-20170630.xsd#mack_PharmaEngineIncMember" xlink:type="locator" xlink:label="mack_PharmaEngineIncMember" />
    <loc xlink:href="mack-20170630.xsd#mack_SalesMilestonesMember" xlink:type="locator" xlink:label="mack_SalesMilestonesMember" />
    <loc xlink:href="mack-20170630.xsd#mack_DevelopmentAndRegulatoryMilestonesMember" xlink:type="locator" xlink:label="mack_DevelopmentAndRegulatoryMilestonesMember" />
    <loc xlink:href="mack-20170630.xsd#mack_ClinicalTrialsInLungCancerMember" xlink:type="locator" xlink:label="mack_ClinicalTrialsInLungCancerMember" />
    <loc xlink:href="mack-20170630.xsd#mack_SaleMilestoneInMajorNonEuropeanAndNonAsianCountryMember" xlink:type="locator" xlink:label="mack_SaleMilestoneInMajorNonEuropeanAndNonAsianCountryMember" />
    <loc xlink:href="mack-20170630.xsd#mack_SaleMilestoneInMajorEuropeanCountriesMember" xlink:type="locator" xlink:label="mack_SaleMilestoneInMajorEuropeanCountriesMember" />
    <loc xlink:href="mack-20170630.xsd#mack_DevelopmentAndCommercializationMilestonesMember" xlink:type="locator" xlink:label="mack_DevelopmentAndCommercializationMilestonesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember" xlink:type="locator" xlink:label="us-gaap_OneTimeTerminationBenefitsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractTerminationMember" xlink:type="locator" xlink:label="us-gaap_ContractTerminationMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember" xlink:type="locator" xlink:label="mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:type="locator" xlink:label="us-gaap_RestructuringPlanDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:type="locator" xlink:label="us-gaap_RestructuringPlanDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:type="locator" xlink:label="us-gaap_RestructuringPlanAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_SeniorNotesDueTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="mack_SeniorNotesDueTwoThousandTwentyTwoMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_OtherUnrelatedClinicalTrialsMember" xlink:type="locator" xlink:label="mack_OtherUnrelatedClinicalTrialsMember" />
    <loc xlink:href="mack-20170630.xsd#mack_ClinicalTrialsInSmallCellLungCancerMember" xlink:type="locator" xlink:label="mack_ClinicalTrialsInSmallCellLungCancerMember" />
    <loc xlink:href="mack-20170630.xsd#mack_ClinicalTrialsInPancreasAsFirstLineTreatmentMember" xlink:type="locator" xlink:label="mack_ClinicalTrialsInPancreasAsFirstLineTreatmentMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_AssetPurchaseAndSaleAgreementMember" xlink:type="locator" xlink:label="mack_AssetPurchaseAndSaleAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_IpsenSAMember" xlink:type="locator" xlink:label="mack_IpsenSAMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mack_IpsenSAMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mack_AssetPurchaseAndSaleAgreementMember" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_RangeAxis" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_2" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="mack_ClinicalTrialsInPancreasAsFirstLineTreatmentMember" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="mack_ClinicalTrialsInSmallCellLungCancerMember" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="mack_OtherUnrelatedClinicalTrialsMember" order="10430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10500.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_2" order="10510.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mack_SeniorNotesDueTwoThousandTwentyTwoMember" order="10550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10900.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10910.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10930.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ManufacturingFacilityMember" order="10950.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_RestructuringPlanAxis" order="11040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain_2" order="11050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" order="11070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember" order="11090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="11260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_2" order="11270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="11290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" order="11310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_OneTimeTerminationBenefitsMember" order="11330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" order="11360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain_2" order="11370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" order="11390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" order="11410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="mack_DevelopmentAndCommercializationMilestonesMember" order="11710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="mack_SaleMilestoneInMajorEuropeanCountriesMember" order="11730.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="mack_SaleMilestoneInMajorNonEuropeanAndNonAsianCountryMember" order="11750.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="mack_ClinicalTrialsInLungCancerMember" order="11770.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="mack_DevelopmentAndRegulatoryMilestonesMember" order="11830.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="mack_SalesMilestonesMember" order="11850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mack_PharmaEngineIncMember" order="11910.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_AssetSaleFutureMilestonePayments" order="11960.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_TransitionServicesAgreementPeriod" order="12070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="12120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_PaymentOfMakeWholePremiumOfLongTermDebt" order="12140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="12160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest" order="12180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_AssetSaleSubleaseArea" order="12230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="12250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" order="12300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DividendsCommonStockCash" order="12320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DividendPayableDateToBePaidDayMonthAndYear" order="12340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" order="12360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" order="12410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RestructuringAndRelatedActivitiesInitiationDate" order="12460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="12480.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_RestructuringAndRelatedCostNumberOfPositionsAfterHeadcountReduction" order="12500.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RestructuringCharges" order="12550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDescription" order="12590.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_SeverancePaymentsPaymentPeriod" order="12630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_MaximumCollaborativeArrangementMilestonePayments" order="12740.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_PotentialMilestonePaymentsReceivable" order="12760.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_CollaborativeArrangementUpfrontPaymentObligation" order="12850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_CollaborativeArrangementMaximumMilestonePaymentObligation" order="12910.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfDiscontinuedOperationsAndAssetsHeldForSaleDetail" xlink:href="mack-20170630.xsd#Role_DisclosureSaleOfCommercialBusinessScheduleOfDiscontinuedOperationsAndAssetsHeldForSaleDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfDiscontinuedOperationsAndAssetsHeldForSaleDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" />
    <loc xlink:href="mack-20170630.xsd#mack_CommercialBusinessMember" xlink:type="locator" xlink:label="mack_CommercialBusinessMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" order="10140.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="mack_CommercialBusinessMember" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" order="10490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" order="10570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" order="10650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" order="10730.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" order="10890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" order="10970.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" order="11050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" order="11130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" order="11210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" order="11290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" order="11450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" xlink:to="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" order="11530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" order="11610.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" order="11690.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="11770.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfCarryingValueOfAssetsAndLiabilitiesClassifiedAsAssetsHeldForSaleRelatesToCommercialBusinessDetail" xlink:href="mack-20170630.xsd#Role_DisclosureSaleOfCommercialBusinessScheduleOfCarryingValueOfAssetsAndLiabilitiesClassifiedAsAssetsHeldForSaleRelatesToCommercialBusinessDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfCarryingValueOfAssetsAndLiabilitiesClassifiedAsAssetsHeldForSaleRelatesToCommercialBusinessDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" />
    <loc xlink:href="mack-20170630.xsd#mack_CommercialBusinessMember" xlink:type="locator" xlink:label="mack_CommercialBusinessMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" order="10100.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="mack_CommercialBusinessMember" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="10490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent" order="10510.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" order="10530.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfInventoryOfCommercialBusinessDetail" xlink:href="mack-20170630.xsd#Role_DisclosureSaleOfCommercialBusinessScheduleOfInventoryOfCommercialBusinessDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfInventoryOfCommercialBusinessDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" />
    <loc xlink:href="mack-20170630.xsd#mack_CommercialBusinessMember" xlink:type="locator" xlink:label="mack_CommercialBusinessMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:type="locator" xlink:label="us-gaap_InventoryCurrentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryLineItems" xlink:type="locator" xlink:label="us-gaap_InventoryLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryCurrentTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="mack_CommercialBusinessMember" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryRawMaterials" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryWorkInProcess" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryFinishedGoods" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryNet" order="10210.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessSummaryOfChargesRelatedToRestructuringActivitiesDetail" xlink:href="mack-20170630.xsd#Role_DisclosureSaleOfCommercialBusinessSummaryOfChargesRelatedToRestructuringActivitiesDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessSummaryOfChargesRelatedToRestructuringActivitiesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:type="locator" xlink:label="us-gaap_PaymentsForRestructuring" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:type="locator" xlink:label="us-gaap_RestructuringReserveCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:type="locator" xlink:label="us-gaap_EmployeeSeveranceMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_CommercialBusinessMember" xlink:type="locator" xlink:label="mack_CommercialBusinessMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="mack_CommercialBusinessMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserveCurrent" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" order="10300.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureGoingConcernAdditionalInformationDetail" xlink:href="mack-20170630.xsd#Role_DisclosureGoingConcernAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureGoingConcernAdditionalInformationDetail">
    <loc xlink:href="mack-20170630.xsd#mack_PaymentOfMakeWholePremiumOfLongTermDebt" xlink:type="locator" xlink:label="mack_PaymentOfMakeWholePremiumOfLongTermDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EscrowDeposit" xlink:type="locator" xlink:label="us-gaap_EscrowDeposit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:type="locator" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:type="locator" xlink:label="us-gaap_DividendPayableDateToBePaidDayMonthAndYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsCommonStockCash" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStockCash" />
    <loc xlink:href="mack-20170630.xsd#mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset" xlink:type="locator" xlink:label="mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset" />
    <loc xlink:href="mack-20170630.xsd#mack_AssetSaleUpfrontCashPaymentReceived" xlink:type="locator" xlink:label="mack_AssetSaleUpfrontCashPaymentReceived" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="mack-20170630.xsd#mack_SeniorNotesDueTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="mack_SeniorNotesDueTwoThousandTwentyTwoMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_AssetPurchaseAndSaleAgreementMember" xlink:type="locator" xlink:label="mack_AssetPurchaseAndSaleAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_IpsenSAMember" xlink:type="locator" xlink:label="mack_IpsenSAMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mack_IpsenSAMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mack_AssetPurchaseAndSaleAgreementMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mack_SeniorNotesDueTwoThousandTwentyTwoMember" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mack_AssetSaleUpfrontCashPaymentReceived" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DividendsCommonStockCash" order="10490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DividendPayableDateToBePaidDayMonthAndYear" order="10510.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" order="10530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="10550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="10570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EscrowDeposit" order="10590.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mack_PaymentOfMakeWholePremiumOfLongTermDebt" order="10610.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShareAdditionalInformationDetail" xlink:href="mack-20170630.xsd#Role_DisclosureNetIncomeLossPerCommonShareAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShareAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <loc xlink:href="mack-20170630.xsd#mack_ParticipatingSecuritiesOutstandingShares" xlink:type="locator" xlink:label="mack_ParticipatingSecuritiesOutstandingShares" />
    <loc xlink:href="mack-20170630.xsd#mack_UndistributedEarningsLossAllocatedToParticipatingSecurities" xlink:type="locator" xlink:label="mack_UndistributedEarningsLossAllocatedToParticipatingSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="mack_UndistributedEarningsLossAllocatedToParticipatingSecurities" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="mack_ParticipatingSecuritiesOutstandingShares" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_LongTermDebt" order="10330.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedLossPerShareDetail" xlink:href="mack-20170630.xsd#Role_DisclosureNetIncomeLossPerCommonShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedLossPerShareDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedLossPerShareDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10140.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="mack-20170630.xsd#Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:href="mack-20170630.xsd#mack_WarrantLiabilityMember" xlink:type="locator" xlink:label="mack_WarrantLiabilityMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_SilverCreekPharmaceuticalsIncMember" xlink:type="locator" xlink:label="mack_SilverCreekPharmaceuticalsIncMember" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="dei_LegalEntityAxis" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mack_SilverCreekPharmaceuticalsIncMember" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="mack_WarrantLiabilityMember" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10740.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="10860.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail" xlink:href="mack-20170630.xsd#Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:type="locator" xlink:label="us-gaap_LongTermDebtFairValue" />
    <loc xlink:href="mack-20170630.xsd#mack_FairValueInstrumentsTransfersBetweenLevels" xlink:type="locator" xlink:label="mack_FairValueInstrumentsTransfersBetweenLevels" />
    <loc xlink:href="mack-20170630.xsd#mack_FairValueAdjustmentOfWarrantsIncrementalChangeResultingFromAmendment" xlink:type="locator" xlink:label="mack_FairValueAdjustmentOfWarrantsIncrementalChangeResultingFromAmendment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <loc xlink:href="mack-20170630.xsd#mack_SeniorNotesDueTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="mack_SeniorNotesDueTwoThousandTwentyTwoMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeniorNotesMember" xlink:type="locator" xlink:label="us-gaap_SeniorNotesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_SilverCreekPharmaceuticalsIncMember" xlink:type="locator" xlink:label="mack_SilverCreekPharmaceuticalsIncMember" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mack_SilverCreekPharmaceuticalsIncMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_RangeAxis" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10440.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SeniorNotesMember" order="10490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10520.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mack_SeniorNotesDueTwoThousandTwentyTwoMember" order="10630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10680.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="10760.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" order="10840.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate" order="10920.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" order="11000.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" order="11080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="11320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="mack_FairValueAdjustmentOfWarrantsIncrementalChangeResultingFromAmendment" order="11400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="mack_FairValueInstrumentsTransfersBetweenLevels" order="11510.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_LongTermDebtFairValue" order="11580.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_LongTermDebt" order="11600.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="11650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="11670.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail" xlink:href="mack-20170630.xsd#Role_DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" />
    <loc xlink:href="mack-20170630.xsd#mack_WarrantLiabilityCurrent" xlink:type="locator" xlink:label="mack_WarrantLiabilityCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_DividendsPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:type="locator" xlink:label="us-gaap_RestructuringReserveCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:href="mack-20170630.xsd#mack_AccruedDrugPurchaseCostsCurrent" xlink:type="locator" xlink:label="mack_AccruedDrugPurchaseCostsCurrent" />
    <loc xlink:href="mack-20170630.xsd#mack_AccruedClinicalTrialCosts" xlink:type="locator" xlink:label="mack_AccruedClinicalTrialCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <loc xlink:href="mack-20170630.xsd#mack_SilverCreekPharmaceuticalsIncMember" xlink:type="locator" xlink:label="mack_SilverCreekPharmaceuticalsIncMember" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_AccountsPayableAndAccruedLiabilitiesTable" xlink:type="locator" xlink:label="mack_AccountsPayableAndAccruedLiabilitiesTable" />
    <loc xlink:href="mack-20170630.xsd#mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:type="locator" xlink:label="mack_AccountsPayableAndAccruedLiabilitiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="mack_AccountsPayableAndAccruedLiabilitiesTable" order="10110.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesTable" xlink:to="dei_LegalEntityAxis" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mack_SilverCreekPharmaceuticalsIncMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_AccountsPayableCurrent" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="mack_AccruedClinicalTrialCosts" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="mack_AccruedDrugPurchaseCostsCurrent" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_RestructuringReserveCurrent" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_InterestPayableCurrent" order="10460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_DividendsPayableCurrent" order="10500.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="mack_WarrantLiabilityCurrent" order="10540.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" order="10580.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10620.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowings2022NotesAdditionalInformationDetail" xlink:href="mack-20170630.xsd#Role_DisclosureBorrowings2022NotesAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowings2022NotesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseMember" xlink:type="locator" xlink:label="us-gaap_InterestExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_SeniorNotesDueTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="mack_SeniorNotesDueTwoThousandTwentyTwoMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_ScheduleOfDebtInstrumentsTable" xlink:type="locator" xlink:label="mack_ScheduleOfDebtInstrumentsTable" />
    <loc xlink:href="mack-20170630.xsd#mack_ScheduleOfDebtInstrumentsLineItems" xlink:type="locator" xlink:label="mack_ScheduleOfDebtInstrumentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mack_ScheduleOfDebtInstrumentsLineItems" xlink:to="mack_ScheduleOfDebtInstrumentsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mack_ScheduleOfDebtInstrumentsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mack_SeniorNotesDueTwoThousandTwentyTwoMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mack_ScheduleOfDebtInstrumentsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_InterestExpenseMember" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_ScheduleOfDebtInstrumentsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_ScheduleOfDebtInstrumentsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="10400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_ScheduleOfDebtInstrumentsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_ScheduleOfDebtInstrumentsLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_ScheduleOfDebtInstrumentsLineItems" xlink:to="us-gaap_InterestExpense" order="10550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_ScheduleOfDebtInstrumentsLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="10710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mack_ScheduleOfDebtInstrumentsLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="10790.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowingsConvertibleNotesAdditionalInformationDetail" xlink:href="mack-20170630.xsd#Role_DisclosureBorrowingsConvertibleNotesAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowingsConvertibleNotesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EscrowDeposit" xlink:type="locator" xlink:label="us-gaap_EscrowDeposit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <loc xlink:href="mack-20170630.xsd#mack_ConvertibilityOfDebtDebtPriceTestPercentageOfClosingStockPriceUsedInCalculation" xlink:type="locator" xlink:label="mack_ConvertibilityOfDebtDebtPriceTestPercentageOfClosingStockPriceUsedInCalculation" />
    <loc xlink:href="mack-20170630.xsd#mack_DebtInstrumentConversionObligationPeriodOfConsecutiveTrading" xlink:type="locator" xlink:label="mack_DebtInstrumentConversionObligationPeriodOfConsecutiveTrading" />
    <loc xlink:href="mack-20170630.xsd#mack_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessPeriodAfterConsecutiveTradingTerm" xlink:type="locator" xlink:label="mack_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessPeriodAfterConsecutiveTradingTerm" />
    <loc xlink:href="mack-20170630.xsd#mack_ConvertibilityOfDebtStockPriceTestTargetPercentageOfClosingStockPriceToConversionPriceThatMustBeExceeded" xlink:type="locator" xlink:label="mack_ConvertibilityOfDebtStockPriceTestTargetPercentageOfClosingStockPriceToConversionPriceThatMustBeExceeded" />
    <loc xlink:href="mack-20170630.xsd#mack_DebtInstrumentConversionObligationNumberOfConsecutiveTradingTerm" xlink:type="locator" xlink:label="mack_DebtInstrumentConversionObligationNumberOfConsecutiveTradingTerm" />
    <loc xlink:href="mack-20170630.xsd#mack_DebtInstrumentConversionObligationCommonStockClosingSalesPriceTradingPeriod" xlink:type="locator" xlink:label="mack_DebtInstrumentConversionObligationCommonStockClosingSalesPriceTradingPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <loc xlink:href="mack-20170630.xsd#mack_DecreaseToAdditionalPaidInCapitalDueToConversionTransactionCost" xlink:type="locator" xlink:label="mack_DecreaseToAdditionalPaidInCapitalDueToConversionTransactionCost" />
    <loc xlink:href="mack-20170630.xsd#mack_DebtConversionCostsIncurredAndPaid" xlink:type="locator" xlink:label="mack_DebtConversionCostsIncurredAndPaid" />
    <loc xlink:href="mack-20170630.xsd#mack_ReductionInAdditionalPaidInCapitalAttributableToEmbeddedConversionOption" xlink:type="locator" xlink:label="mack_ReductionInAdditionalPaidInCapitalAttributableToEmbeddedConversionOption" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <loc xlink:href="mack-20170630.xsd#mack_IncreaseToAdditionalPaidInCapitalDueToConversion" xlink:type="locator" xlink:label="mack_IncreaseToAdditionalPaidInCapitalDueToConversion" />
    <loc xlink:href="mack-20170630.xsd#mack_TradingPeriodOfCommonStock" xlink:type="locator" xlink:label="mack_TradingPeriodOfCommonStock" />
    <loc xlink:href="mack-20170630.xsd#mack_ValueOfAdditionalSharesIssuedForConversion" xlink:type="locator" xlink:label="mack_ValueOfAdditionalSharesIssuedForConversion" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" />
    <loc xlink:href="mack-20170630.xsd#mack_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" xlink:type="locator" xlink:label="mack_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <loc xlink:href="mack-20170630.xsd#mack_DebtIssuanceCostsUnderwritingDiscountsCommissionsAndOfferingExpenses" xlink:type="locator" xlink:label="mack_DebtIssuanceCostsUnderwritingDiscountsCommissionsAndOfferingExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_TransactionCostsIncurredWithThirdPartiesMember" xlink:type="locator" xlink:label="mack_TransactionCostsIncurredWithThirdPartiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseMember" xlink:type="locator" xlink:label="us-gaap_InterestExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_InterestExpenseMember" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_2" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mack_TransactionCostsIncurredWithThirdPartiesMember" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_RangeAxis" order="10760.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10790.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10990.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="11240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="11260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="11310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" order="11360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_DebtIssuanceCostsUnderwritingDiscountsCommissionsAndOfferingExpenses" order="11380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="11430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" order="11490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" order="11550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11610.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_ValueOfAdditionalSharesIssuedForConversion" order="11670.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_TradingPeriodOfCommonStock" order="11730.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_IncreaseToAdditionalPaidInCapitalDueToConversion" order="11790.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="11850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_ReductionInAdditionalPaidInCapitalAttributableToEmbeddedConversionOption" order="11910.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_DebtConversionCostsIncurredAndPaid" order="11970.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_DecreaseToAdditionalPaidInCapitalDueToConversionTransactionCost" order="12030.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="12120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_DebtInstrumentConversionObligationCommonStockClosingSalesPriceTradingPeriod" order="12170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_DebtInstrumentConversionObligationNumberOfConsecutiveTradingTerm" order="12190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_ConvertibilityOfDebtStockPriceTestTargetPercentageOfClosingStockPriceToConversionPriceThatMustBeExceeded" order="12210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessPeriodAfterConsecutiveTradingTerm" order="12260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_DebtInstrumentConversionObligationPeriodOfConsecutiveTrading" order="12280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_ConvertibilityOfDebtDebtPriceTestPercentageOfClosingStockPriceUsedInCalculation" order="12320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="12450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_EscrowDeposit" order="12520.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpense" order="12570.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowingsScheduleOfFutureMinimumPaymentsUnderLoansPayableDetail" xlink:href="mack-20170630.xsd#Role_DisclosureBorrowingsScheduleOfFutureMinimumPaymentsUnderLoansPayableDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowingsScheduleOfFutureMinimumPaymentsUnderLoansPayableDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <loc xlink:href="mack-20170630.xsd#mack_ContractualInterestIncludedInPayments" xlink:type="locator" xlink:label="mack_ContractualInterestIncludedInPayments" />
    <loc xlink:href="mack-20170630.xsd#mack_DebtInstrumentCarryingAmountIncludingContractualInterest" xlink:type="locator" xlink:label="mack_DebtInstrumentCarryingAmountIncludingContractualInterest" />
    <loc xlink:href="mack-20170630.xsd#mack_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" xlink:type="locator" xlink:label="mack_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10090.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_DebtInstrumentCarryingAmountIncludingContractualInterest" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_ContractualInterestIncludedInPayments" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="10320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" order="10360.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="mack-20170630.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:type="locator" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:type="locator" xlink:label="us-gaap_DividendPayableDateToBePaidDayMonthAndYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsCommonStockCash" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStockCash" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <loc xlink:href="mack-20170630.xsd#mack_EmployeeMember" xlink:type="locator" xlink:label="mack_EmployeeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_StockIncentivePlan2011Member" xlink:type="locator" xlink:label="mack_StockIncentivePlan2011Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mack_StockIncentivePlan2011Member" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mack_EmployeeMember" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10500.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10560.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DividendsCommonStockCash" order="10650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DividendPayableDateToBePaidDayMonthAndYear" order="10670.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" order="10690.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" order="10710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10760.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10870.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10980.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11000.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail" xlink:href="mack-20170630.xsd#Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10640.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10860.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="11220.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail" xlink:href="mack-20170630.xsd#Role_DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail">
    <loc xlink:href="mack-20170630.xsd#mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" xlink:type="locator" xlink:label="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" order="10320.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="mack-20170630.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
    <loc xlink:href="mack-20170630.xsd#mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents" xlink:type="locator" xlink:label="mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_SilverCreekPharmaceuticalsIncMember" xlink:type="locator" xlink:label="mack_SilverCreekPharmaceuticalsIncMember" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mack_SilverCreekPharmaceuticalsIncMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents" order="10440.00" priority="2" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>22
<FILENAME>mack-20170630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2017-08-09T19:46:29.6525140+00:00 -->
<!-- Version            : 2.4.9.2 -->
<!-- Package ID         : A96D3A1EC002FD8DA16B9E2A7F952981-0001274792-001706 -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="mack_DocumentAndEntityInformationAbstract" />
    <label xml:lang="en-US" xlink:label="mack_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Document And Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="mack_DocumentAndEntityInformationAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="mack_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Abstract]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</label>
    <label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</label>
    <loc xlink:href="mack-20170630.xsd#mack_AccruedIntraperiodTaxAllocation" xlink:type="locator" xlink:label="mack_AccruedIntraperiodTaxAllocation" />
    <label xml:lang="en-US" xlink:label="mack_AccruedIntraperiodTaxAllocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued intraperiod tax allocation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_AccruedIntraperiodTaxAllocation" xlink:to="mack_AccruedIntraperiodTaxAllocation_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Receivables Net Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets held for sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Of Disposal Group Including Discontinued Operation Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets held for sale, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Assets Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, non-controlling interest and stockholders&#8217; equity/(deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable, accrued expenses and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Current</label>
    <label xml:lang="en-US" xlink:label="mack_AccruedIntraperiodTaxAllocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued intraperiod tax allocation</label>
    <label xml:lang="en-US" xlink:label="mack_AccruedIntraperiodTaxAllocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Intraperiod Tax Allocation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Taxes Payable Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities held for sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Of Disposal Group Including Discontinued Operation Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities held for sale, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Of Disposal Group Including Discontinued Operation Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:type="locator" xlink:label="us-gaap_MinorityInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinorityInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-controlling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinorityInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minority Interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity/(deficit):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.01 par value: 10,000 shares authorized at June 30, 2017 and December 31, 2016; no shares issued or outstanding at June 30, 2017 or December 31, 2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.01 par value: 200,000 shares authorized at June 30, 2017 and December 31, 2016; 132,741 and 130,197 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated (deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity/(deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, non-controlling interest and stockholders&#8217; equity/(deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Costs And Expenses [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" />
    <label xml:lang="en-US" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total costs and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Costs And Expenses</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from continuing operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnSalesOfAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnSalesOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on sale of asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnSalesOfAssets" xlink:to="us-gaap_GainsLossesOnSalesOfAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnSalesOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gains Losses On Sales Of Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss from continuing operations before income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss from continuing operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discontinued operations:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Discontinued Operations Net Of Tax [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income (loss) from discontinued operations, net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Discontinued Operations Net Of Tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to non-controlling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Attributable To Noncontrolling Interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income (loss) attributable to Merrimack Pharmaceuticals, Inc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain on available-for-sale securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts attributable to Merrimack Pharmaceuticals, Inc.:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:to="us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Amounts Attributable To Reporting Entity Disclosures [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss from continuing operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income (loss) from discontinued operations, net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and dilutive net income (loss) per common share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss from continuing operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Per Basic And Diluted Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss) from discontinued operations, net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares used per share calculations&#8212;basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash dividend paid per common share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="us-gaap_CommonStockDividendsPerShareCashPaid_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Dividends Per Share Cash Paid</label>
    <loc xlink:href="mack-20170630.xsd#mack_NonCashActivityRelatedToDiscontinuedOperations" xlink:type="locator" xlink:label="mack_NonCashActivityRelatedToDiscontinuedOperations" />
    <label xml:lang="en-US" xlink:label="mack_NonCashActivityRelatedToDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash activity related to discontinued operations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_NonCashActivityRelatedToDiscontinuedOperations" xlink:to="mack_NonCashActivityRelatedToDiscontinuedOperations_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" xlink:type="locator" xlink:label="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" />
    <label xml:lang="en-US" xlink:label="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and nonemployees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" xlink:to="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_IncreaseDecreaseInDeferredRent" xlink:type="locator" xlink:label="mack_IncreaseDecreaseInDeferredRent" />
    <label xml:lang="en-US" xlink:label="mack_IncreaseDecreaseInDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in deferred rent.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_IncreaseDecreaseInDeferredRent" xlink:to="mack_IncreaseDecreaseInDeferredRent_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_ReceivablesFromStockOptionExercises" xlink:type="locator" xlink:label="mack_ReceivablesFromStockOptionExercises" />
    <label xml:lang="en-US" xlink:label="mack_ReceivablesFromStockOptionExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents receivable amounts related to amounts owed for stock options exercises that have not been settled as of period end.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_ReceivablesFromStockOptionExercises" xlink:to="mack_ReceivablesFromStockOptionExercises_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</label>
    <loc xlink:href="mack-20170630.xsd#mack_SilverCreekPharmaceuticalsIncMember" xlink:type="locator" xlink:label="mack_SilverCreekPharmaceuticalsIncMember" />
    <label xml:lang="en-US" xlink:label="mack_SilverCreekPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Subsidiary of the Company.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_SilverCreekPharmaceuticalsIncMember" xlink:to="mack_SilverCreekPharmaceuticalsIncMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_SilverCreekPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Silver Creek Inc. [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_SilverCreekPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Silver Creek Pharmaceuticals Inc [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income (loss) from discontinued operations</label>
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss from continuing operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Paid In Kind Interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on extinguishment of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gains Losses On Extinguishment Of Debt</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Benefit from intraperiod tax allocation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:to="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit Intraperiod Tax Allocation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</label>
    <label xml:lang="en-US" xlink:label="mack_NonCashActivityRelatedToDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash activity related to discontinued operations</label>
    <label xml:lang="en-US" xlink:label="mack_NonCashActivityRelatedToDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Activity Related To Discontinued Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">(Gain) loss on sale of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Sale Of Property Plant Equipment</label>
    <label xml:lang="en-US" xlink:label="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</label>
    <label xml:lang="en-US" xlink:label="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense Including Non Employees</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Receivables</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Income Taxes Payable</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable, accrued expenses and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable And Accrued Liabilities</label>
    <label xml:lang="en-US" xlink:label="mack_IncreaseDecreaseInDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</label>
    <label xml:lang="en-US" xlink:label="mack_IncreaseDecreaseInDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Rent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in continuing operations for operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash used in discontinuing operations for operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided By Used In Operating Activities Discontinued Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities and sales of available for sale securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Available For Sale Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds on sale of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Property Plant And Equipment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of available for sale securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Available For Sale Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:to="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sales Of Business Affiliate And Productive Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Changes in restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Restricted Cash</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of options to purchase common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of Series C preferred stock by Silver Creek Inc., net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Preferred Stock And Preference Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Long Term Debt</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDividends" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfDividends_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividends" xlink:to="us-gaap_PaymentsOfDividends_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfDividends_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Dividends</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of Silver Creek convertible promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Convertible Debt</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Period Increase Decrease</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents, beginning of period</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, end of period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash investing and financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment in accounts payable, accrued expenses and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</label>
    <label xml:lang="en-US" xlink:label="mack_ReceivablesFromStockOptionExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables related to stock option exercises in prepaid expenses and other current assets</label>
    <label xml:lang="en-US" xlink:label="mack_ReceivablesFromStockOptionExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Receivables From Stock Option Exercises</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" />
    <label xml:lang="en-US" xlink:label="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables related to property and equipment sale in other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:to="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Or Part Noncash Divestiture Amount Of Consideration Received1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible debt into shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion Converted Instrument Amount1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:type="locator" xlink:label="us-gaap_InterestPaid" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of the Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Discontinued Operations And Disposal Groups [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Commercial Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Groups Including Discontinued Operations Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Going Concern</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Substantial Doubt About Going Concern [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Income (Loss) Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Debt And Equity Securities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Payable, Accrued Expenses and Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Changes And Error Corrections [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements And Changes In Accounting Principles [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Non-Controlling Interest in Subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:to="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Effects Of Changes Net [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Discontinued Operations and Assets Held for Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Carrying Value of Assets and Liabilities Classified as Discontinued Operations Relates to Commercial Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:to="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Long Lived Assets Held For Sale [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Inventory of Commercial Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Inventory Current Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Charges Related to Restructuring Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Restructuring And Related Costs [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Outstanding Securities Excluded from Computation of Diluted Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounts Payable, Accrued Expenses and Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Payments under the Loans Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation Fiscal Year Maturity Schedule Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions Used to Calculate Fair Value of Options Granted to Employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</label>
    <loc xlink:href="mack-20170630.xsd#mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:type="locator" xlink:label="mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" />
    <label xml:lang="en-US" xlink:label="mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of employee and nonemployee service share based compensation allocation of recognized period costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:to="mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</label>
    <label xml:lang="en-US" xlink:label="mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Recognized Stock-Based Compensation Expense</label>
    <label xml:lang="en-US" xlink:label="mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee And Nonemployee Service Share Based Compensation Allocation Of Recognized Period Costs Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</label>
    <loc xlink:href="mack-20170630.xsd#mack_AssetSaleUpfrontCashPayment" xlink:type="locator" xlink:label="mack_AssetSaleUpfrontCashPayment" />
    <label xml:lang="en-US" xlink:label="mack_AssetSaleUpfrontCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset sale upfront&#8203; cash&#8203; payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_AssetSaleUpfrontCashPayment" xlink:to="mack_AssetSaleUpfrontCashPayment_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_AssetSaleFutureMilestonePayments" xlink:type="locator" xlink:label="mack_AssetSaleFutureMilestonePayments" />
    <label xml:lang="en-US" xlink:label="mack_AssetSaleFutureMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset sale future milestone payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_AssetSaleFutureMilestonePayments" xlink:to="mack_AssetSaleFutureMilestonePayments_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset" xlink:type="locator" xlink:label="mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset" />
    <label xml:lang="en-US" xlink:label="mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Working capital adjustment receivable related to sale of asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset" xlink:to="mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_NetMilestonePaymentsEntitledToReceiveAfterAssetSale" xlink:type="locator" xlink:label="mack_NetMilestonePaymentsEntitledToReceiveAfterAssetSale" />
    <label xml:lang="en-US" xlink:label="mack_NetMilestonePaymentsEntitledToReceiveAfterAssetSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net milestone payments entitled to receive after asset sale.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_NetMilestonePaymentsEntitledToReceiveAfterAssetSale" xlink:to="mack_NetMilestonePaymentsEntitledToReceiveAfterAssetSale_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</label>
    <loc xlink:href="mack-20170630.xsd#mack_IpsenSAMember" xlink:type="locator" xlink:label="mack_IpsenSAMember" />
    <label xml:lang="en-US" xlink:label="mack_IpsenSAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Ipsen S.A.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_IpsenSAMember" xlink:to="mack_IpsenSAMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_IpsenSAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ipsen [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_IpsenSAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ipsen S A [Member]</label>
    <loc xlink:href="mack-20170630.xsd#mack_BaxaltaMember" xlink:type="locator" xlink:label="mack_BaxaltaMember" />
    <label xml:lang="en-US" xlink:label="mack_BaxaltaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents entity (Baxalta ) that has a collaboration relationship to the company.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_BaxaltaMember" xlink:to="mack_BaxaltaMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_BaxaltaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Baxalta [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_BaxaltaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Baxalta [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Arrangement and Non-arrangement Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arrangements and Non-arrangement Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</label>
    <loc xlink:href="mack-20170630.xsd#mack_AssetPurchaseAndSaleAgreementMember" xlink:type="locator" xlink:label="mack_AssetPurchaseAndSaleAgreementMember" />
    <label xml:lang="en-US" xlink:label="mack_AssetPurchaseAndSaleAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset purchase and sale agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_AssetPurchaseAndSaleAgreementMember" xlink:to="mack_AssetPurchaseAndSaleAgreementMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_AssetPurchaseAndSaleAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Sale Agreement [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_AssetPurchaseAndSaleAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Purchase And Sale Agreement [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Collaboration Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</label>
    <label xml:lang="en-US" xlink:label="mack_AssetSaleUpfrontCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront cash payment received</label>
    <label xml:lang="en-US" xlink:label="mack_AssetSaleUpfrontCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Sale Upfront Cash Payment</label>
    <label xml:lang="en-US" xlink:label="mack_AssetSaleFutureMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional payments receivable on achievement of certain milestone events</label>
    <label xml:lang="en-US" xlink:label="mack_AssetSaleFutureMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Sale Future Milestone Payments</label>
    <label xml:lang="en-US" xlink:label="mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Working capital adjustment receivable</label>
    <label xml:lang="en-US" xlink:label="mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Working Capital Adjustment Receivable Related To Sale Of Asset</label>
    <label xml:lang="en-US" xlink:label="mack_NetMilestonePaymentsEntitledToReceiveAfterAssetSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net milestone payments expected to be received</label>
    <label xml:lang="en-US" xlink:label="mack_NetMilestonePaymentsEntitledToReceiveAfterAssetSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Milestone Payments Entitled To Receive After Asset Sale</label>
    <loc xlink:href="mack-20170630.xsd#mack_RegulatoryAssetsAbstract" xlink:type="locator" xlink:label="mack_RegulatoryAssetsAbstract" />
    <label xml:lang="en-US" xlink:label="mack_RegulatoryAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_RegulatoryAssetsAbstract" xlink:to="mack_RegulatoryAssetsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="mack_RegulatoryAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Assets [Abstract]</label>
    <loc xlink:href="mack-20170630.xsd#mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="mack_SummaryOfSignificantAccountingPoliciesLineItems" />
    <label xml:lang="en-US" xlink:label="mack_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mack_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="mack_SummaryOfSignificantAccountingPoliciesTable" />
    <label xml:lang="en-US" xlink:label="mack_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_SummaryOfSignificantAccountingPoliciesTable" xlink:to="mack_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <label xml:lang="en-US" xlink:label="mack_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</label>
    <label xml:lang="en-US" xlink:label="mack_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</label>
    <label xml:lang="en-US" xlink:label="mack_SilverCreekPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Silver Creek [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</label>
    <loc xlink:href="mack-20170630.xsd#mack_WarrantPurchaseAgreementsMember" xlink:type="locator" xlink:label="mack_WarrantPurchaseAgreementsMember" />
    <label xml:lang="en-US" xlink:label="mack_WarrantPurchaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant purchase agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_WarrantPurchaseAgreementsMember" xlink:to="mack_WarrantPurchaseAgreementsMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_WarrantPurchaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Purchase Agreements [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_WarrantPurchaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Purchase Agreements [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</label>
    <label xml:lang="en-US" xlink:label="mack_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</label>
    <loc xlink:href="mack-20170630.xsd#mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents" xlink:type="locator" xlink:label="mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents" />
    <label xml:lang="en-US" xlink:label="mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Ownership percentage held by parent and its de facto agents.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents" xlink:to="mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock issued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net cash proceeds from stock issuance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants issued to purchase preferred stock, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</label>
    <label xml:lang="en-US" xlink:label="mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership interest percentage held by parent and its de facto agents</label>
    <label xml:lang="en-US" xlink:label="mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ownership Percentage Held By Parent And Its De Facto Agents</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestTable" xlink:type="locator" xlink:label="us-gaap_MinorityInterestTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minority Interest [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestTable" xlink:to="us-gaap_MinorityInterestTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minority Interest [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:type="locator" xlink:label="us-gaap_MinorityInterestLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minority Interest [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_MinorityInterestLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minority Interest [Line Items]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_MinorityInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period</label>
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss attributable to Silver Creek</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" />
    <label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of Silver Creek Series C preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest Increase From Subsidiary Equity Issuance</label>
    <label xml:lang="en-US" xlink:label="us-gaap_MinorityInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue Arrangement Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Arrangement Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Arrangement Type [Domain]</label>
    <loc xlink:href="mack-20170630.xsd#mack_ClinicalTrialsInPancreasAsFirstLineTreatmentMember" xlink:type="locator" xlink:label="mack_ClinicalTrialsInPancreasAsFirstLineTreatmentMember" />
    <label xml:lang="en-US" xlink:label="mack_ClinicalTrialsInPancreasAsFirstLineTreatmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical trials in pancreas as first line treatment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_ClinicalTrialsInPancreasAsFirstLineTreatmentMember" xlink:to="mack_ClinicalTrialsInPancreasAsFirstLineTreatmentMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_ClinicalTrialsInPancreasAsFirstLineTreatmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Trials in Pancreas as First-Line Treatment [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_ClinicalTrialsInPancreasAsFirstLineTreatmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trials In Pancreas As First Line Treatment [Member]</label>
    <loc xlink:href="mack-20170630.xsd#mack_ClinicalTrialsInSmallCellLungCancerMember" xlink:type="locator" xlink:label="mack_ClinicalTrialsInSmallCellLungCancerMember" />
    <label xml:lang="en-US" xlink:label="mack_ClinicalTrialsInSmallCellLungCancerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical trials in small cell lung cancer.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_ClinicalTrialsInSmallCellLungCancerMember" xlink:to="mack_ClinicalTrialsInSmallCellLungCancerMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_ClinicalTrialsInSmallCellLungCancerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Trials in Small Cell Lung Cancer [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_ClinicalTrialsInSmallCellLungCancerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trials In Small Cell Lung Cancer [Member]</label>
    <loc xlink:href="mack-20170630.xsd#mack_OtherUnrelatedClinicalTrialsMember" xlink:type="locator" xlink:label="mack_OtherUnrelatedClinicalTrialsMember" />
    <label xml:lang="en-US" xlink:label="mack_OtherUnrelatedClinicalTrialsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other unrelated clinical trials.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_OtherUnrelatedClinicalTrialsMember" xlink:to="mack_OtherUnrelatedClinicalTrialsMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_OtherUnrelatedClinicalTrialsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Unrelated Clinical Trials [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_OtherUnrelatedClinicalTrialsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Unrelated Clinical Trials [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Domain]</label>
    <loc xlink:href="mack-20170630.xsd#mack_SeniorNotesDueTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="mack_SeniorNotesDueTwoThousandTwentyTwoMember" />
    <label xml:lang="en-US" xlink:label="mack_SeniorNotesDueTwoThousandTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Senior notes due two thousand twenty two.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_SeniorNotesDueTwoThousandTwentyTwoMember" xlink:to="mack_SeniorNotesDueTwoThousandTwentyTwoMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_SeniorNotesDueTwoThousandTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Notes [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_SeniorNotesDueTwoThousandTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Senior Notes Due Two Thousand Twenty Two [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing Facility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing Facility [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:type="locator" xlink:label="us-gaap_RestructuringPlanAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringPlanAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringPlanAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Plan [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:type="locator" xlink:label="us-gaap_RestructuringPlanDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringPlanDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="us-gaap_RestructuringPlanDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringPlanDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Plan [Domain]</label>
    <loc xlink:href="mack-20170630.xsd#mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember" xlink:type="locator" xlink:label="mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember" />
    <label xml:lang="en-US" xlink:label="mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">January two thousand seventeen corporate restructuring.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember" xlink:to="mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">January 2017 Corporate Restructuring [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">January Two Thousand Seventeen Corporate Restructuring [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost And Reserve [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Restructuring</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Restructuring [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractTerminationMember" xlink:type="locator" xlink:label="us-gaap_ContractTerminationMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ContractTerminationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual Termination Benefits [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractTerminationMember" xlink:to="us-gaap_ContractTerminationMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ContractTerminationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract Termination [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember" xlink:type="locator" xlink:label="us-gaap_OneTimeTerminationBenefitsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_OneTimeTerminationBenefitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One-time Employee Termination Benefits [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OneTimeTerminationBenefitsMember" xlink:to="us-gaap_OneTimeTerminationBenefitsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OneTimeTerminationBenefitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">One Time Termination Benefits [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupClassificationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disposal Group Classification</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupClassificationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Classification [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupClassificationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disposal Group Classification</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DisposalGroupClassificationDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupClassificationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Classification [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discontinued Operations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Discontinued Operations Disposed Of By Sale [Member]</label>
    <loc xlink:href="mack-20170630.xsd#mack_DevelopmentAndCommercializationMilestonesMember" xlink:type="locator" xlink:label="mack_DevelopmentAndCommercializationMilestonesMember" />
    <label xml:lang="en-US" xlink:label="mack_DevelopmentAndCommercializationMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and commercialization milestones.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DevelopmentAndCommercializationMilestonesMember" xlink:to="mack_DevelopmentAndCommercializationMilestonesMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_DevelopmentAndCommercializationMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and Commercialization Milestones [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_DevelopmentAndCommercializationMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development And Commercialization Milestones [Member]</label>
    <loc xlink:href="mack-20170630.xsd#mack_SaleMilestoneInMajorEuropeanCountriesMember" xlink:type="locator" xlink:label="mack_SaleMilestoneInMajorEuropeanCountriesMember" />
    <label xml:lang="en-US" xlink:label="mack_SaleMilestoneInMajorEuropeanCountriesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale milestone in major European countries.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_SaleMilestoneInMajorEuropeanCountriesMember" xlink:to="mack_SaleMilestoneInMajorEuropeanCountriesMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_SaleMilestoneInMajorEuropeanCountriesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale Milestones in Major European Countries [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_SaleMilestoneInMajorEuropeanCountriesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Milestone In Major European Countries [Member]</label>
    <loc xlink:href="mack-20170630.xsd#mack_SaleMilestoneInMajorNonEuropeanAndNonAsianCountryMember" xlink:type="locator" xlink:label="mack_SaleMilestoneInMajorNonEuropeanAndNonAsianCountryMember" />
    <label xml:lang="en-US" xlink:label="mack_SaleMilestoneInMajorNonEuropeanAndNonAsianCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale milestone in major non European and non Asian country.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_SaleMilestoneInMajorNonEuropeanAndNonAsianCountryMember" xlink:to="mack_SaleMilestoneInMajorNonEuropeanAndNonAsianCountryMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_SaleMilestoneInMajorNonEuropeanAndNonAsianCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale Milestones in Major Non-European and Non-Asian Country [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_SaleMilestoneInMajorNonEuropeanAndNonAsianCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Milestone In Major Non European And Non Asian Country [Member]</label>
    <loc xlink:href="mack-20170630.xsd#mack_ClinicalTrialsInLungCancerMember" xlink:type="locator" xlink:label="mack_ClinicalTrialsInLungCancerMember" />
    <label xml:lang="en-US" xlink:label="mack_ClinicalTrialsInLungCancerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical trials in lung cancer.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_ClinicalTrialsInLungCancerMember" xlink:to="mack_ClinicalTrialsInLungCancerMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_ClinicalTrialsInLungCancerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Trials in Lung Cancer [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_ClinicalTrialsInLungCancerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trials In Lung Cancer [Member]</label>
    <loc xlink:href="mack-20170630.xsd#mack_DevelopmentAndRegulatoryMilestonesMember" xlink:type="locator" xlink:label="mack_DevelopmentAndRegulatoryMilestonesMember" />
    <label xml:lang="en-US" xlink:label="mack_DevelopmentAndRegulatoryMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents a milestone that is achieved based off of development and regulatory criteria.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DevelopmentAndRegulatoryMilestonesMember" xlink:to="mack_DevelopmentAndRegulatoryMilestonesMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_DevelopmentAndRegulatoryMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and Regulatory Milestone [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_DevelopmentAndRegulatoryMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development And Regulatory Milestones [Member]</label>
    <loc xlink:href="mack-20170630.xsd#mack_SalesMilestonesMember" xlink:type="locator" xlink:label="mack_SalesMilestonesMember" />
    <label xml:lang="en-US" xlink:label="mack_SalesMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents a milestone that is achieved based off of sales criteria.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_SalesMilestonesMember" xlink:to="mack_SalesMilestonesMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_SalesMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Milestone [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_SalesMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestones [Member]</label>
    <loc xlink:href="mack-20170630.xsd#mack_PharmaEngineIncMember" xlink:type="locator" xlink:label="mack_PharmaEngineIncMember" />
    <label xml:lang="en-US" xlink:label="mack_PharmaEngineIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents an entity (PharmaEngine) with a collaboration relationship to the company.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_PharmaEngineIncMember" xlink:to="mack_PharmaEngineIncMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_PharmaEngineIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PharmaEngine [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_PharmaEngineIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pharma Engine Inc [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</label>
    <loc xlink:href="mack-20170630.xsd#mack_TransitionServicesAgreementPeriod" xlink:type="locator" xlink:label="mack_TransitionServicesAgreementPeriod" />
    <label xml:lang="en-US" xlink:label="mack_TransitionServicesAgreementPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Transition services agreement period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_TransitionServicesAgreementPeriod" xlink:to="mack_TransitionServicesAgreementPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="mack_TransitionServicesAgreementPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transition services agreement period</label>
    <label xml:lang="en-US" xlink:label="mack_TransitionServicesAgreementPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transition Services Agreement Period</label>
    <loc xlink:href="mack-20170630.xsd#mack_PaymentOfMakeWholePremiumOfLongTermDebt" xlink:type="locator" xlink:label="mack_PaymentOfMakeWholePremiumOfLongTermDebt" />
    <label xml:lang="en-US" xlink:label="mack_PaymentOfMakeWholePremiumOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of make-whole premium of long term debt.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_PaymentOfMakeWholePremiumOfLongTermDebt" xlink:to="mack_PaymentOfMakeWholePremiumOfLongTermDebt_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate principal amount outstanding redeemed</label>
    <label xml:lang="en-US" xlink:label="mack_PaymentOfMakeWholePremiumOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional premium payment</label>
    <label xml:lang="en-US" xlink:label="mack_PaymentOfMakeWholePremiumOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Make Whole Premium Of Long Term Debt</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate (as a percent)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Stated Percentage</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate principal amount of interest redeemed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Periodic Payment Interest</label>
    <loc xlink:href="mack-20170630.xsd#mack_AssetSaleSubleaseArea" xlink:type="locator" xlink:label="mack_AssetSaleSubleaseArea" />
    <label xml:lang="en-US" xlink:label="mack_AssetSaleSubleaseArea_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset sale sublease area.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_AssetSaleSubleaseArea" xlink:to="mack_AssetSaleSubleaseArea_lbl" />
    <label xml:lang="en-US" xlink:label="mack_AssetSaleSubleaseArea_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of sublease property</label>
    <label xml:lang="en-US" xlink:label="mack_AssetSaleSubleaseArea_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Sale Sublease Area</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xlink:type="locator" xlink:label="us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" />
    <label xml:lang="en-US" xlink:label="us-gaap_DividendsPayableDateDeclaredDayMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend date declared</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xlink:to="us-gaap_DividendsPayableDateDeclaredDayMonthAndYear_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DividendsPayableDateDeclaredDayMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Payable Date Declared Day Month And Year</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsCommonStockCash" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStockCash" />
    <label xml:lang="en-US" xlink:label="us-gaap_DividendsCommonStockCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Special cash dividend paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStockCash" xlink:to="us-gaap_DividendsCommonStockCash_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DividendsCommonStockCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Common Stock Cash</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:type="locator" xlink:label="us-gaap_DividendPayableDateToBePaidDayMonthAndYear" />
    <label xml:lang="en-US" xlink:label="us-gaap_DividendPayableDateToBePaidDayMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Dividend paid date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:to="us-gaap_DividendPayableDateToBePaidDayMonthAndYear_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DividendPayableDateToBePaidDayMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividend Payable Date To Be Paid Day Month And Year</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:type="locator" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" />
    <label xml:lang="en-US" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend payable, date of record</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:to="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Payable Date Of Record Day Month And Year</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gain from discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Discontinued Operation Income Loss From Discontinued Operation Before Income Tax</label>
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" />
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal group including discontinued operation product revenues net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" />
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal group including discontinued operation license and collaboration revenues.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" />
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal group including discontinued operation other revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" />
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal group including discontinued operation research and development expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" />
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal group including discontinued operation restructuring expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" />
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal group including discontinued operation revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" />
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal group including discontinued operation cost and expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" />
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal group including discontinued operation other income and expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disposal Group Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disposal Group Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Groups Including Discontinued Operations Name [Domain]</label>
    <loc xlink:href="mack-20170630.xsd#mack_CommercialBusinessMember" xlink:type="locator" xlink:label="mack_CommercialBusinessMember" />
    <label xml:lang="en-US" xlink:label="mack_CommercialBusinessMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial business.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_CommercialBusinessMember" xlink:to="mack_CommercialBusinessMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_CommercialBusinessMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Business [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_CommercialBusinessMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Business [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues:</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Revenue [Abstract]</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product revenues, net</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Product Revenues Net</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and collaboration revenues</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation License And Collaboration Revenues</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other revenues</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Other Revenue</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Revenue</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs and expenses:</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Cost And Expenses [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Costs Of Goods Sold</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Research And Development Expenses</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation General And Administrative Expense</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring expenses</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Restructuring Expenses</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total costs and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Operating Expense</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income and expenses:</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Other Income And Expenses [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Interest Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on sale of commercial business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:to="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax</label>
    <label xml:lang="en-US" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (loss) from discontinued operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" />
    <label xml:lang="en-US" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Discontinued Operation Tax Effect Of Discontinued Operation</label>
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total income (loss) from discontinued operations</label>
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent" />
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal group including discontinued operation accounts payable and accrued liabilities current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Of Disposal Group Including Discontinued Operation Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Inventory Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Prepaid And Other Assets Current</label>
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets held for sale</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Property Plant And Equipment Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Intangible Assets Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Goodwill Noncurrent</label>
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total long-term assets held for sale</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Of Disposal Group Including Discontinued Operation Current [Abstract]</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable, accrued expenses and other</label>
    <label xml:lang="en-US" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Accounts Payable And Accrued Expenses And Other Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Deferred Revenue Current</label>
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities held for sale</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenues, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Deferred Revenue Noncurrent</label>
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities held for sale</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:type="locator" xlink:label="us-gaap_InventoryCurrentTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_InventoryCurrentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory Current [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryCurrentTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InventoryCurrentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Current [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryLineItems" xlink:type="locator" xlink:label="us-gaap_InventoryLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_InventoryLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory [Line Item]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InventoryLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" />
    <label xml:lang="en-US" xlink:label="us-gaap_InventoryRawMaterials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InventoryRawMaterials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Raw Materials</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" />
    <label xml:lang="en-US" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work in process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Work In Process</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" />
    <label xml:lang="en-US" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Finished Goods</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Net</label>
    <loc xlink:href="mack-20170630.xsd#mack_RestructuringAndRelatedCostNumberOfPositionsAfterHeadcountReduction" xlink:type="locator" xlink:label="mack_RestructuringAndRelatedCostNumberOfPositionsAfterHeadcountReduction" />
    <label xml:lang="en-US" xlink:label="mack_RestructuringAndRelatedCostNumberOfPositionsAfterHeadcountReduction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Restructuring and related cost number of positions after headcount reduction.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_RestructuringAndRelatedCostNumberOfPositionsAfterHeadcountReduction" xlink:to="mack_RestructuringAndRelatedCostNumberOfPositionsAfterHeadcountReduction_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesInitiationDate" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesInitiationDate" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedActivitiesInitiationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring activity, announcement date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesInitiationDate" xlink:to="us-gaap_RestructuringAndRelatedActivitiesInitiationDate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedActivitiesInitiationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring And Related Activities Initiation Date</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring and related cost, headcount reduction percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring And Related Cost Number Of Positions Eliminated Period Percent</label>
    <label xml:lang="en-US" xlink:label="mack_RestructuringAndRelatedCostNumberOfPositionsAfterHeadcountReduction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring and related cost, number of employees after headcount reduction</label>
    <label xml:lang="en-US" xlink:label="mack_RestructuringAndRelatedCostNumberOfPositionsAfterHeadcountReduction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring And Related Cost Number Of Positions After Headcount Reduction</label>
    <loc xlink:href="mack-20170630.xsd#mack_SeverancePaymentsPaymentPeriod" xlink:type="locator" xlink:label="mack_SeverancePaymentsPaymentPeriod" />
    <label xml:lang="en-US" xlink:label="mack_SeverancePaymentsPaymentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Severance payments payment period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_SeverancePaymentsPaymentPeriod" xlink:to="mack_SeverancePaymentsPaymentPeriod_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDescription" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDescription" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring And Related Activities Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDescription" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDescription_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring And Related Activities Description</label>
    <label xml:lang="en-US" xlink:label="mack_SeverancePaymentsPaymentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance payments payment period</label>
    <label xml:lang="en-US" xlink:label="mack_SeverancePaymentsPaymentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Severance Payments Payment Period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring And Related Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Restructuring And Related Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Restructuring And Related Costs [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:type="locator" xlink:label="us-gaap_EmployeeSeveranceMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance Benefits and Related Costs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeSeveranceMember" xlink:to="us-gaap_EmployeeSeveranceMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Severance [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Cost And Reserve [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost And Reserve [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:type="locator" xlink:label="us-gaap_RestructuringReserveCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accrued Restructuring Expenses at Dec 31, 2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Reserve Current</label>
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expenses</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:type="locator" xlink:label="us-gaap_PaymentsForRestructuring" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Restructuring</label>
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accrued Restructuring Expenses at June 30, 2017</label>
    <loc xlink:href="mack-20170630.xsd#mack_MaximumCollaborativeArrangementMilestonePayments" xlink:type="locator" xlink:label="mack_MaximumCollaborativeArrangementMilestonePayments" />
    <label xml:lang="en-US" xlink:label="mack_MaximumCollaborativeArrangementMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the maximum cumulative amount of milestone payments that can be received over the life of the license and collaboration agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_MaximumCollaborativeArrangementMilestonePayments" xlink:to="mack_MaximumCollaborativeArrangementMilestonePayments_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_PotentialMilestonePaymentsReceivable" xlink:type="locator" xlink:label="mack_PotentialMilestonePaymentsReceivable" />
    <label xml:lang="en-US" xlink:label="mack_PotentialMilestonePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential milestone payments receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_PotentialMilestonePaymentsReceivable" xlink:to="mack_PotentialMilestonePaymentsReceivable_lbl" />
    <label xml:lang="en-US" xlink:label="mack_MaximumCollaborativeArrangementMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum amount of milestone payments that can be received</label>
    <label xml:lang="en-US" xlink:label="mack_MaximumCollaborativeArrangementMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Collaborative Arrangement Milestone Payments</label>
    <label xml:lang="en-US" xlink:label="mack_PotentialMilestonePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential milestone payments receivable</label>
    <label xml:lang="en-US" xlink:label="mack_PotentialMilestonePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Potential Milestone Payments Receivable</label>
    <loc xlink:href="mack-20170630.xsd#mack_CollaborativeArrangementUpfrontPaymentObligation" xlink:type="locator" xlink:label="mack_CollaborativeArrangementUpfrontPaymentObligation" />
    <label xml:lang="en-US" xlink:label="mack_CollaborativeArrangementUpfrontPaymentObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the cumulative amount of nonrefundable, noncreditable upfront license fees paid during the period under the terms of license and collaboration agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_CollaborativeArrangementUpfrontPaymentObligation" xlink:to="mack_CollaborativeArrangementUpfrontPaymentObligation_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_CollaborativeArrangementMaximumMilestonePaymentObligation" xlink:type="locator" xlink:label="mack_CollaborativeArrangementMaximumMilestonePaymentObligation" />
    <label xml:lang="en-US" xlink:label="mack_CollaborativeArrangementMaximumMilestonePaymentObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the maximum cumulative obligation for milestone payments under the terms of license and collaboration agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_CollaborativeArrangementMaximumMilestonePaymentObligation" xlink:to="mack_CollaborativeArrangementMaximumMilestonePaymentObligation_lbl" />
    <label xml:lang="en-US" xlink:label="mack_CollaborativeArrangementUpfrontPaymentObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront license fees paid</label>
    <label xml:lang="en-US" xlink:label="mack_CollaborativeArrangementUpfrontPaymentObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Upfront Payment Obligation</label>
    <label xml:lang="en-US" xlink:label="mack_CollaborativeArrangementMaximumMilestonePaymentObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum milestone payment obligation</label>
    <label xml:lang="en-US" xlink:label="mack_CollaborativeArrangementMaximumMilestonePaymentObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Maximum Milestone Payment Obligation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt [Member]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrestricted cash and cash equivalents</label>
    <loc xlink:href="mack-20170630.xsd#mack_AssetSaleUpfrontCashPaymentReceived" xlink:type="locator" xlink:label="mack_AssetSaleUpfrontCashPaymentReceived" />
    <label xml:lang="en-US" xlink:label="mack_AssetSaleUpfrontCashPaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset sale upfront&#8203; cash&#8203; payment received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_AssetSaleUpfrontCashPaymentReceived" xlink:to="mack_AssetSaleUpfrontCashPaymentReceived_lbl" />
    <label xml:lang="en-US" xlink:label="mack_AssetSaleUpfrontCashPaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront cash payment received</label>
    <label xml:lang="en-US" xlink:label="mack_AssetSaleUpfrontCashPaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Sale Upfront Cash Payment Received</label>
    <label xml:lang="en-US" xlink:label="us-gaap_DividendsCommonStockCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Special cash dividend distributed</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EscrowDeposit" xlink:type="locator" xlink:label="us-gaap_EscrowDeposit" />
    <label xml:lang="en-US" xlink:label="us-gaap_EscrowDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deposited into escrow account</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDeposit" xlink:to="us-gaap_EscrowDeposit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EscrowDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Escrow Deposit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense Benefit</label>
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense (benefit)</label>
    <label xml:lang="en-US" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense in discontinued operations</label>
    <label xml:lang="en-US" xlink:label="mack_AccruedIntraperiodTaxAllocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued income tax provision</label>
    <loc xlink:href="mack-20170630.xsd#mack_DiscontinuedOperationValuationAllowanceFromDisposalOfDiscontinuedOperation" xlink:type="locator" xlink:label="mack_DiscontinuedOperationValuationAllowanceFromDisposalOfDiscontinuedOperation" />
    <label xml:lang="en-US" xlink:label="mack_DiscontinuedOperationValuationAllowanceFromDisposalOfDiscontinuedOperation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Discontinued operation valuation allowance from disposal of discontinued operation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DiscontinuedOperationValuationAllowanceFromDisposalOfDiscontinuedOperation" xlink:to="mack_DiscontinuedOperationValuationAllowanceFromDisposalOfDiscontinuedOperation_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" />
    <label xml:lang="en-US" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax provision in discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:to="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation</label>
    <label xml:lang="en-US" xlink:label="mack_DiscontinuedOperationValuationAllowanceFromDisposalOfDiscontinuedOperation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance in discontinued operations</label>
    <label xml:lang="en-US" xlink:label="mack_DiscontinuedOperationValuationAllowanceFromDisposalOfDiscontinuedOperation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Discontinued Operation Valuation Allowance From Disposal Of Discontinued Operation</label>
    <loc xlink:href="mack-20170630.xsd#mack_UndistributedEarningsLossAllocatedToParticipatingSecurities" xlink:type="locator" xlink:label="mack_UndistributedEarningsLossAllocatedToParticipatingSecurities" />
    <label xml:lang="en-US" xlink:label="mack_UndistributedEarningsLossAllocatedToParticipatingSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Undistributed earnings (loss) allocated to participating securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_UndistributedEarningsLossAllocatedToParticipatingSecurities" xlink:to="mack_UndistributedEarningsLossAllocatedToParticipatingSecurities_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_ParticipatingSecuritiesOutstandingShares" xlink:type="locator" xlink:label="mack_ParticipatingSecuritiesOutstandingShares" />
    <label xml:lang="en-US" xlink:label="mack_ParticipatingSecuritiesOutstandingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Participating securities outstanding shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_ParticipatingSecuritiesOutstandingShares" xlink:to="mack_ParticipatingSecuritiesOutstandingShares_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <label xml:lang="en-US" xlink:label="mack_UndistributedEarningsLossAllocatedToParticipatingSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts allocated to participating securities</label>
    <label xml:lang="en-US" xlink:label="mack_UndistributedEarningsLossAllocatedToParticipatingSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Undistributed Earnings Loss Allocated To Participating Securities</label>
    <label xml:lang="en-US" xlink:label="mack_ParticipatingSecuritiesOutstandingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Participating securities outstanding, shares</label>
    <label xml:lang="en-US" xlink:label="mack_ParticipatingSecuritiesOutstandingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Participating Securities Outstanding Shares</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Face Amount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate principal amount of outstanding debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Options to Purchase Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Compensation Plan [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of the Convertible Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt Securities [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding securities excluded from calculation of diluted loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurement Frequency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring Basis [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Liability Class [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Liability Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]</label>
    <loc xlink:href="mack-20170630.xsd#mack_WarrantLiabilityMember" xlink:type="locator" xlink:label="mack_WarrantLiabilityMember" />
    <label xml:lang="en-US" xlink:label="mack_WarrantLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_WarrantLiabilityMember" xlink:to="mack_WarrantLiabilityMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_WarrantLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Liability [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_WarrantLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Disclosure</label>
    <loc xlink:href="mack-20170630.xsd#mack_FairValueAdjustmentOfWarrantsIncrementalChangeResultingFromAmendment" xlink:type="locator" xlink:label="mack_FairValueAdjustmentOfWarrantsIncrementalChangeResultingFromAmendment" />
    <label xml:lang="en-US" xlink:label="mack_FairValueAdjustmentOfWarrantsIncrementalChangeResultingFromAmendment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value adjustment of warrants incremental change resulting from amendment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_FairValueAdjustmentOfWarrantsIncrementalChangeResultingFromAmendment" xlink:to="mack_FairValueAdjustmentOfWarrantsIncrementalChangeResultingFromAmendment_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value By Balance Sheet Grouping [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Balance Sheet Grouping [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeniorNotesMember" xlink:type="locator" xlink:label="us-gaap_SeniorNotesMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_SeniorNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Senior Convertible Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorNotesMember" xlink:to="us-gaap_SeniorNotesMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SeniorNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Senior Notes [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued to purchase preferred stock, shares</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase preferred stock, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions Risk Free Interest Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions Expected Dividend Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions Expected Volatility Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions Expected Term</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment Of Warrants</label>
    <label xml:lang="en-US" xlink:label="mack_FairValueAdjustmentOfWarrantsIncrementalChangeResultingFromAmendment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrant, incremental change</label>
    <label xml:lang="en-US" xlink:label="mack_FairValueAdjustmentOfWarrantsIncrementalChangeResultingFromAmendment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment Of Warrants Incremental Change Resulting From Amendment</label>
    <loc xlink:href="mack-20170630.xsd#mack_FairValueInstrumentsTransfersBetweenLevels" xlink:type="locator" xlink:label="mack_FairValueInstrumentsTransfersBetweenLevels" />
    <label xml:lang="en-US" xlink:label="mack_FairValueInstrumentsTransfersBetweenLevels_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Instruments Transfers Between Levels</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_FairValueInstrumentsTransfersBetweenLevels" xlink:to="mack_FairValueInstrumentsTransfersBetweenLevels_lbl" />
    <label xml:lang="en-US" xlink:label="mack_FairValueInstrumentsTransfersBetweenLevels_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers between fair value measurement levels</label>
    <label xml:lang="en-US" xlink:label="mack_FairValueInstrumentsTransfersBetweenLevels_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Instruments Transfers Between Levels</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:type="locator" xlink:label="us-gaap_LongTermDebtFairValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtFairValue" xlink:to="us-gaap_LongTermDebtFairValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Fair Value</label>
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate principal amount of loan</label>
    <loc xlink:href="mack-20170630.xsd#mack_AmortizedCostAndFairValueDebtSecuritiesAbstract" xlink:type="locator" xlink:label="mack_AmortizedCostAndFairValueDebtSecuritiesAbstract" />
    <label xml:lang="en-US" xlink:label="mack_AmortizedCostAndFairValueDebtSecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortized Cost and Fair Value Debt Securities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_AmortizedCostAndFairValueDebtSecuritiesAbstract" xlink:to="mack_AmortizedCostAndFairValueDebtSecuritiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="mack_AmortizedCostAndFairValueDebtSecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortized Cost And Fair Value Debt Securities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:type="locator" xlink:label="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of securities held in unrealized loss position</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:to="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gains (losses) on sale of available-for-sale securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Gross Realized Gains</label>
    <loc xlink:href="mack-20170630.xsd#mack_AccruedClinicalTrialCosts" xlink:type="locator" xlink:label="mack_AccruedClinicalTrialCosts" />
    <label xml:lang="en-US" xlink:label="mack_AccruedClinicalTrialCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date arising from ongoing clinical trial activity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_AccruedClinicalTrialCosts" xlink:to="mack_AccruedClinicalTrialCosts_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_AccruedDrugPurchaseCostsCurrent" xlink:type="locator" xlink:label="mack_AccruedDrugPurchaseCostsCurrent" />
    <label xml:lang="en-US" xlink:label="mack_AccruedDrugPurchaseCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued drug purchase costs current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_AccruedDrugPurchaseCostsCurrent" xlink:to="mack_AccruedDrugPurchaseCostsCurrent_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_WarrantLiabilityCurrent" xlink:type="locator" xlink:label="mack_WarrantLiabilityCurrent" />
    <label xml:lang="en-US" xlink:label="mack_WarrantLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant liability current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_WarrantLiabilityCurrent" xlink:to="mack_WarrantLiabilityCurrent_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:type="locator" xlink:label="mack_AccountsPayableAndAccruedLiabilitiesLineItems" />
    <label xml:lang="en-US" xlink:label="mack_AccountsPayableAndAccruedLiabilitiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts payable and accrued liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="mack_AccountsPayableAndAccruedLiabilitiesLineItems_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_AccountsPayableAndAccruedLiabilitiesTable" xlink:type="locator" xlink:label="mack_AccountsPayableAndAccruedLiabilitiesTable" />
    <label xml:lang="en-US" xlink:label="mack_AccountsPayableAndAccruedLiabilitiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts payable and accrued liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesTable" xlink:to="mack_AccountsPayableAndAccruedLiabilitiesTable_lbl" />
    <label xml:lang="en-US" xlink:label="mack_AccountsPayableAndAccruedLiabilitiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Payable And Accrued Liabilities [Table]</label>
    <label xml:lang="en-US" xlink:label="mack_AccountsPayableAndAccruedLiabilitiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities [Table]</label>
    <label xml:lang="en-US" xlink:label="mack_AccountsPayableAndAccruedLiabilitiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Payable And Accrued Liabilities [Line Items]</label>
    <label xml:lang="en-US" xlink:label="mack_AccountsPayableAndAccruedLiabilitiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued goods and services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</label>
    <label xml:lang="en-US" xlink:label="mack_AccruedClinicalTrialCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical trial costs</label>
    <label xml:lang="en-US" xlink:label="mack_AccruedClinicalTrialCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Trial Costs</label>
    <label xml:lang="en-US" xlink:label="mack_AccruedDrugPurchaseCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued drug purchase costs</label>
    <label xml:lang="en-US" xlink:label="mack_AccruedDrugPurchaseCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Drug Purchase Costs Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll and related benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</label>
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued severance expenses</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Payable Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_DividendsPayableCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DividendsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued dividends payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrent" xlink:to="us-gaap_DividendsPayableCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DividendsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Payable Current</label>
    <label xml:lang="en-US" xlink:label="mack_WarrantLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability</label>
    <label xml:lang="en-US" xlink:label="mack_WarrantLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax incentives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:to="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Credits And Other Liabilities Current</label>
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accounts payable, accrued expenses and other</label>
    <loc xlink:href="mack-20170630.xsd#mack_ScheduleOfDebtInstrumentsLineItems" xlink:type="locator" xlink:label="mack_ScheduleOfDebtInstrumentsLineItems" />
    <label xml:lang="en-US" xlink:label="mack_ScheduleOfDebtInstrumentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Debt Instruments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_ScheduleOfDebtInstrumentsLineItems" xlink:to="mack_ScheduleOfDebtInstrumentsLineItems_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_ScheduleOfDebtInstrumentsTable" xlink:type="locator" xlink:label="mack_ScheduleOfDebtInstrumentsTable" />
    <label xml:lang="en-US" xlink:label="mack_ScheduleOfDebtInstrumentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of debt instruments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_ScheduleOfDebtInstrumentsTable" xlink:to="mack_ScheduleOfDebtInstrumentsTable_lbl" />
    <label xml:lang="en-US" xlink:label="mack_ScheduleOfDebtInstrumentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Debt Instruments [Table]</label>
    <label xml:lang="en-US" xlink:label="mack_ScheduleOfDebtInstrumentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Debt Instruments [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseMember" xlink:type="locator" xlink:label="us-gaap_InterestExpenseMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseMember" xlink:to="us-gaap_InterestExpenseMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_ScheduleOfDebtInstrumentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Debt Instruments [Line Items]</label>
    <label xml:lang="en-US" xlink:label="mack_ScheduleOfDebtInstrumentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Debt Instruments [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from the debt issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Debt Net Of Issuance Costs</label>
    <label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment penalty of extinguishment of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Debt Extinguishment Costs</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense recognized for remaining debt discount at settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Debt Discount Premium</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</label>
    <loc xlink:href="mack-20170630.xsd#mack_TransactionCostsIncurredWithThirdPartiesMember" xlink:type="locator" xlink:label="mack_TransactionCostsIncurredWithThirdPartiesMember" />
    <label xml:lang="en-US" xlink:label="mack_TransactionCostsIncurredWithThirdPartiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction costs incurred with third parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_TransactionCostsIncurredWithThirdPartiesMember" xlink:to="mack_TransactionCostsIncurredWithThirdPartiesMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_TransactionCostsIncurredWithThirdPartiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction Costs Incurred With Third Parties [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_TransactionCostsIncurredWithThirdPartiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Costs Incurred With Third Parties [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</label>
    <loc xlink:href="mack-20170630.xsd#mack_DebtIssuanceCostsUnderwritingDiscountsCommissionsAndOfferingExpenses" xlink:type="locator" xlink:label="mack_DebtIssuanceCostsUnderwritingDiscountsCommissionsAndOfferingExpenses" />
    <label xml:lang="en-US" xlink:label="mack_DebtIssuanceCostsUnderwritingDiscountsCommissionsAndOfferingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt issuance costs underwriting discounts commissions and offering expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DebtIssuanceCostsUnderwritingDiscountsCommissionsAndOfferingExpenses" xlink:to="mack_DebtIssuanceCostsUnderwritingDiscountsCommissionsAndOfferingExpenses_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Embedded conversion option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Convertible Carrying Amount Of The Equity Component</label>
    <label xml:lang="en-US" xlink:label="mack_DebtIssuanceCostsUnderwritingDiscountsCommissionsAndOfferingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions and offering expenses</label>
    <label xml:lang="en-US" xlink:label="mack_DebtIssuanceCostsUnderwritingDiscountsCommissionsAndOfferingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs Underwriting Discounts Commissions And Offering Expenses</label>
    <loc xlink:href="mack-20170630.xsd#mack_ValueOfAdditionalSharesIssuedForConversion" xlink:type="locator" xlink:label="mack_ValueOfAdditionalSharesIssuedForConversion" />
    <label xml:lang="en-US" xlink:label="mack_ValueOfAdditionalSharesIssuedForConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of additional shares issued for conversion.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_ValueOfAdditionalSharesIssuedForConversion" xlink:to="mack_ValueOfAdditionalSharesIssuedForConversion_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_TradingPeriodOfCommonStock" xlink:type="locator" xlink:label="mack_TradingPeriodOfCommonStock" />
    <label xml:lang="en-US" xlink:label="mack_TradingPeriodOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Trading period of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_TradingPeriodOfCommonStock" xlink:to="mack_TradingPeriodOfCommonStock_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" xlink:type="locator" xlink:label="mack_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" />
    <label xml:lang="en-US" xlink:label="mack_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the denomination of the principal amount of debt used to state the number of shares that debt can be converted into, and which is used in conversion calculations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" xlink:to="mack_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_IncreaseToAdditionalPaidInCapitalDueToConversion" xlink:type="locator" xlink:label="mack_IncreaseToAdditionalPaidInCapitalDueToConversion" />
    <label xml:lang="en-US" xlink:label="mack_IncreaseToAdditionalPaidInCapitalDueToConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase to additional paid in capital due to conversion.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_IncreaseToAdditionalPaidInCapitalDueToConversion" xlink:to="mack_IncreaseToAdditionalPaidInCapitalDueToConversion_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_ReductionInAdditionalPaidInCapitalAttributableToEmbeddedConversionOption" xlink:type="locator" xlink:label="mack_ReductionInAdditionalPaidInCapitalAttributableToEmbeddedConversionOption" />
    <label xml:lang="en-US" xlink:label="mack_ReductionInAdditionalPaidInCapitalAttributableToEmbeddedConversionOption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduction in additional paid in capital attributable to embedded conversion option.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_ReductionInAdditionalPaidInCapitalAttributableToEmbeddedConversionOption" xlink:to="mack_ReductionInAdditionalPaidInCapitalAttributableToEmbeddedConversionOption_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_DebtConversionCostsIncurredAndPaid" xlink:type="locator" xlink:label="mack_DebtConversionCostsIncurredAndPaid" />
    <label xml:lang="en-US" xlink:label="mack_DebtConversionCostsIncurredAndPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction costs related to conversion of convertible notes due 2020 incurred and paid.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DebtConversionCostsIncurredAndPaid" xlink:to="mack_DebtConversionCostsIncurredAndPaid_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_DecreaseToAdditionalPaidInCapitalDueToConversionTransactionCost" xlink:type="locator" xlink:label="mack_DecreaseToAdditionalPaidInCapitalDueToConversionTransactionCost" />
    <label xml:lang="en-US" xlink:label="mack_DecreaseToAdditionalPaidInCapitalDueToConversionTransactionCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Decrease to additional paid in capital due to conversion transaction cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DecreaseToAdditionalPaidInCapitalDueToConversionTransactionCost" xlink:to="mack_DecreaseToAdditionalPaidInCapitalDueToConversionTransactionCost_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Principal amount of convertible notes due 2020 converted into shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion Original Debt Amount1</label>
    <label xml:lang="en-US" xlink:label="mack_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion ratio, principal amount</label>
    <label xml:lang="en-US" xlink:label="mack_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Principal Amount Denomination For Conversion Into Common Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion rate of common stock shares per $1,000 principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Convertible Conversion Ratio1</label>
    <label xml:lang="en-US" xlink:label="mack_ValueOfAdditionalSharesIssuedForConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Value of additional shares issued for conversion</label>
    <label xml:lang="en-US" xlink:label="mack_ValueOfAdditionalSharesIssuedForConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Value Of Additional Shares Issued For Conversion</label>
    <label xml:lang="en-US" xlink:label="mack_TradingPeriodOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading period</label>
    <label xml:lang="en-US" xlink:label="mack_TradingPeriodOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Period Of Common Stock</label>
    <label xml:lang="en-US" xlink:label="mack_IncreaseToAdditionalPaidInCapitalDueToConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase to additional paid in capital pursuant to conversion</label>
    <label xml:lang="en-US" xlink:label="mack_IncreaseToAdditionalPaidInCapitalDueToConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase To Additional Paid In Capital Due To Conversion</label>
    <label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Loss on extinguishment of debt</label>
    <label xml:lang="en-US" xlink:label="mack_ReductionInAdditionalPaidInCapitalAttributableToEmbeddedConversionOption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in additional paid-in capital attributable to embedded conversion option</label>
    <label xml:lang="en-US" xlink:label="mack_ReductionInAdditionalPaidInCapitalAttributableToEmbeddedConversionOption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reduction In Additional Paid In Capital Attributable To Embedded Conversion Option</label>
    <label xml:lang="en-US" xlink:label="mack_DebtConversionCostsIncurredAndPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs related to conversion of convertible notes due 2020 incurred and paid</label>
    <label xml:lang="en-US" xlink:label="mack_DebtConversionCostsIncurredAndPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion Costs Incurred And Paid</label>
    <label xml:lang="en-US" xlink:label="mack_DecreaseToAdditionalPaidInCapitalDueToConversionTransactionCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in additional paid-in capital</label>
    <label xml:lang="en-US" xlink:label="mack_DecreaseToAdditionalPaidInCapitalDueToConversionTransactionCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Decrease To Additional Paid In Capital Due To Conversion Transaction Cost</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date</label>
    <loc xlink:href="mack-20170630.xsd#mack_DebtInstrumentConversionObligationCommonStockClosingSalesPriceTradingPeriod" xlink:type="locator" xlink:label="mack_DebtInstrumentConversionObligationCommonStockClosingSalesPriceTradingPeriod" />
    <label xml:lang="en-US" xlink:label="mack_DebtInstrumentConversionObligationCommonStockClosingSalesPriceTradingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of trading days within a period of 30 consecutive trading days during which the closing price of the entity&apos;s common stock must exceed the applicable conversion price in order for the debt instruments to be convertible.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DebtInstrumentConversionObligationCommonStockClosingSalesPriceTradingPeriod" xlink:to="mack_DebtInstrumentConversionObligationCommonStockClosingSalesPriceTradingPeriod_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_DebtInstrumentConversionObligationNumberOfConsecutiveTradingTerm" xlink:type="locator" xlink:label="mack_DebtInstrumentConversionObligationNumberOfConsecutiveTradingTerm" />
    <label xml:lang="en-US" xlink:label="mack_DebtInstrumentConversionObligationNumberOfConsecutiveTradingTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of consecutive trading days during which the closing price of the entity&apos;s common stock must exceed the applicable conversion price for at least 20 days in order for the debt instruments to be convertible.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DebtInstrumentConversionObligationNumberOfConsecutiveTradingTerm" xlink:to="mack_DebtInstrumentConversionObligationNumberOfConsecutiveTradingTerm_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_ConvertibilityOfDebtStockPriceTestTargetPercentageOfClosingStockPriceToConversionPriceThatMustBeExceeded" xlink:type="locator" xlink:label="mack_ConvertibilityOfDebtStockPriceTestTargetPercentageOfClosingStockPriceToConversionPriceThatMustBeExceeded" />
    <label xml:lang="en-US" xlink:label="mack_ConvertibilityOfDebtStockPriceTestTargetPercentageOfClosingStockPriceToConversionPriceThatMustBeExceeded_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">When testing, based upon the stock price, whether convertible debt may be converted by the debt holder, represents the ratio, expressed as a percentage, of the closing stock price to the conversion price that must be exceeded.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_ConvertibilityOfDebtStockPriceTestTargetPercentageOfClosingStockPriceToConversionPriceThatMustBeExceeded" xlink:to="mack_ConvertibilityOfDebtStockPriceTestTargetPercentageOfClosingStockPriceToConversionPriceThatMustBeExceeded_lbl" />
    <label xml:lang="en-US" xlink:label="mack_DebtInstrumentConversionObligationCommonStockClosingSalesPriceTradingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of days within 30 consecutive trading days in which the closing price of the entity&apos;s common stock must exceed the conversion price for the notes to be convertible</label>
    <label xml:lang="en-US" xlink:label="mack_DebtInstrumentConversionObligationCommonStockClosingSalesPriceTradingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Conversion Obligation Common Stock Closing Sales Price Trading Period</label>
    <label xml:lang="en-US" xlink:label="mack_DebtInstrumentConversionObligationNumberOfConsecutiveTradingTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of consecutive trading days during which the closing price of the entity&apos;s common stock must exceed the conversion price for at least 20 days in order for the notes to be convertible</label>
    <label xml:lang="en-US" xlink:label="mack_DebtInstrumentConversionObligationNumberOfConsecutiveTradingTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Conversion Obligation Number Of Consecutive Trading Term</label>
    <label xml:lang="en-US" xlink:label="mack_ConvertibilityOfDebtStockPriceTestTargetPercentageOfClosingStockPriceToConversionPriceThatMustBeExceeded_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertibility of debt, closing price of stock test, percentage of stock price to conversion price for the notes that must be exceeded</label>
    <label xml:lang="en-US" xlink:label="mack_ConvertibilityOfDebtStockPriceTestTargetPercentageOfClosingStockPriceToConversionPriceThatMustBeExceeded_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertibility Of Debt Stock Price Test Target Percentage Of Closing Stock Price To Conversion Price That Must Be Exceeded</label>
    <loc xlink:href="mack-20170630.xsd#mack_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessPeriodAfterConsecutiveTradingTerm" xlink:type="locator" xlink:label="mack_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessPeriodAfterConsecutiveTradingTerm" />
    <label xml:lang="en-US" xlink:label="mack_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessPeriodAfterConsecutiveTradingTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of consecutive business days immediately after any five consecutive trading day period during the debt instrument measurement period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessPeriodAfterConsecutiveTradingTerm" xlink:to="mack_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessPeriodAfterConsecutiveTradingTerm_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_DebtInstrumentConversionObligationPeriodOfConsecutiveTrading" xlink:type="locator" xlink:label="mack_DebtInstrumentConversionObligationPeriodOfConsecutiveTrading" />
    <label xml:lang="en-US" xlink:label="mack_DebtInstrumentConversionObligationPeriodOfConsecutiveTrading_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of consecutive trading days prior to the five consecutive business days during the debt instrument measurement period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DebtInstrumentConversionObligationPeriodOfConsecutiveTrading" xlink:to="mack_DebtInstrumentConversionObligationPeriodOfConsecutiveTrading_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_ConvertibilityOfDebtDebtPriceTestPercentageOfClosingStockPriceUsedInCalculation" xlink:type="locator" xlink:label="mack_ConvertibilityOfDebtDebtPriceTestPercentageOfClosingStockPriceUsedInCalculation" />
    <label xml:lang="en-US" xlink:label="mack_ConvertibilityOfDebtDebtPriceTestPercentageOfClosingStockPriceUsedInCalculation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">When testing, based upon the debt price, whether the convertible debt may be converted by the debt holder, represents the percentage of the closing stock price used in the calculation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_ConvertibilityOfDebtDebtPriceTestPercentageOfClosingStockPriceUsedInCalculation" xlink:to="mack_ConvertibilityOfDebtDebtPriceTestPercentageOfClosingStockPriceUsedInCalculation_lbl" />
    <label xml:lang="en-US" xlink:label="mack_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessPeriodAfterConsecutiveTradingTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of consecutive business days immediately after any five consecutive trading day period during the note measurement period</label>
    <label xml:lang="en-US" xlink:label="mack_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessPeriodAfterConsecutiveTradingTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Conversion Obligation Number Of Consecutive Business Period After Consecutive Trading Term</label>
    <label xml:lang="en-US" xlink:label="mack_DebtInstrumentConversionObligationPeriodOfConsecutiveTrading_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of consecutive trading days before five consecutive business days during the note measurement period</label>
    <label xml:lang="en-US" xlink:label="mack_DebtInstrumentConversionObligationPeriodOfConsecutiveTrading_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Conversion Obligation Period Of Consecutive Trading</label>
    <label xml:lang="en-US" xlink:label="mack_ConvertibilityOfDebtDebtPriceTestPercentageOfClosingStockPriceUsedInCalculation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertibility of debt, trading price of debt test, percentage of closing price of stock used in calculation</label>
    <label xml:lang="en-US" xlink:label="mack_ConvertibilityOfDebtDebtPriceTestPercentageOfClosingStockPriceUsedInCalculation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertibility Of Debt Debt Price Test Percentage Of Closing Stock Price Used In Calculation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial conversion price of shares (in dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Convertible Conversion Price1</label>
    <loc xlink:href="mack-20170630.xsd#mack_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" xlink:type="locator" xlink:label="mack_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" />
    <label xml:lang="en-US" xlink:label="mack_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of principal in year four and thereafter.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" xlink:to="mack_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_DebtInstrumentCarryingAmountIncludingContractualInterest" xlink:type="locator" xlink:label="mack_DebtInstrumentCarryingAmountIncludingContractualInterest" />
    <label xml:lang="en-US" xlink:label="mack_DebtInstrumentCarryingAmountIncludingContractualInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of long-term debt before deduction of unamortized discount or premium including contractual interest. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_DebtInstrumentCarryingAmountIncludingContractualInterest" xlink:to="mack_DebtInstrumentCarryingAmountIncludingContractualInterest_lbl" />
    <loc xlink:href="mack-20170630.xsd#mack_ContractualInterestIncludedInPayments" xlink:type="locator" xlink:label="mack_ContractualInterestIncludedInPayments" />
    <label xml:lang="en-US" xlink:label="mack_ContractualInterestIncludedInPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual interest included in gross contractual obligations that must be removed in order to reconcile to gross borrowings at the current reporting date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_ContractualInterestIncludedInPayments" xlink:to="mack_ContractualInterestIncludedInPayments_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remainder of 2017</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Two</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Three</label>
    <label xml:lang="en-US" xlink:label="mack_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 and thereafter</label>
    <label xml:lang="en-US" xlink:label="mack_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Four And Thereafter</label>
    <label xml:lang="en-US" xlink:label="mack_DebtInstrumentCarryingAmountIncludingContractualInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loans payable, gross including contractual interest</label>
    <label xml:lang="en-US" xlink:label="mack_DebtInstrumentCarryingAmountIncludingContractualInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Carrying Amount Including Contractual Interest</label>
    <label xml:lang="en-US" xlink:label="mack_ContractualInterestIncludedInPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less interest</label>
    <label xml:lang="en-US" xlink:label="mack_ContractualInterestIncludedInPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Interest Included In Payments</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less unamortized discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Unamortized Discount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Current</label>
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term debt</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</label>
    <loc xlink:href="mack-20170630.xsd#mack_StockIncentivePlan2011Member" xlink:type="locator" xlink:label="mack_StockIncentivePlan2011Member" />
    <label xml:lang="en-US" xlink:label="mack_StockIncentivePlan2011Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Detail of the plan under which options are granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_StockIncentivePlan2011Member" xlink:to="mack_StockIncentivePlan2011Member_lbl" />
    <label xml:lang="en-US" xlink:label="mack_StockIncentivePlan2011Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Incentive Plan 2011 [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_StockIncentivePlan2011Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Incentive Plan2011 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Relationship to Entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</label>
    <loc xlink:href="mack-20170630.xsd#mack_EmployeeMember" xlink:type="locator" xlink:label="mack_EmployeeMember" />
    <label xml:lang="en-US" xlink:label="mack_EmployeeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mack_EmployeeMember" xlink:to="mack_EmployeeMember_lbl" />
    <label xml:lang="en-US" xlink:label="mack_EmployeeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee [Member]</label>
    <label xml:lang="en-US" xlink:label="mack_EmployeeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock available for grant (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional common stock available for issuance (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</label>
    <label xml:lang="en-US" xlink:label="us-gaap_DividendPayableDateToBePaidDayMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend paid date</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Award</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to Purchase Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense for employee awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</label>
    <label xml:lang="en-US" xlink:label="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stock-based compensation expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Outstanding, Ending balance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price, Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price, Outstanding, Ending balance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value per share of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense related to nonvested stock awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average period over which unrecognized stock-based compensation expense is expected to be recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>23
<FILENAME>mack-20170630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2017-08-09T19:46:29.6535138+00:00 -->
<!-- Version            : 2.4.9.2 -->
<!-- Package ID         : A96D3A1EC002FD8DA16B9E2A7F952981-0001274792-001706 -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/role/TemplateLink" xlink:href="mack-20170630.xsd#TemplateLink" xlink:type="simple" />
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="mack-20170630.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DocumentDocumentAndEntityInformation">
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <loc xlink:href="mack-20170630.xsd#mack_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="mack_DocumentAndEntityInformationAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:href="mack-20170630.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:type="locator" xlink:label="us-gaap_MinorityInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" />
    <loc xlink:href="mack-20170630.xsd#mack_AccruedIntraperiodTaxAllocation" xlink:type="locator" xlink:label="mack_AccruedIntraperiodTaxAllocation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="mack_AccruedIntraperiodTaxAllocation" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="mack-20170630.xsd#Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="mack-20170630.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnSalesOfAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnSalesOfAssets" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ProfitLoss" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="12190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="12430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="12510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:to="us-gaap_NetIncomeLoss" order="12590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" order="12670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" order="12830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" order="12910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="12990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="13070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_CommonStockDividendsPerShareCashPaid" order="13150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:href="mack-20170630.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:type="locator" xlink:label="us-gaap_InterestPaid" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" />
    <loc xlink:href="mack-20170630.xsd#mack_ReceivablesFromStockOptionExercises" xlink:type="locator" xlink:label="mack_ReceivablesFromStockOptionExercises" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDividends" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="mack-20170630.xsd#mack_IncreaseDecreaseInDeferredRent" xlink:type="locator" xlink:label="mack_IncreaseDecreaseInDeferredRent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <loc xlink:href="mack-20170630.xsd#mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" xlink:type="locator" xlink:label="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <loc xlink:href="mack-20170630.xsd#mack_NonCashActivityRelatedToDiscontinuedOperations" xlink:type="locator" xlink:label="mack_NonCashActivityRelatedToDiscontinuedOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="mack-20170630.xsd#mack_SilverCreekPharmaceuticalsIncMember" xlink:type="locator" xlink:label="mack_SilverCreekPharmaceuticalsIncMember" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mack_SilverCreekPharmaceuticalsIncMember" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mack_NonCashActivityRelatedToDiscontinuedOperations" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="mack_IncreaseDecreaseInDeferredRent" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDividends" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_li0l2" order="12160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="12280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="mack_ReceivablesFromStockOptionExercises" order="12320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" order="12360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="12400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="12520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNatureOfBusiness" xlink:href="mack-20170630.xsd#Role_DisclosureNatureOfBusiness" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNatureOfBusiness">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBasisOfPresentationAndConsolidation" xlink:href="mack-20170630.xsd#Role_DisclosureBasisOfPresentationAndConsolidation" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBasisOfPresentationAndConsolidation">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusiness" xlink:href="mack-20170630.xsd#Role_DisclosureSaleOfCommercialBusiness" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusiness">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureGoingConcern" xlink:href="mack-20170630.xsd#Role_DisclosureGoingConcern" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureGoingConcern">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureIncomeTaxes" xlink:href="mack-20170630.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureIncomeTaxes">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShare" xlink:href="mack-20170630.xsd#Role_DisclosureNetIncomeLossPerCommonShare" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShare">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureFairValueOfFinancialInstruments" xlink:href="mack-20170630.xsd#Role_DisclosureFairValueOfFinancialInstruments" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureFairValueOfFinancialInstruments">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureMarketableSecurities" xlink:href="mack-20170630.xsd#Role_DisclosureMarketableSecurities" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureMarketableSecurities">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOther" xlink:href="mack-20170630.xsd#Role_DisclosureAccountsPayableAccruedExpensesAndOther" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOther">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowings" xlink:href="mack-20170630.xsd#Role_DisclosureBorrowings" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowings">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="mack-20170630.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensation">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureRecentAccountingPronouncements" xlink:href="mack-20170630.xsd#Role_DisclosureRecentAccountingPronouncements" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureRecentAccountingPronouncements">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSubsequentEvents" xlink:href="mack-20170630.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSubsequentEvents">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureRecentAccountingPronouncementsPolicies" xlink:href="mack-20170630.xsd#Role_DisclosureRecentAccountingPronouncementsPolicies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureRecentAccountingPronouncementsPolicies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBasisOfPresentationAndConsolidationTables" xlink:href="mack-20170630.xsd#Role_DisclosureBasisOfPresentationAndConsolidationTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBasisOfPresentationAndConsolidationTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessTables" xlink:href="mack-20170630.xsd#Role_DisclosureSaleOfCommercialBusinessTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShareTables" xlink:href="mack-20170630.xsd#Role_DisclosureNetIncomeLossPerCommonShareTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShareTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables" xlink:href="mack-20170630.xsd#Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherTables" xlink:href="mack-20170630.xsd#Role_DisclosureAccountsPayableAccruedExpensesAndOtherTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowingsTables" xlink:href="mack-20170630.xsd#Role_DisclosureBorrowingsTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowingsTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="mack-20170630.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <loc xlink:href="mack-20170630.xsd#mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:type="locator" xlink:label="mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:href="mack-20170630.xsd#Role_DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail">
    <loc xlink:href="mack-20170630.xsd#mack_NetMilestonePaymentsEntitledToReceiveAfterAssetSale" xlink:type="locator" xlink:label="mack_NetMilestonePaymentsEntitledToReceiveAfterAssetSale" />
    <loc xlink:href="mack-20170630.xsd#mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset" xlink:type="locator" xlink:label="mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset" />
    <loc xlink:href="mack-20170630.xsd#mack_AssetSaleFutureMilestonePayments" xlink:type="locator" xlink:label="mack_AssetSaleFutureMilestonePayments" />
    <loc xlink:href="mack-20170630.xsd#mack_AssetSaleUpfrontCashPayment" xlink:type="locator" xlink:label="mack_AssetSaleUpfrontCashPayment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <loc xlink:href="mack-20170630.xsd#mack_AssetPurchaseAndSaleAgreementMember" xlink:type="locator" xlink:label="mack_AssetPurchaseAndSaleAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_BaxaltaMember" xlink:type="locator" xlink:label="mack_BaxaltaMember" />
    <loc xlink:href="mack-20170630.xsd#mack_IpsenSAMember" xlink:type="locator" xlink:label="mack_IpsenSAMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mack_IpsenSAMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mack_BaxaltaMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mack_AssetPurchaseAndSaleAgreementMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mack_AssetSaleUpfrontCashPayment" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mack_AssetSaleFutureMilestonePayments" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mack_NetMilestonePaymentsEntitledToReceiveAfterAssetSale" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBasisOfPresentationAndConsolidationAdditionalInformationDetail" xlink:href="mack-20170630.xsd#Role_DisclosureBasisOfPresentationAndConsolidationAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBasisOfPresentationAndConsolidationAdditionalInformationDetail">
    <loc xlink:href="mack-20170630.xsd#mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents" xlink:type="locator" xlink:label="mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="mack-20170630.xsd#mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="mack_SummaryOfSignificantAccountingPoliciesLineItems" />
    <loc xlink:href="mack-20170630.xsd#mack_WarrantPurchaseAgreementsMember" xlink:type="locator" xlink:label="mack_WarrantPurchaseAgreementsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_SilverCreekPharmaceuticalsIncMember" xlink:type="locator" xlink:label="mack_SilverCreekPharmaceuticalsIncMember" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="mack_SummaryOfSignificantAccountingPoliciesTable" />
    <loc xlink:href="mack-20170630.xsd#mack_RegulatoryAssetsAbstract" xlink:type="locator" xlink:label="mack_RegulatoryAssetsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_RegulatoryAssetsAbstract" xlink:to="mack_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_SummaryOfSignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mack_SilverCreekPharmaceuticalsIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mack_WarrantPurchaseAgreementsMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_SummaryOfSignificantAccountingPoliciesTable" xlink:to="mack_SummaryOfSignificantAccountingPoliciesLineItems" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBasisOfPresentationAndConsolidationScheduleOfNonControllingInterestInSubsidiaryDetail" xlink:href="mack-20170630.xsd#Role_DisclosureBasisOfPresentationAndConsolidationScheduleOfNonControllingInterestInSubsidiaryDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBasisOfPresentationAndConsolidationScheduleOfNonControllingInterestInSubsidiaryDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:type="locator" xlink:label="us-gaap_MinorityInterest_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:type="locator" xlink:label="us-gaap_MinorityInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:type="locator" xlink:label="us-gaap_MinorityInterestLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestTable" xlink:type="locator" xlink:label="us-gaap_MinorityInterestTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_MinorityInterestTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestTable" xlink:to="us-gaap_MinorityInterestLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_MinorityInterest" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_MinorityInterest_li0l2" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessAdditionalInformationDetail" xlink:href="mack-20170630.xsd#Role_DisclosureSaleOfCommercialBusinessAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessAdditionalInformationDetail">
    <loc xlink:href="mack-20170630.xsd#mack_CollaborativeArrangementMaximumMilestonePaymentObligation" xlink:type="locator" xlink:label="mack_CollaborativeArrangementMaximumMilestonePaymentObligation" />
    <loc xlink:href="mack-20170630.xsd#mack_CollaborativeArrangementUpfrontPaymentObligation" xlink:type="locator" xlink:label="mack_CollaborativeArrangementUpfrontPaymentObligation" />
    <loc xlink:href="mack-20170630.xsd#mack_PotentialMilestonePaymentsReceivable" xlink:type="locator" xlink:label="mack_PotentialMilestonePaymentsReceivable" />
    <loc xlink:href="mack-20170630.xsd#mack_MaximumCollaborativeArrangementMilestonePayments" xlink:type="locator" xlink:label="mack_MaximumCollaborativeArrangementMilestonePayments" />
    <loc xlink:href="mack-20170630.xsd#mack_SeverancePaymentsPaymentPeriod" xlink:type="locator" xlink:label="mack_SeverancePaymentsPaymentPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDescription" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDescription" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <loc xlink:href="mack-20170630.xsd#mack_RestructuringAndRelatedCostNumberOfPositionsAfterHeadcountReduction" xlink:type="locator" xlink:label="mack_RestructuringAndRelatedCostNumberOfPositionsAfterHeadcountReduction" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesInitiationDate" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesInitiationDate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:type="locator" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:type="locator" xlink:label="us-gaap_DividendPayableDateToBePaidDayMonthAndYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsCommonStockCash" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStockCash" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xlink:type="locator" xlink:label="us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <loc xlink:href="mack-20170630.xsd#mack_AssetSaleSubleaseArea" xlink:type="locator" xlink:label="mack_AssetSaleSubleaseArea" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <loc xlink:href="mack-20170630.xsd#mack_PaymentOfMakeWholePremiumOfLongTermDebt" xlink:type="locator" xlink:label="mack_PaymentOfMakeWholePremiumOfLongTermDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <loc xlink:href="mack-20170630.xsd#mack_TransitionServicesAgreementPeriod" xlink:type="locator" xlink:label="mack_TransitionServicesAgreementPeriod" />
    <loc xlink:href="mack-20170630.xsd#mack_AssetSaleFutureMilestonePayments" xlink:type="locator" xlink:label="mack_AssetSaleFutureMilestonePayments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <loc xlink:href="mack-20170630.xsd#mack_PharmaEngineIncMember" xlink:type="locator" xlink:label="mack_PharmaEngineIncMember" />
    <loc xlink:href="mack-20170630.xsd#mack_SalesMilestonesMember" xlink:type="locator" xlink:label="mack_SalesMilestonesMember" />
    <loc xlink:href="mack-20170630.xsd#mack_DevelopmentAndRegulatoryMilestonesMember" xlink:type="locator" xlink:label="mack_DevelopmentAndRegulatoryMilestonesMember" />
    <loc xlink:href="mack-20170630.xsd#mack_ClinicalTrialsInLungCancerMember" xlink:type="locator" xlink:label="mack_ClinicalTrialsInLungCancerMember" />
    <loc xlink:href="mack-20170630.xsd#mack_SaleMilestoneInMajorNonEuropeanAndNonAsianCountryMember" xlink:type="locator" xlink:label="mack_SaleMilestoneInMajorNonEuropeanAndNonAsianCountryMember" />
    <loc xlink:href="mack-20170630.xsd#mack_SaleMilestoneInMajorEuropeanCountriesMember" xlink:type="locator" xlink:label="mack_SaleMilestoneInMajorEuropeanCountriesMember" />
    <loc xlink:href="mack-20170630.xsd#mack_DevelopmentAndCommercializationMilestonesMember" xlink:type="locator" xlink:label="mack_DevelopmentAndCommercializationMilestonesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember" xlink:type="locator" xlink:label="us-gaap_OneTimeTerminationBenefitsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractTerminationMember" xlink:type="locator" xlink:label="us-gaap_ContractTerminationMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember" xlink:type="locator" xlink:label="mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:type="locator" xlink:label="us-gaap_RestructuringPlanDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:type="locator" xlink:label="us-gaap_RestructuringPlanAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_SeniorNotesDueTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="mack_SeniorNotesDueTwoThousandTwentyTwoMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_OtherUnrelatedClinicalTrialsMember" xlink:type="locator" xlink:label="mack_OtherUnrelatedClinicalTrialsMember" />
    <loc xlink:href="mack-20170630.xsd#mack_ClinicalTrialsInSmallCellLungCancerMember" xlink:type="locator" xlink:label="mack_ClinicalTrialsInSmallCellLungCancerMember" />
    <loc xlink:href="mack-20170630.xsd#mack_ClinicalTrialsInPancreasAsFirstLineTreatmentMember" xlink:type="locator" xlink:label="mack_ClinicalTrialsInPancreasAsFirstLineTreatmentMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_AssetPurchaseAndSaleAgreementMember" xlink:type="locator" xlink:label="mack_AssetPurchaseAndSaleAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_IpsenSAMember" xlink:type="locator" xlink:label="mack_IpsenSAMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mack_IpsenSAMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mack_AssetPurchaseAndSaleAgreementMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="mack_ClinicalTrialsInPancreasAsFirstLineTreatmentMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="mack_ClinicalTrialsInSmallCellLungCancerMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="mack_OtherUnrelatedClinicalTrialsMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mack_SeniorNotesDueTwoThousandTwentyTwoMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ManufacturingFacilityMember" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_RestructuringPlanAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="10030.14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_OneTimeTerminationBenefitsMember" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" order="10030.16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="mack_DevelopmentAndCommercializationMilestonesMember" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="mack_SaleMilestoneInMajorEuropeanCountriesMember" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="mack_SaleMilestoneInMajorNonEuropeanAndNonAsianCountryMember" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="mack_ClinicalTrialsInLungCancerMember" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="mack_DevelopmentAndRegulatoryMilestonesMember" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="mack_SalesMilestonesMember" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mack_PharmaEngineIncMember" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_AssetSaleFutureMilestonePayments" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_TransitionServicesAgreementPeriod" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_PaymentOfMakeWholePremiumOfLongTermDebt" order="12130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_AssetSaleSubleaseArea" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="12240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DividendsCommonStockCash" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DividendPayableDateToBePaidDayMonthAndYear" order="12330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" order="12400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RestructuringAndRelatedActivitiesInitiationDate" order="12450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="12470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_RestructuringAndRelatedCostNumberOfPositionsAfterHeadcountReduction" order="12490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RestructuringCharges" order="12540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDescription" order="12580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_SeverancePaymentsPaymentPeriod" order="12620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_MaximumCollaborativeArrangementMilestonePayments" order="12730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_PotentialMilestonePaymentsReceivable" order="12750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_CollaborativeArrangementUpfrontPaymentObligation" order="12840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_CollaborativeArrangementMaximumMilestonePaymentObligation" order="12900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfDiscontinuedOperationsAndAssetsHeldForSaleDetail" xlink:href="mack-20170630.xsd#Role_DisclosureSaleOfCommercialBusinessScheduleOfDiscontinuedOperationsAndAssetsHeldForSaleDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfDiscontinuedOperationsAndAssetsHeldForSaleDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <loc xlink:href="mack-20170630.xsd#mack_CommercialBusinessMember" xlink:type="locator" xlink:label="mack_CommercialBusinessMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="mack_CommercialBusinessMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract" xlink:to="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfCarryingValueOfAssetsAndLiabilitiesClassifiedAsAssetsHeldForSaleRelatesToCommercialBusinessDetail" xlink:href="mack-20170630.xsd#Role_DisclosureSaleOfCommercialBusinessScheduleOfCarryingValueOfAssetsAndLiabilitiesClassifiedAsAssetsHeldForSaleRelatesToCommercialBusinessDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfCarryingValueOfAssetsAndLiabilitiesClassifiedAsAssetsHeldForSaleRelatesToCommercialBusinessDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" />
    <loc xlink:href="mack-20170630.xsd#mack_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent" xlink:type="locator" xlink:label="mack_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <loc xlink:href="mack-20170630.xsd#mack_CommercialBusinessMember" xlink:type="locator" xlink:label="mack_CommercialBusinessMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="mack_CommercialBusinessMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="mack_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfInventoryOfCommercialBusinessDetail" xlink:href="mack-20170630.xsd#Role_DisclosureSaleOfCommercialBusinessScheduleOfInventoryOfCommercialBusinessDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfInventoryOfCommercialBusinessDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryLineItems" xlink:type="locator" xlink:label="us-gaap_InventoryLineItems" />
    <loc xlink:href="mack-20170630.xsd#mack_CommercialBusinessMember" xlink:type="locator" xlink:label="mack_CommercialBusinessMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:type="locator" xlink:label="us-gaap_InventoryCurrentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryCurrentTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="mack_CommercialBusinessMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryLineItems" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryRawMaterials" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryWorkInProcess" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryFinishedGoods" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryNet" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessSummaryOfChargesRelatedToRestructuringActivitiesDetail" xlink:href="mack-20170630.xsd#Role_DisclosureSaleOfCommercialBusinessSummaryOfChargesRelatedToRestructuringActivitiesDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessSummaryOfChargesRelatedToRestructuringActivitiesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:type="locator" xlink:label="us-gaap_RestructuringReserveCurrent_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:type="locator" xlink:label="us-gaap_PaymentsForRestructuring" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:type="locator" xlink:label="us-gaap_RestructuringReserveCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:type="locator" xlink:label="us-gaap_EmployeeSeveranceMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_CommercialBusinessMember" xlink:type="locator" xlink:label="mack_CommercialBusinessMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="mack_CommercialBusinessMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserveCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserveCurrent_li0l2" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureGoingConcernAdditionalInformationDetail" xlink:href="mack-20170630.xsd#Role_DisclosureGoingConcernAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureGoingConcernAdditionalInformationDetail">
    <loc xlink:href="mack-20170630.xsd#mack_PaymentOfMakeWholePremiumOfLongTermDebt" xlink:type="locator" xlink:label="mack_PaymentOfMakeWholePremiumOfLongTermDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EscrowDeposit" xlink:type="locator" xlink:label="us-gaap_EscrowDeposit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:type="locator" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:type="locator" xlink:label="us-gaap_DividendPayableDateToBePaidDayMonthAndYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsCommonStockCash" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStockCash" />
    <loc xlink:href="mack-20170630.xsd#mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset" xlink:type="locator" xlink:label="mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset" />
    <loc xlink:href="mack-20170630.xsd#mack_AssetSaleUpfrontCashPaymentReceived" xlink:type="locator" xlink:label="mack_AssetSaleUpfrontCashPaymentReceived" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <loc xlink:href="mack-20170630.xsd#mack_SeniorNotesDueTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="mack_SeniorNotesDueTwoThousandTwentyTwoMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_AssetPurchaseAndSaleAgreementMember" xlink:type="locator" xlink:label="mack_AssetPurchaseAndSaleAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_IpsenSAMember" xlink:type="locator" xlink:label="mack_IpsenSAMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mack_IpsenSAMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mack_AssetPurchaseAndSaleAgreementMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mack_SeniorNotesDueTwoThousandTwentyTwoMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mack_AssetSaleUpfrontCashPaymentReceived" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DividendsCommonStockCash" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DividendPayableDateToBePaidDayMonthAndYear" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EscrowDeposit" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mack_PaymentOfMakeWholePremiumOfLongTermDebt" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="mack-20170630.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <loc xlink:href="mack-20170630.xsd#mack_DiscontinuedOperationValuationAllowanceFromDisposalOfDiscontinuedOperation" xlink:type="locator" xlink:label="mack_DiscontinuedOperationValuationAllowanceFromDisposalOfDiscontinuedOperation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" />
    <loc xlink:href="mack-20170630.xsd#mack_AccruedIntraperiodTaxAllocation" xlink:type="locator" xlink:label="mack_AccruedIntraperiodTaxAllocation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="mack_AccruedIntraperiodTaxAllocation" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="mack_DiscontinuedOperationValuationAllowanceFromDisposalOfDiscontinuedOperation" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShareAdditionalInformationDetail" xlink:href="mack-20170630.xsd#Role_DisclosureNetIncomeLossPerCommonShareAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShareAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <loc xlink:href="mack-20170630.xsd#mack_ParticipatingSecuritiesOutstandingShares" xlink:type="locator" xlink:label="mack_ParticipatingSecuritiesOutstandingShares" />
    <loc xlink:href="mack-20170630.xsd#mack_UndistributedEarningsLossAllocatedToParticipatingSecurities" xlink:type="locator" xlink:label="mack_UndistributedEarningsLossAllocatedToParticipatingSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="mack_UndistributedEarningsLossAllocatedToParticipatingSecurities" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="mack_ParticipatingSecuritiesOutstandingShares" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_LongTermDebt" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedLossPerShareDetail" xlink:href="mack-20170630.xsd#Role_DisclosureNetIncomeLossPerCommonShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedLossPerShareDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedLossPerShareDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="mack-20170630.xsd#Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <loc xlink:href="mack-20170630.xsd#mack_WarrantLiabilityMember" xlink:type="locator" xlink:label="mack_WarrantLiabilityMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_SilverCreekPharmaceuticalsIncMember" xlink:type="locator" xlink:label="mack_SilverCreekPharmaceuticalsIncMember" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="dei_LegalEntityAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mack_SilverCreekPharmaceuticalsIncMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="mack_WarrantLiabilityMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail" xlink:href="mack-20170630.xsd#Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:type="locator" xlink:label="us-gaap_LongTermDebtFairValue" />
    <loc xlink:href="mack-20170630.xsd#mack_FairValueInstrumentsTransfersBetweenLevels" xlink:type="locator" xlink:label="mack_FairValueInstrumentsTransfersBetweenLevels" />
    <loc xlink:href="mack-20170630.xsd#mack_FairValueAdjustmentOfWarrantsIncrementalChangeResultingFromAmendment" xlink:type="locator" xlink:label="mack_FairValueAdjustmentOfWarrantsIncrementalChangeResultingFromAmendment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <loc xlink:href="mack-20170630.xsd#mack_SeniorNotesDueTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="mack_SeniorNotesDueTwoThousandTwentyTwoMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeniorNotesMember" xlink:type="locator" xlink:label="us-gaap_SeniorNotesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_SilverCreekPharmaceuticalsIncMember" xlink:type="locator" xlink:label="mack_SilverCreekPharmaceuticalsIncMember_li0l2" />
    <loc xlink:href="mack-20170630.xsd#mack_SilverCreekPharmaceuticalsIncMember" xlink:type="locator" xlink:label="mack_SilverCreekPharmaceuticalsIncMember" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mack_SilverCreekPharmaceuticalsIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mack_SilverCreekPharmaceuticalsIncMember_li0l2" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SeniorNotesMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mack_SeniorNotesDueTwoThousandTwentyTwoMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="mack_FairValueAdjustmentOfWarrantsIncrementalChangeResultingFromAmendment" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="mack_FairValueInstrumentsTransfersBetweenLevels" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_LongTermDebtFairValue" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_LongTermDebt" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail" xlink:href="mack-20170630.xsd#Role_DisclosureMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:type="locator" xlink:label="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" />
    <loc xlink:href="mack-20170630.xsd#mack_AmortizedCostAndFairValueDebtSecuritiesAbstract" xlink:type="locator" xlink:label="mack_AmortizedCostAndFairValueDebtSecuritiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_AmortizedCostAndFairValueDebtSecuritiesAbstract" xlink:to="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_AmortizedCostAndFairValueDebtSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail" xlink:href="mack-20170630.xsd#Role_DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" />
    <loc xlink:href="mack-20170630.xsd#mack_WarrantLiabilityCurrent" xlink:type="locator" xlink:label="mack_WarrantLiabilityCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_DividendsPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:type="locator" xlink:label="us-gaap_RestructuringReserveCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:href="mack-20170630.xsd#mack_AccruedDrugPurchaseCostsCurrent" xlink:type="locator" xlink:label="mack_AccruedDrugPurchaseCostsCurrent" />
    <loc xlink:href="mack-20170630.xsd#mack_AccruedClinicalTrialCosts" xlink:type="locator" xlink:label="mack_AccruedClinicalTrialCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <loc xlink:href="mack-20170630.xsd#mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:type="locator" xlink:label="mack_AccountsPayableAndAccruedLiabilitiesLineItems" />
    <loc xlink:href="mack-20170630.xsd#mack_SilverCreekPharmaceuticalsIncMember" xlink:type="locator" xlink:label="mack_SilverCreekPharmaceuticalsIncMember" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_AccountsPayableAndAccruedLiabilitiesTable" xlink:type="locator" xlink:label="mack_AccountsPayableAndAccruedLiabilitiesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="mack_AccountsPayableAndAccruedLiabilitiesTable" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesTable" xlink:to="dei_LegalEntityAxis" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mack_SilverCreekPharmaceuticalsIncMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesTable" xlink:to="mack_AccountsPayableAndAccruedLiabilitiesLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_AccountsPayableCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="mack_AccruedClinicalTrialCosts" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="mack_AccruedDrugPurchaseCostsCurrent" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_RestructuringReserveCurrent" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_InterestPayableCurrent" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_DividendsPayableCurrent" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="mack_WarrantLiabilityCurrent" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowings2022NotesAdditionalInformationDetail" xlink:href="mack-20170630.xsd#Role_DisclosureBorrowings2022NotesAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowings2022NotesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <loc xlink:href="mack-20170630.xsd#mack_ScheduleOfDebtInstrumentsLineItems" xlink:type="locator" xlink:label="mack_ScheduleOfDebtInstrumentsLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseMember" xlink:type="locator" xlink:label="us-gaap_InterestExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_SeniorNotesDueTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="mack_SeniorNotesDueTwoThousandTwentyTwoMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_ScheduleOfDebtInstrumentsTable" xlink:type="locator" xlink:label="mack_ScheduleOfDebtInstrumentsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="mack_ScheduleOfDebtInstrumentsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_ScheduleOfDebtInstrumentsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="mack_SeniorNotesDueTwoThousandTwentyTwoMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_ScheduleOfDebtInstrumentsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_InterestExpenseMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_ScheduleOfDebtInstrumentsTable" xlink:to="mack_ScheduleOfDebtInstrumentsLineItems" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_ScheduleOfDebtInstrumentsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_ScheduleOfDebtInstrumentsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_ScheduleOfDebtInstrumentsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_ScheduleOfDebtInstrumentsLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_ScheduleOfDebtInstrumentsLineItems" xlink:to="us-gaap_InterestExpense" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_ScheduleOfDebtInstrumentsLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mack_ScheduleOfDebtInstrumentsLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowingsConvertibleNotesAdditionalInformationDetail" xlink:href="mack-20170630.xsd#Role_DisclosureBorrowingsConvertibleNotesAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowingsConvertibleNotesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EscrowDeposit" xlink:type="locator" xlink:label="us-gaap_EscrowDeposit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <loc xlink:href="mack-20170630.xsd#mack_ConvertibilityOfDebtDebtPriceTestPercentageOfClosingStockPriceUsedInCalculation" xlink:type="locator" xlink:label="mack_ConvertibilityOfDebtDebtPriceTestPercentageOfClosingStockPriceUsedInCalculation" />
    <loc xlink:href="mack-20170630.xsd#mack_DebtInstrumentConversionObligationPeriodOfConsecutiveTrading" xlink:type="locator" xlink:label="mack_DebtInstrumentConversionObligationPeriodOfConsecutiveTrading" />
    <loc xlink:href="mack-20170630.xsd#mack_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessPeriodAfterConsecutiveTradingTerm" xlink:type="locator" xlink:label="mack_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessPeriodAfterConsecutiveTradingTerm" />
    <loc xlink:href="mack-20170630.xsd#mack_ConvertibilityOfDebtStockPriceTestTargetPercentageOfClosingStockPriceToConversionPriceThatMustBeExceeded" xlink:type="locator" xlink:label="mack_ConvertibilityOfDebtStockPriceTestTargetPercentageOfClosingStockPriceToConversionPriceThatMustBeExceeded" />
    <loc xlink:href="mack-20170630.xsd#mack_DebtInstrumentConversionObligationNumberOfConsecutiveTradingTerm" xlink:type="locator" xlink:label="mack_DebtInstrumentConversionObligationNumberOfConsecutiveTradingTerm" />
    <loc xlink:href="mack-20170630.xsd#mack_DebtInstrumentConversionObligationCommonStockClosingSalesPriceTradingPeriod" xlink:type="locator" xlink:label="mack_DebtInstrumentConversionObligationCommonStockClosingSalesPriceTradingPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <loc xlink:href="mack-20170630.xsd#mack_DecreaseToAdditionalPaidInCapitalDueToConversionTransactionCost" xlink:type="locator" xlink:label="mack_DecreaseToAdditionalPaidInCapitalDueToConversionTransactionCost" />
    <loc xlink:href="mack-20170630.xsd#mack_DebtConversionCostsIncurredAndPaid" xlink:type="locator" xlink:label="mack_DebtConversionCostsIncurredAndPaid" />
    <loc xlink:href="mack-20170630.xsd#mack_ReductionInAdditionalPaidInCapitalAttributableToEmbeddedConversionOption" xlink:type="locator" xlink:label="mack_ReductionInAdditionalPaidInCapitalAttributableToEmbeddedConversionOption" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <loc xlink:href="mack-20170630.xsd#mack_IncreaseToAdditionalPaidInCapitalDueToConversion" xlink:type="locator" xlink:label="mack_IncreaseToAdditionalPaidInCapitalDueToConversion" />
    <loc xlink:href="mack-20170630.xsd#mack_TradingPeriodOfCommonStock" xlink:type="locator" xlink:label="mack_TradingPeriodOfCommonStock" />
    <loc xlink:href="mack-20170630.xsd#mack_ValueOfAdditionalSharesIssuedForConversion" xlink:type="locator" xlink:label="mack_ValueOfAdditionalSharesIssuedForConversion" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" />
    <loc xlink:href="mack-20170630.xsd#mack_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" xlink:type="locator" xlink:label="mack_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <loc xlink:href="mack-20170630.xsd#mack_DebtIssuanceCostsUnderwritingDiscountsCommissionsAndOfferingExpenses" xlink:type="locator" xlink:label="mack_DebtIssuanceCostsUnderwritingDiscountsCommissionsAndOfferingExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_TransactionCostsIncurredWithThirdPartiesMember" xlink:type="locator" xlink:label="mack_TransactionCostsIncurredWithThirdPartiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseMember" xlink:type="locator" xlink:label="us-gaap_InterestExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_InterestExpenseMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mack_TransactionCostsIncurredWithThirdPartiesMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_DebtIssuanceCostsUnderwritingDiscountsCommissionsAndOfferingExpenses" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_ValueOfAdditionalSharesIssuedForConversion" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_TradingPeriodOfCommonStock" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_IncreaseToAdditionalPaidInCapitalDueToConversion" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_ReductionInAdditionalPaidInCapitalAttributableToEmbeddedConversionOption" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_DebtConversionCostsIncurredAndPaid" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_DecreaseToAdditionalPaidInCapitalDueToConversionTransactionCost" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_DebtInstrumentConversionObligationCommonStockClosingSalesPriceTradingPeriod" order="12160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_DebtInstrumentConversionObligationNumberOfConsecutiveTradingTerm" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_ConvertibilityOfDebtStockPriceTestTargetPercentageOfClosingStockPriceToConversionPriceThatMustBeExceeded" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessPeriodAfterConsecutiveTradingTerm" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_DebtInstrumentConversionObligationPeriodOfConsecutiveTrading" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_ConvertibilityOfDebtDebtPriceTestPercentageOfClosingStockPriceUsedInCalculation" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="12440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_EscrowDeposit" order="12510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpense" order="12560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowingsScheduleOfFutureMinimumPaymentsUnderLoansPayableDetail" xlink:href="mack-20170630.xsd#Role_DisclosureBorrowingsScheduleOfFutureMinimumPaymentsUnderLoansPayableDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowingsScheduleOfFutureMinimumPaymentsUnderLoansPayableDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <loc xlink:href="mack-20170630.xsd#mack_ContractualInterestIncludedInPayments" xlink:type="locator" xlink:label="mack_ContractualInterestIncludedInPayments" />
    <loc xlink:href="mack-20170630.xsd#mack_DebtInstrumentCarryingAmountIncludingContractualInterest" xlink:type="locator" xlink:label="mack_DebtInstrumentCarryingAmountIncludingContractualInterest" />
    <loc xlink:href="mack-20170630.xsd#mack_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" xlink:type="locator" xlink:label="mack_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_DebtInstrumentCarryingAmountIncludingContractualInterest" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="mack_ContractualInterestIncludedInPayments" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="mack-20170630.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:type="locator" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:type="locator" xlink:label="us-gaap_DividendPayableDateToBePaidDayMonthAndYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsCommonStockCash" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStockCash" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="mack-20170630.xsd#mack_EmployeeMember" xlink:type="locator" xlink:label="mack_EmployeeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_StockIncentivePlan2011Member" xlink:type="locator" xlink:label="mack_StockIncentivePlan2011Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mack_StockIncentivePlan2011Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mack_EmployeeMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DividendsCommonStockCash" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DividendPayableDateToBePaidDayMonthAndYear" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail" xlink:href="mack-20170630.xsd#Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail" xlink:href="mack-20170630.xsd#Role_DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail">
    <loc xlink:href="mack-20170630.xsd#mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" xlink:type="locator" xlink:label="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" xlink:href="mack-20170630.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="mack-20170630.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
    <loc xlink:href="mack-20170630.xsd#mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents" xlink:type="locator" xlink:label="mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="mack-20170630.xsd#mack_SilverCreekPharmaceuticalsIncMember" xlink:type="locator" xlink:label="mack_SilverCreekPharmaceuticalsIncMember" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mack_SilverCreekPharmaceuticalsIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771718000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Aug. 08, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MACK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MERRIMACK PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001274792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,793,256<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772281280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 135,501<span></span>
</td>
<td class="nump">$ 21,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,917<span></span>
</td>
<td class="nump">2,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,295<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">141,563<span></span>
</td>
<td class="nump">57,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">60,682<span></span>
</td>
<td class="nump">674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">11,178<span></span>
</td>
<td class="nump">14,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Assets held for sale, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,135<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">213,450<span></span>
</td>
<td class="nump">81,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable, accrued expenses and other</a></td>
<td class="nump">33,989<span></span>
</td>
<td class="nump">29,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">2,077<span></span>
</td>
<td class="nump">2,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AccruedIntraperiodTaxAllocation', window );">Accrued intraperiod tax allocation</a></td>
<td class="nump">13,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">8,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Liabilities held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,839<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">57,737<span></span>
</td>
<td class="nump">88,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">2,330<span></span>
</td>
<td class="nump">3,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">48,906<span></span>
</td>
<td class="nump">216,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Liabilities held for sale, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,673<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">108,973<span></span>
</td>
<td class="nump">334,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="num">(2,031)<span></span>
</td>
<td class="num">(1,539)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity/(deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value: 10,000 shares authorized at June 30, 2017 and December 31, 2016; no shares issued or outstanding at June 30, 2017 or December 31, 2016</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value: 200,000 shares authorized at June 30, 2017 and December 31, 2016; 132,741 and 130,197 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively</a></td>
<td class="nump">1,327<span></span>
</td>
<td class="nump">1,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">578,103<span></span>
</td>
<td class="nump">702,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated (deficit)</a></td>
<td class="num">(472,922)<span></span>
</td>
<td class="num">(954,799)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity/(deficit)</a></td>
<td class="nump">106,508<span></span>
</td>
<td class="num">(251,120)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, non-controlling interest and stockholders&#8217; equity/(deficit)</a></td>
<td class="nump">$ 213,450<span></span>
</td>
<td class="nump">$ 81,483<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_AccruedIntraperiodTaxAllocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued intraperiod tax allocation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_AccruedIntraperiodTaxAllocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2510-110228<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2510-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6931203856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">132,741,000<span></span>
</td>
<td class="nump">130,197,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">132,741,000<span></span>
</td>
<td class="nump">130,197,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773059040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 19,751<span></span>
</td>
<td class="nump">$ 27,695<span></span>
</td>
<td class="nump">$ 41,356<span></span>
</td>
<td class="nump">$ 55,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">14,798<span></span>
</td>
<td class="nump">8,138<span></span>
</td>
<td class="nump">20,432<span></span>
</td>
<td class="nump">14,590<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">34,549<span></span>
</td>
<td class="nump">35,833<span></span>
</td>
<td class="nump">61,788<span></span>
</td>
<td class="nump">70,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from continuing operations</a></td>
<td class="num">(34,549)<span></span>
</td>
<td class="num">(35,833)<span></span>
</td>
<td class="num">(61,788)<span></span>
</td>
<td class="num">(70,287)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">382<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">396<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(26,762)<span></span>
</td>
<td class="num">(15,858)<span></span>
</td>
<td class="num">(28,741)<span></span>
</td>
<td class="num">(19,148)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnSalesOfAssets', window );">Gain on sale of asset</a></td>
<td class="nump">1,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(659)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="num">(661)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss from continuing operations before income tax benefit</a></td>
<td class="num">(59,885)<span></span>
</td>
<td class="num">(51,633)<span></span>
</td>
<td class="num">(89,091)<span></span>
</td>
<td class="num">(89,348)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">30,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net loss from continuing operations</a></td>
<td class="num">(29,646)<span></span>
</td>
<td class="num">(51,633)<span></span>
</td>
<td class="num">(58,852)<span></span>
</td>
<td class="num">(89,348)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract', window );"><strong>Discontinued operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income (loss) from discontinued operations, net of tax</a></td>
<td class="nump">540,485<span></span>
</td>
<td class="nump">675<span></span>
</td>
<td class="nump">539,538<span></span>
</td>
<td class="num">(268)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">510,839<span></span>
</td>
<td class="num">(50,958)<span></span>
</td>
<td class="nump">480,686<span></span>
</td>
<td class="num">(89,616)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">(724)<span></span>
</td>
<td class="num">(208)<span></span>
</td>
<td class="num">(1,191)<span></span>
</td>
<td class="num">(393)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Merrimack Pharmaceuticals, Inc.</a></td>
<td class="nump">511,563<span></span>
</td>
<td class="num">(50,750)<span></span>
</td>
<td class="nump">481,877<span></span>
</td>
<td class="num">(89,223)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">511,563<span></span>
</td>
<td class="num">(50,735)<span></span>
</td>
<td class="nump">481,877<span></span>
</td>
<td class="num">(89,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract', window );"><strong>Amounts attributable to Merrimack Pharmaceuticals, Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss from continuing operations</a></td>
<td class="num">(28,922)<span></span>
</td>
<td class="num">(51,425)<span></span>
</td>
<td class="num">(57,661)<span></span>
</td>
<td class="num">(88,955)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income (loss) from discontinued operations, net of tax</a></td>
<td class="nump">540,485<span></span>
</td>
<td class="nump">675<span></span>
</td>
<td class="nump">539,538<span></span>
</td>
<td class="num">(268)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Merrimack Pharmaceuticals, Inc.</a></td>
<td class="nump">$ 511,563<span></span>
</td>
<td class="num">$ (50,750)<span></span>
</td>
<td class="nump">$ 481,877<span></span>
</td>
<td class="num">$ (89,223)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Basic and dilutive net income (loss) per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Net loss from continuing operations</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare', window );">Net income (loss) from discontinued operations, net of tax</a></td>
<td class="nump">4.08<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="nump">4.10<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net income (loss) per share</a></td>
<td class="nump">$ 3.86<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares used per share calculations&#8212;basic and diluted</a></td>
<td class="nump">132,457<span></span>
</td>
<td class="nump">126,161<span></span>
</td>
<td class="nump">131,528<span></span>
</td>
<td class="nump">121,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Cash dividend paid per common share</a></td>
<td class="nump">$ 1.055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e557-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnSalesOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnSalesOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4613673-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation, when the per share amount is the same.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569643-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772206368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 480,686<span></span>
</td>
<td class="num">$ (89,616)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income (loss) from discontinued operations</a></td>
<td class="nump">539,538<span></span>
</td>
<td class="num">(268)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Loss from continuing operations</a></td>
<td class="num">(58,852)<span></span>
</td>
<td class="num">(89,348)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">2,374<span></span>
</td>
<td class="nump">3,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">4,887<span></span>
</td>
<td class="nump">14,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation', window );">Benefit from intraperiod tax allocation</a></td>
<td class="num">(30,239)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">2,058<span></span>
</td>
<td class="nump">2,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_NonCashActivityRelatedToDiscontinuedOperations', window );">Non-cash activity related to discontinued operations</a></td>
<td class="nump">15,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Gain) loss on sale of property and equipment</a></td>
<td class="num">(512)<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees', window );">Stock-based compensation expense</a></td>
<td class="nump">9,529<span></span>
</td>
<td class="nump">6,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Accounts receivable</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(4,022)<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="nump">8,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and other</a></td>
<td class="nump">2,494<span></span>
</td>
<td class="num">(8,454)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
<td class="num">(209)<span></span>
</td>
<td class="nump">579<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in continuing operations for operating activities</a></td>
<td class="num">(49,094)<span></span>
</td>
<td class="num">(69,898)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash used in discontinuing operations for operating activities</a></td>
<td class="num">(46,416)<span></span>
</td>
<td class="num">(34,528)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(95,510)<span></span>
</td>
<td class="num">(104,426)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(287)<span></span>
</td>
<td class="num">(2,050)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales of available for sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds on sale of property and equipment</a></td>
<td class="nump">1,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of available for sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,262)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets', window );">Proceeds from sale of business</a></td>
<td class="nump">575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Changes in restricted cash</a></td>
<td class="num">(60,008)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">515,809<span></span>
</td>
<td class="num">(63,312)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options to purchase common stock</a></td>
<td class="nump">6,079<span></span>
</td>
<td class="nump">2,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt</a></td>
<td class="num">(175,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payment of dividend</a></td>
<td class="num">(140,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of Silver Creek convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(306,322)<span></span>
</td>
<td class="nump">3,623<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">113,977<span></span>
</td>
<td class="num">(164,115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">21,524<span></span>
</td>
<td class="nump">185,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">135,501<span></span>
</td>
<td class="nump">21,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment in accounts payable, accrued expenses and other</a></td>
<td class="nump">349<span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_ReceivablesFromStockOptionExercises', window );">Receivables related to stock option exercises in prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1', window );">Receivables related to property and equipment sale in other current assets</a></td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible debt into shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flows</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="nump">28,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember', window );">Silver Creek Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of Series C preferred stock by Silver Creek Inc., net of issuance costs</a></td>
<td class="nump">2,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and nonemployees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_NonCashActivityRelatedToDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash activity related to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_NonCashActivityRelatedToDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_ReceivablesFromStockOptionExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents receivable amounts related to amounts owed for stock options exercises that have not been settled as of period end.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_ReceivablesFromStockOptionExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) for continuing operations, discontinued operations, other comprehensive income, and items charged (credited) directly to shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507043&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest. Includes, but is not limited to, payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762881120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of the Business</a></td>
<td class="text"><div>

<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of the Business</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Merrimack Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. The Company&#8217;s mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers. All of the Company&#8217;s product candidates, including three in clinical studies and several others in preclinical development, fit into the Company&#8217;s strategy of (1) understanding the biological problems the Company is trying to solve, (2) designing specific solutions and (3) developing those solutions for biomarker-selected patients. This three-pronged strategy seeks to ensure optimal patient outcomes. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 3, 2017,<font style="font-weight:bold;"> </font>the Company completed the previously announced transaction (the &#8220;Asset Sale&#8221;) with Ipsen S.A. (&#8220;Ipsen&#8221;). Pursuant to the Asset Purchase and Sale Agreement, dated as of January&#160;7, 2017 (the &#8220;Asset Sale Agreement&#8221;), between the Company and Ipsen, the Company sold to Ipsen its right, title and interest in the non-cash assets, equipment, inventory, contracts and intellectual property primarily related to or used in the Company&#8217;s business operations and activities involving or relating to developing, manufacturing and commercializing ONIVYDE, the Company&#8217;s first commercial product, and MM-436 (the &#8220;Commercial Business&#8221;). The Company received $575.0 million in cash, subject to a working capital adjustment, and is eligible to receive up to $450.0 million in additional regulatory approval-based milestone payments. The working capital adjustment is currently estimated as a $2.2 million receivable presented in prepaid expenses and other currents assets within the condensed consolidated balance sheets, which is expected to be received in the third quarter of 2017. The Company also retained the right to receive net milestone payments of up to $33.0 million that may become payable pursuant to the license and collaboration agreement with Baxalta Incorporated, Baxalta US Inc. and Baxalta GmbH (collectively, &#8220;Baxalta&#8221;) for the ex-U.S. development and commercialization of ONIVYDE. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s non-commercial assets, including its clinical and preclinical development programs (the &#8220;Pipeline Business&#8221;), were not included in the Asset Sale and remain assets of the Company. As of the closing of the Asset Sale, the Company&#8217;s most advanced programs are as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MM-121 (seribantumab), a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. The Company is currently conducting the Phase 2 randomized SHERLOC clinical trial evaluating MM-121 in heregulin positive non-small cell lung cancer patients and plans to initiate the Phase 2 randomized SHERBOC clinical trial in 2017 in heregulin positive, hormone receptor positive, ErbB2 (HER2) negative, metastatic breast cancer patients;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MM-141 (istiratumab), a fully human bispecific tetravalent monoclonal antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1 (&#8220;IGF-1&#8221;) receptor and ErbB3 (HER3) cell surface receptors. The Company is currently conducting the Phase 2 randomized CARRIE clinical trial evaluating MM-141 in previously untreated metastatic pancreatic cancer patients with high levels of free IGF-1 in combination with nab-paclitaxel and gemcitabine; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MM-310, an antibody-directed nanotherapeutic (&#8220;ADN&#8221;) that contains a novel prodrug of the highly potent chemotherapy docetaxel and targets the ephrin receptor A2 (&#8220;EphA2&#8221;) receptor, which is highly expressed in most solid tumor types. MM-310 was designed to improve the therapeutic window of docetaxel in major oncology indications, such as prostate, ovarian, bladder, gastric, pancreatic and lung cancers. The Company initiated a Phase 1 clinical trial to evaluate safety and preliminary activity of MM-310 in the first quarter of 2017.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to its clinical-stage programs, the Company has several product candidates in preclinical development and a discovery effort advancing additional candidate medicines.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to companies in the biopharmaceutical industry, including, among other things, its ability to secure additional capital to fund operations, success of clinical trials, development by competitors of new technological innovations, dependence on collaborative arrangements, protection of proprietary technology, compliance with government regulations and dependence on key personnel. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of capital, adequate personnel, infrastructure and extensive compliance reporting capabilities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. Until such time, if ever, as the Company can generate sufficient product revenues, the Company expects to finance its cash needs through a combination of equity offerings, debt financings, collaborations, licensing arrangements and other marketing and distribution arrangements. The Company could also engage in discussions with third parties regarding partnerships, joint ventures, combinations or divestitures of one or more of its businesses as it seeks to further the development of its research programs, improve its cash position and maximize stockholder value.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6910169584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Consolidation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><div>

<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Basis of Presentation and Consolidation</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The accompanying condensed consolidated financial statements as of June&#160;30, 2017 and December&#160;31, 2016, and for the three and six months ended June&#160;30, 2017 and 2016, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) and generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) for condensed consolidated financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, these condensed consolidated financial statements reflect all adjustments which are necessary for a fair statement of the Company&#8217;s financial position and results of its operations, as of and for the periods presented. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2016 filed with the SEC on March 1, 2017.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information presented in the condensed consolidated financial statements and related notes as of June&#160;30, 2017, and for the three and six months ended June&#160;30, 2017 and 2016, is unaudited. The December&#160;31, 2016 condensed consolidated balance sheets included herein were derived from the audited financial statements as of that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interim results for the three and six months ended June&#160;30, 2017 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2017, or any future period.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2017, the Commercial Business met all the conditions to be classified as a discontinued operation since the disposal of the Commercial Business represented a strategic shift that will have a major effect on the Company&#8217;s operations and financial results. The Company will not have further significant involvement in the operations of the discontinued Commercial Business. The operating results of the Commercial Business are reported as a loss from discontinued operations, net of tax in the condensed consolidated statements of operations and comprehensive income (loss) for all periods presented. The gain recognized on the sale of the Commercial Business is presented in income (loss) from discontinued operations, net of tax in the consolidated statement of operations and comprehensive income (loss). In addition, in the condensed consolidated balance sheets as of December 31, 2016, the assets and liabilities held for sale have been presented separately. For additional information, see Note 3, &#8220;Sale of Commercial Business.&#8221;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These condensed consolidated financial statements include the accounts of the Company and Silver Creek Pharmaceuticals, Inc. (&#8220;Silver Creek&#8221;), representing a variable interest entity that the Company is required to consolidate. All intercompany transactions and balances have been eliminated in consolidation.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2017, the Company&#8217;s unrestricted cash and cash equivalents includes $2.6 million of cash and cash equivalents held by Silver Creek. This $2.6 million held by Silver Creek is designated for the operations of Silver Creek.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the first quarter of 2017, Silver Creek entered into a Series C preferred stock financing, issuing 1.4 million shares of Series C preferred stock at $1.50 per share for proceeds of $2.0 million. In conjunction with this sale in the first quarter of 2017, Silver Creek also issued warrants to purchase 1.8 million shares of Silver Creek Series C preferred stock to investors. In the second quarter of 2017, Silver Creek issued 0.4 million shares of Series C preferred stock at $1.50 per share for proceeds of $0.6 million. In conjunction with this sale in the second quarter of 2017, Silver Creek issued warrants to purchase 0.3 million shares of Silver Creek Series C preferred stock to investors. In June 2017, Silver Creek amended the warrant purchase agreements to increase the number of shares for which each warrant is redeemable. The incremental increase in the number of shares the warrants may be redeemed for as a result of the amendment was 1.3 million shares. As of June 30, 2017, the Company held a 51% ownership interest in Silver Creek and maintained control over the Silver Creek Board of Directors through its voting rights. As such, the Company remains the primary beneficiary of Silver Creek.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The change in the non-controlling interest related to Silver Creek was as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Controlling</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2016</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,539</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to Silver Creek</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,191</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Silver Creek Series C preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">699</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at June&#160;30, 2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,031</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Controlling</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2015</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">239</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to Silver Creek</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(393</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at June&#160;30, 2016</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(154</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762881120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Commercial Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations And Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Sale of Commercial Business</a></td>
<td class="text"><div>

<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Sale of Commercial Business</p>
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Ipsen</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April&#160;3, 2017, the Company completed the sale of the Commercial Business to Ipsen. Pursuant to the Asset Sale Agreement, the Company may be entitled to up to $450.0 million in additional payments based on the achievement by or on behalf of Ipsen of certain milestone events if the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) approves ONIVYDE for certain indications as follows: (i) $225.0 million upon the regulatory approval by the FDA of ONIVYDE for the first-line treatment of metastatic adenocarcinoma of the pancreas (a)&#160;in combination with fluorouracil and leucovorin (with or without oxaliplatin), (b)&#160;in combination with gemcitabine and abraxane or (c)&#160;following submission and filing of regulatory approval by Ipsen for purposes of commercialization by Ipsen; (ii) $150.0 million upon the regulatory approval by the FDA of ONIVYDE for the treatment of small cell lung cancer after failure of first-line chemotherapy; and (iii) $75.0 million upon the regulatory approval by the FDA of ONIVYDE for an additional indication unrelated to those described above.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the sale of the Commercial Business, on April 3, 2017, the Company entered into a transition services agreement<font style="font-weight:bold;"> </font>with Ipsen pursuant to which the Company and Ipsen are providing certain services to each other for a period of 24 months following the closing, including Ipsen&#8217;s agreement to manufacture MM-310 and to perform certain quality related services in accordance with a manufacturing services agreement, the accounting impact of which is immaterial.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the completion of the Asset Sale, on April 3, 2017, the Company irrevocably deposited the redemption price of the 11.50% senior secured notes due 2022 (the &#8220;2022 Notes&#8221;) of $175.0 million outstanding aggregate principal amount, interest of $7.4 million through the redemption date and an additional make-whole premium payment of approximately $20.1 million with U.S. Bank National Association as trustee (the &#8220;Trustee&#8221;) under the Indenture dated as of December 22, 2015 (the &#8220;Indenture&#8221;) and irrevocably instructed the Trustee to apply such amount to the redemption in full of the 2022 Notes on the redemption date of April 27, 2017. The Indenture was satisfied and discharged on April 3, 2017.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the completion of the Asset Sale, on April 3, 2017, the Company entered into a sublease with Ipsen, pursuant to which Ipsen is subleasing from the Company approximately 70,237 square feet of leased space in the Company&#8217;s Cambridge, Massachusetts facility through the end of the term of the lease on June 30, 2019. Payments under the sublease are recorded as an offset to rent expense in the condensed consolidated statement of operations and comprehensive income (loss).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also in connection with the completion of the Asset Sale, on April 3, 2017, the Company entered into an intellectual property license agreement with Ipsen, pursuant to which Ipsen granted to the Company a perpetual, worldwide, non-exclusive, royalty-free, fully paid-up license in and to all patents included in the transferred intellectual property, other than certain patents relating to generic liposomal technology, with respect to which the license will be exclusive, in each case for use outside of the Commercial Business. The Company granted to Ipsen a non-exclusive, royalty-free, fully paid up, perpetual, irrevocable and worldwide license to all patents it owned at the time of the closing of the transaction contemplated by the Asset Sale Agreement for use in connection with the Commercial Business. This transfer of intellectual property did not impact the financial statements as no amounts related to the intellectual property had previously been recorded.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 5, 2017, the Company announced that its Board of Directors authorized and declared a special cash dividend of $140.0 million on the Company's common stock. The special dividend was payable on May 26, 2017 to stockholders of record as of the close of business on May 17, 2017. The special dividend resulted in a decrease to additional paid-in capital.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Discontinued Operations and Assets Held for Sale</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements for the three and six months ended June 30, 2017 and 2016 reflect the operations of the Commercial Business as a discontinued operation. The Company recorded a gain of approximately $598.2 million on the Asset Sale, which is included in gain from discontinued operations on the condensed consolidated statements of operations and comprehensive income (loss).&#160;Discontinued operations for the three and six months ended June 30, 2017 and 2016 includes the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenues, net</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,851</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,135</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,819</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration revenues</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,332</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,797</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,645</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other revenues</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,498</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,973</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,498</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,681</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,905</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,962</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs and expenses:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,872</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,890</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,583</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,302</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,700</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,181</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,542</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,709</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,885</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restructuring expenses</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,216</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,535</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total costs and expenses</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,216</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,716</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,834</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,649</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income and expenses:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,509</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,290</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,743</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,581</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain on sale of commercial business</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">598,120</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">598,120</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income (loss) from discontinued operations</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">592,395</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">675</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">591,448</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(268</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,910</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,910</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total income (loss) from discontinued operations</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">540,485</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">675</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">539,538</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(268</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying value of the assets and liabilities of the Commercial Business classified as &#8220;Discontinued operations&#8221; in the condensed consolidated balance sheets is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,194</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,554</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,547</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets held for sale</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,295</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,553</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,977</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,605</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total long-term assets held for sale</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,135</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable, accrued expenses and other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,613</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenues</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,226</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities held for sale</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,839</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenues, net of current portion</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,673</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities held for sale</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,673</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:8pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory of the Commercial Business as of December 31, 2016 consisted of the following:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,483</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work in process</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,651</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,420</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventory</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,554</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Restructuring Activities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 8, 2017, the Company announced a reduction in headcount by approximately 30% in connection with the Asset Sale and the completion of its strategic pipeline review. Upon the closing of the Asset Sale and the completion of its strategic pipeline review, the Company had approximately 80 employees. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under this corporate restructuring, for the three and six months ended June 30, 2017, the Company recognized total restructuring expenses of $4.2 million and $9.5 million, respectively, which was related to contractual termination benefits for employees with pre-existing severance arrangements. These one-time employee termination benefits are comprised of severance, benefits and related costs, all of which are expected to result in cash expenditures. The majority of these payments were made during the second quarter of 2017. The remaining payments represent severance payments that will be paid over one year. The expense of $9.5 million was included in discontinued operations, as the costs are directly associated with the sale of the Commercial Business.</p>
<p style="margin-bottom:6pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the charges related to the restructuring activities as of June 30, 2017:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accrued Restructuring Expenses at December&#160;31, 2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less: Payments</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accrued Restructuring Expenses at June&#160;30, 2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Severance, benefits and related costs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,521</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,124</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,397</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,521</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,124</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,397</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These amounts are included in accounts payable, accrued expenses and other in the June 30, 2017 balance sheet.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">License and Collaboration Agreements Related to the Asset Sale</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Baxalta</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 23, 2014, the Company and Baxter International Inc., Baxter Healthcare Corporation and Baxter Healthcare SA entered into a license and collaboration agreement (the &#8220;Baxalta Agreement&#8221;) for the development and commercialization of ONIVYDE outside of the United States and Taiwan (the &#8220;Licensed Territory&#8221;). In connection with Baxter International Inc.&#8217;s separation of the Baxalta business, the Baxalta Agreement was assigned to Baxalta during the second quarter of 2015. As part of the Baxalta Agreement, the Company granted Baxalta an exclusive, royalty-bearing right and license under the Company&#8217;s patent rights and know-how to develop and commercialize ONIVYDE in the Licensed Territory.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 3, 2017, the Baxalta Agreement and all related agreements, including the Company&#8217;s agreement related to the commercial supply of ONIVYDE, were assigned to Ipsen in connection with the Asset Sale. Pursuant to the Asset Sale Agreement, the Company retained the right to receive net milestone payments of up to $33.0 million that may become payable pursuant to the Baxalta Agreement for the ex-U.S. development and commercialization of ONIVYDE, which is comprised of potential payments of $18.0 million from the sale of ONIVYDE in two additional major European countries, $5.0 million related to the sale of ONIVYDE in the first major non-European, non-Asian country and $10.0 million for the first patient dosed in a pivotal clinical trial in an indication other than pancreatic cancer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PharmaEngine, Inc.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 5, 2011, the Company and PharmaEngine, Inc. (&#8220;PharmaEngine&#8221;) entered into an assignment, sublicense and collaboration agreement (the &#8220;PharmaEngine Agreement&#8221;) under which the Company reacquired rights in Europe and certain countries in Asia to ONIVYDE. In exchange, the Company agreed to pay PharmaEngine a nonrefundable, noncreditable upfront payment of $10.0 million and up to an additional $80.0 million in aggregate development and regulatory milestones and $130.0 million in aggregate sales milestones. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 3, 2017, the PharmaEngine Agreement and all related agreements, including the Company&#8217;s agreement related to its commercial supply of ONIVYDE, were assigned to Ipsen in connection with the Asset Sale.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6917638880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going Concern</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Going Concern</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 205-40, <font style="font-style:italic;">Going Concern</font>, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2016, the Company had $21.5 million in unrestricted cash and cash equivalents, had suffered recurring losses from operations and had negative working capital and cash outflows from operating activities. Based on the evaluation completed in connection with the filing of the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2016, including consideration of management&#8217;s plans, the Company previously concluded that there was substantial doubt as to its ability to continue as a going concern within one year after March 1, 2017, the date that the consolidated financial statements were issued.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 3, 2017, the Company closed the Asset Sale with Ipsen and received a $575.0 million upfront cash payment, subject to a working capital adjustment. The working capital adjustment is currently estimated as a $2.2 million receivable expected to be received in the third quarter of 2017. The Company used a portion of the cash payment to redeem the $175.0 million outstanding aggregate principal amount of the 2022 Notes, which also required an additional make-whole premium payment of approximately $20.1 million, and deposited $60.0 million into an escrow account in response to a lawsuit filed by the trustee and certain holders of its 4.50% convertible notes due 2020 (the &#8220;Convertible Notes&#8221;). The Company distributed $140.0 million of the upfront cash payment in the form of a special cash dividend to stockholders, which was payable on May 26, 2017 to stockholders of record as of the close of business on May 17, 2017. After consideration of the Company&#8217;s cash and cash equivalents balance at March 31, 2017 of $17.2 million and the net proceeds from the Asset Sale, the Company has concluded that the previous conditions and events that raised substantial doubt about its ability to continue as a going concern have been alleviated. The Company updated its going concern assessment for the three months ended June 30, 2017 and concluded the Company is able to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762883184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Income Taxes</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Deferred tax assets and liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using future enacted tax rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company completed the Asset Sale and recorded the income tax implications of the sale in the second quarter of 2017. The Asset Sale generated taxable income for the Company which has resulted in income tax expense.&#160; The Company released a portion of its valuation allowance in the three months ended June 30, 2017 as it is now able to utilize its net operating loss carryforwards to offset the taxable income generated from the Asset Sale. The Company&#8217;s current income tax expense for the six months ended June 30, 2017 is $8.1 million, which is comprised primarily of federal Alternative Minimum Tax and state income tax. </p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intraperiod tax allocation rules require the Company to allocate the provision for income taxes between continuing operations and other categories of earnings, such as discontinued operations. In periods in which there is pre-tax loss from continuing operations and pre-tax income in other categories of earnings, such as discontinued operations, the Company must allocate to continuing operations a tax benefit for the loss in continuing operations with an offsetting tax expense to discontinued operations.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three and six months ended June 30, 2017, the Company recognized an income tax benefit of $30.2 million in continuing operations and income tax expense in discontinued operations of $51.9 million related to the income generated in connection with the Asset Sale. As of June 30, 2017, the Company recorded an accrued income tax provision of $13.5 million. </p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Asset Sale, the Company recorded an income tax provision in discontinued operations of $223.3 million prior to the release of the valuation allowance. The Company released $171.4 million of its valuation allowance in discontinued operations during the three months ended June 30, 2017, resulting in a total income tax expense of $51.9 million in discontinued operations.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6916525072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Common Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) Per Common Share</a></td>
<td class="text"><div>

<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. Net Income (Loss) Per Common Share</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net income (loss) per share is calculated by dividing the net income (loss) attributable to Merrimack Pharmaceuticals, Inc, by the weighted-average number of common shares outstanding during the period. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to Merrimack Pharmaceuticals, Inc. by the weighted-average number of dilutive common shares outstanding during the period. Dilutive shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options based on the treasury stock method. In a period when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods where a loss is reported, there is no difference in basic and dilutive loss per share. .</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows the two-class method when computing net income (loss) per share, when it has issued shares that meet the definition participating securities. The two&#8211;class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participating rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based on their respective rights to receive dividends, as if all income for the period has been distributed or losses to be allocated if they are contractually required to fund losses. There were no amounts allocated to participating securities for the three and six months ended June 30, 2017 and 2016, as the Company was in a loss position and had no shares that met the definition of participating securities outstanding as of June 30, 2017 and 2016. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as discussed in Note 10, &#8220;Borrowings,&#8221; in July 2013, the Company issued $125.0 million aggregate principal amount of Convertible Notes in an underwritten public offering. Following the repayment and satisfaction in full of the Company&#8217;s obligations to Hercules Technology Growth Capital, Inc. (&#8220;Hercules&#8221;) under its Loan and Security Agreement with Hercules (the &#8220;Loan Agreement&#8221;), which occurred in December 2015, upon any conversion of the Convertible Notes, the Convertible Notes may be settled, at the Company&#8217;s election, in cash, shares of the Company&#8217;s common stock or a combination of cash and shares of the Company&#8217;s common stock. For purposes of calculating the maximum dilutive impact, it is presumed that the conversion premium will be settled in common stock, inclusive of a contractual make-whole provision resulting from a fundamental change, and the resulting potential common shares included in diluted earnings per share if the effect is more dilutive. As of June&#160;30, 2017, $60.8 million aggregate principal amount of the Convertible Notes remained outstanding.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The stock options and conversion premium on the Convertible Notes are excluded from the calculation of diluted loss per share because the net loss for the three and six months ended June&#160;30, 2016 causes such securities to be anti-dilutive. Outstanding securities excluded from the calculation of diluted loss per share for the three and six months ended June&#160;30, 2017 and 2016 are shown in the chart below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,915</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,647</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,915</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,647</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of the Convertible Notes</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,158</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,158</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,158</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,158</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771790144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. Fair Value of Financial Instruments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is determined based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect certain market assumptions. As a basis for considering such assumptions, GAAP establishes a three-tier value hierarchy, which prioritizes the inputs used to develop the assumptions and for measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets for identical assets; (Level 2) inputs other than the quoted prices in active markets that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recurring Fair Value Measurements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of cash, restricted cash, prepaid expenses, accounts receivable, accounts payable and accrued expenses, and other short-term assets and liabilities approximate their respective fair values due to the short-term maturities of these assets and liabilities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables show assets measured at fair value on a recurring basis as of June&#160;30, 2017 and December&#160;31, 2016:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,931</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,931</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Silver Creek warrant liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,062</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,062</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,373</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,373</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Silver Creek warrant liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,499</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,499</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, Silver Creek issued warrants to purchase an aggregate of 1.9 million shares of Silver Creek Series C preferred stock (the &#8220;Silver Creek warrants&#8221;). During the first quarter of 2017, Silver Creek issued additional Silver Creek warrants to purchase an aggregate of 1.8 million shares of Silver Creek Series C preferred stock. During the second quarter of 2017, Silver Creek issued additional Silver Creek warrants to purchase an aggregate of 0.3 million shares of Silver Creek Series C preferred stock. <font style="color:#000000;">In June 2017, Silver Creek amended the outstanding warrant purchase agreements to increase the number of shares for which each warrant is redeemable. </font>The Silver Creek warrants were valued at $4.1 million and $1.5 million as of June 30, 2017 and December 31, 2016, respectively, using a Black-Scholes option pricing model, probability-weighted for different exercise scenarios. The key assumptions utilized in the Black-Scholes option pricing model as of June 30, 2017 were a risk-free interest rate of 2.1%, expected dividend yield of 0.0%, expected volatility of 60.4% and expected term of 6.4 years &#8211; 7.0 years. The key assumptions utilized in the Black-Scholes option pricing model as of December 31, 2016 were a risk-free interest rate of 2.3%, expected dividend yield of 0.0%, expected volatility of 61.7% and expected term of 6.9 years. Changes in the fair value of the Silver Creek warrants are recognized as a component of &#8220;other income and expenses&#8221; in the condensed consolidated statements of operations and comprehensive income (loss). The change in fair value for both the three and six months ended June&#160;30, 2017 was $1.0 million, inclusive of $0.8 million incremental change resulting from the amendment to the warrant purchase agreements, and is recorded in other income (expense) on the statement of operations and comprehensive loss.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no changes in valuation techniques or transfers between the fair value measurement levels during the three or six months ended June&#160;30, 2017 or during the year ended December&#160;31, 2016. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Fair Value Measurements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated fair value of the Convertible Notes was $36.7 million as of June&#160;30, 2017. The Company estimated the fair value of the Convertible Notes by using a quoted market rate in an inactive market, which is classified as a Level 2 input. The carrying value of the Convertible Notes was $48.9 million as of June&#160;30, 2017 due to the bifurcation of the conversion feature of the Convertible Notes as described more fully in Note 10, &#8220;Borrowings.&#8221;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed in Note 10, &#8220;Borrowings,&#8221; in December 2015, the Company closed a private placement of $175.0 million aggregate principal amount of 2022 Notes. The Company estimated the fair value of the 2022 Notes by using publicly-available information related to one of the 2022 Notes borrower&#8217;s portfolio of debt investments based on unobservable inputs, which is classified as a Level 3 input. In connection with the completion of the Asset Sale, on April 3, 2017, the liability under the 2022 Notes was satisfied. The Company incurred a loss on extinguishment of $25.0 million as a result of the early repayment of the 2022 Notes, which is included in interest expense on the statement of operations. For additional information, see Note 3, &#8220;Sale of Commercial Business.&#8221;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762860672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div>

<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8. Marketable Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">As of both June 30, 2017 and December 31, 2016, the Company maintained only cash equivalents comprised of money market funds. As of June 30, 2017, the Company did not hold any securities that were in an unrealized loss position. There were no realized gains or losses on available-for-sale securities for the three or six months ended June 30, 2017 or 2016.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=4738149<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2289146<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6919361632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable, Accrued Expenses and Other<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable, Accrued Expenses and Other</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. Accounts Payable, Accrued Expenses and Other</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable, accrued expenses and other as of June&#160;30, 2017 and December&#160;31, 2016 consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,298</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,692</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued goods and services</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,467</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,233</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial costs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,382</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,776</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued drug purchase costs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">480</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and related benefits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,362</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,394</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued severance expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,736</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">774</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,261</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,100</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued dividends payable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Silver Creek warrant liability</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,062</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,499</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax incentives</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,402</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,402</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accounts payable, accrued expenses and other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,989</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,369</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6916525072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text"><div>

<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10. Borrowings</p>
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">2022 Notes</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 22, 2015, the Company closed a private placement of $175.0 million aggregate principal amount of 2022 Notes. As a result of this placement, the Company received net proceeds of approximately $168.5 million, after deducting private placement and offering expenses payable by the Company. In connection with the completion of the Asset Sale on April 3, 2017, the liability under the 2022 Notes was satisfied. For additional information, see Note 3, &#8220;Sale of Commercial Business.&#8221; The 2022 Notes bore interest at a rate of 11.50% per year, payable semi-annually on June 15 and December 15 of each year, beginning on June 15, 2016.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2022 Notes contained customary covenants, including covenants that limited or restricted the Company&#8217;s ability to incur liens, incur indebtedness and make certain restricted payments, but did not contain covenants related to future financial performance. The 2022 Notes were secured by a first priority lien on substantially all of the Company&#8217;s assets.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assessed the 2022 Notes pursuant to ASC 815, <font style="font-style:italic;">Derivatives and Hedging</font>, to determine if any features necessitated bifurcation from the host instrument. The Company concluded that none of the embedded redemption features within the 2022 Notes required bifurcation, as these features were clearly and closely related to the host instrument.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt issuance costs incurred by the Company are accounted for as a direct deduction to the carrying value of the 2022 Notes and are amortized to interest expense using the effective interest method over the life of the 2022 Notes. In connection with the completion of the Asset Sale, on April 3, 2017, the Company voluntarily settled the principle liability of the 2022 Notes. As a result of the early repayment, for the three and six months ended June 30, 2017 a loss on extinguishment of $25.0 million was incurred As a result of the early repayment, a loss on extinguishment of $25.0 million was recognized in interest expense in the condensed consolidated statement of operations and comprehensive income (loss) for the three and six months ended June 30, 2017. The $25.0 million loss on extinguishment included a $20.1 million prepayment penalty and $4.9 million of amortization expense recognized for the remaining debt discount at settlement as a result of the early repayment, which is included in interest expense on the statement of operations. For the three and six months ended June&#160;30, 2017, interest expense related to the 2022 Notes was $1.5 million and $6.7 million, respectively. For the three and six months ended June&#160;30, 2016, interest expense related to the 2022 Notes was $5.2 million and $10.4 million, respectively. These amounts are included in discontinued operations.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Convertible Notes</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2013, the Company issued $125.0 million aggregate principal amount of Convertible Notes in an underwritten public offering. As a result of the Convertible Notes offering, the Company received net proceeds of approximately $120.6 million, after deducting underwriting discounts and commissions and offering expenses payable by the Company.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Convertible Notes bear interest at a rate of 4.50% per year, payable semiannually in arrears on January 15 and July 15 of each year, beginning on January 15, 2014. The Convertible Notes are general unsecured senior obligations of the Company and rank (i) senior in right of payment to any of the Company&#8217;s indebtedness that is expressly subordinated in right of payment to the Convertible Notes, (ii) equal in right of payment to any of the Company&#8217;s unsecured indebtedness that is not so subordinated, (iii) effectively junior in right of payment to any of the Company&#8217;s secured indebtedness to the extent of the value of the assets securing such indebtedness and (iv) structurally junior to all indebtedness and other liabilities (including trade payables) of the Company&#8217;s subsidiaries.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company separately accounted for the liability and equity components of the Convertible Notes by bifurcating gross proceeds between the indebtedness, or liability component, and the embedded conversion option, or equity component. This bifurcation was done by estimating an effective interest rate as of the date of issuance for similar notes which do not contain an embedded conversion option. The gross proceeds received from the issuance of the Convertible Notes less the initial amount allocated to the indebtedness resulted in a $53.8 million allocation to the embedded conversion option. The embedded conversion option was recorded in stockholders&#8217; deficit and as debt discount, to be subsequently amortized as interest expense over the term of the Convertible Notes. Underwriting discounts and commissions and offering expenses totaled $4.4 million and were allocated to the indebtedness and the embedded conversion option based on their relative values.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 13, 2016, the Company entered into separate, privately-negotiated conversion agreements (the &#8220;Conversion Agreements&#8221;) with certain holders of the Convertible Notes. Under the Conversion Agreements, such holders agreed to convert an aggregate principal amount of $64.2 million of Convertible Notes held by them. The Company initially settled each $1,000 principal amount of Convertible Notes surrendered for conversion by delivering 136 shares of the Company&#8217;s common stock on April 18, 2016. In total, the Company issued an aggregate of 8,732,152 shares of its common stock on this initial closing date. In addition, pursuant to the Conversion Agreements, at the additional closings (as defined in the Conversion Agreements), the Company issued an aggregate of 3,635,511 shares of the Company&#8217;s common stock representing an aggregate of $27.7 million as additional payments in respect of the conversion of the Convertible Notes. The number of additional shares was determined based on the daily VWAP (as defined in the Conversion Agreements) of the Company&#8217;s common stock for each of the trading days in the 10-day trading period following the date of the Conversion Agreements. The issuance of 12,367,663 total shares of the Company&#8217;s common stock pursuant to the Conversion Agreements resulted in an increase to common stock and additional paid-in capital of $101.0 million.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the conversion, the Company recognized an overall loss on extinguishment of $14.6 million representing the difference between the total settlement consideration transferred to the holders that was attributed to the liability component of the Convertible Notes, based on the fair value of that component at the time of conversion, and the net carrying value of the liability. The loss on extinguishment was recorded as interest expense during the second quarter of 2016. The remaining settlement consideration transferred was allocated to the reacquisition of the embedded conversion option and recognized as a $39.8 million reduction of additional paid-in capital. Transaction costs incurred with third parties related to the conversion were allocated to the liability and equity components and resulted in an additional $0.2 million of interest expense and a $0.2 million reduction of additional paid-in capital.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The outstanding Convertible Notes will mature on July 15, 2020 (the &#8220;Maturity Date&#8221;), unless earlier repurchased by the Company or converted at the option of holders. Holders may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding April 15, 2020 only under the following circumstances:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">during any calendar quarter commencing after September 30, 2013 (and only during such calendar quarter), if the last reported sale price of the Company&#8217;s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">during the five business day period after any five consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price (as defined in the Convertible Notes) per $1,000 principal amount of Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate on each such trading day; or</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upon the occurrence of specified corporate events set forth in the indenture governing the Convertible Notes.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On or after April 15, 2020 until the close of business on the business day immediately preceding the Maturity Date, holders may convert their Convertible Notes at any time, regardless of the foregoing circumstances.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the repayment and satisfaction in full of the Company&#8217;s obligations to Hercules under the Loan Agreement, which occurred in December 2015, upon any conversion of the Convertible Notes, the Convertible Notes may be settled, at the Company&#8217;s election, in cash, shares of the Company&#8217;s common stock or a combination of cash and shares of the Company&#8217;s common stock.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial conversion rate of the Convertible Notes was 160.0000 shares of the Company&#8217;s common stock per $1,000 principal amount of Convertible Notes, which is equivalent to an initial conversion price of $6.25 per share of common stock. As a result of the special dividend that was payable on May 26, 2017 to stockholders of record as of the close of business on May 17, 2017, the conversion rate of the Convertible Notes was adjusted from 160.0000 shares of the Company&#8217;s common stock per $1,000 principal amount of Convertible Notes to 235.2112 shares of the Company&#8217;s common stock per $1,000 principal amount of Convertible Notes. The conversion rate will be subject to further adjustment in some events, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the Maturity Date, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with a lawsuit filed by the trustee and certain holders of the Convertible Notes in the Court of Chancery in the State of Delaware, captioned <font style="font-style:italic;">Wells Fargo Bank, National Association, Wolverine Flagship Fund Trading Limited, Highbridge International LLC, and Highbridge Tactical Credit&#160;&amp; Convertibles Master Fund, L.P. v. Merrimack Pharmaceuticals, Inc. </font>(the &#8220;Delaware Action&#8221;), the Company deposited $60.0 million in proceeds from the Asset Sale into an escrow account. The funds will remain in escrow for the duration of the Delaware Action in order to provide security to the plaintiffs for their claims in the Delaware Action. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three and six months ended June&#160;30, 2017, interest expense related to the Convertible Notes was $1.7 million and $3.3 million, respectively. For the three and six months ended June&#160;30, 2016, interest expense related to the Convertible Notes was $1.9 million and $5.3 million, respectively. The year-over-year decrease was primarily attributable to interest expense related to a reduction in the principal based on the conversion of some of the Convertible Notes that occurred in April 2016.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Future Minimum Payments under Outstanding Borrowings</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum payments under outstanding borrowings as of June&#160;30, 2017 are as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remainder of 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,368</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,736</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,736</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020 and thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,527</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,367</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less interest</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,576</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less unamortized discount</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,885</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less current portion</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term debt</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,906</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6918798592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11. Stock-Based Compensation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">As of December 31, 2015, there were 2.5 million shares of common stock available to be granted under the Company&#8217;s 2011 Stock Incentive Plan (the &#8220;2011 Plan&#8221;). The 2011 Plan is administered by the Company&#8217;s board of directors and permits the Company to grant incentive and non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, 4.1 million additional shares of common stock became available for grant to employees, officers, directors and consultants under the 2011 Plan. At June&#160;30, 2017, there were 2.3 million shares remaining available for grant under the 2011 Plan. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During both the three and six months ended June&#160;30, 2017, the Company issued options to purchase 19.4 million shares of common stock. During the six months ended June&#160;30, 2016 the Company issued options to purchase 3.8 million shares of common stock. These options generally vest over a three-year period for employees. Options granted to directors vest immediately.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described in Note 3, &#8220;Sale of Commercial Business,&#8221; the Board of Directors authorized and declared a special cash dividend of $140.0 million on the Company's common stock, which was payable on May 26, 2017 to stockholders of record as of the close of business on May 17, 2017. The Board of Directors determined, in accordance with the adjustment provision of each of the Company&#8217;s 1999 Stock Option Plan, as amended, the 2008 Stock Incentive Plan, as amended, and the 2011 Plan (collectively, the &#8220;Equity Plans&#8221;), that the special cash dividend was unusual and non-recurring and that appropriate adjustment to the stock options to purchase shares of the Corporation&#8217;s common stock outstanding under the Equity Plans was required. The Company treated this adjustment as a modification to the original stock option grant because the terms of the agreements were modified in order to preserve the value of the option awards after a large non-recurring cash dividend. The calculation of the incremental compensation expense is based on the excess of the fair value of the award measured immediately before and after the modification. As a result, the Company recognized an incremental compensation expense of $5.6 million associated with the modification in the second quarter of 2017.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of stock options granted to employees during the three and six months ended June&#160;30, 2017 and 2016 was estimated at the date of grant using the following assumptions:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7 &#8211; 2.0%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1 &#8211; 1.5%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7 &#8211; 2.1%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5 &#8211; 1.8%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7 &#8211; 6.1 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0 &#8211; 5.8 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7 &#8211; 6.1 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0 &#8211; 5.9 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67 &#8211; 69%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65 &#8211; 68%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66 &#8211; 67%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the simplified method to calculate the expected term, as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. The computation of expected volatility is based on the historical volatility of comparable companies from a representative peer group selected based on industry and market capitalization. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected life of the stock options. Management estimates expected forfeitures based on historical experience and recognizes compensation costs only for those equity awards expected to vest.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-09, &#8220;Compensation &#8211; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,&#8221; which simplifies several areas of accounting for share-based payment transactions, including the income tax consequences, classification of awards as either liabilities or equity and classification of excess tax benefits on the statement of cash flows. This guidance also permits a new entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures when they occur. The Company adopted the guidance, electing to account for forfeitures when they occur, and it did not have an impact on the consolidated financial statements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized stock-based compensation expense during the three and six months ended June&#160;30, 2017 and 2016 as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee awards:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,916</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,465</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,383</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,991</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,818</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,102</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,146</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,086</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,734</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,567</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,529</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,077</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity during the six months ended June&#160;30, 2017:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise&#160;Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December&#160;31, 2016</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,024</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.77</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.97</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,564</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,388</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.46</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,562</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.29</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,935</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.24</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.74%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at June&#160;30, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,915</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.43</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.87</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.74%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at June&#160;30, 2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,870</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.43</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.86</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at June&#160;30, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,560</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.81</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.98</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value per share of stock options granted during the three and six months ended June&#160;30, 2017 was $0.38 and $0.38, respectively. The weighted-average grant date fair value per share of stock options granted during the three and six months ended June&#160;30, 2016 was $3.73 and $3.35, respectively.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value is calculated as the difference between the exercise price of the stock options and the fair value of the underlying common stock. The aggregate intrinsic value of stock options exercised during the three and six months ended June&#160;30, 2017 was $0.9 million and $2.3 million, respectively. The aggregate intrinsic value of stock options exercised during the three and six months ended June&#160;30, 2016 was $0.6 million and $2.7 million, respectively.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2017, there was $6.1 million of total unrecognized stock-based compensation expense related to unvested employee stock awards. The Company expects to recognize this expense over a weighted-average period of approximately 2.9 years.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762838256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes And Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12. Recent Accounting Pronouncements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">In May 2014, the FASB issued ASU 2014-09, &#8220;Revenue from Contracts with Customers (Topic 606),&#8221; which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. This guidance was originally effective for interim and annual periods beginning after December 15, 2016 and allows for adoption using a full retrospective method, or a modified retrospective method. Early adoption was originally not permitted. Subsequent to the issuance of ASU 2014-09, the FASB also issued the following updates related to ASC 606, <font style="font-style:italic;">Revenue from Contracts with Customers</font>:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2015, the FASB issued ASU 2015-14, &#8220;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,&#8221; whereby the effective date for the new revenue standard was deferred by one year. As a result of ASU 2015-14, the new revenue standard is now effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, and early adoption is now permitted for annual periods beginning after December 15, 2016, including interim periods within that annual period.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, the FASB issued ASU 2016-08, &#8220;Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net),&#8221; to clarify the implementation guidance on principal versus agent considerations.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2016, the FASB issued ASU 2016-10, &#8220;Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,&#8221; to clarify the principle for determining whether a good or service is &#8220;separately identifiable&#8221; from other promises in the contract and to clarify the categorization of licenses of intellectual property.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2016, the FASB issued ASU 2016-12, &#8220;Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Technical Expedients,&#8221; to clarify guidance on transition, determining collectability, non-cash consideration and the presentation of sales and other similar taxes.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not currently have any revenue generating contracts with customers due to the sale of its commercial business in the second quarter of 2017. The Company expects to adopt the new revenue standard on January 1, 2018 using the modified retrospective approach.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2016, the FASB issued ASU 2016-01, &#8220;Financial Instruments &#8211; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities,&#8221; which contains a number of provisions related to the measurement, presentation and disclosure of financial instruments. This guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within those annual periods. Early adoption of this guidance is not permitted with the exception of certain specific presentation requirements that are not currently applicable to the Company. The Company does not anticipate a material impact to the consolidated financial statements as a result of the adoption of this guidance.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU 2016-02, &#8220;Leases (Topic 842),&#8221; which supersedes all existing lease accounting guidance within ASC 840, <font style="font-style:italic;">Leases</font>. The new standard requires that lease assets and lease liabilities be recognized by lessees for those leases previously classified as operating leases under ASC 840, with limited exceptions. This update also creates a new definition of a lease and provides guidance as to whether a contract is or contains a lease. This guidance will be effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual reporting periods, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the consolidated financial statements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13, &#8220;Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&#8221; which represents a new credit loss standard that will change the impairment model for most financial assets and certain other financial instruments. Specifically, this guidance will require entities to utilize a new &#8220;expected loss&#8221; model as it relates to trade and other receivables. In addition, entities will be required to recognize an allowance for estimated credit losses on available-for-sale debt securities, regardless of the length of time that a security has been in an unrealized loss position. This guidance will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the consolidated financial statements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2016, the FASB issued ASU 2016-15, &#8220;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,&#8221; which is intended to reduce diversity in practice in how entities present certain types of cash transactions in the statement of cash flows. This guidance also clarifies how the predominance principle should be applied when classifying cash receipts and cash payments that have attributes of more than one class of cash flows. This guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within those annual reporting periods, and early adoption is permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company does not anticipate a material impact to the consolidated financial statements as a result of the adoption of this guidance.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, the FASB issued ASU 2017-09, &#8220;Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting,&#8221; which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard should be applied prospectively to awards modified on or after the adoption date. This guidance will be effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the consolidated financial statements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#8217;s consolidated financial statements upon adoption.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6655324640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13. Subsequent Events</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">In July 2017, Silver Creek issued 1.7 million shares of Series C preferred stock at $1.50 per share for proceeds of $2.6 million. As of June 30, 2017, the Company held a 51% ownership interest in Silver Creek and maintained control over the Silver Creek board of directors through its voting rights. As a result of Silver Creek&#8217;s issuance of additional shares of Series C preferred stock in July 2017, the Company will evaluate whether the Silver Creek financial statements should continue to be consolidated. &#160;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762880160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes And Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div>

<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">In May 2014, the FASB issued ASU 2014-09, &#8220;Revenue from Contracts with Customers (Topic 606),&#8221; which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. This guidance was originally effective for interim and annual periods beginning after December 15, 2016 and allows for adoption using a full retrospective method, or a modified retrospective method. Early adoption was originally not permitted. Subsequent to the issuance of ASU 2014-09, the FASB also issued the following updates related to ASC 606, <font style="font-style:italic;">Revenue from Contracts with Customers</font>:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2015, the FASB issued ASU 2015-14, &#8220;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,&#8221; whereby the effective date for the new revenue standard was deferred by one year. As a result of ASU 2015-14, the new revenue standard is now effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, and early adoption is now permitted for annual periods beginning after December 15, 2016, including interim periods within that annual period.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, the FASB issued ASU 2016-08, &#8220;Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net),&#8221; to clarify the implementation guidance on principal versus agent considerations.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2016, the FASB issued ASU 2016-10, &#8220;Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,&#8221; to clarify the principle for determining whether a good or service is &#8220;separately identifiable&#8221; from other promises in the contract and to clarify the categorization of licenses of intellectual property.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2016, the FASB issued ASU 2016-12, &#8220;Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Technical Expedients,&#8221; to clarify guidance on transition, determining collectability, non-cash consideration and the presentation of sales and other similar taxes.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not currently have any revenue generating contracts with customers due to the sale of its commercial business in the second quarter of 2017. The Company expects to adopt the new revenue standard on January 1, 2018 using the modified retrospective approach.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2016, the FASB issued ASU 2016-01, &#8220;Financial Instruments &#8211; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities,&#8221; which contains a number of provisions related to the measurement, presentation and disclosure of financial instruments. This guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within those annual periods. Early adoption of this guidance is not permitted with the exception of certain specific presentation requirements that are not currently applicable to the Company. The Company does not anticipate a material impact to the consolidated financial statements as a result of the adoption of this guidance.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU 2016-02, &#8220;Leases (Topic 842),&#8221; which supersedes all existing lease accounting guidance within ASC 840, <font style="font-style:italic;">Leases</font>. The new standard requires that lease assets and lease liabilities be recognized by lessees for those leases previously classified as operating leases under ASC 840, with limited exceptions. This update also creates a new definition of a lease and provides guidance as to whether a contract is or contains a lease. This guidance will be effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual reporting periods, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the consolidated financial statements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13, &#8220;Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&#8221; which represents a new credit loss standard that will change the impairment model for most financial assets and certain other financial instruments. Specifically, this guidance will require entities to utilize a new &#8220;expected loss&#8221; model as it relates to trade and other receivables. In addition, entities will be required to recognize an allowance for estimated credit losses on available-for-sale debt securities, regardless of the length of time that a security has been in an unrealized loss position. This guidance will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the consolidated financial statements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2016, the FASB issued ASU 2016-15, &#8220;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,&#8221; which is intended to reduce diversity in practice in how entities present certain types of cash transactions in the statement of cash flows. This guidance also clarifies how the predominance principle should be applied when classifying cash receipts and cash payments that have attributes of more than one class of cash flows. This guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within those annual reporting periods, and early adoption is permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company does not anticipate a material impact to the consolidated financial statements as a result of the adoption of this guidance.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, the FASB issued ASU 2017-09, &#8220;Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting,&#8221; which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard should be applied prospectively to awards modified on or after the adoption date. This guidance will be effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period. The Company is currently evaluating the potential impact that the adoption of this guidance may have on the consolidated financial statements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#8217;s consolidated financial statements upon adoption.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6647879728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Consolidation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock', window );">Schedule of Non-Controlling Interest in Subsidiary</a></td>
<td class="text"><div>

<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The change in the non-controlling interest related to Silver Creek was as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Controlling</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2016</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,539</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to Silver Creek</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,191</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Silver Creek Series C preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">699</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at June&#160;30, 2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,031</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Controlling</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2015</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">239</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to Silver Creek</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(393</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at June&#160;30, 2016</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(154</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4M<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591554-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763710992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Commercial Business (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations And Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Discontinued Operations and Assets Held for Sale</a></td>
<td class="text"><div>

<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Discontinued operations for the three and six months ended June 30, 2017 and 2016 includes the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenues, net</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,851</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,135</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,819</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration revenues</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,332</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,797</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,645</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other revenues</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,498</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,973</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,498</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,681</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,905</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,962</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs and expenses:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,872</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,890</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,583</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,302</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,700</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,181</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,542</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,709</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,885</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restructuring expenses</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,216</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,535</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total costs and expenses</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,216</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,716</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,834</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,649</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income and expenses:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,509</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,290</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,743</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,581</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain on sale of commercial business</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">598,120</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">598,120</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income (loss) from discontinued operations</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">592,395</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">675</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">591,448</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(268</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,910</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,910</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total income (loss) from discontinued operations</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">540,485</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">675</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">539,538</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(268</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock', window );">Schedule of Carrying Value of Assets and Liabilities Classified as Discontinued Operations Relates to Commercial Business</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The carrying value of the assets and liabilities of the Commercial Business classified as &#8220;Discontinued operations&#8221; in the condensed consolidated balance sheets is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,194</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,554</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,547</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets held for sale</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,295</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,553</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,977</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,605</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total long-term assets held for sale</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,135</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable, accrued expenses and other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,613</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenues</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,226</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities held for sale</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,839</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenues, net of current portion</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,673</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities held for sale</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,673</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory of Commercial Business</a></td>
<td class="text"><div>

<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Inventory of the Commercial Business as of December 31, 2016 consisted of the following:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,483</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work in process</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,651</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,420</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventory</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,554</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of Charges Related to Restructuring Activities</a></td>
<td class="text"><div>

<p style="margin-bottom:6pt;margin-top:12pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table summarizes the charges related to the restructuring activities as of June 30, 2017:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accrued Restructuring Expenses at December&#160;31, 2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less: Payments</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accrued Restructuring Expenses at June&#160;30, 2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Severance, benefits and related costs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,521</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,124</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,397</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,521</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,124</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,397</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721665-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1474-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=SL51724579-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721663-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721659-107760<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721671-107760<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721677-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762856800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Outstanding Securities Excluded from Computation of Diluted Loss Per Share</a></td>
<td class="text"><div>

<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Outstanding securities excluded from the calculation of diluted loss per share for the three and six months ended June&#160;30, 2017 and 2016 are shown in the chart below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,915</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,647</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,915</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,647</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of the Convertible Notes</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,158</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,158</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,158</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,158</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6920052016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div>

<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following tables show assets measured at fair value on a recurring basis as of June&#160;30, 2017 and December&#160;31, 2016:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,931</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,931</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Silver Creek warrant liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,062</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,062</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,373</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,373</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Silver Creek warrant liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,499</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,499</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762735008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable, Accrued Expenses and Other (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable, Accrued Expenses and Other</a></td>
<td class="text"><div>

<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Accounts payable, accrued expenses and other as of June&#160;30, 2017 and December&#160;31, 2016 consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,298</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,692</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued goods and services</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,467</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,233</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial costs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,382</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,776</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued drug purchase costs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">480</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and related benefits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,362</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,394</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued severance expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,736</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">774</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,261</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,100</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued dividends payable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Silver Creek warrant liability</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,062</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,499</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax incentives</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,402</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,402</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accounts payable, accrued expenses and other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,989</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,369</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773289088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of Future Minimum Payments under the Loans Payable</a></td>
<td class="text"><div>

<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Future minimum payments under outstanding borrowings as of June&#160;30, 2017 are as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remainder of 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,368</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,736</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,736</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020 and thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,527</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,367</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less interest</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,576</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less unamortized discount</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,885</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less current portion</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term debt</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,906</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the aggregate amount of payments due on known contractual obligations for the five years following the date of the latest balance sheet and the combined aggregate amount of maturities of known contractual obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph a<br> -Subparagraph 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6917665184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Calculate Fair Value of Options Granted to Employees</a></td>
<td class="text"><div>

<p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The fair value of stock options granted to employees during the three and six months ended June&#160;30, 2017 and 2016 was estimated at the date of grant using the following assumptions:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7 &#8211; 2.0%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1 &#8211; 1.5%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7 &#8211; 2.1%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5 &#8211; 1.8%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7 &#8211; 6.1 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0 &#8211; 5.8 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7 &#8211; 6.1 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0 &#8211; 5.9 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67 &#8211; 69%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65 &#8211; 68%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66 &#8211; 67%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock', window );">Schedule of Recognized Stock-Based Compensation Expense</a></td>
<td class="text"><div>

<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company recognized stock-based compensation expense during the three and six months ended June&#160;30, 2017 and 2016 as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee awards:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,916</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,465</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,383</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,991</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,818</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,102</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,146</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,086</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,734</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,567</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,529</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,077</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table summarizes stock option activity during the six months ended June&#160;30, 2017:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise&#160;Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December&#160;31, 2016</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,024</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.77</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.97</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,564</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,388</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.46</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,562</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.29</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,935</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.24</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.74%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at June&#160;30, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,915</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.43</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.87</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.74%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at June&#160;30, 2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,870</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.43</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.86</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at June&#160;30, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,560</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.81</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.98</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of employee and nonemployee service share based compensation allocation of recognized period costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771695104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of the Business - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Apr. 03, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mack_IpsenSAMember', window );">Ipsen [Member] | Asset Sale Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AssetSaleUpfrontCashPayment', window );">Upfront cash payment received</a></td>
<td class="nump">$ 575,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset', window );">Working capital adjustment receivable</a></td>
<td class="nump">2,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mack_IpsenSAMember', window );">Ipsen [Member] | Asset Sale Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AssetSaleFutureMilestonePayments', window );">Additional payments receivable on achievement of certain milestone events</a></td>
<td class="nump">450,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mack_BaxaltaMember', window );">Baxalta [Member] | License and Collaboration Agreements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_NetMilestonePaymentsEntitledToReceiveAfterAssetSale', window );">Net milestone payments expected to be received</a></td>
<td class="nump">$ 33,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_AssetSaleFutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset sale future milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_AssetSaleFutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_AssetSaleUpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset sale upfront&#8203; cash&#8203; payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_AssetSaleUpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_NetMilestonePaymentsEntitledToReceiveAfterAssetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net milestone payments entitled to receive after asset sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_NetMilestonePaymentsEntitledToReceiveAfterAssetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working capital adjustment receivable related to sale of asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mack_IpsenSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mack_IpsenSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mack_AssetPurchaseAndSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mack_AssetPurchaseAndSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mack_BaxaltaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mack_BaxaltaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771944832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Consolidation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 135,501<span></span>
</td>
<td class="nump">$ 17,200<span></span>
</td>
<td class="nump">$ 135,501<span></span>
</td>
<td class="nump">$ 21,524<span></span>
</td>
<td class="nump">$ 21,491<span></span>
</td>
<td class="nump">$ 185,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember', window );">Silver Creek [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Net cash proceeds from stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents', window );">Ownership interest percentage held by parent and its de facto agents</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember', window );">Silver Creek [Member] | Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Preferred stock price per share</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Net cash proceeds from stock issuance</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase preferred stock, shares</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember', window );">Silver Creek [Member] | Warrant Purchase Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase preferred stock, shares</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ownership percentage held by parent and its de facto agents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mack_WarrantPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mack_WarrantPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760763744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Consolidation - Schedule of Non-Controlling Interest in Subsidiary (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Minority Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,539)<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to Silver Creek</a></td>
<td class="num">$ (724)<span></span>
</td>
<td class="num">$ (208)<span></span>
</td>
<td class="num">(1,191)<span></span>
</td>
<td class="num">(393)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Balance at the end of the period</a></td>
<td class="num">$ (2,031)<span></span>
</td>
<td class="num">$ (154)<span></span>
</td>
<td class="num">(2,031)<span></span>
</td>
<td class="num">$ (154)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Minority Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Issuance of Silver Creek Series C preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569655-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776420032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Commercial Business - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 05, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 03, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jan. 08, 2017 </div>
<div>Employee</div>
</th>
<th class="th">
<div>May 05, 2011 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 22, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Aggregate principal amount outstanding redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear', window );">Dividend date declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  05,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Special cash dividend paid</a></td>
<td class="nump">$ 140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendPayableDateToBePaidDayMonthAndYear', window );">Dividend paid date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 26,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear', window );">Dividend payable, date of record</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 17,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember', window );">January 2017 Corporate Restructuring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesInitiationDate', window );">Restructuring activity, announcement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  08,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Restructuring and related cost, headcount reduction percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_RestructuringAndRelatedCostNumberOfPositionsAfterHeadcountReduction', window );">Restructuring and related cost, number of employees after headcount reduction | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember', window );">January 2017 Corporate Restructuring [Member] | Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember', window );">January 2017 Corporate Restructuring [Member] | Contractual Termination Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="nump">$ 9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember', window );">January 2017 Corporate Restructuring [Member] | One-time Employee Termination Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDescription', window );">Restructuring And Related Activities Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">One-time employee termination benefits are comprised of severance, benefits and related costs, all of which are expected to result in cash expenditures. The majority of these payments were made during the second quarter of 2017. The remaining payments represent severance payments that will be paid over one year.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_SeverancePaymentsPaymentPeriod', window );">Severance payments payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mack_SeniorNotesDueTwoThousandTwentyTwoMember', window );">2022 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mack_AssetPurchaseAndSaleAgreementMember', window );">Asset Sale Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_TransitionServicesAgreementPeriod', window );">Transition services agreement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Special cash dividend paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Gain from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 598,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mack_AssetPurchaseAndSaleAgreementMember', window );">Asset Sale Agreement [Member] | 2022 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Aggregate principal amount outstanding redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_PaymentOfMakeWholePremiumOfLongTermDebt', window );">Additional premium payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Aggregate principal amount of interest redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mack_IpsenSAMember', window );">Ipsen [Member] | Asset Sale Agreement [Member] | Manufacturing Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AssetSaleSubleaseArea', window );">Area of sublease property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mack_IpsenSAMember', window );">Ipsen [Member] | Asset Sale Agreement [Member] | Clinical Trials in Pancreas as First-Line Treatment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AssetSaleFutureMilestonePayments', window );">Additional payments receivable on achievement of certain milestone events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mack_IpsenSAMember', window );">Ipsen [Member] | Asset Sale Agreement [Member] | Clinical Trials in Small Cell Lung Cancer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AssetSaleFutureMilestonePayments', window );">Additional payments receivable on achievement of certain milestone events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mack_IpsenSAMember', window );">Ipsen [Member] | Asset Sale Agreement [Member] | Other Unrelated Clinical Trials [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AssetSaleFutureMilestonePayments', window );">Additional payments receivable on achievement of certain milestone events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mack_IpsenSAMember', window );">Ipsen [Member] | Asset Sale Agreement [Member] | Development and Commercialization Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_MaximumCollaborativeArrangementMilestonePayments', window );">Maximum amount of milestone payments that can be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mack_IpsenSAMember', window );">Ipsen [Member] | Asset Sale Agreement [Member] | Sale Milestones in Major European Countries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_PotentialMilestonePaymentsReceivable', window );">Potential milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mack_IpsenSAMember', window );">Ipsen [Member] | Asset Sale Agreement [Member] | Sale Milestones in Major Non-European and Non-Asian Country [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_PotentialMilestonePaymentsReceivable', window );">Potential milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mack_IpsenSAMember', window );">Ipsen [Member] | Asset Sale Agreement [Member] | Clinical Trials in Lung Cancer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_PotentialMilestonePaymentsReceivable', window );">Potential milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mack_IpsenSAMember', window );">Ipsen [Member] | Asset Sale Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AssetSaleFutureMilestonePayments', window );">Additional payments receivable on achievement of certain milestone events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mack_PharmaEngineIncMember', window );">PharmaEngine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_CollaborativeArrangementUpfrontPaymentObligation', window );">Upfront license fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mack_PharmaEngineIncMember', window );">PharmaEngine [Member] | Development and Regulatory Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_CollaborativeArrangementMaximumMilestonePaymentObligation', window );">Maximum milestone payment obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mack_PharmaEngineIncMember', window );">PharmaEngine [Member] | Sales Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_CollaborativeArrangementMaximumMilestonePaymentObligation', window );">Maximum milestone payment obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_AssetSaleFutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset sale future milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_AssetSaleFutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_AssetSaleSubleaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset sale sublease area.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_AssetSaleSubleaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_CollaborativeArrangementMaximumMilestonePaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum cumulative obligation for milestone payments under the terms of license and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_CollaborativeArrangementMaximumMilestonePaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_CollaborativeArrangementUpfrontPaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the cumulative amount of nonrefundable, noncreditable upfront license fees paid during the period under the terms of license and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_CollaborativeArrangementUpfrontPaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_MaximumCollaborativeArrangementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum cumulative amount of milestone payments that can be received over the life of the license and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_MaximumCollaborativeArrangementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_PaymentOfMakeWholePremiumOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of make-whole premium of long term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_PaymentOfMakeWholePremiumOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_PotentialMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_PotentialMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_RestructuringAndRelatedCostNumberOfPositionsAfterHeadcountReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and related cost number of positions after headcount reduction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_RestructuringAndRelatedCostNumberOfPositionsAfterHeadcountReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_SeverancePaymentsPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Severance payments payment period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_SeverancePaymentsPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_TransitionServicesAgreementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transition services agreement period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_TransitionServicesAgreementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendPayableDateToBePaidDayMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the declared dividend will be paid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendPayableDateToBePaidDayMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the dividend to be paid was declared, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableDateDeclaredDayMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the holder must own the stock to be entitled to the dividend, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableDateOfRecordDayMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of a specific restructuring plan and related activities including the facts and circumstances leading to the restructuring or decision to exit an activity, and the expected completion date. This concept and related items would be utilized for each plan if multiple exit plans have been implemented in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesInitiationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the restructuring activities were initiated or are expected to be initiated, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesInitiationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mack_SeniorNotesDueTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mack_SeniorNotesDueTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mack_AssetPurchaseAndSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mack_AssetPurchaseAndSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mack_IpsenSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mack_IpsenSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=mack_ClinicalTrialsInPancreasAsFirstLineTreatmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=mack_ClinicalTrialsInPancreasAsFirstLineTreatmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=mack_ClinicalTrialsInSmallCellLungCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=mack_ClinicalTrialsInSmallCellLungCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=mack_OtherUnrelatedClinicalTrialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=mack_OtherUnrelatedClinicalTrialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=mack_DevelopmentAndCommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=mack_DevelopmentAndCommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=mack_SaleMilestoneInMajorEuropeanCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=mack_SaleMilestoneInMajorEuropeanCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=mack_SaleMilestoneInMajorNonEuropeanAndNonAsianCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=mack_SaleMilestoneInMajorNonEuropeanAndNonAsianCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=mack_ClinicalTrialsInLungCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=mack_ClinicalTrialsInLungCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mack_PharmaEngineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mack_PharmaEngineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=mack_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=mack_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=mack_SalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=mack_SalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760422784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Commercial Business - Schedule of Discontinued Operations and Assets Held for Sale (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract', window );"><strong>Other income and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income tax expense</a></td>
<td class="num">$ (51,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (51,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Total income (loss) from discontinued operations</a></td>
<td class="nump">540,485<span></span>
</td>
<td class="nump">$ 675<span></span>
</td>
<td class="nump">539,538<span></span>
</td>
<td class="num">$ (268)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mack_CommercialBusinessMember', window );">Commercial Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet', window );">Product revenues, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,851<span></span>
</td>
<td class="nump">16,135<span></span>
</td>
<td class="nump">22,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues', window );">License and collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,332<span></span>
</td>
<td class="nump">7,797<span></span>
</td>
<td class="nump">30,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,498<span></span>
</td>
<td class="nump">1,973<span></span>
</td>
<td class="nump">1,498<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,681<span></span>
</td>
<td class="nump">25,905<span></span>
</td>
<td class="nump">54,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,872<span></span>
</td>
<td class="nump">3,890<span></span>
</td>
<td class="nump">2,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,302<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
<td class="nump">18,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,542<span></span>
</td>
<td class="nump">8,709<span></span>
</td>
<td class="nump">23,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses', window );">Restructuring expenses</a></td>
<td class="nump">4,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total costs and expenses</a></td>
<td class="nump">4,216<span></span>
</td>
<td class="nump">27,716<span></span>
</td>
<td class="nump">25,834<span></span>
</td>
<td class="nump">44,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract', window );"><strong>Other income and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense', window );">Interest expense</a></td>
<td class="num">(1,509)<span></span>
</td>
<td class="num">(5,290)<span></span>
</td>
<td class="num">(6,743)<span></span>
</td>
<td class="num">(10,581)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">Gain on sale of commercial business</a></td>
<td class="nump">598,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">598,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Income (loss) from discontinued operations</a></td>
<td class="nump">592,395<span></span>
</td>
<td class="nump">675<span></span>
</td>
<td class="nump">591,448<span></span>
</td>
<td class="num">(268)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income tax expense</a></td>
<td class="num">(51,910)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,910)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Total income (loss) from discontinued operations</a></td>
<td class="nump">$ 540,485<span></span>
</td>
<td class="nump">$ 675<span></span>
</td>
<td class="nump">$ 539,538<span></span>
</td>
<td class="num">$ (268)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation cost and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DisposalGroupIncludingDiscontinuedOperationCostAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation license and collaboration revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DisposalGroupIncludingDiscontinuedOperationLicenseAndCollaborationRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation other income and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DisposalGroupIncludingDiscontinuedOperationOtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation product revenues net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DisposalGroupIncludingDiscontinuedOperationProductRevenuesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation restructuring expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DisposalGroupIncludingDiscontinuedOperationRestructuringExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507043&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1063-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1060-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mack_CommercialBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mack_CommercialBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771978688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Sale of Commercial Business - Schedule of Carrying Value of Assets and Liabilities Classified as Assets Held for Sale Relates to Commercial Business (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current assets held for sale</a></td>
<td class="nump">$ 33,295<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Total long-term assets held for sale</a></td>
<td class="nump">9,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities held for sale</a></td>
<td class="nump">56,839<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Total liabilities held for sale</a></td>
<td class="nump">25,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mack_CommercialBusinessMember', window );">Commercial Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">17,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory</a></td>
<td class="nump">14,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,547<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current assets held for sale</a></td>
<td class="nump">33,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent', window );">Property and equipment, net</a></td>
<td class="nump">1,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets, net</a></td>
<td class="nump">3,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent', window );">Goodwill</a></td>
<td class="nump">3,605<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Total long-term assets held for sale</a></td>
<td class="nump">9,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent', window );">Accounts payable, accrued expenses and other</a></td>
<td class="nump">20,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent', window );">Deferred revenues</a></td>
<td class="nump">36,226<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities held for sale</a></td>
<td class="nump">56,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent', window );">Deferred revenues, net of current portion</a></td>
<td class="nump">25,673<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Total liabilities held for sale</a></td>
<td class="nump">$ 25,673<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation accounts payable and accrued liabilities current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpensesAndOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2510-110228<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred revenue attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred revenue attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2510-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2510-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2510-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2510-110228<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2510-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mack_CommercialBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mack_CommercialBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763601568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Sale of Commercial Business - Schedule of Inventory of Commercial Business (Detail) - Commercial Business [Member]<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 4,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">8,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,420<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 14,554<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mack_CommercialBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mack_CommercialBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760791328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Commercial Business - Summary of Charges Related to Restructuring Activities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost And Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Accrued Restructuring Expenses at Dec 31, 2016</a></td>
<td class="nump">$ 774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Accrued Restructuring Expenses at June 30, 2017</a></td>
<td class="nump">1,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mack_CommercialBusinessMember', window );">Commercial Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost And Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expenses</a></td>
<td class="nump">9,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Less: Payments</a></td>
<td class="nump">8,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Accrued Restructuring Expenses at June 30, 2017</a></td>
<td class="nump">1,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mack_CommercialBusinessMember', window );">Commercial Business [Member] | Severance Benefits and Related Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost And Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expenses</a></td>
<td class="nump">9,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Less: Payments</a></td>
<td class="nump">8,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Accrued Restructuring Expenses at June 30, 2017</a></td>
<td class="nump">$ 1,397<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mack_CommercialBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mack_CommercialBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775577248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 05, 2017</div></th>
<th class="th"><div>Apr. 03, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 22, 2015</div></th>
<th class="th"><div>Jul. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Unrestricted cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,501<span></span>
</td>
<td class="nump">$ 17,200<span></span>
</td>
<td class="nump">$ 21,524<span></span>
</td>
<td class="nump">$ 21,491<span></span>
</td>
<td class="nump">$ 185,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Special cash dividend distributed</a></td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendPayableDateToBePaidDayMonthAndYear', window );">Dividend paid date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 26,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear', window );">Dividend payable, date of record</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 17,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Aggregate principal amount outstanding redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Deposited into escrow account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mack_SeniorNotesDueTwoThousandTwentyTwoMember', window );">2022 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mack_AssetPurchaseAndSaleAgreementMember', window );">Asset Sale Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Special cash dividend distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mack_AssetPurchaseAndSaleAgreementMember', window );">Asset Sale Agreement [Member] | 2022 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Aggregate principal amount outstanding redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_PaymentOfMakeWholePremiumOfLongTermDebt', window );">Additional premium payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mack_IpsenSAMember', window );">Ipsen [Member] | Asset Sale Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AssetSaleUpfrontCashPaymentReceived', window );">Upfront cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset', window );">Working capital adjustment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_AssetSaleUpfrontCashPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset sale upfront&#8203; cash&#8203; payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_AssetSaleUpfrontCashPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_PaymentOfMakeWholePremiumOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of make-whole premium of long term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_PaymentOfMakeWholePremiumOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working capital adjustment receivable related to sale of asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_WorkingCapitalAdjustmentReceivableRelatedToSaleOfAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendPayableDateToBePaidDayMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the declared dividend will be paid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendPayableDateToBePaidDayMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the holder must own the stock to be entitled to the dividend, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableDateOfRecordDayMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mack_SeniorNotesDueTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mack_SeniorNotesDueTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mack_AssetPurchaseAndSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mack_AssetPurchaseAndSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mack_IpsenSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mack_IpsenSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760443968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="num">$ (30,239)<span></span>
</td>
<td class="num">(30,239)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income tax expense in discontinued operations</a></td>
<td class="nump">51,900<span></span>
</td>
<td class="nump">51,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AccruedIntraperiodTaxAllocation', window );">Accrued income tax provision</a></td>
<td class="nump">13,530<span></span>
</td>
<td class="nump">$ 13,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation', window );">Income tax provision in discontinued operations</a></td>
<td class="nump">223,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DiscontinuedOperationValuationAllowanceFromDisposalOfDiscontinuedOperation', window );">Valuation allowance in discontinued operations</a></td>
<td class="nump">$ 171,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_AccruedIntraperiodTaxAllocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued intraperiod tax allocation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_AccruedIntraperiodTaxAllocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DiscontinuedOperationValuationAllowanceFromDisposalOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discontinued operation valuation allowance from disposal of discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DiscontinuedOperationValuationAllowanceFromDisposalOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507043&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=79507043&amp;loc=d3e38679-109324<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775032320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Common Share - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jul. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_UndistributedEarningsLossAllocatedToParticipatingSecurities', window );">Amounts allocated to participating securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_ParticipatingSecuritiesOutstandingShares', window );">Participating securities outstanding, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Aggregate principal amount of outstanding debt</a></td>
<td class="nump">$ 60,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_ParticipatingSecuritiesOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Participating securities outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_ParticipatingSecuritiesOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_UndistributedEarningsLossAllocatedToParticipatingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Undistributed earnings (loss) allocated to participating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_UndistributedEarningsLossAllocatedToParticipatingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6931204032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Common Share - Schedule of Outstanding Securities Excluded from Computation of Diluted Loss Per Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Outstanding Options to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding securities excluded from calculation of diluted loss per share</a></td>
<td class="nump">18,915<span></span>
</td>
<td class="nump">21,647<span></span>
</td>
<td class="nump">18,915<span></span>
</td>
<td class="nump">21,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Conversion of the Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding securities excluded from calculation of diluted loss per share</a></td>
<td class="nump">12,158<span></span>
</td>
<td class="nump">12,158<span></span>
</td>
<td class="nump">12,158<span></span>
</td>
<td class="nump">12,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760806576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Schedule of Assets Measured at Fair Value on a Recurring Basis (Detail) - Recurring Basis [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">$ 128,931<span></span>
</td>
<td class="nump">$ 12,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">128,931<span></span>
</td>
<td class="nump">12,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="nump">4,062<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 [Member] | Silver Creek [Member] | Warrant Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="nump">$ 4,062<span></span>
</td>
<td class="nump">$ 1,499<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=mack_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=mack_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776400304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Additional Information (Detail) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 22, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_FairValueInstrumentsTransfersBetweenLevels', window );">Transfers between fair value measurement levels</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,887,000<span></span>
</td>
<td class="nump">$ 14,566,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Aggregate principal amount of outstanding debt</a></td>
<td class="nump">48,900,000<span></span>
</td>
<td class="nump">48,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Convertible Notes [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value of debt</a></td>
<td class="nump">36,700,000<span></span>
</td>
<td class="nump">36,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mack_SeniorNotesDueTwoThousandTwentyTwoMember', window );">2022 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember', window );">Silver Creek Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_FairValueAdjustmentOfWarrantsIncrementalChangeResultingFromAmendment', window );">Change in fair value of warrant, incremental change</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember', window );">Silver Creek Inc. [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember', window );">Silver Creek Inc. [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember', window );">Silver Creek Inc. [Member] | Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase preferred stock, shares</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants to purchase preferred stock, value</a></td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_FairValueAdjustmentOfWarrantsIncrementalChangeResultingFromAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value adjustment of warrants incremental change resulting from amendment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_FairValueAdjustmentOfWarrantsIncrementalChangeResultingFromAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_FairValueInstrumentsTransfersBetweenLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Instruments Transfers Between Levels</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_FairValueInstrumentsTransfersBetweenLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mack_SeniorNotesDueTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mack_SeniorNotesDueTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929329088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AmortizedCostAndFairValueDebtSecuritiesAbstract', window );"><strong>Amortized Cost And Fair Value Debt Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1', window );">Number of securities held in unrealized loss position | Security</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains', window );">Realized gains (losses) on sale of available-for-sale securities | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_AmortizedCostAndFairValueDebtSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized Cost and Fair Value Debt Securities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_AmortizedCostAndFairValueDebtSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross profit realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investment positions in available-for-sale investments in a continuous unrealized loss position for which an other-than-temporary impairment (OTTI) has not been recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761493088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable, Accrued Expenses and Other - Schedule of Accounts Payable, Accrued Expenses and Other (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AccountsPayableAndAccruedLiabilitiesLineItems', window );"><strong>Accounts Payable And Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 8,298<span></span>
</td>
<td class="nump">$ 2,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued goods and services</a></td>
<td class="nump">5,467<span></span>
</td>
<td class="nump">8,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AccruedClinicalTrialCosts', window );">Accrued clinical trial costs</a></td>
<td class="nump">10,382<span></span>
</td>
<td class="nump">8,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AccruedDrugPurchaseCostsCurrent', window );">Accrued drug purchase costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related benefits</a></td>
<td class="nump">1,362<span></span>
</td>
<td class="nump">3,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Accrued severance expenses</a></td>
<td class="nump">1,736<span></span>
</td>
<td class="nump">774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">1,261<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Accrued dividends payable</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent', window );">Deferred tax incentives</a></td>
<td class="nump">1,402<span></span>
</td>
<td class="nump">1,402<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable, accrued expenses and other</a></td>
<td class="nump">33,989<span></span>
</td>
<td class="nump">29,369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember', window );">Silver Creek [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AccountsPayableAndAccruedLiabilitiesLineItems', window );"><strong>Accounts Payable And Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_WarrantLiabilityCurrent', window );">Warrant liability</a></td>
<td class="nump">$ 4,062<span></span>
</td>
<td class="nump">$ 1,499<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_AccountsPayableAndAccruedLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_AccountsPayableAndAccruedLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_AccruedClinicalTrialCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date arising from ongoing clinical trial activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_AccruedClinicalTrialCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_AccruedDrugPurchaseCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued drug purchase costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_AccruedDrugPurchaseCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_WarrantLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant liability current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_WarrantLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income during the current period and current obligations not separately disclosed in the balance sheet (other liabilities, current).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760895424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - 2022 Notes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2015</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_ScheduleOfDebtInstrumentsLineItems', window );"><strong>Schedule Of Debt Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,887<span></span>
</td>
<td class="nump">$ 14,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,762<span></span>
</td>
<td class="nump">$ 15,858<span></span>
</td>
<td class="nump">28,741<span></span>
</td>
<td class="nump">19,148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mack_SeniorNotesDueTwoThousandTwentyTwoMember', window );">2022 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_ScheduleOfDebtInstrumentsLineItems', window );"><strong>Schedule Of Debt Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds from the debt issuance</a></td>
<td class="nump">$ 168,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">$ 10,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Prepayment penalty of extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization expense recognized for remaining debt discount at settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mack_SeniorNotesDueTwoThousandTwentyTwoMember', window );">2022 Notes [Member] | Interest Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_ScheduleOfDebtInstrumentsLineItems', window );"><strong>Schedule Of Debt Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_ScheduleOfDebtInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Debt Instruments [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_ScheduleOfDebtInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mack_SeniorNotesDueTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mack_SeniorNotesDueTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776075424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Convertible Notes - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 26, 2017</div></th>
<th class="th">
<div>Apr. 18, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 13, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2013 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 31, 2013 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 03, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,741,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,741,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,197,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,887,000<span></span>
</td>
<td class="nump">$ 14,566,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 15,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,762,000<span></span>
</td>
<td class="nump">$ 15,858,000<span></span>
</td>
<td class="nump">$ 28,741,000<span></span>
</td>
<td class="nump">$ 19,148,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds from the debt issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Embedded conversion option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,800,000<span></span>
</td>
<td class="nump">$ 53,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DebtIssuanceCostsUnderwritingDiscountsCommissionsAndOfferingExpenses', window );">Underwriting discounts and commissions and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Principal amount of convertible notes due 2020 converted into shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock', window );">Conversion ratio, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion rate of common stock shares per $1,000 principal amount</a></td>
<td class="nump">235.2112<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160.0000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,732,152<span></span>
</td>
<td class="nump">3,635,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,367,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,367,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_ValueOfAdditionalSharesIssuedForConversion', window );">Value of additional shares issued for conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_TradingPeriodOfCommonStock', window );">Trading period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_IncreaseToAdditionalPaidInCapitalDueToConversion', window );">Increase to additional paid in capital pursuant to conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_ReductionInAdditionalPaidInCapitalAttributableToEmbeddedConversionOption', window );">Reduction in additional paid-in capital attributable to embedded conversion option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DebtInstrumentConversionObligationNumberOfConsecutiveTradingTerm', window );">Number of consecutive trading days during which the closing price of the entity's common stock must exceed the conversion price for at least 20 days in order for the notes to be convertible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_ConvertibilityOfDebtStockPriceTestTargetPercentageOfClosingStockPriceToConversionPriceThatMustBeExceeded', window );">Convertibility of debt, closing price of stock test, percentage of stock price to conversion price for the notes that must be exceeded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessPeriodAfterConsecutiveTradingTerm', window );">Number of consecutive business days immediately after any five consecutive trading day period during the note measurement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DebtInstrumentConversionObligationPeriodOfConsecutiveTrading', window );">Number of consecutive trading days before five consecutive business days during the note measurement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price of shares (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Deposited into escrow account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DebtInstrumentConversionObligationCommonStockClosingSalesPriceTradingPeriod', window );">Number of days within 30 consecutive trading days in which the closing price of the entity's common stock must exceed the conversion price for the notes to be convertible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_ConvertibilityOfDebtDebtPriceTestPercentageOfClosingStockPriceUsedInCalculation', window );">Convertibility of debt, trading price of debt test, percentage of closing price of stock used in calculation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes [Member] | Transaction Costs Incurred With Third Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DecreaseToAdditionalPaidInCapitalDueToConversionTransactionCost', window );">Reduction in additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes [Member] | Interest Expense [Member] | Transaction Costs Incurred With Third Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DebtConversionCostsIncurredAndPaid', window );">Transaction costs related to conversion of convertible notes due 2020 incurred and paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_ConvertibilityOfDebtDebtPriceTestPercentageOfClosingStockPriceUsedInCalculation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>When testing, based upon the debt price, whether the convertible debt may be converted by the debt holder, represents the percentage of the closing stock price used in the calculation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_ConvertibilityOfDebtDebtPriceTestPercentageOfClosingStockPriceUsedInCalculation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_ConvertibilityOfDebtStockPriceTestTargetPercentageOfClosingStockPriceToConversionPriceThatMustBeExceeded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>When testing, based upon the stock price, whether convertible debt may be converted by the debt holder, represents the ratio, expressed as a percentage, of the closing stock price to the conversion price that must be exceeded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_ConvertibilityOfDebtStockPriceTestTargetPercentageOfClosingStockPriceToConversionPriceThatMustBeExceeded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DebtConversionCostsIncurredAndPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction costs related to conversion of convertible notes due 2020 incurred and paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DebtConversionCostsIncurredAndPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DebtInstrumentConversionObligationCommonStockClosingSalesPriceTradingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of trading days within a period of 30 consecutive trading days during which the closing price of the entity's common stock must exceed the applicable conversion price in order for the debt instruments to be convertible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DebtInstrumentConversionObligationCommonStockClosingSalesPriceTradingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessPeriodAfterConsecutiveTradingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of consecutive business days immediately after any five consecutive trading day period during the debt instrument measurement period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessPeriodAfterConsecutiveTradingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DebtInstrumentConversionObligationNumberOfConsecutiveTradingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of consecutive trading days during which the closing price of the entity's common stock must exceed the applicable conversion price for at least 20 days in order for the debt instruments to be convertible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DebtInstrumentConversionObligationNumberOfConsecutiveTradingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DebtInstrumentConversionObligationPeriodOfConsecutiveTrading">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of consecutive trading days prior to the five consecutive business days during the debt instrument measurement period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DebtInstrumentConversionObligationPeriodOfConsecutiveTrading</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the denomination of the principal amount of debt used to state the number of shares that debt can be converted into, and which is used in conversion calculations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DebtIssuanceCostsUnderwritingDiscountsCommissionsAndOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt issuance costs underwriting discounts commissions and offering expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DebtIssuanceCostsUnderwritingDiscountsCommissionsAndOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DecreaseToAdditionalPaidInCapitalDueToConversionTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease to additional paid in capital due to conversion transaction cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DecreaseToAdditionalPaidInCapitalDueToConversionTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_IncreaseToAdditionalPaidInCapitalDueToConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase to additional paid in capital due to conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_IncreaseToAdditionalPaidInCapitalDueToConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_ReductionInAdditionalPaidInCapitalAttributableToEmbeddedConversionOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in additional paid in capital attributable to embedded conversion option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_ReductionInAdditionalPaidInCapitalAttributableToEmbeddedConversionOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_TradingPeriodOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading period of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_TradingPeriodOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_ValueOfAdditionalSharesIssuedForConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of additional shares issued for conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_ValueOfAdditionalSharesIssuedForConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21506-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mack_TransactionCostsIncurredWithThirdPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mack_TransactionCostsIncurredWithThirdPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761644608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Schedule of Future Minimum Payments under the Loans Payable (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 48,906<span></span>
</td>
<td class="nump">$ 216,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2017</a></td>
<td class="nump">1,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2018</a></td>
<td class="nump">2,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2019</a></td>
<td class="nump">2,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter', window );">2020 and thereafter</a></td>
<td class="nump">63,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_DebtInstrumentCarryingAmountIncludingContractualInterest', window );">Loans payable, gross including contractual interest</a></td>
<td class="nump">70,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_ContractualInterestIncludedInPayments', window );">Less interest</a></td>
<td class="num">(9,576)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less unamortized discount</a></td>
<td class="num">(11,885)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 48,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_ContractualInterestIncludedInPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest included in gross contractual obligations that must be removed in order to reconcile to gross borrowings at the current reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_ContractualInterestIncludedInPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_DebtInstrumentCarryingAmountIncludingContractualInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt before deduction of unamortized discount or premium including contractual interest. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_DebtInstrumentCarryingAmountIncludingContractualInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of principal in year four and thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761232944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 05, 2017</div></th>
<th class="th"><div>Feb. 29, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,388,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Special cash dividend paid</a></td>
<td class="nump">$ 140.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendPayableDateToBePaidDayMonthAndYear', window );">Dividend paid date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 26,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear', window );">Dividend payable, date of record</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 17,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="nump">$ 3.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense related to nonvested stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which unrecognized stock-based compensation expense is expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mack_StockIncentivePlan2011Member', window );">Stock Incentive Plan 2011 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares of common stock available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional common stock available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400,000<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mack_StockIncentivePlan2011Member', window );">Stock Incentive Plan 2011 [Member] | Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendPayableDateToBePaidDayMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the declared dividend will be paid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendPayableDateToBePaidDayMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the holder must own the stock to be entitled to the dividend, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableDateOfRecordDayMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mack_StockIncentivePlan2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mack_StockIncentivePlan2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mack_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mack_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776099936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Assumptions Used to Calculate Fair Value of Options Granted to Employees (Detail) - Options to Purchase Common Stock [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 10 months 25 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6918798832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Recognized Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 8,734<span></span>
</td>
<td class="nump">$ 3,567<span></span>
</td>
<td class="nump">$ 9,529<span></span>
</td>
<td class="nump">$ 6,077<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense for employee awards</a></td>
<td class="nump">4,916<span></span>
</td>
<td class="nump">1,465<span></span>
</td>
<td class="nump">5,383<span></span>
</td>
<td class="nump">2,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense for employee awards</a></td>
<td class="nump">$ 3,818<span></span>
</td>
<td class="nump">$ 2,102<span></span>
</td>
<td class="nump">$ 4,146<span></span>
</td>
<td class="nump">$ 3,086<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and nonemployees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_AllocatedShareBasedCompensationExpenseIncludingNonEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760801904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Detail)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Beginning balance | shares</a></td>
<td class="nump">19,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted | shares</a></td>
<td class="nump">19,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised | shares</a></td>
<td class="num">(2,562)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited | shares</a></td>
<td class="num">(16,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Ending balance | shares</a></td>
<td class="nump">18,915<span></span>
</td>
<td class="nump">19,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and expected to vest | shares</a></td>
<td class="nump">18,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable | shares</a></td>
<td class="nump">12,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Outstanding, Beginning balance | $ / shares</a></td>
<td class="nump">$ 5.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">2.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Forfeited | $ / shares</a></td>
<td class="nump">6.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Outstanding, Ending balance | $ / shares</a></td>
<td class="nump">2.43<span></span>
</td>
<td class="nump">$ 5.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Vested and expected to vest | $ / shares</a></td>
<td class="nump">2.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercisable | $ / shares</a></td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term</a></td>
<td class="text">5 years 10 months 14 days<span></span>
</td>
<td class="text">5 years 11 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Vested and expected to vest</a></td>
<td class="text">5 years 10 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">3 years 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 440<span></span>
</td>
<td class="nump">$ 7,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest | $</a></td>
<td class="nump">440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762141328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember', window );">Silver Creek [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Net cash proceeds from stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents', window );">Ownership interest percentage held by parent and its de facto agents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember', window );">Silver Creek [Member] | Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Preferred stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Net cash proceeds from stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember', window );">Silver Creek [Member] | Series C Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Preferred stock price per share</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Net cash proceeds from stock issuance</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ownership percentage held by parent and its de facto agents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mack_OwnershipPercentageHeldByParentAndItsDeFactoAgents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mack_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mack_SilverCreekPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,V#"4L?(\\#P    !,"   +    7W)E;',O+G)E;'.MDD^+
MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V
M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F'
M.>RGGD7E2B.5^S3%":4A+<TXP)6E/S/WJVR;A5ND9T*YKCM+1[873T$7LF<;
M!I99-G\LCNVW<+ZT+/0:S>,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C
M-R."?S]PN -02P,$%     @ S8,)2V;S"V""    L0   !    !D;V-0<F]P
M<R]A<' N>&UL38Y-"\(P$$3_2NG=;BGB06) L$?!D_>0;FP@R8;-"OGYIH(?
MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    " #-@PE+#++!>.\    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+!3L,P#(9?!>7>NFG18%'7"X@32$A, G&+'&^+:-HH,6KW]J1E
MZX3@ 3C&_O/YL^0:O<(^T'/H/06V%*]&UW91H=^( [-7 !$/Y'3,4Z)+S5T?
MG.;T#'OP&C_TGJ LBA4X8FTT:YB F5^(HJD-*@RDN0\GO,$%[S]#.\,, K7D
MJ.,(,I<@FFFB/XYM#1? !&,*+GX7R"S$N?HG=NZ ."7':)?4, SY4,VYM(.$
MMZ?'EWG=S':1=8>4?D6K^.AI(\Z37ZN[^^V#:,I"WF3%;5:LMW*ERK6JKM\G
MUQ]^%V'7&[NS_]CX+-C4\.LNFB]02P,$%     @ S8,)2YE<G",0!@  G"<
M !,   !X;"]T:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T
M$W-I=MNTF83M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY
M\^XN8NB&B)3R>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2
MP]R"BPA+>!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?
M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA
M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M
M&N#C\7@XMLO2BW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_K
MFVB<"HU;3]-K=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K
M>A(5M>5 TR  6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T
M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)
MI#-ZG7TZSFN4?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R
M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M<VAE970Q+GAM;'U6VX[;(!#]%<L?L#;@2Q(YEI)452NU4K15M\_$(;&UV+A
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MZ\V+?&%,$A51_*1BJ563GA:47*2>YFK.ATXU+"3KQRX<37\%RK]02P,$%
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M8GU?GBD56(:%*QFPE"UT7!!\%FJ:R#GK^TB_$+0=>B08&W7Q#U!+ P04
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M)^OPW:K"783O_E+X 4&Z2I!&@O2_):[%7/Z3A"UZJL V<9H<*4VOXR0OO//
MWB3Q3?Z$C]-^SVTCM",GX_%E8_]K8SR@E,T%CE"+'VPV)-0^'*_P;,<Q&PUO
MNND'L?D;%[\!4$L#!!0    ( ,V#"4O+]3R5M $  -(#   8    >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL?5-A;]L@$/TKB!]0$L=IH\BVU'2:-FF5HE;;
M/A/[;*,"YP&.VW]?P*[G;=:^ '?<>_?N.+(!S8MM 1QY55+;G+;.=4?&;-F"
MXO8&.]#^ID:CN/.F:9CM#/ J@I1DR69SRQ07FA99])U-D6'OI-!P-L3V2G'S
M=@*)0TZW],/Q))K6!0<KLHXW\ SN>W<VWF(S2R44:"M0$P-U3N^WQU,:XF/
M#P&#79Q)J.2"^!*,KU5.-T$02"A=8.!^N\(#2!F(O(Q?$R>=4P;@\OS!_CG6
M[FNY< L/*'^*RK4Y/5!20<U[Z9YP^ )3/7M*IN*_P16D#P]*?(X2I8TK*7OK
M4$TL7HKBK^,N=-R'\6:_GV#K@&0")#/@$/.P,5%4_HD[7F0&!V+&WG<\//'V
MF/C>E,$96Q'OO'CKO==BF]YF[!J(IIC3&),L8^8(YMGG%,E:BE/R#SQ9A^]6
M%>XB?/>'PKMU@G25((T$Z7]+7(LY_)6$+7JJP#1QFBPIL==QDA?>>6#OD_@F
MO\/':7_DIA':D@LZ_[*Q_S6B R]E<^-'J/4?;#8DU"X<[_S9C&,V&@Z[Z0>Q
M^1L7[U!+ P04    " #-@PE+MTG9>[4!  #2 P  &    'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;'U386_<( S]*X@?4'*Y=&U/2:1>IVF3-NG4:=MG+G$2
M5, 9D$OW[P<DS;(VVQ? QN_YV9A\1/-D.P!'GI74MJ"=<_V!,5MUH+B]PAZT
MOVG0*.Z\:5IF>P.\CB E69HD[YCB0M,RC[Z3*7,<G!0:3H;802EN?AU!XEC0
M'7UQ/(JV<\'!RKSG+7P%]ZT_&6^QA:46"K05J(F!IJ#WN\,Q"_$QX+N T:[.
M)%1R1GP*QJ>ZH$D0!!(J%QBXWR[P %(&(B_CY\Q)EY0!N#Z_L'^(M?M:SMS"
M \H?HG9=06\IJ:'A@W2/.'Z$N9YK2N;B/\,%I \/2GR."J6-*ZD&ZU#-+%Z*
MXL_3+G3<Q^GFYFZ&;0/2&9 N@-N8ATV)HO+WW/$R-S@2,_6^Y^&)=X?4]Z8*
MSMB*>.?%6^^]E+OL+F>70#3''*>8=!VS1##/OJ1(MU(<TS?P=!N^WU2XC_#]
M7PK_09!M$F21(/MOB1LQU\FK)&S54P6FC=-D286#CI.\\BX#>Y_&-_D3/DW[
M%VY:H2TYH_,O&_O?(#KP4I(K/T*=_V"+(:%QX7CCSV8:L\EPV,\_B"W?N/P-
M4$L#!!0    ( ,V#"4MN'G2HLP$  -(#   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;'U386_<( S]*X@?4"[DVE6G)%*OT]1*FW3JM/4SES@)*L0I
MD$OW[P<DS;(MVQ? QN_YV9AL1/-B6P!'WK3J;$Y;Y_H#8[9L00M[A3UT_J9&
MHX7SIFF8[0V(*H*T8GRWNV%:R(X66?2=3)'AX)3LX&2(';06YL<1%(XY3>B[
MXTDVK0L.5F2]:. KN&_]R7B++2R5U-!9B1TQ4.?T+CD<]R$^!GR7,-K5F81*
MSH@OP7BL<KH+@D!!Z0*#\-L%[D&I0.1EO,Z<=$D9@.OS._NG6+NOY2PLW*-Z
MEI5K<WI+206U&)1[PO$!YGJN*9F+_PP74#X\*/$Y2E0VKJ0<K$,]LW@I6KQ-
MN^SB/DXW:3K#M@%\!O %<!OSL"E15/Y1.%%D!D=BIM[W(CQQ<N"^-V5PQE;$
M.R_>>N^E2*Z3C%T"T1QSG&+X.F:)8)Y]2<&W4ASY7W"^#4\W%:81GOZF\!\$
M^TV"?238_[?$K9CTCR1LU5,-IHG39$F)0Q<G>>5=!O:.QS?Y%3Y-^Q=A&ME9
M<D;G7S;VOT9TX*7LKOP(M?Z#+8:"VH7C!W\VTYA-AL-^_D%L^<;%3U!+ P04
M    " #-@PE+J#?$>+4!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q]4]MNW" 0_17$!X1=UIM$*]M2-E'52JFT2I7DF;7'%P48%_ Z_?L"
M=ARWM?H"S##GS)EA2 <T;[8!<.1=26TSVCC7'1BS10-*V"OL0/N;"HT2SINF
M9K8S(,H(4I+QS>::*=%JFJ?1=S)YBKV3K8:3(;972IA?1Y X9'1+/QQ/;=VX
MX&!YVHD:?H![[D[&6VQF*5L%VK:HB8$JHW?;PS$)\3'@I87!+LXD5')&? O&
MMS*CFR ()!0N, B_7> >I Q$7L;/B9/.*0-P>?Y@_Q)K][6<A85[E*]MZ9J,
MWE)20B5ZZ9YP^ I3/7M*IN(?X0+2AP<E/D>!TL:5%+UUJ"86+T6)]W%O==R'
M\6:WGV#K #X!^ RXC7G8F"@J?Q!.Y*G!@9BQ]YT(3[P]<-^;(CAC*^*=%V^]
M]Y)O]TG*+H%HBCF.,7P9,T<PSSZGX&LICOP?.%^'[U85[B)\]X?"_3I!LDJ0
M1(+DOR6NQ5S_E80M>JK U'&:+"FPUW&2%]YY8.]X?)//\'':OPM3M]J2,SK_
MLK'_%:(#+V5SY4>H\1]L-B14+AQO_-F,8S8:#KOI!['Y&^>_ 5!+ P04
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M_LD,7V"JYYJ2J?AO< :)X4$)YBB-='$E9>^\41,+2E'\==R%COLPWEQ?8.N
M= *D,^ V MB8*"I_X)X7F34#L6/O.QZ>>+-/L3=E<,96Q#L4[]![+C8W2<;.
M@6B*.8PQZ3)FCF#(/J=(UU(<TG_@Z3I\NZIP&^';/Q3^)_]NE6 7"78?EK@6
M\[=*MNBI MO$:7*D-+V.D[SPS@-[E\8W^1T^3OLCMXW0CIR,QY>-_:^-\8!2
MDBL<H18_V&Q(J'TX?L*S'<=L-+SIIA_$YF]<O -02P,$%     @ S8,)2X;B
M]K&T 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&UL?5/;;MP@
M$/T5Q >$7=:;1"O;4C91U4JIM$J5Y)FUQQ<%&!?P.OW[ G8<M[7Z LPPY\R9
M84@'-&^V 7#D74EM,]HXUQT8LT4#2M@K[$#[FPJ-$LZ;IF:V,R#*"%*2\<WF
MFBG1:IJGT7<R>8J]DZV&DR&V5TJ87T>0.&1T2S\<3VW=N.!@>=J)&GZ >^Y.
MQEML9BE;!=JVJ(F!*J-WV\,Q"?$QX*6%P2[.)%1R1GP+QK<RHYL@""04+C (
MOUW@'J0,1%[&SXF3SBD#<'G^8/\2:_>UG(6%>Y2O;>F:C-Y24D(E>NF></@*
M4SU[2J;B'^$"TH<')3Y'@=+&E12]=:@F%B]%B?=Q;W7<A_$FV4^P=0"? 'P&
MW,8\;$P4E3\()_+4X$#,V/M.A"?>'KCO31&<L17QSHNWWGO)M]>[E%T"T11S
M'&/X,F:.8)Y]3L'74ASY/W"^#M^M*MQ%^.X/A<DZ0;)*D$2"Y+\EKL7L_TK"
M%CU58.HX3984V.LXR0OO/+!W/+[)9_@X[=^%J5MMR1F=?]G8_PK1@9>RN?(C
MU/@/-AL2*A>.-_YLQC$;#8?=](/8_(WSWU!+ P04    " #-@PE+<LO)HK0!
M  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q]4V%OVR 0_2N(
M'U 2DB519%MJ6DV=M$E1IZV?B7VV4<'G HZ[?S_ KNMVUKX =]Q[]^XXDA[-
MLZT!''G5JK$IK9UKCXS9O 8M[ VVT/B;$HT6SINF8K8U((H(THKQU6K'M) -
MS9+H.YLLP<XIV<#9$-MI+<R?$RCL4[JF;XY'6=4N.%B6M**"G^!^M6?C+3:Q
M%%)#8R4VQ$"9TMOU\;0-\3'@MX3>SLXD5')!? [&MR*EJR (%.0N, B_7>$.
ME I$7L;+R$FGE $X/[^Q?XVU^UHNPL(=JB=9N#JE!TH**$6GW"/V#S#6\X62
ML?CO< 7EPX,2GR-'9>-*\LXZU".+EZ+%Z[#+)N[]<,/W(VP9P$< GP"'F(<-
MB:+R>^%$EACLB1EZWXKPQ.LC][W)@S.V(MYY\=9[K]EZMTO8-1"-,:<AAL]C
MI@CFV:<4?"G%B?\#Y\OPS:+"381O/BC<+Q-L%PFVD6#[WQ*78@Z?DK!93S68
M*DZ3)3EV39SDF7<:V%L>W^0]?)CV'\)4LK'D@LZ_;.Q_B>C 2UG=^!&J_0>;
M# 6E"\>]/YMAS ;#83O^(#9]X^PO4$L#!!0    ( ,V#"4N[5KD\M0$  -(#
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;'U3VV[<(!#]%<0'!*]W
MDTU7MJ5LHJB56FF5JNDS:X]M%&!<P.OT[PO8<:W$R@LPPSEG+@S9@.;%M@".
MO"JI;4Y;Y[H#8[9L07%[A1UH?U.C4=QYTS3,=@9X%4E*LC1);ICB0M,BB[Z3
M*3+LG10:3H;87BEN_AY!XI#3#7US/(FF=<'!BJSC#?P$]ZL[&6^Q6:42"K05
MJ(F!.J=WF\-Q%_ 1\"Q@L(LS"96<$5^"\:W*:1(2 @FE"PK<;Q>X!RF#D$_C
MSZ1)YY"!N#R_J3_&VGTM9V[A'N5O4;DVI[>45%#S7KHG'+["5,\U)5/QW^$"
MTL-#)CY&B=+&E92]=:@F%9^*XJ_C+G3<A_%FGTZT=4(Z$=*9<!OCL#%0S/R!
M.UYD!@=BQMYW/#SQYI#ZWI3!&5L1[WSRUGLOQ>;F2\8N06C"'$=,NL3,".;5
MYQ#I6HAC^H&>KM.WJQEN(WV[C+Y/U@5VJP*[*+#[M,05S/Y]D6S14P6FB=-D
M28F]CI.\\,X#>Q<?D?V'C]/^@YM&:$O.Z/S+QO[7B Y\*LF5'Z'6?[#9D%"[
M<-S[LQG';#0<=M,/8O,W+OX!4$L#!!0    ( ,V#"4O_FL??M $  -(#   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;'U3VV[4,!#]%<L?4.]Z4UJM
MDDC=(@022*LBZ+,WF216?0FVLRE_S]A)0X"(%]LSGG/FS'B<C]:]^ X@D%>M
MC"]H%T)_9,Q7'6CA;VP/!F\:Z[0(:+J6^=Z!J!-(*\9WNW=,"VEHF2??V96Y
M'8*2!LZ.^$%KX7Z>0-FQH'OZYGB2;1>B@Y5Y+UKX"N%;?W9HL86EEAJ,E]80
M!TU!'_;'4Q;C4\!W":-?G4FLY&+M2S0^U07=14&@H J10>!VA4=0*A*AC!\S
M)UU21N#Z_,;^(=6.M5R$AT>KGF4=NH+>4U)#(P85GNSX$>9Z;BF9B_\,5U 8
M'I5@CLHJGU92#3Y8/;.@%"U>IUV:M(_3S2V?8=L /@/X KA/>=B4*"E_+X(H
M<V='XJ;>]R(^\?[(L3=5=*96I#L4[]%[+?=W/&?72#3'G*88OHY9(ABR+RGX
M5HH3_P?.M^&'386'!#_\H?"P39!M$F2)(/MOB5LQV5])V*JG&ER;ILF3R@XF
M3?+*NPSL0WI$]CM\FO8OPK72>'*Q 5\V];^Q-@!*V=W@"'7XP19#01/B\0[/
M;AJSR0BVGW\06[YQ^0M02P,$%     @ S8,)2R!+=?:U 0  T@,  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL?5/;;MLP#/T501]0)4K:=(%MH.DP
M;, &!!W6/2LV;0O5Q9/DN/O[4;+K>9NQ%TFD> X/*2H;K'OQ+4 @KUH9G],V
MA.[(F"];T,+?V X,WM36:1'0= WSG0-1)9!6C&\V=TP+:6B1)=_9%9GM@Y(&
MSH[X7FOA?IY V2&G6_KF>))-&Z*#%5DG&O@*X5MW=FBQF:62&HR7UA '=4X?
MML?3/L:G@&<)@U^<2:SD8NU+-#Y5.=U$0:"@#)%!X':%1U J$J&,'Q,GG5-&
MX/+\QOXAU8ZU7(2'1ZN^RRJT.;VGI():]"H\V>$C3/7<4C(5_QFNH# \*L$<
MI54^K:3L?;!Z8D$I6KR.NS1I'\8;_FZ"K0/X!. SX#[E86.BI/R]"*+(G!V(
M&WO?B?C$VR/'WI31F5J1[E"\1^^UV!YN,W:-1%/,:8SARY@Y@B'[G(*OI3CQ
M?^!\';Y;5;A+\-T?"N_6"?:K!/M$L/]OB6LQA[^2L$5/-;@F39,GI>U-FN2%
M=Q[8!Y[>Y'?X..U?A&ND\>1B [YLZG]M;0"4LKG!$6KQ@\V&@CK$XP'/;ARS
MT0BVFWX0F[]Q\0M02P,$%     @ S8,)2_*X5VBV 0  T@,  !D   !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL;5-A;]L@$/TKB!]0$I*N661;:CI-F[1)
M4:=UGXE]ME&!\P#'W;\?8-=S.W\![KCW[MUQ9 /:9]<">/*BE7$Y;;WOCHRY
ML@4MW UV8,)-C58+'TS;,-=9$%4":<7X9O.!:2$-+;+D.]LBP]XK:>!LB>NU
M%O;/"10..=W25\>C;%H?':S(.M' #_ _N[,-%IM9*JG!.(F&6*AS>K\]GO8Q
M/@4\21C<XDQB)1?$YVA\K7*ZB8) 0>DC@PC;%1Y J4@49/R>..F<,@*7YU?V
MSZGV4,M%.'A ]4M6OLWI@9(*:M$K_XC#%YCJN:5D*OX;7$&%\*@DY"A1N;22
MLG<>]<02I&CQ,N[2I'T8;V[Y!%L'\ G 9\ AY6%CHJ3\D_"BR"P.Q(Z][T1\
MXNV1A]Z4T9E:D>Z">!>\UV)[=\C8-1)-,:<QAB]CY@@6V.<4?"W%B?\'Y^OP
MW:K"78+OWBC<K1/L5PGVB6#_AH"_*W$MYN.[)&S14PVV2=/D2(F]29.\\,X#
M>Y\>D?T+'Z?]N["--(Y<T(>73?VO$3T$*9N;,$)M^&"SH:#V\7@7SG8<L]'P
MV$T_B,W?N/@+4$L#!!0    ( ,V#"4M3,2+YM@$  -(#   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;'53VVZ<,!#]%<L?$(.7-IL5(&535:W42JM$
M:9^],( 57ZAMEO3O8QM":4)>;,_XG#,7C_-1FR?; 3CT+(6R!>Z<ZP^$V*H#
MR>R5[D'YFT8;R9PW34ML;X#5D20%H4GRF4C&%2[SZ#N9,M>#$US!R2 [2,G,
MWR,(/18XQ:^.>]YV+CA(F?>LA0=PC_W)>(LL*C67H"S7"AEH"GR;'HY9P$?
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M_F;C_"M$![Z4S9U?H<8_L-E14+E@?O2V&==L=!QVTPMB\S/._P!02P,$%
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M?]G8_PK1@4]E=>-'J/$?;#(D5"X<]_YLAC$;#(?M^(/8](WSOU!+ P04
M" #-@PE+PSRQTKD!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6QM4]MNG# 0_17+'Q#OLB39K  IFRIJI59:I6KZ[(4!K/A";+.D?]^Q(90F
MO-B>\3EG+AYG@[$OK@7PY$U)[7+:>M\=&'-E"XJ[*].!QIO:6,4]FK9AKK/
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M\65C_VMC/& JFRL<H18_V&Q(J'TXWN+9CF,V&MYTTP]B\S<N_@)02P,$%
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MGG=_*O=2&K#4\,%VL++W[K00L#=NFMJY&BZ?86%D-UZL=+K=\W]02P,$%
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MZ+"A<))ZF:@U[\=(OY&LM2,R&.9T_A=02P,$%     @ S8,)2S=?'_5" P
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M*A CWT6+21I,V6!01&F(C ( L$1V6Z,$-@HCBHE1!0A%QD;$)R#BB,9A#*\
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MW=_4TFH&Q05:9]]^ :G3*JGMCPK7<\Z]!PC7M"7T@Q4(<>NSPC5;V 7GS1P
MEA>H@NR%-*@6;XZ$5I"+*3T!UE $#XI48> Y3@0J6-9VEJK8CF8I.7-<UFA'
M+7:N*DC_+1$F[<)V[6O@K3P57 9 EC;PA'XA_M[LJ)B!7N505JAF):DMBHX+
M^]6=;V<2KP"_2]2RF[$EG>P)^9"3[X>%[<B"$$8YEPI0/"YHA3"60J*,OUK3
M[E-*XNWXJKY5WH67/61H1?"?\L"+A9W8U@$=X1GS-])^0]I/:%O:_ ]T05C
M924B1TXP4_]6?F:<5%I%E%+!S^Y9UNK9:OTKS4SP-,'K"2+W(X*O"?X7(7A(
M"#0A>#9#J GALQDB38@&!- MEEK]->0P2REI+=J=GP;*8^K.([&_N0RJ[53O
MQ 8P$;UD?NBEX"*%-&;98;P;3#2[AZS'$+=' %% 7X5GJF+IC>B#&E9C1.P,
M:I@4V4R+;,<0WT_,5GSC@OI*P+];4-\L$!@% B40W D$@QWI,+'"U HS\+&:
M1*PG$9M'B#LCH=%(:# 2#HQTF/"!D4G$>A*Q>82X,Q(9C41C(X%G%HB- O'S
M9R(Q"B2&I8P&)S<9[9;KA8[ZF5/-C*EFAE3Q8-=FHU21D]QGZK;F"6!7$KBY
MKRI$3ZK;,"LGYYK+E;N)]@WMU9/WW2"^=.<KUQ!?N_--UZ^^Y+ON^1/24UDS
M:T^XN&7577@DA"-1O_,BSDPA&G8_P>C(Y3 68]JUK6["2:,[,N@_"[+_4$L#
M!!0    ( ,V#"4MM!^>7/0(  # '   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,X+GAM;(U5VXZ;,!#]%<0'K,,U)")(FTO52JVTVFK;9X=, EJ#J>V$[=_7
M-H0-X":\8'LXY_C,&,9Q3=D[SP"$]5&0DJ_L3(AJB1!/,R@P?Z(5E/+-D;("
M"[ED)\0K!OB@205![FP6H@+GI9W$.O;"DIB>!<E+>&$6/Q<%9G_70&B]LAW[
M&GC-3YE0 93$%3[!3Q!OU0N3*]2I'/("2I[3TF)P7-G/SG(7*;P&_,JAYC=S
M2V6RI_1=+;X=5O9,&0("J5 *6 X7V  A2DC:^--JVMV6BG@[OZI_T;G+7/:8
MPX:2W_E!9"L[LJT#'/&9B%=:?X4VG\"VVN2_PP6(A"LG<H^4$JZ?5GKF@A:M
MBK12X(]FS$L]UJW^E68FN"W![0AR[WL$KR5XGP3_+L%O"?[4'8*6$ QV0$WN
MNIA;+' 2,UI;K/D<*JR^.F<9R.-*55"?CGXGZ\EE]))X012CBQ)J,>L&X]Y@
MPD4?LAU#G Z!I('.A6MRL79'=+>_P6:,F,\&'AZ*[.Z*]&QZQF)YFN_WBK4P
M"_A& 5\+>#T!SRP0& 6"L8-P4(=U@PDTIFS.(EHXP:"@8Y3KA/Y\4--)6KM'
M6KW$0F-BH2&Q_WQ"<Z/ ?'II(Z- -*&TT;@<KC/\7S:34-M)J-TC5),8NOG=
M"V GW7NYE=)S*511;J)=>W]V5;L8Q-?.<N,8XEMY'33=^U.^N4M^8';*2V[M
MJ9!-2K>2(Z4"I/G9D_2=R>NK6Q X"C6=RSEKFGBS$+1J[R?479+)/U!+ P04
M    " #-@PE+QKU!,2,"  !-!P  &0   'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6R55>V.FS 0?!7$ YPQAI"<"%(O5=5*K11=U>MO)]D$= 93VPG7MZ]M
M",J139O^B3^8&6:'K)UW4KWJ$L $;[5H]#(LC6D?"=';$FJN'V0+C7VREZKF
MQB[5@>A6 =]Y4BU('$4S4O.J"8O<[ZU5D<NC$54#:Q7H8UUS]?L)A.R6(0W/
M&\_5H31N@Q1YRP_P'<R/=JWLBHPJNZJ&1E>R"13LE^$'^KBBS!$\XJ6"3E_,
M U?*1LI7M_BR6X:1<P0"ML9)<#N<8 5"."7KX]<@&H[O=,3+^5G]DR_>%K/A
M&E92_*QVIER&\S#8P9X?A7F6W6<8"DK#8*C^*YQ 6+AS8M^QE4+[WV![U$;6
M@XJU4O.W?JP:/W:#_IF&$^*!$(\$FOR5P 8"FQ!([\R7^I$;7N1*=H'JOU;+
MW9^"/C(;YM9M^NS\,UNMMKNG@LWBG)R<T(!YZC'Q!6:"6"&(=(00:V!T$:,N
M8L]/WKE@N !#!9@78.\$$EP@0042Q$$ZR:''9![3> R-YPM&)V%@,);=*"=%
MW:2(FQDN,$,%9O?GD:$"V1UY])CT7WE@L)MYS%$W<\1-A@LL4('%_7G0"&^4
M"/$PGW9*=%5K$DW[:86@:+)8W+!SHV\I8N>6!-YT-/Z/4/"VH^R>4-A50V"A
M7*.04,C%N>8NFF]<':I&!QMI[!'I#[*]E :L8O1@ R[MW38N!.R-FV9VKOH#
MOE\8V0Z7%QEOT.(/4$L#!!0    ( ,V#"4OK66DPQ ,  !X2   9    >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;)58[6Z;,!1]%<0#%&SS6261FC3M)FU2
MM6G;;YHX"1K@#)QF>_N9CZ9@'U+Z)X!S[O&YML\U>'86Y>_JP+FT_N994<WM
M@Y3'6\>I-@>>)]6-./)"_;,399Y(]5CNG>I8\F3;!.690UTW</(D+>S%K&E[
M*A<S<9)96O"GTJI.>9Z4_Y8\$^>Y3>S7AF_I_B#K!F<Q.R9[_IW+'\>G4CTY
M%Y9MFO.B2D5AE7PWM^_([2-C=4"#^)GR<]6[M^I4GH7X73]\WLYMMU;$,[Z1
M-46B+B]\Q;.L9E(Z_G2D]J7/.K!__\K^T"2ODGE.*KX2V:]T*P]S.[*M+=\E
MITQ^$^=/O$O(MZTN^R_\A6<*7BM1?6Q$5C6_UN9429%W+$I*GOQMKVG17,\=
M_VL8#J!= +T$J+ZO!; N@%T"Z/4 KPOPWGKPK@;X78#_UD-P-2#H H*I/81=
M0*@%..WH-M-UG\AD,2O%V2K;%7=,ZH5-;D.U(#9U8S/_S7]JQBK5^K)@H3MS
M7FJB#K-L,;2'">(A9&5"R!"Q-A$L?,,X2N1%*45*E]0@H)J(=Q'W)D)/=@U(
M_"'D 4"HUM,CP'@A3I?!B6$- 1N,%\4$'B3P&@)O0,"TF6TQ88,I&HPV'*MW
M$>MKB(%,'\KT#9G$]301+<;O=>%%4>BZFI1[WY!"/#\(^L"!H@ J"L# >9@@
MA 3A]*F+($%D*O!#;>HB,":QZQJ#LIH '$B*H:08#(J/"8B+*XT[?5C(2+$B
M0$6@5RMB),R"$(W,%.10%JQ,=X0:LNA8;2/8[>0#=B?8[P097ELUC\1T*PE]
M]UK.V+9D@F^7Q#0NU3OKIL*TKH$<RL+>):9Y"8M'*+![R0?L2[!_"3!P&.DI
M(Y"VKZX1*!H;$NQ< JP;$5T, E%=S'70< _'18"Z@$+;E580I*VM-02-5"2*
MRPD%Y20*]'X0:&0GI[@^4+,^L$A;#LL.U/<*@5;I@.$5X% 4KCB4 5&Q+HH9
M?450T[NXH21<P2BH8/$8!2Y+U)]N7HI+" 7[O[XJ5@@4C[W.XCI#0T Q)A77
M&1I](%M<'2CRM)$M ,4,]\.P\1FP:SSR5L6P71F9GBW#3F1@IV9:F5MV($+Z
MK[0W>I&:A%HC%+G1;/: 4=%(:B/?"\#/L:^G9OK4(\C04X%K "0^LK[3^R+-
M>;EO#B J:R-.A:P_E'JMET...UI_T6KM*W)[WQY5O-&T)R=?DW*?%I7U+*3Z
M7FZ^:G="2*YTNC>J,!QXLKT\9'PGZ]M0W9?MB47[(,6Q.XUQ+D="B_]02P,$
M%     @ S8,)2X%PE \7 @  #P8  !D   !X;"]W;W)K<VAE971S+W-H965T
M-#$N>&ULC55K;YLP%/TKB!]0\TR:")":Q[1)FQ1UZO;9(3<!U<;,=D+W[^=7
M*:$L[1=L7Y]S?*X?EZQC_%E4 -)[H:01N5])V2X1$F4%%(L[UD*C9HZ,4RS5
MD)^0:#G@@R%1@J(@F"&*Z\8O,A/;\2)C9TGJ!G;<$V=*,?^[ L*ZW _]U\!C
M?:JD#J B:_$)?H)\:G=<C5"O<J@I-*)FC<?AF/L/X7*;:KP!_*JA$X.^IS/9
M,_:L!]\.N1]H0T"@E%H!J^8":R!$"RD;?YRFWR^IB</^J_H7D[O*98\%K!GY
M71]DE?OWOG> (SX3^<BZK^#R27W/)?\=+D 47#M1:Y2,"//URK.0C#H5987B
M%]O6C6D[.S-;.-HT(7*$J"=$MPFQ(\1OA/ F(7&$Y+,KI(Z0CE9 -G>SF1LL
M<9%QUGG<7H<6ZUL7+E-U7*4.FM,Q<VH_A8I>BG@QR]!%"SG,RF*B 6:VN(9L
MWD/"'H&4@=Y%-.5B%;VCQXOY]1+K*<S]R,8G=+:W=:[,QI-;%AN!^$I@,2V0
M3 HD1B 9""1!,-ISBTD-IC&8$6)S"W%E(ITTD4Z8"$<F+&;^?Q/K#Q&;#Q';
M6PB;"!K<9@K\9$J+\$IV;J0^B4&TKUX/D7X-H_@J7*[#B?A&53O[>M[D;:G\
M@?FI;H2W9U*]0?-2CHQ)4,:#.^6\4M6Y'Q X2MV=JSZW-<H.)&M=^47]/Z#X
M!U!+ P04    " #-@PE+"I+SCIP"  "O"0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6R-EMV.FS 0A5\%\0 +MOE=D4A-JJJ56BG:JNVUDS@!+6!J
M.\GV[6L;@A)[LNU-P.;,S#<V.;BZ</$J:\94\-:UO5R$M5+#<Q3)7<TZ*I_X
MP'K]Y,!%1Y4>BF,D!\'HW@9U;83C.(LZVO3ALK)S&[&L^$FU3<\V(I"GKJ/B
MSXJU_+((47B=>&F.M3(3T;(:Z)%]9^K'L!%Z%,U9]DW'>MGP/A#LL @_H.<U
M2DV 5?QLV$7>W >FE2WGKV;P9;\(8T/$6K93)@75ES-;L[8UF33'[REI.-<T
M@;?WU^R?;/.ZF2V5;,W;7\U>U8NP"(,].]!3JU[XY3.;&DK#8.K^*SNS5LL-
MB:ZQXZVTO\'N)!7OIBP:I:-OX[7I[?4RY;^&P0%X"L!S $K>#2!3 '$"HI',
MMOJ1*KJL!+\$8MRM@9J7 CT3O9@[,VG7SC[3W4H]>UXF,:ZBLTDT:5:C!M]H
M',4:4*2S)-( ,P4&*;"-)W<4!$Y P 3$)DCN$B1.&Z,FMYK>:@I<%DXGO@AG
M)891$A E 5!2!V74I#=5TB3+'11?5&#R8%52$"4%4#(')?6JH)@4[@;[JB+/
M,Y@E UDR@,7M./.J)$4,%\G!(CE0Q-GA5>XW3#*W7U]$2)G * 6(4@ HI8-2
M^"@Y<39H[8OR_ %)"9*4/@F*'9+2)\$9<DA\$4;Q@_U!,6PW,0"#7+^)?9K2
M=9QW-?<H#YP/ 2B>]2&_C&>0ZW^I[G%@"T08P"$N#H;>R\);'%^&2Y(]6A_8
M4I'OJ1@_^,LCV I1\O^^CF +0X"'(=?9)]&M:VNC\W;)5Z&D=!<ENOERFJ/,
M-RJ.32^#+5?Z(VP_E0?.%=,9XR>=L=:GIWG0LH,RM[F^%^,18APH/DS'HV@^
MHRW_ E!+ P04    " #-@PE+=H!*8[<"  "."@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6R-5NMNVC 4?I4H#]#$B2^A J1!BS9IDZI.VWZ[8"!J
M$F>.@>[M9SL&$=LI_"&Q^2[GV,<GGIZX>._VC,GHHZZ:;A;OI6P?DZ1;[UE-
MNP?>LD;]L^6BIE(-Q2[I6L'HQI#J*LG2%"<U+9MX/C5S+V(^Y0=9E0U[$5%W
MJ&LJ_BU8Q4^S&,3GB==RMY=Z(IE/6[IC/YG\U;X(-4HN*INR9DU7\B82;#N+
MOX#'%<":8!"_2W;JKMXCG<H;Y^]Z\&TSBU,=$:O86FH)JAY'MF15I954''^M
M:'SQU,3K][/ZRB2ODGFC'5ORZD^YD?M97,31AFWIH9*O_/25V810'-GLO[,C
MJQ1<1Z(\UKSJS&^T/G22UU9%A5+3C_Y9-N9YLOIG6IB064)V(0#X*2&WA/Q>
M K0$>"\!60*ZEX M 3N$I%\LL_I/5-+Y5/!3)/H":JFN4_"(U?ZN]:393O.?
MVH!.S1[G$*!I<M1"%K/H,=D5)H-DB%D&,$/$DX\@Z1#R?%-D]:E(HC*]I)L%
MT\T,/Q^DB\,">5 @-P+P2@"DT$FCQQ"#:7J3HG 6;.6# $1X)!88C 5ZL9#"
MV1;HN6288'=K?!1 !7*TGGL4NM8J" 1.7CX*3  LPGFA8%[(RRLC("R @P+X
M_ETF00'B19 C[)P*XB\:06DZ4HY%T*?P?"!P"F51^#ZX0&,^DZ#/)+"B3A$L
M0I@\; +2<"]);Q^.I04-RFBP;+85W((- QII;N#V";&88?&[X3P%4"CS@P9>
MT)BXJ%7(,86CJ84;&<@"I>.>6 L:+&(*1IW"'0_X+0^"B>N4>TYP,FH4;F?
M[V<P&Y,(=PZ [C_Y(-P[ +ZCPUL0N5&=R=576-_4?E"Q*YLN>N-2?=#-9W?+
MN61*,GU0H>_5Y? RJ-A6ZE>BWD5_0^H'DK?V]I=<KJ#S_U!+ P04    " #-
M@PE+TYP,P+L$  #I&   &0   'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6R5
MF=MRHS@0AE_%Y0<(J"4A2#FNVIS&3K)5J9G:W6L2*[%KP'B!Q+-OOX 5CU%W
M$Y*+V."_3Y+ZD[!G^Z+\6:VMK2>_\FQ;74S7=;T[#X+J>6WSM#HK=G;;?/)2
ME'E:-Y?E:U#M2INN.J,\"R ,HR!/-]OI?-;=>RSGL^*MSC9;^UA.JK<\3\O_
M+FU6["^F8OIQX_OF=5VW-X+Y;)>^VA^V_FOW6#97P='+:I/;;;4IMI/2OEQ,
M_Q#G#ZHSZ!1_;^R^.GD_:4MY*HJ?[<5R=3$-VXQL9I_KUD7:O+S;*YMEK:<F
MCW^=T^DQ9FMX^O[#^VU7?%/,4UK9JR+[9[.JUQ?3>#I9V9?T+:N_%_N%=07I
MZ<15_V#?;=;(VTR:&,]%5G7_)\]O55WDSDN32I[^.KQNMMWKWOG_,*,-P!G
MT4#(00/I#.31 (8C*&>@?AN800/M#/310(I!@\@91&,-C#,P8U.*G4$\UB!Q
M!LE8 Q%^S%PXVN0XV;]G&X8+%Q_3+<";ON"PL+J5>IW6Z7Q6%OM)>6BV7=KV
MM#AOK!KG[=UN[7<?-JNU:NZ^SQ6(6?#>>G*:RX,&>AKH:ZXHC>QKKBF-ZFMN
M*(WN:VY':+Y1FJBO65 :T]<L1_BY&^'G'FM >&/X0/F)CYJ@F<CC; (]F]!Y
MD#T/">U!TAYDYT&=>I"A-[8'C>XTVTXC)!@EPM!3+D<K'RAE*!)SJNSEK^C\
M%<I?A-X:6QXTYB26BF.#<KK#.J%T%+$I:3HE30RIUV)+2@-TE(B.$B$/)O;F
M+4+U0&0B0(4OL%#H6,=X?@F/,36]=X3'1*B8'4I#%VE0D5(QPQ33'N+Q'9+0
M'A*<@_:(<)/@<D&'W9_'LC'*7E;MOD*"/,1+2!B?G"$1+HR&PG'[AD#AP( /
M<RR22OHYC1#=?R+JI\S 40#19-)/&= (:1E3,S=&V<^+0:Z@F(OV10Q(I8:"
M,7P4&)!*>IOGM<#DBQ0,16/0)RBN17XTC1<E&NZ;4:K;SU3]K!F4"LQ2);U6
MNG0B :?PD_H,A+^O7SEI?W/SD4&)(BYQ!H\"\Q'MWE=.=!HH-A*$!G]>L%!&
M4FOA;5X+0BA -EM+Y'77W1AEOU(&XR(F*HW] F*\/1DSM(P9Y O,?"43/QHA
M4DP@8" .!,25/]Q 0#P40WL&,! '3%5T6EHX46_.U-"6 =SAE."O C\:X$67
M4/R] \Q?I.SGQ? 7"/[Z&] -*5),((:]0+!7:3\0)8J80 QV@<"N,GX@2L0]
M;C"D!(*4*O$#42(N$$,V(,BF_2W"B>+3;>L,/3U^INKGP_ ','^D\CKGFQ.=
MKN5#WZ!S]&CE/6"F(66_ H9I@'&%'AB .)T:(JL%)4S(0A/<WI+L;NQ1RX$R
M)4-421!5"\8'@TDIOO!8S<!/$O#S=]P;4L3LC))[@"= I1E020944GVA8(9!
MDL"+]F%'BAC8289!DL"+-HP/!B_2?*%@!@F2.))HKZ.6$C?ZT+E:,LTKB;.&
M9O)53&>H<'S-BND,A0\0*O)[WHG,9S4')U]:MC\"_)F6KYMM-7DJZKK(NR\I
M7XJBMHW/\*P9P;5-5\>+S+[4[5O3O"\/7[X?+NIBYWY8"(Z_;LS_!U!+ P04
M    " #-@PE+.Q-*Y$P"  ":!P  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6R-5=N.FS 0_17$>Q=L<XT(4I.J:J566FVU[;.3. &MP=1VDNW?US8$
ML3!I]P5?.'/.F8&QBZN0+ZIB3'NO#6_5VJ^T[E9!H/85:ZAZ$!UKS9NCD W5
M9BE/@>HDHP<7U/  AV$2-+1N_;)P>X^R+,19\[IEC])3YZ:A\L^&<7%=^\B_
M;3S5ITK;C: L.GIB/YA^[AZE604CRZ%N6*MJT7J2'=?^1[3:(F(#'.)GS:YJ
M,O=L*CLA7NSBZV'MA]81XVRO+04UPX5M&>>6R?CX/9#ZHZ8-G,YO[)]=\B:9
M'55L*_BO^J"KM9_YWH$=Z9GK)W']PH:$8M\;LO_&+HP;N'5B-/:"*_?T]F>E
M13.P&"L-?>W'NG7C=>"_A<$!> C 8P"*_AE A@ R"PAZ9R[53U33LI#BZLG^
M:W74_A1H14PQ]W;3U<Z],]DJLWLIHP05P<42#9A-C\$3#'Z+V *(>(0$QL#H
M H,NL(LG4Q<XAPD(2$ <030EB&=9])#40=H>DN5A,LMDB<(HR28E>6,F LU$
M"S,DPC!!#!+$[R]' A(DRW(DLV^VZ3'Q)%-$D@Q624&5=,& 0Y3-9 !02A)8
M)@-E,D@FG\D H+LR.2B3 S4C,Y5\H9*0&*>P# KAC@L!H6C><N%"*0U)<D_I
M3F\C0&G>%@-HJO0AC],[I4-P_R(,*"5S);Q40BC+[IP4".YT](Y61__K]5XH
MF!R2]M;Z3N6I;I6W$]J<M^Y4/ JAF:$,'XSMRER4XX*SH[;3U,QE?UOT"RVZ
MX28,QNNX_ M02P,$%     @ S8,)2Q^.E%@' P  [ P  !D   !X;"]W;W)K
M<VAE971S+W-H965T-#8N>&ULE5?K;ILP%'X5Q . C<VM2B*M29M,VJ2JT[;?
M-'$25, ,G*1[^QEP$-@G*?L3L/-=? [F V877KW71\:$]9%G13VWCT*4#ZY;
M;X\L3VJ'EZR0_^QYE2="#JN#6Y<52W8M*<]<#Z' S9.TL!>S=NZE6LSX261I
MP5XJJS[E>5+]?609O\QM;%\G7M/#4303[F)6)@?V@XF?Y4LE1VZOLDMS5M0I
M+ZR*[>?V%_RPP7%#:!&_4G:I!^=64\H;Y^_-X.MN;J-F12QC6]%()/)P9DN6
M98V27,<?)6KWG@UQ>'Y5?VZ+E\6\)35;\NQWNA/'N1W9UH[MDU,F7OEEPU1!
MOFVIZK^Q,\LDO%F)]-CRK&Y_K>VI%CQ7*G(I>?+1'=.B/5Z4_I4&$SQ%\'H"
MIG<)1!'(5 )5!#J5X"N"/Y40*$+0$[S@+B%4A'"J0Z0(D49PN\O17M]5(I+%
MK.(7J^JV:)DT=P)^B.0.VC:3[89I_Y.7N):SYP4-PIE[;H04YK'#> ,,(<$8
MLS0Q-(C&F)6)\<:()Q,1HC'D^5.1]><B&T#$(SW&E1WKV^:!;?-: 3(J-X8%
M""A 6@$Z%#!*[3!^BRE:#(Y)%"&$8"<*.E'#R?.UECUVF'#H1&^8^*")#Y@0
MK1P(0V&3 #0)  %?,X$P 6P2@B8A<&&PMI$[#":#?OG.#9<(=(D %^VBK#I,
M-#!!#M'NJ2<31)Q0[_P4I36D1'RXJ!@L*@:*TI:RBLW6(2?6B@)!6N(\ R#/
MT>S6("B$B\((3D@$E$7U:$.F4>!@/;L^08V7<R.P,; <_2X 03<V*(83#GN
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MH![A*0=Z+P+(BU4PH@>W!O(Q(O$M'SX5V7PH<N-F""8K-/QPF*Q!)FX$,"B
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MT3"PH__*+[S2\KX2S=B)2IJ_P>XLE:AM%EU*S=Z&9]F8Y]7FOX7! =@&X#&
M9/\,(#: . '14)D9ZD>FV'K9B6O0#:O5LGY3H >B)W/7=YJY,[_IT4K=>UG3
M.%M&ESZ1U6P&#9YHT+UB.U>0[%T3Z0K&,C!4Q@;/$M X=R"0IH A!!PK,0G(
M- &*X00)F" Q"9*[!,Y4; 8--9IFF*PBQ@F,H2"& ACL8"B (7D.8U(0DP(8
MXF#2&>8#IBF&,1F(R0!,XF"R.0:E!:$P)P<Y.<"A#B>?SUI>N*HMH/(O80$6
M4P#%I$XQ!5!,GGDV)(KAXQL#H-GYC><DO8H^DL<H$$#*7=(@RB<DNL@R#PBT
M@D>$ 5#A@@91,0'A19)Z0+ =(#('X=@%$0"$/;:#8-M @&]@US>L: I*%[Y-
MAV#C0(!S8-<YK,B9.N(Z.OV?E80-!@$.@UV'L2)O.?<@V&(0X#'8]1@KRN]
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MN?0#]',/^XS$-0"FI/B HM$S1:4NA[[2:!0H3/][6FS1J3;9+TZC$Y)R MF
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MN_B'R=I/JUAR.C-'N5C@-DD_9/%V0,W468^5W66YNRBR^W*3"]RH[MSR%OO
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MJB-!>E55B1%45<6BU\F07DF/@(CWCH6U _(^#$0W '%?B_FWO]$OMNC^ 6,
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MQ%O;Y<?V'4.]YRTR1_-=Y_FV(Y$&D:Q'&J9MH5$I6R]^GZP_I(]:YJ\)N&@
MU]=?RNIW-C25"*\%E\H(;N[7>/_ )#G2!B]58+>*PRDB/Q,R]V/^$%V(%^0!
M\3H5=R$)VKVHKAAQ"%8^Q&+VX!9M6'RGUAONJ<KI(=4]A(#=O76[$F)UA_E*
MDVY(8E>_$L+Z<VWM.Z(M5^"^)60V OC2"&<,C+>4TKEP53N"%D(])00!E1"
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M>C)6$S[C=>2)*S_6]>9/_P]02P,$%     @ S8,)2Q?6X=AJ @  XPT   T
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MY>NM0&_EZZU ;^7KK4!OY>MM0&_CZVU ;^/K;4!O.\-9"3HLX>MM0&_CZVU
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M'N:S[@_HZ1=02P$"% ,4    " #-@PE+'R// \     3 @  "P
M    @ $     7W)E;',O+G)E;'-02P$"% ,4    " #-@PE+9O,+8((   "Q
M    $               @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( ,V#"4L,LL%X[P   "L"   1              "  9D!  !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( ,V#"4N97)PC$ 8  )PG   3
M      "  ;<"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ S8,)
M2Q^C/'IE @  %@@  !@              ( !^ @  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( ,V#"4M/49,W!P0  /X2   8
M      "  9,+  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M" #-@PE+L6Q*=3H"  "T!P  &               @ '0#P  >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ S8,)2^ U)C0X!0  YAH  !@
M             ( !0!(  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( ,V#"4M@EE ?+P4  -L9   8              "  :X7  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #-@PE+)BHJ];0!  #2
M P  &               @ $3'0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ S8,)2T2832RU 0  T@,  !@              ( !_1X
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( ,V#"4O+]3R5
MM $  -(#   8              "  >@@  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    " #-@PE+MTG9>[4!  #2 P  &
M@ '2(@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ S8,)
M2VX>=*BS 0  T@,  !D              ( !O20  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    " #-@PE+J#?$>+4!  #2 P  &0
M        @ &G)@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( ,V#"4NBNT9-M0$  -(#   9              "  9,H  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ S8,)2ZK!_4FS 0  T@,
M !D              ( !?RH  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    " #-@PE+AN+VL;0!  #2 P  &0              @ %I+
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( ,V#"4MRR\FB
MM $  -(#   9              "  50N  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ S8,)2[M6N3RU 0  T@,  !D
M ( !/S   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #-
M@PE+_YK'W[0!  #2 P  &0              @ $K,@  >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( ,V#"4L@2W7VM0$  -(#   9
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M970R,BYX;6Q02P$"% ,4    " #-@PE+),_J [<!  #2 P  &0
M    @ '9/0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M ,V#"4O#/+'2N0$  -(#   9              "  <<_  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ S8,)2[E/[36V 0  T@,  !D
M             ( !MT$  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    " #-@PE+*LY 1<\!  "<!   &0              @ &D0P  >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( ,V#"4M&U@IG_0$
M .D%   9              "  :I%  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ S8,)2_K>[ DD P  @@T  !D              ( !
MWD<  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #-@PE+
M]ML+T68"  #:!P  &0              @ $Y2P  >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( ,V#"4O%:D6LV00  ,X<   9
M      "  =9-  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ S8,)2U:^-47G P  21$  !D              ( !YE(  'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #-@PE+:.<KA+H"  #L"@
M&0              @ $$5P  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( ,V#"4O.HF\-T0$  (X$   9              "  ?59  !X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ S8,)2SL^M(=(
M @  LP<  !D              ( !_5L  'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    " #-@PE+-U\?]4(#  #M#@  &0
M@ %\7@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( ,V#
M"4N(M6G!/0(  ,8&   9              "  ?5A  !X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ S8,)2_Z:$FM? @  (@@  !D
M         ( !:60  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
M    " #-@PE+;0?GEST"   P!P  &0              @ '_9@  >&PO=V]R
M:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( ,V#"4O&O4$Q(P(  $T'
M   9              "  7-I  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL
M4$L! A0#%     @ S8,)2^M9:3#$ P  'A(  !D              ( !S6L
M 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #-@PE+@7"4
M#Q<"   /!@  &0              @ '(;P  >&PO=V]R:W-H965T<R]S:&5E
M=#0Q+GAM;%!+ 0(4 Q0    ( ,V#"4L*DO..G (  *\)   9
M  "  19R  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @
MS8,)2W: 2F.W @  C@H  !D              ( !Z70  'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"% ,4    " #-@PE+TYP,P+L$  #I&   &0
M            @ '7=P  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4
M Q0    ( ,V#"4L[$TKD3 (  )H'   9              "  <E\  !X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ S8,)2Q^.E%@' P
M[ P  !D              ( !3'\  'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6Q02P$"% ,4    " #-@PE+]<#^WLX"  "O"P  &0              @ &*
M@@  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( ,V#"4LU
MJ>LM? (  $4(   9              "  8^%  !X;"]W;W)K<VAE971S+W-H
M965T-#@N>&UL4$L! A0#%     @ S8,)2^^)D:<6 P  I P  !D
M     ( !0H@  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
M" #-@PE+31  NYP"  "2"@  &0              @ &/BP  >&PO=V]R:W-H
M965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( ,V#"4MBH-;K2E@  #./ 0 4
M              "  6*.  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0
M   ( ,V#"4L7UN'8:@(  .,-   -              "  =[F  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ S8,)2W 63ZOD P  _B    \
M ( !<^D  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ,V#"4L6_TPVV@$
M )L>   :              "  83M  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( ,V#"4M*E27=QP$  (@>   3              "
M 9;O  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     [ #L #Q   ([Q
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.7.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>133</ContextCount>
  <ElementCount>281</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>45</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Basis of Presentation and Consolidation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBasisOfPresentationAndConsolidation</Role>
      <ShortName>Basis of Presentation and Consolidation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Sale of Commercial Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusiness</Role>
      <ShortName>Sale of Commercial Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureGoingConcern</Role>
      <ShortName>Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Net Income (Loss) Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShare</Role>
      <ShortName>Net Income (Loss) Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureFairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureMarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Accounts Payable, Accrued Expenses and Other</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOther</Role>
      <ShortName>Accounts Payable, Accrued Expenses and Other</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureRecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Recent Accounting Pronouncements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureRecentAccountingPronouncementsPolicies</Role>
      <ShortName>Recent Accounting Pronouncements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureRecentAccountingPronouncements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Basis of Presentation and Consolidation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBasisOfPresentationAndConsolidationTables</Role>
      <ShortName>Basis of Presentation and Consolidation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBasisOfPresentationAndConsolidation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Sale of Commercial Business (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessTables</Role>
      <ShortName>Sale of Commercial Business (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusiness</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Net Income (Loss) Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShareTables</Role>
      <ShortName>Net Income (Loss) Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShare</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureFairValueOfFinancialInstruments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Accounts Payable, Accrued Expenses and Other (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherTables</Role>
      <ShortName>Accounts Payable, Accrued Expenses and Other (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOther</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowingsTables</Role>
      <ShortName>Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowings</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Nature of the Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Nature of the Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Basis of Presentation and Consolidation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBasisOfPresentationAndConsolidationAdditionalInformationDetail</Role>
      <ShortName>Basis of Presentation and Consolidation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Basis of Presentation and Consolidation - Schedule of Non-Controlling Interest in Subsidiary (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBasisOfPresentationAndConsolidationScheduleOfNonControllingInterestInSubsidiaryDetail</Role>
      <ShortName>Basis of Presentation and Consolidation - Schedule of Non-Controlling Interest in Subsidiary (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Sale of Commercial Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessAdditionalInformationDetail</Role>
      <ShortName>Sale of Commercial Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Sale of Commercial Business - Schedule of Discontinued Operations and Assets Held for Sale (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfDiscontinuedOperationsAndAssetsHeldForSaleDetail</Role>
      <ShortName>Sale of Commercial Business - Schedule of Discontinued Operations and Assets Held for Sale (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Sale of Commercial Business - Schedule of Carrying Value of Assets and Liabilities Classified as Assets Held for Sale Relates to Commercial Business (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfCarryingValueOfAssetsAndLiabilitiesClassifiedAsAssetsHeldForSaleRelatesToCommercialBusinessDetail</Role>
      <ShortName>Sale of Commercial Business - Schedule of Carrying Value of Assets and Liabilities Classified as Assets Held for Sale Relates to Commercial Business (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Sale of Commercial Business - Schedule of Inventory of Commercial Business (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessScheduleOfInventoryOfCommercialBusinessDetail</Role>
      <ShortName>Sale of Commercial Business - Schedule of Inventory of Commercial Business (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Sale of Commercial Business - Summary of Charges Related to Restructuring Activities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSaleOfCommercialBusinessSummaryOfChargesRelatedToRestructuringActivitiesDetail</Role>
      <ShortName>Sale of Commercial Business - Summary of Charges Related to Restructuring Activities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Going Concern - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureGoingConcernAdditionalInformationDetail</Role>
      <ShortName>Going Concern - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Net Income (Loss) Per Common Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShareAdditionalInformationDetail</Role>
      <ShortName>Net Income (Loss) Per Common Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShareTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Net Income (Loss) Per Common Share - Schedule of Outstanding Securities Excluded from Computation of Diluted Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedLossPerShareDetail</Role>
      <ShortName>Net Income (Loss) Per Common Share - Schedule of Outstanding Securities Excluded from Computation of Diluted Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureNetIncomeLossPerCommonShareTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Fair Value of Financial Instruments - Schedule of Assets Measured at Fair Value on a Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value of Financial Instruments - Schedule of Assets Measured at Fair Value on a Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail</Role>
      <ShortName>Fair Value of Financial Instruments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Accounts Payable, Accrued Expenses and Other - Schedule of Accounts Payable, Accrued Expenses and Other (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail</Role>
      <ShortName>Accounts Payable, Accrued Expenses and Other - Schedule of Accounts Payable, Accrued Expenses and Other (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Borrowings - 2022 Notes - Additional Information (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowings2022NotesAdditionalInformationDetail</Role>
      <ShortName>Borrowings - 2022 Notes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Borrowings - Convertible Notes - Additional Information (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowingsConvertibleNotesAdditionalInformationDetail</Role>
      <ShortName>Borrowings - Convertible Notes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Borrowings - Schedule of Future Minimum Payments under the Loans Payable (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureBorrowingsScheduleOfFutureMinimumPaymentsUnderLoansPayableDetail</Role>
      <ShortName>Borrowings - Schedule of Future Minimum Payments under the Loans Payable (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Calculate Fair Value of Options Granted to Employees (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Assumptions Used to Calculate Fair Value of Options Granted to Employees (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Stock-Based Compensation - Schedule of Recognized Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Recognized Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mack-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merrimackpharma.com/20170630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mack-20170630.xml</File>
    <File>mack-20170630.xsd</File>
    <File>mack-20170630_cal.xml</File>
    <File>mack-20170630_def.xml</File>
    <File>mack-20170630_lab.xml</File>
    <File>mack-20170630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0001564590-17-016988-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-17-016988-xbrl.zip
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M,SN6O@'\&%AR01/ .WPR9C0PN!#GY3/5$S<?__[L+XOU?WVU^%E&Q-S*O\[
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MCEEF;] S=X>QHI8HWL\A+5VWUV\?1*&5V+J\AT.:P-9@N'X3I: Y8/ZQW>Y
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M/0W>OI!*SEL)O=7?U>;MK+=*P+/7!G8U?D^Z@0TJK+^OX4NAM5HK.FP#!)5
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M+?:X!:2J\&_MN+>?D6X=?P.5,T@E"-![ @)43B7M:CMWVL#_4'8W@4^O[T&
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MQZYXC/QUQOVL]X\TL%DH%Q]8VWO,5F*U_DKWE,T0[;&!8UP'LKK#E4XK53>
MLZYPJ#9J>WE4'E<8^ &%+Y=F*UL;N] ZE'VB=\05UP>N'UGX3XRJ;YE[3X.;
M@-*?WR8D@(]H'#$;]@J"_IEBQ4=U_ZH[7$_1\CM<GC4T2VS'U_$GW[O[08-I
M_I3:VM;2MF+GYA4-OPZ48CO\=9P59LBP'L6)Z+16K-$J%.NY#Z)L8(J(@3E>
M0NWV]J^5[E,OW6?< $LI3?R!><!:ZS3Q<7JQMN%AJY0J+H#N$+LZQF%+N[?:
M)*/2EOBYM,<=!'17[\$?PL0IKWQ8]BCD31W#$S#-]G#YZO4.X!UF8T?Q!LQ>
MQUSJRW#HG5T#_8-@#J3F\T+E+6UQ"KH[#.TV!UW8>(F-+(&SYPZV>@4[V#ZS
ML]30J=(&9BP"DXV'8 Z#J):B58[15KZ-HR]^]+\TRM<<6D?I(]I>'MY5$J[]
M=W.,)$*GW=EC-_PH0CIB7G+N4M\NIYJ/<31BMA<G(R7 6;(POF<#'WX-OI$@
M2OX OP C!-S_]13/M;Z.P?:&H.9%QE6\A#JFM+-MS3HK5C7E5=A>P"Z7H(TB
MX5"$\%#B6J !@P@V1O](+);;XC'.0'H=:RD6+0M9\628);'9UI2S8K9TT"\>
M^+,JZE\P!0>N?='Q@K6]^V8.NK_\MQN]<=C]?]]%;_[S/_X#_YH9831WZ6_/
M<(TKXK([[S7V66+C^9LI">Z8=S7RH\B?OF[-HO23R)_Q/_EOF <N</2Z]<N;
M,4!R]< KW5^/?-<1'XS)E+GSUS_8%"3Y"WTPOOM3XHGO0O9O^MK$I<2?",IK
MSX?8R16+1P'QPC%\ )]Z5#QU3P)&X(U&\N SW([9- 2F#']L1!-JI DBW.2K
M&3Y2=K^XN]YBL]+V=]U/@HL$SCVV*".ZT^QV?A&;_@RQ'D.U92P%G T#U&[3
M>(&(^&\RG;WYKP$HF#=87$6\>?:)^>:EP4*#&"/FSW(K %?Q1XT1X>&^9]R0
MZ2A@SAUM&)])&!)[$H<TBD) -HEP%3^.H@GS?H+]-6P,1P,C\@WJA4@4_M ,
M^!<-M4$\!VG$ H,C$[UO%U2,,8[=,>.-"OG?8=/X 1M8@MKLOPF-*0M#7N,:
MXDLR%*8OM@E_9^#'=Q/.#2$0,P+A#('>_/7.8IHMYQB@-<5K(:'OQD+*Q,[A
M'00>IC.09="(V9!I^$WR+MC5Y(',Q:X D:Y_QS$(;_P)/V@:UZZ;,F715F8B
M:XG+.<PA$07JL;3D#3=!*>+?!K3P=<,(OJ'B=2'%^R2P/%;TA/@8EN"F3TI[
M;!A\UH"'R%H#!Y]R2N_F".L+\^72?O%7TN8 :#"1TU!>C1.#^U]($T#D/?#*
M"^ME@G;\/)R!>APS6T(S;N-%^V4*K'B7#Q[^XA&@++Y;(/0JI"[%#&G&3L@E
M^&K$U!4 YMTA'=/=A)3^#"5.],&83W$'XM?(ME@_!*M4TQ2F5:@J5B7V9,J#
MJXJOGG$]"YAKM!L&VH,&;A$?3W>YHKSYSP12\#O\2R8V*@B7BPQ^"FQWS_PX
M=.= 4 _,JXU?('#$YL7HRZJ(9^@-3.;GM-$#BR;&QUE(/>.V>0T:3/H)_UA^
MNFE\BP-,?45&PM=B5?C4GF"0B+R%KS"N[X WA!R@A#D&"9'-_T:\F 2)&(#7
M\:8OD+,!VL52,B0-8T2C!PI0RRC"UW.@&[F/@;$=!%ALDX$^#!#K\!"+7 $T
MR^[HB!6!N%?HJP'<>+#1,&AZ4(6ZXA[^ZP?S!G<% D!XF"WBHJS$0F#Y21?\
M ]@?&&%N!**H'4$! 8L3/;]./8P2>VKX"T<$WT*D#(IW#T+/M6,@5D]TP4*V
M&Z 6O7@,/XH#_!)7 $Z:HFL-(O9O_.SKEX__^-]W[QMK01DST$O2SU(5VN#+
M??Y\U6GWBFQ?^GCF&N1X23(U +SP>8WGW7ZWV0)S U8)S0WH82!#PPCCT;\
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M$=N\S@>!6< N$2-(QSO@<EGWB/.7?&(G13M\Z\6G;F-17<[+2. #<>HU(8#
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M8RNAP,E!T@O?Z9KC V# :@]X,68-Y.( @RQ*2Z4?)E3R(WB49CZ7@QXS I4
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M&JN)%"#7,/@/NN@?D3)4B+=A>MGE#WXLL>XG7#6 !RHS37(?,;=(T7/(%N+
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M#ER<7XSC=8$I ?W ,2Z8+4^>X5**Z>]PT$KJ5TO,CH[.C.(;&L:#'[C. W,
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M);2,*$H9;6AJ0RHM1 <\3JO+M;Q:-"G]Z$4TH&&4GJ15.4<[M]*<VIZCZ;(
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M%1E:I^@&913='KQFO& >L(D?A\1SPI=JA+K-P7XY74D)" 8]A(.@#,E*>GL
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MO&6V3/&/7KOU["^XD60?__D?!T#=B>Q9IVEPS!@):@YIS4XFLZOJ@^_UHTA
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M8%0G_+71! F BX7L$>CF19/0$/H%^54 :O9:;Q:,"UL& 6ZE MS %[LQ!P%
M?-Z25#G7.0@]Z-@$%J!S[$;()./ GW(8N$+#IU!-X0<;-%F#P\K5DHT^(N?'
M')Y?)$A^:?@"LQD*MV(0,=?<W4-!?\2T9D4AP:J+<N+3^ G*'A= ST](PD4
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M%"V2=+KV\9R(1U^5=,6) +_A4(UY_)4A^0U8D"#;A149[1\0_6M;9DT&8[1
MD0I1# $=.D#_=9^30_3?A+ !V2Z<R!#]'X7^286:1/^T^C\:_3O]?']A+/0^
M&+3^,WD#6) @4X85&?(&"K3& VOD')H2)1UJDCO0D&B />A-T /T1?411.M$
MDP^ !0DJ)&@L=%11L#^<D[YJP(L62O(B**B #IWW:M]VOOD)K0-.K@06),B(
M846&P@D%6L]FUFA"Q07(4-FQ^:RM403\H&C^3\/UX4OYF4EHW6CR!; @T5$[
MU@!DR!=8^P*V;4VG([10=52)CND,M*]] ":DM(=@6ITF3#5&5JV(ZG6M\;01
MP 14 ]:H^[4.Z*1!; !ZHWU[/Y#G42"J>D;NV2+[";HB[&LL20.Q!2IV^"9>
ME*KF3D[OV)37B!J(]Q$(2A\*K0YCKMG-W^&8/!I*[5"LVE=A=^;8=^'9:<^E
MZ>T8C@=LVSV:X=2:]>O>M;'-F=EJ8.M42@-'CL8NX.KU9?8Y1.1."6UJ/JH%
M,%LE=PPK>^!OOZ;R^27GJQ=O@,S?^%+UF$]C\07N_#J(W*^___@#8[\5%Q47
M?)RK7L@BE+H?\6?3N_5,G:%[KMJYOU9-6O,.I,7-F.^].GG[%X#E# 8GJGFK
M>H//8O[JY$Q]:CN3X63F_*7:-?7MOFW^& _Z)[^K06=C_O&'(XBIIAZMMMUC
MYZJ-_7,M(586XAJA?7NQJA<L]:0M2: VLW6[!ZQ^[U-I6I-GAX$,;"L[$$1O
MK3$'*(,A*?H.K\\$J![V=<7](.\@?"'8)8Q(]0Q>GTBRZ?@ >))MI*YZ@*O3
MPJ\$^Q3P\-:I:_I*]4VY];?I<EQ\I0Z0X)YJ*JO:C]\Z[+?RY(N(Q_IL2L^/
MA9M$L3GU>07>LZ\;_*];BL,+Z;=1W?NS(:I+0=+/U=F2YJBC[$P2W=9=6KE0
M5NI$'=.;G6D:E+I-<Q+[;I+_Z/8G(#0_.X4ZTN<>Z$^?F_;*JOVW=TC#?C4E
MR[V!2W,26WO@=R%[*R[BE,?76</L8<]>=[[VBN.SMTS&"^'RI2C-2=5.W6 (
M8(KE*HBNA3IW))K/?5?$\%=U&J@C =,@X>N>Q$EYHO78:;*U\WA%;P8W]69]
M+ONFT6U\UC&M#S:DWYCC&F&$BT,[O9=5U9=2G?&1J:'NM9^=_,WL66]XAQ'K
ML3?KTR/W[.6^[^,'O>F=3P=C)D7QZTL1BI@'P36[4LW851MWQHV 3#OW[#Q'
M??QC/J5[[&/^\\P PR#6<UO?J73BUX%F9(^Y5??$.E5';4HW]B],1WG5D94-
MK#*EZ',?]+DT()!8GPKT.CN^QRJQC$;X=4X7;]9V(DT64:P+1=1\]80;<$4Z
MO#AC2)]&51PTI XLLH?E,RFBL$I/ZLS!ZI$Z^<E(CWX^D6'2#6_I"1504D>6
MZI.ZU+D8L:?.-S'GJ*B;ET[ET2=;Y#W_]2&?.\X.LF>S64;^9M)J>V>I88/U
M5CIG9::P/]WH)%0OS8\;7;L#SU1/]OQ$!'.O$OQ__"]59V^H*^7-\T2R@\LV
M ZG 2,-4JG.E<T<@5D=Y9$=\9V=**?*/5K%2M+*(LA,>*OY"Q5+</'3)G.!3
M.O1DPU%HI8;Y:PHIOZ >=*Q.UX(I:L NW!M]8+8:M"_+ U6R!0OH@7_C&@\F
M&SI,>M!\Q;ZE=\@(3#%OFIUOI"9.\1X\/XI.&FHT-S:Z63H8!0Q@?&5^#LOG
MM#@S(GN(<7[R WP9*-REN"'_"E;9"5,\<-.@<CR+/HA)#4<?+;;V](LS+T 6
ME>,LQ'>W?( A]^/J /7(\N-VO<JIBA="G7>H)X89N#Z8MR38RD%E54)3FGP9
M9D;F[E$K&S/JC=>N4G8V$/R\4-<*I-D9'A(> \/+CU'/^O(>?BK4C>,XM-N)
MS?7X<@O'JDZ6"+2@5U8Z7OK>KHJ^5OL,2AF!B?VE1B8S-EYV2E3F"<K\.>OC
MR #-=&E&1P=<9"<%CWMCYT&5#X_2B+[I689C5Z?T'U:=TN[# NY[[,6@UF,O
MG%%O1.=>;*,410D?#!7\H:A@#P9MH1QN\1\B,]2Y24GFI2U(GH.?2<;E'L;E
M[A*ECOJG:, D3Y70.FJ=B]-SAO<O="%^4>_Z@+.8'E,-#P*1])3TM*WPJA@B
M0CTE-20U[!*\1)<M 9+TM-7P[J9+?/U6LIA!^W=+?/;EU^=S%3+/NZZQF"?B
M0"5\@G8K6^+'+8.E 7N4]C2''=R78O<F19&3;;]D3J__,UH82:&P($$*M5VA
M[(I"V;T1*10I%"G4\1C*)H4BA2*%.ERA1C<8:KI#H?#U%^_,>O>/[RNA=_D5
M6PFN?1%X!ZK<$[0:)^.'! EC_#IHVPY>O))VD':0=I!VD':0=N##A+0#"Q*D
M'903Q01+L494NZ?1!F/(?F%!HK/V:W0CC#SNV4RU19%HH2*EP8)$AY6F7U&:
M46]*2H,!&%(:O-@0TR %AI0&+S:WF69VE])09K+^5>=5I/ID!7YRC39B0\8-
M"Q*=-6[C@TL 23U(/=JO'C?\Y1EI"VD+:<M6,JEJRZ[B/=(6TI:.:\NXJBV3
M/=.8CW:JRWZ2V#JO[ME8]XY!8>FKF[<O3J6063?]Y2H[*6,IDD6DV^KF?9E%
MUF&YE/G4K;W]A'D1W"",$K;@5W"75)W7X*ONU M?)E'LPRW@AZI[N]0==+EI
M(QVI^EK=4IG+*#3]<+GT)4M749CU5%=]?;,>O-5G9TVCX172I&@:+6ZOD&_U
MB"Z-J725:?._XK$>AOXS].&MYG&TU$/47:]#]2AXQ940ZC"(*(4Y(0+SR.(A
M@#+,BOA:=Q*&:?!5)"#$E9_ E/F_K)6T&GN\>6-M9<!<-_Z6*=S-#^&FJ6[Z
M_6VA&L7K,P1]J8_!4&>IJ"_R]M&%( #.HOMUI7-RCWW@(;_4C:H+$<OU#V$2
MS86?I*K+>3&<"I[J9 .A>LRK]RQ:8,MJSVM7'6D$/PVN]1$(B1ZY,#W/LS[A
M:U@C??3!UH;6)95JSA$I'W@,T]B<CZ) >.N'/-3]ZD]=-TK#!*B#G:N^\%H8
MIKG_LU('_+>GYZ_+G>_S\RLV_OQ?*]V@NOS[T_-_57ZNAO*\/ZL<LE ^1JEB
MN4U#_\K7SX#Z?)=-[.DO+]B[I5+CK&4\X/='UH.;Z5.LLD.:LG.L2B.NG-Q@
M%+VP/1)4ZDJ=J<&XFOIJ\O+UJZI)I'OO9P?MK+)[:TBXFQWLXX=ND"I2SMO(
M1TO0%_Y=ZPK,/C5MX3(WX%*NVZRK)V6MZV%6^OI0G\#G%\I"J'&I(SRRF:M.
MG[GUXZS[O'K.A0C%W-<S/U,]@$4/5!D:U?Q^'D3?I#($H,&7J6].:^"!C(K3
MC3@+8:JJDQ22Z^??M*E<RV$5!;Y[S;3QR;K^9R,NS*5Z;ICJ\Z+6;V8./8C%
M+:U3;Y?=7PNYK/_?%D*_!IA)UTWCZLD$W .+(LRI#OF+6-G % #1OK<UAT,H
M.O&]-9NHAOKP(#?)1:D@5'N*=%?V>:%-A81;?NK2E\WG#I0/G]IXZ,!Q>N*#
M8IA.][=ZV]?OGW6VNWZ_-T;8X(N6A]7N3T.$&)7EWH3F3D7[ZW&][:\G/7M(
M[:^IN_X..2#MKO_STYTNC 8*HH(6HD54@!Y).@D!-1'L:X&(, ZK@\._[FL3
M9L_T(8E1*GGHR5]PZ!@1_3&)WJF5Z&VG-W"HN>]A4.-IPDWKG_HQJ)A%:H1.
M=I/L)OHS1,ANUH^!MIN=TP$R=YV!&I.;2-&11IG%![:<;:$RD=WL#-28W$2R
MFX\;57[RGEXFRMS^_21%Z:JIE'QQH$(]0=^(+<N EN'1@+X1>_#5DYDY@NY>
MT-G[N1O[P=?V[5P-P/,)XU.$#-%5(Y$@NFHL=$17[<*3Z HK,D176) @NFHL
M=$17[<*3Z HK,GO4!)#2$'\1=,1?'<:3^.MX&<?'[^?<E8SC9R&%[@ZDVFMX
MXDH$T<JT8S(].VI.Z=,:&4NA$QFV&\C\A!80XSF08Z#>=FC-:J]+(M5IGE$C
M>L&"1$=UA.BE"2C9UG \0HM41U6G 4:-Z 4+$AW5$:*7)J TL@;3 5JD.JHZ
M#3!JE)%#"TU'E8;XI@DH.=9L9J-%JJ.J@WK/'J(V<)@P^[L(S?$1H<>XM_1#
M7\)O];DM#TNL'1>W!W>':QELC2@CV&?[.1E*G.A5BWH>CF#;'9*!-;6G.$PE
MPK8"F)!"HWS$;*CA(69K)WK$;/==:MM]!X>I)&9KAO(1LZ&&AYBMG>@1L]VW
MY-(>'EIR2<S62>4[_ED5K=0L-'@1U;43/:*Z^X8G^U.BNB8@A7H;XJXDJA>E
MZAAIIW?LE9T]Z$W0P_8E2O2YZKL/%J^Y8F&']_)HZ+5#XVHO*+EOK^\*GIWV
M9K 7=#TALFWW<J;69##$86/W-["=5$HT-I<H$34\1(E$B42)#UKXC\98CXDB
M2D1I<XD24<-#E$B42)3X *AGULB9X;"Q1(G-L+E'HL2V:Q8:O(@CB2.)(Q\
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MT:!T>GD9BTN>U+T?C$S8\7=>/G8^-,MQU-M6!PUFS_R0)8LHE3STI,7$=U>
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M)UN&V>JI?"J5G#<#:BD!@PW1 AOW[$)@:OI%"0]@ L;"C2Y#&*%GP'I^P15
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M_^5G<25"L*GS.%J"8H&EY4JEOOG)@IV!)**EB"5[!HX\F-]Q?_R+5?S8?LG
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MAE;KS_7R52_;LOWPKT[Z8)E%$*BE+@R]^'>V.-;_SD::[:"'%6O 5U*\R/\
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MYT#17V XKX/(_?K[CS\P]EO^XW-W(;PT@)\6AX)F^SN^*!D4OV*^]^KD[5\
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M&@L=T56[\"2ZPE?(_,CAV\WHE(5<;S/CTCFHU-&X 7I2>X*9+!A.9(RO0*Y
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MH-0+PNK39D]LH#1 AXAGL"!!.H(5&>*9<HG-<';H$I1TJ$E+T&,%#"KKS?R
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M#8D&-&</+%HGFGP +$A0(4%CH:.*@GN<(-^W!F.\A57D15!0 1TZ[X64#SU
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M.EB\YHJ%'=[+HZ'7#HVKO:#DOKV^*WAVVIO!7M#UA,BVW<N96I/!$(>-W=_
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MUAG.^YJ&$S=,^)S$3:N5(]4X\5LG[[#]WJ3>RJ0F.[.IB=:H/NS8J":]5>W
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M!L*;.7A-17N26Z&U+TYH^(Z[Z#(2/UC"#F#X/CO_&DJ9B-V;8'2F%W1+&PP
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M'TD&LGG$68,BX1Q9U12QA\BTP&,](C2/^/:P%[#E+]W8?PP2"_LN^?GW$6/
MY'H*[FQ.&/(^4Q+.+WW'"[D+Y$Z.^('KAWAR/<<T0F8<4@JBKP/I\3%!Z/)'
M#SU@+W*@VEQZ9@&XH7B.W,GYZYQ_AY$_N0Z>,(T%5M!4B)QAE6ZQ@]UG].!A
M]C,.%)0H(&!<;!90UX$!,$;L24GL7 *&Q>:\X#OS/\[_&P)L'G!EHV",*%V
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MG%L:P__<8,4[6U"DD+L7)RJ[H_4KHA3YP9*43 E,^?O&MT^2>RV2;ZZT?UA
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M!H'ES_F(K #T.S71Q2=3^A>Q;.Z#@\]O,.E.PM(YKJ SJ(0 = I=KPCR'R;
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M[AJD[>R_%*:38Z/O+.X:ICCW4X#SZM1T38IOADR?-9+=(M-BGG>&WOM7L^C
MZ?X91A^,]@SI6'LE]1H"D5>GC8IO3C_Y^&J63TJSO%)*@#*,LWB+H$@4P0ET
MI _I'15V3FR;O4!R9ZV9AXK^,XB0P^P0G\I#3TFWX0(%N=NRI'ZO5/K9!2MF
M%(=JE53SM5Y;K/A.PDVNMOD\"@+)ZC4ELMI+2N,0YCG]GQMF\#83$$"TZ<UF
M .ZJG]>-<W)@3E^Z"JIE)#2SGCI$U#DOHZ [D1BQS=L.(]:P@/X#!4\JW%>2
MT9VW2W4W7B.Z#7ITEVZH=R2(09=CHK@N@FA^%P7VPB+H'),0PIT<'47&SNDO
M6?+1-*"6#J<(9:F(@N[;)%O:9'K:4K:VM^8;I/(D&-.TAY2F7;Z2:ZTEZ>1K
M*$4=S.Z>K]I@^*;[-.D&$F/XJP!UOAY42K3B-*]-BI:_$WPP2=%F-G9N.2FZ
MQ\;-%4(V6^UU6[O(AC8RR-&:\&4VF1&=7G7)7V=/BW1;(YW,[0E??KX1$!B9
M9]#._)<X@ H<C R\M(-#I4=!)(+NL28L\P@)X?=0#=8Z\D1ZX[[JP5+WJQ!]
MC_4?P"\N\-AC/0@*A(@\3FF]V%%8\0P' 7ZFJIR<4O.5Y_.VUR-6C;@9H3\@
M[YK=DDL<A.Z_^(!QJ)HQRN;?78"6;@3J92A!3'<;$FO-<WKBT3<C\=*.;@"Q
MCH),29Q7);J4/:J9U;UN*IS/?N:9(<X="FR69S<'O10(5>T->["-D$-88B!C
MZSNBT%X3$K&<&/A2D: VMH&67NCP_DDE!+2S37<\E.5*W3 6V<X%;J140V@O
MQ.C@<O:2\:%]H2K)C#U")0O:QHZ'-1,C2V[;5+O N&4=F=;8VCVT*;-VTU-8
M$B ;EH1W?WLR02:I?%L"8WLRM=Z6P,Q63?JKD4WNWJ0XIRL- B/B5'*WU<G8
M1_5B%]TS9_KEKVU*;D8W)XDU+F?7%P1@MDY1AE^(I["URU?SF!QR5)-9QE<A
M(F[FQIS:>./5+J@A!%W54  4;!G:7JF!\#NN8<.[Z#19Z_4N?-'PP\@RWP;"
M2X1CA/#21FOGX<-S[#\A*@BU3;5%$17&,"V8"!%AC%JEN5>$+L#G"[3"Q(55
M#6T^V&EL(_>FXS^9]7\7N#8Z40]V5!*%^M R8CR=)=$]]'^<WI1E.&56QNWL
MG,YD.H%YNUC^@Q\$.=?^N>79D<=GK;3#K?5QH8(78<J O'WTW#FG23EPL4-'
MQW1^VU'H/J%I8,G>:-;"(.V+E/8=RXUV%E%H$2$Q(Y,97=6[O,A>E=@)&VU,
M<3&5V%R;6L$<5<^X*=Y::].%%7Z+2'B&+E_8(45L%TIS7P]#G<R@SN9(HUE0
M/^(Y7BZQSQ%.T;8\1&)PXZ'CV=FBE( Q.]VXOEDLN3=<7P OI*RB G]C=H L
M0F>Z,)#N+)<K_I4;6AYS\^96 >\.9-DQK$2^=K?Q."I349#CAYMKG]U+CYR)
M[["A03.LCA24O7MZ@.'27?LE@$S",' ?HY YH:?XDBY4AZJ;W/Q>@6R!]@9\
M+9E3)6^.-Q4#S&3I-P0G#&5]0]DQK9_I16DFJTA V>%MAVYG0MH'>M)#A/D>
MD7.% P4,(20US^,<-'DF(+.WE$3_YZM[MK.V?;Y*B38S.^B^[MONBBHT[KN_
M0#Y>NCZW!#9F #U<8Y4ET-)H';S#G.X.W#GERF.?QHR"WUT-,:5WEH\R_/ =
M%#RS1LW^/'7,$8:82]B@O!!B-D.L&BKM\P1[98T'ZVW564&PIIS$6-_.I@NT
M=?U,.^M08I@QS7A,,]Z?-./QUN#QUF!)!M5R.K=.L=FQ\4\W7$P7;D /CP&K
M7P.F_$+):F^AQBNUV:#K'&OP_-\:0GLA1@=I[R7C@^=]%9FQ .3U%8!T4S?1
MUND[LVN9>0&?0"4$QAH*(VHH=!BOX,NY"Q_OE.4;E2NV2TET57LA*TMIFM[>
MUUK(3-"QQF+_:BQJ-I]!U%0 YZY<+46?#<_Z+"@X-;++'\S<A104])=SVO:\
MKCP]"8&-N+JTJD9(YC!9+W91C5"/M3)R-X&W*+GQ13,P)PA6=$0)$/K;J%M?
MZ 6WW/=Y6::N6^[E4^)[F;=JM]Q_-K+(05:HDEONOQC]II1/?867:YT:V0E0
M059(&=Z)F?U_&[]AN?*[DSZKBS5*#PS%"SB&/AE:3-$0H!A9IJLX1VI2;\3M
MI4:7GX-F0O/\*H'*?FZ'E1ETXFI2HT\; .%+<R'%39)#WQ; &:P*EVB:+'I5
M;G$FZJ>]T''P7&\!P+ZH,\@ML9^'KL9:KL'(@/FR%TI/IL)&B+P7RJYQ052*
MQ^GQT#5B\4\WZ]HR:4^,[+W2S,9M6+0HL-F3E=&T;%4 ,O2]LN-2Y@RXT[W9
M5G06R0NX]L<%H]Q(08 Q=->+GMX9&3Y]QGR[]D>D'5,RX=\/W9!/?[K5\283
M\,.^O-W2MFBG'Z3-C,Z;8XG.8%<1-1]1$O=+^YYQG_(-II9T<IM0PSY9S88S
MK666HC3Z$XNG2=+<=QP?"F'E9644.LB(3H=5N-Z\\/%.DXM_^%;<,0\Y:?P%
M(H $,84F0V% S\ 1:^(6:Z=KW_8BAVVVZ325X1%"K6$/G(U(7DR?_K-@;&F^
MU0> BI*?@\EQW$7D'JVR-I)9=.;:_PM9P16.@HGO3!=T0(M9SM)"M3%4APM:
MBL4I'1U44* Z@G&"/V.]8C/ZY@A]CYC=Y;!SY!75;9;'>-0$0,E88S756$TU
M5E.-U52M5%-).$U?<355GP&(;JNI3HSVU;17337XL$E[=H0H/#+RH@>]F.2,
M2X'#OKCS5,\6 HFA9UJW=LXTHBI16]@'X$\00.Q+R$?&(63$!5\: SF%KCHC
M*A:U*<3,P2K$'+JVJ_-^"TFEE5A'T1P>13VS",M[6[+84UQ)W=HU)\KTS8C7
MP-G7?&<(A0.O$7I P9-K(YZNO,/>=V:"DQ YDV<K<,@4AY:7_YZEM'W'X5\H
MO$<VGOM,^<3)!E<X2#YBOP-U+>V:,]V7L^@2A\^H.+,4Y/KHB"'-L!:S/0D"
M5GS)U.O96OPDL0*X+ F#ER\HL%V"R'62'L-%I 8$M2.):_-\?@BJW?!C.*A?
MZ0_#3((_D3M?L"E$C_'6'/$O65KHE>4&G>,+9LU4J.\\R_^&'7?FQFT[>$T"
M^W9W@7:"+X@?W8YA]\EUZ.:=I3K05WH[8QHJ<"ZL]3=Z4EC04R$TT ,BVY&(
M.5:F^ RQ'/06))2AVM4[S*=26V2A],)V:)BZJOG_^X/NN%F".,AF:G=<4T$J
M5.5? TQ ]H^6X4V%+,V4WBY,G$3A@IX;_P6[V4(K&Z9#F'#\1,]F3$?2<P2?
M"9WB5\H#-$<H/00 6UAO/Z;YG4W=D.4U7OL.4^B1Y;$.1;S7$5N("W<UQ9=^
MR*J-P"D"8-*O1M0.6EWO< 3-E"@A %T%W#"@!BM=9NX38I8L_<T)<$U4$]%]
M,P4=[KNU5,B1V7YR((QV,#O3 :&3<O,YW=M9EO5=NZF0LET%G.S3XJ"F[O:[
M7GF=^_I-?XE'+2*$M<R0_>\3W?X:QF7:R+"NTE6M2PO5;X%@!<U)CWM,?9)*
M\H+)-I@6V26;.Y:RD ;5'EOKDBVQ:HU(7)%;N]6&?96H]6<2 4./:T%JE>M"
M83 =QE4/L[C$S6!"IW$)L3695-J<1@-)FS$4UBI?ID#6Z'5J&+)5#O8,T0]&
MI^\9AFAA>$= :70BK!XHRT.#&2P?C2Z@T N+3 !8 &7TH43S_)')!1!(C=N
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M\5:-I!&5B7U0QHIGLAK%I,(Y:Z&B@DC:;<5>R:)K]K?8PTS%B[(\XS;80]$
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M=$@R<'0=!X]QPNQ@Y$9GC,)(!PVQV=^F)"'H5K9\$(3P1@+R\?S-W"T?QFH
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MO<646NJ@GC",L#_;WP8P27N51E=%?H$_!&%!5D]8IY>E"6A]=Z&/Q8E'+\F
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MRL7^PL7;C$2[L+B#608[G'_"ZF4\([$8O&\;@]!-ZR=98OG$>N3%985ENR^
MW#B01?=]3A=*\8QU0';4A-B3SAMW>GX=ASC-,>NR5'O((DEPH?2#*)U:P !V
M+\PAX32*KFG-]T6<S$48AZIN&5B*DA0=FLU-\8PS@<V%C33A.S6(.BHOM)\
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M62%,23:U:,JH;'$1%/0D'Z+OWIT@RLP_>6--'5+K,J(V7OHIH5:3D98ROJN
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M@0J5 OH0$%A-VN53=UL@C!@<Z]5V5K>LO[=L6O;#,-\XT*\H%4]*RDQ51"W
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M9%"?W07!2/[MP!Q44@ >Q!$AALF+.'5 &D2-4=YQ/M%FNNN05!9#[<>&I6V
MQL9)QS =G,XD#H^VO%ZQM(>I7:SR502MX>J!+&8)6?OK%M4VW2;31L2N[H@9
MIQ>NZ')ZL_5XI&!>&+MSA6MS&&X%^)J5Z]AQ#=<3:\2_1RY0+0;NZ&_\<P C
M/8L2J'I0V_MU_=[%[9"<="H6J% B<<W7CWB _42!.7ZQNNY9)9\KC1TQ4]<Y
MY8DNT=Z^-+HVZ9%J&?%L;T2NW75+M?U8Y-J/IJEN5,[R\Z-K"^U3/52OSC29
M,\UR\PZ;$5WR%Z:+) 3HU?% /4#,7KYVP7.4$9^W.]:@!(@R9WSD=E)G=+V$
MK4(T35/&RB9'JOL0)+-.@KU W>7&9NX-IR@5HL<H;R60'#'?R"(ZCH35-AG]
MYRXOX.!TLQ9A<7Z5AKR.-$C.GRDS\!W.=PDT"H97^ROZEPC^JGR M(-,_PQD
M Z^3PRD3Y L39%"2!CTS/@OB8#2KI Z%C#R42?IXMXU 4CC?P=:J$A'K0G,\
MH*>6'C\+$AC!=O^,<?%C1G9;2I!Y*XA>>&,S^9V@G1ZESO9(($8,,Y*HO6K+
MH"+(]GN7 :YZ+K366Q@]>;FYC(_3>+/;&-S!-[]H=@%<A^'@QIV#]^.:O97/
MI)<7OO T46.GF_:7.(U)QGK5&32]//ZR61_%0S@.9ITQ%)XVZ.L6 AEDDD\,
M3QJ\[N>OXWBF9;?Y$*?T=W&0W-,8ED5@YP%O=3HN$6V,:^26:H;6;8S4ON&6
M9*&2+B0)\R^]/%9W6L.K,<):L)ZTA&4.5$2U]2C<0Y<'L9OL+GYZ+C[MP#W=
MK*L&?^=!DN#H;"\/;.*##BSGY_*HG.<[,7=+=ES>4K>(,\BDY]#]MVM DQ,W
M*NE:I1%?>JUWIHZ+[(=CI-9](!T*J%<R+ LRI^M2DA?18:*GLDD.Q +W2AQ5
M?>;7Y!?@NPUW5'=Q_NN'#..KE"H1SHL[ZLE,[[;[88Z^5^P#[Z"C$,5RNJ9H
M4"SPH(PB\F*[5Y5?QT7Q,",7(*O6ZUV)%@%>:-8%M5Y">G<MTIO,S"Z_;'%8
MX.@B?HDC3)V-!3-KAVE-=&W@[9N9Q((B@0;M8YQ$OIE9K_P&S*R;D0N05;^9
ME=*3B/VPLK\3Z(<.%68V[>P0JG7I-1$XM+67$I&O=M8A045+:V/D(J2E:&T5
M:C_L#<8@VK(R#LNZM "L0XNBO]SX:DL-Z2A:4,4NCR6A:"T/+;)Q;"(M=^AF
M]M$*:*1(6F Z&#3$JR?B%*VKJHNJU,(/6^D34ZNA=++.5Y&TF$A5^7*S1A*;
MZ:L!?VI]-)3OI*7.9_D,4!4UJE&%!*=*NOB F)*RD55NU83O_('BSM=41F>X
M^(QQRIH!*3E%;9 C*M8&H;NK2Y.MDDH"4$D!$B3P#DJS5(.:RO6HO$R1P_[+
ML.YO*DD]"DG5_,ZFUCX^Z12@CTL\]B@FZNFF5KPVUKUDBTZ(U0%@](SY$I:C
M2^MR+XM:ILY/&47U2X H<<<W;@N%!PSLU, G,%;Z/^(B%R!5UO,A"*V.?WO!
MV2.IGLP\/67X*2C@WH]&.O&6;O0!PP:*DY @-=O7*<59$?\7CLY)7JS2J"K"
M;TS%7#W290:A>J&Z-ES]W4$3A9-MOJ0! 1$H2*/&TX+#89^2EEDJ3$;)FXQA
M^D)D*US%@4Q7IC)U\W3P)8@3J!M>DRP/DMJ,RJOTIS3#00*47Y,\OR5YS+(F
M_]^._A(4]J7VLD;6FY2?>J>ST[JDPNPYG3."[._Y' >X[=K\UV><1'"XW97$
MBFFO@I!9'TNZUSDRG2A?I7Y)UW5 9MU17:6HHA0!J:BD M6(K3V(0T)5;];5
M1]]-Z^8^D.R^P>\?,TKYG5C&CT&<:F5A]>".4Q4%%"Z&9@D!/P%\]#4X$9Q_
M@TB*F$)0KQ-( D^IEIRRWU:.R L_HR/T-L^AS/F%"/C0NA'%C.X/[)LA1Z7\
M&7K#,T$89CL:>M%/QF&0/&1QD$ HI)[:ZX%@$ MV 7,2T9\'6;:'K*EX5)J#
MR13/&#V*BN&<50Q'<!2C?R&/2?P4<"=*SV4[5I!9/&=D]_1,_QN(3P99G)?O
M3>E1E, _0K$B5,"2$(TAXY=9VRL-"YZHR:3SO6B_QEUDNZ=;4=_*H)T#/S6>
M1P_",=:^+I!N3I4<)XHHTJK@-P2T*.1X9U>205D1'0;J*LQA9RM=1>G\_OCV
M8"X5XZ@5V_SJ,"2)KIYLH\1/=0I27_EML(?]D![1A9;5>CQ<Z[RF,H%JY$O4
M$;CR+(P"M.4DL(Q5(-Q-4E$QJWLQ$"TQY[ +W5/N6* +T8W.67P _RKU[:AO
M@0EGO1==HT.7E)O S;*@,BRI-]+I:3KAX1(3_U9GV=^;"?%ZU,/&N=:J+<V>
M9;K)8C5YHA&D#D$P2URT G.H=\+ISYI3ZA<!4>..=^SN4GV!9"KM/K!O,P7O
M F+*]'9X3M2<N9@G0J*<!3;0C#P.9TZB#DJ%*'/+1PDD3>;7_7N'\GN29VQ3
MG8,,(,OP>$K^ =\E&L3PL)ORL92[3;&UL;\EO^;U&@YD ,B0Q,9%,.D&<+G9
M)F2/\1U.@F+L1J  S,@=#<)UIUXT_*%_2]C6D''TZ!&G>!W/V_Q876Y$FX\^
MRTB8C\2&!#I+>XA<S!V&BL"PV$&'<?H/&A,X#;69JN7X!6?L>@I_V>(TGZA#
MBWR(;W[ Z8)@I$?MP-QQ77:1F-.8!T1 U+CC';N%K9:='N8XX,@'\"/.[YT@
MC!C> <UA@"01^G"4'Q('4624?ZP7RE[B&-)V+ZXFVT87E?>27E*<-(FM30:;
MTJF(KEWG]/_'K$G53?&,LW'!LP90,^U7A6]?M21J5 1?H,*&(HE?YDVQZ(N0
M&+-R">)*#B0ET+(\/$-L.<)6N6JPJX^D"!*ACP_P,UQA-E+<)^6EIHR_V:F/
MP.K-BO#NPV<<[1)\LVX^,S*H:U !I7\[.0S5R8VR1 M%R>PM1OW]XMQ-7'4E
M1S1YJ5NKT E7KT!A"(Q%Y7%7BE JCGAH23>3$NM\Y0>*$AI4E%&%!E-(H]$%
MO=>&Q]VY3[&6Q'P9CM(P(=G@LF/Q-5@RU7G=X?.]8 PS!)T0[6L51U9KW"S1
MS9N>&18-T6"8GV)(!B0PY>#YCL7J#XT? &13$JZ&M2_))+J'K"LPS5=A#!N&
MVCARN^GZ2WY&T9^TT@%@5/:X <N%"8@,LL#CQ:25?D&TY.Q;F.0;TP\S]BK\
M]NF<J1Z@#APR?5J44J3:LQXG;N@V(R'&40Y]R8":3[BX65_E^0XN,)4?&NI
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MHE"-*OY>2S+E4JV/0$>(Q&:EW*Q74<2F!@3)_7- %P0TX>@#R<Y+CZ0<".F
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M\3/]ZZ_TW_1?] ?(ZOSM_P=02P,$%     @ SH,)2]WBWW#Q2   ,H4% !4
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MALDAB9 3HPN4_=E^=E5T]1?!8%IMA*FNZYVM?H_I'90?DXF;$"TX:U@(.'@
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M_1+H,;OQ.N2GMLICK?927&\*SN']:)W.;1I> 4\!1UN=-.E=)5]3>(/=3KQ
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MS<)U(_(;^>,H]-BK"3!S_3ST^ZC(A+,J&[(_1R>[)[5+U/UA^@,!=4G]](-
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MD^&-%L=?"XN3?4V4XV-Q#XU*];T,G.VG!<?'6M,^$)^=)^,@6D6! -HQ!G"
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MU(4T@(!HK9I$F4UW7U<:PZK;B8."UCR 4.K]A\4N%/LE@:V]9LH>@KCR53J
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M[</C"!IX')<ZIG][2V=!G>K__O\!4$L! A0#%     @ S8,)2U V\I%<^@
M66\5 !$              ( !     &UA8VLM,C Q-S V,S N>&UL4$L! A0#
M%     @ S8,)2["#JH8I%   ']4  !$              ( !B_H  &UA8VLM
M,C Q-S V,S N>'-D4$L! A0#%     @ S8,)2_;&!LZ!$0  Z1,! !4
M         ( !XPX! &UA8VLM,C Q-S V,S!?8V%L+GAM;%!+ 0(4 Q0    (
M ,Z#"4N__Y_,Q#0  '^A P 5              "  9<@ 0!M86-K+3(P,3<P
M-C,P7V1E9BYX;6Q02P$"% ,4    " #.@PE+)67N9LYU  #SJP8 %0
M        @ &.50$ ;6%C:RTR,#$W,#8S,%]L86(N>&UL4$L! A0#%     @
MSH,)2]WBWW#Q2   ,H4% !4              ( !C\L! &UA8VLM,C Q-S V
@,S!?<')E+GAM;%!+!08     !@ & (H!  "S% (    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
